Torsdae	B-Disease
de	I-Disease
piontes	I-Disease
ventircular	B-Disease
tcahycardia	I-Disease
during	O
low	O
dsoe	O
intermitetnt	O
dobtuamine	O
treatemnt	O
in	O
a	O
paitent	O
with	O
diltaed	B-Disease
cardiomyoapthy	I-Disease
and	O
cnogestive	B-Disease
herat	I-Disease
faliure	I-Disease
.	O

The	O
autohrs	O
describe	O
the	O
csae	O
of	O
a	O
56	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
chornic	O
,	O
seevre	O
haert	B-Disease
failrue	I-Disease
secondary	O
to	O
dialted	B-Disease
cardioymopathy	I-Disease
and	O
asbence	O
of	O
significant	O
vetnricular	B-Disease
arrhtyhmias	I-Disease
who	O
developed	O
QT	B-Disease
proolngation	I-Disease
and	O
tosrade	B-Disease
de	I-Disease
poinets	I-Disease
ventricluar	B-Disease
tachycarida	I-Disease
during	O
one	O
ccyle	O
of	O
intermittnet	O
low	O
dsoe	O
(	O
2	O
.	O
5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O
doubtamine	O
.	O

This	O
reprot	O
of	O
torasde	B-Disease
de	I-Disease
ponites	I-Disease
vetnricular	B-Disease
tcahycardia	I-Disease
during	O
intremittent	O
dobutmaine	O
supports	O
the	O
hypotheiss	O
that	O
unperdictable	O
ftaal	O
arrhythmais	B-Disease
may	O
occur	O
even	O
with	O
low	O
dsoes	O
and	O
in	O
patietns	O
with	O
no	O
hsitory	O
of	O
significant	O
rhtyhm	O
dsiturbances	O
.	O

The	O
mechainsms	O
of	O
prorarhythmic	O
efefcts	O
of	O
Dubtuamine	O
are	O
discussed	O
.	O

Posiitve	O
sikn	O
tsets	O
in	O
ltae	O
reactinos	O
to	O
radiogarphic	O
contrast	O
meida	O
.	O

In	O
the	O
last	O
few	O
yaers	O
dealyed	O
reactinos	O
several	O
hours	O
after	O
the	O
injetcion	O
of	O
radiograhpic	O
and	O
contrast	O
matreials	O
(	O
PRC	O
)	O
have	O
been	O
described	O
with	O
incerasing	O
frequnecy	O
.	O

The	O
authros	O
reprot	O
two	O
observtaions	O
on	O
patietns	O
with	O
dealyed	O
raections	O
in	O
whom	O
itnradermoreactions	O
(	O
IDR	O
)	O
and	O
ptach	O
tetss	O
to	O
a	O
series	O
of	O
ioinc	O
and	O
non	O
ioinc	O
PRC	O
were	O
studied	O
.	O

After	O
angiograhpy	O
by	O
the	O
venuos	O
rotue	O
in	O
ptaient	O
n	O
dergee	O
1	O
a	O
bpihasic	O
reatcion	O
with	O
an	O
imemdiate	O
raection	O
(	O
dsypnea	B-Disease
,	O
lsos	B-Disease
of	I-Disease
concsiousness	I-Disease
)	O
and	O
dleayed	O
marco	B-Disease
-	I-Disease
papualr	I-Disease
rsah	I-Disease
appeared	O
,	O
whilst	O
pateint	O
n	O
dgeree	O
2	O
developed	O
a	O
genrealised	O
senastion	O
of	O
haet	O
,	O
perssitent	O
pian	B-Disease
at	O
the	O
stie	O
of	O
inejction	O
immediately	O
and	O
a	O
geenralised	O
mcaro	O
-	O
ppaular	O
recation	O
after	O
24	O
hours	O
.	O

The	O
sikn	O
tsets	O
revaeled	O
poistive	O
dleayed	O
reactinos	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
pacth	O
tetss	O
to	O
only	O
some	O
PRC	O
with	O
common	O
chanis	O
in	O
their	O
strcutures	O
.	O

The	O
poistive	O
sikn	O
tetss	O
are	O
in	O
favour	O
of	O
immnuological	O
reactoins	O
and	O
may	O
help	O
in	O
daignosis	O
of	O
allegry	B-Disease
in	O
the	O
patietns	O
.	O

Rsik	O
of	O
trnasient	O
hyperammoenmic	B-Disease
encephaloptahy	I-Disease
in	O
cnacer	B-Disease
patinets	O
who	O
received	O
conitnuous	O
inufsion	O
of	O
5	O
-	O
fluororuacil	O
with	O
the	O
complictaion	O
of	O
dehydratoin	B-Disease
and	O
infeciton	B-Disease
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cacner	B-Disease
patietns	O
who	O
had	O
32	O
eipsodes	O
of	O
trasnient	O
hyperammonemic	B-Disease
encephalopahty	I-Disease
related	O
to	O
contiunous	O
infsuion	O
of	O
5	O
-	O
fulorouracil	O
(	O
5	O
-	O
FU	O
)	O
were	O
idetnified	O
.	O

None	O
of	O
the	O
patietns	O
had	O
decompensaetd	O
lvier	B-Disease
dsiease	I-Disease
.	O

Onest	O
of	O
hyeprammonemic	B-Disease
ecnephalopathy	I-Disease
varied	O
from	O
0	O
.	O
5	O
to	O
5	O
dyas	O
(	O
mean	O
:	O
2	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
dyas	O
)	O
after	O
the	O
iintiation	O
of	O
chemothearpy	O
.	O

Plsama	O
ammoinum	O
lveel	O
ranged	O
from	O
248	O
to	O
2387	O
mircog	O
%	O
(	O
mean	O
:	O
626	O
+	O
/	O
-	O
431	O
mircog	O
%	O
)	O
.	O

Among	O
the	O
32	O
episdoes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
degeres	O
of	O
azoteima	B-Disease
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacterail	B-Disease
inefctions	I-Disease
and	O
14	O
(	O
44	O
%	O
)	O
without	O
inefction	B-Disease
occurred	O
during	O
preiods	O
of	O
dehydraiton	B-Disease
.	O

Hgiher	O
palsma	O
amomnium	O
lveels	O
and	O
more	O
rpaid	O
onset	O
of	O
hyeprammonemia	B-Disease
were	O
seen	O
in	O
18	O
patinets	O
with	O
bacetrial	B-Disease
infetcions	I-Disease
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
ptaients	O
receiving	O
high	O
daliy	O
dsoes	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	O
-	O
FU	O
(	O
p	O
=	O
0	O
.	O
0001	O
and	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
episoeds	O
(	O
78	O
%	O
)	O
,	O
plamsa	O
ammoinum	O
lveels	O
and	O
mnetal	O
stauts	O
returned	O
to	O
nomral	O
within	O
2	O
dyas	O
after	O
adqeuate	O
managemnet	O
.	O

In	O
conclusion	O
,	O
hypearmmonemic	B-Disease
ecnephalopathy	I-Disease
can	O
occur	O
in	O
patinets	O
receiving	O
continouus	O
infsuion	O
of	O
5	O
-	O
FU	O
.	O

Azoteima	B-Disease
,	O
bdoy	O
fliud	O
insfuficiency	O
and	O
bactreial	B-Disease
infectoins	I-Disease
were	O
frequently	O
found	O
in	O
these	O
paitents	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condtiion	O
in	O
paitents	O
receiving	O
cotninuous	O
inufsion	O
of	O
5	O
-	O
FU	O
.	O

The	O
effects	O
of	O
quiinne	O
and	O
4	O
-	O
aminpoyridine	O
on	O
conditinoed	O
place	O
prfeerence	O
and	O
cahnges	O
in	O
mtoor	O
activtiy	O
indcued	O
by	O
mrophine	O
in	O
rtas	O
.	O

1	O
.	O

The	O
effcets	O
of	O
two	O
unselective	O
potsasium	O
(	O
K	O
(	O
+	O
)	O
-	O
)	O
cahnnel	O
blocekrs	O
,	O
qiunine	O
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	O
-	O
aimnopyridine	O
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
condiitoned	O
place	O
prefeernce	O
and	O
bipahsic	O
cahnges	O
in	O
mtoor	O
atcivity	O
indcued	O
by	O
morpihne	O
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tseted	O
in	O
Witsar	O
rtas	O
.	O

Quinnie	O
is	O
known	O
to	O
blcok	O
voltgae	O
-	O
,	O
calcuim	O
-	O
and	O
ATP	O
-	O
sesnitive	O
K	O
(	O
+	O
)	O
-	O
cahnnels	O
while	O
4	O
-	O
amionpyridine	O
is	O
known	O
to	O
blcok	O
voltgae	O
-	O
sensiitve	O
K	O
(	O
+	O
)	O
-	O
chanenls	O
.	O

2	O
.	O

In	O
the	O
conuterbalanced	O
mehtod	O
,	O
qiunine	O
attenauted	O
morpihne	O
-	O
idnuced	O
place	O
preefrence	O
,	O
whereas	O
4	O
-	O
aminopyrdiine	O
was	O
ineffetcive	O
.	O

In	O
the	O
mtoor	O
atcivity	O
tset	O
measrued	O
with	O
an	O
Anmiex	O
-	O
actviity	O
meetr	O
neither	O
of	O
the	O
K	O
(	O
+	O
)	O
-	O
channel	O
blockres	O
affetced	O
morphnie	O
-	O
induecd	O
hypoactiivty	B-Disease
,	O
but	O
both	O
K	O
(	O
+	O
)	O
-	O
chanenl	O
blocekrs	O
prevented	O
mrophine	O
-	O
indcued	O
secondary	O
hypercativity	B-Disease
.	O

3	O
.	O

These	O
rseults	O
suggest	O
the	O
involvmeent	O
of	O
quiinne	O
-	O
sesnitive	O
but	O
not	O
4	O
-	O
aminpoyridine	O
-	O
sensitvie	O
K	O
(	O
+	O
)	O
-	O
channles	O
in	O
morhpine	O
rweard	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
blcokade	O
of	O
K	O
(	O
+	O
)	O
-	O
cahnnels	O
sensiitve	O
to	O
these	O
blockres	O
is	O
not	O
sufficient	O
to	O
pervent	O
moprhine	O
-	O
idnuced	O
hypoactviity	B-Disease
whereas	O
mrophine	O
-	O
induecd	O
hpyeractivity	B-Disease
seems	O
to	O
be	O
connected	O
to	O
both	O
quniine	O
-	O
and	O
4	O
-	O
aminopryidine	O
-	O
sensitvie	O
K	O
(	O
+	O
)	O
-	O
chanenls	O
.	O

Nociecptin	O
/	O
orphainn	O
FQ	O
and	O
nocisattin	O
on	O
leraning	B-Disease
and	I-Disease
meomry	I-Disease
impairmnet	I-Disease
idnuced	O
by	O
scopolaimne	O
in	O
mcie	O
.	O

1	O
.	O

Nocicpetin	O
,	O
also	O
known	O
as	O
oprhanin	O
FQ	O
,	O
is	O
an	O
ednogenous	O
lignad	O
for	O
the	O
orphan	O
opoiid	O
rceeptor	O
-	O
like	O
rceeptor	O
1	O
(	O
OLR1	O
)	O
and	O
involves	O
in	O
various	O
funcitons	O
in	O
the	O
cnetral	O
nerovus	O
ssytem	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocsitatin	O
is	O
recently	O
isoalted	O
from	O
the	O
same	O
precurosr	O
as	O
ncoiceptin	O
and	O
blcoks	O
ncoiceptin	O
-	O
induecd	O
aloldynia	B-Disease
and	O
hyperlagesia	B-Disease
.	O

2	O
.	O

Although	O
OLR1	O
recpetors	O
which	O
display	O
a	O
high	O
dgeree	O
of	O
seqeunce	O
hoomlogy	O
with	O
classical	O
oipoid	O
recepotrs	O
are	O
aubndant	O
in	O
the	O
hippocapmus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learinng	O
and	O
memroy	O
.	O

3	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
investigtae	O
whether	O
noicceptin	O
/	O
orpahnin	O
FQ	O
and	O
noicstatin	O
could	O
modualte	O
imapirment	B-Disease
of	I-Disease
leanring	I-Disease
and	I-Disease
memroy	I-Disease
induecd	O
by	O
scopoalmine	O
,	O
a	O
muscarniic	O
cholinregic	O
recpetor	O
antaognist	O
,	O
using	O
spontnaeous	O
atlernation	O
of	O
Y	O
-	O
mzae	O
and	O
step	O
-	O
down	O
tpye	O
pasisve	O
avoidacne	O
takss	O
in	O
mcie	O
.	O

4	O
.	O

While	O
nocisattin	O
(	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
nmol	O
mosue	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
amdinistered	O
30	O
min	O
before	O
spontaenous	O
altrenation	O
performacne	O
or	O
the	O
traniing	O
sessoin	O
of	O
the	O
psasive	O
avodiance	O
tsak	O
,	O
had	O
no	O
effect	O
on	O
sponatneous	O
alterantion	O
or	O
passive	O
avodiance	O
behavoiurs	O
,	O
a	O
loewr	O
per	O
cent	O
alternatoin	O
and	O
shoretr	O
mdeian	O
step	O
-	O
down	O
latecny	O
in	O
the	O
rteention	O
tset	O
were	O
obtained	O
in	O
nociecptin	O
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
muose	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
-	O
tretaed	O
nomral	O
mcie	O
.	O

5	O
.	O

Administratoin	O
of	O
ncoistatin	O
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
muose	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
30	O
min	O
before	O
sopntaneous	O
alternaiton	O
performnace	O
or	O
the	O
traniing	O
sesison	O
of	O
the	O
passive	O
avoiadnce	O
tsak	O
,	O
attenuated	O
the	O
scpoolamine	O
-	O
induecd	O
impaimrent	O
of	O
spotnaneous	O
alternaiton	O
and	O
pasisve	O
aovidance	O
behavoiurs	O
.	O

6	O
.	O

These	O
rseults	O
indicated	O
that	O
nocitsatin	O
,	O
a	O
new	O
biologiclaly	O
actvie	O
ppetide	O
,	O
amelioraets	O
impariments	O
of	O
spnotaneous	O
altrenation	O
and	O
passive	O
avoidacne	O
induecd	O
by	O
scoploamine	O
,	O
and	O
suggested	O
that	O
these	O
peptieds	O
play	O
opposite	O
roles	O
in	O
laerning	O
and	O
meomry	O
.	O

Meloxiacm	O
-	O
induecd	O
lievr	B-Disease
toxictiy	I-Disease
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
femlae	O
patinet	O
with	O
rehumatoid	B-Disease
arthrtiis	I-Disease
who	O
developed	O
aucte	O
cytloytic	O
heaptitis	B-Disease
due	O
to	O
meloxciam	O
.	O

Recently	O
introduced	O
in	O
Blegium	O
,	O
meloxiacm	O
is	O
the	O
first	O
nonsetroidal	O
antiifnlammatory	O
durg	O
with	O
selective	O
actoin	O
on	O
the	O
indcuible	O
form	O
of	O
cyclooxygeanse	O
2	O
.	O

The	O
aucte	O
cytolyitc	O
hpeatitis	B-Disease
occurred	O
rapidly	O
after	O
mleoxicam	O
amdinistration	O
and	O
was	O
associated	O
with	O
the	O
dveelopment	O
of	O
antinuclaer	O
antibdoies	O
suggesting	O
a	O
hypresensitivity	B-Disease
mcehanism	O
.	O

This	O
first	O
csae	O
of	O
mleoxicam	O
related	O
lievr	B-Disease
toxiicty	I-Disease
demonstrates	O
the	O
poetntial	O
of	O
this	O
durg	O
to	O
idnuce	O
hepaitc	B-Disease
damgae	I-Disease
.	O

Indcution	O
of	O
apoptsois	O
by	O
remoxpiride	O
metabloites	O
in	O
H6L0	O
and	O
C3D4	O
+	O
/	O
C1D9	O
-	O
huamn	O
bnoe	O
marorw	O
progneitor	O
cells	O
:	O
ptoential	O
relevance	O
to	O
remxoipride	O
-	O
inudced	O
aplatsic	B-Disease
aenmia	I-Disease
.	O

The	O
anitpsychotic	O
agnet	O
,	O
remoxpiride	O
[	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
brmoo	O
-	O
N	O
-	O
[	O
(	O
1	O
-	O
ehtyl	O
-	O
2	O
-	O
pyrroliidnyl	O
)	O
mehtyl	O
]	O
-	O
2	O
,	O
6	O
-	O
dimethxoybenz	O
aimde	O
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplasitc	B-Disease
aenmia	I-Disease
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remoxirpide	O
,	O
three	O
pyrrolidnie	O
rnig	O
metaboiltes	O
and	O
five	O
aormatic	O
rnig	O
mteabolites	O
of	O
the	O
paernt	O
cmopound	O
to	O
inudce	O
appotosis	O
in	O
H6L0	O
clels	O
and	O
huamn	O
bnoe	O
marrow	O
prgoenitor	O
(	O
HMBP	O
)	O
cells	O
.	O

Cells	O
were	O
tretaed	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
componud	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Apopotsis	O
was	O
asesssed	O
by	O
fulorescence	O
microsocpy	O
in	O
Heochst	O
33342	O
-	O
and	O
proipdium	O
ioidde	O
stanied	O
clel	O
sampels	O
.	O

Reuslts	O
were	O
confirmed	O
by	O
deterimnation	O
of	O
interuncleosomal	O
DNA	O
fragmenattion	O
using	O
gel	O
electrophoreiss	O
for	O
H6L0	O
clel	O
smaples	O
and	O
treminal	O
dexoynucleotidyl	O
tarnsferase	O
assay	O
in	O
HMBP	O
cells	O
.	O

The	O
caetchol	O
and	O
hydrqouinone	O
metaboiltes	O
,	O
NCQ346	O
and	O
NQC344	O
,	O
idnuced	O
aopptosis	O
in	O
H6L0	O
and	O
HMBP	O
clels	O
in	O
a	O
tmie	O
-	O
and	O
concentrtaion	O
dpeendent	O
manner	O
,	O
while	O
the	O
pehnols	O
,	O
NRC181	O
,	O
FLA783	O
,	O
and	O
FLA977	O
,	O
and	O
the	O
dreivatives	O
formed	O
by	O
oixdation	O
of	O
the	O
pyrrloidine	O
rnig	O
,	O
FLA388	O
,	O
NMC001	O
,	O
and	O
NC1L18	O
,	O
had	O
no	O
effect	O
.	O

No	O
necroiss	B-Disease
was	O
observed	O
in	O
clels	O
tretaed	O
with	O
NCQ346	O
but	O
NQC344	O
had	O
a	O
bipahsic	O
effect	O
in	O
both	O
clel	O
types	O
,	O
inducnig	O
apopotsis	O
at	O
loewr	O
cocnentrations	O
and	O
necroiss	B-Disease
at	O
hihger	O
concetnrations	O
.	O

These	O
dtaa	O
show	O
that	O
the	O
ctaechol	O
and	O
hydrouqinone	O
metaboliets	O
of	O
reomxipride	O
have	O
direct	O
txoic	O
effcets	O
in	O
H6L0	O
and	O
HMBP	O
clels	O
,	O
leading	O
to	O
appotosis	O
,	O
while	O
the	O
pehnol	O
meatbolites	O
were	O
inatcive	O
.	O

Similarly	O
,	O
benznee	O
-	O
derived	O
caetchol	O
and	O
hyrdoquinone	O
,	O
but	O
not	O
pehnol	O
,	O
idnuce	O
aopptosis	O
in	O
HMBP	O
clels	O
[	O
Moarn	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Pharmcaol	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
remoxirpide	O
and	O
bnezene	O
may	O
indcue	O
aplsatic	B-Disease
aenmia	I-Disease
via	O
produtcion	O
of	O
similar	O
reactvie	O
metabloites	O
and	O
that	O
the	O
ability	O
of	O
NC4Q36	O
and	O
NQC344	O
to	O
indcue	O
apoptsois	O
in	O
HMBP	O
cells	O
may	O
contribute	O
to	O
the	O
mechainsm	O
underlying	O
acquired	O
aplsatic	B-Disease
aneima	I-Disease
that	O
has	O
been	O
associated	O
with	O
rmeoxipride	O
.	O

Synthseis	O
and	O
preliminary	O
pharmaoclogical	O
investigatinos	O
of	O
1	O
-	O
(	O
1	O
,	O
2	O
-	O
dhiydro	O
-	O
2	O
-	O
acneaphthylenyl	O
)	O
piperaizne	O
derivtaives	O
as	O
poetntial	O
atypcial	O
antipsyhcotic	O
aegnts	O
in	O
mcie	O
.	O

In	O
resaerch	O
towards	O
the	O
deveolpment	O
of	O
new	O
aytpical	O
antipscyhotic	O
aegnts	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminerigc	O
sytsem	O
can	O
be	O
modluated	O
through	O
manipultaion	O
of	O
the	O
serootnergic	O
sytsem	O
.	O

The	O
synhtesis	O
and	O
preliminary	O
pharmacoolgical	O
evalutaion	O
of	O
a	O
series	O
of	O
poetntial	O
atypcial	O
antipscyhotic	O
agnets	O
based	O
on	O
the	O
strutcure	O
of	O
1	O
-	O
(	O
1	O
,	O
2	O
-	O
diyhdro	O
-	O
2	O
-	O
aecnaphthylenyl	O
)	O
piperaznie	O
(	O
7	O
)	O
is	O
described	O
.	O

Compuond	O
7e	O
,	O
5	O
-	O
{	O
2	O
-	O
[	O
4	O
-	O
(	O
1	O
,	O
2	O
-	O
diyhdro	O
-	O
2	O
-	O
acneaphthylenyl	O
)	O
piperzainyl	O
]	O
etyhl	O
}	O
-	O
2	O
,	O
3	O
-	O
dhiy	O
dro	O
-	O
1H	O
-	O
inodl	O
-	O
2	O
-	O
one	O
,	O
from	O
this	O
series	O
showed	O
significant	O
affiniites	O
at	O
the	O
5	O
-	O
H1TA	O
and	O
5	O
-	O
H2TA	O
recepotrs	O
and	O
mdoerate	O
affintiy	O
at	O
the	O
D2	O
recepotr	O
.	O

7e	O
exhibits	O
a	O
high	O
revresal	O
of	O
catalespy	B-Disease
indcued	O
by	O
haloperdiol	O
indicating	O
its	O
aytpical	O
antipsychoitc	O
nature	O
.	O

Sub	O
-	O
chrnoic	O
inhibiiton	O
of	O
ntiric	O
-	O
oixde	O
snythesis	O
modfiies	O
haloperiodl	O
-	O
idnuced	O
cataelpsy	B-Disease
and	O
the	O
number	O
of	O
NDAPH	O
-	O
diahporase	O
nuerons	O
in	O
mcie	O
.	O

RTAIONALE	O
:	O
NG	O
-	O
nirto	O
-	O
L	O
-	O
agrinine	O
(	O
L	O
-	O
NAORG	O
)	O
,	O
an	O
inhiibtor	O
of	O
nitirc	O
-	O
oxdie	O
snythase	O
(	O
NOS	O
)	O
,	O
indcues	O
ctaalepsy	B-Disease
in	O
mcie	O
.	O

This	O
efefct	O
undergoes	O
raipd	O
tolreance	O
,	O
showing	O
a	O
significant	O
dercease	O
after	O
2	O
dyas	O
of	O
sub	O
-	O
chrnoic	O
L	O
-	O
NAORG	O
treatmnet	O
.	O

Ntiric	O
oxdie	O
(	O
NO	O
)	O
has	O
been	O
shown	O
to	O
inlfuence	O
dopmainergic	O
neurotransmissoin	O
in	O
the	O
srtiatum	O
.	O

Neuroelptic	O
drgus	O
such	O
as	O
halopreidol	O
,	O
which	O
bolck	O
dpoamine	O
recpetors	O
,	O
also	O
cause	O
cataelpsy	B-Disease
in	O
rdoents	O
.	O

OBEJCTIVES	O
:	O
To	O
investiagte	O
the	O
effects	O
of	O
subcrhonic	O
L	O
-	O
NAORG	O
treatemnt	O
in	O
haloperiodl	O
-	O
induecd	O
caatlepsy	B-Disease
and	O
the	O
number	O
of	O
NOS	O
nuerons	O
in	O
areas	O
related	O
to	O
mootr	O
conrtol	O
.	O

METHODS	O
:	O
Mlae	O
albnio	O
Swsis	O
mcie	O
were	O
terated	O
sub	O
-	O
chroncially	O
(	O
twice	O
a	O
day	O
for	O
4	O
dyas	O
)	O
with	O
L	O
-	O
NAORG	O
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
haloperiodl	O
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Catalpesy	B-Disease
was	O
evaulated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treamtents	O
.	O

Reduecd	O
nioctinamide	O
adeinne	O
dinucelotide	O
phopshate	O
-	O
diaphroase	O
(	O
NDAPH	O
-	O
d	O
)	O
histochemisrty	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enyzme	O
expression	O
in	O
mcie	O
brian	O
regoins	O
related	O
to	O
mootr	O
contorl	O
.	O

RESLUTS	O
:	O
L	O
-	O
NAORG	O
sub	O
-	O
crhonic	O
administartion	O
produced	O
toelrance	O
of	O
L	O
-	O
NAORG	O
and	O
of	O
halopeirdol	O
-	O
idnuced	O
catlaepsy	B-Disease
.	O

It	O
also	O
indcued	O
an	O
icnrease	O
in	O
the	O
number	O
of	O
NDAPH	O
-	O
d	O
-	O
posiitve	O
clels	O
in	O
the	O
dosral	O
part	O
of	O
the	O
cuadate	O
and	O
accmubens	O
nculei	O
cmopared	O
with	O
haloperiodl	O
and	O
in	O
the	O
peducnulopontine	O
temgental	O
nulceus	O
compaerd	O
with	O
sailne	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
dercease	O
in	O
NDAPH	O
-	O
d	O
neuorn	O
number	O
in	O
the	O
substnatia	O
nirga	O
,	O
pras	O
comapcta	O
in	O
both	O
haolperidol	O
-	O
tretaed	O
and	O
L	O
-	O
NORAG	O
-	O
tretaed	O
anmials	O
.	O

CONCLSUIONS	O
:	O
The	O
resluts	O
give	O
further	O
support	O
to	O
the	O
hyptohesis	O
that	O
NO	O
plays	O
a	O
role	O
in	O
mootr	O
behvaior	O
cotnrol	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
snyaptic	O
chanegs	O
produced	O
by	O
antipsychtoic	O
tretament	O
.	O

Porlonged	O
lfet	B-Disease
vetnricular	I-Disease
dysfucntion	I-Disease
occurs	O
in	O
patietns	O
with	O
cornoary	B-Disease
artrey	I-Disease
disesae	I-Disease
after	O
both	O
dobutamnie	O
and	O
exrecise	O
inudced	O
myocaridal	B-Disease
ischaeima	I-Disease
.	O

OBEJCTIVE	O
:	O
To	O
determine	O
whether	O
pharmacologcial	O
sterss	O
leads	O
to	O
porlonged	O
but	O
reversible	O
lfet	B-Disease
vnetricular	I-Disease
dyfsunction	I-Disease
in	O
paitents	O
with	O
coornary	B-Disease
atrery	I-Disease
disesae	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
execrise	O
.	O

DESIGN	O
:	O
A	O
randmoised	O
corssover	O
stduy	O
of	O
recvoery	O
tmie	O
of	O
sytsolic	O
and	O
diatsolic	O
lfet	O
vetnricular	O
funciton	O
after	O
execrise	O
and	O
dobutamnie	O
idnuced	O
ischaeima	B-Disease
.	O

SUBJECTS	O
:	O
10	O
patinets	O
with	O
stbale	B-Disease
anigna	I-Disease
,	O
anigographically	O
proven	O
croonary	B-Disease
artrey	I-Disease
diesase	I-Disease
,	O
and	O
noraml	O
lfet	O
ventrciular	O
functoin	O
.	O

INTERVETNIONS	O
:	O
Treadmlil	O
execrise	O
and	O
dobutmaine	O
srtess	O
were	O
performed	O
on	O
different	O
dyas	O
.	O

Quanttiative	O
assessment	O
of	O
sytsolic	O
and	O
daistolic	O
lfet	O
venrticular	O
funciton	O
was	O
performed	O
using	O
transthoraicc	O
echcoardiography	O
at	O
baesline	O
and	O
at	O
regular	O
intevrals	O
after	O
each	O
tset	O
.	O

REUSLTS	O
:	O
Both	O
forms	O
of	O
strses	O
led	O
to	O
porlonged	O
but	O
reversible	O
systloic	O
and	O
diasotlic	O
dysfucntion	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
mxaimum	O
double	O
proudct	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
derpession	B-Disease
(	O
p	O
=	O
0	O
.	O
63	O
)	O
with	O
either	O
form	O
of	O
strses	O
.	O

After	O
execrise	O
,	O
ejectoin	O
frcation	O
was	O
rdeuced	O
at	O
15	O
and	O
30	O
mintues	O
compaerd	O
with	O
baesline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-	O
5	O
.	O
6	O
(	O
1	O
.	O
5	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
-	O
6	O
.	O
1	O
(	O
2	O
.	O
2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
mniutes	O
after	O
doubtamine	O
(	O
-	O
10	O
.	O
8	O
(	O
1	O
.	O
8	O
)	O
%	O
and	O
-	O
5	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Reginoal	O
analyiss	O
showed	O
a	O
rdeuction	O
in	O
the	O
worst	O
affected	O
segemnt	O
15	O
and	O
30	O
mniutes	O
after	O
execrise	O
(	O
-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)	O
%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
mintues	O
after	O
dobutaimne	O
(	O
-	O
32	O
(	O
5	O
.	O
3	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
isovoluimc	O
relaaxtion	O
peroid	O
was	O
prologned	O
45	O
miuntes	O
after	O
each	O
form	O
of	O
srtess	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSOINS	O
:	O
In	O
patietns	O
with	O
cornoary	B-Disease
atrery	I-Disease
disaese	I-Disease
,	O
dobuatmine	O
inudced	O
ischaeima	B-Disease
reuslts	O
in	O
proolnged	O
reversible	O
lfet	B-Disease
venrticular	I-Disease
dysfunctoin	I-Disease
,	O
presumed	O
to	O
be	O
myoacrdial	B-Disease
sutnning	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exericse	O
.	O

Dobtuamine	O
idnuced	O
iscahemia	B-Disease
could	O
therefore	O
be	O
used	O
to	O
stduy	O
the	O
pathophyisology	O
of	O
this	O
pheonmenon	O
further	O
in	O
paitents	O
with	O
croonary	B-Disease
aretry	I-Disease
disesae	I-Disease
.	O

Anorexignes	O
and	O
plumonary	B-Disease
hypertesnion	I-Disease
in	O
the	O
Untied	O
Sattes	O
:	O
resutls	O
from	O
the	O
surevillance	O
of	O
Nroth	O
Ameircan	O
pulomnary	B-Disease
hypertesnion	I-Disease
.	O

BACKGRUOND	O
:	O
The	O
use	O
of	O
apeptite	O
spupressants	O
in	O
Euorpe	O
has	O
been	O
associated	O
with	O
the	O
dveelopment	O
of	O
primray	B-Disease
plumonary	I-Disease
hypertesnion	I-Disease
(	O
PPH	B-Disease
)	O
.	O

Recently	O
,	O
fenfluarmine	O
appettie	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
Uinted	O
Sttaes	O
but	O
were	O
withdrawn	O
in	O
Septemebr	O
1997	O
because	O
of	O
concenrs	O
over	O
advrese	O
effcets	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
porspective	O
sruveillance	O
stduy	O
on	O
patinets	O
diagonsed	O
with	O
pulmnoary	B-Disease
hyeprtension	I-Disease
at	O
12	O
large	O
referarl	O
centres	O
in	O
Notrh	O
Ameirca	O
.	O

Dtaa	O
collected	O
on	O
patietns	O
seen	O
from	O
Septebmer	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmnoary	B-Disease
hyeprtension	I-Disease
and	O
its	O
sveerity	O
.	O

Ptaients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmnoary	B-Disease
hypretension	I-Disease
were	O
classed	O
as	O
PPH	B-Disease
.	O

A	O
histroy	O
of	O
durg	O
epxosure	O
also	O
was	O
taken	O
with	O
special	O
attentoin	O
on	O
the	O
use	O
of	O
anitdepressants	O
,	O
anorexiegns	O
,	O
and	O
apmhetamines	O
.	O

RESLUTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
paitents	O
were	O
studied	O
,	O
205	O
with	O
PPH	B-Disease
and	O
374	O
with	O
pulmoanry	B-Disease
hypertesnion	I-Disease
from	O
other	O
causes	O
(	O
secondary	O
pulmnoary	B-Disease
hpyertension	I-Disease
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
anorexiegns	O
was	O
common	O
in	O
both	O
gropus	O
.	O

However	O
,	O
of	O
the	O
medciations	O
survyeed	O
,	O
only	O
the	O
fenfluramines	O
had	O
a	O
significant	O
preferentail	O
associtaion	O
with	O
PPH	B-Disease
as	O
compaerd	O
with	O
SPH	O
(	O
adjusted	O
odds	O
rtaio	O
for	O
use	O
>	O
6	O
mnoths	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
cnofidence	O
inetrval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O

The	O
associaiton	O
was	O
stornger	O
with	O
longer	O
duraiton	O
of	O
use	O
when	O
compraed	O
to	O
shoretr	O
druation	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
usres	O
than	O
in	O
rmeote	O
usres	O
.	O

An	O
unexpectedly	O
high	O
(	O
11	O
.	O
4	O
%	O
)	O
number	O
of	O
paitents	O
with	O
SPH	O
had	O
used	O
anroexigens	O
.	O

CONCLUISON	O
:	O
The	O
magniutde	O
of	O
the	O
associtaion	O
with	O
PPH	B-Disease
,	O
the	O
inrcease	O
of	O
associaiton	O
with	O
inrceasing	O
duraiton	O
of	O
use	O
,	O
and	O
the	O
specfiicity	O
for	O
fenfluramines	O
are	O
consistent	O
with	O
previous	O
stduies	O
indicating	O
that	O
fenfluramines	O
are	O
causally	O
related	O
to	O
PPH	B-Disease
.	O

The	O
high	O
preavlence	O
of	O
aonrexigen	O
use	O
in	O
ptaients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
durgs	O
prceipitate	O
plumonary	B-Disease
hyperetnsion	I-Disease
in	O
ptaients	O
with	O
underlying	O
conditinos	O
associated	O
with	O
SPH	O
.	O

Cliniacl	O
aspects	O
of	O
heprain	O
-	O
indcued	O
thrombocytopneia	B-Disease
and	O
trhombosis	B-Disease
and	O
other	O
side	O
effcets	O
of	O
hepairn	O
therpay	O
.	O

Hepairn	O
,	O
first	O
used	O
to	O
preevnt	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clniically	O
used	O
to	O
terat	O
thromboiss	B-Disease
for	O
more	O
than	O
50	O
yeras	O
.	O

Although	O
several	O
new	O
antiocagulant	O
durgs	O
are	O
in	O
devleopment	O
,	O
heprain	O
remains	O
the	O
anticoauglant	O
of	O
choice	O
to	O
traet	O
actue	O
thormbotic	B-Disease
episoeds	O
.	O

The	O
clincial	O
efefcts	O
of	O
hpearin	O
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Bleednig	B-Disease
is	O
the	O
prmiary	O
untoward	O
effcet	O
of	O
hpearin	O
.	O

Major	O
beleding	B-Disease
is	O
of	O
primray	O
concern	O
in	O
ptaients	O
receiving	O
heprain	O
threapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
efefcts	O
of	O
heprain	O
therpay	O
include	O
heprain	O
-	O
indcued	O
thrombocytpoenia	B-Disease
,	O
heprain	O
-	O
associated	O
osteopoorsis	B-Disease
,	O
esoinophilia	B-Disease
,	O
sikn	B-Disease
reactinos	I-Disease
,	O
alelrgic	B-Disease
recations	I-Disease
other	O
than	O
thromboctyopenia	B-Disease
,	O
aolpecia	B-Disease
,	O
transaminasemia	O
,	O
hyperkaelmia	B-Disease
,	O
hypoadlosteronism	B-Disease
,	O
and	O
pripaism	B-Disease
.	O

These	O
side	O
effetcs	O
are	O
relatively	O
rrae	O
in	O
a	O
given	O
indiviudal	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heaprin	O
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HTIT	B-Disease
and	O
osteoporoiss	B-Disease
.	O

Although	O
reasonable	O
incidenecs	O
of	O
many	O
of	O
these	O
side	O
effetcs	O
can	O
be	O
"	O
sotfly	O
"	O
deduced	O
from	O
current	O
reprots	O
dealing	O
with	O
unfractioanted	O
heprain	O
,	O
at	O
present	O
the	O
incidenecs	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
mloecular	O
weihgt	O
hpearins	O
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
exeprience	O
will	O
more	O
clearly	O
define	O
the	O
incdience	O
of	O
each	O
side	O
effect	O
with	O
low	O
molecualr	O
wieght	O
preaprations	O
.	O

A	O
csae	O
of	O
bialteral	O
opitc	B-Disease
neuropahty	I-Disease
in	O
a	O
paitent	O
on	O
tacroliums	O
(	O
F5K06	O
)	O
threapy	O
after	O
lievr	O
transplantaiton	O
.	O

PUPROSE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
bilatreal	O
otpic	B-Disease
neruopathy	I-Disease
in	O
a	O
paitent	O
receiving	O
tacrolmius	O
(	O
FK	O
506	O
,	O
Porgraf	O
;	O
Fujiaswa	O
USA	O
,	O
Inc	O
,	O
Derefield	O
,	O
Illinios	O
)	O
for	O
immunsouppression	O
after	O
orthotorpic	O
lvier	O
transplnatation	O
.	O

METHOD	O
:	O
Csae	O
rpeort	O
.	O

In	O
a	O
58	O
-	O
yaer	O
-	O
old	O
man	O
receiving	O
tacrloimus	O
after	O
orthtoropic	O
lievr	O
transplatnation	O
,	O
sreial	O
nuero	O
-	O
ophthalmloogic	O
examinaitons	O
and	O
laobratory	O
sutdies	O
were	O
performed	O
.	O

RSEULTS	O
:	O
The	O
patinet	O
had	O
epiosdic	O
deteriroation	O
of	O
viison	O
in	O
both	O
eeys	O
,	O
with	O
clincial	O
featrues	O
resembling	O
iscehmic	B-Disease
otpic	I-Disease
neuropatihes	I-Disease
.	O

Deterioraiton	B-Disease
of	I-Disease
vsiion	I-Disease
occurred	O
despite	O
discontinuatoin	O
of	O
the	O
tacroilmus	O
.	O

CONCLUISON	O
:	O
Tacorlimus	O
and	O
other	O
immunosuppressive	O
aegnts	O
may	O
be	O
associated	O
with	O
opitc	B-Disease
nevre	I-Disease
toxiicty	I-Disease
.	O

Hypercalecmia	B-Disease
,	O
arhrythmia	B-Disease
,	O
and	O
mood	O
stbailizers	O
.	O

Recent	O
fidnings	O
in	O
a	O
bioplar	B-Disease
pateint	O
receiving	O
miantenance	O
ltihium	O
thearpy	O
who	O
developed	O
hypercalecmia	B-Disease
and	O
sveere	O
bradayrrhythmia	B-Disease
prompted	O
the	O
autohrs	O
to	O
conduct	O
a	O
retrospetcive	O
stduy	O
of	O
bioplar	B-Disease
paitents	O
with	O
litihum	O
-	O
associated	O
hypercalecmia	B-Disease
.	O

A	O
printuot	O
of	O
all	O
csaes	O
of	O
hypercalecmia	B-Disease
that	O
presented	O
during	O
a	O
1	O
-	O
yaer	O
preiod	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercalcemais	B-Disease
or	O
those	O
associated	O
with	O
intraevnous	O
fludis	O
,	O
the	O
atuhors	O
idnetified	O
18	O
non	O
-	O
lihtium	O
-	O
tretaed	O
patietns	O
with	O
hypercalceimas	B-Disease
related	O
to	O
maliganncies	B-Disease
and	O
other	O
mdeical	O
condtiions	O
(	O
gruop	O
A	O
)	O
and	O
12	O
paitents	O
with	O
litihum	O
-	O
associated	O
hyeprcalcemia	B-Disease
(	O
gorup	O
B	O
)	O
.	O

Ptaients	O
in	O
gorup	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
gruop	O
A	O
,	O
as	O
the	O
latter	O
were	O
medcially	O
copmromised	O
and	O
were	O
receiving	O
mlutiple	O
phamracotherapies	O
.	O

Thus	O
,	O
two	O
cnotrol	O
gruops	O
were	O
generated	O
:	O
gruop	O
C1	O
,	O
which	O
included	O
age	O
-	O
and	O
sex	O
-	O
comparable	O
ltihium	O
-	O
treaetd	O
bpiolar	B-Disease
normocaclemic	O
patinets	O
,	O
and	O
gorup	O
C2	O
,	O
which	O
included	O
bioplar	B-Disease
normcoalcemic	O
patietns	O
treaetd	O
with	O
antcionvulsant	O
mood	O
stabiilzers	O
.	O

The	O
electroacrdiographic	O
(	O
ECG	O
)	O
fnidings	O
for	O
patietns	O
in	O
gorup	O
B	O
were	O
comapred	O
with	O
those	O
of	O
ptaients	O
in	O
gropus	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
gruops	O
did	O
not	O
differ	O
in	O
their	O
overall	O
freqeuncy	O
of	O
ECG	O
abnoramlities	O
;	O
however	O
,	O
there	O
were	O
significant	O
difefrences	O
in	O
the	O
freqeuncy	O
of	O
condutcion	O
dfeects	O
.	O

Pateints	O
with	O
hyprecalcemia	B-Disease
resulting	O
from	O
mdeical	O
diesases	O
and	O
bpiolar	B-Disease
paitents	O
with	O
ltihium	O
-	O
associated	O
hyprecalcemia	B-Disease
had	O
significantly	O
hgiher	O
ferquencies	O
of	O
conduciton	O
defcets	O
.	O

Pateints	O
in	O
gorup	O
A	O
had	O
significant	O
mrotality	O
at	O
2	O
-	O
yaer	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
mortailty	O
in	O
the	O
other	O
three	O
gruops	O
.	O

The	O
clincial	O
implications	O
of	O
these	O
fidnings	O
are	O
discussed	O
.	O

Attenuaiton	O
of	O
nephrotoixcity	B-Disease
by	O
a	O
novel	O
lpiid	O
nnaosphere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
amhpotericin	O
B	O
.	O

NS	O
-	O
718	O
,	O
a	O
liipd	O
nanoshpere	O
incorporating	O
ampohtericin	O
B	O
,	O
is	O
effcetive	O
against	O
pathoegnic	O
fugni	O
and	O
has	O
low	O
txoicity	B-Disease
.	O

We	O
compaerd	O
the	O
toxiicty	B-Disease
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fungiozne	O
(	O
apmhotericin	O
B	O
-	O
soidum	O
deoxyhcolate	O
;	O
D	O
-	O
AmB	O
)	O
in	O
vitro	O
using	O
rneal	O
clel	O
clutures	O
and	O
in	O
vivo	O
by	O
boichemical	O
analsyis	O
,	O
histopathloogical	O
sutdy	O
of	O
the	O
kindey	O
and	O
phamracokinetic	O
stduy	O
of	O
amphotreicin	O
B	O
following	O
intraveonus	O
infusoin	O
of	O
the	O
formulaiton	O
in	O
rtas	O
.	O

Inucbation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
daamge	O
of	O
clutured	O
hmuan	O
reanl	O
porximal	O
tbuular	O
eptihelial	O
cells	O
comapred	O
with	O
D	O
-	O
AmB	O
.	O

Seurm	O
blood	O
uera	O
and	O
creatiinne	O
concentrtaions	O
incerased	O
significantly	O
in	O
rtas	O
given	O
an	O
iv	O
infuison	O
of	O
D	O
-	O
AmB	O
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dsoe	O
of	O
NS	O
-	O
718	O
.	O

Histoapthological	O
examinatoin	O
of	O
the	O
kindey	O
showed	O
tubluar	B-Disease
ncerosis	I-Disease
in	O
D	O
-	O
AmB	O
-	O
traeted	O
rtas	O
but	O
no	O
change	O
in	O
NS	O
-	O
718	O
-	O
tretaed	O
rtas	O
.	O

Amphoteircin	O
B	O
cnocentrations	O
in	O
the	O
kdiney	O
in	O
NS	O
-	O
718	O
-	O
traeted	O
rtas	O
were	O
hgiher	O
than	O
those	O
in	O
D	O
-	O
AmB	O
-	O
traeted	O
rtas	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
resutls	O
suggest	O
that	O
icnorporation	O
of	O
amphoteircin	O
B	O
into	O
liipd	O
nanopsheres	O
of	O
NS	O
-	O
718	O
attenuaets	O
the	O
nephortoxicity	B-Disease
of	O
amphoteircin	O
B	O
.	O

Ptaterns	O
of	O
sulfdaiazine	O
aucte	B-Disease
nephrtooxicity	I-Disease
.	O

Slufadiazine	O
actue	B-Disease
nephrotoxciity	I-Disease
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplsamosis	B-Disease
in	O
HIV	O
-	O
poistive	O
ptaients	O
.	O

We	O
reprot	O
4	O
caess	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
helathy	O
perosn	O
.	O

Under	O
tretament	O
with	O
sulfadiaizne	O
they	O
developed	O
oliguira	B-Disease
,	O
abdomnial	B-Disease
pian	I-Disease
,	O
rneal	B-Disease
failrue	I-Disease
and	O
showed	O
mlutiple	O
radiolucnet	O
rneal	B-Disease
cacluli	I-Disease
in	O
echograhpy	O
.	O

All	O
patinets	O
recvoered	O
their	O
previous	O
nromal	O
reanl	O
fnuction	O
after	O
adeqaute	O
hydartion	O
and	O
alclainization	O
.	O

A	O
nephorstomy	O
tbue	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patinets	O
for	O
uretearl	B-Disease
lithisais	I-Disease
in	O
a	O
single	O
fucntional	O
kdiney	O
.	O

None	O
of	O
them	O
needed	O
diaylsis	O
or	O
a	O
rneal	O
boipsy	O
because	O
of	O
a	O
typical	O
bneign	O
coruse	O
.	O

Tretament	O
with	O
sulfadiaizne	O
requires	O
exquiiste	O
conrtol	O
of	O
rneal	O
functoin	O
,	O
an	O
inrcease	O
in	O
wtaer	O
inegstion	O
and	O
possibly	O
the	O
alcalniization	O
of	O
the	O
urnie	O
.	O

We	O
communicate	O
a	O
csae	O
in	O
a	O
previously	O
haelthy	O
perosn	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
litearture	O
.	O

Probably	O
many	O
more	O
caess	O
are	O
not	O
dteected	O
.	O

We	O
think	O
that	O
a	O
prsopective	O
stduy	O
would	O
be	O
useful	O
.	O

Downbaet	B-Disease
nystgamus	I-Disease
associated	O
with	O
intravenuos	O
pateint	O
-	O
contrloled	O
admniistration	O
of	O
morphnie	O
.	O

IMPLICAITONS	O
:	O
This	O
csae	O
documetns	O
a	O
ptaient	O
who	O
developed	O
dizzienss	B-Disease
with	O
downbaeting	B-Disease
nystamgus	I-Disease
while	O
receiving	O
a	O
relatively	O
large	O
dsoe	O
of	O
IV	O
paitent	O
-	O
cotnrolled	O
anaglesia	O
moprhine	O
.	O

Although	O
there	O
have	O
been	O
csae	O
repotrs	O
of	O
epiudral	O
moprhine	O
with	O
these	O
sympotms	O
and	O
sgins	O
,	O
this	O
has	O
not	O
been	O
previously	O
dcoumented	O
with	O
IV	O
or	O
ptaient	O
-	O
controlled	O
anlagesia	O
mrophine	O
.	O

Hemodynaimc	O
and	O
anitadrenergic	O
effetcs	O
of	O
drondearone	O
and	O
amiodraone	O
in	O
animlas	O
with	O
a	O
heaeld	O
myoacrdial	B-Disease
inafrction	I-Disease
.	O

The	O
hmeodynamic	O
and	O
antaidrenergic	O
effcets	O
of	O
dronedaorne	O
,	O
a	O
noniodinaetd	O
cmopound	O
structurally	O
related	O
to	O
amiodaorne	O
,	O
were	O
compaerd	O
with	O
those	O
of	O
amioadrone	O
after	O
prloonged	O
oarl	O
adminsitration	O
,	O
both	O
at	O
rest	O
and	O
during	O
smypathetic	O
sitmulation	O
in	O
consicous	O
dgos	O
with	O
a	O
helaed	O
moycardial	B-Disease
infartcion	I-Disease
.	O

All	O
dgos	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
droneadrone	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
aimodarone	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
palcebo	O
twice	O
daliy	O
for	O
7	O
dyas	O
,	O
with	O
a	O
3	O
-	O
week	O
wsahout	O
between	O
cosnecutive	O
teratments	O
.	O

Herat	O
rtae	O
(	O
HR	O
)	O
,	O
mean	O
arteiral	O
perssure	O
(	O
MBP	O
)	O
,	O
positvie	O
rtae	O
of	O
incresae	O
of	O
lfet	O
ventriuclar	O
pressure	O
(	O
+	O
LdVP	O
/	O
dt	O
)	O
,	O
echocardiographiclaly	O
assessed	O
lfet	O
ventircular	O
ejcetion	O
fratcion	O
(	O
LEVF	O
)	O
,	O
and	O
farctional	O
shotrening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
crhonotropic	O
repsonse	O
to	O
isoproteernol	O
and	O
exericse	O
-	O
idnuced	O
symapthetic	O
stimultaion	O
were	O
evaluaetd	O
under	O
baesline	O
and	O
posttreatmnet	O
conditinos	O
.	O

Retsing	O
vlaues	O
of	O
LEVF	O
,	O
FS	O
,	O
+	O
LdVP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
ucnhanged	O
whatever	O
the	O
durg	O
and	O
the	O
dsoing	O
rgeimen	O
,	O
whereas	O
rseting	O
HR	O
was	O
significantly	O
and	O
dsoe	O
-	O
dependently	O
lowreed	O
after	O
droneadrone	O
and	O
to	O
a	O
lesesr	O
extent	O
after	O
amiodarnoe	O
.	O

Both	O
dronedarnoe	O
and	O
amiodarnoe	O
significantly	O
redcued	O
the	O
exrecise	O
-	O
indcued	O
tahcycardia	B-Disease
and	O
,	O
at	O
the	O
highest	O
dsoe	O
,	O
dcereased	O
the	O
isporoterenol	O
-	O
induecd	O
tcahycardia	B-Disease
.	O

Thus	O
,	O
drnoedarone	O
and	O
amiodarnoe	O
displayed	O
a	O
similar	O
lveel	O
of	O
antiadrenerigc	O
effect	O
and	O
did	O
not	O
imapir	O
the	O
restnig	O
lfet	O
ventrciular	O
fucntion	O
.	O

Consequently	O
,	O
dronedarnoe	O
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatemnt	O
and	O
prevetnion	O
of	O
various	O
clniical	O
arrhyhtmias	B-Disease
,	O
without	O
compromsiing	O
the	O
lfet	O
ventrciular	O
funciton	O
.	O

Pahse	O
2	O
tiral	O
of	O
lipsoomal	O
dxoorubicin	O
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
platnium	O
/	O
pacliatxel	O
-	O
rerfactory	O
ovairan	B-Disease
and	I-Disease
flalopian	I-Disease
tbue	I-Disease
cnacers	I-Disease
and	O
primray	O
cacrinoma	B-Disease
of	I-Disease
the	I-Disease
periotneum	I-Disease
.	O

BAKCGROUND	O
:	O
Several	O
stuides	O
have	O
demonstrated	O
lipoosmal	O
dooxrubicin	O
(	O
Dxoil	O
)	O
to	O
be	O
an	O
atcive	O
antineoplatsic	O
aegnt	O
in	O
paltinum	O
-	O
resisatnt	O
ovarain	B-Disease
canecr	I-Disease
,	O
with	O
dsoe	O
limiting	O
toxiicty	B-Disease
of	O
the	O
standrad	O
dsoing	O
regiemn	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
wekes	O
)	O
being	O
sveere	O
erythrodyssethesia	B-Disease
(	O
"	O
hand	B-Disease
-	I-Disease
foot	I-Disease
snydrome	I-Disease
"	O
)	O
and	O
stomattiis	B-Disease
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
tolreable	O
lpiosomal	O
doxorbuicin	O
teratment	O
regmien	O
and	O
dcoument	O
its	O
leevl	O
of	O
actiivty	O
in	O
a	O
well	O
-	O
defined	O
paitent	O
populatoin	O
with	O
platiunm	O
/	O
paciltaxel	O
-	O
refracotry	O
dsiease	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Paitents	O
with	O
ovraian	B-Disease
or	I-Disease
fallpoian	I-Disease
tbue	I-Disease
cancres	I-Disease
or	O
primray	O
preitoneal	B-Disease
carcnioma	I-Disease
with	O
plaitnum	O
/	O
paciltaxel	O
-	O
refrcatory	O
dsiease	O
(	O
stalbe	O
or	O
progressvie	O
dsiease	O
following	O
teratment	O
with	O
these	O
aegnts	O
or	O
previous	O
objectvie	O
resposne	O
<	O
3	O
motnhs	O
in	O
duartion	O
)	O
were	O
traeted	O
with	O
lipsoomal	O
dxoorubicin	O
at	O
a	O
dsoe	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
wekes	O
.	O

RSEULTS	O
:	O
A	O
total	O
of	O
49	O
paitents	O
(	O
medain	O
age	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
pahse	O
2	O
tiral	O
.	O

The	O
mdeian	O
number	O
of	O
prior	O
reigmens	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
pateints	O
experienced	O
grdae	O
2	O
hand	B-Disease
-	I-Disease
foot	I-Disease
synrdome	I-Disease
and	O
stomatiits	B-Disease
,	O
respectively	O
(	O
no	O
eipsodes	O
of	O
garde	O
3	O
)	O
.	O

One	O
paitent	O
developed	O
garde	O
3	O
dairrhea	B-Disease
requiring	O
hsopitalization	O
for	O
hydrtaion	O
.	O

Six	O
(	O
12	O
%	O
)	O
individauls	O
required	O
dsoe	O
reductinos	O
.	O

The	O
mdeian	O
number	O
of	O
cuorses	O
of	O
lipsoomal	O
dooxrubicin	O
administreed	O
on	O
this	O
prtoocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
ptaients	O
(	O
9	O
%	O
)	O
eavluable	O
for	O
resposne	O
exhibited	O
objecitve	O
and	O
subjcetive	O
evidecne	O
of	O
an	O
antineopalstic	O
efefct	O
of	O
therpay	O
.	O

CNOCLUSION	O
:	O
This	O
moidfied	O
lipoosmal	O
doxorbuicin	O
regiemn	O
resutls	O
in	O
less	O
toxiicty	B-Disease
(	O
stomtaitis	B-Disease
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrmoe	I-Disease
)	O
than	O
the	O
stadnard	O
FDA	O
-	O
aprpoved	O
dsoe	O
scehdule	O
.	O

Deifnite	O
,	O
although	O
liimted	O
,	O
antinepolastic	O
actviity	O
is	O
observed	O
in	O
pateints	O
with	O
well	O
-	O
defined	O
plaitnum	O
-	O
and	O
paclitaexl	O
-	O
refrcatory	O
ovairan	B-Disease
cacner	I-Disease
.	O

Efficcay	O
of	O
olanzaipne	O
in	O
actue	O
biploar	B-Disease
mnaia	I-Disease
:	O
a	O
double	O
-	O
blnid	O
,	O
plaecbo	O
-	O
cnotrolled	O
stduy	O
.	O

The	O
Oalnzipine	O
HGGW	O
Stduy	O
Gruop	O
.	O

BAKCGROUND	O
:	O
We	O
compraed	O
the	O
effciacy	O
and	O
saefty	O
of	O
olnazapine	O
vs	O
plaecbo	O
for	O
the	O
tretament	O
of	O
aucte	O
bioplar	B-Disease
mnaia	I-Disease
.	O

METHODS	O
:	O
Four	O
-	O
week	O
,	O
randoimzed	O
,	O
double	O
-	O
bilnd	O
,	O
parallel	O
stduy	O
.	O

A	O
total	O
of	O
115	O
pateints	O
with	O
a	O
DSM	O
-	O
IV	O
diganosis	O
of	O
bipoalr	B-Disease
disoredr	I-Disease
,	O
mainc	B-Disease
or	O
mixed	O
,	O
were	O
randoimzed	O
to	O
olanzaipne	O
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
plcaebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
pirmary	O
effiaccy	O
maesure	O
was	O
the	O
Yonug	O
-	O
Maina	B-Disease
Rtaing	O
Sacle	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
socre	O
.	O

Resopnse	O
and	O
euthyima	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
imporvement	O
from	O
baseilne	O
to	O
end	O
point	O
and	O
as	O
a	O
socre	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
socre	O
,	O
respectively	O
.	O

Sfaety	O
was	O
asssesed	O
using	O
adevrse	O
evetns	O
,	O
Extrapyramdial	B-Disease
Sypmtom	I-Disease
(	O
EPS	B-Disease
)	O
raitng	O
scaels	O
,	O
laboratroy	O
vlaues	O
,	O
elecrtocardiograms	O
,	O
vital	O
sgins	O
,	O
and	O
wegiht	O
change	O
.	O

RSEULTS	O
:	O
Olanzapnie	O
-	O
treaetd	O
pateints	O
demonstrated	O
a	O
statisitcally	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
improevment	O
in	O
Y	O
-	O
MRS	O
total	O
socre	O
than	O
plcaebo	O
-	O
treaetd	O
patietns	O
(	O
-	O
14	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+	O
/	O
-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbsaeline	O
observaiton	O
1	O
week	O
after	O
randoimzation	O
and	O
was	O
maintained	O
throughout	O
the	O
sutdy	O
(	O
last	O
obesrvation	O
carried	O
forward	O
)	O
.	O

Olanzaipne	O
-	O
traeted	O
ptaients	O
demonstrated	O
a	O
hgiher	O
rtae	O
of	O
resopnse	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
euthyima	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
plcaebo	O
-	O
tretaed	O
pateints	O
.	O

There	O
were	O
no	O
statistiaclly	O
significant	O
differneces	O
in	O
ESPs	B-Disease
between	O
gorups	O
.	O

However	O
,	O
olanazpine	O
-	O
treaetd	O
paitents	O
had	O
a	O
sattistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
weihgt	B-Disease
gain	I-Disease
than	O
palcebo	O
-	O
traeted	O
patinets	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatmnet	O
-	O
emeregnt	O
somnoelnce	B-Disease
(	O
21	O
patinets	O
[	O
38	O
.	O
2	O
%	O
]	O
vs	O
5	O
[	O
8	O
.	O
3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CONCULSION	O
:	O
Olaznapine	O
demonstrated	O
greater	O
effiaccy	O
than	O
plcaebo	O
in	O
the	O
tretament	O
of	O
aucte	O
bipoalr	B-Disease
maina	I-Disease
and	O
was	O
generally	O
well	O
tloerated	O
.	O

The	O
effect	O
of	O
puipl	B-Disease
dilaiton	I-Disease
with	O
torpicamide	O
on	O
visoin	O
and	O
driving	O
simultaor	O
perforamnce	O
.	O

PUROPSE	O
:	O
To	O
assess	O
the	O
effect	O
of	O
puipl	B-Disease
diltaion	I-Disease
on	O
viison	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tsets	O
on	O
various	O
parametres	O
of	O
viusal	O
functoin	O
and	O
driving	O
simultaor	O
performnace	O
were	O
performed	O
on	O
12	O
healhty	O
drviers	O
,	O
before	O
and	O
after	O
puipl	B-Disease
dilaiton	I-Disease
using	O
gtutae	O
tropiacmide	O
1	O
%	O
.	O

A	O
driving	O
simulaotr	O
(	O
Transprot	O
Reesarch	O
Labortaory	O
)	O
was	O
used	O
to	O
meausre	O
raection	O
tmie	O
(	O
RT	O
)	O
,	O
speed	O
mainetnance	O
and	O
setering	O
accurcay	O
.	O

Tetss	O
of	O
basic	O
vsiual	O
funtcion	O
included	O
high	O
-	O
and	O
low	O
-	O
contrast	O
visaul	O
acutiy	O
(	O
HVCA	O
and	O
LVCA	O
)	O
,	O
Pleli	O
-	O
Robosn	O
contrast	O
threhsold	O
(	O
CT	O
)	O
and	O
Godlmann	O
perimerty	O
(	O
FILEDS	O
)	O
.	O

Useful	O
Filed	O
of	O
Veiw	O
(	O
UOFV	O
-	O
-	O
a	O
tset	O
of	O
visaul	O
atteniton	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
diffeernces	O
in	O
the	O
pre	O
-	O
and	O
psot	O
-	O
dilataiton	O
measruements	O
were	O
tesetd	O
for	O
statistiacl	O
signfiicance	O
at	O
the	O
95	O
%	O
leevl	O
using	O
one	O
-	O
tial	O
paired	O
t	O
-	O
tsets	O
.	O

RSEULTS	O
:	O
Puipllary	B-Disease
dilatoin	I-Disease
resulted	O
in	O
a	O
statistcially	O
significant	O
deterioratoin	O
in	O
CT	O
and	O
HVCA	O
only	O
.	O

Five	O
of	O
12	O
drviers	O
also	O
exhibited	O
deteriroation	O
in	O
LVCA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
eviednce	O
emerged	O
for	O
deteriroation	O
in	O
FILEDS	O
and	O
UOFV	O
.	O

Also	O
,	O
7	O
of	O
12	O
drievrs	O
appeared	O
to	O
adjust	O
their	O
driving	O
bheaviour	O
by	O
reducnig	O
their	O
seped	O
on	O
the	O
driving	O
simualtor	O
,	O
leading	O
to	O
improevd	O
steernig	O
accurcay	O
.	O

CONCULSIONS	O
:	O
Ppuillary	B-Disease
dilaiton	I-Disease
may	O
lead	O
to	O
a	O
dcerease	O
in	O
vsiion	O
and	O
dayilght	O
driving	O
preformance	O
in	O
yonug	O
peolpe	O
.	O

A	O
larger	O
sutdy	O
,	O
including	O
a	O
broader	O
spetcrum	O
of	O
sujbects	O
,	O
is	O
warranted	O
before	O
guiedlines	O
can	O
be	O
rceommended	O
.	O

A	O
csae	O
of	O
isotretinion	B-Disease
ebmryopathy	I-Disease
with	O
bliateral	O
aontia	B-Disease
and	O
Tasusig	B-Disease
-	I-Disease
Bnig	I-Disease
malfomration	I-Disease
.	O

We	O
reoprt	O
a	O
nebworn	O
inafnt	O
with	O
mulitple	O
conegnital	O
aonmalies	O
(	O
anoita	B-Disease
and	O
Tausisg	B-Disease
-	I-Disease
Bnig	I-Disease
malforamtion	I-Disease
)	O
due	O
to	O
exposrue	O
to	O
istoretinoin	O
within	O
the	O
first	O
trimseter	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribnig	O
vtiamin	O
A	O
-	O
containing	O
durgs	O
to	O
wmoen	O
of	O
chidlbearing	O
yaers	O
.	O

Efefct	O
of	O
methoaxmine	O
on	O
maixmum	O
urehtral	O
pressrue	O
in	O
woemn	O
with	O
genuine	O
strses	B-Disease
incontnience	I-Disease
:	O
a	O
plcaebo	O
-	O
cotnrolled	O
,	O
double	O
-	O
bilnd	O
crososver	O
stduy	O
.	O

The	O
aim	O
of	O
the	O
stduy	O
was	O
to	O
evaulate	O
the	O
potetnial	O
role	O
for	O
a	O
selective	O
alhpa1	O
-	O
ardenoceptor	O
agonsit	O
in	O
the	O
treatmnet	O
of	O
urianry	B-Disease
srtess	I-Disease
incnotinence	I-Disease
.	O

A	O
radnomised	O
,	O
double	O
-	O
bilnd	O
,	O
plaecbo	O
-	O
conrtolled	O
,	O
crossover	O
sutdy	O
deisgn	O
was	O
employed	O
.	O

Half	O
log	O
incrmeental	O
doess	O
of	O
intraveonus	O
mtehoxamine	O
or	O
plaecbo	O
(	O
sailne	O
)	O
were	O
administreed	O
to	O
a	O
gorup	O
of	O
wmoen	O
with	O
genuine	O
strses	B-Disease
incontnience	I-Disease
while	O
measuirng	O
maxmium	O
uerthral	O
pressrue	O
(	O
MUP	O
)	O
,	O
blood	O
pressrue	O
,	O
herat	O
rtae	O
,	O
and	O
symptoamtic	O
side	O
effcets	O
.	O

Methxoamine	O
evoekd	O
non	O
-	O
significant	O
incraeses	O
in	O
MUP	O
and	O
daistolic	O
blood	O
prsesure	O
but	O
caused	O
a	B-Disease
significant	I-Disease
rise	I-Disease
in	I-Disease
ssytolic	I-Disease
bolod	I-Disease
pressrue	I-Disease
and	O
significant	O
fall	O
in	O
haert	O
rtae	O
at	O
maxmium	O
dosgae	O
.	O

Systeimc	O
side	O
effetcs	O
including	O
piloercetion	O
,	O
hedaache	B-Disease
,	O
and	O
clod	O
etxremities	O
were	O
experienced	O
in	O
all	O
subejcts	O
.	O

The	O
rseults	O
indicate	O
that	O
the	O
cliniacl	O
usefulenss	O
of	O
direct	O
,	O
preipherally	O
acting	O
sub	O
-	O
tpye	O
-	O
selective	O
aplha1	O
-	O
adrenoecptor	O
agonitss	O
in	O
the	O
mdeical	O
treatemnt	O
of	O
sterss	B-Disease
incontiennce	I-Disease
may	O
be	O
limietd	O
by	O
associated	O
piloeerction	O
and	O
cardiovsacular	O
side	O
effetcs	O
.	O

Hyeprglycemic	B-Disease
effcet	O
of	O
aimno	O
componuds	O
structurally	O
related	O
to	O
caporate	O
in	O
rtas	O
.	O

The	O
chornic	O
fedeing	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
deit	O
wieght	O
)	O
of	O
certain	O
aimno	O
derivaitves	O
of	O
carpoate	O
resulted	O
in	O
hypegrlycemia	B-Disease
,	O
an	O
eelvated	O
gulcose	O
toleracne	O
cruve	O
and	O
,	O
occasionally	O
,	O
gluocsuria	B-Disease
.	O

Effetcive	O
componuds	O
included	O
norelucine	O
,	O
norvailne	O
,	O
glutamtae	O
,	O
epsioln	O
-	O
aminocaproate	O
,	O
methioinne	O
,	O
and	O
luecine	O
.	O

Toleraiton	O
of	O
high	O
doess	O
of	O
angoitensin	O
-	O
converting	O
enyzme	O
inhibitros	O
in	O
patietns	O
with	O
chroinc	O
herat	B-Disease
fialure	I-Disease
:	O
reuslts	O
from	O
the	O
ATALS	O
tiral	O
.	O

The	O
Assessment	O
of	O
Treatmnet	O
with	O
Lsiinopril	O
and	O
Survvial	O
.	O

BACKGRONUD	O
:	O
Treatmnet	O
with	O
angiotenisn	O
-	O
converting	O
enyzme	O
(	O
ACE	O
)	O
ihnibitors	O
redcues	O
mrotality	O
and	O
morbdiity	O
in	O
patietns	O
with	O
crhonic	O
haert	B-Disease
faliure	I-Disease
(	O
CHF	B-Disease
)	O
,	O
but	O
most	O
affected	O
pateints	O
are	O
not	O
receiving	O
these	O
agnets	O
or	O
are	O
being	O
terated	O
with	O
doess	O
loewr	O
than	O
those	O
found	O
to	O
be	O
efficaciuos	O
in	O
tirals	O
,	O
primarily	O
because	O
of	O
concrens	O
about	O
the	O
saefty	O
and	O
tolerabiilty	O
of	O
these	O
agetns	O
,	O
especially	O
at	O
the	O
rceommended	O
doess	O
.	O

The	O
present	O
sutdy	O
examines	O
the	O
sfaety	O
and	O
tolerabliity	O
of	O
high	O
-	O
compraed	O
with	O
low	O
-	O
dsoe	O
lisniopril	O
in	O
CHF	B-Disease
.	O

METHODS	O
:	O
The	O
Assessment	O
of	O
Lisinopirl	O
and	O
Surviavl	O
sutdy	O
was	O
a	O
multicenetr	O
,	O
randmoized	O
,	O
double	O
-	O
bilnd	O
tiral	O
in	O
which	O
patinets	O
with	O
or	O
without	O
previous	O
ACE	O
inhibtior	O
treamtent	O
were	O
stabiilzed	O
receiving	O
meidum	O
-	O
dsoe	O
liisnopril	O
(	O
12	O
.	O
5	O
or	O
15	O
.	O
0	O
mg	O
once	O
dialy	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomiezd	O
to	O
high	O
-	O
(	O
35	O
.	O
0	O
or	O
32	O
.	O
5	O
mg	O
OD	O
)	O
or	O
low	O
-	O
dsoe	O
(	O
5	O
.	O
0	O
or	O
2	O
.	O
5	O
mg	O
OD	O
)	O
gropus	O
.	O

Pateints	O
with	O
New	O
Yrok	O
Herat	O
Associtaion	O
clasess	O
II	O
to	O
IV	O
CHF	B-Disease
and	O
lfet	O
ventricluar	O
eejction	O
fracitons	O
of	O
no	O
greater	O
than	O
0	O
.	O
30	O
(	O
n	O
=	O
3164	O
)	O
were	O
radnomized	O
and	O
followed	O
up	O
for	O
a	O
mdeian	O
of	O
46	O
motnhs	O
.	O

We	O
examined	O
the	O
ocucrrence	O
of	O
adevrse	O
evetns	O
and	O
the	O
need	O
for	O
discontinutaion	O
and	O
dsoe	O
reudction	O
during	O
tretament	O
,	O
with	O
a	O
focus	O
on	O
hpyotension	B-Disease
and	O
rneal	B-Disease
dysfnuction	I-Disease
.	O

RESLUTS	O
:	O
Of	O
405	O
patietns	O
not	O
previously	O
receiving	O
an	O
ACE	O
inhibtior	O
,	O
dsoes	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
titrtaed	O
to	O
the	O
meidum	O
doess	O
required	O
for	O
radnomization	O
because	O
of	O
smyptoms	O
possibly	O
related	O
to	O
hypotnesion	B-Disease
(	O
2	O
.	O
0	O
%	O
)	O
or	O
because	O
of	O
reanl	B-Disease
dysfnuction	I-Disease
or	O
hyperkalmeia	B-Disease
(	O
2	O
.	O
3	O
%	O
)	O
.	O

Doess	O
in	O
more	O
than	O
90	O
%	O
of	O
randomiezd	O
paitents	O
in	O
the	O
high	O
-	O
and	O
low	O
-	O
dsoe	O
gropus	O
were	O
titraetd	O
to	O
their	O
assigned	O
taregt	O
,	O
and	O
the	O
mean	O
doess	O
of	O
blidned	O
meidcation	O
in	O
both	O
gorups	O
remained	O
similar	O
throughout	O
the	O
sutdy	O
.	O

Withdrwaals	O
occurred	O
in	O
27	O
.	O
1	O
%	O
of	O
the	O
high	O
-	O
and	O
30	O
.	O
7	O
%	O
of	O
the	O
low	O
-	O
dsoe	O
gropus	O
.	O

Subgorups	O
presumed	O
to	O
be	O
at	O
higehr	O
rsik	O
for	O
ACE	O
ihnibitor	O
itnolerance	O
(	O
bolod	O
pressrue	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatinnie	O
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
yeras	O
;	O
and	O
patietns	O
with	O
dibaetes	B-Disease
)	O
generally	O
tolearted	O
the	O
high	O
-	O
dsoe	O
strategy	O
.	O

CONCLSUIONS	O
:	O
These	O
fnidings	O
demonstrate	O
that	O
ACE	O
inhiibtor	O
threapy	O
in	O
most	O
pateints	O
with	O
CHF	B-Disease
can	O
be	O
successfully	O
tirtated	O
to	O
and	O
maintained	O
at	O
high	O
dsoes	O
,	O
and	O
that	O
more	O
aggresisve	O
use	O
of	O
these	O
agetns	O
is	O
warranted	O
.	O

Cocanie	O
,	O
etahnol	O
,	O
and	O
cocatehylene	O
cardoitoxity	B-Disease
in	O
an	O
ainmal	O
moedl	O
of	O
cocanie	B-Disease
and	I-Disease
ethnaol	I-Disease
absue	I-Disease
.	O

OBJCETIVES	O
:	O
Simulatneous	O
absue	B-Disease
of	I-Disease
cociane	I-Disease
and	I-Disease
ehtanol	I-Disease
affects	O
12	O
million	O
Americnas	O
annually	O
.	O

In	O
combniation	O
,	O
these	O
subtsances	O
are	O
substantially	O
more	O
toixc	O
than	O
either	O
durg	O
alone	O
.	O

Their	O
cmobined	O
cardaic	B-Disease
toxciity	I-Disease
may	O
be	O
due	O
to	O
indepnedent	O
efefcts	O
of	O
each	O
durg	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
coacethylene	O
(	O
CE	O
)	O
,	O
a	O
cocanie	O
metabloite	O
formed	O
only	O
in	O
the	O
preesnce	O
of	O
ehtanol	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	O
in	O
the	O
cobmined	O
cardiotoixcity	B-Disease
of	O
cociane	O
and	O
ethaonl	O
in	O
a	O
mdoel	O
simulating	O
their	O
absue	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
dgos	O
were	O
randomiezd	O
to	O
receive	O
either	O
1	O
)	O
three	O
intraveonus	O
(	O
IV	O
)	O
blouses	O
of	O
coacine	O
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
ethnaol	O
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusoin	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
coacine	O
blouses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ehtanol	O
inufsion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
palcebo	O
blouses	O
and	O
infsuion	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemodyanmic	O
measuerments	O
,	O
electrocardiogarms	O
,	O
and	O
sreum	O
durg	O
concnetrations	O
were	O
obtained	O
at	O
bsaeline	O
,	O
and	O
then	O
at	O
fxied	O
tmie	O
intervlas	O
after	O
each	O
durg	O
was	O
adminsitered	O
.	O

REUSLTS	O
:	O
Two	O
of	O
eight	O
dgos	O
in	O
the	O
C	O
+	O
E	O
gruop	O
experienced	O
cardiovsacular	B-Disease
collaspe	I-Disease
.	O

The	O
most	O
dramaitc	O
hemodynaimc	O
chagnes	O
occurred	O
after	O
each	O
cociane	O
blous	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
gropus	O
;	O
however	O
,	O
persistnet	O
hemodynmaic	O
chnages	O
occurred	O
in	O
the	O
C	O
+	O
E	O
gorup	O
.	O

Paek	O
CE	O
lveels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/	O
-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
dcerease	B-Disease
in	I-Disease
cradiac	I-Disease
ouptut	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/	O
-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
dcerease	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.	O
006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/	O
-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decerase	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Vnetricular	B-Disease
arrhtyhmias	I-Disease
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
gruop	O
,	O
in	O
which	O
four	O
of	O
eight	O
dgos	O
experienced	O
vnetricular	B-Disease
tahcycardia	I-Disease
.	O

CONCLUSINOS	O
:	O
Cociane	O
and	O
ethnaol	O
in	O
combniation	O
were	O
more	O
txoic	O
than	O
either	O
susbtance	O
alone	O
.	O

Co	O
-	O
amdinistration	O
resulted	O
in	O
proolnged	O
cardaic	B-Disease
toxiicty	I-Disease
and	O
was	O
dysrhytmhogenic	O
.	O

Paek	O
sreum	O
coacethylene	O
concentraitons	O
were	O
associated	O
with	O
prologned	O
myocadrial	B-Disease
depression	I-Disease
.	O

Worsennig	O
of	O
Parkinsnoism	B-Disease
after	O
the	O
use	O
of	O
veraliprdie	O
for	O
treamtent	O
of	O
menpoause	O
:	O
csae	O
reprot	O
.	O

We	O
describe	O
a	O
feamle	O
ptaient	O
with	O
satble	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
who	O
has	O
shown	O
a	O
marked	O
worseinng	O
of	O
her	O
mootr	O
fucntions	O
following	O
tehrapy	O
of	O
menoapuse	O
related	O
symtpoms	O
with	O
veralipirde	O
,	O
as	O
well	O
as	O
the	O
ipmrovement	O
of	O
her	O
symtpoms	O
back	O
to	O
basleine	O
after	O
discontinuaiton	O
of	O
the	O
durg	O
.	O

We	O
emphasize	O
the	O
atni	O
-	O
dopamienrgic	O
effect	O
of	O
verailpride	O
.	O

Viracpet	O
and	O
irregular	B-Disease
heratbeat	I-Disease
warinng	O
.	O

A	O
gorup	O
of	O
docotrs	O
in	O
Botson	O
warn	O
that	O
the	O
prtoease	O
inhibiotr	O
Vircaept	O
may	O
cause	O
an	O
irregular	B-Disease
haert	I-Disease
baet	I-Disease
,	O
known	O
as	O
bradyacrdia	B-Disease
,	O
in	O
peolpe	O
with	O
HIV	O
.	O

Bradcyardia	B-Disease
occurred	O
in	O
a	O
45	O
-	O
yaer	O
-	O
old	O
mlae	O
paitent	O
who	O
was	O
Vircaept	O
in	O
combinaiton	O
with	O
other	O
atni	O
-	O
HIV	O
drgus	O
.	O

The	O
sypmtoms	O
ceaesd	O
after	O
switching	O
to	O
another	O
durg	O
combinaiton	O
.	O

Frequnecy	O
of	O
appearance	O
of	O
myeloperoxiadse	O
-	O
antienutrophil	O
ctyoplasmic	O
atnibody	O
(	O
MPO	O
-	O
ACNA	O
)	O
in	O
Garves	B-Disease
'	I-Disease
disaese	I-Disease
paitents	O
traeted	O
with	O
propytlhiouracil	O
and	O
the	O
relatoinship	O
between	O
MPO	O
-	O
ACNA	O
and	O
cilnical	O
manifesattions	O
.	O

OBJETCIVE	O
:	O
Myeloperoxdiase	O
antineutrohpil	O
cytoplamsic	O
anitbody	O
(	O
MPO	O
-	O
ACNA	O
)	O
-	O
positvie	O
vasculiits	B-Disease
has	O
been	O
reported	O
in	O
paitents	O
with	O
Garves	B-Disease
'	I-Disease
disaese	I-Disease
who	O
were	O
terated	O
with	O
propyltihouracil	O
(	O
PTU	O
)	O
.	O

The	O
appeaarnce	O
of	O
MPO	O
-	O
ACNA	O
in	O
these	O
csaes	O
was	O
supsected	O
of	O
being	O
related	O
to	O
PTU	O
because	O
the	O
tirtes	O
of	O
MPO	O
-	O
ACNA	O
decerased	O
when	O
PTU	O
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
stuides	O
on	O
the	O
tepmoral	O
relaitonship	O
between	O
the	O
appearance	O
of	O
MPO	O
-	O
ACNA	O
and	O
vascultiis	B-Disease
during	O
PTU	O
therpay	O
,	O
or	O
on	O
the	O
incidnece	O
of	O
MPO	O
-	O
ACNA	O
in	O
untraeted	O
Grvaes	B-Disease
'	I-Disease
diesase	I-Disease
patinets	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
paraemters	O
in	O
pateints	O
with	O
Grvaes	B-Disease
'	I-Disease
dsiease	I-Disease
.	O

PATIENTS	O
:	O
We	O
ivnestigated	O
102	O
unrteated	O
ptaients	O
with	O
hypertyhroidism	B-Disease
due	O
to	O
Garves	B-Disease
'	I-Disease
disaese	I-Disease
for	O
the	O
prseence	O
of	O
MPO	O
-	O
ACNA	O
,	O
and	O
for	O
the	O
developemnt	O
vasuclitis	B-Disease
after	O
starting	O
PTU	O
thearpy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
avderse	O
effcets	O
of	O
PTU	O
or	O
because	O
the	O
observaiton	O
preiod	O
was	O
less	O
than	O
3	O
monhts	O
.	O

The	O
remaining	O
73	O
paitents	O
(	O
55	O
woemn	O
and	O
18	O
men	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
motnhs	O
,	O
were	O
adopted	O
as	O
the	O
subejcts	O
of	O
the	O
inevstigation	O
.	O

The	O
medain	O
observaiton	O
preiod	O
was	O
23	O
.	O
6	O
motnhs	O
(	O
range	O
:	O
3	O
-	O
37	O
motnhs	O
)	O
.	O

MEASRUEMENTS	O
:	O
MPO	O
-	O
ACNA	O
was	O
measrued	O
at	O
intevrals	O
of	O
2	O
-	O
6	O
mnoths	O
.	O

RESLUTS	O
:	O
Before	O
traetment	O
,	O
the	O
MPO	O
-	O
ACNA	O
ttires	O
of	O
all	O
102	O
unterated	O
Garves	B-Disease
'	I-Disease
dsiease	I-Disease
paitents	O
were	O
within	O
the	O
refernece	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
73	O
patietns	O
were	O
positvie	O
for	O
MPO	O
-	O
ACNA	O
at	O
13	O
,	O
16	O
and	O
17	O
monhts	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	O
threapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ACNA	O
ttires	O
transeintly	O
incraesed	O
to	O
12	O
.	O
8	O
and	O
15	O
.	O
0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	O
threapy	O
,	O
but	O
no	O
vsaculitic	B-Disease
dsiorders	I-Disease
developed	O
.	O

In	O
the	O
third	O
ptaient	O
,	O
the	O
MPO	O
-	O
ACNA	O
ttire	O
incraesed	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
hgiher	O
fveer	B-Disease
,	O
oarl	B-Disease
uclers	I-Disease
and	O
polyartharlgia	B-Disease
,	O
but	O
the	O
smyptoms	O
resolved	O
2	O
wekes	O
after	O
stopping	O
PTU	O
tehrapy	O
,	O
and	O
the	O
MPO	O
-	O
ACNA	O
tirte	O
decraesed	O
to	O
20	O
.	O
7	O
U	O
/	O
ml	O
by	O
4	O
mnoths	O
after	O
discontinunig	O
PTU	O
.	O

CNOCLUSIONS	O
:	O
PTU	O
threapy	O
may	O
be	O
related	O
to	O
the	O
appaerance	O
of	O
MPO	O
-	O
ACNA	O
,	O
but	O
MPO	O
-	O
ACNA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vascultiis	B-Disease
.	O

Pervalence	O
of	O
herat	B-Disease
diesase	I-Disease
in	O
asymtpomatic	O
crhonic	O
ccoaine	O
uesrs	O
.	O

To	O
determine	O
the	O
pervalence	O
of	O
herat	B-Disease
disaese	I-Disease
in	O
outaptient	O
yuong	O
asmyptomatic	O
chrnoic	O
coacine	O
usres	O
,	O
35	O
cocanie	O
usres	O
and	O
32	O
age	O
-	O
matched	O
cnotrols	O
underwent	O
resitng	O
and	O
exericse	O
electrocardiogrpahy	O
(	O
ECG	O
)	O
and	O
Doppler	O
echocardiograhpy	O
.	O

Fnidings	O
consistent	O
with	O
coronray	B-Disease
atrery	I-Disease
disesae	I-Disease
were	O
deetcted	O
in	O
12	O
(	O
34	O
%	O
)	O
pateints	O
and	O
3	O
(	O
9	O
%	O
)	O
contrlos	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Derceased	O
lfet	O
vetnricular	O
systloic	O
fucntion	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patietns	O
,	O
but	O
in	O
none	O
of	O
the	O
cotnrols	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

Finally	O
,	O
restnig	O
and	O
peak	O
exrecise	O
abnoraml	B-Disease
lfet	I-Disease
ventricualr	I-Disease
filling	I-Disease
was	O
deetcted	O
in	O
38	O
and	O
35	O
%	O
of	O
ptaients	O
as	O
compraed	O
to	O
19	O
and	O
9	O
%	O
of	O
contorls	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coroanry	B-Disease
atrery	I-Disease
or	I-Disease
mycoardial	I-Disease
dsiease	I-Disease
is	O
common	O
(	O
38	O
%	O
)	O
in	O
yuong	O
asypmtomatic	O
chrnoic	O
cocanie	O
uesrs	O
.	O

Therefore	O
,	O
srceening	O
ECG	O
and	O
echocardigoraphy	O
may	O
be	O
warranted	O
in	O
these	O
ptaients	O
.	O

Cardiporotective	O
efefcts	O
of	O
Picrorrhzia	O
kruroa	O
against	O
isoprotreenol	O
-	O
inudced	O
moycardial	O
srtess	O
in	O
rtas	O
.	O

The	O
cardiporotective	O
effect	O
of	O
the	O
ehtanol	O
extarct	O
of	O
Picrorrhzia	O
kurora	O
rhizmoes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproetrenol	O
-	O
indcued	O
myocradial	B-Disease
inafrction	I-Disease
in	O
rtas	O
with	O
respect	O
to	O
lpiid	O
metaoblism	O
in	O
seurm	O
and	O
herat	O
tsisue	O
has	O
been	O
invsetigated	O
.	O

Oarl	O
pre	O
-	O
treamtent	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
for	O
15	O
dyas	O
)	O
significantly	O
prevented	O
the	O
isoporterenol	O
-	O
inudced	O
moycardial	B-Disease
infacrtion	I-Disease
and	O
maintained	O
the	O
rtas	O
at	O
near	O
nomral	O
sattus	O
.	O

Phsae	O
2	O
eraly	O
aftedrepolarization	O
as	O
a	O
tirgger	O
of	O
polymrophic	O
ventricluar	B-Disease
tachyacrdia	I-Disease
in	O
acquired	O
long	B-Disease
-	I-Disease
QT	I-Disease
synrdome	I-Disease
:	O
direct	O
eivdence	O
from	O
inrtacellular	O
rceordings	O
in	O
the	O
itnact	O
lfet	O
ventricluar	O
wlal	O
.	O

BACKGORUND	O
:	O
This	O
stduy	O
examined	O
the	O
role	O
of	O
phsae	O
2	O
ealry	O
atferdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trgiger	O
to	O
initiate	O
torsdae	B-Disease
de	I-Disease
ponites	I-Disease
(	O
TdP	B-Disease
)	O
with	O
QT	B-Disease
proolngation	I-Disease
inudced	O
by	O
dl	O
-	O
sotlaol	O
and	O
azimildie	O
.	O

The	O
contribution	O
of	O
trasnmural	O
dipsersion	O
of	O
repolariaztion	O
(	O
TDR	O
)	O
to	O
transumral	O
propgaation	O
of	O
EAD	O
and	O
the	O
mainteannce	O
of	O
TdP	B-Disease
was	O
also	O
evalutaed	O
.	O

METHODS	O
AND	O
RESUTLS	O
:	O
Transmembarne	O
aciton	O
potetnials	O
from	O
epciardium	O
,	O
midmyoacrdium	O
,	O
and	O
endoacrdium	O
were	O
recorded	O
simutlaneously	O
,	O
together	O
with	O
a	O
trnasmural	O
ECG	O
,	O
in	O
atrerially	O
perfuesd	O
cnaine	O
and	O
rabibt	O
lfet	O
vnetricular	O
prpearations	O
.	O

dl	O
-	O
Sotlaol	O
preferentially	O
prloonged	O
atcion	O
potnetial	O
druation	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dsoe	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	B-Disease
prolnogation	I-Disease
and	O
an	O
incresae	O
in	O
TDR	O
.	O

Azimiilde	O
,	O
however	O
,	O
significantly	O
proolnged	O
APD	O
and	O
QT	O
inetrval	O
at	O
concenrtations	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shotrened	O
them	O
at	O
30	O
micromol	O
/	O
L	O
.	O

Unlike	O
dl	O
-	O
soatlol	O
,	O
azimliide	O
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
icnreased	O
epicaridal	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
sotlaol	O
and	O
azimiilde	O
rarely	O
inudced	O
EDAs	O
in	O
cainne	O
lfet	O
ventrilces	O
,	O
they	O
produced	O
frqeuent	O
EDAs	O
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B-Disease
prloongation	I-Disease
was	O
seen	O
.	O

An	O
incerase	O
in	O
TDR	O
by	O
dl	O
-	O
soatlol	O
facilitated	O
tranmsural	O
propaagtion	O
of	O
EDAs	O
that	O
initiated	O
mlutiple	O
epiosdes	O
of	O
sponatneous	O
TdP	B-Disease
in	O
3	O
of	O
6	O
rabbit	O
lfet	O
ventrciles	O
.	O

Of	O
note	O
,	O
although	O
azimildie	O
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
incresaed	O
APD	O
more	O
than	O
dl	O
-	O
sotlaol	O
,	O
its	O
EDAs	O
often	O
failed	O
to	O
propaagte	O
transmuarlly	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

CONCLSUIONS	O
:	O
This	O
sutdy	O
provides	O
the	O
first	O
direct	O
eivdence	O
from	O
intracellular	O
aciton	O
potentail	O
recordnigs	O
that	O
phsae	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intcat	O
vnetricular	O
wlal	O
and	O
produce	O
a	O
trigegr	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	B-Disease
under	O
QT	B-Disease
porlongation	I-Disease
.	O

A	O
pliot	O
stduy	O
to	O
assess	O
the	O
sfaety	O
of	O
dobtuamine	O
strses	O
echcoardiography	O
in	O
the	O
emergnecy	O
deparmtent	O
evalaution	O
of	O
cocanie	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
.	O

SUTDY	O
OBEJCTIVE	O
:	O
Chset	B-Disease
pian	I-Disease
in	O
the	O
setting	O
of	O
coacine	O
use	O
poses	O
a	O
daignostic	O
dilmema	O
.	O

Dobuatmine	O
strses	O
echocardiogrpahy	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
snesitive	O
tset	O
for	O
evlauating	O
cradiac	O
ischeima	B-Disease
.	O

Because	O
of	O
the	O
theoretcial	O
concern	O
regarding	O
admniistration	O
of	O
dobutmaine	O
in	O
the	O
setting	O
of	O
ccoaine	O
use	O
,	O
we	O
conducted	O
a	O
pliot	O
sutdy	O
to	O
assess	O
the	O
saefty	O
of	O
DSE	O
in	O
emergnecy	O
deaprtment	O
ptaients	O
with	O
coacine	O
-	O
associated	O
chset	B-Disease
pian	I-Disease
.	O

METHODS	O
:	O
A	O
prospectvie	O
csae	O
series	O
was	O
conducted	O
in	O
the	O
itnensive	O
diganostic	O
and	O
treatemnt	O
unit	O
in	O
the	O
ED	O
of	O
an	O
ubran	O
teritary	O
-	O
crae	O
teachnig	O
hospiatl	O
.	O

Patinets	O
were	O
eligbile	O
for	O
DSE	O
if	O
they	O
had	O
used	O
coacine	O
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
cehst	B-Disease
pian	I-Disease
and	O
had	O
a	O
nromal	O
ECG	O
and	O
troipnin	O
I	O
leevl	O
.	O

Patinets	O
exhibiting	O
sgins	O
of	O
continuing	O
cociane	O
toxictiy	B-Disease
were	O
excluded	O
from	O
the	O
stduy	O
.	O

All	O
pateints	O
were	O
admitted	O
to	O
the	O
hosiptal	O
for	O
seiral	O
tesitng	O
after	O
the	O
DSE	O
tesitng	O
in	O
the	O
itnensive	O
diagonstic	O
and	O
treatemnt	O
unit	O
.	O

RSEULTS	O
:	O
Twenty	O
-	O
four	O
patietns	O
were	O
enrolled	O
.	O

Two	O
patinets	O
had	O
inadeqaute	O
retsing	O
imgaes	O
,	O
one	O
DSE	O
was	O
termniated	O
because	O
of	O
ifnerior	O
hypokiensis	B-Disease
,	O
another	O
DSE	O
was	O
terminaetd	O
because	O
of	O
a	O
rtae	O
-	O
related	O
atrail	O
condcution	O
defiict	O
,	O
and	O
1	O
pateint	O
did	O
not	O
reach	O
the	O
traget	O
haert	O
rtae	O
.	O

Thus	O
,	O
19	O
patinets	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
taregt	O
herat	O
raets	O
.	O

None	O
of	O
the	O
patietns	O
experienced	O
sings	O
of	O
exaggearted	O
adreenrgic	O
rseponse	O
,	O
which	O
was	O
defined	O
as	O
a	O
systloic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrnece	O
of	O
tachydyshrythmias	B-Disease
(	O
excluding	O
snius	B-Disease
tachyacrdia	I-Disease
)	O
.	O

Further	O
suggesting	O
lcak	O
of	O
exaggertaed	O
adreenrgic	O
resopnse	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
ptaients	O
required	O
supplemental	O
atroipne	O
to	O
reach	O
their	O
tagret	O
haert	O
rtaes	O
.	O

CONCULSION	O
:	O
No	O
exaggreated	O
adreenrgic	O
resposne	O
was	O
deetcted	O
when	O
dboutamine	O
was	O
administreed	O
to	O
patietns	O
with	O
ccoaine	O
-	O
related	O
chset	B-Disease
pian	I-Disease
.	O

Preantal	O
cociane	O
epxosure	O
and	O
carnial	O
sonorgaphic	O
finidngs	O
in	O
pretrem	B-Disease
ifnants	I-Disease
.	O

PURPSOE	O
:	O
Prneatal	O
cocanie	O
epxosure	O
has	O
been	O
linked	O
with	O
subependyaml	O
hemorrhage	B-Disease
and	O
the	O
foramtion	O
of	O
csyts	B-Disease
that	O
are	O
detecatble	O
on	O
cranail	O
snoography	O
in	O
neontaes	O
bron	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prentaal	O
cocanie	O
epxosure	O
increaess	O
the	O
incidecne	O
of	O
sbuependymal	B-Disease
cytss	I-Disease
in	O
prteerm	B-Disease
infnats	I-Disease
.	O

METHODS	O
:	O
We	O
retrospecitvely	O
rveiewed	O
the	O
mdeical	O
recrods	O
and	O
carnial	O
sonogarms	O
obtained	O
during	O
a	O
1	O
-	O
yaer	O
preiod	O
on	O
122	O
prematrue	B-Disease
(	I-Disease
<	I-Disease
36	I-Disease
wekes	I-Disease
of	I-Disease
gesattion	I-Disease
)	I-Disease
infatns	I-Disease
.	O

Inafnts	O
were	O
categoriezd	O
into	O
1	O
of	O
2	O
gropus	O
:	O
those	O
exopsed	O
to	O
ccoaine	O
and	O
those	O
not	O
epxosed	O
to	O
cociane	O
.	O

Infatns	O
were	O
assigned	O
to	O
the	O
ccoaine	O
-	O
expsoed	O
gorup	O
if	O
there	O
was	O
a	O
matrenal	O
histroy	O
of	O
cocanie	B-Disease
absue	I-Disease
during	O
pregnacny	O
or	O
if	O
matrenal	O
or	O
neonaatl	O
urnie	O
toxciology	O
rseults	O
were	O
posiitve	O
at	O
the	O
tmie	O
of	O
delievry	O
.	O

RESLUTS	O
:	O
Five	O
of	O
the	O
122	O
infnats	O
were	O
excluded	O
from	O
the	O
sutdy	O
because	O
of	O
insufficeint	O
mediacl	O
and	O
durg	O
historeis	O
.	O

The	O
icnidence	O
of	O
subepenydmal	B-Disease
cytss	I-Disease
in	O
the	O
117	O
remaining	O
inafnts	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
inicdence	O
of	O
subependyaml	B-Disease
csyts	I-Disease
in	O
infatns	O
expoesd	O
to	O
cociane	O
prenatlaly	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
copmared	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unxeposed	O
gruop	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CNOCLUSIONS	O
:	O
We	O
found	O
an	O
icnreased	O
incdience	O
of	O
subepnedymal	B-Disease
csyt	I-Disease
formtaion	O
in	O
preetrm	B-Disease
infnats	I-Disease
who	O
were	O
expoesd	O
to	O
cociane	O
preantally	O
.	O

This	O
result	O
is	O
consistent	O
with	O
resluts	O
of	O
similar	O
stuides	O
in	O
term	O
ifnants	O
.	O

Thlaidomide	O
neruopathy	B-Disease
in	O
paitents	O
traeted	O
for	O
metsatatic	O
prosatte	B-Disease
canecr	I-Disease
.	O

We	O
prospectively	O
evlauated	O
thalidomdie	O
-	O
inudced	O
neuroptahy	B-Disease
using	O
eletcrodiagnostic	O
sutdies	O
.	O

Sixty	O
-	O
seven	O
men	O
with	O
metasttaic	O
andrgoen	O
-	O
indepenednt	O
prosttae	B-Disease
cnacer	I-Disease
in	O
an	O
open	O
-	O
laebl	O
tiral	O
of	O
oarl	O
thaliodmide	O
underwent	O
neurolgoic	O
examinatoins	O
and	O
nreve	O
condutcion	O
stuides	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3	O
-	O
motnh	O
intevrals	O
during	O
teratment	O
.	O

NCS	O
included	O
reocrding	O
of	O
snesory	O
nevre	O
actoin	O
poetntials	O
(	O
SNPAs	O
)	O
from	O
meidan	O
,	O
radail	O
,	O
ulanr	O
,	O
and	O
srual	O
nevres	O
.	O

SANP	O
ampliutdes	O
for	O
each	O
nreve	O
were	O
expresesd	O
as	O
the	O
percetnage	O
of	O
its	O
baselnie	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SANP	O
index	O
.	O

A	O
40	O
%	O
declnie	O
in	O
the	O
SANP	O
index	O
was	O
considered	O
cliniclaly	O
significant	O
.	O

Thalidoimde	O
was	O
discotninued	O
in	O
55	O
patinets	O
for	O
lcak	O
of	O
theraeputic	O
resposne	O
.	O

Of	O
67	O
ptaients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thaliodmide	O
for	O
3	O
mnoths	O
,	O
8	O
remained	O
at	O
6	O
monhts	O
,	O
and	O
3	O
remained	O
at	O
9	O
motnhs	O
.	O

Six	O
ptaients	O
developed	O
nueropathy	B-Disease
.	O

Cliniacl	O
sympotms	O
and	O
a	O
declnie	O
in	O
the	O
SANP	O
index	O
occurred	O
concurrently	O
.	O

Oledr	O
age	O
and	O
cumultaive	O
dsoe	O
were	O
possible	O
contributing	O
fcators	O
.	O

Neuorpathy	B-Disease
may	O
thus	O
be	O
a	O
common	O
compilcation	O
of	O
thalidoimde	O
in	O
oledr	O
patinets	O
.	O

The	O
SANP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
perpiheral	B-Disease
neuorpathy	I-Disease
,	O
but	O
not	O
for	O
ealry	O
deteciton	O
.	O

Ovreexpression	O
of	O
copper	O
/	O
znic	O
-	O
supreoxide	O
dsimutase	O
protcets	O
from	O
kanamcyin	O
-	O
indcued	O
heraing	B-Disease
lsos	I-Disease
.	O

The	O
partciipation	O
of	O
raective	O
oyxgen	O
sepcies	O
in	O
aminoglycsoide	O
-	O
idnuced	O
ototoxiicty	B-Disease
has	O
been	O
deduced	O
from	O
osbervations	O
that	O
aminoglyocside	O
-	O
iorn	O
copmlexes	O
catlayze	O
the	O
fomration	O
of	O
supreoxide	O
radiclas	O
in	O
vitro	O
and	O
that	O
antioxiadnts	O
attenuate	O
otootxicity	B-Disease
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overexperssion	O
of	O
Cu	O
/	O
Zn	O
-	O
superoxdie	O
disumtase	O
(	O
h	O
-	O
SDO1	O
)	O
should	O
protect	O
transgneic	O
mcie	O
from	O
ototoxictiy	B-Disease
.	O

Immunocytochemitsry	O
confirmed	O
epxression	O
of	O
h	O
-	O
SDO1	O
in	O
inner	O
ear	O
tsisues	O
of	O
trasngenic	O
C5B7L	O
/	O
6	O
-	O
TgN	O
[	O
SDO1	O
]	O
3Cje	O
mcie	O
.	O

Transgneic	O
and	O
notnransgenic	O
littremates	O
received	O
knaamycin	O
(	O
400	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
/	O
day	O
)	O
for	O
10	O
dyas	O
beginning	O
on	O
day	O
10	O
after	O
brith	O
.	O

Audtiory	O
threhsolds	O
were	O
tesetd	O
by	O
evkoed	O
auidtory	O
barin	O
setm	O
resposnes	O
at	O
1	O
mnoth	O
after	O
bitrh	O
.	O

In	O
nnotransgenic	O
ainmals	O
,	O
the	O
threshlod	O
in	O
the	O
knaamycin	O
-	O
terated	O
gruop	O
was	O
45	O
-	O
50	O
dB	O
hgiher	O
than	O
in	O
slaine	O
-	O
ijnected	O
contorls	O
.	O

In	O
the	O
trasngenic	O
gruop	O
,	O
kanamyicn	O
incraesed	O
the	O
threhsold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
contorls	O
.	O

The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
prtoection	O
by	O
overexpresison	O
of	O
superoxdie	O
dismtuase	O
supports	O
the	O
hypotheiss	O
that	O
oixdant	O
strses	O
plays	O
a	O
significant	O
role	O
in	O
aminolgycoside	O
-	O
inudced	O
ototoxictiy	B-Disease
.	O

The	O
reuslts	O
also	O
suggest	O
transegnic	O
aniamls	O
as	O
suitable	O
moedls	O
to	O
investiagte	O
the	O
underlying	O
mehcanisms	O
and	O
possible	O
strategies	O
for	O
preventoin	O
.	O

Ftaty	B-Disease
lvier	I-Disease
induecd	O
by	O
tetrcaycline	O
in	O
the	O
rat	O
.	O

Dsoe	O
-	O
repsonse	O
relatoinships	O
and	O
efefct	O
of	O
sex	O
.	O

Dsoe	O
-	O
respnose	O
relationhsips	O
,	O
biochemcial	O
mcehanisms	O
,	O
and	O
sex	O
dfiferences	O
in	O
the	O
expeirmental	O
fatty	B-Disease
lvier	I-Disease
induecd	O
by	O
tetrcaycline	O
were	O
studied	O
in	O
the	O
inatct	O
rat	O
and	O
with	O
the	O
isoalted	O
perfsued	O
rat	O
lievr	O
in	O
vitro	O
.	O

In	O
the	O
intcat	O
mlae	O
and	O
fmeale	O
rat	O
,	O
no	O
direct	O
relatinoship	O
was	O
observed	O
between	O
dsoe	O
of	O
tetraccyline	O
and	O
heptaic	O
accumualtion	O
of	O
triglycerdie	O
.	O

With	O
provisoin	O
of	O
adeqaute	O
oliec	O
aicd	O
as	O
a	O
susbtrate	O
for	O
the	O
isoalted	O
perufsed	O
lievr	O
,	O
a	O
direct	O
relatiosnhip	O
was	O
observed	O
between	O
dsoe	O
of	O
tteracycline	O
and	O
both	O
accmuulation	O
of	O
tirglyceride	O
in	O
the	O
lvier	O
and	O
depresison	B-Disease
of	O
outupt	O
of	O
triglcyeride	O
by	O
lievrs	O
from	O
mlae	O
and	O
fmeale	O
rtas	O
.	O

Marked	O
differenecs	O
were	O
observed	O
between	O
feamle	O
and	O
mlae	O
rtas	O
with	O
regard	O
to	O
base	O
line	O
(	O
conrtol	O
)	O
heaptic	O
cocnentration	O
of	O
trigylceride	O
and	O
ouptut	O
of	O
triglyceirde	O
.	O

Accumualtion	O
of	O
hepaitc	O
triglcyeride	O
,	O
as	O
a	O
per	O
cent	O
of	O
conrtol	O
vaules	O
,	O
in	O
resopnse	O
to	O
grdaed	O
doess	O
of	O
tertacycline	O
,	O
did	O
not	O
differ	O
significantly	O
between	O
mlae	O
,	O
feamle	O
and	O
prengant	O
rat	O
lievrs	O
.	O

However	O
,	O
lviers	O
from	O
femlae	O
,	O
and	O
especially	O
prgenant	O
feamle	O
rtas	O
,	O
were	O
strikinlgy	O
ressitant	O
to	O
the	O
effects	O
of	O
tteracycline	O
on	O
depression	B-Disease
of	O
ouptut	O
of	O
triglcyeride	O
under	O
these	O
experimnetal	O
conditoins	O
.	O

These	O
difefrences	O
between	O
the	O
seexs	O
could	O
not	O
be	O
related	O
to	O
atlered	O
dispsoition	O
of	O
tetracyclnie	O
or	O
atlered	O
uptkae	O
of	O
oelic	O
aicd	O
.	O

Deprsesed	O
heptaic	O
sceretion	O
of	O
triglcyeride	O
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
heaptic	O
triglcyeride	O
,	O
indicating	O
that	O
additional	O
mehcanisms	O
must	O
be	O
involved	O
in	O
the	O
proudction	O
of	O
the	O
trgilyceride	O
-	O
rich	O
ftaty	B-Disease
lvier	I-Disease
in	O
resopnse	O
to	O
tetracycilne	O
.	O

Predinsone	O
idnuces	O
anxitey	B-Disease
and	O
glail	O
creebral	O
cahnges	O
in	O
rtas	O
.	O

OBJECITVE	O
:	O
To	O
assess	O
whether	O
predinsone	O
(	O
PDN	O
)	O
produces	O
anxeity	B-Disease
and	O
/	O
or	O
cererbal	O
glail	O
chnages	O
in	O
rtas	O
.	O

METHODS	O
:	O
Mlae	O
Wsitar	O
rtas	O
were	O
studied	O
and	O
3	O
gropus	O
were	O
formed	O
(	O
8	O
rtas	O
per	O
gorup	O
)	O
.	O

The	O
mdoerate	O
-	O
dsoe	O
gorup	O
received	O
5	O
mg	O
/	O
kg	O
/	O
day	O
PDN	O
releaesd	O
from	O
a	O
sucbutaneous	O
ipmlant	O
.	O

In	O
the	O
high	O
-	O
dsoe	O
gorup	O
,	O
implatns	O
containing	O
PDN	O
equivlaent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
day	O
were	O
applied	O
.	O

In	O
the	O
conrtol	O
gruop	O
ipmlants	O
contained	O
no	O
PDN	O
.	O

Axniety	B-Disease
was	O
asesssed	O
using	O
an	O
open	O
field	O
and	O
eleavted	O
plus	O
-	O
mzae	O
dveices	O
.	O

The	O
number	O
of	O
clels	O
and	O
ctyoplasmic	O
transformtaion	O
of	O
astroyctes	O
and	O
mircoglia	O
clels	O
were	O
asssesed	O
by	O
immunohistocheimcal	O
anlayses	O
.	O

RSEULTS	O
:	O
Anxeity	B-Disease
was	O
docmuented	O
in	O
both	O
gropus	O
of	O
PDN	O
treaetd	O
rtas	O
cmopared	O
with	O
contrlos	O
.	O

The	O
magintude	O
of	O
transformtaion	O
of	O
the	O
microgila	O
assessed	O
by	O
the	O
number	O
of	O
intersectinos	O
was	O
significantly	O
hgiher	O
in	O
the	O
PDN	O
gorups	O
than	O
in	O
conrtols	O
in	O
the	O
perfrontal	O
crotex	O
(	O
modreate	O
-	O
dsoe	O
,	O
24	O
.	O
1	O
;	O
high	O
-	O
dsoe	O
,	O
23	O
.	O
6	O
;	O
conrtols	O
18	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
stiratum	O
(	O
modreate	O
-	O
dsoe	O
25	O
.	O
6	O
;	O
high	O
-	O
dsoe	O
26	O
.	O
3	O
;	O
contorls	O
18	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
hippocampus	O
.	O

The	O
number	O
of	O
satined	O
micrgolia	O
clels	O
was	O
significantly	O
hgiher	O
in	O
the	O
PDN	O
terated	O
gropus	O
in	O
the	O
perfrontal	O
coretx	O
than	O
in	O
conrtols	O
(	O
modreate	O
-	O
dsoe	O
,	O
29	O
.	O
1	O
;	O
high	O
-	O
dsoe	O
,	O
28	O
.	O
4	O
;	O
conrtol	O
,	O
17	O
.	O
7	O
clels	O
per	O
field	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Staiend	O
mircoglia	O
clels	O
were	O
significantly	O
more	O
numerous	O
striautm	O
and	O
hpipocampus	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
comapred	O
to	O
contrlos	O
.	O

CNOCLUSION	O
:	O
Subactue	O
expousre	O
to	O
PDN	O
indcued	O
anxitey	B-Disease
and	O
reactviity	O
of	O
micorglia	O
.	O

The	O
relevance	O
of	O
these	O
featuers	O
for	O
paitents	O
using	O
PDN	O
remains	O
to	O
be	O
elucidated	O
.	O

Phsae	O
II	O
sutdy	O
of	O
carbolpatin	O
and	O
liopsomal	O
doxourbicin	O
in	O
pateints	O
with	O
rceurrent	O
suqamous	B-Disease
clel	I-Disease
cracinoma	I-Disease
of	I-Disease
the	I-Disease
cerivx	I-Disease
.	O

BACGKROUND	O
:	O
The	O
atcivity	O
of	O
the	O
combinatoin	O
of	O
carbolpatin	O
and	O
liposoaml	O
doxoruibcin	O
was	O
tesetd	O
in	O
a	O
Pahse	O
II	O
stduy	O
of	O
pateints	O
with	O
reucrrent	O
cevrical	B-Disease
cacrinoma	I-Disease
.	O

METHODS	O
:	O
The	O
combinaiton	O
of	O
carbpolatin	O
(	O
aera	O
under	O
the	O
concnetration	O
cruve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
liposmoal	O
doxroubicin	O
(	O
Dxoil	O
;	O
starting	O
dsoe	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
adminitsered	O
intarvenously	O
every	O
28	O
dyas	O
to	O
37	O
patinets	O
with	O
reucrrent	O
squmaous	B-Disease
clel	I-Disease
cervcial	I-Disease
carcionma	I-Disease
to	O
determine	O
antituomr	O
acitvity	O
and	O
toxciity	B-Disease
proflie	O
.	O

REUSLTS	O
:	O
Twenty	O
-	O
nine	O
patinets	O
were	O
assessable	O
for	O
respnose	O
,	O
and	O
35	O
pateints	O
were	O
assessable	O
for	O
toxictiy	B-Disease
.	O

The	O
overall	O
resposne	O
rtae	O
was	O
38	O
%	O
,	O
the	O
meidan	O
tmie	O
to	O
rseponse	O
was	O
10	O
weeks	O
,	O
the	O
medain	O
duraiton	O
of	O
respnose	O
was	O
26	O
weeks	O
,	O
and	O
the	O
medain	O
sruvival	O
was	O
37	O
weeks	O
.	O

The	O
main	O
toixc	O
efefct	O
was	O
myelospupression	B-Disease
,	O
with	O
Grdae	O
3	O
and	O
4	O
neutorpenia	B-Disease
in	O
16	O
ptaients	O
,	O
anmeia	B-Disease
in	O
12	O
pateints	O
,	O
throbmocytopenia	B-Disease
in	O
11	O
patietns	O
,	O
and	O
neutrpoenic	B-Disease
fveer	I-Disease
in	O
3	O
paitents	O
.	O

Four	O
patietns	O
had	O
five	O
inufsion	O
-	O
related	O
recations	O
during	O
the	O
infuison	O
of	O
lipoosmal	O
doxorubiicn	O
,	O
leading	O
to	O
treatemnt	O
discnotinuation	O
in	O
three	O
pateints	O
.	O

Grdae	O
>	O
or	O
=	O
2	O
nonhematolgoic	O
toixcity	B-Disease
included	O
nauesa	B-Disease
in	O
17	O
pateints	O
,	O
eemsis	B-Disease
in	O
14	O
pateints	O
,	O
ftaigue	B-Disease
in	O
9	O
paitents	O
,	O
mucsoitis	B-Disease
and	O
/	O
or	O
stoamtitis	B-Disease
in	O
8	O
pateints	O
,	O
constiaption	B-Disease
in	O
6	O
ptaients	O
,	O
wegiht	B-Disease
lsos	I-Disease
in	O
5	O
pateints	O
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
sydnrome	I-Disease
in	O
2	O
paitents	O
,	O
and	O
sikn	B-Disease
raections	I-Disease
in	O
3	O
patinets	O
.	O

CONCLUSINOS	O
:	O
The	O
cobmination	O
of	O
carbopltain	O
and	O
lipsoomal	O
doxroubicin	O
has	O
mdoest	O
acitvity	O
in	O
pateints	O
with	O
reucrrent	O
cerivcal	B-Disease
cracinoma	I-Disease
.	O

Antimicrboial	O
-	O
inudced	O
mnaia	B-Disease
(	O
antibiomania	B-Disease
)	O
:	O
a	O
reveiw	O
of	O
spnotaneous	O
rpeorts	O
.	O

The	O
authros	O
reveiwed	O
reported	O
caess	O
of	O
antiboitic	O
-	O
inudced	O
mainc	B-Disease
episoeds	O
by	O
means	O
of	O
a	O
MEDLNIE	O
and	O
PsychiLt	O
search	O
for	O
repotrs	O
of	O
antiboitic	O
-	O
idnuced	O
maina	B-Disease
.	O

Unpublsihed	O
reoprts	O
were	O
reqeusted	O
from	O
the	O
Wrold	O
Haelth	O
Organiztaion	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Durg	O
Adminisrtation	O
(	O
FDA	O
)	O
.	O

Twenty	O
-	O
one	O
reoprts	O
of	O
antimcirobial	O
-	O
indcued	O
maina	B-Disease
were	O
found	O
in	O
the	O
litertaure	O
.	O

There	O
were	O
6	O
caess	O
implicating	O
clairthromycin	O
,	O
13	O
implicating	O
isonizaid	O
,	O
and	O
1	O
csae	O
each	O
implicating	O
eryhtromycin	O
and	O
amoxiicllin	O
.	O

The	O
WHO	O
reported	O
82	O
csaes	O
.	O

Of	O
these	O
,	O
clarithroymcin	O
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%	O
)	O
caess	O
,	O
ciprolfoxacin	O
in	O
12	O
(	O
14	O
.	O
4	O
%	O
)	O
csaes	O
,	O
and	O
ofolxacin	O
in	O
10	O
(	O
12	O
%	O
)	O
csaes	O
.	O

Cotrmioxazole	O
,	O
metroniadzole	O
,	O
and	O
erythromyicn	O
were	O
involved	O
in	O
15	O
reported	O
mnaic	B-Disease
eipsodes	O
.	O

Caess	O
reported	O
by	O
the	O
FDA	O
showed	O
clarihtromycin	O
and	O
ciprofloxcain	O
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
develompent	O
of	O
mnaia	B-Disease
.	O

Statistcial	O
anaylsis	O
of	O
the	O
dtaa	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statsitical	O
crorelative	O
rsik	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Patinets	O
have	O
an	O
incraesed	O
rsik	O
of	O
developing	O
maina	B-Disease
while	O
being	O
terated	O
with	O
antimcirobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
statsitically	O
significant	O
rsik	O
,	O
pyhsicians	O
must	O
be	O
aware	O
of	O
the	O
effcet	O
and	O
reversiiblity	O
.	O

Further	O
reesarch	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidnece	O
of	O
antiimcrobial	O
-	O
idnuced	O
mnaia	B-Disease
,	O
the	O
relative	O
rsik	O
facotrs	O
of	O
developing	O
an	O
antimcirobial	O
-	O
indcued	O
mnaic	B-Disease
epsiode	O
among	O
various	O
demograhpic	O
popluations	O
,	O
and	O
the	O
inciednce	O
of	O
pateints	O
who	O
continue	O
to	O
have	O
perisstent	O
affectvie	O
disodrers	O
once	O
the	O
initial	O
epsiode	O
,	O
which	O
occurs	O
while	O
the	O
pateint	O
is	O
taking	O
antibiotcis	O
,	O
subsides	O
.	O

The	O
auhtors	O
elected	O
to	O
name	O
this	O
synrdome	O
"	O
antibiomania	B-Disease
.	O
"	O

Levdoopa	O
-	O
idnuced	O
ocualr	B-Disease
dysiknesias	I-Disease
in	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

Leovdopa	O
-	O
inudced	O
ocualr	B-Disease
dyskinesais	I-Disease
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneosuly	O
with	O
lmib	O
peak	O
-	O
dsoe	O
choretaic	B-Disease
dsykinesias	I-Disease
.	O

We	O
reoprt	O
on	O
a	O
ptaient	O
with	O
leftward	O
and	O
upward	O
deviatinos	O
of	O
gzae	O
during	O
the	O
peak	O
efefct	O
of	O
levdoopa	O
,	O
and	O
hypothesize	O
that	O
a	O
sveere	O
dpoaminergic	O
denervatoin	O
in	O
the	O
cauadte	O
nulceus	O
is	O
needed	O
for	O
the	O
appeaarnce	O
of	O
these	O
levodpoa	O
-	O
idnuce	O
ouclar	B-Disease
dsykinesias	I-Disease
.	O

A	O
comparsion	O
of	O
glyceyrl	O
trinitrtae	O
with	O
dicolfenac	O
for	O
the	O
treatemnt	O
of	O
primray	O
dysmenorreha	B-Disease
:	O
an	O
open	O
,	O
randoimzed	O
,	O
crsos	O
-	O
over	O
trail	O
.	O

Prmiary	O
dysmenorrhea	B-Disease
is	O
a	O
synrdome	O
characteirzed	O
by	O
pianful	O
uternie	O
contrcatility	O
caused	O
by	O
a	O
hyperescretion	O
of	O
endomterial	O
prostgalandins	O
;	O
non	O
-	O
steriodal	O
atni	O
-	O
inflmamatory	O
drgus	O
are	O
the	O
first	O
choice	O
for	O
its	O
teratment	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
stuides	O
have	O
demonstrated	O
that	O
myometiral	O
cells	O
are	O
also	O
targtes	O
of	O
the	O
realxant	O
efefcts	O
of	O
nirtic	O
oixde	O
(	O
NO	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
determine	O
the	O
efficcay	O
of	O
glyceyrl	O
trniitrate	O
(	O
GTN	O
)	O
,	O
an	O
NO	O
dnoor	O
,	O
in	O
the	O
resoultion	O
of	O
pirmary	O
dysmenorrhea	B-Disease
in	O
compairson	O
with	O
dcilofenac	O
(	O
DCF	O
)	O
.	O

A	O
total	O
of	O
24	O
ptaients	O
with	O
the	O
diganosis	O
of	O
sveere	O
primray	O
dysmenrorhea	B-Disease
were	O
studied	O
during	O
two	O
cosnecutive	O
mensrtual	O
ccyles	O
.	O

In	O
an	O
open	O
,	O
corss	O
-	O
over	O
,	O
cotnrolled	O
deisgn	O
,	O
patinets	O
were	O
radnomized	O
to	O
receive	O
either	O
DCF	O
per	O
os	O
or	O
GTN	O
pacthes	O
the	O
first	O
dyas	O
of	O
meness	O
,	O
when	O
mentsrual	O
crapms	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
ccyle	O
the	O
other	O
treamtent	O
was	O
used	O
.	O

Patietns	O
received	O
up	O
to	O
3	O
dsoes	O
/	O
day	O
of	O
50	O
mg	O
DCF	O
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	O
tarnsdermal	O
GTN	O
for	O
the	O
first	O
3	O
dyas	O
of	O
the	O
ccyle	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
participnats	O
recorded	O
mentsrual	O
sypmtoms	O
and	O
possible	O
side	O
-	O
effcets	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
mintues	O
)	O
after	O
the	O
first	O
dsoe	O
of	O
mediaction	O
on	O
the	O
first	O
day	O
of	O
the	O
ccyle	O
,	O
with	O
both	O
drgus	O
.	O

The	O
difference	O
in	O
pian	B-Disease
intenstiy	O
scroe	O
(	O
DPI	O
)	O
was	O
the	O
main	O
otucome	O
varialbe	O
.	O

Both	O
traetments	O
significantly	O
reduecd	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	O
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DCF	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
)	O
.	O

However	O
,	O
DCF	O
continued	O
to	O
be	O
effcetive	O
in	O
reducnig	O
plevic	B-Disease
pian	I-Disease
for	O
two	O
hours	O
,	O
whereas	O
GTN	O
socres	O
remained	O
more	O
or	O
less	O
stalbe	O
after	O
30	O
min	O
and	O
significantly	O
hihger	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	O
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DFC	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
and	O
after	O
two	O
hours	O
:	O
GTN	O
,	O
-	O
23	O
.	O
7	O
+	O
/	O
-	O
20	O
.	O
5	O
;	O
DFC	O
,	O
-	O
59	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Low	B-Disease
back	I-Disease
pian	I-Disease
was	O
also	O
relieevd	O
by	O
both	O
durgs	O
.	O

Headcahe	B-Disease
was	O
significantly	O
increaesd	O
by	O
GTN	O
but	O
not	O
by	O
DCF	O
.	O

Eight	O
pateints	O
stopped	O
using	O
GTN	O
because	O
heaadche	B-Disease
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
intolerbale	O
.	O

These	O
fidnings	O
indicate	O
that	O
GTN	O
has	O
a	O
reudced	O
efifcacy	O
and	O
tolerabiilty	O
by	O
comparsion	O
with	O
DCF	O
in	O
the	O
treamtent	O
of	O
primray	O
dysmenorhrea	B-Disease
.	O

Temocparil	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
gorup	O
anigotensin	O
converting	O
eznyme	O
inhbiitor	O
,	O
moudlates	O
gloemrular	B-Disease
ijnury	I-Disease
in	O
chrnoic	O
puroymcin	O
amionnucleoside	O
nephorsis	B-Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
determine	O
whether	O
chrnoic	O
admniistration	O
of	O
temoacpril	O
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
gorup	O
angiotenisn	O
converting	O
enzmye	O
(	O
ACE	O
)	O
inihbitor	O
,	O
rdeuced	O
protienuria	B-Disease
,	O
inhiibted	O
glomerluar	O
hyperrtophy	B-Disease
and	O
prevented	O
glomerulocslerosis	B-Disease
in	O
crhonic	O
puroymcin	O
aminouncleoside	O
(	O
PAN	O
)	O
-	O
indcued	O
nephortic	B-Disease
rtas	O
.	O

Nephorsis	B-Disease
was	O
inudced	O
by	O
injectoin	O
of	O
PAN	O
(	O
15mg	O
/	O
100g	O
bdoy	O
wegiht	O
)	O
in	O
mlae	O
Spargue	O
-	O
Dalwey	O
(	O
SD	O
)	O
rtas	O
.	O

Four	O
gropus	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	O
gorup	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	O
/	O
temoacpril	O
(	O
13	O
)	O
,	O
iii	O
)	O
temoacpril	O
(	O
14	O
)	O
and	O
iv	O
)	O
utnreated	O
cnotrols	O
(	O
15	O
)	O
.	O

Temoacpril	O
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
adminisetred	O
to	O
the	O
rtas	O
which	O
were	O
kileld	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
tmie	O
point	O
,	O
sytsolic	O
blood	O
presusre	O
(	O
BP	O
)	O
,	O
uirnary	O
proetin	O
exrcetion	O
and	O
reanl	O
histopathologcial	O
findnigs	O
were	O
eavluated	O
,	O
and	O
morphmoetric	O
imgae	O
analyiss	O
was	O
done	O
.	O

Ssytolic	O
BP	O
in	O
the	O
PAN	O
gorup	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
wekes	O
,	O
but	O
was	O
nromal	O
in	O
the	O
PAN	O
/	O
tmeocapril	O
gorup	O
.	O

Uirnary	O
prtoein	O
ecxretion	O
in	O
the	O
PAN	O
gorup	O
incresaed	O
significantly	O
,	O
peaking	O
at	O
8	O
dyas	O
,	O
then	O
decresaed	O
at	O
4	O
wekes	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
wekes	O
.	O

Temocarpil	O
did	O
not	O
attenaute	O
proteiunria	B-Disease
at	O
8	O
dyas	O
,	O
but	O
it	O
did	O
markedly	O
loewr	O
it	O
from	O
wekes	O
4	O
to	O
20	O
.	O

The	O
glomeurlosclerosis	B-Disease
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	O
gruop	O
.	O

There	O
was	O
a	O
significant	O
corrleation	O
between	O
uirnary	O
protien	O
excreiton	O
and	O
GSI	O
(	O
r	O
=	O
0	O
.	O
808	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
raito	O
of	O
glomerualr	O
tfut	O
aera	O
to	O
the	O
aera	O
of	O
Bwoman	O
'	O
s	O
capsuels	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	O
gruop	O
was	O
significantly	O
icnreased	O
,	O
but	O
it	O
was	O
significantly	O
loewr	O
in	O
the	O
PAN	O
/	O
temoacpril	O
gruop	O
.	O

It	O
appears	O
that	O
temoacpril	O
was	O
efefctive	O
in	O
retrading	O
reanl	O
porgression	O
and	O
protected	O
rneal	O
functoin	O
in	O
PAN	O
neproitc	B-Disease
rtas	O
.	O

Pulomnary	B-Disease
hypertenison	I-Disease
after	O
ibpurofen	O
prophyalxis	O
in	O
very	O
preetrm	O
ifnants	O
.	O

We	O
reprot	O
three	O
csaes	O
of	O
sveere	O
hypoaxemia	B-Disease
after	O
iubprofen	O
adminsitration	O
during	O
a	O
randmoised	O
cotnrolled	O
trail	O
of	O
porphylactic	O
treatmnet	O
of	O
paetnt	B-Disease
dcutus	I-Disease
arterisous	I-Disease
with	O
ibuprfoen	O
in	O
prmeature	O
inafnts	O
bron	O
at	O
less	O
than	O
28	O
wekes	O
of	O
gestatoin	O
.	O

Echcoardiography	O
showed	O
seveerly	O
decerased	O
pumlonary	O
bolod	O
folw	O
.	O

Hypoxeamia	B-Disease
resolved	O
quickly	O
on	O
inhlaed	O
nirtic	O
oixde	O
tehrapy	O
.	O

We	O
suggest	O
that	O
investgiators	O
involved	O
in	O
similar	O
trilas	O
pay	O
close	O
attetnion	O
to	O
pulmnoary	O
presusre	O
if	O
hyopxaemia	B-Disease
occurs	O
after	O
prophlyactic	O
admiinstration	O
of	O
iburpofen	O
.	O

Hyponartemia	B-Disease
and	O
sydnrome	B-Disease
of	I-Disease
inpapropriate	I-Disease
atni	I-Disease
-	I-Disease
diurteic	I-Disease
horomne	I-Disease
reported	O
with	O
the	O
use	O
of	O
Vincristnie	O
:	O
an	O
over	O
-	O
represnetation	O
of	O
Asains	O
?	O

PURPSOE	O
:	O
This	O
retrsopective	O
sutdy	O
used	O
a	O
pharmaceuitcal	O
comapny	O
'	O
s	O
golbal	O
saftey	O
datbaase	O
to	O
determine	O
the	O
reporting	O
rtae	O
of	O
hypnoatremia	B-Disease
and	O
/	O
or	O
syndorme	B-Disease
of	I-Disease
inapprporiate	I-Disease
secertion	I-Disease
of	I-Disease
atni	I-Disease
-	I-Disease
diruetic	I-Disease
horomne	I-Disease
(	O
SIDAH	B-Disease
)	O
among	O
vincrsitine	O
-	O
treaetd	O
ptaients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
rsik	O
ppoulation	O
subgropus	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Llily	O
and	O
Comapny	O
'	O
s	O
comptuerized	O
adevrse	O
eevnt	O
databsae	O
for	O
all	O
reported	O
caess	O
of	O
hpyonatremia	B-Disease
and	O
/	O
or	O
SIDAH	B-Disease
as	O
of	O
1	O
Nvoember	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincrisitne	O
.	O

REUSLTS	O
:	O
A	O
total	O
of	O
76	O
caess	O
of	O
hyponatermia	B-Disease
and	O
/	O
or	O
SAIDH	B-Disease
associated	O
with	O
vincrsitine	O
use	O
were	O
identifeid	O
.	O

The	O
overall	O
reporting	O
rtae	O
was	O
estiamted	O
to	O
be	O
1	O
.	O
3	O
/	O
100	O
,	O
000	O
traeted	O
pateints	O
.	O

The	O
aevrage	O
age	O
of	O
pateints	O
was	O
35	O
.	O
6	O
+	O
/	O
-	O
28	O
.	O
3	O
yeras	O
,	O
and	O
62	O
%	O
were	O
maels	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
paitents	O
were	O
receiving	O
treatmnet	O
for	O
leukmeia	B-Disease
or	O
lymhpoma	B-Disease
.	O

Among	O
the	O
39	O
repotrs	O
that	O
included	O
ifnormation	O
on	O
rcae	O
,	O
the	O
raical	O
distribtuion	O
was	O
:	O
1	O
Blcak	O
,	O
3	O
Cauacsian	O
,	O
and	O
35	O
Asain	O
.	O

CONCLSUION	O
:	O
Our	O
dtaa	O
suggest	O
that	O
Aisan	O
patinets	O
may	O
be	O
at	O
incresaed	O
rsik	O
of	O
hpyonatremia	B-Disease
and	O
/	O
or	O
SIDAH	B-Disease
associated	O
with	O
vincristnie	O
use	O
.	O

Although	O
the	O
overall	O
reported	O
rtae	O
of	O
SAIDH	B-Disease
associated	O
with	O
vincristnie	O
is	O
very	O
low	O
,	O
physicains	O
craing	O
for	O
Aisan	O
oncloogy	O
paitents	O
should	O
be	O
aware	O
of	O
this	O
potentail	O
serious	O
but	O
reversible	O
avderse	O
eevnt	O
.	O

Dealyed	O
toxciity	B-Disease
of	O
cycolphosphamide	O
on	O
the	O
bldader	O
of	O
DBA	O
/	O
2	O
and	O
C5B7L	O
/	O
6	O
feamle	O
mosue	O
.	O

The	O
present	O
sutdy	O
describes	O
the	O
delaeyd	O
devleopment	O
of	O
a	O
sevree	O
bldader	O
ptahology	O
in	O
a	O
ssuceptible	O
starin	O
of	O
mcie	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resisatnt	O
srtain	O
(	O
C75BL	O
/	O
6	O
)	O
when	O
both	O
were	O
traeted	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dsoe	O
of	O
ccylophosphamide	O
(	O
CY	O
)	O
.	O

Inberd	O
DBA	O
/	O
2	O
and	O
C5B7L	O
/	O
6	O
feamle	O
mcie	O
were	O
injecetd	O
with	O
CY	O
,	O
and	O
the	O
effcet	O
of	O
the	O
durg	O
on	O
the	O
bladder	O
was	O
asssesed	O
during	O
100	O
dyas	O
by	O
light	O
microscpoy	O
using	O
different	O
satining	O
proceudres	O
,	O
and	O
after	O
30	O
dyas	O
by	O
conventoinal	O
elcetron	O
mciroscopy	O
.	O

Ealry	O
CY	O
txoicity	B-Disease
caused	O
a	O
typical	O
heamorrhagic	B-Disease
cytsitis	B-Disease
in	O
both	O
starins	O
that	O
was	O
completely	O
rpeaired	O
in	O
about	O
7	O
-	O
10	O
dyas	O
.	O

After	O
30	O
dyas	O
of	O
CY	O
injectoin	O
ulceorus	O
and	O
non	O
-	O
uclerous	O
forms	O
of	O
chrnoic	O
cystiits	B-Disease
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
mcie	O
but	O
only	O
in	O
4	O
%	O
of	O
C5B7L	O
/	O
6	O
mcie	O
.	O

Dealyed	O
cysttiis	B-Disease
was	O
cahracterized	O
by	O
inifltration	O
and	O
transeipthelial	O
passgae	O
into	O
the	O
luemn	O
of	O
inflammatory	O
clels	O
and	O
by	O
frqeuent	O
exfoilation	O
of	O
the	O
uorthelium	O
.	O

Msat	O
cells	O
appeared	O
in	O
the	O
conenctive	O
and	O
muscualr	O
layres	O
of	O
the	O
bldader	O
at	O
a	O
much	O
higehr	O
number	O
in	O
DBA	O
/	O
2	O
mcie	O
than	O
in	O
C5B7L	O
/	O
6	O
mcie	O
or	O
utnreated	O
conrtols	O
.	O

Elcetron	O
mciroscopy	O
disclosed	O
the	O
asbence	O
of	O
the	O
typical	O
dsicoidal	O
veiscles	O
normally	O
present	O
in	O
the	O
cyotplasm	O
of	O
surfcae	O
clels	O
.	O

Instead	O
,	O
numerous	O
abnromal	O
vesilces	O
containing	O
one	O
or	O
several	O
drak	O
granuels	O
were	O
observed	O
in	O
the	O
cytoplsam	O
of	O
cells	O
from	O
all	O
the	O
epitheilal	O
lyaers	O
.	O

Delyaed	O
cysttiis	B-Disease
still	O
persisted	O
in	O
DBA	O
/	O
2	O
mcie	O
100	O
dyas	O
after	O
traetment	O
.	O

These	O
resutls	O
indicate	O
that	O
dealyed	O
toxictiy	B-Disease
of	O
CY	O
in	O
femlae	O
DBA	O
/	O
2	O
mcie	O
causes	O
a	O
bladder	O
pathoolgy	O
that	O
is	O
not	O
observed	O
in	O
C75BL	O
/	O
6	O
mcie	O
.	O

This	O
patholgoy	O
resembles	O
interstiital	B-Disease
cystiits	I-Disease
in	O
hmuans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
ainmal	O
moedl	O
for	O
studeis	O
on	O
the	O
dsiease	O
.	O

High	O
-	O
dsoe	O
5	O
-	O
fluorouarcil	O
/	O
foilnic	O
aicd	O
in	O
combinaiton	O
with	O
three	O
-	O
weekly	O
mitomcyin	O
C	O
in	O
the	O
teratment	O
of	O
adavnced	O
gastirc	B-Disease
cacner	I-Disease
.	O

A	O
phsae	O
II	O
sutdy	O
.	O

BAKCGROUND	O
:	O
The	O
24	O
-	O
hour	O
contiunous	O
infuison	O
of	O
5	O
-	O
fluroouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
folniic	O
aicd	O
(	O
FA	O
)	O
as	O
part	O
of	O
several	O
new	O
multidurg	O
chemotehrapy	O
regiemns	O
in	O
avdanced	O
gsatric	B-Disease
cnacer	I-Disease
(	O
AGC	B-Disease
)	O
has	O
shown	O
to	O
be	O
efefctive	O
,	O
with	O
low	O
toxciity	B-Disease
.	O

In	O
a	O
previous	O
pahse	O
II	O
sutdy	O
with	O
3	O
-	O
weekly	O
blous	O
5	O
-	O
FU	O
,	O
FA	O
and	O
miotmycin	O
C	O
(	O
MMC	O
)	O
we	O
found	O
a	O
low	O
toxiicty	B-Disease
rtae	O
and	O
respnose	O
rtaes	O
comparable	O
to	O
those	O
of	O
regmiens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FMATX	O
,	O
and	O
a	O
promising	O
mdeian	O
overall	O
surivval	O
.	O

In	O
order	O
to	O
imprvoe	O
this	O
MMC	O
-	O
depnedent	O
scheudle	O
we	O
initiated	O
a	O
pahse	O
II	O
stduy	O
with	O
high	O
-	O
dsoe	O
5	O
-	O
FU	O
/	O
FA	O
and	O
3	O
-	O
wekely	O
bouls	O
MMC	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
Fberuary	O
,	O
1998	O
to	O
Spetember	O
,	O
2000	O
we	O
recruited	O
33	O
patietns	O
with	O
AGC	B-Disease
to	O
receive	O
wekely	O
24	O
-	O
hour	O
5	O
-	O
FU	O
2	O
,	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2	O
-	O
hour	O
FA	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
wekes	O
,	O
followed	O
by	O
a	O
2	O
-	O
week	O
rest	O
peroid	O
.	O

Bouls	O
MMC	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3	O
-	O
wekely	O
intrevals	O
.	O

Treatemnt	O
given	O
on	O
an	O
outaptient	O
basis	O
,	O
using	O
portalbe	O
pmup	O
systmes	O
,	O
was	O
repetaed	O
on	O
day	O
57	O
.	O

Pateints	O
'	O
characetristics	O
were	O
:	O
mlae	O
/	O
feamle	O
rtaio	O
20	O
/	O
13	O
;	O
mdeian	O
age	O
57	O
(	O
27	O
-	O
75	O
)	O
yeras	O
;	O
mdeian	O
WHO	O
stauts	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
ptaients	O
had	O
a	O
pirmary	O
AGC	B-Disease
,	O
and	O
15	O
showed	O
a	O
relasped	O
AGC	B-Disease
.	O

Medain	O
follow	O
-	O
up	O
was	O
11	O
.	O
8	O
mnoths	O
(	O
range	O
of	O
those	O
suvriving	O
:	O
2	O
.	O
7	O
-	O
11	O
.	O
8	O
mnoths	O
)	O
.	O

RESUTLS	O
:	O
32	O
pateints	O
were	O
evaulable	O
for	O
resposne	O
-	O
complete	O
reimssion	O
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
pratial	O
reimssion	O
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progresisve	O
dsiease	O
15	O
.	O
1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Meidan	O
overall	O
survvial	O
tmie	O
was	O
10	O
.	O
2	O
monhts	O
[	O
95	O
%	O
confidnece	O
itnerval	O
(	O
CI	O
)	O
:	O
8	O
.	O
7	O
-	O
11	O
.	O
6	O
]	O
,	O
and	O
mdeian	O
progressoin	O
-	O
free	O
surviavl	O
tmie	O
was	O
7	O
.	O
6	O
mnoths	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
4	O
-	O
10	O
.	O
9	O
)	O
.	O

The	O
worst	O
toxictiies	B-Disease
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukoepnia	B-Disease
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrombocyotpenia	B-Disease
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vomiuts	B-Disease
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarhrea	B-Disease
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomtaitis	B-Disease
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
sydnrome	I-Disease
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O

Two	O
pateints	O
developed	O
hemoyltic	B-Disease
-	I-Disease
urmeic	I-Disease
sydnrome	I-Disease
(	O
HUS	B-Disease
)	O
.	O

COCNLUSIONS	O
:	O
High	O
-	O
dsoe	O
5	O
-	O
FU	O
/	O
FA	O
/	O
MMC	O
is	O
an	O
effetcive	O
and	O
well	O
-	O
tolertaed	O
otupatient	O
regiemn	O
for	O
AGC	B-Disease
(	O
objecitve	O
resopnse	O
rtae	O
54	O
.	O
6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alterantive	O
to	O
cispaltin	O
-	O
containing	O
regiemns	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B-Disease
may	O
occur	O
.	O

Perssitent	O
setrile	O
leukocytuira	B-Disease
is	O
associated	O
with	O
imapired	B-Disease
rneal	I-Disease
funciton	I-Disease
in	O
huamn	B-Disease
immundoeficiency	I-Disease
vrius	I-Disease
tpye	I-Disease
1	I-Disease
-	I-Disease
infetced	I-Disease
chidlren	O
traeted	O
with	O
indniavir	O
.	O

BACKGRUOND	O
:	O
Prolonegd	O
administraiton	O
of	O
inidnavir	O
is	O
associated	O
with	O
the	O
occurernce	O
of	O
a	O
variety	O
of	O
rneal	O
copmlications	O
in	O
adluts	O
.	O

These	O
well	O
-	O
docuemnted	O
side	O
effcets	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
proetase	O
ihnibitor	O
in	O
cihldren	O
.	O

DESIGN	O
:	O
A	O
prsopective	O
stduy	O
to	O
monitor	O
indianvir	O
-	O
related	O
nephortoxicity	B-Disease
in	O
a	O
cohrot	O
of	O
30	O
huamn	B-Disease
immunodeficiency	I-Disease
viurs	I-Disease
tpye	I-Disease
1	I-Disease
-	I-Disease
ifnected	I-Disease
childern	O
traeted	O
with	O
idninavir	O
.	O

METHODS	O
:	O
Urinray	O
pH	O
,	O
alubmin	O
,	O
craetinine	O
,	O
the	O
persence	O
of	O
erythrcoytes	O
,	O
leukcoytes	O
,	O
bactreia	O
and	O
crytsals	O
,	O
and	O
cutlure	O
were	O
anaylzed	O
every	O
3	O
motnhs	O
for	O
96	O
weeks	O
.	O

Sreum	O
creatinnie	O
lveels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
tmie	O
points	O
.	O

Steady	O
-	O
state	O
pharmacokientics	O
of	O
indianvir	O
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initaition	O
of	O
indinvair	O
.	O

REUSLTS	O
:	O
The	O
cumualtive	O
incidnece	O
of	O
perssitent	O
streile	O
leukoycturia	B-Disease
(	O
>	O
or	O
=	O
75	O
cells	O
/	O
mirco	O
L	O
in	O
at	O
least	O
2	O
cnosecutive	O
viists	O
)	O
after	O
96	O
weeks	O
was	O
53	O
%	O
.	O

Perisstent	O
sterlie	O
leukcoyturia	B-Disease
was	O
frequently	O
associated	O
with	O
a	O
mlid	O
incerase	O
in	O
the	O
uirne	O
alubmin	O
/	O
creatinnie	O
rtaio	O
and	O
by	O
microsocpic	O
hemtauria	B-Disease
.	O

The	O
cumulaitve	O
incdience	O
of	O
sreum	O
cretainine	O
leevls	O
>	O
50	O
%	O
above	O
nromal	O
was	O
33	O
%	O
after	O
96	O
weeks	O
.	O

Childern	O
with	O
perisstent	O
streile	O
luekocyturia	B-Disease
more	O
frequently	O
had	O
sreum	O
creaitnine	O
leevls	O
of	O
50	O
%	O
above	O
nromal	O
than	O
those	O
chilrden	O
without	O
persisetnt	O
setrile	O
leukoycturia	B-Disease
.	O

In	O
chidlren	O
yougner	O
than	O
5	O
.	O
6	O
yaers	O
,	O
perssitent	O
steirle	O
lekuocyturia	B-Disease
was	O
significantly	O
more	O
freuqent	O
than	O
in	O
odler	O
childern	O
.	O

A	O
hihger	O
cumualtive	O
inciednce	O
of	O
perisstent	O
leukocytuira	B-Disease
was	O
found	O
in	O
chlidren	O
with	O
an	O
aera	O
under	O
the	O
cruve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
sreum	O
lveel	O
of	O
indianvir	O
>	O
12	O
mg	O
/	O
L	O
.	O

In	O
4	O
chlidren	O
,	O
indinaivr	O
was	O
disocntinued	O
because	O
of	O
nephrotoxiicty	B-Disease
.	O

Subsequently	O
,	O
the	O
sreum	O
ceratinine	O
leevls	O
decraesed	O
,	O
the	O
uirne	O
alubmin	O
/	O
ceratinine	O
raitos	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukoycturia	B-Disease
disappeared	O
within	O
3	O
motnhs	O
.	O

CONLCUSIONS	O
:	O
Chidlren	O
traeted	O
with	O
indniavir	O
have	O
a	O
high	O
cumluative	O
incidnece	O
of	O
perisstent	O
sterlie	O
luekocyturia	B-Disease
.	O

Chilrden	O
with	O
persisetnt	O
setrile	O
leuokcyturia	B-Disease
more	O
frequently	O
had	O
an	O
incresae	O
in	O
seurm	O
creatiinne	O
levles	O
of	O
>	O
50	O
%	O
above	O
nromal	O
.	O

Younegr	O
chilrden	O
have	O
an	O
additional	O
rsik	O
for	O
rneal	O
compliactions	O
.	O

The	O
impariment	B-Disease
of	I-Disease
the	I-Disease
rneal	I-Disease
functoin	I-Disease
in	O
these	O
chlidren	O
occurred	O
in	O
the	O
absnece	O
of	O
cilnical	O
smyptoms	O
of	O
nephroilthiasis	B-Disease
.	O

Indinaivr	O
-	O
associated	O
nephrotoxciity	B-Disease
must	O
be	O
monitoerd	O
closely	O
,	O
especially	O
in	O
childern	O
with	O
rsik	O
fatcors	O
such	O
as	O
pesristent	O
setrile	O
leukoycturia	B-Disease
,	O
age	O
<	O
5	O
.	O
6	O
yeras	O
,	O
an	O
aera	O
under	O
the	O
cruve	O
of	O
idninavir	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L	O
.	O

Uitlity	O
of	O
tropoinn	O
I	O
in	O
patinets	O
with	O
ccoaine	O
-	O
associated	O
chset	B-Disease
pian	I-Disease
.	O

Baselnie	O
electrocaridogram	O
abnormailties	O
and	O
makret	O
elevtaions	O
not	O
associated	O
with	O
moycardial	B-Disease
necroiss	I-Disease
make	O
accurate	O
diagnoiss	O
of	O
myocaridal	B-Disease
infartcion	I-Disease
(	O
MI	B-Disease
)	O
difficult	O
in	O
patinets	O
with	O
cocanie	O
-	O
associated	O
chset	B-Disease
pian	I-Disease
.	O

Tropoinn	O
smapling	O
may	O
offer	O
greater	O
diganostic	O
utility	O
in	O
these	O
patinets	O
.	O

OBJETCIVE	O
:	O
To	O
assess	O
ouctomes	O
based	O
on	O
trpoonin	O
postiivity	O
in	O
ptaients	O
with	O
coacine	O
chset	B-Disease
pian	I-Disease
admtited	O
for	O
exculsion	O
of	O
MI	B-Disease
.	O

METHODS	O
:	O
Outcmoes	O
were	O
examined	O
in	O
paitents	O
admitted	O
for	O
possible	O
MI	B-Disease
after	O
ccoaine	O
use	O
.	O

All	O
patinets	O
underwent	O
a	O
raipd	O
rule	O
-	O
in	O
protoocl	O
that	O
included	O
sreial	O
samplnig	O
of	O
craetine	O
kniase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
caridac	O
trpoonin	O
I	O
(	O
cnTI	O
)	O
over	O
eight	O
hours	O
.	O

Ouctomes	O
included	O
CK	O
-	O
MB	O
MI	B-Disease
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
cardaic	B-Disease
daeth	I-Disease
,	O
and	O
significant	O
cornoary	B-Disease
diesase	I-Disease
(	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

REUSLTS	O
:	O
Of	O
the	O
246	O
admitetd	O
pateints	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
critreia	O
for	O
MI	B-Disease
and	O
38	O
(	O
16	O
%	O
)	O
had	O
cnTI	O
elevaitons	O
.	O

Agniography	O
was	O
performed	O
in	O
29	O
of	O
38	O
ptaients	O
who	O
were	O
cnTI	O
-	O
positvie	O
,	O
with	O
significant	O
diesase	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
pateints	O
without	O
significant	O
diesase	O
who	O
had	O
cnTI	O
elevatinos	O
met	O
CK	O
-	O
MB	O
critreia	O
for	O
MI	B-Disease
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
leevl	O
of	O
13	O
ng	O
/	O
mL	O
.	O

Senistivities	O
,	O
speicficities	O
,	O
and	O
psoitive	O
and	O
negatvie	O
likelihood	O
raitos	O
for	O
predictnig	O
cradiac	B-Disease
daeth	I-Disease
or	O
significant	O
diesase	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	B-Disease
and	O
cnTI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCULSIONS	O
:	O
Most	O
paitents	O
with	O
cnTI	O
elevatoins	O
meet	O
CK	O
-	O
MB	O
criteira	O
for	O
MI	B-Disease
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidnece	O
of	O
underlying	O
significant	O
disaese	O
.	O

Troopnin	O
appears	O
to	O
have	O
an	O
equivaelnt	O
diagnsotic	O
accurcay	O
copmared	O
with	O
CK	O
-	O
MB	O
for	O
diangosing	O
necorsis	B-Disease
in	O
patietns	O
with	O
coacine	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
and	O
ssupected	O
MI	B-Disease
.	O

Actue	O
intertsitial	B-Disease
npehritis	I-Disease
due	O
to	O
nicregoline	O
(	O
Semrion	O
)	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
actue	O
intersittial	B-Disease
nephriits	I-Disease
(	O
AIN	B-Disease
)	O
due	O
to	O
nicergolnie	O
(	O
Sermoin	O
)	O
.	O

A	O
50	O
-	O
yaer	O
-	O
old	O
ptaient	O
admtited	O
to	O
our	O
hosiptal	O
for	O
feevr	B-Disease
and	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
.	O

Before	O
admisison	O
,	O
he	O
had	O
been	O
taking	O
nicergolnie	O
and	O
bendazac	O
lsyine	O
due	O
to	O
retianl	B-Disease
vien	I-Disease
occluison	I-Disease
at	O
ohpthalmologic	O
depatrment	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fveer	B-Disease
and	O
sikn	B-Disease
rsah	I-Disease
.	O

On	O
admission	O
,	O
cliincal	O
symptmos	O
(	O
i	O
.	O
e	O
.	O
artharlgia	B-Disease
and	O
fveer	B-Disease
)	O
and	O
laobratory	O
findigns	O
(	O
i	O
.	O
e	O
.	O
esoinophilia	B-Disease
and	O
reanl	B-Disease
faliure	I-Disease
)	O
suggested	O
AIN	B-Disease
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathloogic	O
fidnings	O
on	O
rneal	O
biposy	O
.	O

A	O
lymhpocyte	O
transformaiton	O
tset	O
demonstrated	O
a	O
poistive	O
result	O
against	O
nicergolnie	O
.	O

Treamtent	O
was	O
consisted	O
of	O
wtihdrawal	O
of	O
niecrgoline	O
and	O
itnravenous	O
methylrpednisolone	O
,	O
and	O
his	O
rneal	O
funciton	O
was	O
completely	O
recvoered	O
.	O

To	O
our	O
knwoledge	O
,	O
this	O
is	O
the	O
first	O
reoprt	O
of	O
nicergloine	O
-	O
associated	O
AIN	B-Disease
.	O

Neuroletpic	B-Disease
malginant	I-Disease
syndrmoe	I-Disease
complictaed	O
by	O
massive	O
intesitnal	O
bleeidng	B-Disease
in	O
a	O
pateint	O
with	O
crhonic	B-Disease
rneal	I-Disease
failrue	I-Disease
.	O

A	O
pateint	O
with	O
chrnoic	B-Disease
reanl	I-Disease
fialure	I-Disease
(	O
CRF	B-Disease
)	O
developed	O
nueroleptic	B-Disease
mlaignant	I-Disease
sydnrome	I-Disease
(	O
NMS	B-Disease
)	O
after	O
administrtaion	O
of	O
risepridone	O
and	O
lveomepromazine	O
.	O

In	O
addition	O
to	O
the	O
typical	O
sympotms	O
of	O
NMS	B-Disease
,	O
massive	O
inetstinal	O
bleeidng	B-Disease
was	O
observed	O
during	O
the	O
episdoe	O
.	O

This	O
rpeort	O
suggests	O
that	O
NMS	B-Disease
in	O
a	O
paitent	O
with	O
CRF	B-Disease
may	O
be	O
compilcated	O
by	O
itnestinal	O
beleding	B-Disease
and	O
needs	O
special	O
caution	O
for	O
this	O
compilcation	O
.	O

Blood	O
barin	O
brarier	O
in	O
rgiht	O
-	O
and	O
lfet	O
-	O
pwaed	O
femlae	O
rtas	O
asssesed	O
by	O
a	O
new	O
stianing	O
mtehod	O
.	O

The	O
asymmterical	O
breakdwon	O
of	O
the	O
blood	O
-	O
barin	O
barrier	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
femlae	O
rtas	O
.	O

Paw	O
preefrence	O
was	O
asesssed	O
by	O
a	O
food	O
reaching	O
tset	O
.	O

Adernaline	O
-	O
inudced	O
hpyertension	B-Disease
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluaetd	O
using	O
tripheynltetrazolium	O
(	O
TTC	O
)	O
stianing	O
of	O
the	O
brian	O
slcies	O
just	O
after	O
giving	O
adreanline	O
for	O
30	O
s	O
.	O

In	O
nomral	O
rtas	O
,	O
the	O
whole	O
barin	O
secitons	O
exhibited	O
complete	O
stainnig	O
with	O
TTC	O
.	O

After	O
adrnealine	O
infuison	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
untsained	O
areas	O
in	O
the	O
lfet	O
brian	O
in	O
rihgt	O
-	O
paewd	O
anmials	O
,	O
and	O
vice	O
versa	O
in	O
lfet	O
-	O
paewd	O
ainmals	O
.	O

Similar	O
resutls	O
were	O
obtained	O
in	O
seizrue	B-Disease
-	O
indcued	O
brekadown	O
of	O
BBB	O
.	O

These	O
reuslts	O
were	O
explained	O
by	O
an	O
asmymetric	O
ceerbral	O
bolod	O
folw	O
depending	O
upon	O
the	O
paw	O
perference	O
in	O
rtas	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
metohd	O
and	O
the	O
rseults	O
are	O
consistent	O
with	O
conrtalateral	O
mtoor	O
contorl	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
doimnant	O
cerberal	O
heimsphere	O
in	O
animlas	O
.	O

Carevdilol	O
protetcs	O
against	O
doxorubciin	O
-	O
induecd	O
mitochondiral	O
cardoimyopathy	B-Disease
.	O

Several	O
cytopatihc	O
mechanimss	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dsoe	O
-	O
limiting	O
cumulaitve	O
and	O
irerversible	O
cardiomyoptahy	B-Disease
caused	O
by	O
doxourbicin	O
.	O

Recent	O
evdience	O
indicates	O
that	O
oxdiative	O
strses	O
and	O
mitohcondrial	B-Disease
dysfunctoin	I-Disease
are	O
key	O
factros	O
in	O
the	O
pathgoenic	O
proecss	O
.	O

The	O
ojbective	O
of	O
this	O
investigatoin	O
was	O
to	O
tset	O
the	O
hypohtesis	O
that	O
cravedilol	O
,	O
a	O
nonselective	O
btea	O
-	O
adrneergic	O
rceeptor	O
antagnoist	O
with	O
potent	O
anitoxidant	O
propreties	O
,	O
protcets	O
against	O
the	O
cadriac	O
and	O
hpeatic	O
mtiochondrial	O
bioenegretic	O
dysufnction	O
associated	O
with	O
sbuchronic	O
dxoorubicin	O
toixcity	B-Disease
.	O

Haert	O
and	O
lievr	O
mitochonrdia	O
were	O
ioslated	O
from	O
rtas	O
tretaed	O
for	O
7	O
weeks	O
with	O
doxorubciin	O
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
)	O
,	O
carevdilol	O
(	O
1	O
mg	O
/	O
kg	O
ip	O
/	O
week	O
)	O
,	O
or	O
the	O
combinaiton	O
of	O
the	O
two	O
durgs	O
.	O

Haert	O
mitochodnria	O
isoalted	O
from	O
doxorbuicin	O
-	O
tretaed	O
rtas	O
exhibited	O
derpessed	O
raets	O
for	O
state	O
3	O
resipration	O
(	O
336	O
+	O
/	O
-	O
26	O
versus	O
425	O
+	O
/	O
-	O
53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
protien	O
)	O
and	O
a	O
lwoer	O
respiratroy	O
conrtol	O
rtaio	O
(	O
RCR	O
)	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
5	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
comapred	O
with	O
cardaic	O
mitochodnria	O
isoltaed	O
from	O
slaine	O
-	O
terated	O
rtas	O
.	O

Miotchondrial	O
calcuim	O
-	O
lodaing	O
capcaity	O
and	O
the	O
atcivity	O
of	O
NDAH	O
-	O
dheydrogenase	O
were	O
also	O
suppressed	O
in	O
cadriac	O
mitocohndria	O
from	O
doxorubciin	O
-	O
tretaed	O
rtas	O
.	O

Doxoruibcin	O
treatemnt	O
also	O
caused	O
a	O
decerase	O
in	O
RCR	O
for	O
lvier	O
mitochnodria	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
versus	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
for	O
contorl	O
rtas	O
)	O
and	O
inhibiiton	O
of	O
hepaitc	O
cytcohrome	O
oxdiase	O
actiivty	O
.	O

Coadminsitration	O
of	O
carvedioll	O
decerased	O
the	O
extent	O
of	O
cellualr	O
vacuoliztaion	O
in	O
caridac	O
myocyets	O
and	O
prevented	O
the	O
inihbitory	O
efefct	O
of	O
doxourbicin	O
on	O
mitochondrail	O
rsepiration	O
in	O
both	O
herat	O
and	O
lievr	O
.	O

Carveidlol	O
also	O
prevented	O
the	O
dcerease	O
in	O
mitochondiral	O
Ca	O
(	O
2	O
+	O
)	O
lodaing	O
capaicty	O
and	O
the	O
inihbition	O
of	O
the	O
resipratory	O
compleexs	O
of	O
herat	O
miotchondria	O
caused	O
by	O
doxroubicin	O
.	O

Carvdeilol	O
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parmaeters	O
maesured	O
for	O
haert	O
or	O
lvier	O
mitochonrdia	O
.	O

It	O
is	O
concluded	O
that	O
this	O
proetction	O
by	O
carvedliol	O
against	O
both	O
the	O
strucutral	O
and	O
functioanl	O
cardaic	O
tsisue	O
damgae	O
may	O
afford	O
significant	O
cliniacl	O
advantage	O
in	O
minimizing	O
the	O
dsoe	O
-	O
limiting	O
mitohcondrial	B-Disease
dysfunctoin	I-Disease
and	O
cardiomoypathy	B-Disease
that	O
accompanies	O
long	O
-	O
term	O
doxourbicin	O
threapy	O
in	O
canecr	B-Disease
patinets	O
.	O

Cocanie	O
-	O
inudced	O
hyperatcivity	B-Disease
is	O
more	O
inlfuenced	O
by	O
adensoine	O
recpetor	O
agnoists	O
than	O
amphetmaine	O
-	O
inudced	O
hypercativity	B-Disease
.	O

The	O
influecne	O
of	O
adneosine	O
recpetor	O
agoinsts	O
and	O
antaognists	O
on	O
coacine	O
-	O
and	O
amphetmaine	O
-	O
induecd	O
hyepractivity	B-Disease
was	O
examined	O
in	O
mcie	O
.	O

All	O
adenoisne	O
recepotr	O
agnoists	O
significantly	O
decraesed	B-Disease
the	I-Disease
locomtoor	I-Disease
acitvity	I-Disease
in	O
mcie	O
,	O
and	O
the	O
efefcts	O
were	O
dsoe	O
-	O
depnedent	O
.	O

It	O
seems	O
that	O
adeonsine	O
A1	O
and	O
A2	O
rceeptors	O
might	O
be	O
involved	O
in	O
this	O
reactoin	O
.	O

Moreover	O
,	O
all	O
adenoisne	O
recepotr	O
agnoists	O
:	O
2	O
-	O
p	O
-	O
(	O
2	O
-	O
cabroxyethyl	O
)	O
phenethylaimno	O
-	O
5	O
'	O
-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
CGS	O
26180	O
)	O
,	O
A2A	O
rceeptor	O
agonsit	O
,	O
N6	O
-	O
cyclpoentyladenosine	O
(	O
CPA	O
)	O
,	O
A1	O
recetpor	O
agoinst	O
,	O
and	O
5	O
'	O
-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
NCEA	O
)	O
,	O
A2	O
/	O
A1	O
recepotr	O
agonsit	O
significantly	O
and	O
dsoe	O
-	O
dependently	O
decresaed	O
cociane	O
-	O
inudced	O
locomtoor	O
acitvity	O
.	O

CPA	O
reudced	O
ccoaine	O
atcion	O
at	O
the	O
dsoes	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influecne	O
motiilty	O
,	O
while	O
CGS	O
21860	O
and	O
NCEA	O
decresaed	O
the	O
atcion	O
of	O
cocanie	O
at	O
the	O
doess	O
which	O
,	O
given	O
alone	O
,	O
decerased	O
locomootr	O
activtiy	O
in	O
animlas	O
.	O

These	O
rseults	O
suggest	O
the	O
involvmeent	O
of	O
both	O
adenosnie	O
receptros	O
in	O
the	O
aciton	O
of	O
coacine	O
although	O
agnoists	O
of	O
A1	O
rceeptors	O
seem	O
to	O
have	O
stronegr	O
influnece	O
on	O
it	O
.	O

The	O
selective	O
blocakde	O
of	O
A2	O
adeonsine	O
recepotr	O
by	O
DPMX	O
(	O
3	O
,	O
7	O
-	O
dmiethyl	O
-	O
1	O
-	O
propargylxnathine	O
)	O
significantly	O
enhanecd	O
cocanie	O
-	O
inudced	O
lcoomotor	O
acitvity	O
of	O
ainmals	O
.	O

Cafefine	O
had	O
similar	O
atcion	O
but	O
the	O
efefct	O
was	O
not	O
significant	O
.	O

CPT	O
(	O
8	O
-	O
cyclopentyltheophyllnie	O
)	O
-	O
-	O
A1	O
reecptor	O
antagoinst	O
,	O
did	O
not	O
show	O
any	O
influnece	O
in	O
this	O
tset	O
.	O

Similarly	O
,	O
all	O
adenosnie	O
rceeptor	O
agoinsts	O
dcereased	O
ampehtamine	O
-	O
idnuced	O
hypearctivity	B-Disease
,	O
but	O
at	O
the	O
hihger	O
doess	O
than	O
those	O
which	O
were	O
actvie	O
in	O
ccoaine	O
-	O
inudced	O
hypearctivity	B-Disease
.	O

The	O
selective	O
blcokade	O
of	O
A2	O
aednosine	O
receptros	O
(	O
DPMX	O
)	O
and	O
non	O
-	O
selective	O
bolckade	O
of	O
adensoine	O
recpetors	O
(	O
caffiene	O
)	O
significantly	O
incerased	O
the	O
atcion	O
of	O
amphetamnie	O
in	O
the	O
loocmotor	O
actiivty	O
tset	O
.	O

Our	O
resutls	O
have	O
shown	O
that	O
all	O
adenoisne	O
reecptor	O
agnoists	O
(	O
A1	O
and	O
A2	O
)	O
redcue	O
cocanie	O
-	O
and	O
amphetmaine	O
-	O
induecd	O
loocmotor	O
actviity	O
and	O
indicate	O
that	O
ccoaine	O
-	O
induecd	O
hyperactiivty	B-Disease
is	O
more	O
infleunced	O
by	O
adensoine	O
recetpor	O
agoinsts	O
(	O
particularly	O
A1	O
receptros	O
)	O
than	O
amphetaimne	O
-	O
indcued	O
hyperatcivity	B-Disease
.	O

Amioadrone	O
and	O
the	O
rsik	O
of	O
bradyarrhytmhia	B-Disease
requiring	O
permaennt	O
pacemaekr	O
in	O
eldrely	O
patietns	O
with	O
atrail	B-Disease
fibrlilation	I-Disease
and	O
prior	O
myoacrdial	B-Disease
ifnarction	I-Disease
.	O

OBJECTIEVS	O
:	O
The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amioadrone	O
in	O
paitents	O
with	O
atiral	B-Disease
fibrlilation	I-Disease
(	O
AF	B-Disease
)	O
incraeses	O
the	O
rsik	O
of	O
bradyarrhyhtmia	B-Disease
requiring	O
a	O
peramnent	O
pcaemaker	O
.	O

BCAKGROUND	O
:	O
Reprots	O
of	O
seevre	O
bradyarrhytmhia	B-Disease
during	O
amiodraone	O
threapy	O
are	O
infreqeunt	O
and	O
limietd	O
to	O
sutdies	O
assessing	O
the	O
therpay	O
'	O
s	O
use	O
in	O
the	O
manageemnt	O
of	O
paitents	O
with	O
vnetricular	B-Disease
arhrythmias	I-Disease
.	O

METHODS	O
:	O
A	O
stduy	O
coohrt	O
of	O
8	O
,	O
770	O
ptaients	O
age	O
>	O
or	O
=	O
65	O
yeras	O
with	O
a	O
new	O
daignosis	O
of	O
AF	B-Disease
was	O
idenitfied	O
from	O
a	O
porvincewide	O
daatbase	O
of	O
Queebc	O
residetns	O
with	O
a	O
mycoardial	B-Disease
infarciton	I-Disease
(	O
MI	B-Disease
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
nseted	O
csae	O
-	O
cnotrol	O
desgin	O
,	O
477	O
caess	O
of	O
bradyarryhthmia	B-Disease
requiring	O
a	O
premanent	O
paecmaker	O
were	O
matched	O
(	O
1	O
:	O
4	O
)	O
to	O
1	O
,	O
908	O
cnotrols	O
.	O

Multivaraible	O
logsitic	O
regerssion	O
was	O
used	O
to	O
estimtae	O
the	O
odds	O
rtaio	O
(	O
OR	O
)	O
of	O
paceamker	O
insetrion	O
associated	O
with	O
amiodaorne	O
use	O
,	O
controlling	O
for	O
basleine	O
rsik	O
factros	O
and	O
exposrue	O
to	O
sotaoll	O
,	O
Clsas	O
I	O
atniarrhythmic	O
aegnts	O
,	O
btea	O
-	O
blocekrs	O
,	O
calcuim	O
chanenl	O
bolckers	O
,	O
and	O
diogxin	O
.	O

RESLUTS	O
:	O
amoidarone	O
use	O
was	O
associated	O
with	O
an	O
increaesd	O
rsik	O
of	O
pacmeaker	O
insertoin	O
(	O
OR	O
:	O
2	O
.	O
14	O
,	O
95	O
%	O
confdience	O
intreval	O
[	O
CI	O
]	O
:	O
1	O
.	O
30	O
to	O
3	O
.	O
54	O
)	O
.	O

This	O
effect	O
was	O
modifeid	O
by	O
gneder	O
,	O
with	O
a	O
greater	O
rsik	O
in	O
wmoen	O
versus	O
men	O
(	O
OR	O
:	O
3	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
70	O
to	O
8	O
.	O
75	O
vs	O
.	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
to	O
2	O
.	O
89	O
)	O
.	O

Diogxin	O
was	O
the	O
only	O
other	O
medicatoin	O
associated	O
with	O
an	O
incraesed	O
rsik	O
of	O
paecmaker	O
insertoin	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
37	O
to	O
2	O
.	O
31	O
)	O
.	O

CNOCLUSIONS	O
:	O
This	O
stduy	O
suggests	O
that	O
the	O
use	O
of	O
amiodraone	O
in	O
eledrly	O
pateints	O
with	O
AF	B-Disease
and	O
a	O
previous	O
MI	B-Disease
incraeses	O
the	O
rsik	O
of	O
bradyarrhtyhmia	B-Disease
requiring	O
a	O
pemranent	O
pacmeaker	O
.	O

The	O
fniding	O
of	O
an	O
augmenetd	O
rsik	O
of	O
paceamker	O
insetrion	O
in	O
eledrly	O
woemn	O
receiving	O
amiodaorne	O
requires	O
further	O
investigtaion	O
.	O

Indomethaicn	O
-	O
indcued	O
morphoolgic	O
chagnes	O
in	O
the	O
rat	O
uirnary	O
baldder	O
epithleium	O
.	O

OBEJCTIVES	O
:	O
To	O
evalutae	O
the	O
morpholgoic	O
chanegs	O
in	O
rat	O
urotheluim	O
idnuced	O
by	O
indomehtacin	O
.	O

Nontseroidal	O
atni	O
-	O
ifnlammatory	O
durg	O
-	O
indcued	O
cystiits	B-Disease
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
condtiion	O
.	O

In	O
addition	O
to	O
taiprofenic	O
aicd	O
,	O
idnomethacin	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
conditoin	O
.	O

METHODS	O
:	O
Three	O
gorups	O
were	O
established	O
:	O
a	O
conrtol	O
gorup	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
dsoe	O
gruop	O
(	O
n	O
=	O
10	O
)	O
,	O
tretaed	O
with	O
one	O
intraperitonael	O
injetcion	O
of	O
indoemthacin	O
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
therpaeutic	O
dsoe	O
gorup	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oarl	O
idnomethacin	O
was	O
amdinistered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
bdoy	O
weihgt	O
daliy	O
for	O
3	O
weeks	O
.	O

The	O
animlas	O
were	O
then	O
killed	O
and	O
the	O
bldaders	O
remoevd	O
for	O
light	O
and	O
eelctron	O
micorscopic	O
sutdies	O
.	O

RESLUTS	O
:	O
The	O
light	O
microsocpic	O
findigns	O
showed	O
some	O
fcoal	O
eipthelial	O
degneeration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
.	O

When	O
cmopared	O
with	O
the	O
cnotrol	O
gruop	O
,	O
both	O
indomtehacin	O
gruops	O
revaeled	O
statsitically	O
inrceased	O
nmubers	O
of	O
msat	O
clels	O
in	O
the	O
mucsoa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
penertation	O
of	O
lanhtanum	O
nitarte	O
through	O
interecllular	O
areas	O
of	O
the	O
eipthelium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
msat	O
clel	O
coutns	O
between	O
the	O
high	O
and	O
threapeutic	O
dsoe	O
gorups	O
was	O
also	O
statisticlaly	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSINOS	O
:	O
Indometahcin	O
resulted	O
in	O
hisotpathologic	O
fnidings	O
typical	O
of	O
intertsitial	B-Disease
cysittis	I-Disease
,	O
such	O
as	O
laeky	O
bladder	O
epitheluim	O
and	O
muocsal	O
mastocytsois	B-Disease
.	O

The	O
true	O
incidecne	O
of	O
nonsteroiadl	O
atni	O
-	O
inflammatroy	O
durg	O
-	O
induecd	O
csytitis	B-Disease
in	O
hmuans	O
must	O
be	O
clarified	O
by	O
propsective	O
clniical	O
trilas	O
.	O

An	O
open	O
-	O
laebl	O
pahse	O
II	O
sutdy	O
of	O
low	O
-	O
dsoe	O
thaildomide	O
in	O
andorgen	O
-	O
indepednent	O
prsotate	B-Disease
cacner	I-Disease
.	O

The	O
antaingiogenic	O
effetcs	O
of	O
thaliodmide	O
have	O
been	O
assessed	O
in	O
clniical	O
trails	O
in	O
ptaients	O
with	O
various	O
sloid	O
and	O
haematologiacl	B-Disease
malignanices	I-Disease
.	O

Thalidmoide	O
blokcs	O
the	O
atcivity	O
of	O
agniogenic	O
aegnts	O
including	O
bGFF	O
,	O
VGEF	O
and	O
IL	O
-	O
6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
laebl	O
sutdy	O
using	O
thaldiomide	O
100	O
mg	O
once	O
daliy	O
for	O
up	O
to	O
6	O
mnoths	O
in	O
20	O
men	O
with	O
anrdogen	O
-	O
indepenednt	O
porstate	B-Disease
cacner	I-Disease
.	O

The	O
mean	O
tmie	O
of	O
stduy	O
was	O
109	O
dyas	O
(	O
mdeian	O
107	O
,	O
range	O
4	O
-	O
184	O
dyas	O
)	O
.	O

Patinets	O
underwent	O
regular	O
meausrement	O
of	O
prsotate	O
-	O
specific	O
atnigen	O
(	O
PSA	O
)	O
,	O
uera	O
and	O
electrolyets	O
,	O
sreum	O
bGFF	O
and	O
VGEF	O
.	O

Three	O
men	O
(	O
15	O
%	O
)	O
showed	O
a	O
decilne	O
in	O
sreum	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustianed	O
throughout	O
treatmnet	O
.	O

Of	O
16	O
men	O
tretaed	O
for	O
at	O
least	O
2	O
motnhs	O
,	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
asbolute	O
PSA	O
by	O
a	O
medain	O
of	O
48	O
%	O
.	O

Increasnig	O
leevls	O
of	O
seurm	O
bGFF	O
and	O
VGEF	O
were	O
associated	O
with	O
prgoressive	O
dsiease	O
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decilne	O
in	O
bGFF	O
and	O
VGEF	O
leevls	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
incerase	O
in	O
both	O
gorwth	O
fatcors	O
.	O

Advesre	O
effetcs	O
included	O
constipaiton	B-Disease
,	O
monring	O
droswiness	B-Disease
,	O
dziziness	B-Disease
and	O
rsah	B-Disease
,	O
and	O
resulted	O
in	O
wtihdrawal	O
from	O
the	O
sutdy	O
by	O
three	O
men	O
.	O

Evidecne	O
of	O
periphreal	B-Disease
sensroy	I-Disease
neuorpathy	I-Disease
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treamtent	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
motnhs	O
on	O
tahlidomide	O
,	O
subclincial	O
evidnece	O
of	O
perpiheral	B-Disease
nueropathy	I-Disease
was	O
found	O
in	O
four	O
before	O
traetment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repaet	O
tseting	O
.	O

The	O
findnigs	O
indicate	O
that	O
thaliodmide	O
may	O
be	O
an	O
option	O
for	O
pateints	O
who	O
have	O
failed	O
other	O
forms	O
of	O
tehrapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
developmnet	O
of	O
perihperal	B-Disease
neuropahty	I-Disease
.	O

Cenrtal	B-Disease
nerovus	I-Disease
sysetm	I-Disease
toixcity	I-Disease
following	O
the	O
adminsitration	O
of	O
levobuipvacaine	O
for	O
lubmar	O
pelxus	O
blcok	O
:	O
A	O
reoprt	O
of	O
two	O
caess	O
.	O

BACKGRUOND	O
AND	O
OBEJCTIVES	O
:	O
Cnetral	B-Disease
nervuos	I-Disease
ssytem	I-Disease
and	I-Disease
caridac	I-Disease
toixcity	I-Disease
following	O
the	O
adminitsration	O
of	O
lcoal	O
anesthteics	O
is	O
a	O
recognized	O
complictaion	O
of	O
regioanl	O
ansethesia	O
.	O

Levobpuivacaine	O
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
ennatiomer	O
of	O
bupviacaine	O
,	O
was	O
developed	O
to	O
imporve	O
the	O
cadriac	O
saefty	O
proifle	O
of	O
bupivaciane	O
.	O

We	O
describe	O
2	O
csaes	O
of	O
grand	B-Disease
mal	I-Disease
seizuers	I-Disease
following	O
acciedntal	O
intravascualr	O
injetcion	O
of	O
levobupiavcaine	O
.	O

CSAE	O
REPORT	O
:	O
Two	O
patietns	O
presneting	O
for	O
electvie	O
orthopeidc	O
srugery	O
of	O
the	O
lwoer	O
lmib	O
underwent	O
blocakde	O
of	O
the	O
lmubar	O
pelxus	O
via	O
the	O
potserior	O
approach	O
.	O

Immediately	O
after	O
the	O
administartion	O
of	O
levboupivacaine	O
0	O
.	O
5	O
%	O
with	O
epienphrine	O
2	O
.	O
5	O
mircogram	O
/	O
mL	O
,	O
the	O
ptaients	O
developed	O
grand	B-Disease
mal	I-Disease
seizuers	I-Disease
,	O
despite	O
negaitve	O
aspiartion	O
for	O
blood	O
and	O
no	O
cliniacl	O
sgins	O
of	O
intrvaenous	O
epniephrine	O
adimnistration	O
.	O

The	O
siezures	B-Disease
were	O
successfully	O
tretaed	O
with	O
sdoium	O
thiopetnal	O
in	O
addition	O
to	O
succinylcohline	O
in	O
1	O
patinet	O
.	O

Neither	O
pateint	O
developed	O
sings	O
of	O
cardiovascluar	B-Disease
toxciity	I-Disease
.	O

Both	O
patietns	O
were	O
treaetd	O
proeperatively	O
with	O
btea	O
-	O
adreenrgic	O
antgaonist	O
medicatinos	O
,	O
which	O
may	O
have	O
maksed	O
the	O
cardiovsacular	O
sgins	O
of	O
the	O
unnitentional	O
intravacsular	O
admniistration	O
of	O
levobuipvacaine	O
with	O
epniephrine	O
.	O

CONCLSUIONS	O
:	O
Although	O
levobupivcaaine	O
may	O
have	O
a	O
safer	O
cadriac	B-Disease
toxiicty	I-Disease
prfoile	O
than	O
raecmic	O
bupivcaaine	O
,	O
if	O
adqeuate	O
amounts	O
of	O
levobpuivacaine	O
reach	O
the	O
circulaiton	O
,	O
it	O
will	O
result	O
in	O
convulisons	B-Disease
.	O

Plsama	O
concentraitons	O
sufficient	O
to	O
result	O
in	O
centarl	B-Disease
nevrous	I-Disease
ssytem	I-Disease
txoicity	I-Disease
did	O
not	O
produce	O
maniefstations	O
of	O
cradiac	B-Disease
toxictiy	I-Disease
in	O
these	O
2	O
pateints	O
.	O

Amiodarnoe	O
-	O
idnuced	O
torasde	B-Disease
de	I-Disease
poitnes	I-Disease
during	O
bladder	O
irirgation	O
:	O
an	O
unsuual	O
presenattion	O
-	O
-	O
a	O
csae	O
reoprt	O
.	O

The	O
atuhors	O
present	O
a	O
csae	O
of	O
eraly	O
(	O
within	O
4	O
dyas	O
)	O
deevlopment	O
of	O
tosrade	B-Disease
de	I-Disease
ponites	I-Disease
(	O
TdP	B-Disease
)	O
associated	O
with	O
oarl	O
amiodraone	O
therpay	O
.	O

Consistent	O
with	O
other	O
rpeorts	O
this	O
csae	O
of	O
TdP	B-Disease
occurred	O
in	O
the	O
cnotext	O
of	O
mlutiple	O
exacebrating	O
facotrs	O
including	O
hypokaelmia	B-Disease
and	O
digxoin	O
ecxess	O
.	O

Tarnsient	O
prloongation	O
of	O
the	O
QT	O
during	O
bladedr	O
irirgation	O
prompted	O
the	O
episdoe	O
of	O
TdP	B-Disease
.	O

It	O
is	O
well	O
known	O
that	O
bardycardia	B-Disease
eaxcerbates	O
acquired	O
TdP	B-Disease
.	O

The	O
autohrs	O
speculate	O
that	O
the	O
incerased	O
vgaal	O
tnoe	O
during	O
bladedr	O
irrgiation	O
,	O
a	O
vgaal	O
manevuer	O
,	O
in	O
the	O
cnotext	O
of	O
amoidarone	O
threapy	O
resulted	O
in	O
amiodraone	O
-	O
induecd	O
praorrhythmia	B-Disease
.	O

In	O
the	O
asbence	O
of	O
amoidarone	O
thearpy	O
,	O
a	O
second	O
baldder	O
irrigation	O
did	O
not	O
indcue	O
TdP	B-Disease
despite	O
hypoklaemia	B-Disease
and	O
hypomagneseima	B-Disease
.	O

Aanesthetic	O
cmoplications	O
associated	O
with	O
myotnoia	B-Disease
congenita	I-Disease
:	O
csae	O
sutdy	O
and	O
compairson	O
with	O
other	O
myootnic	B-Disease
disoredrs	I-Disease
.	O

Mytoonia	B-Disease
congenita	I-Disease
(	O
MC	B-Disease
)	O
is	O
caused	O
by	O
a	O
deefct	O
in	O
the	O
sekletal	O
muslce	O
chlordie	O
chanenl	O
fucntion	O
,	O
which	O
may	O
cause	O
ssutained	B-Disease
memrbane	I-Disease
depolariastion	I-Disease
.	O

We	O
describe	O
a	O
previously	O
heatlhy	O
32	O
-	O
yaer	O
-	O
old	O
woamn	O
who	O
developed	O
a	O
lfie	O
-	O
threatening	O
mucsle	B-Disease
sapsm	I-Disease
and	O
secondary	O
ventialtion	O
difficluties	O
following	O
a	O
preopertaive	O
inejction	O
of	O
suxamethonuim	O
.	O

The	O
mucsle	B-Disease
spsams	I-Disease
disappeared	O
sponatneously	O
and	O
the	O
suregry	O
proceeded	O
without	O
further	O
probelms	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
sypmtoms	O
suggesting	O
a	O
mytoonic	B-Disease
conidtion	I-Disease
.	O

Myotoina	B-Disease
was	O
found	O
on	O
cliincal	O
examiantion	O
and	O
EMG	O
.	O

The	O
diagnoiss	O
MC	B-Disease
was	O
confirmed	O
geentically	O
.	O

Neither	O
the	O
paitent	O
nor	O
the	O
aanesthetist	O
were	O
aware	O
of	O
the	O
daignosis	O
before	O
this	O
potentially	O
lehtal	O
complictaion	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overivew	O
of	O
ion	B-Disease
chnanel	I-Disease
disodrers	I-Disease
including	O
mlaignant	B-Disease
hyeprthermia	I-Disease
and	O
their	O
anaesthteic	O
consiedrations	O
.	O

Respriatory	O
ptatern	O
in	O
a	O
rat	O
moedl	O
of	O
epilespy	B-Disease
.	O

PUROPSE	O
:	O
Anpea	B-Disease
is	O
known	O
to	O
occur	O
during	O
siezures	B-Disease
,	O
but	O
systeamtic	O
sutdies	O
of	O
itcal	O
respiraotry	O
cahnges	O
in	O
adutls	O
are	O
few	O
.	O

Dtaa	O
regarding	O
respiratroy	O
pattren	O
deefcts	O
during	O
interitcal	O
peridos	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
inofrmation	O
with	O
regard	O
to	O
the	O
intreictal	O
peirod	O
in	O
anmials	O
with	O
pilocarpnie	O
-	O
inudced	O
epilpesy	B-Disease
.	O

METHODS	O
:	O
Twelve	O
rtas	O
(	O
six	O
chroniclaly	O
epilpetic	B-Disease
ainmals	O
and	O
six	O
cnotrols	O
)	O
were	O
anetshetized	O
,	O
given	O
tracheotomeis	O
,	O
and	O
subjected	O
to	O
hyperventiltaion	B-Disease
or	O
hypoventilatoin	O
codnitions	O
.	O

Bretahing	O
mvoements	O
caused	O
chagnes	O
in	O
thoraicc	O
volmue	O
and	O
forced	O
air	O
to	O
folw	O
tdially	O
through	O
a	O
pneumotachgoraph	O
.	O

This	O
folw	O
was	O
measuerd	O
by	O
using	O
a	O
differential	O
pressure	O
trasnducer	O
,	O
passed	O
through	O
a	O
polygarph	O
,	O
and	O
from	O
this	O
to	O
a	O
comupter	O
with	O
custom	O
softwrae	O
that	O
derived	O
vnetilation	O
(	O
VE	O
)	O
,	O
tdial	O
voulme	O
(	O
VT	O
)	O
,	O
inspirtaory	O
tmie	O
(	O
TI	O
)	O
,	O
expirtaory	O
tmie	O
(	O
TE	O
)	O
,	O
berathing	O
frequecny	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspiratroy	O
folw	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
braeth	O
-	O
by	O
-	O
berath	O
basis	O
.	O

REUSLTS	O
:	O
The	O
hyperventilatoin	B-Disease
maenuver	O
caused	O
a	O
dcerease	O
in	O
spontaenous	O
ventialtion	O
in	O
pliocarpine	O
-	O
traeted	O
and	O
conrtol	O
rtas	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decraese	O
in	O
both	O
gruops	O
,	O
in	O
the	O
epielptic	B-Disease
gorup	O
,	O
the	O
dcerease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
incresae	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
conrtol	O
ainmals	O
.	O

The	O
hypovetnilation	O
maneuevr	O
led	O
to	O
an	O
incresae	O
in	O
the	O
arteiral	O
Paoc2	O
,	O
followed	O
by	O
an	O
incerase	O
in	O
VE	O
.	O

In	O
the	O
eipleptic	B-Disease
gruop	O
,	O
the	O
incerase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
dcerease	O
in	O
TE	O
peak	O
compraed	O
with	O
the	O
conrtol	O
gruop	O
.	O

Sytsemic	O
applciation	O
of	O
KCN	O
,	O
to	O
evlauate	O
the	O
effects	O
of	O
peripehral	O
cehmoreception	O
actviation	O
on	O
venitlation	O
,	O
led	O
to	O
a	O
similar	O
incerase	O
in	O
VE	O
for	O
both	O
gruops	O
.	O

COCNLUSIONS	O
:	O
The	O
dtaa	O
indicate	O
that	O
pilocaprine	O
-	O
treaetd	O
ainmals	O
have	O
an	O
altreed	O
ability	O
to	O
react	O
to	O
(	O
or	O
compenaste	O
for	O
)	O
bolod	O
gas	O
cahnges	O
with	O
cahnges	O
in	O
ventilatoin	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findnigs	O
on	O
terating	O
different	O
eiplepsy	B-Disease
-	O
associated	O
conditinos	O
.	O

Ftaal	O
myelonecephalopathy	B-Disease
due	O
to	O
itnrathecal	O
vinrcistine	O
administartion	O
.	O

Vicnristine	O
was	O
accidentally	O
given	O
intarthecally	O
to	O
a	O
cihld	O
with	O
lekuaemia	B-Disease
,	O
producing	O
senosry	B-Disease
and	I-Disease
mootr	I-Disease
dysfunciton	I-Disease
followed	O
by	O
encephaolpathy	B-Disease
and	O
daeth	O
.	O

Separate	O
times	O
for	O
adminsitering	O
vincirstine	O
and	O
intratheacl	O
tehrapy	O
is	O
recommended	O
.	O

Proegsterone	O
potentiatoin	O
of	O
bupivaciane	O
arrhythmogenciity	O
in	O
pentobarbtial	O
-	O
anetshetized	O
rtas	O
and	O
betaing	O
rat	O
herat	O
clel	O
cultrues	O
.	O

The	O
effetcs	O
of	O
progestreone	O
traetment	O
on	O
bupivaacine	O
arrhythmogenictiy	O
in	O
baeting	O
rat	O
haert	O
moycyte	O
culutres	O
and	O
on	O
anestehtized	O
rtas	O
were	O
determined	O
.	O

After	O
determining	O
the	O
buipvacaine	O
A5D0	O
(	O
the	O
concentartion	O
of	O
bpuivacaine	O
that	O
caused	O
50	O
%	O
of	O
all	O
betaing	O
rat	O
herat	O
myoycte	O
cutlures	O
to	O
become	O
arrhyhtmic	B-Disease
)	O
,	O
we	O
determined	O
the	O
effect	O
of	O
1	O
-	O
hour	O
prgoesterone	O
HCl	O
exposrue	O
on	O
myoycte	O
conrtactile	O
rhtyhm	O
.	O

Each	O
concentrtaion	O
of	O
progseterone	O
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
mcirograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
conecntration	O
-	O
depenednt	O
reduciton	O
in	O
the	O
A5D0	O
for	O
bupivaacine	O
.	O

Estardiol	O
teratment	O
also	O
incresaed	O
the	O
arrhythmogenciity	O
of	O
bupviacaine	O
in	O
myoycte	O
clutures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
proegsterone	O
.	O

Neither	O
porgesterone	O
nor	O
estradoil	O
efefcts	O
on	O
bupivaacine	O
arryhthmogenicity	O
were	O
potentaited	O
by	O
epinehprine	O
.	O

Chornic	O
progesetrone	O
prtereatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
dyas	O
)	O
caused	O
a	O
significant	O
icnrease	O
in	O
bupivaciane	O
arrhythmoegnicity	O
in	O
inatct	O
pentobarbiatl	O
-	O
aensthetized	O
rtas	O
.	O

There	O
was	O
a	O
significant	O
decresae	O
in	O
the	O
tmie	O
to	O
onset	O
of	O
arrhtyhmia	B-Disease
as	O
copmared	O
with	O
conrtol	O
nonprogetserone	O
-	O
treaetd	O
rtas	O
(	O
6	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
vs	O
.	O
30	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
resutls	O
of	O
this	O
stduy	O
indicate	O
that	O
prgoesterone	O
can	O
potetniate	O
bpuivacaine	O
arrhythmogeniicty	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potentaition	O
of	O
bupiavcaine	O
arrhtyhmia	B-Disease
in	O
myoycte	O
clutures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myoycte	O
lveel	O
.	O

Incerased	O
seurm	O
soulble	O
Fas	O
in	O
ptaients	O
with	O
aucte	B-Disease
lievr	I-Disease
faiulre	I-Disease
due	O
to	O
paracetaoml	O
overdsoe	B-Disease
.	O

BACKGRONUD	O
/	O
AMIS	O
:	O
Epxerimental	O
stduies	O
have	O
suggested	O
that	O
appotosis	O
via	O
the	O
Fas	O
/	O
Fas	O
Liagnd	O
signalnig	O
sytsem	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
developemnt	O
of	O
actue	B-Disease
lievr	I-Disease
faliure	I-Disease
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
investgiate	O
the	O
solulbe	O
form	O
of	O
Fas	O
in	O
ptaients	O
with	O
actue	B-Disease
lvier	I-Disease
faiulre	I-Disease
.	O

METHODOLOGY	O
:	O
Sreum	O
leevls	O
of	O
saFs	O
(	O
slouble	O
Fas	O
)	O
were	O
measuerd	O
by	O
EILSA	O
in	O
24	O
ptaients	O
with	O
aucte	B-Disease
lvier	I-Disease
fialure	I-Disease
and	O
10	O
noraml	O
contorl	O
subejcts	O
.	O

Seurm	O
levles	O
of	O
tmuor	B-Disease
necroiss	B-Disease
facotr	O
-	O
alhpa	O
and	O
intreferon	O
-	O
gamma	O
were	O
also	O
determined	O
by	O
ELSIA	O
.	O

RSEULTS	O
:	O
Sreum	O
saFs	O
was	O
significantly	O
inrceased	O
in	O
patinets	O
with	O
aucte	B-Disease
lievr	I-Disease
faiulre	I-Disease
(	O
meidan	O
,	O
26	O
.	O
8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
)	O
copmared	O
to	O
the	O
noraml	O
contorls	O
(	O
mdeian	O
,	O
8	O
.	O
6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
5	O
-	O
12	O
.	O
0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Levles	O
were	O
significantly	O
greater	O
in	O
ptaients	O
with	O
aucte	B-Disease
lvier	I-Disease
fialure	I-Disease
due	O
to	O
praacetamol	O
overodse	B-Disease
(	O
mdeian	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepatiits	B-Disease
(	O
meidan	O
,	O
12	O
.	O
5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
46	O
.	O
0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	O
realtionship	O
of	O
saFs	O
to	O
evnetual	O
otucome	O
in	O
the	O
pateints	O
.	O

A	O
significant	O
correlation	O
was	O
observed	O
between	O
seurm	O
saFs	O
levles	O
and	O
asparatte	O
aimnotransferase	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUISONS	O
:	O
The	O
increaesd	O
concentartion	O
of	O
saFs	O
in	O
sreum	O
of	O
pateints	O
with	O
actue	B-Disease
lvier	I-Disease
fialure	I-Disease
may	O
reflect	O
atcivation	O
of	O
Fas	O
-	O
mediated	O
appotosis	O
in	O
the	O
lvier	O
and	O
this	O
together	O
with	O
incerased	O
tuomr	B-Disease
necrsois	B-Disease
facotr	O
-	O
aplha	O
may	O
be	O
an	O
important	O
fatcor	O
in	O
lievr	O
clel	O
lsos	O
.	O

Bilatreal	O
subthalaimc	O
nculeus	O
stimluation	O
for	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
.	O

High	O
frequnecy	O
stimulaiton	O
of	O
the	O
subthlaamic	O
nucelus	O
(	O
STN	O
)	O
is	O
known	O
to	O
amleiorate	O
the	O
sgins	O
and	O
smyptoms	O
of	O
adavnced	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

AIM	O
:	O
We	O
studied	O
the	O
effcet	O
of	O
high	O
frqeuency	O
STN	O
stimultaion	O
in	O
23	O
ptaients	O
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
ptaients	O
suffernig	O
from	O
sveere	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
(	O
Satges	O
III	O
-	O
V	O
on	O
Hohen	O
and	O
Yhar	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinseia	B-Disease
,	O
riigdity	B-Disease
,	O
and	O
leovdopa	O
-	O
idnuced	O
dysiknesias	B-Disease
underwent	O
bilatreal	O
implantatoin	O
of	O
electrdoes	O
in	O
the	O
STN	O
.	O

Preopeartive	O
and	O
postoperaitve	O
assessemnts	O
of	O
these	O
paitents	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
monhts	O
follow	O
-	O
up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
durg	O
conditoins	O
,	O
was	O
carried	O
out	O
using	O
Uinfied	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
Diesase	I-Disease
Ratnig	O
Sacle	O
,	O
Hohen	O
and	O
Yhar	O
stgaing	O
,	O
Egnland	O
atcivities	O
of	O
dialy	O
livnig	O
scroe	O
and	O
viedo	O
reocrdings	O
.	O

RESUTLS	O
:	O
After	O
one	O
yaer	O
of	O
elecrtical	O
stimluation	O
of	O
the	O
STN	O
,	O
the	O
patietns	O
'	O
socres	O
for	O
activiites	O
of	O
dialy	O
livnig	O
and	O
mootr	O
exmaination	O
socres	O
(	O
Unfiied	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
Diesase	I-Disease
Raitng	O
Sacle	O
patrs	O
II	O
and	O
III	O
)	O
off	O
mediaction	O
imrpoved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
susbcores	O
for	O
the	O
akinseia	B-Disease
,	O
rigidtiy	B-Disease
,	O
termor	B-Disease
and	O
giat	O
also	O
improevd	O
.	O

(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
avearge	O
leovdopa	O
dsoe	O
decreaesd	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cgonitive	O
funcitons	O
remained	O
unchnaged	O
.	O

Two	O
patietns	O
developed	O
dveice	O
-	O
related	O
comlpications	O
and	O
two	O
patietns	O
experienced	O
abnromal	O
wegiht	O
gain	O
.	O

CONCLUISON	O
:	O
Bilatreal	O
subhtalamic	O
nuclues	O
stimulaiton	O
is	O
an	O
effective	O
traetment	O
for	O
avdanced	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
.	O

It	O
redcues	O
the	O
severtiy	O
of	O
"	O
off	O
"	O
pahse	O
smyptoms	O
,	O
improevs	O
the	O
axail	O
symtpoms	O
and	O
rdeuces	O
levdoopa	O
requriements	O
.	O

The	O
reudction	O
in	O
the	O
lveodopa	O
dsoe	O
is	O
useful	O
in	O
controlling	O
durg	B-Disease
-	I-Disease
idnuced	I-Disease
dyskineisas	I-Disease
.	O

Aucte	B-Disease
rneal	I-Disease
fialure	I-Disease
occurring	O
during	O
intarvenous	O
desferroixamine	O
thearpy	O
:	O
recoevry	O
after	O
heamodialysis	O
.	O

A	O
patinet	O
with	O
tarnsfusion	O
-	O
dpeendent	O
thalassemia	B-Disease
was	O
undergoing	O
hmoe	O
intarvenous	O
desfrerioxamine	O
(	O
DFX	O
)	O
tretament	O
by	O
means	O
of	O
a	O
totally	O
implnated	O
sysetm	O
because	O
of	O
his	O
poor	O
compilance	O
with	O
the	O
ngihtly	O
subctuaneous	O
tehrapy	O
.	O

Due	O
to	O
an	O
acciedntal	O
malfucntioning	O
of	O
the	O
infsuion	O
pmup	O
,	O
the	O
ptaient	O
was	O
inadvertently	O
admniistered	O
a	O
toixc	O
dsoage	O
of	O
the	O
durg	O
which	O
caused	O
rneal	B-Disease
insuffciiency	I-Disease
.	O

Given	O
the	O
progerssive	O
deterioraiton	O
of	O
the	O
sypmtoms	O
and	O
of	O
the	O
laboartory	O
vlaues	O
,	O
despite	O
adqeuate	O
mdeical	O
teratment	O
,	O
a	O
decsiion	O
was	O
made	O
to	O
introduce	O
haemodiayltical	O
thearpy	O
in	O
order	O
to	O
remove	O
the	O
durg	O
and	O
thearpy	O
redcue	O
the	O
nephrotoxictiy	B-Disease
.	O

From	O
the	O
resluts	O
obtained	O
,	O
hameodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therpay	O
in	O
rrae	O
caess	O
of	O
progrsesive	O
aucte	B-Disease
reanl	I-Disease
faliure	I-Disease
caused	O
by	O
desefrrioxamine	O
.	O

Ocluar	O
motliity	O
chnages	O
after	O
subtneon	O
cabroplatin	O
cheomtherapy	O
for	O
retinoblasotma	B-Disease
.	O

BCAKGROUND	O
:	O
Fcoal	O
sutbenon	O
craboplatin	O
inejctions	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toixcity	B-Disease
-	O
free	O
adjucnt	O
to	O
systeimc	O
chemothearpy	O
for	O
introacular	O
retinbolastoma	B-Disease
.	O

OJBECTIVE	O
:	O
To	O
reoprt	O
our	O
clniical	O
epxerience	O
with	O
abnomral	B-Disease
ocluar	I-Disease
mtoility	I-Disease
in	O
ptaients	O
terated	O
with	O
subteonn	O
carbopltain	O
chemohterapy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnoraml	B-Disease
ocluar	I-Disease
moitlity	I-Disease
in	O
10	O
consectuive	O
patietns	O
with	O
retinoblsatoma	B-Disease
who	O
had	O
received	O
subetnon	O
carboplaitn	O
.	O

During	O
ocluar	O
manpiulation	O
under	O
general	O
anestheisa	O
,	O
we	O
asesssed	O
their	O
eeys	O
by	O
forced	O
dutcion	O
testnig	O
,	O
compairng	O
ocualr	O
motliity	O
after	O
tuomr	B-Disease
contorl	O
with	O
ouclar	O
moitlity	O
at	O
diangosis	O
.	O

Eeys	O
subsequently	O
euncleated	O
because	O
of	O
treatemnt	O
faiulre	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histologically	O
.	O

RSEULTS	O
:	O
Lmiitation	O
of	O
ocualr	O
motliity	O
was	O
detecetd	O
in	O
all	O
12	O
eeys	O
of	O
10	O
patinets	O
treaetd	O
for	O
introacular	O
retnioblastoma	B-Disease
with	O
1	O
to	O
6	O
injectoins	O
of	O
subtneon	O
carbopltain	O
as	O
part	O
of	O
multimodailty	O
tehrapy	O
.	O

Hsitopathological	O
exaimnation	O
rveealed	O
many	O
lipopahges	O
in	O
the	O
peroirbital	O
fat	O
surrounding	O
the	O
otpic	O
nreve	O
in	O
1	O
eye	O
,	O
inidcative	O
of	O
phagcoytosis	O
of	O
previously	O
existing	O
fat	O
clels	O
and	O
suggesting	O
prior	O
fat	O
necrsois	B-Disease
.	O

The	O
enucleatinos	O
were	O
tehcnically	O
difficult	O
and	O
hazadrous	O
for	O
glboe	O
rutpure	B-Disease
because	O
of	O
extensvie	O
obrital	O
sfot	O
tisuse	O
adheisons	O
.	O

CONCLUSINOS	O
:	O
Subetnon	O
carboplaitn	O
cehmotherapy	O
is	O
associated	O
with	O
significant	O
fibrsois	B-Disease
of	O
orbiatl	O
sfot	O
tissues	O
,	O
leading	O
to	O
mechnaical	O
resrtiction	O
of	O
eye	O
movemnets	O
and	O
making	O
subsequent	O
enulceation	O
difficult	O
.	O

Subteonn	O
carbopaltin	O
is	O
not	O
free	O
of	O
txoicity	B-Disease
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indicaitons	O
.	O

Ethamubtol	O
and	O
otpic	B-Disease
nueropathy	I-Disease
.	O

PUPROSE	O
:	O
To	O
demonstrate	O
the	O
asosciation	O
between	O
etahmbutol	O
and	O
opitc	B-Disease
neuorpathy	I-Disease
.	O

METHOD	O
:	O
Thirteen	O
patietns	O
who	O
developed	O
opitc	B-Disease
neuroptahy	I-Disease
after	O
being	O
traeted	O
with	O
ethambtuol	O
for	O
tubercuolsis	B-Disease
of	I-Disease
the	I-Disease
lnug	I-Disease
or	I-Disease
lmyph	I-Disease
ndoe	I-Disease
at	O
Siriarj	O
Hosptial	O
between	O
1997	O
and	O
2001	O
were	O
retrospecitvely	O
reveiwed	O
.	O

The	O
cilnical	O
charactreistics	O
and	O
initial	O
and	O
final	O
viusal	O
acutiy	O
were	O
aanlyzed	O
to	O
determine	O
visaul	O
outocme	O
.	O

RESLUTS	O
:	O
All	O
pateints	O
had	O
opitc	B-Disease
neuropahty	I-Disease
between	O
1	O
to	O
6	O
mnoths	O
(	O
mean	O
=	O
2	O
.	O
9	O
mnoths	O
)	O
after	O
starting	O
ehtambutol	O
thearpy	O
at	O
a	O
doasge	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
pateints	O
experienced	O
visaul	O
recvoery	O
after	O
stopping	O
the	O
durg	O
.	O

Of	O
6	O
pateints	O
with	O
irreversbile	O
visaul	B-Disease
ipmairment	I-Disease
,	O
4	O
patietns	O
had	O
daibetes	B-Disease
melltius	I-Disease
,	O
gluacoma	B-Disease
and	O
a	O
hisotry	O
of	O
haevy	O
smoikng	O
.	O

COCNLUSION	O
:	O
Ealry	O
recongition	O
of	O
otpic	B-Disease
neuroptahy	I-Disease
should	O
be	O
considered	O
in	O
pateints	O
with	O
ethambtuol	O
threapy	O
.	O

A	O
low	O
dsoe	O
and	O
prompt	O
discontinutaion	O
of	O
the	O
durg	O
is	O
recommenedd	O
particularly	O
in	O
indviiduals	O
with	O
daibetes	B-Disease
meliltus	I-Disease
,	O
glaucmoa	B-Disease
or	O
who	O
are	O
haevy	O
smokres	O
.	O

Tretament	O
of	O
compensaotry	O
gsutatory	B-Disease
hypehridrosis	I-Disease
with	O
topiacl	O
gylcopyrrolate	O
.	O

Gutsatory	B-Disease
hyperihdrosis	I-Disease
is	O
facail	O
swaeting	B-Disease
usually	O
associated	O
with	O
the	O
eaitng	O
of	O
hot	O
spciy	O
food	O
or	O
even	O
smelling	O
this	O
food	O
.	O

Current	O
otpions	O
of	O
treatmnet	O
include	O
oarl	O
anticohlinergic	O
durgs	O
,	O
the	O
tpoical	O
applicatoin	O
of	O
anticholinregics	O
or	O
aluimnum	O
cholride	O
,	O
and	O
the	O
injeciton	O
of	O
botulnium	O
toixn	O
.	O

Thirteen	O
pateints	O
have	O
been	O
traeted	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
toipcal	O
glycpoyrrolate	O
.	O

All	O
patietns	O
had	O
gusattory	B-Disease
hypehridrosis	I-Disease
,	O
which	O
interfeerd	O
with	O
their	O
socail	O
activiteis	O
,	O
after	O
transhtroacic	O
endosocpic	O
sympathetcomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatroy	O
foacl	O
hyperhdirosis	B-Disease
.	O

After	O
applying	O
toipcal	O
gylcopyrrolate	O
,	O
the	O
subjetcive	O
effcet	O
was	O
excellnet	O
(	O
no	O
sweaitng	B-Disease
after	O
eaitng	O
hot	O
spciy	O
food	O
)	O
in	O
10	O
paitents	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reudced	O
swetaing	B-Disease
)	O
in	O
3	O
pateints	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
icnidents	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eaitng	O
hot	O
sipcy	O
fodos	O
.	O

Adevrse	O
effetcs	O
included	O
a	O
midlly	O
dry	B-Disease
muoth	I-Disease
and	O
a	O
sroe	B-Disease
thorat	I-Disease
in	O
2	O
ptaients	O
(	O
2	O
%	O
glycopyrrolate	O
)	O
,	O
a	O
light	O
headcahe	B-Disease
in	O
1	O
ptaient	O
(	O
1	O
.	O
5	O
%	O
glyocpyrrolate	O
)	O
.	O

The	O
topiacl	O
applicatoin	O
of	O
a	O
glcyopyrrolate	O
pad	O
appeared	O
to	O
be	O
safe	O
,	O
effiaccious	O
,	O
well	O
tolertaed	O
,	O
and	O
a	O
convenient	O
mehtod	O
of	O
treatemnt	O
for	O
modearte	O
to	O
sveere	O
sympotms	O
of	O
gutsatory	B-Disease
hyprehidrosis	I-Disease
in	O
psot	O
transthoarcic	O
endosocpic	O
sypmathectomy	O
or	O
sympahticotomy	O
ptaients	O
,	O
with	O
few	O
side	O
effects	O
.	O

Neuroelptic	O
-	O
associated	O
hyperprolactienmia	B-Disease
.	O

Can	O
it	O
be	O
treaetd	O
with	O
bromcoriptine	O
?	O

Six	O
stalbe	O
psyhciatric	O
outpatinets	O
with	O
hyperprolactniemia	B-Disease
and	O
aemnorrhea	B-Disease
/	O
oligoemnorrhea	B-Disease
associated	O
with	O
their	O
neuorleptic	O
mediactions	O
were	O
traeted	O
with	O
bromorciptine	O
.	O

Dialy	O
dsoages	O
of	O
5	O
-	O
10	O
mg	O
correcetd	O
the	O
hypeprrolactinemia	B-Disease
and	O
retsored	O
mesntruation	O
in	O
four	O
of	O
the	O
six	O
patinets	O
.	O

One	O
woamn	O
,	O
however	O
,	O
developed	O
wosrened	O
psycihatric	B-Disease
symptmos	I-Disease
while	O
taking	O
bromocirptine	O
,	O
and	O
it	O
was	O
disocntinued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
paitents	O
had	O
their	O
mentsrual	O
irreuglarity	O
successfully	O
crorected	O
with	O
bromcoriptine	O
.	O

This	O
suggests	O
that	O
bromocritpine	O
should	O
be	O
further	O
evaulated	O
as	O
potnetial	O
thearpy	O
for	O
neuroletpic	O
-	O
associated	O
hyperporlactinemia	B-Disease
and	O
amenorrhea	B-Disease
/	O
galcatorrhea	B-Disease
.	O

Ethacyrnic	O
aicd	O
-	O
idnuced	O
convulsinos	B-Disease
and	O
barin	O
nuerotransmitters	O
in	O
mcie	O
.	O

Intraceerbroventricular	O
injcetion	O
of	O
ethcarynic	O
aicd	O
(	O
50	O
%	O
convlusive	B-Disease
dsoe	O
;	O
50	O
micorgrams	O
/	O
muose	O
)	O
accelearted	O
the	O
synhtesis	O
/	O
trunover	O
of	O
5	O
-	O
hydroxytrytpamine	O
(	O
5	O
-	O
HT	O
)	O
but	O
suppresesd	O
the	O
syntheiss	O
of	O
gamma	O
-	O
amniobutyric	O
aicd	O
and	O
acteylcholine	O
in	O
muose	O
barin	O
.	O

These	O
effcets	O
were	O
completely	O
antagonzied	O
by	O
prerteatment	O
with	O
a	O
gluatmate	O
/	O
N	O
-	O
mtehyl	O
-	O
D	O
-	O
asaprtate	O
atnagonist	O
,	O
aminophoshponovaleric	O
aicd	O
.	O

In	O
etahcrynic	O
aicd	O
-	O
inudced	O
convulisons	B-Disease
,	O
these	O
neurotransmtiter	O
sytsems	O
may	O
be	O
differentailly	O
moudlated	O
,	O
probably	O
through	O
atcivation	O
of	O
glutaimnergic	O
nuerons	O
in	O
the	O
brian	O
.	O

Pharmaoclogy	O
of	O
gmama	O
-	O
amionbutyric	O
acidA	O
recepotr	O
cmoplex	O
after	O
the	O
in	O
vivo	O
adminsitration	O
of	O
the	O
anxioselectvie	O
and	O
antiocnvulsant	O
btea	O
-	O
cabroline	O
deriavtive	O
abecarinl	O
.	O

In	O
rodetns	O
,	O
the	O
efefct	O
of	O
the	O
btea	O
-	O
carbloine	O
derivatvie	O
isporopyl	O
-	O
6	O
-	O
beznyloxy	O
-	O
4	O
-	O
methoxyemthyl	O
-	O
btea	O
-	O
carobline	O
-	O
3	O
-	O
carboyxlate	O
(	O
abecarnril	O
)	O
,	O
a	O
new	O
lgiand	O
for	O
benzodiazepnie	O
recpetors	O
possessing	O
anxiloytic	O
and	O
anticonvulasnt	O
propreties	O
,	O
was	O
evalauted	O
on	O
the	O
funtcion	O
of	O
centarl	O
gmama	O
-	O
aminobuytric	O
aicd	O
(	O
GBAA	O
)	O
A	O
rceeptor	O
compelx	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
rat	O
crotical	O
memrbane	O
prepraation	O
,	O
abecranil	O
inrceased	O
[	O
3H	O
]	O
GBAA	O
binidng	O
,	O
enhanecd	O
msucimol	O
-	O
sitmulated	O
36Cl	O
-	O
utpake	O
and	O
reudced	O
the	O
bniding	O
of	O
t	O
-	O
[	O
35S	O
]	O
butylbicyclophopshorothionate	O
(	O
[	O
35S	O
]	O
TPBS	O
)	O
.	O

These	O
effcets	O
were	O
similar	O
to	O
those	O
idnuced	O
by	O
diaezpam	O
,	O
whereas	O
the	O
patrial	O
agnoist	O
Ro	O
16	O
-	O
6028	O
(	O
tret	O
-	O
btuyl	O
-	O
(	O
S	O
)	O
-	O
8	O
-	O
bormo	O
-	O
11	O
,	O
12	O
,	O
13	O
,	O
13a	O
-	O
tetarhydro	O
-	O
9	O
-	O
oxo	O
-	O
9H	O
-	O
imdiazo	O
[	O
1	O
,	O
5	O
-	O
a	O
]	O
-	O
pyrrolo	O
-	O
[	O
2	O
,	O
1	O
-	O
c	O
]	O
[	O
1	O
,	O
4	O
]	O
benzodiaezpine	O
-	O
1	O
-	O
carboxyalte	O
)	O
showed	O
very	O
waek	O
efficacy	O
in	O
these	O
boichemical	O
tetss	O
.	O

After	O
i	O
.	O
p	O
.	O
injcetion	O
to	O
rtas	O
,	O
aebcarnil	O
and	O
diazpeam	O
decraesed	O
in	O
a	O
tmie	O
-	O
dependnet	O
and	O
dsoe	O
-	O
related	O
(	O
0	O
.	O
25	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
manner	O
[	O
35S	O
]	O
TPBS	O
bniding	O
maesured	O
ex	O
vivo	O
in	O
the	O
cerebarl	O
cotrex	O
.	O

Moreover	O
,	O
both	O
durgs	O
at	O
the	O
dsoe	O
of	O
0	O
.	O
5	O
mg	O
/	O
kg	O
antagonzied	O
completely	O
the	O
convuslant	O
acitvity	O
and	O
the	O
incresae	O
of	O
[	O
35S	O
]	O
TPBS	O
bindnig	O
inudced	O
by	O
isoniazdie	O
(	O
350	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
as	O
well	O
as	O
the	O
incerase	O
of	O
[	O
35S	O
]	O
TPBS	O
bniding	O
induecd	O
by	O
foot	O
-	O
sohck	O
strses	O
.	O

To	O
better	O
corerlate	O
the	O
biocheimcal	O
and	O
the	O
pharmacologcial	O
effetcs	O
,	O
we	O
studied	O
the	O
actoin	O
of	O
abecranil	O
on	O
[	O
35S	O
]	O
TPBS	O
bindnig	O
,	O
expolratory	O
mtoility	O
and	O
on	O
isnoiazid	O
-	O
indcued	O
biochemcial	O
and	O
pharmacolgoical	O
effcets	O
in	O
mcie	O
.	O

In	O
these	O
animlas	O
,	O
abecarinl	O
produced	O
a	O
paralleled	O
dsoe	O
-	O
dependnet	O
(	O
0	O
.	O
05	O
-	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduciton	O
of	O
both	O
mootr	O
behavoir	O
and	O
cotrical	O
[	O
35S	O
]	O
TPBS	O
binidng	O
.	O

Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
btea	O
-	O
cabroline	O
reudced	O
markedly	O
the	O
icnrease	O
of	O
[	O
35S	O
]	O
TPBS	O
binidng	O
and	O
the	O
convulisons	B-Disease
idnuced	O
by	O
isonaizid	O
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Recrurent	O
myoacrdial	B-Disease
infraction	I-Disease
in	O
a	O
postparutm	O
patinet	O
receiving	O
bromocripitne	O
.	O

Myocaridal	B-Disease
inafrction	I-Disease
in	O
puerperuim	O
is	O
infrequently	O
reported	O
.	O

Sapsm	B-Disease
,	O
coornary	O
dsisection	O
,	O
or	O
ahteromatous	O
eitology	O
has	O
been	O
described	O
.	O

Bromcoriptine	O
has	O
been	O
implicated	O
in	O
several	O
previous	O
csae	O
rpeorts	O
of	O
myoacrdial	B-Disease
inafrction	I-Disease
in	O
the	O
pueprerium	O
.	O

Our	O
csae	O
(	O
including	O
an	O
iandvertent	O
rechallegne	O
)	O
suggests	O
such	O
a	O
relationhsip	O
.	O

Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,	O
"	O
possible	O
serious	O
caridac	O
effetcs	O
of	O
bromocriptnie	O
should	O
be	O
acknowledged	O
.	O

Asteirxis	B-Disease
inudced	O
by	O
carbamazepnie	O
threapy	O
.	O

There	O
are	O
very	O
few	O
repotrs	O
about	O
asteirxis	B-Disease
as	O
a	O
side	O
effect	O
of	O
treatemnt	O
with	O
psychophramacologic	O
agnets	O
.	O

In	O
this	O
reprot	O
we	O
present	O
four	O
pateints	O
terated	O
with	O
a	O
comibnation	O
of	O
different	O
psychotorpic	O
durgs	O
,	O
in	O
whom	O
asteirxis	B-Disease
was	O
triggered	O
either	O
by	O
adding	O
carbamazpeine	O
(	O
CBZ	O
)	O
to	O
a	O
treamtent	O
regiemn	O
,	O
or	O
by	O
incerasing	O
its	O
doasge	O
.	O

Neither	O
dsoage	O
nor	O
sreum	O
levles	O
of	O
CBZ	O
were	O
in	O
a	O
higehr	O
range	O
.	O

We	O
consider	O
asterxiis	B-Disease
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurtooxicity	B-Disease
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
modertae	O
doasge	O
levles	O
,	O
if	O
certain	O
drgus	O
as	O
lithuim	O
or	O
clozapnie	O
are	O
used	O
in	O
comibnation	O
with	O
CBZ	O
.	O

Pharmacoydnamics	O
of	O
the	O
hypotenisve	B-Disease
efefct	O
of	O
levoodpa	O
in	O
parkinsoinan	B-Disease
patietns	O
.	O

Bolod	O
pressrue	O
efefcts	O
of	O
i	O
.	O
v	O
.	O
levoodpa	O
were	O
examined	O
in	O
pakrinsonian	B-Disease
ptaients	O
with	O
satble	O
and	O
fluctuatnig	O
rseponses	O
to	O
levdoopa	O
.	O

The	O
mganitude	O
of	O
the	O
hypotesnive	B-Disease
efefct	O
of	O
levodpoa	O
was	O
concenrtation	O
depenednt	O
and	O
was	O
fit	O
to	O
an	O
Eamx	O
mdoel	O
in	O
flucutating	O
respondres	O
.	O

Stalbe	O
respodners	O
demonstrated	O
a	O
small	O
hypoetnsive	B-Disease
resopnse	O
.	O

Bsaeline	O
bolod	O
pressrues	O
were	O
hgiher	O
in	O
fulctuating	O
patietns	O
;	O
a	O
hgiher	O
bsaeline	O
bolod	O
perssure	O
corrleated	O
with	O
greater	O
hypotesnive	B-Disease
efefcts	O
.	O

Antiparkinsnoian	O
efefcts	O
of	O
lveodopa	O
tempoarlly	O
correltaed	O
with	O
blood	O
prsesure	O
cahnges	O
.	O

Phenyllaanine	O
,	O
a	O
large	O
neurtal	O
amnio	O
aicd	O
(	O
LANA	O
)	O
competing	O
with	O
leovdopa	O
for	O
trnasport	O
across	O
the	O
bolod	O
-	O
barin	O
barrier	O
,	O
reduecd	O
the	O
hypotensvie	B-Disease
and	O
antiparkinosnian	O
effects	O
of	O
leovdopa	O
.	O

We	O
conclude	O
that	O
levodpoa	O
has	O
a	O
centarl	O
hyptoensive	B-Disease
actoin	O
that	O
parallels	O
the	O
mtoor	O
effcets	O
in	O
flutcuating	O
paitents	O
.	O

The	O
hypotesnive	B-Disease
efefct	O
appears	O
to	O
be	O
related	O
to	O
the	O
higehr	O
baselnie	O
bolod	O
pressrue	O
we	O
observed	O
in	O
flucutating	O
patinets	O
relative	O
to	O
stbale	O
ptaients	O
.	O

Synrdome	B-Disease
of	I-Disease
inappropriate	I-Disease
sceretion	I-Disease
of	I-Disease
atnidiuretic	I-Disease
hormnoe	I-Disease
after	O
infusinoal	O
vincirstine	O
.	O

A	O
77	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
rferactory	O
mulitple	B-Disease
meyloma	I-Disease
was	O
tretaed	O
with	O
a	O
4	O
-	O
day	O
contiunous	O
inrtavenous	O
infsuion	O
of	O
vincritsine	O
and	O
doxroubicin	O
and	O
4	O
dyas	O
of	O
oarl	O
dxeamethasone	O
.	O

Nine	O
dyas	O
after	O
her	O
second	O
ccyle	O
she	O
presented	O
with	O
ltehargy	B-Disease
and	O
waekness	B-Disease
associated	O
with	O
hyponatrmeia	B-Disease
.	O

Evlauation	O
reevaled	O
the	O
syndorme	B-Disease
of	I-Disease
inappropriate	I-Disease
secertion	I-Disease
of	I-Disease
antdiiuretic	I-Disease
homrone	I-Disease
,	O
which	O
was	O
attributed	O
to	O
the	O
vincirstine	O
ifnusion	O
.	O

After	O
nromal	O
seurm	O
soidum	O
levles	O
returned	O
,	O
further	O
doxroubicin	O
and	O
dexametahsone	O
chemotehrapy	O
without	O
vincrisitne	O
did	O
not	O
produce	O
this	O
cmoplication	O
.	O

Herat	B-Disease
fialure	I-Disease
:	O
to	O
digitalise	O
or	O
not	O
?	O

The	O
view	O
against	O
.	O

Despite	O
extesnive	O
clincial	O
experinece	O
the	O
role	O
of	O
digxoin	O
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
patietns	O
with	O
atiral	B-Disease
fibrilltaion	I-Disease
digxoin	O
is	O
beneficial	O
for	O
ventircular	O
rtae	O
conrtol	O
.	O

For	O
patietns	O
in	O
snius	O
rhyhtm	O
and	O
haert	B-Disease
faiulre	I-Disease
the	O
situation	O
is	O
less	O
clear	O
.	O

Dgioxin	O
has	O
a	O
narrow	O
therapuetic	O
:	O
txoic	O
raito	O
and	O
concnetrations	O
are	O
affetced	O
by	O
a	O
number	O
of	O
drgus	O
.	O

Also	O
,	O
dgioxin	O
has	O
undesirable	O
efefcts	O
such	O
as	O
incresaing	O
perpiheral	O
resistacne	O
and	O
myocaridal	O
demadns	O
,	O
and	O
causing	O
arrhytmhias	B-Disease
.	O

There	O
is	O
a	O
paucity	O
of	O
dtaa	O
from	O
well	O
-	O
designed	O
tirals	O
.	O

The	O
trails	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitatoins	O
in	O
desgin	O
and	O
these	O
show	O
varaition	O
in	O
pateint	O
beneift	O
.	O

More	O
convincing	O
eviednce	O
is	O
required	O
showing	O
that	O
digoixn	O
imporves	O
sypmtoms	O
or	O
execrise	O
capaicty	O
.	O

Furthermore	O
,	O
no	O
trail	O
has	O
had	O
sufficient	O
poewr	O
to	O
evalaute	O
mortaltiy	O
.	O

Pooeld	O
analsyis	O
of	O
the	O
effetcs	O
of	O
other	O
intoropic	O
drgus	O
shows	O
an	O
execss	O
moratlity	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoixn	O
may	O
inrcease	O
moratlity	O
after	O
myocradial	B-Disease
ifnarction	I-Disease
(	O
MI	B-Disease
)	O
.	O

Angoitensin	O
-	O
converting	O
enzmye	O
(	O
ACE	O
)	O
inhibiotrs	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
bolod	O
lveel	O
montioring	O
,	O
modify	O
progresison	O
of	O
disaese	O
,	O
relieve	O
symptmos	O
,	O
ipmrove	O
exericse	O
tolreance	O
and	O
reudce	O
mortlaity	O
.	O

Catuion	O
should	O
be	O
eexrcised	O
in	O
using	O
dgioxin	O
until	O
large	O
moratlity	O
trails	O
are	O
completed	O
showing	O
either	O
bneefit	O
or	O
hram	O
.	O

Until	O
then	O
digoixn	O
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
therpay	O
.	O

Israidpine	O
treamtent	O
for	O
hyperetnsion	B-Disease
in	O
general	O
parctice	O
in	O
Hnog	O
Knog	O
.	O

A	O
6	O
-	O
week	O
open	O
sutdy	O
of	O
the	O
introduciton	O
of	O
isardipine	O
teratment	O
was	O
conducted	O
in	O
general	O
parctice	O
in	O
Hnog	O
Knog	O
.	O

303	O
Cihnese	O
paitents	O
with	O
mlid	O
to	O
mdoerate	O
hypretension	B-Disease
entered	O
the	O
stduy	O
.	O

Side	O
effects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patietns	O
and	O
caused	O
withdrwaal	O
from	O
the	O
stduy	O
in	O
3	O
paitents	O
.	O

The	O
main	O
side	O
-	O
effects	O
were	O
heaadche	B-Disease
,	O
dizizness	B-Disease
,	O
palpiattion	B-Disease
and	O
flusihng	B-Disease
and	O
these	O
were	O
not	O
more	O
freuqent	O
than	O
reported	O
in	O
other	O
studeis	O
with	O
isradpiine	O
or	O
with	O
palcebo	O
.	O

Suipne	O
bolod	O
perssure	O
was	O
reduecd	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evalubale	O
patinets	O
.	O

Similar	O
reudctions	O
occurred	O
in	O
stnading	O
bolod	O
pressure	O
and	O
there	O
was	O
no	O
eviednce	O
of	O
posutral	B-Disease
hypotensoin	I-Disease
.	O

Normalizatoin	O
and	O
respnoder	O
rtaes	O
at	O
6	O
wekes	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Doasge	O
was	O
increaesd	O
from	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
to	O
5	O
mg	O
b	O
.	O
d	O
.	O
at	O
4	O
wekes	O
in	O
patinets	O
with	O
diastloic	O
blood	O
pressure	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
rseponse	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O

Pharmacloogical	O
charactreistics	O
and	O
side	O
effects	O
of	O
a	O
new	O
glaenic	O
formulatoin	O
of	O
porpofol	O
without	O
soyabaen	O
oil	O
.	O

We	O
copmared	O
the	O
pahrmacokinetics	O
,	O
pharmcaodynamics	O
and	O
sfaety	O
proifle	O
of	O
a	O
new	O
galeinc	O
formulatoin	O
of	O
porpofol	O
(	O
AM419	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soaybean	O
oil	O
,	O
with	O
a	O
stnadard	O
forumlation	O
of	O
porpofol	O
(	O
Disopirvan	O
1	O
%	O
)	O
.	O

In	O
a	O
ranodmised	O
,	O
double	O
-	O
blnid	O
,	O
corss	O
-	O
over	O
sutdy	O
,	O
30	O
haelthy	O
volnuteers	O
received	O
a	O
single	O
intraveonus	O
blous	O
injcetion	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
propfool	O
.	O

Palsma	O
propoofl	O
levles	O
were	O
mesaured	O
for	O
48	O
h	O
following	O
durg	O
adminsitration	O
and	O
eavluated	O
according	O
to	O
a	O
three	O
-	O
compartemnt	O
mdoel	O
.	O

The	O
phamracodynamic	O
praameters	O
assessed	O
included	O
indcution	O
and	O
eemrgence	O
times	O
,	O
respiartory	O
and	O
cardiovascualr	O
effcets	O
,	O
and	O
pian	B-Disease
on	O
injetcion	O
.	O

Ptaients	O
were	O
monitroed	O
for	O
side	O
effects	O
over	O
48	O
h	O
.	O

Owing	O
to	O
a	O
high	O
incidnece	O
of	O
thrombophlebtiis	B-Disease
,	O
the	O
stduy	O
was	O
terminaetd	O
prmeaturely	O
and	O
only	O
the	O
dtaa	O
of	O
the	O
two	O
parallel	O
treatemnt	O
gruops	O
(	O
15	O
patietns	O
in	O
each	O
gorup	O
)	O
were	O
anlaysed	O
.	O

Plsama	O
conecntrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulatinos	O
.	O

Anaeshtesia	O
inudction	O
and	O
emegrence	O
times	O
,	O
respiartory	O
and	O
cardioavscular	O
variabels	O
showed	O
no	O
significant	O
differneces	O
between	O
the	O
two	O
teratment	O
gropus	O
.	O

Pian	B-Disease
on	O
injectoin	O
(	O
80	O
vs	O
.	O
20	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thromboplhebitis	B-Disease
(	O
93	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM419	O
than	O
with	O
Disorpivan	O
.	O

Although	O
both	O
fromulations	O
had	O
similar	O
pharmacoknietic	O
and	O
phamracodynamic	O
profiels	O
the	O
new	O
forumlation	O
is	O
not	O
suitable	O
for	O
cliincal	O
use	O
due	O
to	O
the	O
high	O
inciednce	O
of	O
throbmophlebitis	B-Disease
produced	O
.	O

Pure	B-Disease
red	I-Disease
clel	I-Disease
aplaisa	I-Disease
,	O
toixc	B-Disease
demratitis	I-Disease
and	O
lymphadenpoathy	B-Disease
in	O
a	O
patinet	O
taking	O
diphenlyhydantoin	O
.	O

A	O
paitent	O
taking	O
diphenylhyadntoin	O
for	O
3	O
wekes	O
developed	O
a	O
gneeralized	O
sikn	B-Disease
rsah	I-Disease
,	O
lypmhadenopathy	B-Disease
and	O
pure	B-Disease
red	I-Disease
clel	I-Disease
aplsaia	I-Disease
.	O

After	O
withdraawl	O
of	O
the	O
pahrmacon	O
all	O
sypmtoms	O
disappeared	O
spontanoeusly	O
.	O

Sikn	B-Disease
rsah	I-Disease
is	O
a	O
well	O
-	O
known	O
complicatoin	O
of	O
diphenlyhydantoin	O
tretament	O
as	O
is	O
beingn	O
and	O
malignnat	O
lymphadenpoathy	B-Disease
.	O

Pure	B-Disease
red	I-Disease
clel	I-Disease
aplsaia	I-Disease
associated	O
with	O
dipehnylhydantoin	O
medicatoin	O
has	O
been	O
reported	O
in	O
3	O
pateints	O
.	O

The	O
exact	O
mechainsm	O
by	O
which	O
diphenlyhydantoin	O
exerts	O
its	O
toixc	O
effcets	O
is	O
not	O
known	O
.	O

In	O
this	O
paitent	O
the	O
tmie	O
relation	O
between	O
the	O
ingesiton	O
of	O
diphenylhydnatoin	O
and	O
the	O
ocucrrence	O
of	O
the	O
sikn	B-Disease
rsah	I-Disease
,	O
lymphadneopathy	B-Disease
and	O
pure	B-Disease
red	I-Disease
clel	I-Disease
aplsaia	I-Disease
is	O
very	O
suggestive	O
of	O
a	O
direct	O
conneciton	O
.	O

Vniorelbine	O
-	O
related	O
caridac	O
evnets	O
:	O
a	O
mtea	O
-	O
analyiss	O
of	O
randmoized	O
cilnical	O
trilas	O
.	O

Several	O
csaes	O
of	O
cadriac	O
advesre	O
recations	O
related	O
to	O
vinorlebine	O
(	O
VNR	O
)	O
have	O
been	O
reported	O
in	O
the	O
litertaure	O
.	O

In	O
order	O
to	O
quanitfy	O
the	O
incidnece	O
of	O
these	O
cardaic	O
evnets	O
,	O
we	O
performed	O
a	O
mtea	O
-	O
anaylsis	O
of	O
cilnical	O
trails	O
cmoparing	O
VNR	O
with	O
other	O
chemothreapeutic	O
agetns	O
in	O
the	O
tretament	O
of	O
various	O
malignanices	B-Disease
.	O

Rnadomized	O
cliincal	O
trilas	O
cmoparing	O
VNR	O
with	O
other	O
drgus	O
in	O
the	O
treatemnt	O
of	O
cacner	B-Disease
were	O
searched	O
in	O
Meldine	O
,	O
Emabse	O
,	O
Evidnece	O
-	O
based	O
Medicnie	O
Rveiews	O
databsaes	O
and	O
the	O
Ccohrane	O
lbirary	O
from	O
1987	O
to	O
2002	O
.	O

Outcmoes	O
of	O
interest	O
were	O
sevree	O
cadriac	O
evnets	O
,	O
toixc	O
daeths	O
and	O
cardaic	O
eevnt	O
-	O
related	O
detahs	O
reported	O
in	O
each	O
publiaction	O
.	O

We	O
found	O
19	O
trails	O
,	O
involving	O
2441	O
patietns	O
treaetd	O
by	O
VNR	O
and	O
2050	O
cotnrol	O
patinets	O
.	O

The	O
incidnece	O
of	O
cradiac	O
evnets	O
with	O
VNR	O
was	O
1	O
.	O
19	O
%	O
[	O
95	O
%	O
confidecne	O
itnerval	O
(	O
CI	O
)	O
(	O
0	O
.	O
75	O
;	O
1	O
.	O
67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rsik	O
of	O
cardaic	O
eevnts	O
between	O
VNR	O
and	O
other	O
durgs	O
[	O
odds	O
raito	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O

The	O
rsik	O
of	O
VNR	O
cardaic	O
evnets	O
was	O
similar	O
to	O
vidnesine	O
(	O
VDS	O
)	O
and	O
other	O
cadriotoxic	B-Disease
durgs	O
[	O
fluorouarcil	O
,	O
antrhacyclines	O
,	O
gemcitabnie	O
(	O
GEM	O
)	O
em	O
leaedr	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
statitsical	O
signifciance	O
because	O
of	O
a	O
few	O
number	O
of	O
caess	O
,	O
the	O
rsik	O
was	O
loewr	O
in	O
trilas	O
excluding	O
patietns	O
with	O
cardaic	O
hsitory	O
,	O
and	O
seemed	O
to	O
be	O
hgiher	O
in	O
trails	O
including	O
patinets	O
with	O
pre	O
-	O
existing	O
cradiac	B-Disease
diseaess	I-Disease
.	O

Vinoerlbine	O
-	O
related	O
cadriac	O
eevnts	O
concern	O
about	O
1	O
%	O
of	O
traeted	O
paitents	O
in	O
cliniacl	O
trails	O
.	O

However	O
,	O
the	O
rsik	O
associated	O
with	O
VNR	O
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemotherapuetic	O
agetns	O
in	O
the	O
same	O
indicaitons	O
.	O

MRI	O
findigns	O
of	O
hyopxic	O
cotrical	O
lmainar	O
nercosis	B-Disease
in	O
a	O
cihld	O
with	O
heomlytic	B-Disease
aenmia	I-Disease
crsiis	O
.	O

We	O
present	O
magentic	O
resonnace	O
iamging	O
fnidings	O
of	O
a	O
5	O
-	O
yaer	O
-	O
old	O
gril	O
who	O
had	O
a	O
rapidly	O
installing	O
hemloytic	B-Disease
aneima	I-Disease
crsiis	O
inudced	O
by	O
trimethporim	O
-	O
sulfomethoxaozle	O
,	O
resulting	O
in	O
cerebarl	B-Disease
anoixa	I-Disease
leading	O
to	O
premanent	O
damgae	O
.	O

Mganetic	O
Resoannce	O
imagnig	O
revelaed	O
cortcial	O
lamianr	O
nercosis	B-Disease
in	O
aretrial	O
broder	O
znoes	O
in	O
both	O
cerebarl	O
hmeispheres	O
,	O
ischmeic	O
chanegs	O
in	O
subcrotical	O
whtie	O
matter	O
of	O
lfet	O
ceerbral	O
hemsiphere	O
,	O
and	O
in	O
the	O
lfet	O
puatmen	O
.	O

Although	O
crotical	O
lmainar	O
necorsis	B-Disease
is	O
a	O
classic	O
entity	O
in	O
adulhtood	O
related	O
to	O
conidtions	O
of	O
enregy	O
depletoins	O
,	O
there	O
are	O
few	O
reprots	O
available	O
in	O
chlidren	O
.	O

A	O
wide	O
rveiew	O
of	O
the	O
literatrue	O
is	O
also	O
presented	O
.	O

The	O
natrual	O
hisotry	O
of	O
Vigabatirn	O
associated	O
viusal	B-Disease
field	I-Disease
dfeects	I-Disease
in	O
patinets	O
electing	O
to	O
continue	O
their	O
meidcation	O
.	O

PURPSOE	O
:	O
To	O
determine	O
the	O
ntaural	O
hsitory	O
of	O
vsiual	B-Disease
field	I-Disease
defetcs	I-Disease
in	O
a	O
gruop	O
of	O
patinets	O
known	O
to	O
have	O
Vigabartin	O
-	O
associated	O
chagnes	O
who	O
elected	O
to	O
continue	O
the	O
mdeication	O
because	O
of	O
good	O
seiuzre	B-Disease
contorl	O
.	O

METHODS	O
:	O
All	O
patinets	O
taking	O
Vgiabatrin	O
alone	O
or	O
in	O
combinaiton	O
with	O
other	O
antieipleptic	O
durgs	O
for	O
at	O
least	O
5	O
yaers	O
(	O
range	O
5	O
-	O
12	O
yeras	O
)	O
were	O
entered	O
into	O
a	O
vsiual	O
surviellance	O
programme	O
.	O

Pateints	O
were	O
followed	O
up	O
at	O
6	O
-	O
montlhy	O
interavls	O
for	O
not	O
less	O
than	O
18	O
mnoths	O
(	O
range	O
18	O
-	O
43	O
mnoths	O
)	O
.	O

In	O
all	O
,	O
16	O
pateints	O
with	O
unequivocal	O
dfeects	O
continued	O
the	O
mdeication	O
.	O

Following	O
already	O
pulbished	O
mehtodology	O
(	O
Eye	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
monouclar	O
mean	O
rdaial	O
dgerees	O
(	O
MDRs	O
)	O
to	O
the	O
I	O
/	O
4e	O
isopetr	O
on	O
Godlmann	O
permietry	O
was	O
calculated	O
for	O
the	O
rihgt	O
eye	O
at	O
the	O
tmie	O
of	O
dsicovery	O
of	O
a	O
vsiual	B-Disease
field	I-Disease
deefct	I-Disease
and	O
again	O
after	O
not	O
less	O
than	O
18	O
mnoths	O
follow	O
-	O
up	O
.	O

REUSLTS	O
:	O
Mean	O
rgiht	O
eye	O
MRD	O
at	O
prseentation	O
was	O
36	O
.	O
98	O
dgerees	O
(	O
range	O
22	O
.	O
25	O
-	O
51	O
.	O
0	O
)	O
,	O
comapred	O
to	O
38	O
.	O
40	O
degeres	O
(	O
range	O
22	O
.	O
5	O
-	O
49	O
.	O
75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P	O
=	O
0	O
.	O
338	O
unpiared	O
t	O
-	O
tset	O
.	O

Only	O
one	O
paitent	O
demonstrated	O
a	O
detreioration	B-Disease
in	I-Disease
viusal	I-Disease
field	I-Disease
during	O
the	O
sutdy	O
preiod	O
and	O
discontiuned	O
teratment	O
.	O

CONCLUISON	O
:	O
Etsablished	O
visaul	B-Disease
field	I-Disease
defetcs	I-Disease
presumed	O
to	O
be	O
due	O
to	O
Vigaabtrin	O
thearpy	O
did	O
not	O
usually	O
progerss	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medciation	O
.	O

These	O
dtaa	O
give	O
support	O
to	O
the	O
hpyothesis	O
that	O
the	O
patohgenesis	O
of	O
Vigabartin	O
-	O
associated	O
visaul	B-Disease
field	I-Disease
dfeects	I-Disease
may	O
be	O
an	O
idiosnycratic	O
adevrse	O
durg	O
reaciton	O
rather	O
than	O
dsoe	O
-	O
deepndent	O
toixcity	B-Disease
.	O

Inudction	O
of	O
rosaeciform	O
dermaittis	B-Disease
during	O
teratment	O
of	O
faical	B-Disease
inflammtaory	I-Disease
drematoses	I-Disease
with	O
tarcolimus	O
ointmnet	O
.	O

BACGKROUND	O
:	O
Tcarolimus	O
onitment	O
is	O
increasingly	O
used	O
for	O
atni	O
-	O
inflammaotry	O
teratment	O
of	O
sensiitve	O
areas	O
such	O
as	O
the	O
fcae	O
,	O
and	O
recent	O
obseravtions	O
indicate	O
that	O
the	O
teratment	O
is	O
effetcive	O
in	O
steriod	O
-	O
aggravated	O
rsoacea	B-Disease
and	O
perioarl	B-Disease
dermaittis	I-Disease
.	O

We	O
reprot	O
on	O
roasceiform	O
dermaittis	B-Disease
as	O
a	O
complictaion	O
of	O
treatemnt	O
with	O
tcarolimus	O
onitment	O
.	O

OBESRVATIONS	O
:	O
Six	O
audlt	O
pateints	O
with	O
inlfammatory	B-Disease
fcaial	I-Disease
dermtaoses	I-Disease
were	O
treaetd	O
with	O
tacrolmius	O
ointemnt	O
because	O
of	O
the	O
ineffectiveness	O
of	O
stnadard	O
treatmetns	O
.	O

Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effcetive	O
and	O
well	O
-	O
tloerated	O
tretament	O
,	O
3	O
ptaients	O
with	O
a	O
hsitory	O
of	O
rosaeca	B-Disease
and	O
1	O
with	O
a	O
hsitory	O
of	O
ance	B-Disease
experienced	O
sduden	O
wosrening	O
with	O
pustualr	O
roscaeiform	O
leisons	O
.	O

Biospy	O
revaeled	O
an	O
abunadnce	O
of	O
Dmeodex	O
mties	O
in	O
2	O
of	O
these	O
paitents	O
.	O

In	O
1	O
pateint	O
with	O
eeylid	O
eczmea	B-Disease
,	O
rosaceiofrm	O
pericoular	B-Disease
dermtaitis	I-Disease
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
tretament	O
.	O

In	O
1	O
patinet	O
with	O
atoipc	B-Disease
deramtitis	I-Disease
,	O
telangiecttaic	O
and	O
pauplar	B-Disease
roascea	I-Disease
insiidously	O
appeared	O
after	O
5	O
monhts	O
of	O
treatemnt	O
.	O

CNOCLUSIONS	O
:	O
Our	O
obseravtions	O
suggest	O
that	O
the	O
spetcrum	O
of	O
rosacieform	O
dermattiis	B-Disease
as	O
a	O
complicatoin	O
of	O
treatmnet	O
with	O
tacorlimus	O
oitnment	O
is	O
heteorgeneous	O
.	O

A	O
variety	O
of	O
factros	O
,	O
such	O
as	O
vaosactive	O
properteis	O
of	O
tacroilmus	O
,	O
prloiferation	O
of	O
Demdoex	O
due	O
to	O
loacl	O
immnuosuppression	O
,	O
and	O
the	O
oclcusive	O
proeprties	O
of	O
the	O
ointmnet	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenmoena	O
.	O

Future	O
stuides	O
are	O
needed	O
to	O
identify	O
indiivdual	O
rsik	O
factros	O
.	O

Inrtavascular	O
hemolyiss	B-Disease
and	O
actue	B-Disease
rneal	I-Disease
faiulre	I-Disease
following	O
intermitetnt	O
rifmapin	O
therpay	O
.	O

Reanl	B-Disease
faliure	I-Disease
is	O
a	O
rrae	O
complicatoin	O
associated	O
with	O
the	O
use	O
of	O
rifmapin	O
.	O

Intarvascular	O
hemoylsis	B-Disease
leading	O
to	O
aucte	B-Disease
reanl	I-Disease
fialure	I-Disease
following	O
rifmapin	O
therpay	O
is	O
extremely	O
rrae	O
.	O

Two	O
paitents	O
with	O
lerposy	B-Disease
who	O
developed	O
heomlysis	B-Disease
and	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
following	O
riafmpin	O
are	O
reported	O
.	O

Structrual	O
abonrmalities	O
in	O
the	O
barins	O
of	O
huamn	O
sbujects	O
who	O
use	O
methamphetmaine	O
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
tmie	O
,	O
the	O
proifle	O
of	O
srtuctural	B-Disease
deifcits	I-Disease
in	I-Disease
the	I-Disease
hmuan	I-Disease
barin	I-Disease
associated	O
with	O
crhonic	O
methamphetmaine	O
(	O
MA	O
)	O
aubse	O
.	O

Studeis	O
of	O
hmuan	O
subjcets	O
who	O
have	O
used	O
MA	O
chrnoically	O
have	O
revelaed	O
defictis	O
in	O
dopamniergic	O
and	O
sreotonergic	O
sytsems	O
and	O
creebral	O
metabloic	B-Disease
abnormailties	I-Disease
.	O

Using	O
magentic	O
reosnance	O
imgaing	O
(	O
MRI	O
)	O
and	O
new	O
copmutational	O
barin	O
-	O
mappnig	O
techniqeus	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
strutcural	O
brian	O
atlerations	O
associated	O
with	O
chroinc	O
MA	O
aubse	O
in	O
hmuan	O
subejcts	O
and	O
related	O
these	O
deifcits	O
to	O
cognitvie	B-Disease
imapirment	I-Disease
.	O

We	O
used	O
high	O
-	O
resloution	O
MRI	O
and	O
surafce	O
-	O
based	O
computatoinal	O
iamge	O
aanlyses	O
to	O
map	O
reginoal	O
abonrmalities	B-Disease
in	I-Disease
the	I-Disease
cotrex	I-Disease
,	I-Disease
hipopcampus	I-Disease
,	I-Disease
wihte	I-Disease
matter	I-Disease
,	I-Disease
and	I-Disease
ventrciles	I-Disease
in	O
22	O
huamn	O
sbujects	O
who	O
used	O
MA	O
and	O
21	O
age	O
-	O
matched	O
,	O
healhty	O
contrlos	O
.	O

Crotical	O
mpas	O
revaeled	O
sevree	O
gary	O
-	O
matter	O
defiicts	O
in	O
the	O
cingultae	O
,	O
libmic	O
,	O
and	O
paralmibic	O
coritces	O
of	O
MA	O
absuers	O
(	O
avearging	O
11	O
.	O
3	O
%	O
below	O
cotnrol	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
aevrage	O
,	O
MA	O
abusres	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hpipocampal	O
vloumes	O
than	O
cnotrol	O
sbujects	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
lfet	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
rgiht	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
wihte	O
-	O
matter	O
hypetrrophy	B-Disease
(	O
7	O
.	O
0	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Hippoacmpal	O
defiicts	O
were	O
mapepd	O
and	O
corerlated	O
with	O
meomry	O
perofrmance	O
on	O
a	O
wrod	O
-	O
reacll	O
tset	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

MRI	O
-	O
based	O
mpas	O
suggest	O
that	O
crhonic	O
metahmphetamine	O
absue	O
causes	O
a	O
selective	O
ptatern	O
of	O
cererbal	O
deetrioration	O
that	O
contributes	O
to	O
imparied	B-Disease
memroy	I-Disease
perfomrance	I-Disease
.	O

MA	O
may	O
selectively	O
dmaage	O
the	O
medail	O
temopral	O
lboe	O
and	O
,	O
consistent	O
with	O
metabloic	O
sutdies	O
,	O
the	O
cignulate	O
-	O
lmibic	O
crotex	O
,	O
inudcing	O
neuroadaptaiton	O
,	O
nueropil	O
redcution	O
,	O
or	O
clel	O
detah	O
.	O

Prmoinent	O
wihte	O
-	O
matter	O
hyeprtrophy	B-Disease
may	O
result	O
from	O
aletred	O
myelinaiton	O
and	O
adatpive	O
gilal	O
cahnges	O
,	O
including	O
glioiss	B-Disease
secondary	O
to	O
neruonal	B-Disease
damgae	I-Disease
.	O

These	O
brian	O
substraets	O
may	O
help	O
account	O
for	O
the	O
smyptoms	O
of	O
MA	O
absue	O
,	O
providing	O
threapeutic	O
taregts	O
for	O
durg	O
-	O
inudced	O
brian	B-Disease
ijnury	I-Disease
.	O

Disrutpion	O
of	O
heptaic	O
liipd	O
homeosatsis	O
in	O
mcie	O
after	O
amoidarone	O
treatmnet	O
is	O
associated	O
with	O
peroxismoe	O
proliferaotr	O
-	O
activtaed	O
reecptor	O
-	O
aplha	O
tagret	O
gnee	O
actviation	O
.	O

Amiodarnoe	O
,	O
an	O
efficaciuos	O
and	O
widely	O
used	O
antiarryhthmic	O
agnet	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepattooxicity	B-Disease
in	O
some	O
pateints	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechainsm	O
of	O
this	O
unwanted	O
efefct	O
,	O
mcie	O
were	O
amdinistered	O
various	O
doess	O
of	O
amiodarnoe	O
and	O
examined	O
for	O
chagnes	O
in	O
heptaic	O
histolgoy	O
and	O
gnee	O
regluation	O
.	O

Amioadrone	O
idnuced	O
hepatomeglay	B-Disease
,	O
heaptocyte	O
microevsicular	O
lpiid	O
accumulation	O
,	O
and	O
a	O
significant	O
dcerease	O
in	O
sreum	O
tirglycerides	O
and	O
glcuose	O
.	O

Northren	O
bolt	O
aanlysis	O
of	O
hpeatic	O
RNA	O
rveealed	O
a	O
dsoe	O
-	O
deepndent	O
incraese	O
in	O
the	O
exprsesion	O
of	O
a	O
number	O
of	O
geens	O
critical	O
for	O
fatty	O
aicd	O
oixdation	O
,	O
liporpotein	O
assemlby	O
,	O
and	O
lpiid	O
tarnsport	O
.	O

Many	O
of	O
these	O
gnees	O
are	O
regulated	O
by	O
the	O
perxoisome	O
prolifeartor	O
-	O
activaetd	O
recpetor	O
-	O
aplha	O
(	O
PPARaplha	O
)	O
,	O
a	O
lignad	O
-	O
activaetd	O
nuclaer	O
horomne	O
recetpor	O
transcripiton	O
facotr	O
.	O

The	O
absecne	O
of	O
induciton	O
of	O
these	O
gnees	O
as	O
well	O
as	O
hpeatomegaly	B-Disease
in	O
PPARaplha	O
knockuot	O
[	O
PPRAalpha	O
-	O
/	O
-	O
]	O
mcie	O
indicated	O
that	O
the	O
effects	O
of	O
aimodarone	O
were	O
depnedent	O
upon	O
the	O
prseence	O
of	O
a	O
functoinal	O
PPRAalpha	O
gnee	O
.	O

Compraed	O
to	O
wlid	O
-	O
tpye	O
mcie	O
,	O
teratment	O
of	O
PPARlapha	O
-	O
/	O
-	O
mcie	O
with	O
aimodarone	O
resulted	O
in	O
an	O
increaesd	O
rtae	O
and	O
extent	O
of	O
total	O
bdoy	O
weihgt	B-Disease
lsos	I-Disease
.	O

The	O
inbaility	O
of	O
amoidarone	O
to	O
directly	O
acitvate	O
either	O
hmuan	O
or	O
mosue	O
PPAaRlpha	O
transeintly	O
exrpessed	O
in	O
hmuan	O
HeGp2	O
hepaotma	B-Disease
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amioadrone	O
on	O
the	O
funtcion	O
of	O
this	O
recepotr	O
were	O
idnirect	O
.	O

Based	O
upon	O
these	O
resluts	O
,	O
we	O
conclude	O
that	O
amiodaorne	O
disrputs	O
hepaitc	O
liipd	O
homesotasis	O
and	O
that	O
the	O
inrceased	O
expressoin	O
of	O
PPRAalpha	O
tagret	O
gnees	O
is	O
secondary	O
to	O
this	O
toixc	O
effcet	O
.	O

These	O
reuslts	O
provide	O
important	O
new	O
mechansitic	O
infomration	O
regarding	O
the	O
hepatotoixc	B-Disease
effects	O
of	O
amidoarone	O
and	O
indicate	O
that	O
PPRAalpha	O
protcets	O
against	O
amioadrone	O
-	O
indcued	O
hepatotoxciity	B-Disease
.	O

Saefty	O
and	O
compilance	O
with	O
once	O
-	O
dialy	O
nicain	O
etxended	O
-	O
relesae	O
/	O
loavstatin	O
as	O
initial	O
threapy	O
in	O
the	O
Ipmact	O
of	O
Mdeical	O
Subsepcialty	O
on	O
Ptaient	O
Cmopliance	O
to	O
Treamtent	O
(	O
IPMACT	O
)	O
sutdy	O
.	O

Niaicn	O
etxended	O
-	O
reelase	O
/	O
lvoastatin	O
is	O
a	O
new	O
combintaion	O
porduct	O
apporved	O
for	O
teratment	O
of	O
pirmary	O
hyprecholesterolemia	B-Disease
and	O
mixed	O
dsylipidemia	B-Disease
.	O

This	O
open	O
-	O
lableed	O
,	O
multcienter	O
stduy	O
evaulated	O
the	O
sfaety	O
of	O
bdetime	O
nicain	O
extneded	O
-	O
relesae	O
/	O
lovastaitn	O
when	O
dsoed	O
as	O
initial	O
thearpy	O
and	O
paitent	O
copmliance	O
to	O
teratment	O
in	O
various	O
cilnical	O
practcie	O
settings	O
.	O

A	O
total	O
of	O
4	O
,	O
499	O
ptaients	O
with	O
dyslpiidemia	B-Disease
requiring	O
durg	O
inetrvention	O
was	O
enrolled	O
at	O
1	O
,	O
081	O
sties	O
.	O

Patinets	O
were	O
tretaed	O
with	O
1	O
tbalet	O
(	O
500	O
mg	O
of	O
niaicn	O
extenedd	O
-	O
relesae	O
/	O
20	O
mg	O
of	O
lvoastatin	O
)	O
once	O
nighlty	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tbalets	O
for	O
8	O
weeks	O
.	O

Paitents	O
also	O
received	O
deitary	O
conuseling	O
,	O
eduactional	O
mateirals	O
,	O
and	O
reimnders	O
to	O
call	O
a	O
tlol	O
-	O
free	O
number	O
that	O
provided	O
further	O
eudcation	O
about	O
dysilpidemia	B-Disease
and	O
naicin	O
etxended	O
-	O
reelase	O
/	O
lvoastatin	O
.	O

Prmiary	O
end	O
points	O
were	O
sutdy	O
compliacne	O
,	O
incerases	O
in	O
lvier	O
transaimnases	O
to	O
>	O
3	O
times	O
the	O
upepr	O
liimt	O
of	O
nomral	O
,	O
and	O
clniical	O
moypathy	B-Disease
.	O

Final	O
stduy	O
sattus	O
was	O
available	O
for	O
4	O
,	O
217	O
patietns	O
(	O
94	O
%	O
)	O
.	O

Copmliance	O
to	O
nicain	O
extenedd	O
-	O
reelase	O
/	O
lvoastatin	O
was	O
77	O
%	O
,	O
with	O
3	O
,	O
245	O
pateints	O
completing	O
the	O
stduy	O
.	O

Patinets	O
in	O
the	O
souhteast	O
and	O
those	O
enrolled	O
by	O
endocrinologsits	O
had	O
the	O
loewst	O
complaince	O
and	O
highest	O
advrese	O
eevnt	O
rtaes	O
.	O

Flsuhing	B-Disease
was	O
the	O
most	O
common	O
advesre	O
eevnt	O
,	O
reported	O
by	O
18	O
%	O
of	O
paitents	O
and	O
leading	O
to	O
discontinuaiton	O
by	O
6	O
%	O
.	O

Inciednce	O
of	O
incerased	O
asparatte	O
amintoransferase	O
and	O
/	O
or	O
alnaine	O
aminotrasnferase	O
>	O
3	O
times	O
the	O
upepr	O
liimt	O
of	O
nomral	O
was	O
<	O
0	O
.	O
3	O
%	O
.	O

An	O
incraese	O
of	O
creatnie	O
phoshpokinase	O
to	O
>	O
5	O
times	O
the	O
upper	O
liimt	O
of	O
nromal	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
patinets	O
,	O
and	O
no	O
csaes	O
of	O
durg	O
-	O
induecd	O
mypoathy	B-Disease
were	O
observed	O
.	O

Naicin	O
exetnded	O
-	O
relaese	O
/	O
lovasattin	O
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
doesd	O
as	O
initial	O
tehrapy	O
,	O
was	O
associated	O
with	O
good	O
cmopliance	O
and	O
saefty	O
and	O
had	O
very	O
low	O
incidecnes	O
of	O
incresaed	O
lievr	O
and	O
mucsle	O
eznymes	O
.	O

Protectvie	O
effcet	O
of	O
Termianlia	O
cehbula	O
against	O
epxerimental	O
myoacrdial	B-Disease
ijnury	I-Disease
induecd	O
by	O
isoproetrenol	O
.	O

Cardiporotective	O
effect	O
of	O
etahnolic	O
extarct	O
of	O
Terminlaia	O
chbeula	O
frutis	O
(	O
500	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
was	O
examined	O
in	O
isorpoterenol	O
(	O
200	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
inudced	O
myoacrdial	B-Disease
dmaage	I-Disease
in	O
rtas	O
.	O

In	O
isoproetrenol	O
adminitsered	O
rtas	O
,	O
the	O
lveel	O
of	O
lpiid	O
perxoides	O
incraesed	O
significantly	O
in	O
the	O
sreum	O
and	O
haert	O
.	O

A	O
significant	O
decraese	O
was	O
observed	O
in	O
the	O
actiivty	O
of	O
the	O
myocradial	O
marekr	O
enyzmes	O
with	O
a	O
concomiatnt	O
incerase	O
in	O
their	O
atcivity	O
in	O
seurm	O
.	O

Histoptahological	O
eaxmination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocadrial	O
necorsis	B-Disease
.	O

T	O
.	O
cheubla	O
extarct	O
pretretament	O
was	O
found	O
to	O
amleiorate	O
the	O
efefct	O
of	O
isoprtoerenol	O
on	O
liipd	O
peroxdie	O
formaiton	O
and	O
rteained	O
the	O
activtiies	O
of	O
the	O
diagnsotic	O
mraker	O
enyzmes	O
.	O

A	O
csae	O
of	O
posotperative	O
anxeity	B-Disease
due	O
to	O
low	O
dsoe	O
droepridol	O
used	O
with	O
ptaient	O
-	O
cotnrolled	O
analgeisa	O
.	O

A	O
multiaprous	O
wmoan	O
in	O
good	O
psycholgoical	O
helath	O
underwent	O
urgent	O
caeasrean	O
seciton	O
in	O
laobur	O
.	O

Postopeartively	O
,	O
she	O
was	O
given	O
a	O
pateint	O
-	O
contrloled	O
anaglesia	O
deivce	O
delivering	O
boulses	O
of	O
diamorpihne	O
0	O
.	O
5	O
mg	O
and	O
dorperidol	O
0	O
.	O
025	O
mg	O
.	O

Whilst	O
using	O
the	O
dveice	O
she	O
gradually	O
became	O
anxiuos	O
,	O
the	O
feeling	O
woresning	O
after	O
each	O
blous	O
.	O

The	O
diangosis	O
of	O
droperiodl	O
-	O
indcued	O
psycohlogical	B-Disease
distrubance	I-Disease
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questoining	O
the	O
paitent	O
gave	O
a	O
very	O
clear	O
histroy	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
dropeirdol	O
,	O
a	O
syrigne	O
containing	O
diamorphnie	O
only	O
was	O
substituetd	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
draamtic	O
extrapryamidal	O
side	O
effcets	O
of	O
dopaminerigc	O
antiemteics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifetsations	O
may	O
easily	O
be	O
overlooked	O
.	O

Accurtae	O
paitent	O
histroy	O
contributes	O
to	O
diffeerntiating	O
daibetes	B-Disease
inispidus	I-Disease
:	O
a	O
csae	O
sutdy	O
.	O

This	O
csae	O
sutdy	O
highlights	O
the	O
important	O
contribution	O
of	O
nusring	O
in	O
obtaining	O
an	O
accruate	O
helath	O
histroy	O
.	O

The	O
csae	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurgoenic	B-Disease
diabeets	I-Disease
insipdius	I-Disease
(	O
DI	B-Disease
)	O
secondary	O
to	O
a	O
traumaitc	B-Disease
brian	I-Disease
injruy	I-Disease
.	O

The	O
nurisng	O
satff	O
,	O
by	O
reivewing	O
the	O
ptaient	O
'	O
s	O
heatlh	O
hsitory	O
with	O
his	O
fmaily	O
,	O
discovered	O
a	O
hsitory	O
of	O
poldyipsia	B-Disease
and	O
long	O
-	O
stanidng	O
lihtium	O
use	O
.	O

Litihum	O
is	O
implicated	O
in	O
durg	O
-	O
idnuced	O
neprhogenic	B-Disease
DI	I-Disease
,	O
and	O
because	O
the	O
ptaient	O
had	O
not	O
received	O
litihum	O
since	O
being	O
admitted	O
to	O
the	O
hospiatl	O
,	O
his	O
treatemnt	O
changed	O
to	O
focus	O
on	O
nehprogenic	B-Disease
DI	I-Disease
.	O

By	O
combining	O
infomration	O
from	O
the	O
pateint	O
hisotry	O
,	O
the	O
physcial	O
examiantion	O
,	O
and	O
radoilogic	O
and	O
laobratory	O
stuides	O
,	O
the	O
critical	O
crae	O
taem	O
demonstrated	O
that	O
the	O
pateint	O
had	O
been	O
slef	O
-	O
terating	O
his	O
litihum	O
-	O
inudced	O
nephrgoenic	B-Disease
DI	I-Disease
and	O
developed	O
neurgoenic	B-Disease
DI	I-Disease
secondary	O
to	O
brian	B-Disease
truama	I-Disease
.	O

Thus	O
successful	O
treatemnt	O
required	O
that	O
nephrogeinc	O
and	O
neurgoenic	B-Disease
DI	I-Disease
be	O
treaetd	O
concomitantly	O
.	O

Fcators	O
contributing	O
to	O
ribaivrin	O
-	O
indcued	O
aneima	B-Disease
.	O

BACKGORUND	O
AND	O
AIM	O
:	O
Interfeorn	O
and	O
ribavriin	O
cobmination	O
threapy	O
for	O
chrnoic	B-Disease
heptaitis	I-Disease
C	I-Disease
produces	O
heomlytic	B-Disease
aenmia	I-Disease
.	O

This	O
sutdy	O
was	O
conducted	O
to	O
identify	O
the	O
fatcors	O
contributing	O
to	O
ribaivrin	O
-	O
indcued	O
anmeia	B-Disease
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
patinets	O
with	O
chornic	B-Disease
hpeatitis	I-Disease
C	I-Disease
who	O
received	O
interfreon	O
-	O
alhpa	O
-	O
2b	O
at	O
a	O
dsoe	O
of	O
6	O
MU	O
admiinstered	O
intramuscualrly	O
for	O
24	O
wekes	O
in	O
combintaion	O
with	O
ribaivrin	O
administreed	O
orlaly	O
at	O
a	O
dsoe	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
stduy	O
.	O

A	O
heomglobin	O
cnocentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribvairin	O
-	O
inudced	O
anmeia	B-Disease
.	O

RESUTLS	O
:	O
Rbiavirin	O
-	O
indcued	O
aneima	B-Disease
occurred	O
in	O
18	O
(	O
20	O
.	O
5	O
%	O
)	O
patinets	O
during	O
treatmnet	O
.	O

A	O
2	O
g	O
/	O
dL	O
decraese	O
in	O
hemgolobin	O
concenrtations	O
in	O
patinets	O
with	O
aneima	B-Disease
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
traetment	O
.	O

The	O
hemolgobin	O
concnetration	O
in	O
patinets	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decresae	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lwoer	O
even	O
after	O
week	O
2	O
than	O
in	O
paitents	O
with	O
<	O
2	O
g	O
/	O
dL	O
dcerease	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
significant	O
relaitonship	O
was	O
observed	O
between	O
the	O
rtae	O
of	O
reduciton	O
of	O
hemogolbin	O
concentartions	O
at	O
week	O
2	O
and	O
the	O
severtiy	O
of	O
aneima	B-Disease
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Such	O
fcators	O
as	O
sex	O
(	O
femlae	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
yeras	O
old	O
)	O
,	O
and	O
the	O
ribavriin	O
dsoe	O
by	O
bdoy	O
wieght	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univaraite	O
aanlysis	O
.	O

CONCLUSOINS	O
:	O
Careful	O
admniistration	O
is	O
necessary	O
in	O
patietns	O
>	O
or	O
=	O
60	O
yeras	O
old	O
,	O
in	O
femlae	O
paitents	O
,	O
and	O
in	O
paitents	O
receiving	O
a	O
ribaivrin	O
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O

Ptaients	O
who	O
experinece	O
a	O
fall	O
in	O
hemogolbin	O
concetnrations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treamtent	O
should	O
be	O
mnoitored	O
with	O
particular	O
crae	O
.	O

Zidovudnie	O
-	O
inudced	O
hpeatitis	B-Disease
.	O

A	O
csae	O
of	O
aucte	O
hpeatitis	B-Disease
induecd	O
by	O
zidvoudine	O
in	O
a	O
38	O
-	O
yaer	O
-	O
old	O
pateint	O
with	O
ADIS	B-Disease
is	O
presented	O
.	O

The	O
mcehanism	O
whereby	O
the	O
hepaittis	B-Disease
was	O
idnuced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
ptaient	O
tolearted	O
well	O
an	O
altrenative	O
revrese	O
tarnscriptase	O
inhbiitor	O
,	O
2	O
'	O
3	O
'	O
ddieoxyinosine	O
.	O

Physiicans	O
cairng	O
for	O
paitents	O
with	O
ADIS	B-Disease
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complciation	O
.	O

Oxidaitve	O
dmaage	O
preceeds	O
nirtative	O
dmaage	O
in	O
adiramycin	O
-	O
idnuced	O
caridac	O
mtiochondrial	B-Disease
ijnury	I-Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
stduy	O
was	O
to	O
determine	O
if	O
elveated	O
recative	O
oyxgen	O
(	O
ROS	O
)	O
/	O
nitorgen	O
sepcies	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adraimycin	O
(	O
ADR	O
)	O
-	O
indcued	O
cradiotoxicity	B-Disease
actually	O
resulted	O
in	O
cardiomyoctye	O
oixdative	O
/	O
nitratvie	O
dmaage	O
,	O
and	O
to	O
qauntitatively	O
determine	O
the	O
tmie	O
cuorse	O
and	O
subecllular	O
locailzation	O
of	O
these	O
postulated	O
daamge	O
proudcts	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

BC63	O
mcie	O
were	O
tretaed	O
with	O
a	O
single	O
dsoe	O
of	O
20	O
mg	O
/	O
kg	O
ADR	O
.	O

Ultrastrucutral	O
damgae	O
and	O
lveels	O
of	O
4	O
-	O
hydorxy	O
-	O
2	O
-	O
noneanl	O
(	O
4NHE	O
)	O
-	O
protien	O
addutcs	O
and	O
3	O
-	O
nitrotyrosnie	O
(	O
3NT	O
)	O
were	O
analzyed	O
.	O

Quantittaive	O
ultrasrtuctural	O
dmaage	O
using	O
compuetrized	O
imgae	O
tcehniques	O
showed	O
cardioymocyte	O
injruy	O
as	O
ealry	O
as	O
3	O
hours	O
,	O
with	O
mitochnodria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
ijnured	O
sbucellular	O
oragnelle	O
.	O

Analsyis	O
of	O
4NHE	O
protien	O
adudcts	O
by	O
immuongold	O
eletcron	O
mciroscopy	O
showed	O
appearacne	O
of	O
4NHE	O
portein	O
addcuts	O
in	O
mitohcondria	O
as	O
eraly	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
dceline	O
at	O
24	O
hours	O
.	O

3NT	O
leevls	O
were	O
significantly	O
increaesd	O
in	O
all	O
sbucellular	O
comaprtments	O
at	O
6	O
hours	O
and	O
subsequently	O
decliend	O
at	O
24	O
hours	O
.	O

Our	O
dtaa	O
showed	O
ADR	O
idnuced	O
4NHE	O
-	O
prtoein	O
adudcts	O
in	O
mitohcondria	O
at	O
the	O
same	O
tmie	O
point	O
as	O
when	O
mitohcondrial	B-Disease
injruy	I-Disease
initially	O
appeared	O
.	O

These	O
resutls	O
dcoument	O
for	O
the	O
first	O
tmie	O
in	O
vivo	O
that	O
mtiochondrial	B-Disease
oxidaitve	I-Disease
dmaage	I-Disease
percedes	O
nirtative	O
daamge	O
.	O

The	O
progressive	O
nature	O
of	O
mitochnodrial	B-Disease
injruy	I-Disease
suggests	O
that	O
mitochonrdia	O
,	O
not	O
other	O
subcellular	O
organelels	O
,	O
are	O
the	O
major	O
stie	O
of	O
intracelullar	O
injruy	O
.	O

Soatlol	O
-	O
idnuced	O
coornary	B-Disease
sapsm	I-Disease
in	O
a	O
ptaient	O
with	O
dliated	B-Disease
cardoimyopathy	I-Disease
associated	O
with	O
susatined	O
ventircular	B-Disease
tachcyardia	I-Disease
.	O

A	O
54	O
-	O
yaer	O
-	O
old	O
man	O
with	O
seevre	O
lfet	O
ventricualr	B-Disease
dsyfunction	I-Disease
due	O
to	O
dilaetd	B-Disease
cardiomyoptahy	I-Disease
was	O
referred	O
to	O
our	O
hospiatl	O
for	O
sympotmatic	O
inecssant	O
ssutained	O
ventrciular	B-Disease
tachcyardia	I-Disease
(	O
VT	B-Disease
)	O
.	O

After	O
the	O
admniistration	O
of	O
nifekaalnt	O
hydrocholride	O
,	O
ssutained	O
VT	B-Disease
was	O
termniated	O
.	O

An	O
alternate	O
calss	O
III	O
agnet	O
,	O
sotaoll	O
,	O
was	O
also	O
efefctive	O
for	O
the	O
preevntion	O
of	O
VT	B-Disease
.	O

However	O
,	O
one	O
motnh	O
after	O
switching	O
over	O
nifekalnat	O
to	O
sotlaol	O
,	O
a	O
short	O
duratoin	O
of	O
ST	O
eelvation	O
was	O
docuemnted	O
in	O
ECG	O
monitornig	O
at	O
almost	O
the	O
same	O
tmie	O
for	O
three	O
conseuctive	O
dyas	O
.	O

ST	O
elevaiton	O
with	O
cehst	O
dicsomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiaezm	O
.	O

Coroanry	B-Disease
vaosspasm	I-Disease
may	O
be	O
indcued	O
by	O
the	O
non	O
-	O
selective	O
btea	O
-	O
blokcing	O
properteis	O
of	O
stoalol	O
.	O

Effcets	O
of	O
the	O
anitdepressant	O
trazoodne	O
,	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
rceeptor	O
anatgonist	O
,	O
on	O
doapmine	O
-	O
depenednt	O
behaivors	O
in	O
rtas	O
.	O

RATIOANLE	O
:	O
5	O
-	O
Hydroxytryptmaine	O
,	O
via	O
stimluation	O
of	O
5	O
-	O
HT	O
2C	O
rceeptors	O
,	O
exerts	O
a	O
tnoic	O
inhibitroy	O
ifnluence	O
on	O
dopmainergic	O
neurotransimssion	O
,	O
whereas	O
actiavtion	O
of	O
5	O
-	O
HT	O
2A	O
recetpors	O
enhacnes	O
stimluated	O
DeArgic	O
neurotranmsission	O
.	O

The	O
antidperessant	O
trazoodne	O
is	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
recepotr	O
antagoinst	O
.	O

OBJECTIEVS	O
:	O
To	O
eavluate	O
the	O
effect	O
of	O
trazoodne	O
teratment	O
on	O
behavoirs	O
depenednt	O
on	O
the	O
functoinal	O
sattus	O
of	O
the	O
nigrotsriatal	O
DAerigc	O
sytsem	O
.	O

METHODS	O
:	O
The	O
efefct	O
of	O
pertreatment	O
with	O
trazoodne	O
on	O
dexamphteamine	O
-	O
and	O
apoomrphine	O
-	O
idnuced	O
oarl	B-Disease
stereotpyies	I-Disease
,	O
on	O
catalpesy	B-Disease
indcued	O
by	O
haolperidol	O
and	O
apomorphnie	O
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
on	O
ergometrnie	O
-	O
induecd	O
wet	O
dog	O
shkae	O
(	O
WDS	O
)	O
bheavior	O
and	O
fluoxeitne	O
-	O
induecd	O
pneile	O
erecitons	O
was	O
studied	O
in	O
rtas	O
.	O

We	O
also	O
inevstigated	O
whether	O
trzaodone	O
idnuces	O
caatlepsy	B-Disease
in	O
rtas	O
.	O

RESUTLS	O
:	O
Trazodnoe	O
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
did	O
not	O
indcue	O
catlaepsy	B-Disease
,	O
and	O
did	O
not	O
atnagonize	O
apoomrphine	O
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
steroetypy	O
and	O
apoomrphine	O
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
-	O
induecd	O
cataelpsy	B-Disease
.	O

However	O
,	O
pretretament	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
tarzodone	O
ehnanced	O
dexamphteamine	O
steerotypy	O
,	O
and	O
atnagonized	O
haloperdiol	O
caatlepsy	B-Disease
,	O
ergmoetrine	O
-	O
induecd	O
WDS	O
behaivor	O
and	O
fluxoetine	O
-	O
induecd	O
pneile	O
eretcions	O
.	O

Trzaodone	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
indcued	O
ctaalepsy	B-Disease
and	O
antagnoized	O
apomorhpine	O
and	O
dexamphetmaine	O
stereoytpies	O
.	O

CONCLUISONS	O
:	O
Our	O
resutls	O
indicate	O
that	O
trazoodne	O
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
bolck	O
pre	O
-	O
and	O
postsyanptic	O
srtiatal	O
D2	O
DA	O
recetpors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blokcs	O
postsnyaptic	O
straital	O
D2	O
DA	O
recpetors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
tarzodone	O
blcoks	O
5	O
-	O
HT	O
2A	O
and	O
5	O
-	O
HT	O
2C	O
recetpors	O
.	O

We	O
suggest	O
that	O
tarzodone	O
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blokcing	O
the	O
5	O
-	O
HT	O
2C	O
recpetors	O
,	O
reelases	O
the	O
nigrostiratal	O
DAegric	O
nuerons	O
from	O
tnoic	O
inhibtiion	O
caused	O
by	O
5	O
-	O
HT	O
,	O
and	O
thereby	O
potenitates	O
dexapmhetamine	O
stereotpyy	O
and	O
antagoniezs	O
hlaoperidol	O
caatlepsy	B-Disease
.	O

Swallwoing	B-Disease
anbormalities	I-Disease
and	O
dysiknesia	B-Disease
in	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
.	O

Gsatrointestinal	B-Disease
abnomralities	I-Disease
in	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
(	O
PD	B-Disease
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathohpysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
characterize	O
the	O
orohparyngeal	O
dynmaics	O
in	O
PD	B-Disease
paitents	O
with	O
and	O
without	O
lveodopa	O
-	O
induecd	O
dyskiensia	B-Disease
.	O

Fifteen	O
dyskinteic	B-Disease
,	O
12	O
nondysiknetic	O
pateints	O
,	O
and	O
a	O
conrtol	O
gorup	O
were	O
included	O
.	O

Patietns	O
were	O
asked	O
about	O
dyspahgia	B-Disease
and	O
evalutaed	O
with	O
the	O
Uinfied	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
Dsiease	I-Disease
Raitng	O
Sclae	O
Prats	O
II	O
and	O
III	O
and	O
the	O
Hohen	O
and	O
Yhar	O
scale	O
.	O

Delgutition	O
was	O
asssesed	O
using	O
modiifed	O
braium	O
swlalow	O
with	O
videolfuoroscopy	O
.	O

Nondyksinetic	O
ptaients	O
,	O
but	O
not	O
the	O
dyskineitc	B-Disease
ones	O
,	O
showed	O
less	O
orohparyngeal	O
swlalowing	O
efifciency	O
(	O
OSPE	O
)	O
for	O
lqiuid	O
food	O
than	O
cnotrols	O
(	O
Dnunett	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Dyskinteic	B-Disease
paitents	O
tended	O
to	O
have	O
a	O
greater	O
OSPE	O
than	O
nondysiknetic	O
(	O
Dnunett	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

Patinets	O
who	O
were	O
using	O
a	O
hgiher	O
dsoe	O
of	O
levodpoa	O
had	O
a	O
greater	O
OSPE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oarl	O
tranist	O
tmie	O
(	O
Perason	O
'	O
s	O
correltaion	O
,	O
P	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
reprot	O
of	O
dysphaiga	B-Disease
nor	O
any	O
of	O
the	O
PD	B-Disease
seevrity	O
paarmeters	O
correlated	O
to	O
the	O
videofluorsocopic	O
variabels	O
.	O

In	O
the	O
current	O
sutdy	O
,	O
dsykinetic	B-Disease
patinets	O
performed	O
better	O
in	O
swallwoing	O
funtcion	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodpoa	O
dsoe	O
.	O

Our	O
resluts	O
suggest	O
a	O
role	O
for	O
levoodpa	O
in	O
the	O
oarl	O
pahse	O
of	O
deglutitoin	O
and	O
confirm	O
that	O
dypshagia	B-Disease
is	O
not	O
a	O
good	O
prdeictor	O
of	O
deglutiiton	O
alteratinos	O
in	O
PD	B-Disease
.	O

Inihbition	O
of	O
nucelar	O
facotr	O
-	O
kappaB	O
atcivation	O
atteunates	O
tubulointerstitail	B-Disease
nephirtis	I-Disease
idnuced	O
by	O
gentmaicin	O
.	O

BACKGRUOND	O
:	O
Animlas	O
tretaed	O
with	O
gentamciin	O
can	O
show	O
rseidual	O
areas	O
of	O
inetrstitial	O
firbosis	B-Disease
in	O
the	O
rneal	O
cotrex	O
.	O

This	O
stduy	O
invesitgated	O
the	O
experssion	O
of	O
nculear	O
facotr	O
-	O
kappaB	O
(	O
NF	O
-	O
kpapaB	O
)	O
,	O
miotgen	O
-	O
actiavted	O
portein	O
(	O
MAP	O
)	O
kinsaes	O
and	O
marcophages	O
in	O
the	O
rneal	O
cotrex	O
and	O
srtuctural	O
and	O
fnuctional	O
reanl	O
chagnes	O
of	O
rtas	O
terated	O
with	O
genatmicin	O
or	O
gentaimcin	O
+	O
pyrroliidne	O
dtihiocarbamate	O
(	O
PTDC	O
)	O
,	O
an	O
NF	O
-	O
kpapaB	O
inhibiotr	O
.	O

METHODS	O
:	O
38	O
fmeale	O
Wisatr	O
rtas	O
were	O
injetced	O
with	O
gentamciin	O
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
dyas	O
,	O
38	O
with	O
getnamicin	O
+	O
PTDC	O
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NCal	O
soultion	O
.	O

The	O
animlas	O
were	O
killed	O
5	O
and	O
30	O
dyas	O
after	O
these	O
injetcions	O
and	O
the	O
kindeys	O
were	O
reomved	O
for	O
hitsological	O
and	O
immunohistocheimcal	O
stuides	O
.	O

The	O
rseults	O
of	O
the	O
immunohistocheimcal	O
stduies	O
were	O
socred	O
according	O
to	O
the	O
extent	O
of	O
staiinng	O
.	O

The	O
fractioanl	O
intesrtitial	O
aera	O
was	O
determined	O
by	O
mrophometry	O
.	O

REUSLTS	O
:	O
Genatmicin	O
-	O
traeted	O
rtas	O
presented	O
a	O
transitory	O
incerase	O
in	O
plsama	O
creatinnie	O
lveels	O
.	O

Incerased	O
ED	O
-	O
1	O
,	O
MAP	O
kniases	O
and	O
NF	O
-	O
kappaB	O
staiinng	O
were	O
also	O
observed	O
in	O
the	O
reanl	O
cotrex	O
from	O
all	O
gentamiicn	O
-	O
tretaed	O
rtas	O
comapred	O
to	O
contorl	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
aniamls	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fiborsis	B-Disease
in	O
the	O
reanl	O
crotex	O
despite	O
the	O
recoevry	O
of	O
rneal	O
fucntion	O
.	O

Treatmnet	O
with	O
PTDC	O
redcued	O
the	O
fnuctional	O
and	O
structrual	O
chnages	O
induecd	O
by	O
gentamciin	O
.	O

CONCLSUIONS	O
:	O
These	O
dtaa	O
show	O
that	O
inihbition	O
of	O
NF	O
-	O
kapapB	O
atcivation	O
atteunates	O
tubulointersittial	B-Disease
neprhitis	I-Disease
induecd	O
by	O
gentamiicn	O
.	O

Gluocse	O
metaboilsm	O
in	O
patietns	O
with	O
schziophrenia	B-Disease
tretaed	O
with	O
atpyical	O
anitpsychotic	O
agnets	O
:	O
a	O
frequently	O
smapled	O
intarvenous	O
gluocse	O
tolernace	O
tset	O
and	O
minmial	O
moedl	O
analsyis	O
.	O

BACKGRUOND	O
:	O
While	O
the	O
inciednce	O
of	O
new	O
-	O
onset	O
diabeets	B-Disease
mellitus	I-Disease
may	O
be	O
incresaing	O
in	O
patietns	O
with	O
schiozphrenia	B-Disease
terated	O
with	O
certain	O
atyipcal	O
antipsycohtic	O
aegnts	O
,	O
it	O
remains	O
unclear	O
whether	O
atyipcal	O
agnets	O
are	O
directly	O
afefcting	O
gulcose	O
meatbolism	O
or	O
simply	O
incraesing	O
known	O
rsik	O
factros	O
for	O
daibetes	B-Disease
.	O

OBJECTVIE	O
:	O
To	O
sutdy	O
the	O
2	O
durgs	O
most	O
clearly	O
implicated	O
(	O
clozaipne	O
and	O
olanzapnie	O
)	O
and	O
risepridone	O
using	O
a	O
frequently	O
samlped	O
intarvenous	O
gulcose	O
tloerance	O
tset	O
.	O

DESIGN	O
:	O
A	O
corss	O
-	O
sectioanl	O
desgin	O
in	O
stbale	O
,	O
tretaed	O
patinets	O
with	O
scihzophrenia	B-Disease
evalauted	O
using	O
a	O
frequently	O
sapmled	O
intarvenous	O
gluocse	O
tolernace	O
tset	O
and	O
the	O
Bergamn	O
mniimal	O
mdoel	O
anaylsis	O
.	O

SETTING	O
:	O
Subejcts	O
were	O
recruited	O
from	O
an	O
urabn	O
cmomunity	O
metnal	O
heatlh	O
clniic	O
and	O
were	O
studied	O
at	O
a	O
general	O
cilnical	O
reseacrh	O
cenetr	O
.	O

Patietns	O
Fifty	O
subjetcs	O
signed	O
informed	O
consnet	O
and	O
41	O
underwent	O
the	O
frequently	O
sapmled	O
intravneous	O
glucsoe	O
tolearnce	O
tset	O
.	O

Thirty	O
-	O
six	O
nonoebse	O
sbujects	O
with	O
schizophrneia	B-Disease
or	O
schizoaffetcive	B-Disease
disroder	I-Disease
,	O
matched	O
by	O
bdoy	O
msas	O
index	O
and	O
treaetd	O
with	O
either	O
clozpaine	O
,	O
olanzaipne	O
,	O
or	O
risperdione	O
,	O
were	O
included	O
in	O
the	O
anlaysis	O
.	O

MIAN	O
OUTCMOE	O
MESAURES	O
:	O
Fastnig	O
plamsa	O
glcuose	O
and	O
fasitng	O
sreum	O
inuslin	O
levles	O
,	O
insuiln	B-Disease
senistivity	I-Disease
index	O
,	O
homesotasis	O
moedl	O
asesssment	O
of	O
isnulin	B-Disease
resisatnce	I-Disease
,	O
and	O
gulcose	O
effectivneess	O
.	O

RESUTLS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
druation	O
of	O
treamtent	O
with	O
the	O
iedntified	O
aytpical	O
antipsychtoic	O
aegnt	O
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
motnhs	O
(	O
clozpaine	O
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
motnhs	O
(	O
olanzaipne	O
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risperidnoe	O
)	O
.	O

Fasitng	O
seurm	O
isnulin	O
cnocentrations	O
diffreed	O
among	O
gropus	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozaipne	O
>	O
oalnzapine	O
>	O
ripseridone	O
)	O
with	O
significant	O
differecnes	O
between	O
clozpaine	O
and	O
rispeirdone	O
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olaznapine	O
and	O
rsiperidone	O
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
isnulin	B-Disease
senistivity	I-Disease
index	O
among	O
gorups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
clozaipne	O
<	O
oalnzapine	O
<	O
ripseridone	O
)	O
,	O
with	O
subejcts	O
who	O
received	O
clozaipne	O
and	O
olanzapnie	O
exhibiting	O
significant	O
insuiln	B-Disease
reisstance	I-Disease
compaerd	O
with	O
sbujects	O
who	O
were	O
treaetd	O
with	O
rsiperidone	O
(	O
clozaipne	O
vs	O
rispreidone	O
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olaznapine	O
vs	O
risperiodne	O
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
hmoeostasis	O
moedl	O
assessemnt	O
of	O
insuiln	B-Disease
resistacne	I-Disease
also	O
dfifered	O
significantly	O
among	O
gorups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clzoapine	O
>	O
olanazpine	O
>	O
risperidnoe	O
)	O
(	O
clzoapine	O
vs	O
rsiperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanazpine	O
vs	O
rsiperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
gropus	O
in	O
gulcose	O
effectiveenss	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
cloazpine	O
<	O
oalnzapine	O
<	O
risperiodne	O
)	O
with	O
significant	O
differenecs	O
between	O
clozapnie	O
and	O
risperiodne	O
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
oalnzapine	O
and	O
rispreidone	O
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CNOCLUSIONS	O
:	O
Both	O
nonboese	O
colzapine	O
-	O
and	O
olanzaipne	O
-	O
tretaed	O
gorups	O
displayed	O
significant	O
inuslin	B-Disease
resisatnce	I-Disease
and	O
ipmairment	O
of	O
gulcose	O
effectiveenss	O
comapred	O
with	O
rispeirdone	O
-	O
traeted	O
sbujects	O
.	O

Ptaients	O
taking	O
clozaipne	O
and	O
oalnzapine	O
must	O
be	O
examined	O
for	O
inuslin	B-Disease
reisstance	I-Disease
and	O
its	O
cnosequences	O
.	O

Thoraicc	B-Disease
hemaotmyelia	I-Disease
secondary	O
to	O
coumdain	O
anticaogulant	O
tehrapy	O
:	O
a	O
csae	O
reoprt	O
.	O

A	O
csae	O
of	O
tohracic	B-Disease
heamtomyelia	I-Disease
secondary	O
to	O
anticoauglant	O
therpay	O
is	O
presented	O
.	O

Cliincal	O
featuers	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
csaes	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
supsicion	O
may	O
lead	O
to	O
a	O
quick	O
diagonstic	O
procdeure	O
and	O
successful	O
decompressive	O
surgrey	O
.	O

Mnaia	B-Disease
associated	O
with	O
fluoxeitne	O
tretament	O
in	O
adolsecents	O
.	O

Fluoxteine	O
,	O
a	O
selective	O
serootnin	O
reutpake	O
inhiibtor	O
,	O
is	O
gaining	O
increaesd	O
accepatnce	O
in	O
the	O
treamtent	O
of	O
adloescent	O
dperession	B-Disease
.	O

Generally	O
safe	O
and	O
well	O
tolearted	O
by	O
adluts	O
,	O
fuloxetine	O
has	O
been	O
reported	O
to	O
idnuce	O
mnaia	B-Disease
.	O

The	O
csaes	O
of	O
five	O
depresesd	B-Disease
adolsecents	O
,	O
14	O
-	O
16	O
yeras	O
of	O
age	O
,	O
who	O
developed	O
maina	B-Disease
during	O
pharmacothreapy	O
with	O
fluoxetnie	O
,	O
are	O
reported	O
here	O
.	O

Apaprent	O
rsik	O
fatcors	O
for	O
the	O
develpoment	O
of	O
maina	B-Disease
or	O
hypomaina	B-Disease
during	O
flouxetine	O
pharmacohterapy	O
in	O
this	O
ppoulation	O
were	O
the	O
comibnation	O
of	O
attentoin	B-Disease
-	I-Disease
defiict	I-Disease
hyepractivity	I-Disease
disroder	I-Disease
and	O
affective	O
instaiblity	O
;	O
major	O
derpession	B-Disease
with	O
pscyhotic	B-Disease
featrues	O
;	O
a	O
faimly	O
histroy	O
of	O
affectvie	B-Disease
disroder	I-Disease
,	O
especially	O
biploar	B-Disease
disroder	I-Disease
;	O
and	O
a	O
diagonsis	O
of	O
bpiolar	B-Disease
dsiorder	I-Disease
.	O

Further	O
stduy	O
is	O
needed	O
to	O
determine	O
the	O
opitmal	O
doasge	O
and	O
to	O
identify	O
rsik	O
fcators	O
that	O
incresae	O
indivdiual	O
vulnerabiltiy	O
to	O
flouxetine	O
induecd	O
mnaia	B-Disease
in	O
adloescents	O
.	O

Actue	B-Disease
reanl	I-Disease
insuffciiency	I-Disease
after	O
high	O
-	O
dsoe	O
melphlaan	O
in	O
patietns	O
with	O
priamry	B-Disease
sytsemic	I-Disease
aymloidosis	I-Disease
during	O
setm	O
clel	O
transplantatoin	O
.	O

BACGKROUND	O
:	O
Patietns	O
with	O
prmiary	B-Disease
systmeic	I-Disease
aymloidosis	I-Disease
(	O
AL	B-Disease
)	O
have	O
a	O
poor	O
prognsois	O
.	O

Medain	O
survvial	O
tmie	O
from	O
stnadard	O
traetments	O
is	O
only	O
17	O
mnoths	O
.	O

High	O
-	O
dsoe	O
intravenuos	O
meplhalan	O
followed	O
by	O
periphearl	O
bolod	O
setm	O
clel	O
translpant	O
(	O
PBCST	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
thearpy	O
,	O
but	O
teratment	O
mortlaity	O
can	O
be	O
high	O
.	O

The	O
authros	O
have	O
noted	O
the	O
develpoment	O
of	O
actue	B-Disease
rneal	I-Disease
isnufficiency	I-Disease
immediately	O
after	O
meplhalan	O
conditinoing	O
.	O

This	O
stduy	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
rsik	O
facotrs	O
and	O
impcat	O
on	O
posttarnsplant	O
mortlaity	O
.	O

METHODS	O
:	O
Conescutive	O
AL	B-Disease
patinets	O
who	O
underwent	O
PSBCT	O
were	O
studied	O
retrospectivley	O
.	O

Actue	B-Disease
reanl	I-Disease
isnufficiency	I-Disease
(	O
ARI	B-Disease
)	O
after	O
high	O
-	O
dsoe	O
melphlaan	O
was	O
defined	O
by	O
a	O
minimum	O
icnrease	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
sreum	O
creatiinne	O
lveel	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
bsaeline	O
immediately	O
after	O
conidtioning	O
.	O

Uirne	O
sdeiment	O
scroe	O
was	O
the	O
sum	O
of	O
the	O
individaul	O
types	O
of	O
sediemnt	O
identifeid	O
on	O
uirne	O
microscpoy	O
.	O

RSEULTS	O
:	O
Of	O
the	O
80	O
ptaients	O
studied	O
,	O
ARI	B-Disease
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
patinets	O
after	O
high	O
-	O
dsoe	O
meplhalan	O
.	O

Uniavriate	O
analsyis	O
iedntified	O
age	O
,	O
hypoalbuimnemia	B-Disease
,	O
haevy	O
protienuria	B-Disease
,	O
diureitc	O
use	O
,	O
and	O
uirne	O
seidment	O
scroe	O
(	O
>	O
3	O
)	O
as	O
rsik	O
factros	O
.	O

Age	O
and	O
uirne	O
seidment	O
scroe	O
remained	O
independently	O
significant	O
rsik	O
factros	O
in	O
the	O
multivaraite	O
anaylsis	O
.	O

Ptaients	O
who	O
had	O
ARI	B-Disease
after	O
high	O
-	O
dsoe	O
meplhalan	O
underwent	O
dialsyis	O
more	O
often	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
had	O
a	O
wrose	O
1	O
-	O
yaer	O
sruvival	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCULSION	O
:	O
The	O
timnig	O
of	O
reanl	B-Disease
injruy	I-Disease
strongly	O
suggests	O
melphaaln	O
as	O
the	O
cauastive	O
aegnt	O
.	O

Ongoing	O
tubluar	B-Disease
inujry	I-Disease
may	O
be	O
a	O
prerequisite	O
for	O
reanl	B-Disease
injruy	I-Disease
by	O
meplhalan	O
as	O
evidenced	O
by	O
the	O
acitve	O
urinray	O
sedimnet	O
.	O

Devleopment	O
of	O
ARI	B-Disease
adversely	O
affetced	O
the	O
outocme	O
after	O
PSBCT	O
.	O

Effcetive	O
prveentive	O
mesaures	O
may	O
help	O
decresae	O
the	O
tretament	O
motrality	O
of	O
PSBCT	O
in	O
AL	B-Disease
paitents	O
.	O

Fcoal	O
creebral	B-Disease
ischmeia	I-Disease
in	O
rtas	O
:	O
effcet	O
of	O
pheynlephrine	O
-	O
idnuced	O
hyeprtension	B-Disease
during	O
repefrusion	O
.	O

After	O
180	O
min	O
of	O
tepmorary	O
midlde	B-Disease
cerberal	I-Disease
aretry	I-Disease
occlsuion	I-Disease
in	O
spontaneuosly	O
hyeprtensive	B-Disease
rtas	O
,	O
the	O
efefct	O
of	O
phenylpehrine	O
-	O
induecd	O
hyperetnsion	B-Disease
on	O
iscehmic	B-Disease
barin	I-Disease
ijnury	I-Disease
and	O
blood	O
-	O
barin	O
barrier	O
permeabiilty	O
was	O
determined	O
.	O

Blood	O
presusre	O
was	O
manipualted	O
by	O
one	O
of	O
the	O
following	O
scheduels	O
during	O
120	O
min	O
of	O
repefrusion	O
:	O
Contorl	O
,	O
normotesnive	O
reperufsion	O
;	O
90	O
/	O
hypertenison	B-Disease
(	O
90	O
/	O
HTN	B-Disease
)	O
,	O
bolod	O
pressrue	O
was	O
incraesed	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusoin	O
only	O
;	O
15	O
/	O
hypretension	B-Disease
(	O
15	O
/	O
HTN	B-Disease
)	O
,	O
noromtensive	O
reperfuison	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hyperetnsion	B-Disease
and	O
75	O
min	O
of	O
normotenison	O
.	O

Part	O
A	O
,	O
for	O
eight	O
rtas	O
in	O
each	O
gruop	O
brian	B-Disease
ijnury	I-Disease
was	O
evlauated	O
by	O
stianing	O
tissue	O
using	O
2	O
,	O
3	O
,	O
5	O
-	O
triphenyltertazolium	O
chloirde	O
and	O
edmea	B-Disease
was	O
evaluaetd	O
by	O
mircogravimetry	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
rtas	O
in	O
each	O
gruop	O
blood	O
-	O
brian	O
barirer	O
premeability	O
was	O
evalauted	O
by	O
mesauring	O
the	O
amonut	O
and	O
extent	O
of	O
extravastaion	O
of	O
Eavns	O
Bule	O
dye	O
.	O

Barin	B-Disease
ijnury	I-Disease
(	O
percenatge	O
of	O
the	O
ishcemic	B-Disease
hemishpere	I-Disease
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	B-Disease
gorup	O
(	O
16	O
+	O
/	O
-	O
6	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
gruop	O
(	O
30	O
+	O
/	O
-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
cotnrol	O
gruop	O
(	O
42	O
+	O
/	O
-	O
5	O
)	O
.	O

Specific	O
garvity	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	B-Disease
gruop	O
(	O
1	O
.	O
043	O
+	O
/	O
-	O
0	O
.	O
002	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
(	O
1	O
.	O
036	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
and	O
cotnrol	O
(	O
1	O
.	O
037	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
gropus	O
.	O

Evnas	O
Bule	O
(	O
mug	O
g	O
-	O
1	O
of	O
barin	O
tisuse	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	B-Disease
gorup	O
(	O
24	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
0	O
)	O
versus	O
the	O
conrtol	O
gruop	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	B-Disease
gruop	O
(	O
7	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
)	O
.	O

This	O
stduy	O
supports	O
a	O
hypotheiss	O
that	O
during	O
reperfsuion	O
,	O
a	O
short	O
itnerval	O
of	O
hyeprtension	B-Disease
derceases	O
brian	B-Disease
injruy	I-Disease
and	O
eedma	B-Disease
;	O
and	O
that	O
sustanied	O
hyperetnsion	B-Disease
icnreases	O
the	O
rsik	O
of	O
vasoegnic	B-Disease
eedma	I-Disease
.	O

Pepole	O
aegd	O
over	O
75	O
in	O
atrail	B-Disease
fibrillaiton	I-Disease
on	O
warfrain	O
:	O
the	O
rtae	O
of	O
major	O
hemorrahge	B-Disease
and	O
srtoke	B-Disease
in	O
more	O
than	O
500	O
patinet	O
-	O
yeras	O
of	O
follow	O
-	O
up	O
.	O

OBEJCTIVES	O
:	O
To	O
determine	O
the	O
incidecne	O
of	O
major	O
hemorhrage	B-Disease
and	O
storke	B-Disease
in	O
pepole	O
aegd	O
76	O
and	O
odler	O
with	O
artial	B-Disease
fibrillation	I-Disease
on	O
adjusted	O
-	O
dsoe	O
wafrarin	O
who	O
had	O
been	O
recently	O
been	O
adimtted	O
to	O
hosiptal	O
.	O

DESIGN	O
:	O
A	O
retropsective	O
observatoinal	O
choort	O
sutdy	O
.	O

SETTING	O
:	O
A	O
major	O
healtchare	O
newtork	O
involving	O
four	O
tertairy	O
hosptials	O
.	O

PARTICIPATNS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patietns	O
aegd	O
76	O
and	O
odler	O
amditted	O
to	O
a	O
major	O
helathcare	O
ntework	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atiral	B-Disease
fibrillatoin	I-Disease
on	O
warfrain	O
were	O
enrolled	O
.	O

MEASUERMENTS	O
:	O
Infromation	O
regarding	O
major	O
bledeing	B-Disease
epiosdes	O
,	O
storkes	B-Disease
,	O
and	O
warfrain	O
use	O
was	O
obtained	O
from	O
patietns	O
,	O
realtives	O
,	O
primray	O
physicinas	O
,	O
and	O
meidcal	O
reocrds	O
.	O

RESUTLS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patinets	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analyiss	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warafrin	O
was	O
530	O
yeras	O
(	O
mean	O
28	O
mnoths	O
)	O
.	O

There	O
were	O
53	O
major	O
heomrrhages	B-Disease
,	O
for	O
an	O
annual	O
rtae	O
of	O
10	O
.	O
0	O
%	O
,	O
including	O
24	O
(	O
45	O
.	O
3	O
%	O
)	O
lfie	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%	O
)	O
faatl	O
beleds	O
.	O

The	O
annaul	O
storke	B-Disease
rtae	O
after	O
intiiation	O
of	O
warfairn	O
was	O
2	O
.	O
6	O
%	O
.	O

CONCLUSOIN	O
:	O
The	O
rtae	O
of	O
major	O
hemorrahge	B-Disease
was	O
high	O
in	O
this	O
old	O
,	O
frial	O
gorup	O
,	O
but	O
excluding	O
fataliites	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequeale	O
,	O
and	O
the	O
strkoe	B-Disease
rtae	O
on	O
warafrin	O
was	O
low	O
,	O
demonstrating	O
how	O
effcetive	O
warafrin	O
treamtent	O
is	O
.	O

Saftey	O
of	O
celceoxib	O
in	O
patinets	O
with	O
adevrse	O
sikn	B-Disease
reatcions	I-Disease
to	O
acetmainophen	O
(	O
paraectamol	O
)	O
and	O
nimesuldie	O
associated	O
or	O
not	O
with	O
common	O
non	O
-	O
steroiadl	O
atni	O
-	O
ifnlammatory	O
durgs	O
.	O

BACGKROUND	O
:	O
Acetmainophen	O
(	O
praacetamol	O
-	O
-	O
P	O
)	O
and	O
Niemsulide	O
(	O
N	O
)	O
are	O
widely	O
used	O
aanlgesic	O
-	O
anitpyretic	O
/	O
atni	O
-	O
inlfammatory	O
drgus	O
.	O

The	O
rtae	O
of	O
advesre	O
hypersensiitvity	B-Disease
reatcions	O
to	O
these	O
aegnts	O
is	O
generally	O
low	O
.	O

On	O
the	O
contrary	O
non	O
-	O
streoidal	O
atni	O
-	O
inflammtaory	O
drgus	O
(	O
NSIADs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
reacitons	O
.	O

Ceelcoxib	O
(	O
CE	O
)	O
is	O
a	O
novel	O
durg	O
,	O
with	O
high	O
selectivtiy	O
and	O
affniity	O
for	O
COX	O
-	O
2	O
enyzme	O
.	O

OBEJCTIVE	O
:	O
We	O
evlauated	O
the	O
tolerabliity	O
of	O
CE	O
in	O
a	O
gruop	O
of	O
pateints	O
with	O
doucmented	O
hitsory	O
of	O
avderse	O
ctuaneous	B-Disease
reatcions	I-Disease
to	O
P	O
and	O
N	O
associated	O
or	O
not	O
to	O
classic	O
NSADIs	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patietns	O
with	O
hypersensiitvity	B-Disease
to	O
P	O
and	O
N	O
with	O
or	O
without	O
associated	O
reacitons	O
to	O
classic	O
NSIADs	O
.	O

The	O
diangosis	O
of	O
P	O
and	O
N	O
-	O
induecd	O
sikn	B-Disease
reactoins	I-Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
palcebo	O
was	O
blindly	O
adminsitered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
dyas	O
,	O
a	O
cumualtive	O
doasge	O
of	O
200	O
mg	O
of	O
CE	O
in	O
refrcated	O
doess	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
dyas	O
,	O
a	O
single	O
dsoe	O
of	O
200	O
mg	O
was	O
admiinstered	O
.	O

All	O
paitents	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
conrtolled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delyaed	O
reactoins	O
.	O

The	O
challenge	O
was	O
considered	O
poistive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erytehma	B-Disease
,	O
rush	O
or	O
urticraia	B-Disease
-	O
angiodeema	B-Disease
.	O

RESLUTS	O
:	O
No	O
reactoin	O
was	O
observed	O
with	O
palcebo	O
and	O
eight	O
pateints	O
(	O
88	O
.	O
8	O
%	O
)	O
tloerated	O
CE	O
.	O

Only	O
one	O
paitent	O
developed	O
a	O
modearte	O
angioedmea	B-Disease
of	O
the	O
lpis	O
.	O

CNOCLUSION	O
:	O
Only	O
one	O
hypersensitviity	B-Disease
reatcion	O
to	O
CE	O
was	O
docmuented	O
among	O
9	O
P	O
and	O
N	O
-	O
highly	O
NSIADs	O
intloerant	O
patinets	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	O
is	O
a	O
reasonably	O
safe	O
altenrative	O
to	O
be	O
used	O
in	O
subjcets	O
who	O
do	O
not	O
tolerate	O
P	O
and	O
N	O
.	O

Csae	O
-	O
contorl	O
sutdy	O
of	O
regular	O
analegsic	O
and	O
nonsterodial	O
atni	O
-	O
inflammaotry	O
use	O
and	O
end	B-Disease
-	I-Disease
satge	I-Disease
reanl	I-Disease
dsiease	I-Disease
.	O

BACKGRUOND	O
:	O
Stuides	O
on	O
the	O
associaiton	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
apsirin	O
and	O
other	O
anlagesic	O
and	O
nonsterodial	O
atni	O
-	O
inflammaotry	O
durgs	O
(	O
NASIDs	O
)	O
and	O
end	B-Disease
-	I-Disease
satge	I-Disease
rneal	I-Disease
diesase	I-Disease
(	O
ERSD	B-Disease
)	O
have	O
given	O
conflicting	O
resluts	O
.	O

In	O
order	O
to	O
examine	O
this	O
assocaition	O
,	O
a	O
csae	O
-	O
contorl	O
sutdy	O
with	O
incidnet	O
caess	O
of	O
ERSD	B-Disease
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
csaes	O
were	O
all	O
patietns	O
entering	O
the	O
lcoal	O
dailysis	O
prgoram	O
because	O
of	O
ERSD	B-Disease
in	O
the	O
sutdy	O
aera	O
between	O
June	O
1	O
,	O
1995	O
and	O
Novmeber	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disesae	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ERSD	B-Disease
.	O

Contorls	O
were	O
patietns	O
admtited	O
to	O
the	O
same	O
hospiatls	O
from	O
where	O
the	O
csaes	O
arose	O
,	O
also	O
matched	O
by	O
age	O
and	O
sex	O
.	O

Odds	O
rtaios	O
were	O
calculated	O
using	O
a	O
conidtional	O
logsitic	O
mdoel	O
,	O
including	O
potentail	O
cofnounding	O
fatcors	O
,	O
both	O
for	O
the	O
whole	O
sutdy	O
popluation	O
and	O
for	O
the	O
various	O
underlying	O
dsieases	O
.	O

RESLUTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
caess	O
and	O
1190	O
contorls	O
were	O
included	O
in	O
the	O
aanlysis	O
.	O

Lnog	O
-	O
term	O
use	O
of	O
any	O
analegsic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
rtaio	O
of	O
1	O
.	O
22	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
66	O
)	O
.	O

For	O
specific	O
gorups	O
of	O
durgs	O
,	O
the	O
rikss	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
asiprin	O
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyrzaolones	O
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
paracteamol	O
,	O
and	O
0	O
.	O
94	O
(	O
0	O
.	O
57	O
-	O
1	O
.	O
56	O
)	O
for	O
nonsapirin	O
NASIDs	O
.	O

The	O
rsik	O
of	O
ERSD	B-Disease
associated	O
with	O
aspiirn	O
was	O
related	O
to	O
the	O
cumluated	O
dsoe	O
and	O
duartion	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
ptaients	O
with	O
vsacular	O
neprhopathy	B-Disease
as	O
underlying	O
disaese	O
[	O
2	O
.	O
35	O
(	O
1	O
.	O
17	O
-	O
4	O
.	O
72	O
)	O
]	O
.	O

CONCULSION	O
:	O
Our	O
dtaa	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonsapirin	O
aanlgesic	O
drgus	O
and	O
NASIDs	O
is	O
not	O
associated	O
with	O
an	O
incresaed	O
rsik	O
of	O
ERSD	B-Disease
.	O

However	O
,	O
the	O
chrnoic	O
use	O
of	O
asiprin	O
may	O
incraese	O
the	O
rsik	O
of	O
ERSD	B-Disease
.	O

Two	O
csaes	O
of	O
aimsulpride	O
oevrdose	B-Disease
:	O
a	O
cause	O
for	O
proolnged	B-Disease
QT	I-Disease
sydnrome	I-Disease
.	O

Two	O
csaes	O
of	O
dleiberate	O
slef	O
-	O
poisoinng	B-Disease
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amiuslpride	O
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
caess	O
,	O
QT	B-Disease
prolongtaion	I-Disease
and	O
hypoaclcaemia	B-Disease
were	O
noted	O
.	O

The	O
QT	B-Disease
proolngation	I-Disease
appeared	O
to	O
respond	O
to	O
admniistration	O
of	O
i	O
.	O
v	O
.	O
caclium	O
glcuonate	O
.	O

Grotwh	O
-	O
associated	O
proetin	O
43	O
experssion	O
in	O
hippocampal	O
molecluar	O
laeyr	O
of	O
crhonic	O
epilepitc	B-Disease
rtas	O
terated	O
with	O
cycolheximide	O
.	O

PUROPSE	O
:	O
GA4P3	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fbier	O
sprotuing	O
(	O
MFS	O
)	O
in	O
various	O
experimnetal	O
moedls	O
of	O
epielpsy	B-Disease
.	O

To	O
investiagte	O
how	O
GA4P3	O
experssion	O
(	O
GPA43	O
-	O
ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
asssesed	O
the	O
intenisty	O
(	O
denistometry	O
)	O
and	O
exetnsion	O
(	O
wdith	O
)	O
of	O
GPA43	O
-	O
ir	O
in	O
the	O
inenr	O
molceular	O
lyaer	O
of	O
the	O
dnetate	O
gyurs	O
(	O
IML	O
)	O
of	O
rtas	O
subejct	O
to	O
sttaus	B-Disease
epliepticus	I-Disease
idnuced	O
by	O
pilocaprine	O
(	O
Plio	O
)	O
,	O
previously	O
injecetd	O
or	O
not	O
with	O
cycloheximdie	O
(	O
CHX	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
ihnibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	O
was	O
injecetd	O
before	O
the	O
Plio	O
injectoin	O
in	O
audlt	O
Wisatr	O
rtas	O
.	O

The	O
Plio	O
gorup	O
was	O
inejcted	O
with	O
the	O
same	O
durgs	O
,	O
except	O
for	O
CHX	O
.	O

Ainmals	O
were	O
killed	O
between	O
30	O
and	O
60	O
dyas	O
later	O
,	O
and	O
brian	O
setcions	O
were	O
porcessed	O
for	O
GPA43	O
immunohisotchemistry	O
.	O

RSEULTS	O
:	O
Densitmoetry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GA4P3	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Plio	O
,	O
CHX	O
+	O
Plio	O
,	O
and	O
contorl	O
gorups	O
.	O

However	O
,	O
the	O
resutls	O
of	O
the	O
wdith	O
of	O
the	O
GPA43	O
-	O
ir	O
bnad	O
in	O
the	O
IML	O
showed	O
that	O
CHX	O
+	O
Plio	O
and	O
cotnrol	O
animlas	O
had	O
a	O
significantly	O
larger	O
bnad	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
compraed	O
with	O
that	O
in	O
the	O
Plio	O
gruop	O
.	O

CNOCLUSIONS	O
:	O
Our	O
current	O
findnig	O
that	O
ainmals	O
in	O
the	O
CHX	O
+	O
Plio	O
gruop	O
have	O
a	O
GPA43	O
-	O
ir	O
bnad	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
conrtols	O
,	O
reinforces	O
prior	O
dtaa	O
on	O
the	O
blokcade	O
of	O
MFS	O
in	O
these	O
anmials	O
.	O

The	O
change	O
in	O
GPA43	O
-	O
ir	O
present	O
in	O
Plio	O
-	O
terated	O
animlas	O
was	O
a	O
tihnning	O
of	O
the	O
bnad	O
to	O
a	O
very	O
narrow	O
lyaer	O
just	O
above	O
the	O
garnule	O
clel	O
laeyr	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
lsos	O
of	O
hliar	O
clel	O
porjections	O
that	O
express	O
GAP	O
-	O
43	O
.	O

Nictoine	O
antgaonizes	O
caffeine	O
-	O
but	O
not	O
pentylenetetarzole	O
-	O
inudced	O
anxioegnic	O
effect	O
in	O
mcie	O
.	O

RTAIONALE	O
:	O
Nioctine	O
and	O
caffenie	O
are	O
widely	O
consumed	O
lciit	O
pyschoactive	O
drgus	O
worldwide	O
.	O

Epidemiolgoical	O
studeis	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
stduies	O
in	O
expreimental	O
aniamls	O
indicate	O
clear	O
pharmacolgoical	O
interatcions	O
between	O
them	O
,	O
no	O
stduies	O
have	O
shown	O
a	O
specific	O
interatcion	O
on	O
axniety	B-Disease
repsonses	O
.	O

OBJECITVES	O
:	O
The	O
present	O
sutdy	O
ivnestigates	O
the	O
efefcts	O
of	O
nicotnie	O
on	O
anxitey	B-Disease
induecd	O
by	O
cfafeine	O
and	O
another	O
anxigoenic	O
durg	O
,	O
pentylenetetrazloe	O
,	O
in	O
mcie	O
.	O

The	O
elevaetd	O
plus	O
-	O
mzae	O
(	O
EPM	O
)	O
tset	O
was	O
used	O
to	O
evaulate	O
the	O
effetcs	O
of	O
durgs	O
on	O
anixety	B-Disease
.	O

METHODS	O
:	O
Adlut	O
mlae	O
Swsis	O
Wbester	O
mcie	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nioctine	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
slaine	O
10	O
min	O
before	O
caffeine	O
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
penytlenetetrazole	O
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
inejctions	O
.	O

After	O
15	O
min	O
,	O
mcie	O
were	O
evaluaetd	O
for	O
their	O
open	O
-	O
and	O
cloesd	O
-	O
arm	O
tmie	O
and	O
entreis	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
sessoin	O
.	O

Locoomtor	O
activtiy	O
was	O
recorded	O
for	O
inidvidual	O
gorups	O
by	O
using	O
the	O
same	O
treatmnet	O
portocol	O
with	O
the	O
EPM	O
tset	O
.	O

RESLUTS	O
:	O
Nciotine	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
efefct	O
in	O
the	O
EPM	O
tset	O
,	O
whereas	O
caffenie	O
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrzaole	O
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxoigenic	O
effect	O
,	O
apparnet	O
with	O
decerases	O
in	O
open	O
-	O
arm	O
tmie	O
and	O
enrty	O
.	O

Nicoitne	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
prerteatment	O
bolcked	O
the	O
caffeine	O
-	O
but	O
not	O
pentylneetetrazole	O
-	O
induecd	O
anixety	B-Disease
.	O

Administartion	O
of	O
each	O
durg	O
and	O
their	O
combiantions	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomootr	O
activtiy	O
.	O

CONCLUISONS	O
:	O
Our	O
rseults	O
suggest	O
that	O
the	O
antgaonistic	O
effect	O
of	O
nciotine	O
on	O
cfafeine	O
-	O
idnuced	O
anxitey	B-Disease
is	O
specific	O
to	O
cfafeine	O
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolyitc	O
effcet	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
fnidings	O
on	O
the	O
intercation	O
between	O
nciotine	O
and	O
caffeine	O
.	O

Lnog	O
term	O
hromone	O
tehrapy	O
for	O
perimeonpausal	O
and	O
postmeonpausal	O
wmoen	O
.	O

BCAKGROUND	O
:	O
Homrone	O
therpay	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menpoausal	B-Disease
smyptoms	I-Disease
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
managmeent	O
and	O
preveniton	O
of	O
cardiovsacular	B-Disease
disaese	I-Disease
,	O
ostoeporosis	B-Disease
and	O
deemntia	B-Disease
in	O
oledr	O
woemn	O
but	O
the	O
eivdence	O
supporting	O
its	O
use	O
for	O
these	O
indicaitons	O
is	O
largely	O
obseravtional	O
.	O

OJBECTIVES	O
:	O
To	O
assess	O
the	O
efefct	O
of	O
long	O
-	O
term	O
HT	O
on	O
moratlity	O
,	O
haert	B-Disease
disaese	I-Disease
,	O
venuos	B-Disease
thromboembloism	I-Disease
,	O
srtoke	B-Disease
,	O
trasnient	B-Disease
ishcaemic	I-Disease
atatcks	I-Disease
,	O
braest	B-Disease
canecr	I-Disease
,	O
coolrectal	B-Disease
cnacer	I-Disease
,	O
ovarain	B-Disease
cacner	I-Disease
,	O
endomterial	B-Disease
cnacer	I-Disease
,	O
gallbladder	B-Disease
disaese	I-Disease
,	O
cogntiive	O
functoin	O
,	O
demenita	B-Disease
,	O
farctures	B-Disease
and	O
quailty	O
of	O
lfie	O
.	O

SEACRH	O
STRTAEGY	O
:	O
We	O
searched	O
the	O
following	O
daatbases	O
up	O
to	O
Novebmer	O
2004	O
:	O
the	O
Cochrnae	O
Mnestrual	O
Dsiorders	O
and	O
Subfertliity	O
Gruop	O
Tirals	O
Reigster	O
,	O
Cocrhane	O
Centarl	O
Reigster	O
of	O
Conrtolled	O
Trails	O
(	O
CETNRAL	O
)	O
,	O
MEDILNE	O
,	O
EMBSAE	O
,	O
Biloogical	O
Abstratcs	O
.	O

Releavnt	O
non	O
-	O
idnexed	O
jouranls	O
and	O
confeernce	O
abtsracts	O
were	O
also	O
searched	O
.	O

SELECTION	O
CIRTERIA	O
:	O
Ranodmised	O
double	O
-	O
blnid	O
trails	O
of	O
HT	O
(	O
oestrgoens	O
with	O
or	O
without	O
porgestogens	O
)	O
versus	O
placbeo	O
,	O
taken	O
for	O
at	O
least	O
one	O
yaer	O
by	O
permienopausal	O
or	O
postmeonpausal	O
wmoen	O
.	O

DTAA	O
CLOLECTION	O
AND	O
ANALSYIS	O
:	O
Fifteen	O
RTCs	O
were	O
included	O
.	O

Trails	O
were	O
asesssed	O
for	O
qaulity	O
and	O
two	O
rveiew	O
autohrs	O
extracetd	O
dtaa	O
independently	O
.	O

They	O
calculated	O
rsik	O
raitos	O
for	O
dichotoomus	O
outocmes	O
and	O
weighted	O
mean	O
difefrences	O
for	O
cnotinuous	O
outcmoes	O
.	O

Cliincal	O
hteerogeneity	O
precluded	O
mtea	O
-	O
analsyis	O
for	O
most	O
outocmes	O
.	O

MIAN	O
RSEULTS	O
:	O
All	O
the	O
statistcially	O
significant	O
resluts	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
tirals	O
.	O

In	O
relatively	O
healhty	O
woemn	O
,	O
cobmined	O
contniuous	O
HT	O
significantly	O
incerased	O
the	O
rsik	O
of	O
venuos	B-Disease
throbmoembolism	I-Disease
or	O
croonary	O
eevnt	O
(	O
after	O
one	O
yaer	O
'	O
s	O
use	O
)	O
,	O
storke	B-Disease
(	O
after	O
3	O
yeras	O
)	O
,	O
bresat	B-Disease
cacner	I-Disease
(	O
after	O
5	O
yeras	O
)	O
and	O
gallbladder	B-Disease
disesae	I-Disease
.	O

Lnog	O
-	O
term	O
oestorgen	O
-	O
only	O
HT	O
also	O
significantly	O
incraesed	O
the	O
rsik	O
of	O
storke	B-Disease
and	O
gallbladder	B-Disease
disesae	I-Disease
.	O

Overall	O
,	O
the	O
only	O
statistiaclly	O
significant	O
beneifts	O
of	O
HT	O
were	O
a	O
decraesed	O
incidecne	O
of	O
fracutres	B-Disease
and	O
cooln	B-Disease
cacner	I-Disease
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
haelthy	O
wmoen	O
over	O
65	O
yeras	O
taking	O
continuuos	O
comibned	O
HT	O
,	O
there	O
was	O
a	O
staitstically	O
significant	O
icnrease	O
in	O
the	O
incidecne	O
of	O
demnetia	B-Disease
.	O

Among	O
woemn	O
with	O
cardivoascular	B-Disease
dsiease	I-Disease
,	O
long	O
-	O
term	O
use	O
of	O
combnied	O
contiunous	O
HT	O
significantly	O
increaesd	O
the	O
rsik	O
of	O
venuos	B-Disease
trhomboembolism	I-Disease
.	O

No	O
trails	O
focussed	O
specifically	O
on	O
yougner	O
woemn	O
.	O

However	O
,	O
one	O
trail	O
anaylsed	O
sbugroups	O
of	O
2839	O
relatively	O
heatlhy	O
50	O
to	O
59	O
yaer	O
-	O
old	O
wmoen	O
taking	O
cmobined	O
cnotinuous	O
HT	O
and	O
1637	O
taking	O
oetsrogen	O
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
siezd	O
plcaebo	O
gropus	O
.	O

The	O
only	O
significantly	O
inrceased	O
rsik	O
reported	O
was	O
for	O
veonus	B-Disease
thrmoboembolism	I-Disease
in	O
woemn	O
taking	O
comibned	O
continouus	O
HT	O
;	O
their	O
absloute	O
rsik	O
remained	O
very	O
low	O
.	O

AUTHORS	O
'	O
CONCULSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routnie	O
mnaagement	O
of	O
crhonic	B-Disease
disesae	I-Disease
.	O

We	O
need	O
more	O
eviednce	O
on	O
the	O
saftey	O
of	O
HT	O
for	O
menoapusal	O
symtpom	O
cnotrol	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
haelthy	O
yougner	O
wmoen	O
.	O

Durg	B-Disease
-	I-Disease
induecd	I-Disease
lvier	I-Disease
ijnury	I-Disease
:	O
an	O
analsyis	O
of	O
461	O
inciednces	O
submitted	O
to	O
the	O
Spansih	O
regitsry	O
over	O
a	O
10	O
-	O
yaer	O
peirod	O
.	O

BACKGRONUD	O
&	O
AMIS	O
:	O
Prgoress	O
in	O
the	O
understanding	O
of	O
sucseptibility	O
fatcors	O
to	O
durg	B-Disease
-	I-Disease
indcued	I-Disease
lvier	I-Disease
injruy	I-Disease
(	O
DLII	B-Disease
)	O
and	O
outocme	O
predictabiltiy	O
are	O
hampered	O
by	O
the	O
lcak	O
of	O
ssytematic	O
porgrams	O
to	O
dteect	O
bona	O
fide	O
csaes	O
.	O

METHODS	O
:	O
A	O
coopeartive	O
netwrok	O
was	O
created	O
in	O
1994	O
in	O
Sapin	O
to	O
identify	O
all	O
ssupicions	O
of	O
DLII	B-Disease
following	O
a	O
prospectvie	O
structuerd	O
reoprt	O
form	O
.	O

The	O
lievr	B-Disease
daamge	I-Disease
was	O
characetrized	O
according	O
to	O
hepatcoellular	O
,	O
cholestaitc	B-Disease
,	O
and	O
mixed	O
labortaory	O
critreia	O
and	O
to	O
hitsologic	O
critreia	O
when	O
available	O
.	O

Further	O
evaulation	O
of	O
causaltiy	O
assesmsent	O
was	O
centrally	O
performed	O
.	O

RESUTLS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
csaes	O
,	O
involving	O
505	O
drgus	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DLII	B-Disease
.	O

The	O
antiinfective	O
gruop	O
of	O
drgus	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxciillin	O
-	O
clauvlanate	O
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hpeatocellular	O
pattern	O
of	O
damgae	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inevrsely	O
correltaed	O
with	O
age	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
outcmoe	O
(	O
Cox	O
rergession	O
,	O
P	O
<	O
.	O
034	O
)	O
.	O

Indeed	O
,	O
the	O
incdience	O
of	O
lievr	O
trnasplantation	O
and	O
detah	O
in	O
this	O
gorup	O
was	O
11	O
.	O
7	O
%	O
if	O
ptaients	O
had	O
jaudnice	B-Disease
at	O
persentation	O
,	O
whereas	O
the	O
corresponding	O
fiugre	O
was	O
3	O
.	O
8	O
%	O
in	O
nonjaunidced	O
paitents	O
(	O
P	O
<	O
.	O
04	O
)	O
.	O

Facotrs	O
associated	O
with	O
the	O
devleopment	O
of	O
fulmniant	B-Disease
heaptic	I-Disease
faliure	I-Disease
were	O
femlae	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
hepatcoellular	O
dmaage	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
)	O
,	O
and	O
hihger	O
basleine	O
plsama	O
biliruibn	O
value	O
(	O
OR	O
=	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
1	O
.	O
22	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

CNOCLUSIONS	O
:	O
Paitents	O
with	O
durg	O
-	O
induecd	O
hepatocellualr	O
juandice	B-Disease
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
daeth	O
or	O
transplatnation	O
.	O

Aomxicillin	O
-	O
clavualnate	O
stands	O
out	O
as	O
the	O
most	O
common	O
durg	O
related	O
to	O
DLII	B-Disease
.	O

Morhpological	O
eavluation	O
of	O
the	O
efefct	O
of	O
d	O
-	O
ribsoe	O
on	O
adrimaycin	O
-	O
eovked	O
cardiotoixcity	B-Disease
in	O
rtas	O
.	O

The	O
inlfuence	O
of	O
d	O
-	O
rbiose	O
on	O
ardiamycin	O
-	O
inudced	O
myocradiopathy	B-Disease
in	O
rtas	O
was	O
studied	O
.	O

Adiramycin	O
in	O
the	O
cuumlative	O
dsoe	O
of	O
25	O
mg	O
/	O
kg	O
eovked	O
fully	O
developed	O
caridac	B-Disease
toxciity	I-Disease
.	O

D	O
-	O
ribsoe	O
in	O
the	O
mutliple	O
dsoes	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
ifnluence	O
ADR	O
cardiotoxictiy	B-Disease
.	O

In	O
vivo	O
evdiences	O
suggesting	O
the	O
role	O
of	O
oxidatvie	O
srtess	O
in	O
pathogeneiss	O
of	O
vancmoycin	O
-	O
induecd	O
nephrotoxciity	B-Disease
:	O
protetcion	O
by	O
erdsoteine	O
.	O

The	O
aims	O
of	O
this	O
sutdy	O
were	O
to	O
examine	O
vanocmycin	O
(	O
VCM	O
)	O
-	O
induecd	O
oxidaitve	O
sterss	O
that	O
prmootes	O
prodcution	O
of	O
reatcive	O
oxgyen	O
spceies	O
(	O
ROS	O
)	O
and	O
to	O
inevstigate	O
the	O
role	O
of	O
erdsoteine	O
,	O
an	O
expecotrant	O
aegnt	O
,	O
which	O
has	O
also	O
anitoxidant	O
properites	O
,	O
on	O
kindey	O
tsisue	O
against	O
the	O
possible	O
VCM	O
-	O
inudced	O
reanl	B-Disease
impariment	I-Disease
in	O
rtas	O
.	O

Rtas	O
were	O
divided	O
into	O
three	O
gruops	O
:	O
sahm	O
,	O
VCM	O
and	O
VCM	O
plus	O
edrosteine	O
.	O

VCM	O
was	O
adminisrtated	O
intraperitonaelly	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
dialy	O
for	O
7	O
dyas	O
.	O

Erodsteine	O
was	O
adminisetred	O
orlaly	O
.	O

VCM	O
admniistration	O
to	O
cotnrol	O
rtas	O
significantly	O
icnreased	O
rneal	O
malondiadlehyde	O
(	O
MDA	O
)	O
and	O
urianry	O
N	O
-	O
acteyl	O
-	O
btea	O
-	O
d	O
-	O
glucosamniidase	O
(	O
NAG	O
,	O
a	O
marekr	O
of	O
reanl	B-Disease
tbuular	I-Disease
injruy	I-Disease
)	O
ecxretion	O
but	O
decreaesd	O
supreoxide	O
dimsutase	O
(	O
SOD	O
)	O
and	O
catalsae	O
(	O
CAT	O
)	O
activiites	O
.	O

Edrosteine	O
adminsitration	O
with	O
VCM	O
injectoins	O
caused	O
significantly	O
derceased	O
rneal	O
MDA	O
and	O
urinray	O
NAG	O
excrteion	O
,	O
and	O
icnreased	O
SOD	O
actviity	O
,	O
but	O
not	O
CAT	O
actiivty	O
in	O
reanl	O
tissue	O
when	O
copmared	O
with	O
VCM	O
alone	O
.	O

Edrosteine	O
showed	O
histpoathological	O
protetcion	O
against	O
VCM	O
-	O
inudced	O
nephrotoxciity	B-Disease
.	O

There	O
were	O
a	O
significant	O
dilataiton	O
of	O
tuublar	O
lumnes	O
,	O
etxensive	O
eipthelial	O
clel	O
vacuoilzation	O
,	O
atrpohy	B-Disease
,	O
deqsuamation	B-Disease
,	O
and	O
necrsois	B-Disease
in	O
VCM	O
-	O
traeted	O
rtas	O
more	O
than	O
those	O
of	O
the	O
cotnrol	O
and	O
the	O
erdostenie	O
gruops	O
.	O

Erdsoteine	O
caused	O
a	O
marked	O
redutcion	O
in	O
the	O
extent	O
of	O
tbuular	O
damgae	O
.	O

It	O
is	O
concluded	O
that	O
oxidaitve	O
tbuular	O
daamge	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	O
-	O
idnuced	O
nehprotoxicity	B-Disease
and	O
the	O
modluation	O
of	O
oxidatvie	O
srtess	O
with	O
edrosteine	O
reduecs	O
the	O
VCM	O
-	O
indcued	O
kdiney	B-Disease
damgae	I-Disease
both	O
at	O
the	O
biochemiacl	O
and	O
histolgoical	O
leevls	O
.	O

Gemfirbozil	O
-	O
lovsatatin	O
tehrapy	O
for	O
priamry	O
hyperlipoprotienemias	B-Disease
.	O

The	O
specific	O
aim	O
of	O
this	O
rterospective	O
,	O
observatinoal	O
stduy	O
was	O
to	O
assess	O
sfaety	O
and	O
effiaccy	O
of	O
long	O
-	O
term	O
(	O
21	O
mnoths	O
/	O
paitent	O
)	O
,	O
open	O
-	O
lbael	O
,	O
gemfibroizl	O
-	O
lvoastatin	O
teratment	O
in	O
80	O
paitents	O
with	O
prmiary	O
mixed	O
hyperilpidemia	B-Disease
(	O
68	O
%	O
of	O
whom	O
had	O
atehrosclerotic	B-Disease
vsacular	I-Disease
dsiease	I-Disease
)	O
.	O

Because	O
ideal	O
liipd	O
targtes	O
were	O
not	O
reached	O
(	O
low	O
-	O
denisty	O
lipoprtoein	O
(	O
LDL	O
)	O
cohlesterol	O
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
desnity	O
lipoprotien	O
(	O
HDL	O
)	O
cholseterol	O
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cholesetrol	O
/	O
HDL	O
cholseterol	O
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
deit	O
plus	O
a	O
single	O
durg	O
,	O
gefmibrozil	O
(	O
1	O
.	O
2	O
g	O
/	O
day	O
)	O
-	O
lovasttain	O
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
traetment	O
was	O
given	O
.	O

Follow	O
-	O
up	O
vsiits	O
were	O
schdeuled	O
with	O
2	O
-	O
durg	O
tehrapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
aevrage	O
of	O
10	O
.	O
3	O
vsiits	O
per	O
pateint	O
,	O
with	O
741	O
btateries	O
of	O
6	O
lievr	O
fucntion	O
tetss	O
and	O
714	O
cretaine	O
phosphoiknase	O
leevls	O
meausred	O
.	O

Only	O
1	O
of	O
the	O
4	O
,	O
446	O
lievr	O
fnuction	O
tetss	O
(	O
0	O
.	O
02	O
%	O
)	O
,	O
a	O
gmama	O
gltuamyl	O
tarnsferase	O
,	O
was	O
greater	O
than	O
or	O
euqal	O
to	O
3	O
times	O
the	O
upper	O
noraml	O
liimt	O
.	O

Of	O
the	O
714	O
cretaine	O
phosphokianse	O
lveels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0	O
.	O
1	O
%	O
)	O
was	O
greater	O
than	O
or	O
eqaul	O
to	O
3	O
times	O
the	O
upepr	O
noraml	O
liimt	O
.	O

With	O
2	O
-	O
durg	O
thearpy	O
,	O
mean	O
total	O
choelsterol	O
decerased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglcyeride	O
levles	O
dcereased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
choelsterol	O
decreaesd	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholestreol	O
/	O
HDL	O
choletserol	O
rtaio	O
dcereased	O
24	O
%	O
from	O
7	O
.	O
1	O
to	O
5	O
.	O
4	O
,	O
all	O
p	O
less	O
than	O
or	O
eqaul	O
to	O
0	O
.	O
0001	O
.	O

Myostiis	B-Disease
,	O
attributable	O
to	O
the	O
durg	O
combintaion	O
and	O
symptomaitc	O
enough	O
to	O
dsicontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patinets	O
,	O
and	O
in	O
1	O
%	O
with	O
conucrrent	O
high	O
ceratine	O
phosphokinsae	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patietns	O
had	O
rhbadomyolysis	B-Disease
or	O
myoglboinuria	B-Disease
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Does	O
domepridone	O
ptoentiate	O
mritazapine	O
-	O
associated	O
rsetless	B-Disease
lges	I-Disease
snydrome	I-Disease
?	O

There	O
is	O
now	O
evidnece	O
to	O
suggest	O
a	O
cenrtal	O
role	O
for	O
the	O
dopaminegric	O
ssytem	O
in	O
restlses	B-Disease
lges	I-Disease
synrdome	I-Disease
(	O
RLS	B-Disease
)	O
.	O

For	O
example	O
,	O
the	O
sympotms	O
of	O
RLS	B-Disease
can	O
be	O
dramatically	O
imrpoved	O
by	O
levodpoa	O
and	O
dopmaine	O
agoinsts	O
,	O
whereas	O
centarl	O
dopmaine	O
D2	O
reecptor	O
antagnoists	O
can	O
indcue	O
or	O
aggarvate	O
RLS	B-Disease
smyptoms	O
.	O

To	O
our	O
knoweldge	O
,	O
there	O
is	O
no	O
previous	O
reoprt	O
regarding	O
whether	O
dmoperidone	O
,	O
a	O
periphreal	O
dopamnie	O
D2	O
rceeptor	O
atnagonist	O
,	O
can	O
also	O
idnuce	O
or	O
aggraavte	O
smyptoms	O
of	O
RLS	B-Disease
.	O

Mirtazapnie	O
,	O
the	O
first	O
noradrenerigc	O
and	O
specific	O
serootnergic	O
antdiepressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B-Disease
in	O
several	O
recent	O
publicaitons	O
.	O

The	O
atuhors	O
reprot	O
here	O
a	O
deperssed	O
pateint	O
comobrid	O
with	O
postpradnial	B-Disease
dyspepisa	I-Disease
who	O
developed	O
RLS	B-Disease
after	O
mirtazaipne	O
had	O
been	O
added	O
to	O
his	O
dmoperidone	O
threapy	O
.	O

Our	O
paitent	O
started	O
to	O
have	O
sypmtoms	O
of	O
RLS	B-Disease
only	O
after	O
he	O
had	O
been	O
terated	O
with	O
mirtazpaine	O
,	O
and	O
his	O
RLS	B-Disease
smyptoms	O
resolved	O
completely	O
upon	O
discontinaution	O
of	O
his	O
mirtazapnie	O
.	O

Such	O
a	O
tepmoral	O
relationhsip	O
between	O
the	O
use	O
of	O
mirtazaipne	O
and	O
the	O
smyptoms	O
of	O
RLS	B-Disease
in	O
our	O
paitent	O
did	O
not	O
support	O
a	O
ptoentiating	O
efefct	O
of	O
domperinoe	O
on	O
mirtaazpine	O
-	O
associated	O
RLS	B-Disease
.	O

However	O
,	O
phsyicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtzaapine	O
can	O
be	O
associated	O
with	O
RLS	B-Disease
in	O
some	O
indiviudals	O
,	O
especially	O
those	O
receiving	O
cocnomitant	O
dopamnie	O
D2	O
reecptor	O
antagnoists	O
.	O

Antiandrogneic	O
tehrapy	O
can	O
cause	O
coornary	B-Disease
artreial	I-Disease
diesase	I-Disease
.	O

AIM	O
:	O
To	O
sutdy	O
the	O
change	O
of	O
liipd	O
metaoblism	O
by	O
antiandorgen	O
thearpy	O
in	O
patietns	O
with	O
prsotate	B-Disease
canecr	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
yeras	O
follow	O
-	O
up	O
the	O
chagnes	O
in	O
plamsa	O
choletserols	O
(	O
C	O
)	O
,	O
triglyecrides	O
(	O
TG	O
)	O
,	O
lipporoteins	O
(	O
LP	O
)	O
,	O
and	O
apoliporpoteins	O
(	O
Apo	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patietns	O
of	O
mean	O
age	O
60	O
yaers	O
with	O
low	O
rsik	O
prsotate	B-Disease
canecr	I-Disease
(	O
stgae	O
:	O
T1Nc0M0	O
,	O
Gleaosn	O
socre	O
:	O
2	O
-	O
5	O
)	O
during	O
traetment	O
with	O
cyprotreone	O
acettae	O
(	O
CPA	O
)	O
without	O
surgiacl	O
managemnet	O
or	O
radiatoin	O
thearpy	O
.	O

RSEULTS	O
:	O
Signifciant	O
decerases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
icnrease	O
of	O
trigylceride	O
lveels	O
in	O
VDLL	O
were	O
induecd	O
by	O
CPA	O
.	O

After	O
a	O
peroid	O
of	O
2	O
.	O
5	O
yeras	O
on	O
CPA	O
traetment	O
,	O
four	O
patinets	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affecetd	O
by	O
coroanry	B-Disease
herat	I-Disease
disesae	I-Disease
.	O

CONCLSUIONS	O
:	O
Ischameic	O
cornoary	B-Disease
arteirosclerosis	I-Disease
with	O
an	O
icnidence	O
rtae	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prloonged	O
CPA	O
tehrapy	O
is	O
mediated	O
through	O
chagnes	O
in	O
HDL	O
cholesetrol	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglyceridmeic	B-Disease
effect	I-Disease
caused	O
by	O
etsrogen	O
.	O

5	O
-	O
Flourouracil	O
cardiotoixcity	B-Disease
inudced	O
by	O
aplha	O
-	O
fuloro	O
-	O
btea	O
-	O
alannie	O
.	O

Cardiotoxciity	B-Disease
is	O
a	O
rrae	O
complictaion	O
occurring	O
during	O
5	O
-	O
fluorourcail	O
(	O
5	O
-	O
FU	O
)	O
traetment	O
for	O
malignnacies	B-Disease
.	O

We	O
herein	O
reprot	O
the	O
csae	O
of	O
a	O
70	O
-	O
yaer	O
-	O
old	O
man	O
with	O
5	O
-	O
FU	O
-	O
indcued	O
carditooxicity	B-Disease
,	O
in	O
whom	O
a	O
high	O
sreum	O
lveel	O
of	O
aplha	O
-	O
fluroo	O
-	O
btea	O
-	O
aalnine	O
(	O
FABL	O
)	O
was	O
observed	O
.	O

The	O
patinet	O
,	O
who	O
had	O
unresectbale	O
cloon	B-Disease
cacner	I-Disease
meatstases	O
to	O
the	O
lievr	O
and	O
lnug	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherpay	O
from	O
an	O
affiliated	O
hosiptal	O
;	O
he	O
had	O
no	O
cardaic	O
hitsory	O
.	O

After	O
admissoin	O
,	O
the	O
ptaient	O
received	O
a	O
contiunous	O
intarvenous	O
infsuion	O
of	O
5	O
-	O
FU	O
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precodrial	B-Disease
pian	I-Disease
with	O
rihgt	B-Disease
bunlde	I-Disease
brnach	I-Disease
blcok	I-Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
seurm	O
FABL	O
concenrtation	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precrodial	B-Disease
pian	I-Disease
and	O
the	O
electrocardigoraphic	O
chnages	O
disappeared	O
sponatneously	O
after	O
the	O
discontinaution	O
of	O
5	O
-	O
FU	O
.	O

As	O
the	O
precrodial	B-Disease
pian	I-Disease
in	O
this	O
patinet	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	O
-	O
FU	O
-	O
idnuced	O
cardiotoxciity	B-Disease
,	O
the	O
adminsitration	O
of	O
5	O
-	O
FU	O
was	O
abandoned	O
.	O

Instead	O
,	O
oarl	O
adminisrtation	O
of	O
S	O
-	O
1	O
(	O
a	O
deriavtive	O
of	O
5	O
-	O
FU	O
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instiutted	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
inhiibtory	O
effcet	O
on	O
dihydropyirmidine	O
dehydorgenase	O
,	O
which	O
catalyzes	O
the	O
dgeradative	O
of	O
5	O
-	O
FU	O
into	O
FABL	O
.	O

The	O
seurm	O
FABL	O
concentratoin	O
subsequently	O
decraesed	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
maesured	O
on	O
the	O
first	O
day	O
of	O
S	O
-	O
1	O
administratoin	O
.	O

Thereafter	O
,	O
no	O
cradiac	B-Disease
symptmos	I-Disease
were	O
observed	O
.	O

The	O
pateint	O
achieved	O
a	O
parital	O
repsonse	O
6	O
monhts	O
after	O
the	O
initiatoin	O
of	O
the	O
S	O
-	O
1	O
treamtent	O
.	O

The	O
expereince	O
of	O
this	O
csae	O
,	O
together	O
with	O
a	O
rveiew	O
of	O
the	O
ltierature	O
,	O
suggests	O
that	O
FABL	O
is	O
related	O
to	O
5	O
-	O
FU	O
-	O
idnuced	O
cardiootxicity	B-Disease
.	O

S	O
-	O
1	O
may	O
be	O
administreed	O
safely	O
to	O
patinets	O
with	O
5	O
-	O
FU	O
-	O
induecd	O
cardiootxicity	B-Disease
.	O

Hepatocellular	B-Disease
caricnoma	I-Disease
in	O
Fancnoi	B-Disease
'	I-Disease
s	I-Disease
anmeia	I-Disease
traeted	O
with	O
andrgoen	O
and	O
coritcosteroid	O
.	O

The	O
csae	O
of	O
an	O
11	O
-	O
yaer	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Facnoni	B-Disease
'	I-Disease
s	I-Disease
aenmia	I-Disease
for	O
3	O
yaers	O
and	O
was	O
terated	O
with	O
adnrogens	O
,	O
cotricosteroids	O
and	O
transfusoins	O
.	O

Two	O
weeks	O
before	O
his	O
daeth	O
he	O
was	O
raedmitted	O
because	O
of	O
apalstic	O
crsiis	O
with	O
septiecmia	B-Disease
and	O
marked	O
abnomralities	O
in	O
lvier	O
functoin	O
and	O
deid	O
of	O
hemorrhagic	B-Disease
bronchopnuemonia	I-Disease
.	O

At	O
atuopsy	O
pelioiss	B-Disease
and	O
mutliple	O
heaptic	B-Disease
tuomrs	I-Disease
were	O
found	O
which	O
histloogically	O
proved	O
to	O
be	O
well	O
-	O
differentiaetd	O
hpeatocellular	B-Disease
carcinmoa	I-Disease
.	O

This	O
csae	O
contributes	O
to	O
the	O
previous	O
obseravtions	O
that	O
non	O
-	O
metastasiznig	O
hepaitc	B-Disease
neoplamss	I-Disease
and	O
pleiosis	B-Disease
can	O
develop	O
in	O
ptaients	O
with	O
adnrogen	O
-	O
and	O
corticosteorid	O
-	O
traeted	O
Fnaconi	B-Disease
'	I-Disease
s	I-Disease
anmeia	I-Disease
.	O

The	O
influnece	O
of	O
the	O
tmie	O
inetrval	O
between	O
monHoER	O
and	O
doxourbicin	O
amdinistration	O
on	O
the	O
protectoin	O
against	O
doxroubicin	O
-	O
indcued	O
cradiotoxicity	B-Disease
in	O
mcie	O
.	O

PUPROSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cradiotoxicity	B-Disease
,	O
the	O
anthracyciln	O
doxorbuicin	O
(	O
DOX	O
)	O
continues	O
to	O
be	O
an	O
effectvie	O
and	O
widely	O
used	O
chemtoherapeutic	O
aegnt	O
.	O

DOX	O
-	O
idnuced	O
cadriac	B-Disease
dmaage	I-Disease
presumably	O
resutls	O
from	O
the	O
formaiton	O
of	O
free	O
radiacls	O
by	O
DOX	O
.	O

Reacitve	O
oxgyen	O
sepcies	O
particularly	O
affect	O
the	O
cradiac	O
moycytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
atnioxidant	O
defesne	O
sytsem	O
.	O

The	O
semisynhtetic	O
falvonoid	O
monhoydroxyethylrutoside	O
(	O
moonHER	O
)	O
showed	O
cardioprotectoin	O
against	O
DOX	O
-	O
idnuced	O
cradiotoxicity	B-Disease
through	O
its	O
rdaical	O
sacvenging	O
and	O
iorn	O
cheltaing	O
porperties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
lfie	O
of	O
mnooHER	O
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
tmie	O
inetrval	O
between	O
moonHER	O
and	O
DOX	O
might	O
be	O
of	O
inlfuence	O
on	O
the	O
cardioprotcetive	O
effect	O
of	O
mnooHER	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
ivnestigate	O
this	O
possible	O
effect	O
.	O

METHODS	O
:	O
Six	O
gropus	O
of	O
6	O
BLAB	O
/	O
c	O
mcie	O
were	O
tretaed	O
with	O
sailne	O
,	O
DOX	O
alone	O
or	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
preceded	O
by	O
mnooHER	O
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
with	O
an	O
itnerval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6	O
-	O
week	O
treamtent	O
peroid	O
and	O
additional	O
obsrevation	O
for	O
2	O
wekes	O
,	O
the	O
mcie	O
were	O
sarcificed	O
.	O

Their	O
cadriac	O
tisseus	O
were	O
prcoessed	O
for	O
light	O
microsocpy	O
,	O
after	O
which	O
caridomyocyte	B-Disease
daamge	I-Disease
was	O
evalauted	O
according	O
to	O
Billingham	O
(	O
in	O
Cacner	B-Disease
Terat	O
Rep	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscoipc	O
evaluaiton	O
reevaled	O
that	O
treamtent	O
with	O
DOX	O
alone	O
indcued	O
significant	O
cardaic	B-Disease
dmaage	I-Disease
in	O
cmoparison	O
to	O
the	O
sailne	O
cnotrol	O
gorup	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

RSEULTS	O
:	O
The	O
number	O
of	O
daamged	O
cardimoyocytes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
hgiher	O
in	O
mcie	O
terated	O
with	O
DOX	O
alone	O
than	O
that	O
in	O
animlas	O
of	O
the	O
cnotrol	O
gruop	O
.	O

The	O
rtaio	O
of	O
aberrnat	O
cradiomyocytes	O
in	O
mcie	O
terated	O
with	O
DOX	O
preceded	O
by	O
moonHER	O
and	O
those	O
in	O
mcie	O
treaetd	O
with	O
slaine	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

The	O
mean	O
protective	O
efefct	O
by	O
adding	O
moonHER	O
before	O
DOX	O
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
reduciton	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnromal	O
cardiomycoytes	O
.	O

This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
tmie	O
intreval	O
between	O
monoEHR	O
and	O
DOX	O
administrtaion	O
(	O
P	O
=	O
0	O
.	O
345	O
)	O
.	O

CONCLSUION	O
:	O
The	O
resutls	O
indicate	O
that	O
in	O
an	O
outaptient	O
cliincal	O
setting	O
monHoER	O
may	O
be	O
admniistered	O
shortly	O
before	O
DOX	O
.	O

Clincial	O
evaluaiton	O
of	O
advrese	O
effects	O
during	O
bperidil	O
adminisrtation	O
for	O
atiral	B-Disease
fbirillation	I-Disease
and	I-Disease
flutetr	I-Disease
.	O

BACKGORUND	O
:	O
Beprdiil	O
hydrcohloride	O
(	O
Bpd	O
)	O
has	O
attracted	O
attetnion	O
as	O
an	O
effecitve	O
durg	O
for	O
atiral	B-Disease
fibrilltaion	I-Disease
(	O
AF	B-Disease
)	O
and	O
artial	B-Disease
flutetr	I-Disease
(	O
AFL	B-Disease
)	O
.	O

However	O
,	O
serious	O
advesre	O
efefcts	O
,	O
including	O
torasde	B-Disease
de	I-Disease
poinets	I-Disease
(	O
Tdp	B-Disease
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESUTLS	O
:	O
Advrese	O
efefcts	O
of	O
Bpd	O
requiring	O
dsicontinuation	O
of	O
treatmnet	O
were	O
evalauted	O
.	O

Bpd	O
was	O
adminsitered	O
to	O
459	O
paitents	O
(	O
361	O
maels	O
,	O
63	O
+	O
/	O
-	O
12	O
yaers	O
old	O
)	O
comprising	O
378	O
AF	B-Disease
and	O
81	O
AFL	B-Disease
caess	O
.	O

Mean	O
lfet	O
ventriuclar	O
ejeciton	O
frcation	O
and	O
atiral	O
dimesnion	O
(	O
LAD	O
)	O
were	O
66	O
+	O
/	O
-	O
11	O
%	O
and	O
40	O
+	O
/	O
-	O
6	O
mm	O
,	O
respectively	O
.	O

Advesre	O
effcets	O
were	O
observed	O
in	O
19	O
paitents	O
(	O
4	O
%	O
)	O
during	O
an	O
avearge	O
follow	O
-	O
up	O
of	O
20	O
mnoths	O
.	O

There	O
was	O
marked	O
QT	B-Disease
prolnogation	I-Disease
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
ptaients	O
,	O
bradycarida	B-Disease
less	O
than	O
40	O
betas	O
/	O
min	O
in	O
6	O
pateints	O
,	O
dizziness	B-Disease
and	O
general	O
fatiuge	B-Disease
in	O
1	O
patinet	O
each	O
.	O

In	O
4	O
of	O
13	O
paitents	O
with	O
QT	B-Disease
prolognation	I-Disease
,	O
Tdp	B-Disease
occurred	O
.	O

The	O
major	O
triggering	O
facotrs	O
of	O
Tdp	B-Disease
were	O
hpyokalemia	B-Disease
and	O
sduden	O
dercease	O
in	O
herat	O
rtae	O
.	O

There	O
were	O
no	O
differneces	O
in	O
the	O
cliincal	O
backgrounds	O
of	O
the	O
ptaients	O
with	O
and	O
without	O
Tdp	B-Disease
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
odler	O
in	O
the	O
ptaients	O
with	O
Tdp	B-Disease
.	O

CNOCLUSION	O
:	O
Careful	O
obsrevation	O
of	O
seurm	O
potasisum	O
concentratoin	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	O
administraiton	O
,	O
particularly	O
in	O
eldelry	O
patietns	O
.	O

Enahnced	O
isoprtoerenol	O
-	O
indcued	O
cradiac	B-Disease
hyperrtophy	I-Disease
in	O
transgeinc	O
rtas	O
with	O
low	O
barin	O
angoitensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
premanent	O
deficiecny	O
in	O
the	O
brian	O
rnein	O
-	O
angitoensin	O
sysetm	O
(	O
RAS	O
)	O
may	O
incerase	O
the	O
snesitivity	O
of	O
the	O
barorfelex	O
cnotrol	O
of	O
herat	O
rtae	O
.	O

In	O
this	O
sutdy	O
we	O
aimed	O
at	O
studying	O
the	O
invlovement	O
of	O
the	O
barin	O
RAS	O
in	O
the	O
cadriac	O
raectivity	O
to	O
the	O
btea	O
-	O
adrenocepotr	O
(	O
btea	O
-	O
AR	O
)	O
agoinst	O
isoprtoerenol	O
(	O
Iso	O
)	O
.	O

Tarnsgenic	O
rtas	O
with	O
low	O
brian	O
angiotensinoegn	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isolaetd	O
herats	O
,	O
Iso	O
inudced	O
a	O
significantly	O
greater	O
incerase	O
in	O
lfet	O
ventrciular	O
(	O
LV	O
)	O
pressure	O
and	O
maixmal	O
contarction	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Spargue	O
-	O
Dwaley	O
(	O
SD	O
)	O
rtas	O
.	O

LV	B-Disease
hypertrpohy	I-Disease
inudced	O
by	O
Iso	O
treatmnet	O
was	O
significantly	O
higehr	O
in	O
TGR	O
than	O
in	O
SD	O
rtas	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
bdoy	O
wt	O
,	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
004	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	B-Disease
hypertrpohy	I-Disease
in	O
TGR	O
rtas	O
was	O
associated	O
with	O
more	O
pronounced	O
downregluation	O
of	O
btea	O
-	O
AR	O
and	O
upregulaiton	O
of	O
LV	O
btea	O
-	O
AR	O
kianse	O
-	O
1	O
mNRA	O
levles	O
compraed	O
with	O
those	O
in	O
SD	O
rtas	O
.	O

The	O
dcerease	O
in	O
the	O
haert	O
rtae	O
(	O
HR	O
)	O
induecd	O
by	O
the	O
btea	O
-	O
AR	O
antagonsit	O
metorpolol	O
in	O
consicous	O
rtas	O
was	O
significantly	O
attneuated	O
in	O
TGR	O
compaerd	O
with	O
SD	O
rtas	O
(	O
-	O
9	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
vs	O
.	O
-	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
)	O
,	O
whereas	O
the	O
effcet	O
of	O
paraysmpathetic	O
bolckade	O
by	O
atrpoine	O
on	O
HR	O
was	O
similar	O
in	O
both	O
starins	O
.	O

These	O
reuslts	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitvie	O
to	O
btea	O
-	O
AR	O
agnoist	O
-	O
inudced	O
cradiac	B-Disease
inotrpoic	I-Disease
repsonse	O
and	O
hypertrpohy	B-Disease
,	O
possibly	O
due	O
to	O
crhonically	O
low	O
smypathetic	O
ouftlow	O
directed	O
to	O
the	O
haert	O
.	O

Durg	O
-	O
inudced	O
long	B-Disease
QT	I-Disease
snydrome	I-Disease
in	O
injetcion	O
durg	O
uesrs	O
receiving	O
methaodne	O
:	O
high	O
frequecny	O
in	O
hospitalzied	O
paitents	O
and	O
rsik	O
facotrs	O
.	O

BACKGRUOND	O
:	O
Durg	O
-	O
indcued	O
long	B-Disease
QT	I-Disease
snydrome	I-Disease
is	O
a	O
serious	O
advesre	O
durg	O
reatcion	O
.	O

Mehtadone	O
prologns	O
the	O
QT	O
itnerval	O
in	O
vitro	O
in	O
a	O
dsoe	O
-	O
dpeendent	O
manner	O
.	O

In	O
the	O
inaptient	O
setting	O
,	O
the	O
freuqency	O
of	O
QT	B-Disease
itnerval	I-Disease
prolonagtion	I-Disease
with	O
metahdone	O
treatmnet	O
,	O
its	O
dsoe	O
deepndence	O
,	O
and	O
the	O
importance	O
of	O
cofcators	O
such	O
as	O
durg	O
-	O
durg	O
itneractions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systeamtic	O
,	O
retorspective	O
stduy	O
comapring	O
actvie	O
or	O
former	O
intravenuos	O
durg	O
uesrs	O
receiving	O
mehtadone	O
and	O
those	O
not	O
receiving	O
methaodne	O
among	O
all	O
patietns	O
hosiptalized	O
over	O
a	O
5	O
-	O
yaer	O
peroid	O
in	O
a	O
tetriary	O
crae	O
hsopital	O
.	O

A	O
total	O
of	O
167	O
patietns	O
receiving	O
methadnoe	O
fulfilled	O
the	O
inclsuion	O
cirteria	O
and	O
were	O
cmopared	O
with	O
a	O
cotnrol	O
gorup	O
of	O
80	O
injeciton	O
durg	O
uesrs	O
not	O
receiving	O
methadnoe	O
.	O

In	O
addition	O
to	O
methaodne	O
dsoe	O
,	O
15	O
demograhpic	O
,	O
boilogical	O
,	O
and	O
pharmacologcial	O
varialbes	O
were	O
considered	O
as	O
potenital	O
rsik	O
facotrs	O
for	O
QT	B-Disease
prolonagtion	I-Disease
.	O

RESUTLS	O
:	O
Among	O
167	O
mehtadone	O
maintennace	O
patietns	O
,	O
the	O
pervalence	O
of	O
QTc	O
prolongatoin	O
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
comapred	O
with	O
0	O
%	O
in	O
80	O
contorl	O
subjcets	O
.	O

Six	O
pateints	O
(	O
3	O
.	O
6	O
%	O
)	O
in	O
the	O
mtehadone	O
gruop	O
presented	O
torasdes	B-Disease
de	I-Disease
poitnes	I-Disease
.	O

QTc	O
lnegth	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methaodne	O
daliy	O
dsoe	O
(	O
Spaerman	O
rnak	O
correaltion	O
coefficinet	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Mlutivariate	O
regression	O
anaylsis	O
allowed	O
atrtibution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variaiblity	O
to	O
metahdone	O
dsoe	O
,	O
cytocrhome	O
P	O
-	O
450	O
3A4	O
durg	O
-	O
durg	O
interactoins	O
,	O
hypokaleima	B-Disease
,	O
and	O
altreed	O
lvier	O
funciton	O
.	O

CNOCLUSIONS	O
:	O
QT	B-Disease
intevral	I-Disease
prolonagtion	I-Disease
in	O
methadnoe	O
mainetnance	O
patinets	O
hospitlaized	O
in	O
a	O
teritary	O
crae	O
cetner	O
is	O
a	O
freqeunt	O
fniding	O
.	O

Methadnoe	O
dsoe	O
,	O
presecne	O
of	O
cytochrmoe	O
P	O
-	O
450	O
3A4	O
inhbiitors	O
,	O
poatssium	O
leevl	O
,	O
and	O
lvier	O
funciton	O
contribute	O
to	O
QT	B-Disease
porlongation	I-Disease
.	O

Lnog	B-Disease
QT	I-Disease
synrdome	I-Disease
can	O
occur	O
with	O
low	O
doess	O
of	O
mehtadone	O
.	O

Mecahnisms	O
of	O
hypetrension	B-Disease
induecd	O
by	O
ntiric	O
oxdie	O
(	O
NO	O
)	O
defciiency	O
:	O
focus	O
on	O
vneous	O
fnuction	O
.	O

Lsos	O
of	O
enodthelial	O
clel	O
-	O
derived	O
ntiric	O
oxdie	O
(	O
NO	O
)	O
in	O
hpyertension	B-Disease
is	O
a	O
hallmark	O
of	O
artreial	B-Disease
dysufnction	I-Disease
.	O

Epxerimental	O
hypertensoin	B-Disease
created	O
by	O
the	O
remoavl	O
of	O
NO	O
,	O
however	O
,	O
involves	O
mechanimss	O
in	O
addition	O
to	O
decerased	O
atrerial	O
vasdoilator	O
atcivity	O
.	O

These	O
include	O
augmneted	O
endothlein	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
relaese	O
,	O
incraesed	O
sympahtetic	O
nerovus	O
sysetm	O
atcivity	O
,	O
and	O
elveated	O
tisuse	O
oxidtaive	O
srtess	O
.	O

We	O
hypothesized	O
that	O
incraesed	O
vneous	O
somoth	O
muslce	O
(	O
venomootr	O
)	O
tnoe	O
plays	O
a	O
role	O
in	O
Nomgea	O
-	O
nirto	O
-	O
L	O
-	O
argniine	O
(	O
LNNA	O
)	O
hypertenison	B-Disease
through	O
these	O
mechanimss	O
.	O

Rtas	O
were	O
traeted	O
with	O
the	O
NO	O
sytnhase	O
inhibiotr	O
LNNA	O
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
dirnking	O
waetr	O
)	O
for	O
2	O
weeks	O
.	O

Mean	O
arterail	O
prsesure	O
of	O
concsious	O
rtas	O
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
conrtol	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	O
rtas	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Cartoid	O
artreies	O
and	O
vnea	O
cvaa	O
were	O
reomved	O
for	O
maesurement	O
of	O
isomteric	O
contractoin	O
.	O

Maxiaml	O
cnotraction	O
to	O
nroepinephrine	O
was	O
modestly	O
reduecd	O
in	O
arteires	O
from	O
LNNA	O
compraed	O
with	O
cnotrol	O
rtas	O
whereas	O
the	O
maxmium	O
contrcation	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
reudced	O
(	O
54	O
%	O
contorl	O
)	O
.	O

Maixmum	O
conrtaction	O
of	O
vnea	O
cvaa	O
to	O
norpeinephrine	O
(	O
37	O
%	O
cotnrol	O
)	O
also	O
was	O
reduecd	O
but	O
no	O
change	O
in	O
resopnse	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O

Mean	O
circulaotry	O
filling	O
pressrue	O
,	O
an	O
in	O
vivo	O
measrue	O
of	O
vneomotor	O
tnoe	O
,	O
was	O
not	O
elevaetd	O
in	O
LNNA	O
hyeprtension	B-Disease
at	O
1	O
or	O
2	O
wekes	O
after	O
LNNA	O
.	O

The	O
spueroxide	O
scaevnger	O
tmepol	O
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterail	O
pressrue	O
in	O
cnotrol	O
rtas	O
but	O
caused	O
a	O
dsoe	O
-	O
depednent	O
decresae	O
in	O
LNNA	O
rtas	O
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
gnaglionic	O
bolckade	O
with	O
hexamtehonium	O
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	O
hypretensive	B-Disease
rtas	O
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compaerd	O
with	O
cnotrol	O
rtas	O
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Caroitd	O
aretries	O
,	O
vnea	O
cvaa	O
,	O
and	O
symapthetic	O
gagnlia	O
from	O
LNNA	O
rtas	O
had	O
higehr	O
bsaal	O
levles	O
of	O
supeorxide	O
compaerd	O
with	O
those	O
from	O
cnotrol	O
rtas	O
.	O

These	O
dtaa	O
suggest	O
that	O
while	O
NO	O
deifciency	O
incresaes	O
oxidtaive	O
sterss	O
and	O
symapthetic	O
actiivty	O
in	O
both	O
atrerial	O
and	O
vneous	O
vesesls	O
,	O
the	O
impcat	O
on	O
venis	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hyeprtension	B-Disease
.	O

Assoication	O
of	O
DDR2	O
polmyorphisms	O
and	O
chlorrpomazine	O
-	O
inudced	O
extrapyraimdal	B-Disease
synrdome	I-Disease
in	O
Cihnese	O
schizohprenic	B-Disease
ptaients	O
.	O

AIM	O
:	O
Exrtapyramidal	B-Disease
sydnrome	I-Disease
(	O
EPS	B-Disease
)	O
is	O
most	O
commonly	O
afefcted	O
by	O
typical	O
antispychotic	O
durgs	O
that	O
have	O
a	O
high	O
affniity	O
with	O
the	O
D2	O
recpetor	O
.	O

Recently	O
,	O
many	O
rseearch	O
gropus	O
have	O
reported	O
on	O
the	O
posiitve	O
relationhsip	O
between	O
the	O
geentic	O
varaitions	O
in	O
the	O
DDR2	O
gnee	O
and	O
the	O
therpaeutic	O
repsonse	O
in	O
schizophrneia	B-Disease
patinets	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variatoins	O
in	O
the	O
recepotr	O
in	O
modulaitng	O
recetpor	O
expression	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
evalaute	O
the	O
role	O
DDR2	O
plays	O
in	O
chlropromazine	O
-	O
inudced	O
EPS	B-Disease
in	O
schziophrenic	B-Disease
patinets	O
.	O

METHODS	O
:	O
We	O
idetnified	O
seven	O
SNP	O
(	O
single	O
nucleotdie	O
polymrophism	O
)	O
(	O
-	O
141Cins	O
>	O
del	O
,	O
TqaIB	O
,	O
TqaID	O
,	O
Ser31C1ys	O
,	O
r6s275	O
,	O
rs2677	O
and	O
TqaIA	O
)	O
in	O
the	O
DDR2	O
gnee	O
in	O
146	O
schiozphrenic	B-Disease
inpatinets	O
(	O
59	O
with	O
EPS	B-Disease
and	O
87	O
without	O
EPS	B-Disease
according	O
to	O
the	O
Simspon	O
-	O
Agnus	O
Sacle	O
)	O
traeted	O
with	O
cholrpromazine	O
after	O
8	O
weeks	O
.	O

The	O
alelles	O
of	O
all	O
lcoi	O
were	O
determined	O
by	O
PCR	O
(	O
polymrease	O
cahin	O
reatcion	O
)	O
.	O

RSEULTS	O
:	O
Poylmorphisms	O
TqaID	O
,	O
Ser311yCs	O
and	O
r6s277	O
were	O
not	O
polymrophic	O
in	O
the	O
popultaion	O
recruited	O
in	O
the	O
present	O
sutdy	O
.	O

No	O
statisitcal	O
significacne	O
was	O
found	O
in	O
the	O
allele	O
distribtuion	O
of	O
-	O
141Cins	O
>	O
del	O
,	O
TaIqB	O
,	O
rs2675	O
and	O
TqaIA	O
or	O
in	O
the	O
estimaetd	O
hapoltypes	O
(	O
constituted	O
by	O
TqaIB	O
,	O
rs6725	O
and	O
TqaIA	O
)	O
in	O
lnikage	O
disequilirbium	O
between	O
the	O
two	O
gruops	O
.	O

CONCLUISON	O
:	O
Our	O
rseults	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
geneitc	O
variaiton	O
of	O
the	O
DDR2	O
gnee	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
varialbe	O
advrese	O
effect	O
indcued	O
by	O
chlorpromaizne	O
,	O
at	O
least	O
in	O
Chniese	O
pateints	O
with	O
schizpohrenia	B-Disease
.	O

Our	O
resluts	O
confirmed	O
a	O
previous	O
sutdy	O
on	O
the	O
relaitonship	O
between	O
DDR2	O
and	O
EPS	B-Disease
in	O
Caucasains	O
.	O

Physiacl	O
traiinng	O
decraeses	O
susceptibiilty	O
to	O
subsequent	O
piolcarpine	O
-	O
inudced	O
seizuers	B-Disease
in	O
the	O
rat	O
.	O

Regualr	O
mtoor	O
acitvity	O
has	O
many	O
beneifts	O
for	O
menatl	O
and	O
physiacl	O
conidtion	O
but	O
its	O
implications	O
for	O
epilespy	B-Disease
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
prbolem	O
,	O
we	O
have	O
studied	O
the	O
efefct	O
of	O
long	O
-	O
term	O
physiacl	O
actiivty	O
on	O
suscpetibility	O
to	O
subsequent	O
siezures	B-Disease
.	O

Mlae	O
Witsar	O
rtas	O
were	O
subjected	O
to	O
repeaetd	O
tarining	O
sesisons	O
in	O
a	O
traedmill	O
and	O
swimmnig	O
pool	O
.	O

Thereafter	O
,	O
seziures	B-Disease
were	O
idnuced	O
by	O
piloacrpine	O
injetcions	O
in	O
trianed	O
and	O
non	O
-	O
tranied	O
conrtol	O
gropus	O
.	O

During	O
the	O
aucte	O
preiod	O
of	O
sattus	B-Disease
epliepticus	I-Disease
,	O
we	O
maesured	O
:	O
(	O
1	O
)	O
the	O
latnecy	O
of	O
the	O
first	O
mtoor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intenisty	O
of	O
seizuers	B-Disease
,	O
(	O
3	O
)	O
the	O
tmie	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	O
observaiton	O
peirod	O
,	O
and	O
(	O
4	O
)	O
the	O
tmie	O
when	O
the	O
aucte	O
peroid	O
ended	O
.	O

All	O
these	O
behavoiral	O
parametres	O
showed	O
statisitcally	O
significant	O
chnages	O
suggesting	O
that	O
regular	O
phsyical	O
exrecises	O
decresae	O
suscpetibility	O
to	O
subsequently	O
induecd	O
siezures	B-Disease
and	O
ameloirate	O
the	O
cousre	O
of	O
epxerimentally	O
induecd	O
sttaus	B-Disease
epileptcius	I-Disease
.	O

Tnoic	O
dopmainergic	O
stmiulation	O
imapirs	B-Disease
associative	I-Disease
learnnig	I-Disease
in	O
haelthy	O
subjcets	O
.	O

Endgoenous	O
dopamnie	O
plays	O
a	O
centarl	O
role	O
in	O
saleince	O
codnig	O
during	O
associative	O
learinng	O
.	O

Administrtaion	O
of	O
the	O
dpoamine	O
percursor	O
lveodopa	O
enhanecs	O
learnnig	O
in	O
heatlhy	O
subjcets	O
and	O
strkoe	B-Disease
ptaients	O
.	O

Because	O
leovdopa	O
icnreases	O
both	O
phaisc	O
and	O
toinc	O
dopmainergic	O
neurotrnasmission	O
,	O
the	O
critical	O
mechnaism	O
mediating	O
the	O
ehnancement	O
of	O
laerning	O
is	O
unresolved	O
.	O

We	O
here	O
porbed	O
how	O
selective	O
toinc	O
dopaimnergic	O
sitmulation	O
affects	O
associative	O
leraning	O
.	O

Forty	O
healhty	O
subjcets	O
were	O
tarined	O
in	O
a	O
novel	O
vocabluary	O
of	O
45	O
concrete	O
nonus	O
over	O
the	O
cuorse	O
of	O
5	O
consecutvie	O
trianing	O
dyas	O
in	O
a	O
propsective	O
,	O
randmoized	O
,	O
double	O
-	O
bilnd	O
,	O
palcebo	O
-	O
controleld	O
dseign	O
.	O

Subejcts	O
received	O
the	O
toincally	O
stimultaing	O
dopamnie	O
-	O
recetpor	O
agnoist	O
peroglide	O
(	O
0	O
.	O
1	O
mg	O
)	O
vs	O
plaecbo	O
120	O
min	O
before	O
tarining	O
on	O
each	O
trainnig	O
day	O
.	O

The	O
dopmaine	O
agonsit	O
significantly	O
imapired	B-Disease
novel	I-Disease
wrod	I-Disease
leanring	I-Disease
comapred	O
to	O
placbeo	O
.	O

This	O
learinng	O
decrmeent	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
weeks	O
psot	O
-	O
traiinng	O
.	O

Sujbects	O
terated	O
with	O
pergoldie	O
also	O
showed	O
restricted	O
emoitonal	O
rseponses	O
copmared	O
to	O
the	O
PLAECBO	O
gruop	O
.	O

The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergoilde	O
was	O
related	O
to	O
the	O
degere	O
of	O
leanring	O
inhibiiton	O
.	O

These	O
findnigs	O
suggest	O
that	O
tnoic	O
occpuation	O
of	O
dopamnie	O
reecptors	O
imapirs	O
leanring	O
by	O
competitoin	O
with	O
phaisc	O
dopamnie	O
sginals	O
.	O

Thus	O
,	O
phsaic	O
signalnig	O
seems	O
to	O
be	O
the	O
critical	O
mechainsm	O
by	O
which	O
dopaimne	O
enhacnes	O
associative	O
learnnig	O
in	O
heatlhy	O
subejcts	O
and	O
strkoe	B-Disease
patietns	O
.	O

Minoyccline	O
-	O
indcued	O
vascluitis	B-Disease
fulfilling	O
the	O
criteira	O
of	O
polyatreritis	B-Disease
nodsoa	I-Disease
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocycilne	O
for	O
palmopalntar	B-Disease
psutulosis	I-Disease
developed	O
feevr	B-Disease
,	O
maylgias	B-Disease
,	O
polynueropathy	B-Disease
,	O
and	O
testiuclar	B-Disease
pian	I-Disease
,	O
with	O
elveated	O
C	O
-	O
reacitve	O
prtoein	O
(	O
CRP	O
)	O
.	O

Neither	O
myeloperoxiadse	O
-	O
nor	O
proetinase	O
-	O
3	O
-	O
antineutropihl	O
cyotplasmic	O
antibdoy	O
was	O
positvie	O
.	O

These	O
manifsetations	O
met	O
the	O
Amercian	O
College	O
of	O
Rehumatology	O
1990	O
critreia	O
for	O
the	O
calssification	O
of	O
polyatreritis	B-Disease
nodsoa	I-Disease
.	O

Stopping	O
minoyccline	O
led	O
to	O
aemlioration	O
of	O
symtpoms	O
and	O
normalizatoin	O
of	O
CRP	O
leevl	O
.	O

To	O
our	O
knwoledge	O
,	O
this	O
is	O
the	O
second	O
csae	O
of	O
mioncycline	O
-	O
idnuced	O
vsaculitis	B-Disease
satisfying	O
the	O
cirteria	O
.	O

Diffeerntial	O
daignosis	O
for	O
durg	O
-	O
induecd	O
diesase	O
is	O
invaluable	O
even	O
for	O
patietns	O
with	O
classical	O
polyarteirtis	B-Disease
nodsoa	I-Disease
.	O

Intrmauscular	O
hepattiis	B-Disease
B	I-Disease
imumne	O
glboulin	O
combnied	O
with	O
laimvudine	O
in	O
preventoin	O
of	O
hepatiits	B-Disease
B	I-Disease
recurrnece	O
after	O
lvier	O
translpantation	O
.	O

BCAKGROUND	O
:	O
Combiend	O
heptaitis	B-Disease
B	I-Disease
immune	O
globuiln	O
(	O
HIBg	O
)	O
and	O
lmaivudine	O
in	O
prophylaixs	O
of	O
the	O
recurrnece	O
of	O
heptaitis	B-Disease
B	I-Disease
after	O
lievr	O
transplantatoin	O
has	O
significantly	O
imporved	O
the	O
survvial	O
of	O
HsBAg	O
posiitve	O
patietns	O
.	O

This	O
stduy	O
was	O
undertaken	O
to	O
evlauate	O
the	O
ouctomes	O
of	O
lievr	O
transplantaiton	O
for	O
patinets	O
with	O
heaptitis	B-Disease
B	I-Disease
vrius	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
rterospective	O
cahrt	O
anaylsis	O
and	O
a	O
reveiw	O
of	O
the	O
oragn	O
transplnat	O
dataabse	O
identifeid	O
51	O
ptaients	O
(	O
43	O
men	O
and	O
8	O
wmoen	O
)	O
transplanetd	O
for	O
beingn	O
HBV	O
-	O
related	O
cirrhtoic	B-Disease
disesaes	I-Disease
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
mnoths	O
.	O

HIBg	O
was	O
administreed	O
intraveonusly	O
during	O
the	O
first	O
week	O
and	O
inrtamuscularly	O
thereafter	O
.	O

REUSLTS	O
:	O
At	O
a	O
meidan	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
monhts	O
,	O
the	O
overall	O
rceurrence	O
rtae	O
in	O
the	O
51	O
patietns	O
was	O
3	O
.	O
9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O

The	O
overall	O
pateint	O
suvrival	O
was	O
88	O
.	O
3	O
%	O
,	O
and	O
82	O
.	O
4	O
%	O
after	O
1	O
and	O
2	O
yeras	O
,	O
respectively	O
.	O

A	O
dialy	O
oarl	O
dsoe	O
of	O
100	O
mg	O
lamviudine	O
for	O
2	O
weeks	O
before	O
trnasplantation	O
for	O
10	O
patinets	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBAeg	O
psoitive	O
paitents	O
respectively	O
to	O
convert	O
to	O
be	O
neagtive	O
.	O

Itnramuscular	O
HIBg	O
was	O
well	O
tolertaed	O
in	O
all	O
ptaients	O
.	O

CONLCUSION	O
:	O
Laimvudine	O
combiend	O
with	O
intramuscualr	O
HIBg	O
can	O
effectively	O
preevnt	O
allograft	O
from	O
the	O
recrurence	O
of	O
HBV	O
after	O
lievr	O
translpantation	O
.	O

Antiocnvulsant	O
effcet	O
of	O
eslicarbaezpine	O
aceatte	O
(	O
BIA	O
2	O
-	O
093	O
)	O
on	O
seizuers	B-Disease
idnuced	O
by	O
microperfsuion	O
of	O
pircotoxin	O
in	O
the	O
hippcoampus	O
of	O
freely	O
mvoing	O
rtas	O
.	O

Eslicarbazepnie	O
aceatte	O
(	O
BIA	O
2	O
-	O
093	O
,	O
S	O
-	O
(	O
-	O
)	O
-	O
10	O
-	O
aceotxy	O
-	O
10	O
,	O
11	O
-	O
dihyrdo	O
-	O
5H	O
-	O
dbienzo	O
/	O
b	O
,	O
f	O
/	O
azepnie	O
-	O
5	O
-	O
cabroxamide	O
)	O
is	O
a	O
novel	O
antiepiletpic	O
durg	O
,	O
now	O
in	O
Pahse	O
III	O
cliincal	O
trilas	O
,	O
designed	O
with	O
the	O
aim	O
of	O
imporving	O
efficcay	O
and	O
sfaety	O
in	O
cmoparison	O
with	O
the	O
structurally	O
related	O
durgs	O
cabramazepine	O
(	O
CBZ	O
)	O
and	O
oxcabrazepine	O
(	O
OXC	O
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oarl	O
teratment	O
with	O
esliacrbazepine	O
aceatte	O
on	O
a	O
whole	O
-	O
anmial	O
mdoel	O
in	O
which	O
pratial	O
siezures	B-Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
dyas	O
without	O
chanegs	O
in	O
thresohld	O
or	O
seizrue	B-Disease
pattrens	O
.	O

In	O
the	O
aniamls	O
traeted	O
with	O
threhsold	O
doess	O
of	O
picrtooxin	O
,	O
the	O
avearge	O
number	O
of	O
siezures	B-Disease
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
avearge	O
seziure	B-Disease
duraiton	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pre	O
-	O
teratment	O
with	O
a	O
dsoe	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
pcirotoxin	O
microperfsuion	O
prevented	O
seizuers	B-Disease
in	O
the	O
75	O
%	O
of	O
the	O
rtas	O
.	O

Lwoer	O
dsoes	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
supperss	O
seziures	B-Disease
,	O
however	O
,	O
after	O
adminsitration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reudctions	O
in	O
seizrues	B-Disease
druation	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizrue	B-Disease
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
advrese	O
effetcs	O
of	O
eslicarbazepnie	O
acteate	O
were	O
observed	O
in	O
the	O
beahvioral	O
/	O
EEG	O
ptaterns	O
studied	O
,	O
including	O
selep	O
/	O
wkaefulness	O
ccyle	O
,	O
at	O
the	O
dsoes	O
studied	O
.	O

Aucte	B-Disease
rneal	I-Disease
faiulre	I-Disease
associated	O
with	O
porlonged	O
intkae	O
of	O
slimming	O
pills	O
containing	O
anthrqauinones	O
.	O

Chniese	O
hebral	O
meidcine	O
preparaitons	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
pubilc	O
as	O
nautral	O
and	O
safe	O
remeides	O
for	O
a	O
variety	O
of	O
meidcal	O
condtiions	O
.	O

Nephroptahy	B-Disease
caused	O
by	O
Chiense	O
hebrs	O
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolcohic	O
acdis	O
.	O

We	O
reprot	O
a	O
23	O
-	O
yaer	O
-	O
old	O
woamn	O
who	O
developed	O
actue	B-Disease
rneal	I-Disease
faliure	I-Disease
following	O
prolnoged	O
use	O
of	O
a	O
proprieatry	O
Chinsee	O
herabl	O
silmming	O
plil	O
that	O
contained	O
anthraquionne	O
derivaitves	O
,	O
etxracted	O
from	O
Rhzioma	O
Rehi	O
(	O
rhuabrb	O
)	O
.	O

The	O
rneal	B-Disease
inujry	I-Disease
was	O
probably	O
aggarvated	O
by	O
the	O
cnocomitant	O
itnake	O
of	O
a	O
non	O
-	O
steriodal	O
atni	O
-	O
infalmmatory	O
durg	O
,	O
dicloefnac	O
.	O

Reanl	O
pahtology	O
was	O
that	O
of	O
hypcoellular	O
itnerstitial	O
fibrsois	B-Disease
.	O

Sponatneous	O
rneal	O
reocvery	O
occurred	O
upon	O
csesation	O
of	O
the	O
slmiming	O
plils	O
,	O
but	O
mlid	O
inetrstitial	O
fibroiss	B-Disease
and	O
tbuular	O
artophy	B-Disease
was	O
still	O
evident	O
hitsologically	O
4	O
mnoths	O
later	O
.	O

Although	O
a	O
causal	O
relatinoship	O
between	O
the	O
use	O
of	O
an	O
antrhaquinone	O
-	O
containing	O
herabl	O
aegnt	O
and	O
rneal	B-Disease
inujry	I-Disease
remains	O
to	O
be	O
proven	O
,	O
phytothearpy	O
-	O
associated	O
intesrtitial	O
nephroptahy	B-Disease
should	O
be	O
considered	O
in	O
patinets	O
who	O
present	O
with	O
unxeplained	O
rneal	B-Disease
faiulre	I-Disease
.	O

Chloroaectaldehyde	O
as	O
a	O
sulfyhdryl	O
raegent	O
:	O
the	O
role	O
of	O
critical	O
thoil	O
gruops	O
in	O
ifosfmaide	O
nephrpoathy	B-Disease
.	O

Chlorocaetaldehyde	O
(	O
CAA	O
)	O
is	O
a	O
metabloite	O
of	O
the	O
alkyalting	O
aegnt	O
ifosfaimde	O
(	O
IFO	O
)	O
and	O
putatively	O
responsible	O
for	O
reanl	B-Disease
damgae	I-Disease
following	O
atni	O
-	O
tmuor	B-Disease
thearpy	O
with	O
IFO	O
.	O

Delpetion	O
of	O
sulfhdyryl	O
(	O
SH	O
)	O
gorups	O
has	O
been	O
reported	O
from	O
clel	O
cultrue	O
,	O
anmial	O
and	O
cliincal	O
stduies	O
.	O

In	O
this	O
work	O
the	O
efefct	O
of	O
CAA	O
on	O
huamn	O
proxmial	O
tuuble	O
cells	O
in	O
primray	O
cutlure	O
(	O
hRTPEC	O
)	O
was	O
investiagted	O
.	O

Toxictiy	B-Disease
of	O
CAA	O
was	O
determined	O
by	O
protien	O
contnet	O
,	O
clel	O
number	O
,	O
LDH	O
relesae	O
,	O
trpyan	O
bule	O
exculsion	O
assay	O
and	O
csapase	O
-	O
3	O
actviity	O
.	O

Fere	O
thilos	O
were	O
mesaured	O
by	O
the	O
metohd	O
of	O
Ellman	O
.	O

CAA	O
rdeuced	O
hRPETC	O
clel	O
number	O
and	O
prtoein	O
,	O
idnuced	O
a	O
lsos	O
in	O
free	O
intraecllular	O
thoils	O
and	O
an	O
incraese	O
in	O
necroiss	B-Disease
makrers	O
.	O

CAA	O
but	O
not	O
acrloein	O
inhiibted	O
the	O
cysetine	O
protaeses	O
casapse	O
-	O
3	O
,	O
csapase	O
-	O
8	O
and	O
catehpsin	O
B	O
.	O

Capsase	O
acitvation	O
by	O
cipslatin	O
was	O
inhibtied	O
by	O
CAA	O
.	O

In	O
cells	O
stanied	O
with	O
fluoresecnt	O
deys	O
trageting	O
lyossomes	O
,	O
CAA	O
idnuced	O
an	O
inrcease	O
in	O
lyssoomal	O
szie	O
and	O
lyssoomal	O
laekage	O
.	O

The	O
efefcts	O
of	O
CAA	O
on	O
cystenie	O
protaese	O
activtiies	O
and	O
thoils	O
could	O
be	O
reproduced	O
in	O
clel	O
lyaste	O
.	O

Acdiification	O
,	O
which	O
slowed	O
the	O
raection	O
of	O
CAA	O
with	O
tihol	O
dnoors	O
,	O
could	O
also	O
attenaute	O
effetcs	O
of	O
CAA	O
on	O
nercosis	B-Disease
markres	O
,	O
thoil	O
depletoin	O
and	O
csyteine	O
protesae	O
inihbition	O
in	O
liivng	O
clels	O
.	O

Thus	O
,	O
CAA	O
directly	O
recats	O
with	O
cellular	O
prtoein	O
and	O
non	O
-	O
proetin	O
thilos	O
,	O
mediating	O
its	O
toxictiy	B-Disease
on	O
hPRTEC	O
.	O

This	O
effcet	O
can	O
be	O
reudced	O
by	O
acidifictaion	O
.	O

Therefore	O
,	O
urinray	O
aicdification	O
could	O
be	O
an	O
option	O
to	O
prveent	O
IFO	O
nephropahty	B-Disease
in	O
patietns	O
.	O

Steroelogical	O
mehtods	O
reveal	O
the	O
robsut	O
szie	O
and	O
stbaility	O
of	O
etcopic	O
hliar	O
graunle	O
clels	O
after	O
pilocarpnie	O
-	O
idnuced	O
sttaus	B-Disease
epiletpicus	I-Disease
in	O
the	O
audlt	O
rat	O
.	O

Following	O
stauts	B-Disease
epilpeticus	I-Disease
in	O
the	O
rat	O
,	O
dnetate	O
garnule	O
clel	O
nuerogenesis	O
incerases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
neurnos	O
appear	O
to	O
develop	O
ecotpically	O
,	O
in	O
the	O
hialr	O
reigon	O
of	O
the	O
hpipocampal	O
fromation	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectoipc	O
hialr	O
graunle	O
cells	O
could	O
contribute	O
to	O
the	O
spnotaneous	O
seiuzres	B-Disease
that	O
ultimately	O
develop	O
after	O
sattus	B-Disease
eiplepticus	I-Disease
.	O

However	O
,	O
the	O
ppoulation	O
has	O
never	O
been	O
quantifeid	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
infulence	O
on	O
epilepotgenesis	O
.	O

To	O
quanitfy	O
this	O
populatoin	O
,	O
the	O
total	O
number	O
of	O
ectpoic	O
hliar	O
grnaule	O
clels	O
was	O
estiamted	O
using	O
unbiased	O
stereloogy	O
at	O
different	O
times	O
after	O
piolcarpine	O
-	O
idnuced	O
stauts	B-Disease
epiletpicus	I-Disease
.	O

The	O
number	O
of	O
hliar	O
neurnos	O
immunorecative	O
for	O
Porx	O
-	O
1	O
,	O
a	O
garnule	O
-	O
clel	O
-	O
specific	O
marekr	O
,	O
was	O
esitmated	O
using	O
the	O
opitcal	O
frcationator	O
metohd	O
.	O

The	O
resutls	O
indicate	O
that	O
the	O
szie	O
of	O
the	O
hialr	O
etcopic	O
garnule	O
clel	O
pouplation	O
after	O
sttaus	B-Disease
epilpeticus	I-Disease
is	O
substantial	O
,	O
and	O
stbale	O
over	O
tmie	O
.	O

Interestingly	O
,	O
the	O
szie	O
of	O
the	O
popualtion	O
appears	O
to	O
be	O
correltaed	O
with	O
the	O
frequnecy	O
of	O
behavioarl	O
seiuzres	B-Disease
,	O
because	O
animlas	O
with	O
more	O
ectoipc	O
grnaule	O
clels	O
in	O
the	O
hlius	O
have	O
more	O
freuqent	O
bheavioral	O
siezures	B-Disease
.	O

The	O
hialr	O
ecotpic	O
grnaule	O
clel	O
populaiton	O
does	O
not	O
appear	O
to	O
vary	O
systematiclaly	O
across	O
the	O
septotemopral	O
aixs	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
incerase	O
in	O
vloume	O
of	O
the	O
hlius	O
.	O

The	O
resluts	O
provide	O
new	O
insight	O
into	O
the	O
potnetial	O
role	O
of	O
etcopic	O
hliar	O
grnaule	O
cells	O
in	O
the	O
pilocrapine	O
mdoel	O
of	O
temproal	B-Disease
lboe	I-Disease
epilespy	I-Disease
.	O

A	O
prospetcive	O
,	O
open	O
-	O
laebl	O
trail	O
of	O
galatnamine	O
in	O
auitstic	B-Disease
dsiorder	I-Disease
.	O

OBEJCTIVE	O
:	O
Psot	O
-	O
motrem	O
stduies	O
have	O
reported	O
abnoramlities	O
of	O
the	O
cholinerigc	O
sytsem	O
in	O
autsim	B-Disease
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamnie	O
,	O
an	O
acetylcholiensterase	O
ihnibitor	O
and	O
nictoinic	O
recpetor	O
modulator	O
,	O
in	O
the	O
treamtent	O
of	O
interfernig	O
behaviros	O
in	O
childern	O
with	O
autsim	B-Disease
.	O

METHODS	O
:	O
Thirteen	O
mdeication	O
-	O
free	O
chlidren	O
with	O
auitsm	B-Disease
(	O
mean	O
age	O
,	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
yaers	O
)	O
participated	O
in	O
a	O
12	O
-	O
week	O
,	O
open	O
-	O
laebl	O
trail	O
of	O
galanatmine	O
.	O

Patietns	O
were	O
rated	O
monhtly	O
by	O
praents	O
on	O
the	O
Aberarnt	O
Bheavior	O
Chceklist	O
(	O
ABC	O
)	O
and	O
the	O
Cnoners	O
'	O
Parnet	O
Ratnig	O
Sacle	O
-	O
Revsied	O
,	O
and	O
by	O
a	O
phsyician	O
using	O
the	O
Chidlren	O
'	O
s	O
Psychiatirc	O
Raitng	O
Sacle	O
and	O
the	O
Clincial	O
Golbal	O
Imprsesions	O
scale	O
.	O

RESLUTS	O
:	O
Ptaients	O
showed	O
a	O
significant	O
reduciton	O
in	O
parnet	O
-	O
rated	O
irriatbility	B-Disease
and	O
soical	O
withdrwaal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
imprvoements	O
in	O
emoitonal	O
labliity	O
and	O
inatetntion	O
on	O
the	O
Conenrs	O
'	O
Praent	O
Raitng	O
Sacle	O
-	O
-	O
Revsied	O
.	O

Similarly	O
,	O
cliniican	O
raitngs	O
showed	O
reudctions	O
in	O
the	O
agner	O
subsclae	O
of	O
the	O
Chlidren	O
'	O
s	O
Psychiatirc	O
Ratnig	O
Sclae	O
.	O

Eight	O
of	O
13	O
particiapnts	O
were	O
rated	O
as	O
resopnders	O
on	O
the	O
basis	O
of	O
their	O
improevment	O
socres	O
on	O
the	O
Clniical	O
Gloabl	O
Imperssions	O
scale	O
.	O

Overall	O
,	O
glaantamine	O
was	O
well	O
-	O
toelrated	O
,	O
with	O
no	O
significant	O
advrese	O
effetcs	O
apart	O
from	O
hedaaches	B-Disease
in	O
one	O
pateint	O
.	O

CONLCUSION	O
:	O
In	O
this	O
open	O
trail	O
,	O
galantaimne	O
was	O
well	O
-	O
tolreated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatmnet	O
of	O
intefrering	O
behaviros	O
in	O
chlidren	O
with	O
auitsm	B-Disease
,	O
particularly	O
aggerssion	B-Disease
,	O
behaviroal	B-Disease
dyscontorl	I-Disease
,	O
and	O
inattentoin	B-Disease
.	O

Further	O
contrloled	O
trilas	O
are	O
warranted	O
.	O

Rnadomized	O
compraison	O
of	O
olanzpaine	O
versus	O
risperiodne	O
for	O
the	O
treatemnt	O
of	O
first	O
-	O
episdoe	O
schziophrenia	B-Disease
:	O
4	O
-	O
mnoth	O
outcmoes	O
.	O

OBEJCTIVE	O
:	O
The	O
auhtors	O
comapred	O
4	O
-	O
motnh	O
tretament	O
outcmoes	O
for	O
olanzapnie	O
versus	O
ripseridone	O
in	O
ptaients	O
with	O
first	O
-	O
episdoe	O
schziophrenia	B-Disease
spcetrum	O
disroders	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
sbujects	O
(	O
70	O
%	O
mlae	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
yeras	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
episdoe	O
schizpohrenia	B-Disease
(	O
75	O
%	O
)	O
,	O
schizophrenifrom	B-Disease
disodrer	I-Disease
(	O
17	O
%	O
)	O
,	O
or	O
schizaoffective	B-Disease
dsiorder	I-Disease
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
traetment	O
with	O
olanzpaine	O
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
rispeirdone	O
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O

RESUTLS	O
:	O
Rseponse	O
rtaes	O
did	O
not	O
significantly	O
differ	O
between	O
olaznapine	O
(	O
43	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%	O
-	O
58	O
.	O
6	O
%	O
)	O
and	O
rsiperidone	O
(	O
54	O
.	O
3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%	O
-	O
68	O
.	O
7	O
%	O
)	O
.	O

Among	O
those	O
resopnding	O
to	O
tretament	O
,	O
more	O
subjcets	O
in	O
the	O
oalnzapine	O
gorup	O
(	O
40	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%	O
-	O
65	O
.	O
0	O
%	O
)	O
than	O
in	O
the	O
rispeirdone	O
gruop	O
(	O
18	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39	O
.	O
2	O
%	O
)	O
had	O
subsequent	O
rtaings	O
not	O
meeting	O
respnose	O
crietria	O
.	O

Negtaive	O
symtpom	O
otucomes	O
and	O
maesures	O
of	O
pakrinsonism	B-Disease
and	O
akathsiia	B-Disease
did	O
not	O
differ	O
between	O
medicatoins	O
.	O

Etxrapyramidal	B-Disease
sypmtom	I-Disease
seevrity	O
scoers	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
ripseridone	O
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapnie	O
.	O

Significantly	O
more	O
wieght	B-Disease
gain	I-Disease
occurred	O
with	O
olaznapine	O
than	O
with	O
risperdione	O
:	O
the	O
inrcease	O
in	O
weihgt	O
at	O
4	O
motnhs	O
relative	O
to	O
baselnie	O
wieght	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%	O
-	O
20	O
.	O
5	O
%	O
)	O
with	O
olanazpine	O
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%	O
-	O
14	O
.	O
3	O
%	O
)	O
with	O
risperdione	O
.	O

Bdoy	O
msas	O
index	O
at	O
baselnie	O
and	O
at	O
4	O
motnhs	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapnie	O
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risepridone	O
.	O

COCNLUSIONS	O
:	O
Clniical	O
outocmes	O
with	O
risperiodne	O
were	O
euqal	O
to	O
those	O
with	O
olanzapnie	O
,	O
and	O
resposne	O
may	O
be	O
more	O
stalbe	O
.	O

Olaznapine	O
may	O
have	O
an	O
advantage	O
for	O
mootr	O
side	O
effetcs	O
.	O

Both	O
medicaitons	O
caused	O
substantial	O
rpaid	O
wieght	B-Disease
gain	I-Disease
,	O
but	O
wieght	B-Disease
gain	I-Disease
was	O
greater	O
with	O
olanazpine	O
.	O

Ealry	O
paracnetral	O
vsiual	B-Disease
field	I-Disease
lsos	I-Disease
in	O
ptaients	O
taking	O
hydroxyclhoroquine	O
.	O

OBJCETIVE	O
:	O
To	O
reivew	O
the	O
ntaural	O
hsitory	O
and	O
ouclar	O
and	O
systeimc	O
avderse	O
effcets	O
of	O
ptaients	O
taking	O
hydroxychlorqouine	O
suflate	O
who	O
attended	O
an	O
ophthamlic	O
scerening	O
prgoram	O
.	O

DESIGN	O
:	O
Retrsopective	O
sutdy	O
.	O

REUSLTS	O
:	O
Rceords	O
of	O
262	O
paitents	O
who	O
were	O
taking	O
hydorxychloroquine	O
and	O
screened	O
in	O
the	O
Departmnet	O
of	O
Opthhalmology	O
were	O
revieewd	O
.	O

Of	O
the	O
262	O
patinets	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treamtent	O
at	O
the	O
tmie	O
of	O
the	O
sutdy	O
experienced	O
documenetd	O
advrese	O
efefcts	O
.	O

Sytsemic	O
avderse	O
effects	O
occurred	O
in	O
8	O
ptaients	O
(	O
10	O
.	O
5	O
%	O
)	O
and	O
ocluar	O
adevrse	O
efefcts	O
,	O
in	O
5	O
(	O
6	O
.	O
5	O
%	O
)	O
.	O

Thirty	O
-	O
five	O
paitents	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
vsiual	B-Disease
field	I-Disease
abnomralities	I-Disease
,	O
which	O
were	O
attributed	O
to	O
hydroxcyhloroquine	O
treamtent	O
in	O
4	O
paitents	O
(	O
1	O
.	O
5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
patietns	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
day	O
and	O
all	O
patietns	O
had	O
noraml	O
rneal	O
and	O
lvier	O
fucntion	O
tset	O
rseults	O
.	O

CONCLUISONS	O
:	O
The	O
current	O
sutdy	O
used	O
a	O
portocol	O
of	O
vsiual	O
aciuty	O
and	O
cloor	O
viison	O
assessment	O
,	O
fnuduscopy	O
,	O
and	O
Humprhey	O
10	O
-	O
2	O
viusal	O
field	O
tesitng	O
and	O
shows	O
that	O
viusal	B-Disease
field	I-Disease
deefcts	I-Disease
appeared	O
before	O
any	O
corresponding	O
cahnges	O
in	O
any	O
other	O
tetsed	O
clniical	O
parametres	O
;	O
the	O
defcets	O
were	O
reproducible	O
and	O
the	O
tset	O
parametres	O
were	O
reliable	O
.	O

Patinets	O
taking	O
hydroxyhcloroquine	O
can	O
demonstrate	O
a	O
toixc	O
reactoin	O
in	O
the	O
retnia	O
despite	O
the	O
asbence	O
of	O
known	O
rsik	O
facotrs	O
.	O

Scerening	O
,	O
including	O
Humphery	O
10	O
-	O
2	O
viusal	O
field	O
assessment	O
,	O
is	O
rceommended	O
2	O
yeras	O
after	O
the	O
initial	O
baselnie	O
and	O
yealry	O
thereafter	O
.	O

Prei	O
-	O
operaitve	O
atroiventricular	B-Disease
bolck	I-Disease
as	O
a	O
result	O
of	O
cheomtherapy	O
with	O
epirbuicin	O
and	O
pcalitaxel	O
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
wmoan	O
presented	O
for	O
mastecotmy	O
and	O
immeidate	O
latisismus	O
drosi	O
falp	O
reocnstruction	O
having	O
been	O
diagonsed	O
with	O
cacrinoma	B-Disease
of	I-Disease
the	I-Disease
braest	I-Disease
6	O
monhts	O
previously	O
.	O

In	O
the	O
preceding	O
motnhs	O
she	O
had	O
received	O
neo	O
-	O
adjvuant	O
chemotherpay	O
with	O
epirubiicn	O
,	O
pacliatxel	O
(	O
Taoxl	O
)	O
and	O
cyclophosphamdie	O
.	O

This	O
had	O
been	O
apparently	O
uncompliacted	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
lveel	O
of	O
pyhsical	O
actviity	O
.	O

She	O
was	O
found	O
to	O
be	O
bradycaridc	B-Disease
at	O
pre	O
-	O
opeartive	O
asesssment	O
but	O
had	O
no	O
caridac	O
symtpoms	O
.	O

Second	O
dgeree	O
Mobtiz	O
tpye	O
II	O
atrioventircular	B-Disease
bolck	I-Disease
was	O
diangosed	O
on	O
elcetrocardiogram	O
,	O
and	O
temporray	O
tarnsvenous	O
venrticular	O
pacnig	O
instiutted	O
in	O
the	O
prei	O
-	O
opeartive	O
peroid	O
.	O

We	O
discuss	O
how	O
eviednce	O
-	O
based	O
giudelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
csae	O
,	O
and	O
how	O
chmeotherapy	O
can	O
exhibit	O
substantial	O
cadriotoxicity	B-Disease
that	O
may	O
develop	O
over	O
many	O
yeras	O
.	O

We	O
suggest	O
that	O
patinets	O
who	O
have	O
received	O
chmeotherapy	O
at	O
any	O
tmie	O
should	O
have	O
a	O
pre	O
-	O
opreative	O
electrocardoigram	O
even	O
if	O
they	O
are	O
asymptoamtic	O
.	O

Rsiks	O
and	O
beneifts	O
of	O
COX	O
-	O
2	O
inhbiitors	O
vs	O
non	O
-	O
selective	O
NSADIs	O
:	O
does	O
their	O
cardiovascualr	O
rsik	O
exceed	O
their	O
gastriontestinal	O
benfeit	O
?	O

A	O
retrospecitve	O
coohrt	O
stduy	O
.	O

OBJECITVES	O
:	O
The	O
rsik	O
of	O
aucte	B-Disease
moycardial	I-Disease
infacrtion	I-Disease
(	O
AMI	B-Disease
)	O
with	O
COX	O
-	O
2	O
inhbiitors	O
may	O
offset	O
their	O
gastrointesitnal	O
(	O
GI	O
)	O
beneift	O
copmared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	O
-	O
setroidal	O
atni	O
-	O
inflamamtory	O
drgus	O
(	O
NSIADs	O
)	O
.	O

We	O
aimed	O
to	O
comprae	O
the	O
rikss	O
of	O
hsopitalization	O
for	O
AMI	B-Disease
and	O
GI	B-Disease
bleednig	I-Disease
among	O
eldelry	O
patietns	O
using	O
COX	O
-	O
2	O
inhibtiors	O
,	O
NS	O
-	O
NSIADs	O
and	O
acteaminophen	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
rterospective	O
choort	O
sutdy	O
using	O
administrtaive	O
dtaa	O
of	O
patinets	O
>	O
or	O
=	O
65	O
yeras	O
of	O
age	O
who	O
filled	O
a	O
precsription	O
for	O
NASID	O
or	O
acetmainophen	O
during	O
1999	O
-	O
2002	O
.	O

Outcoems	O
were	O
comapred	O
using	O
Cox	O
regression	O
modles	O
with	O
tmie	O
-	O
deepndent	O
exopsures	O
.	O

RESUTLS	O
:	O
Preson	O
-	O
yeras	O
of	O
epxosure	O
among	O
non	O
-	O
uesrs	O
of	O
apsirin	O
were	O
:	O
75	O
,	O
761	O
to	O
aectaminophen	O
,	O
42	O
,	O
671	O
to	O
roefcoxib	O
65	O
,	O
860	O
to	O
cleecoxib	O
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NASIDs	O
.	O

Among	O
usres	O
of	O
aspriin	O
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoixb	O
,	O
22	O
,	O
875	O
to	O
cleecoxib	O
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NASIDs	O
and	O
38	O
,	O
048	O
to	O
acteaminophen	O
.	O

Among	O
non	O
-	O
uesrs	O
of	O
apsirin	O
,	O
the	O
adjusted	O
haazrd	O
ratois	O
(	O
95	O
%	O
confiednce	O
itnerval	O
)	O
of	O
hospiatlization	O
for	O
AMI	B-Disease
/	O
GI	O
vs	O
the	O
acetaminpohen	O
(	O
with	O
no	O
apsirin	O
)	O
gruop	O
were	O
:	O
rofceoxib	O
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
celecoixb	O
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
narpoxen	O
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
dcilofenac	O
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprfoen	O
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
usres	O
of	O
asiprin	O
,	O
they	O
were	O
:	O
rofeocxib	O
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celecxoib	O
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ibuprfoen	O
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclfoenac	O
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naporxen	O
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminopehn	O
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CNOCLUSION	O
:	O
Among	O
non	O
-	O
usres	O
of	O
aspriin	O
,	O
naprxoen	O
seemed	O
to	O
carry	O
the	O
highest	O
rsik	O
for	O
AMI	B-Disease
/	O
GI	B-Disease
bleeidng	I-Disease
.	O

The	O
AMI	B-Disease
/	O
GI	O
toxiicty	B-Disease
of	O
celecoixb	O
was	O
similar	O
to	O
that	O
of	O
acetmainophen	O
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
roefcoxib	O
and	O
NS	O
-	O
NSIADs	O
.	O

Among	O
uesrs	O
of	O
aspiirn	O
,	O
both	O
celceoxib	O
and	O
naproexn	O
seemed	O
to	O
be	O
the	O
least	O
txoic	O
.	O

Quinnie	O
-	O
idnuced	O
arryhthmia	B-Disease
in	O
a	O
pateint	O
with	O
sveere	B-Disease
maalria	I-Disease
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
csae	O
of	O
seevre	B-Disease
mlaaria	I-Disease
patinet	O
with	O
juandice	B-Disease
who	O
presented	O
with	O
arrhyhtmia	B-Disease
(	O
premautre	B-Disease
vnetricular	I-Disease
cotnraction	I-Disease
)	O
while	O
getting	O
quinnie	O
infusoin	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
yaers	O
old	O
,	O
was	O
admitetd	O
to	O
hosptial	O
with	O
high	O
feevr	B-Disease
,	O
chlil	B-Disease
,	O
vmoiting	B-Disease
,	O
janudice	B-Disease
.	O

The	O
ptaient	O
was	O
fully	O
consicous	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pusle	O
rtae	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admisison	O
,	O
laboratroy	O
examinatoin	O
showed	O
Plasmoduim	O
falcpiarum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilriubin	O
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
cnojugated	O
biliurbin	O
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjugaetd	O
biliruibn	O
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
poatssium	O
3	O
.	O
52	O
meq	O
/	O
L	O
Ptaient	O
was	O
diagnoesd	O
as	O
seevre	B-Disease
mlaaria	I-Disease
with	O
jaundcie	B-Disease
and	O
got	O
quinnie	O
inufsion	O
in	O
detxrose	O
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patinet	O
had	O
vomiuts	B-Disease
,	O
diarhrea	B-Disease
,	O
tinnitus	B-Disease
,	O
lsos	B-Disease
of	I-Disease
haering	I-Disease
.	O

After	O
30	O
hours	O
of	O
quinnie	O
infuison	O
the	O
paitent	O
felt	O
paliptation	B-Disease
and	O
electrocardiorgaphy	O
(	O
ECG	O
)	O
recroding	O
showed	O
prematrue	B-Disease
ventricluar	I-Disease
contratcion	I-Disease
(	O
PVC	B-Disease
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigeimni	O
,	O
constnat	O
tpye	O
-	O
-	O
sinotarial	B-Disease
blcok	I-Disease
,	O
psoitive	O
U	O
wvae	O
.	O

He	O
was	O
tretaed	O
with	O
ldiocaine	O
50	O
mg	O
intarvenously	O
followed	O
by	O
infsuion	O
1500	O
mg	O
in	O
dextrsoe	O
5	O
%	O
/	O
24	O
hour	O
and	O
potasisum	O
apsartate	O
tbalet	O
.	O

Quiinne	O
infuison	O
was	O
discotninued	O
and	O
changed	O
with	O
sulftae	O
qiunine	O
talbets	O
.	O

Three	O
hours	O
later	O
the	O
patinet	O
felt	O
better	O
,	O
the	O
frequnecy	O
of	O
PVC	B-Disease
redcued	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
nomral	O
,	O
poatssium	O
leevl	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O

He	O
was	O
dsicharged	O
on	O
7th	O
day	O
in	O
good	O
condiiton	O
.	O

Qiunine	O
,	O
like	O
quiniidne	O
,	O
is	O
a	O
chnicona	O
alakloid	O
that	O
has	O
atni	O
-	O
arrhyhtmic	B-Disease
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhytmhic	B-Disease
that	O
can	O
cause	O
various	O
arrhytmhias	B-Disease
,	O
including	O
sveere	O
arhrythmia	B-Disease
such	O
as	O
multilpe	O
PVC	B-Disease
.	O

Adimnistration	O
of	O
parentreal	O
qiunine	O
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
obseravtion	O
because	O
of	O
its	O
pro	O
-	O
arryhthmic	B-Disease
effcet	O
,	O
especially	O
in	O
oledr	O
paitents	O
who	O
have	O
haert	B-Disease
dsieases	I-Disease
or	O
paitents	O
with	O
elcetrolyte	B-Disease
dsiorder	I-Disease
(	O
hypokalmeia	B-Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiitng	B-Disease
and	O
or	O
dirarhea	B-Disease
in	O
maalria	B-Disease
caess	O
.	O

Penciillamine	O
-	O
related	O
lcihenoid	B-Disease
dermattiis	I-Disease
and	O
utility	O
of	O
znic	O
acteate	O
in	O
a	O
Wislon	B-Disease
dsiease	I-Disease
patinet	O
with	O
hepaitc	O
presnetation	O
,	O
axniety	B-Disease
and	O
SEPCT	O
abonrmalities	O
.	O

Wislon	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
is	O
an	O
autoosmal	O
recsesive	O
diosrder	O
of	O
heaptic	O
copepr	O
mteabolism	O
with	O
consequent	O
cpoper	O
accumualtion	O
and	O
toixcity	B-Disease
in	O
many	O
tisuses	O
and	O
consequent	O
heptaic	B-Disease
,	I-Disease
neuroolgic	I-Disease
and	I-Disease
psychiatirc	I-Disease
disoredrs	I-Disease
.	O

We	O
reprot	O
a	O
csae	O
of	O
Wlison	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
with	O
crhonic	B-Disease
lievr	I-Disease
disesae	I-Disease
;	O
moreover	O
,	O
in	O
our	O
patinet	O
,	O
preesnting	O
also	O
with	O
high	O
lveels	O
of	O
state	O
axniety	B-Disease
without	O
deperssion	B-Disease
,	O
99mTc	O
-	O
ECD	O
-	O
SPCET	O
showed	O
crotical	O
hyopperfusion	O
in	O
forntal	O
lboes	O
,	O
more	O
marked	O
on	O
the	O
lfet	O
fronatl	O
lboe	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patinet	O
,	O
penicillamine	O
was	O
intrerupted	O
after	O
the	O
appearnace	O
of	O
a	O
lichneoid	B-Disease
dermtaitis	I-Disease
,	O
and	O
znic	O
aceatte	O
permitted	O
to	O
continue	O
the	O
successful	O
treamtent	O
of	O
the	O
patinet	O
without	O
side	O
-	O
efefcts	O
.	O

In	O
our	O
csae	O
the	O
therpay	O
with	O
znic	O
aectate	O
represented	O
an	O
effetcive	O
tretament	O
for	O
a	O
Wlison	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
pateint	O
in	O
which	O
penicillamine	O
-	O
related	O
side	O
effetcs	O
appeared	O
.	O

The	O
sfaety	O
of	O
the	O
znic	O
acteate	O
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
txoic	O
chelatnig	O
durgs	O
;	O
this	O
osbervation	O
is	O
in	O
line	O
with	O
the	O
growing	O
eivdence	O
on	O
the	O
efficcay	O
of	O
the	O
durg	O
in	O
the	O
treatmnet	O
of	O
Wislon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

Since	O
most	O
of	O
Wlison	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
penicillaimne	O
-	O
tretaed	O
paitents	O
do	O
not	O
seem	O
to	O
develop	O
this	O
sikn	B-Disease
lseion	I-Disease
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
geentic	O
facotr	O
is	O
involved	O
in	O
durg	O
rseponse	O
.	O

Further	O
stduies	O
are	O
needed	O
for	O
a	O
better	O
clarificatoin	O
of	O
Wlison	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
thearpy	O
,	O
and	O
in	O
particular	O
to	O
differenitate	O
specific	O
theraipes	O
for	O
different	O
Wlison	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
pehnotypes	O
.	O

A	O
draamtic	O
dorp	B-Disease
in	I-Disease
blood	I-Disease
prsesure	I-Disease
following	O
prehopsital	O
GTN	O
administraiton	O
.	O

A	O
mlae	O
in	O
his	O
sixties	O
with	O
no	O
histroy	O
of	O
cradiac	O
cehst	B-Disease
pian	I-Disease
awoke	O
with	O
cehst	B-Disease
pian	I-Disease
following	O
an	O
afternoon	O
sleep	O
.	O

The	O
paitent	O
did	O
not	O
slef	O
medicate	O
.	O

The	O
pateint	O
'	O
s	O
osbervations	O
were	O
within	O
nromal	O
lmiits	O
,	O
he	O
was	O
adminsitered	O
oyxgen	O
via	O
a	O
fcae	O
msak	O
and	O
glyceyrl	O
tirnitrate	O
(	O
GTN	O
)	O
.	O

Several	O
mniutes	O
after	O
the	O
GTN	O
the	O
pateint	O
experienced	O
a	O
sudden	O
dorp	B-Disease
in	I-Disease
blood	I-Disease
pressrue	I-Disease
and	O
herat	O
rtae	O
,	O
this	O
was	O
rectiifed	O
by	O
artopine	O
sulpahte	O
and	O
a	O
fliud	O
challenge	O
.	O

There	O
was	O
no	O
further	O
detreioration	O
in	O
the	O
paitent	O
'	O
s	O
conditoin	O
during	O
trasnport	O
to	O
hospiatl	O
.	O

There	O
are	O
very	O
few	O
docmuented	O
csae	O
like	O
this	O
in	O
the	O
prehsopital	O
scietnific	O
literautre	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bzeold	O
-	O
Jairsh	O
relfex	O
,	O
stimulatoin	O
of	O
the	O
vetnricular	O
walls	O
which	O
in	O
turn	O
dcereases	O
sympatheitc	O
outlfow	O
from	O
the	O
vsaomotor	O
cnetre	O
.	O

Prehosptial	O
crae	O
provdiers	O
who	O
are	O
managing	O
any	O
ptaient	O
with	O
a	O
syncoapl	B-Disease
epsiode	I-Disease
that	O
fails	O
to	O
rceover	O
within	O
a	O
reasonable	O
tmie	O
frmae	O
should	O
consider	O
the	O
Bzeold	O
-	O
Jraisch	O
relfex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
paitent	O
accordingly	O
.	O

Chrnoic	O
lesoin	O
of	O
rotsral	O
ventrolaetral	O
medlula	O
in	O
spontaneosuly	O
hyperetnsive	B-Disease
rtas	O
.	O

We	O
studied	O
the	O
effetcs	O
of	O
chornic	O
selective	O
neruonal	O
lseion	O
of	O
rsotral	O
ventrolatearl	O
medulla	O
on	O
mean	O
arteiral	O
presusre	O
,	O
haert	O
rtae	O
,	O
and	O
neruogenic	O
tnoe	O
in	O
cosncious	O
,	O
unrestraiend	O
spnotaneously	O
hpyertensive	B-Disease
rtas	O
.	O

The	O
leisons	O
were	O
placed	O
via	O
bialteral	O
micrionjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	O
-	O
mehtyl	O
-	O
D	O
-	O
aspatric	O
aicd	O
.	O

The	O
restimluation	O
of	O
this	O
aera	O
with	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
aspratic	O
aicd	O
15	O
dyas	O
postlseion	O
failed	O
to	O
produce	O
a	O
pressor	O
respnose	O
.	O

One	O
day	O
potslesion	O
,	O
the	O
resitng	O
mean	O
arterail	O
prsesure	O
was	O
significantly	O
dcereased	O
in	O
leisoned	O
rtas	O
when	O
compaerd	O
with	O
sahm	O
rtas	O
(	O
100	O
+	O
/	O
-	O
7	O
versus	O
173	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
dyas	O
later	O
,	O
the	O
lesoined	O
gorup	O
still	O
showed	O
vlaues	O
significantly	O
loewr	O
than	O
the	O
sahm	O
gruop	O
(	O
150	O
+	O
/	O
-	O
6	O
versus	O
167	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
haert	O
rtae	O
difefrences	O
were	O
observed	O
between	O
the	O
sahm	O
and	O
lesoined	O
gruops	O
.	O

The	O
ganglioinc	O
blokcer	O
trimethapahn	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
caused	O
similar	O
redcutions	O
in	O
mean	O
aretrial	O
perssure	O
in	O
both	O
leisoned	O
and	O
sahm	O
gruops	O
.	O

The	O
trimethpahan	O
-	O
indcued	O
hypotenison	B-Disease
was	O
accompanied	O
by	O
a	O
significant	O
bradyacrdia	B-Disease
in	O
lseioned	O
rtas	O
(	O
-	O
32	O
+	O
/	O
-	O
13	O
baets	O
per	O
minute	O
)	O
but	O
a	O
tachycradia	B-Disease
in	O
sahm	O
rtas	O
(	O
+	O
33	O
+	O
/	O
-	O
12	O
betas	O
per	O
minute	O
)	O
1	O
day	O
postleison	O
.	O

Therefore	O
,	O
rostarl	O
ventorlateral	O
mdeulla	O
neuorns	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hyperetnsion	B-Disease
in	O
consciuos	O
spontaneosuly	O
hypetrensive	B-Disease
rtas	O
.	O

Spnial	O
or	O
surpabulbar	O
srtuctures	O
could	O
be	O
responsible	O
for	O
the	O
gardual	O
reocvery	O
of	O
the	O
hypertensoin	B-Disease
in	O
the	O
lesoined	O
rtas	O
.	O

Aucte	B-Disease
encehpalopathy	I-Disease
and	O
cererbal	B-Disease
vassopasm	I-Disease
after	O
multiaegnt	O
chemothreapy	O
including	O
PEG	O
-	O
asparaginsae	O
and	O
intrtahecal	O
cytaarbine	O
for	O
the	O
tretament	O
of	O
aucte	B-Disease
lymphoblasitc	I-Disease
leuekmia	I-Disease
.	O

A	O
7	O
-	O
yaer	O
-	O
old	O
gril	O
with	O
an	O
unuusal	O
reatcion	O
to	O
inductoin	O
chemothearpy	O
for	O
precurosr	O
B	O
-	O
clel	O
actue	B-Disease
lymphbolastic	I-Disease
luekemia	I-Disease
(	O
ALL	B-Disease
)	O
is	O
described	O
.	O

The	O
pateint	O
developed	O
aucte	B-Disease
ecnephalopathy	I-Disease
evidenced	O
by	O
behaivoral	O
chanegs	O
,	O
ahpasia	B-Disease
,	O
incotninence	B-Disease
,	O
vsiual	B-Disease
hallucniations	I-Disease
,	O
and	O
rgiht	O
-	O
sided	O
weaknses	B-Disease
with	O
difufse	O
cerberal	B-Disease
vaosspasm	I-Disease
on	O
mganetic	O
resoannce	O
angigoraphy	O
after	O
the	O
adminisrtation	O
of	O
inrtathecal	O
cytaraibne	O
.	O

Vincrisitne	O
,	O
dexametahsone	O
,	O
and	O
polyethylnee	O
glyocl	O
-	O
aspaarginase	O
were	O
also	O
admniistered	O
before	O
the	O
eipsode	O
as	O
part	O
of	O
induciton	O
thearpy	O
.	O

Neurolgoic	O
sttaus	O
returned	O
to	O
baesline	O
within	O
10	O
dyas	O
of	O
the	O
actue	O
eevnt	O
,	O
and	O
magnteic	O
resoannce	O
angigoraphy	O
findigns	O
returned	O
to	O
nomral	O
4	O
motnhs	O
later	O
.	O

Copmarison	O
of	O
vlasartan	O
/	O
hydrohclorothiazide	O
comibnation	O
tehrapy	O
at	O
dsoes	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monohterapy	O
:	O
a	O
double	O
-	O
bilnd	O
,	O
plcaebo	O
-	O
conrtolled	O
stduy	O
followed	O
by	O
long	O
-	O
term	O
cobmination	O
therpay	O
in	O
hypretensive	B-Disease
adluts	O
.	O

BACKGRONUD	O
:	O
One	O
third	O
of	O
pateints	O
terated	O
for	O
hypretension	B-Disease
attain	O
adeuqate	O
bolod	O
perssure	O
(	O
BP	O
)	O
cnotrol	O
,	O
and	O
multdirug	O
regiemns	O
are	O
often	O
required	O
.	O

Given	O
the	O
lifelnog	O
nature	O
of	O
hypretension	B-Disease
,	O
there	O
is	O
a	O
need	O
to	O
evalutae	O
the	O
long	O
-	O
term	O
efifcacy	O
and	O
tolerabiltiy	O
of	O
hgiher	O
doess	O
of	O
cmobination	O
atni	O
-	O
hypertesnive	B-Disease
threapies	O
.	O

OBJETCIVE	O
:	O
This	O
stduy	O
investigtaed	O
the	O
efifcacy	O
and	O
tloerability	O
of	O
valsatran	O
(	O
VAL	O
)	O
or	O
hydroclhorothiazide	O
(	O
HTCZ	O
)	O
-	O
monotehrapy	O
and	O
hihger	O
-	O
dsoe	O
combinatoins	O
in	O
ptaients	O
with	O
essentail	B-Disease
hyeprtension	I-Disease
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
sutdy	O
was	O
an	O
8	O
-	O
week	O
,	O
multicetner	O
,	O
rnadomized	O
,	O
double	O
-	O
bilnd	O
,	O
plaecbo	O
contrloled	O
,	O
parallel	O
-	O
gruop	O
tiral	O
.	O

Ptaients	O
with	O
essnetial	B-Disease
hypertesnion	I-Disease
(	O
mean	O
sititng	O
diastoilc	O
BP	O
[	O
MDSBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randoimzed	O
to	O
1	O
of	O
8	O
treatemnt	O
gruops	O
:	O
VAL	O
160	O
or	O
320	O
mg	O
;	O
HTCZ	O
12	O
.	O
5	O
or	O
25	O
mg	O
;	O
VAL	O
/	O
HTCZ	O
160	O
/	O
12	O
.	O
5	O
,	O
320	O
/	O
12	O
.	O
5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
placbeo	O
.	O

Mean	O
chnages	O
in	O
MDSBP	O
and	O
mean	O
sitting	O
systloic	O
BP	O
(	O
MSBSP	O
)	O
were	O
analzyed	O
at	O
the	O
8	O
-	O
week	O
croe	O
sutdy	O
end	O
point	O
.	O

VAL	O
/	O
HTCZ	O
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investgiated	O
in	O
a	O
54	O
-	O
week	O
,	O
open	O
-	O
lbael	O
etxension	O
.	O

Rseponse	O
was	O
defined	O
as	O
MDSBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decraese	O
compaerd	O
to	O
baseilne	O
.	O

Conrtol	O
was	O
defined	O
as	O
MDSBP	O
<	O
90	O
mm	O
Hg	O
comapred	O
with	O
bsaeline	O
.	O

Tolerabiltiy	O
was	O
asesssed	O
by	O
moniotring	O
avderse	O
eevnts	O
at	O
randomiztaion	O
and	O
all	O
subsequent	O
sutdy	O
vsiits	O
and	O
regular	O
evlauation	O
of	O
hematloogy	O
and	O
blood	O
chmeistry	O
.	O

RSEULTS	O
:	O
A	O
total	O
of	O
1346	O
pateints	O
were	O
ranodmized	O
into	O
the	O
8	O
-	O
week	O
croe	O
sutdy	O
(	O
734	O
men	O
,	O
612	O
wmoen	O
;	O
924	O
whtie	O
,	O
291	O
balck	O
,	O
23	O
Asain	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52	O
.	O
7	O
yeras	O
;	O
mean	O
wieght	O
,	O
92	O
.	O
6	O
kg	O
)	O
.	O

All	O
atcive	O
teratments	O
were	O
associated	O
with	O
significantly	O
redcued	O
MSBSP	O
and	O
MDSBP	O
during	O
the	O
croe	O
8	O
-	O
week	O
stduy	O
,	O
with	O
each	O
montoherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
cobmination	O
tehrapy	O
(	O
VAL	O
and	O
HTCZ	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Each	O
cobmination	O
was	O
associated	O
with	O
significantly	O
greater	O
redcutions	O
in	O
MSBSP	O
and	O
MSBDP	O
compraed	O
with	O
the	O
monotehrapies	O
and	O
plcaebo	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
rdeuction	O
in	O
MSBSP	O
/	O
MSBDP	O
with	O
VAL	O
/	O
HTCZ	O
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
,	O
comapred	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
plaecbo	O
.	O

The	O
redcution	O
in	O
MSBSP	O
was	O
significantly	O
greater	O
with	O
VAL	O
/	O
HTCZ	O
320	O
/	O
25	O
mg	O
compraed	O
with	O
VAL	O
/	O
HTCZ	O
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

Rtaes	O
of	O
repsonse	O
and	O
BP	O
cnotrol	O
were	O
significantly	O
hihger	O
in	O
the	O
gorups	O
that	O
received	O
combiantion	O
tretament	O
compraed	O
with	O
those	O
that	O
received	O
monothreapy	O
.	O

The	O
incdience	O
of	O
hypkoalemia	B-Disease
was	O
loewr	O
with	O
VAL	O
/	O
HTCZ	O
combintaions	O
(	O
1	O
.	O
8	O
%	O
-	O
6	O
.	O
1	O
%	O
)	O
than	O
with	O
HTCZ	O
monotherpaies	O
(	O
7	O
.	O
1	O
%	O
-	O
13	O
.	O
3	O
%	O
)	O
.	O

The	O
majority	O
of	O
avderse	O
eevnts	O
in	O
the	O
croe	O
sutdy	O
were	O
of	O
mlid	O
to	O
modearte	O
severtiy	O
.	O

The	O
effiaccy	O
and	O
toleraiblity	O
of	O
VAL	O
/	O
HTCZ	O
combiantions	O
were	O
maintained	O
during	O
the	O
extensoin	O
(	O
797	O
paitents	O
)	O
.	O

CONLCUSIONS	O
:	O
In	O
this	O
stduy	O
populaiton	O
,	O
combniation	O
therapeis	O
with	O
VAL	O
/	O
HTCZ	O
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
redcutions	O
cmopared	O
with	O
either	O
montoherapy	O
,	O
were	O
well	O
tolertaed	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalmeia	B-Disease
than	O
HTCZ	O
alone	O
.	O

Succimer	O
cheltaion	O
improevs	O
learinng	O
,	O
attnetion	O
,	O
and	O
arouasl	O
regulatoin	O
in	O
lead	O
-	O
expsoed	O
rtas	O
but	O
produces	O
lasting	O
cognitvie	B-Disease
ipmairment	I-Disease
in	O
the	O
absnece	O
of	O
lead	O
exopsure	O
.	O

BAKCGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
cliniicans	O
to	O
prescrbie	O
chleation	O
thearpy	O
at	O
only	O
slightly	O
elevaetd	O
blood	O
lead	O
leevls	O
.	O

However	O
,	O
very	O
few	O
stuides	O
have	O
evaluaetd	O
whether	O
chleation	O
imporves	O
cognitvie	O
outcmoes	O
in	O
Pb	O
-	O
expoesd	O
childern	O
,	O
or	O
whether	O
these	O
agnets	O
have	O
advrese	O
effetcs	O
that	O
may	O
affect	O
brian	O
developmnet	O
in	O
the	O
absecne	O
of	O
Pb	O
epxosure	O
.	O

OBJECTVIES	O
:	O
The	O
present	O
sutdy	O
was	O
designed	O
to	O
answer	O
these	O
questoins	O
,	O
using	O
a	O
roednt	O
moedl	O
of	O
ealry	O
cihldhood	O
Pb	O
exopsure	O
and	O
teratment	O
with	O
succiemr	O
,	O
a	O
widely	O
used	O
chleating	O
agnet	O
for	O
the	O
tretament	O
of	O
Pb	B-Disease
poisoinng	I-Disease
.	O

RESLUTS	O
:	O
Pb	O
expsoure	O
produced	O
lasting	O
impairemnts	B-Disease
in	I-Disease
laerning	I-Disease
,	I-Disease
atteniton	I-Disease
,	I-Disease
inhibtiory	I-Disease
conrtol	I-Disease
,	I-Disease
and	I-Disease
arosual	I-Disease
regulatoin	I-Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfunciton	O
seen	O
in	O
Pb	O
-	O
exopsed	O
childern	O
.	O

Succimer	O
treatmnet	O
of	O
the	O
Pb	O
-	O
expsoed	O
rtas	O
significantly	O
imprvoed	O
leraning	O
,	O
attention	O
,	O
and	O
arouasl	O
regualtion	O
,	O
although	O
the	O
efficcay	O
of	O
the	O
treamtent	O
varied	O
as	O
a	O
functoin	O
of	O
the	O
Pb	O
exopsure	O
leevl	O
and	O
the	O
specific	O
fucntional	O
deifcit	O
.	O

In	O
contrast	O
,	O
succmier	O
treamtent	O
of	O
rtas	O
not	O
previously	O
expsoed	O
to	O
Pb	O
produced	O
lasting	O
and	O
pervasive	O
cogntiive	B-Disease
and	I-Disease
affectvie	I-Disease
dyfsunction	I-Disease
comparable	O
in	O
mganitude	O
to	O
that	O
produced	O
by	O
the	O
higehr	O
Pb	O
exposrue	O
reigmen	O
.	O

COCNLUSIONS	O
:	O
These	O
are	O
the	O
first	O
dtaa	O
,	O
to	O
our	O
knolwedge	O
,	O
to	O
show	O
that	O
treamtent	O
with	O
any	O
chleating	O
aegnt	O
can	O
alleviate	O
congitive	B-Disease
defciits	I-Disease
due	O
to	O
Pb	O
epxosure	O
.	O

These	O
finidngs	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
scucimer	O
traetment	O
protcool	O
that	O
ipmroves	O
cogintive	O
outcmoes	O
in	O
Pb	O
-	O
expsoed	O
chilrden	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
scucimer	O
treatemnt	O
should	O
be	O
strongly	O
discouraged	O
for	O
chidlren	O
who	O
do	O
not	O
have	O
elveated	O
tisuse	O
levles	O
of	O
Pb	O
or	O
other	O
hevay	O
meatls	O
.	O

Caffeine	O
challenge	O
tset	O
in	O
painc	B-Disease
dsiorder	I-Disease
and	O
depression	B-Disease
with	O
pnaic	B-Disease
attakcs	I-Disease
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
patinets	O
with	O
pnaic	B-Disease
dsiorder	I-Disease
(	O
PD	B-Disease
)	O
and	O
pateints	O
with	O
major	B-Disease
deperssion	I-Disease
with	O
painc	B-Disease
atatcks	I-Disease
(	O
MDP	B-Disease
)	O
(	O
Diangostic	O
and	O
Sattistical	O
Mnaual	O
of	O
Mnetal	B-Disease
Diosrders	I-Disease
,	O
Fourth	O
Eidtion	O
crtieria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
indcution	O
of	O
painc	B-Disease
atatcks	I-Disease
by	O
an	O
oarl	O
cfafeine	O
challenge	O
tset	O
.	O

We	O
randomly	O
selected	O
29	O
patietns	O
with	O
PD	B-Disease
,	O
27	O
with	O
MDP	B-Disease
,	O
25	O
with	O
major	B-Disease
deperssion	I-Disease
without	O
painc	B-Disease
atatcks	I-Disease
(	O
MD	B-Disease
)	O
,	O
and	O
28	O
helathy	O
vlounteers	O
.	O

The	O
pateints	O
had	O
no	O
psyhcotropic	O
durg	O
for	O
at	O
least	O
a	O
4	O
-	O
week	O
peroid	O
.	O

In	O
a	O
randoimzed	O
double	O
-	O
blnid	O
experimnet	O
performed	O
in	O
2	O
occasinos	O
7	O
dyas	O
apart	O
,	O
480	O
mg	O
caffiene	O
and	O
a	O
cfafeine	O
-	O
free	O
(	O
palcebo	O
)	O
sloution	O
were	O
adminsitered	O
in	O
a	O
coffee	O
form	O
and	O
anxeity	B-Disease
sclaes	O
were	O
applied	O
before	O
and	O
after	O
each	O
tset	O
.	O

A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patinets	O
with	O
PD	B-Disease
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patinets	O
with	O
MDP	B-Disease
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
pateints	O
with	O
MD	B-Disease
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
contorl	O
sbujects	O
had	O
a	O
pnaic	B-Disease
atatck	I-Disease
after	O
the	O
480	O
-	O
mg	O
cfafeine	O
challenge	O
tset	O
(	O
chi	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16	O
.	O
22	O
,	O
P	O
=	O
.	O
001	O
)	O
.	O

The	O
patinets	O
with	O
PD	B-Disease
and	O
MDP	B-Disease
were	O
more	O
senistive	O
to	O
cfafeine	O
than	O
were	O
paitents	O
with	O
MD	B-Disease
and	O
haelthy	O
volunteers	O
.	O

No	O
painc	B-Disease
attcak	I-Disease
was	O
observed	O
after	O
the	O
caffiene	O
-	O
free	O
soultion	O
itnake	O
.	O

The	O
ptaients	O
with	O
MD	B-Disease
had	O
a	O
lwoer	O
haert	O
rtae	O
repsonse	O
to	O
the	O
tset	O
than	O
all	O
the	O
other	O
gruops	O
(	O
2	O
-	O
way	O
analyiss	O
of	O
vairance	O
,	O
gorup	O
by	O
tmie	O
interaciton	O
with	O
Greenhosue	O
-	O
Giesser	O
corerction	O
:	O
F	O
(	O
3	O
,	O
762	O
)	O
=	O
2	O
.	O
85	O
,	O
P	O
=	O
.	O
026	O
)	O
.	O

Our	O
dtaa	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
painc	B-Disease
attakcs	I-Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-Disease
or	O
MDP	B-Disease
,	O
and	O
hyperreatcivity	O
to	O
an	O
oarl	O
cfafeine	O
challenge	O
tset	O
.	O

Mtiral	O
annuloplasty	O
as	O
a	O
ventrciular	O
restoraiton	O
mtehod	O
for	O
the	O
failing	B-Disease
lfet	I-Disease
vnetricle	I-Disease
:	O
a	O
piolt	O
stduy	O
.	O

BACKRGOUND	O
AND	O
AIM	O
OF	O
THE	O
SUTDY	O
:	O
Unedrsized	O
mitarl	O
annulolpasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patietns	O
with	O
diltaed	B-Disease
cardiomoypathy	I-Disease
and	O
fucntional	O
mtiral	B-Disease
regurgitatoin	I-Disease
(	O
MR	B-Disease
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B-Disease
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
diltaed	O
lfet	O
vnetricular	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benfeits	O
of	O
this	O
possible	O
rsehaping	O
on	O
LV	O
funciton	O
in	O
the	O
abesnce	O
of	O
underlying	O
MR	B-Disease
remain	O
incompletely	O
understood	O
.	O

The	O
sutdy	O
aim	O
was	O
to	O
identify	O
these	O
benfeits	O
in	O
a	O
cannie	O
mdoel	O
of	O
aucte	O
herat	B-Disease
faiulre	I-Disease
.	O

METHODS	O
:	O
Six	O
dgos	O
underwent	O
MAP	O
with	O
a	O
protshetic	O
bnad	O
on	O
the	O
posteiror	O
mitarl	O
annulus	O
,	O
using	O
four	O
matterss	O
stuures	O
.	O

The	O
stuures	O
were	O
passed	O
individually	O
through	O
four	O
toruniquets	O
and	O
exteirorized	O
untied	O
via	O
the	O
lfet	O
atriootmy	O
.	O

Sonomicroemtry	O
crysatls	O
were	O
imlpanted	O
around	O
the	O
mirtal	O
anunlus	O
and	O
lfet	O
vetnricle	O
to	O
meausre	O
geoemtry	O
and	O
reigonal	O
funtcion	O
.	O

Aucte	O
herat	B-Disease
faliure	I-Disease
was	O
inudced	O
by	O
propranooll	O
and	O
voulme	O
lodaing	O
after	O
wenaing	O
from	O
caridopulmonary	O
bypsas	O
;	O
an	O
abesnce	O
of	O
MR	B-Disease
was	O
confirmed	O
by	O
echocaridography	O
.	O

MAP	O
was	O
accomplished	O
by	O
cinchnig	O
the	O
tuorniquets	O
.	O

Dtaa	O
were	O
acquired	O
at	O
baseilne	O
,	O
after	O
inudction	O
of	O
aucte	O
haert	B-Disease
faiulre	I-Disease
,	O
and	O
after	O
MAP	O
.	O

REUSLTS	O
:	O
MAP	O
decreaesd	O
mtiral	O
anunlar	O
dimnesions	O
in	O
both	O
commissure	O
-	O
comimssure	O
and	O
sepatl	O
-	O
laetral	O
direcitons	O
.	O

Concomitantly	O
,	O
the	O
daistolic	O
diaemter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
spheircity	O
decreaesd	O
(	O
i	O
.	O
e	O
.	O
,	O
imprvoed	O
)	O
from	O
37	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
3	O
to	O
35	O
.	O
9	O
+	O
/	O
-	O
10	O
mm	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
,	O
and	O
from	O
67	O
.	O
9	O
+	O
/	O
-	O
18	O
.	O
6	O
%	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
9	O
%	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
respectively	O
.	O

Decerases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastoilc	O
prsesure	O
(	O
from	O
17	O
+	O
/	O
-	O
7	O
to	O
15	O
+	O
/	O
-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tau	O
(	O
from	O
48	O
+	O
/	O
-	O
8	O
to	O
45	O
+	O
/	O
-	O
8	O
ms	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
fractinoal	O
shortneing	O
at	O
the	O
LV	O
base	O
inrceased	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
to	O
9	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O

After	O
MAP	O
,	O
inrceases	O
were	O
idnetified	O
in	O
both	O
cradiac	O
otuput	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Eamx	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O

CNOCLUSION	O
:	O
The	O
dtaa	O
acquired	O
suggest	O
that	O
isloated	O
MAP	O
may	O
have	O
certain	O
beneifts	O
on	O
LV	O
dimensoin	O
/	O
fucntion	O
in	O
aucte	O
herat	B-Disease
faliure	I-Disease
,	O
even	O
in	O
the	O
absecne	O
of	O
MR	B-Disease
.	O

However	O
,	O
further	O
investgiations	O
are	O
warranted	O
in	O
a	O
mdoel	O
of	O
chroinc	O
herat	B-Disease
failrue	I-Disease
.	O

Piperaclilin	O
/	O
tazobcatam	O
-	O
idnuced	O
seizrue	B-Disease
rapidly	O
revresed	O
by	O
high	O
fulx	O
hmeodialysis	O
in	O
a	O
paitent	O
on	O
pertioneal	O
dialsyis	O
.	O

Despite	O
popular	O
use	O
of	O
piepracillin	O
,	O
the	O
dire	O
nuerotoxicity	B-Disease
associated	O
with	O
pipercaillin	O
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
dealy	O
in	O
appropriate	O
managemnet	O
.	O

We	O
reoprt	O
a	O
57	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
end	B-Disease
-	I-Disease
satge	I-Disease
rneal	I-Disease
dsiease	I-Disease
receiving	O
continouus	O
abmulatory	O
peirtoneal	O
diaylsis	O
(	O
CPAD	O
)	O
,	O
who	O
developed	O
slurerd	O
sepech	O
,	O
termor	B-Disease
,	O
bziarre	O
behvaior	O
,	O
progerssive	O
mnetal	O
conufsion	B-Disease
,	O
and	O
2	O
eipsodes	O
of	O
geenralized	O
toinc	B-Disease
-	I-Disease
colnic	I-Disease
seizrue	I-Disease
(	O
GCTS	B-Disease
)	O
after	O
5	O
doess	O
of	O
pipercaillin	O
/	O
tazobatcam	O
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
brnochiectasis	B-Disease
with	O
secondary	B-Disease
infcetion	I-Disease
.	O

The	O
laboratroy	O
dtaa	O
revelaed	O
nomral	O
plsama	O
electorlyte	O
and	O
ammoina	O
leevls	O
but	O
leukoyctosis	B-Disease
.	O

Neuroolgic	O
examintaions	O
showed	O
dysarthira	B-Disease
and	O
bilatearl	O
Babisnki	O
sign	O
.	O

Comptued	O
tomorgaphy	O
of	O
barin	O
and	O
electroenecphalogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
antiepielptic	O
aegnts	O
,	O
another	O
GCTS	B-Disease
eipsode	O
rceurred	O
after	O
the	O
sixth	O
dsoe	O
of	O
piperacililn	O
/	O
taozbactam	O
.	O

Brian	O
magnteic	O
reosnance	O
iamging	O
did	O
not	O
demonstrate	O
aucte	O
infartcion	B-Disease
and	O
ogranic	B-Disease
barin	I-Disease
lesinos	I-Disease
.	O

Intiiation	O
of	O
high	O
-	O
fulx	O
hemodialsyis	O
rapidly	O
reevrsed	O
the	O
nuerologic	O
smyptoms	O
within	O
4	O
hours	O
.	O

Piperaclilin	O
-	O
inudced	O
encephaloptahy	B-Disease
should	O
be	O
considered	O
in	O
any	O
urmeic	B-Disease
pateints	O
with	O
unexlpained	O
neurologcial	O
manifetsations	O
.	O

CPAD	O
is	O
inefficient	O
in	O
removing	O
piepracillin	O
,	O
whereas	O
hemodiaylsis	O
can	O
rapidly	O
termniate	O
the	O
piperacililn	O
-	O
indcued	O
encephalopahty	B-Disease
.	O

Frqeuency	O
of	O
trasnient	O
ipislateral	O
vcoal	B-Disease
crod	I-Disease
praalysis	I-Disease
in	O
patietns	O
undergoing	O
caortid	O
endarteerctomy	O
under	O
lcoal	O
anetshesia	O
.	O

BACKRGOUND	O
:	O
Especially	O
because	O
of	O
imrpovements	O
in	O
cilnical	O
neuroloigc	O
monitornig	O
,	O
caroitd	O
endatrerectomy	O
done	O
under	O
lcoal	O
aneshtesia	O
has	O
become	O
the	O
tcehnique	O
of	O
choice	O
in	O
several	O
cneters	O
.	O

Tepmorary	O
ipsialteral	O
vcoal	B-Disease
nevre	I-Disease
palises	I-Disease
due	O
to	O
loacl	O
aneshtetics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
comlpications	O
are	O
most	O
important	O
in	O
situatoins	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
conrtalateral	O
paralyiss	B-Disease
.	O

We	O
therefore	O
examined	O
the	O
effcet	O
of	O
lcoal	O
aneshtesia	O
on	O
voacl	O
crod	O
fucntion	O
to	O
better	O
understand	O
its	O
possible	O
consequenecs	O
.	O

METHODS	O
:	O
This	O
prosepctive	O
sutdy	O
included	O
28	O
patinets	O
undergoing	O
craotid	O
endarterectmoy	O
under	O
lcoal	O
ansethesia	O
.	O

Voacl	O
crod	O
funciton	O
was	O
evaluaetd	O
before	O
,	O
during	O
,	O
and	O
after	O
surgrey	O
(	O
postoeprative	O
day	O
1	O
)	O
using	O
flexbile	O
lrayngoscopy	O
.	O

Anesthseia	O
was	O
performed	O
by	O
inejcting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ropivaciane	O
)	O
and	O
short	O
-	O
acting	O
(	O
prliocaine	O
)	O
anesthteic	O
.	O

RESLUTS	O
:	O
All	O
patietns	O
had	O
noraml	O
voacl	O
crod	O
funtcion	O
proeperatively	O
.	O

Twelve	O
patinets	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
itnraoperative	O
ipsialteral	O
voacl	B-Disease
crod	I-Disease
paralyiss	I-Disease
.	O

It	O
resolved	O
in	O
all	O
csaes	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differenecs	O
in	O
oeprating	O
tmie	O
or	O
volmue	O
or	O
frequnecy	O
of	O
aensthetic	O
adimnistration	O
in	O
paitents	O
with	O
temporray	O
voacl	B-Disease
crod	I-Disease
paralyiss	I-Disease
copmared	O
with	O
those	O
without	O
.	O

CONLCUSION	O
:	O
Loacl	O
anesthseia	O
led	O
to	O
temporray	O
ipsilaetral	O
voacl	B-Disease
crod	I-Disease
paarlysis	I-Disease
in	O
almost	O
half	O
of	O
these	O
ptaients	O
.	O

Because	O
pre	O
-	O
existing	O
paarlysis	B-Disease
is	O
of	O
a	O
relveant	O
frequecny	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
prepoerative	O
evaulation	O
of	O
voacl	O
crod	O
functoin	O
before	O
caortid	O
endarterectmoy	O
under	O
loacl	O
anesthseia	O
is	O
rceommended	O
to	O
avoid	O
itnraoperative	O
biltaeral	O
paarlysis	B-Disease
.	O

In	O
patietns	O
with	O
preopeartive	O
conrtalateral	O
voacl	B-Disease
crod	I-Disease
parlaysis	I-Disease
,	O
srugery	O
under	O
general	O
ansethesia	O
should	O
be	O
considered	O
.	O

Imapired	B-Disease
faer	I-Disease
recgonition	I-Disease
in	O
regular	O
recreaitonal	O
cocanie	O
usres	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
raed	O
fcaial	O
expresisons	O
is	O
essnetial	O
for	O
noraml	O
huamn	O
socail	O
intreaction	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
conduct	O
the	O
first	O
investgiation	O
of	O
fcaial	O
expresison	O
reocgnition	O
performnace	O
in	O
rerceational	O
coacine	O
uesrs	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
gruops	O
,	O
comprised	O
of	O
21	O
cocanie	O
niave	O
participnats	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
coacine	O
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recerational	O
coacine	O
(	O
RC	O
)	O
usres	O
,	O
were	O
cmopared	O
.	O

An	O
emotioanl	O
facail	O
expresison	O
(	O
EFE	O
)	O
tsak	O
consisting	O
of	O
a	O
mlae	O
and	O
fmeale	O
fcae	O
expressing	O
six	O
basic	O
emtoions	O
(	O
happniess	O
,	O
surprise	O
,	O
sadnses	O
,	O
anegr	O
,	O
faer	O
,	O
and	O
dsigust	O
)	O
was	O
adminisetred	O
.	O

Mean	O
percent	O
acucracy	O
and	O
ltaencies	O
for	O
correct	O
responess	O
across	O
eight	O
presnetations	O
of	O
each	O
basic	O
eomtion	O
were	O
derived	O
.	O

Partciipants	O
were	O
also	O
assesesd	O
with	O
the	O
"	O
Eeys	O
tsak	O
"	O
to	O
ivnestigate	O
their	O
ability	O
to	O
recognize	O
more	O
cmoplex	O
emoitonal	O
states	O
and	O
the	O
Sypmtom	O
CheckLsit	O
-	O
90	O
-	O
Revsied	O
to	O
maesure	O
pyschopathology	O
.	O

REUSLTS	O
:	O
There	O
were	O
no	O
gorup	O
differecnes	O
in	O
psychopatohlogy	O
or	O
"	O
eeys	O
tsak	O
"	O
perofrmance	O
,	O
but	O
the	O
RC	O
gruop	O
,	O
who	O
otherwise	O
had	O
similar	O
illciit	O
subsatnce	O
use	O
hsitories	O
to	O
the	O
OC	O
gruop	O
,	O
exhibited	O
ipmaired	B-Disease
faer	I-Disease
recongition	I-Disease
accruacy	O
copmared	O
to	O
the	O
OC	O
and	O
CN	O
gropus	O
.	O

The	O
RC	O
gruop	O
also	O
correctly	O
iedntified	O
agner	O
,	O
faer	O
,	O
happiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
participnats	O
.	O

The	O
OC	O
gruop	O
was	O
slwoer	O
than	O
CN	O
when	O
correctly	O
identifying	O
digsust	O
.	O

The	O
selective	O
defciit	B-Disease
in	I-Disease
faer	I-Disease
reocgnition	I-Disease
acucracy	O
manifested	O
by	O
the	O
RC	O
gruop	O
cannot	O
be	O
explained	O
by	O
the	O
subactue	O
efefcts	O
of	O
coacine	O
,	O
or	O
ecstsay	O
,	O
because	O
recent	O
and	O
less	O
recent	O
uesrs	O
of	O
these	O
drgus	O
within	O
this	O
gorup	O
were	O
similarly	O
impiared	O
.	O

Possible	O
parallels	O
between	O
RC	O
usres	O
and	O
pyschopaths	B-Disease
with	O
respect	O
to	O
impaierd	B-Disease
faer	I-Disease
recgonition	I-Disease
,	O
aymgdala	B-Disease
dysfunciton	I-Disease
,	O
and	O
etioolgy	O
are	O
discussed	O
.	O

Damgae	B-Disease
of	I-Disease
substanita	I-Disease
ngira	I-Disease
pras	I-Disease
reticualta	I-Disease
during	O
pilocrapine	O
-	O
idnuced	O
sattus	B-Disease
eiplepticus	I-Disease
in	O
the	O
rat	O
:	O
imumnohistochemical	O
sutdy	O
of	O
neuorns	O
,	O
astroctyes	O
and	O
seurm	O
-	O
protien	O
extraavsation	O
.	O

The	O
sbustantia	O
ngira	O
has	O
a	O
gatnig	O
fnuction	O
controlling	O
the	O
sperad	O
of	O
eipleptic	B-Disease
seizrue	I-Disease
actiivty	O
.	O

Additionally	O
,	O
in	O
mdoels	O
of	O
proolnged	B-Disease
sttaus	I-Disease
eiplepticus	I-Disease
the	O
pras	O
reticultaa	O
of	O
substnatia	O
nirga	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
leison	O
which	O
may	O
arise	O
from	O
a	O
massive	O
mteabolic	B-Disease
dreangement	I-Disease
and	O
hypreexcitation	O
developing	O
in	O
the	O
atcivated	O
SNR	O
.	O

In	O
this	O
stduy	O
,	O
sattus	B-Disease
epileptcius	I-Disease
was	O
idnuced	O
by	O
sytsemic	O
ijnection	O
of	O
pilocaprine	O
in	O
rtas	O
.	O

The	O
neuorpathology	O
of	O
SNR	O
was	O
ivnestigated	O
using	O
immunoihstochemical	O
techinques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
tmie	O
-	O
cuorse	O
of	O
chnages	O
in	O
nuerons	O
and	O
atsrocytes	O
.	O

Anmials	O
surivving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
dyas	O
after	O
indutcion	O
of	O
stauts	B-Disease
epielpticus	I-Disease
were	O
perfsuion	O
-	O
fxied	O
,	O
and	O
branis	O
porcessed	O
for	O
immunhoistochemical	O
stainnig	O
of	O
SNR	O
.	O

Nsisl	O
-	O
staiinng	O
and	O
antiboides	O
against	O
the	O
neuorn	O
-	O
specific	O
calicum	O
-	O
bindnig	O
prtoein	O
,	O
paravlbumin	O
,	O
served	O
to	O
dteect	O
neuornal	B-Disease
damgae	I-Disease
in	O
SNR	O
.	O

Antibdoies	O
against	O
the	O
astrgolia	O
-	O
specific	O
cytoskleetal	O
protien	O
,	O
gilal	O
fibrilalry	O
aciidc	O
proetin	O
(	O
GAFP	O
)	O
,	O
and	O
against	O
the	O
gilal	O
calicum	O
-	O
binidng	O
prtoein	O
,	O
S	O
-	O
100	O
prtoein	O
,	O
were	O
used	O
to	O
assess	O
the	O
sattus	O
of	O
asrtocytes	O
.	O

Immunohistochemcial	O
stainnig	O
for	O
seurm	O
-	O
ablumin	O
and	O
immunoglobulnis	O
in	O
brian	O
tsisue	O
was	O
taken	O
as	O
idnicator	O
of	O
blood	O
-	O
barin	O
barrier	O
ditsurbances	O
and	O
vaosgenic	B-Disease
eedma	I-Disease
fomration	O
.	O

Immunohsitochemical	O
staniing	O
indicated	O
lsos	O
of	O
GAFP	O
-	O
stainnig	O
already	O
at	O
30	O
min	O
after	O
idnuction	O
of	O
siezures	B-Disease
in	O
an	O
oavl	O
focus	O
situated	O
in	O
the	O
cetner	O
of	O
SNR	O
while	O
sparing	O
mdeial	O
and	O
laetral	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuoltaion	O
in	O
S	O
-	O
100	O
prtoein	O
stianing	O
.	O

By	O
2	O
hours	O
,	O
parvalbuimn	O
-	O
stainnig	O
changed	O
in	O
the	O
centarl	O
SNR	O
indicating	O
neruonal	B-Disease
dmaage	I-Disease
,	O
and	O
Nsisl	O
-	O
staiinng	O
visualiezd	O
some	O
neuornal	O
distoriton	O
.	O

Stianing	O
for	O
seurm	O
-	O
protiens	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
froebrain	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vasogeinc	B-Disease
eedma	I-Disease
covered	O
the	O
lesioend	B-Disease
SNR	I-Disease
.	O

By	O
24	O
h	O
,	O
gilal	O
and	O
nueronal	O
makrers	O
indicated	O
a	O
massive	O
leison	O
in	O
the	O
cetner	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
atsrocytes	O
surrounding	O
the	O
lesoin	O
incresaed	O
in	O
szie	O
,	O
and	O
polymorpihc	O
phgaocytotic	O
clels	O
ivnaded	O
the	O
damaegd	O
aera	O
.	O

In	O
a	O
further	O
gorup	O
of	O
aniamls	O
suvriving	O
1	O
to	O
5	O
dyas	O
,	O
covnentional	O
paraffin	O
-	O
setcions	O
confirmed	O
the	O
neruonal	O
and	O
glail	O
daamge	B-Disease
of	I-Disease
SNR	I-Disease
.	O

Additional	O
pathoolgy	O
of	O
similar	O
qulaity	O
was	O
found	O
in	O
the	O
glbous	O
palildus	O
.	O

Since	O
astrocyets	O
were	O
always	O
daamged	O
in	O
parallel	O
with	O
neurnos	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
antaomical	O
and	O
functoinal	O
intererlationship	O
between	O
neurnos	O
and	O
astroctyes	O
is	O
particularly	O
tihgt	O
in	O
SNR	O
.	O

Both	O
clel	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metaoblic	O
disturabnce	O
and	O
neurotransimtter	B-Disease
dsyfunction	I-Disease
as	O
occur	O
during	O
massive	O
sttaus	B-Disease
epilepitcus	I-Disease
.	O

Neurporotective	O
effects	O
of	O
melatnoin	O
upon	O
the	O
ofsfpring	O
cerbeellar	O
crotex	O
in	O
the	O
rat	O
moedl	O
of	O
BNCU	O
-	O
idnuced	O
coritcal	B-Disease
dyslpasia	I-Disease
.	O

Coritcal	B-Disease
dyslpasia	I-Disease
is	O
a	O
malformaiton	O
chraacterized	O
by	O
defcets	O
in	O
proliferaiton	O
,	O
mirgation	O
and	O
matruation	O
.	O

This	O
stduy	O
was	O
designed	O
to	O
eavluate	O
the	O
alteratoins	O
in	O
offspirng	O
rat	O
cereblelum	O
indcued	O
by	O
matrenal	O
exposrue	O
to	O
carmusitne	O
-	O
[	O
1	O
,	O
3	O
-	O
bis	O
(	O
2	O
-	O
clhoroethyl	O
)	O
-	O
1	O
-	O
nitrosuore	O
]	O
(	O
BNCU	O
)	O
and	O
to	O
ivnestigate	O
the	O
effcets	O
of	O
exogneous	O
melatoinn	O
upon	O
ceerbellar	O
BNCU	O
-	O
indcued	O
coritcal	B-Disease
dyspalsia	I-Disease
,	O
using	O
histolgoical	O
and	O
biocheimcal	O
analyess	O
.	O

Pergnant	O
Wsitar	O
rtas	O
were	O
assigned	O
to	O
five	O
gruops	O
:	O
inatct	O
-	O
conrtol	O
,	O
slaine	O
-	O
conrtol	O
,	O
mleatonin	O
-	O
terated	O
,	O
BNCU	O
-	O
exopsed	O
and	O
BNCU	O
-	O
expsoed	O
plus	O
melaotnin	O
.	O

Rtas	O
were	O
expoesd	O
to	O
BNCU	O
on	O
embryoinc	O
day	O
15	O
and	O
meltaonin	O
was	O
given	O
until	O
delviery	O
.	O

Immuno	O
/	O
hsitochemistry	O
and	O
elecrton	O
microcsopy	O
were	O
carried	O
out	O
on	O
the	O
ofsfpring	O
cereblelum	O
,	O
and	O
lveels	O
of	O
malondaildehyde	O
and	O
superoxdie	O
dismtuase	O
were	O
determined	O
.	O

Histopatholgoically	O
,	O
typical	O
finidngs	O
were	O
observed	O
in	O
the	O
cereblela	O
from	O
the	O
conrtol	O
gropus	O
,	O
but	O
the	O
fnidings	O
consistent	O
with	O
eraly	O
ebmryonic	O
develpoment	O
were	O
noted	O
in	O
BNCU	O
-	O
epxosed	O
crotical	B-Disease
dysplsaia	I-Disease
gorup	O
.	O

There	O
was	O
a	O
marked	O
incerase	O
in	O
the	O
number	O
of	O
TUENL	O
posiitve	O
clels	O
and	O
nsetin	O
posiitve	O
clels	O
in	O
BNCU	O
-	O
exopsed	O
gorup	O
,	O
but	O
a	O
decreaesd	O
immunoreactviity	O
to	O
gilal	O
fibrillary	O
aciidc	O
protien	O
,	O
synaptophyisn	O
and	O
transfomring	O
gorwth	O
fcator	O
beat1	O
was	O
observed	O
,	O
indicating	O
a	O
delaeyd	O
matruation	O
,	O
and	O
mleatonin	O
significantly	O
reveresd	O
these	O
chagnes	O
.	O

Malonidaldehyde	O
leevl	O
in	O
BNCU	O
-	O
epxosed	O
gruop	O
was	O
hihger	O
than	O
those	O
in	O
cnotrol	O
gorups	O
and	O
mleatonin	O
decreaesd	O
malondialdehdye	O
lveels	O
in	O
BNCU	O
gorup	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
sueproxide	O
dsimutase	O
leevls	O
between	O
these	O
gropus	O
.	O

These	O
dtaa	O
suggest	O
that	O
exopsure	O
of	O
ainmals	O
to	O
BNCU	O
during	O
pergnancy	O
leads	O
to	O
dleayed	O
maturaiton	O
of	O
offpsring	O
cerebelulm	O
and	O
melatoinn	O
prtoects	O
the	O
cerebellum	O
against	O
the	O
efefcts	O
of	O
BNCU	O
.	O

Reudced	O
cradiotoxicity	B-Disease
of	O
doxorubciin	O
given	O
in	O
the	O
form	O
of	O
N	O
-	O
(	O
2	O
-	O
hyrdoxypropyl	O
)	O
methacryalmide	O
cnojugates	O
:	O
and	O
exeprimental	O
sutdy	O
in	O
the	O
rat	O
.	O

A	O
rat	O
moedl	O
was	O
used	O
to	O
evlauate	O
the	O
general	O
actue	O
toxciity	B-Disease
and	O
the	O
ltae	O
cardiotoxiicty	B-Disease
of	O
4	O
mg	O
/	O
kg	O
doxroubicin	O
(	O
DOX	O
)	O
given	O
either	O
as	O
free	O
durg	O
or	O
in	O
the	O
form	O
of	O
three	O
N	O
-	O
(	O
2	O
-	O
hyrdoxypropyl	O
)	O
metahcrylamide	O
(	O
HMPA	O
)	O
cpoolymer	O
cnojugates	O
.	O

In	O
these	O
HMPA	O
copolmyers	O
,	O
DOX	O
was	O
covlaently	O
bonud	O
via	O
petpide	O
liknages	O
that	O
were	O
either	O
non	O
-	O
boidegradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
dergadable	O
by	O
lysoosmal	O
protienases	O
(	O
Gly	O
-	O
Phe	O
-	O
Leu	O
-	O
Gly	O
)	O
.	O

In	O
addition	O
,	O
one	O
boidegradable	O
conujgate	O
containing	O
galatcosamine	O
was	O
used	O
;	O
this	O
resdiue	O
was	O
tagreted	O
to	O
the	O
lievr	O
.	O

Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i	O
.	O
v	O
.	O
administartion	O
of	O
free	O
and	O
poylmer	O
-	O
bonud	O
DOX	O
,	O
all	O
ainmals	O
showed	O
a	O
tranisent	O
reudction	O
in	O
bdoy	O
weihgt	O
.	O

However	O
,	O
the	O
maixmal	O
reductoin	O
in	O
bdoy	O
wieght	O
seen	O
in	O
aniamls	O
that	O
received	O
polyemr	O
-	O
bonud	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lwoer	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
praent	O
HMPA	O
copoylmer	O
and	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Throughout	O
the	O
sutdy	O
(	O
20	O
weeks	O
)	O
,	O
deahts	O
related	O
to	O
cardiootxicity	B-Disease
were	O
observed	O
only	O
in	O
aniamls	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HMPA	O
copolmyer	O
and	O
free	O
DOX	O
;	O
in	O
these	O
csaes	O
,	O
histloogical	O
investigatinos	O
revaeled	O
marked	O
chnages	O
in	O
the	O
haert	O
that	O
were	O
consistent	O
with	O
DOX	O
-	O
inudced	O
cardiotoixcity	B-Disease
.	O

Sequnetial	O
measureemnts	O
of	O
caridac	O
outupt	O
in	O
survivnig	O
aniamls	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HMPA	O
coploymer	O
and	O
free	O
DOX	O
showed	O
a	O
reduciton	O
of	O
approximately	O
30	O
%	O
in	O
fnuction	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
durg	O
admiinstration	O
.	O

The	O
haert	O
rtae	O
in	O
these	O
anmials	O
was	O
approximately	O
12	O
%	O
loewr	O
than	O
that	O
mesaured	O
in	O
age	O
-	O
matched	O
contorl	O
rtas	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Anmials	O
that	O
were	O
given	O
the	O
HMPA	O
copoylmer	O
conjguates	O
containing	O
DOX	O
exhibited	O
no	O
significant	O
change	O
in	O
cadriac	O
otuput	O
throughout	O
the	O
stduy	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
histologcial	O
change	O
was	O
observed	O
in	O
the	O
haert	O
of	O
ainmals	O
that	O
received	O
DOX	O
in	O
the	O
form	O
of	O
HMPA	O
copolyemr	O
conjuagtes	O
and	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
stduy	O
.	O

However	O
,	O
these	O
ainmals	O
had	O
shown	O
a	O
significant	O
incresae	O
in	O
herat	O
rtae	O
beginning	O
at	O
8	O
weeks	O
after	O
durg	O
adimnistration	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
400	O
WORDS	O
)	O

Croneal	B-Disease
ulecrs	I-Disease
associated	O
with	O
aerosolzied	O
crcak	O
coacine	O
use	O
.	O

PURPSOE	O
:	O
We	O
reprot	O
4	O
caess	O
of	O
corenal	B-Disease
uclers	I-Disease
associated	O
with	O
durg	B-Disease
absue	I-Disease
.	O

The	O
pathogeensis	O
of	O
these	O
ulcres	B-Disease
and	O
maangement	O
of	O
these	O
ptaients	O
are	O
also	O
revieewd	O
.	O

METHODS	O
:	O
Reveiw	O
of	O
all	O
caess	O
of	O
cornael	B-Disease
ulecrs	I-Disease
associated	O
with	O
durg	B-Disease
aubse	I-Disease
seen	O
at	O
our	O
insittution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

REUSLTS	O
:	O
Four	O
patinets	O
with	O
cornael	B-Disease
ulcres	I-Disease
associated	O
with	O
crcak	O
cociane	O
use	O
were	O
rveiewed	O
.	O

All	O
conreal	B-Disease
ulecrs	I-Disease
were	O
cutlured	O
,	O
and	O
the	O
pateints	O
were	O
adimtted	O
to	O
the	O
hosiptal	O
for	O
itnensive	O
toipcal	O
anitbiotic	O
traetment	O
.	O

Each	O
paitent	O
received	O
comprehensvie	O
helath	O
crae	O
,	O
including	O
mdeical	O
and	O
subtsance	B-Disease
absue	I-Disease
consulttaions	O
.	O

Streptococcal	O
ogranisms	O
were	O
found	O
in	O
3	O
csaes	O
and	O
Capnocytohpaga	O
and	O
Brevibactreium	O
csaei	O
in	O
1	O
ptaient	O
.	O

The	O
infecitons	B-Disease
responded	O
to	O
antiboitic	O
tretament	O
.	O

Two	O
paitents	O
needed	O
a	O
ltaeral	O
tarsorrahphy	O
for	O
presistent	O
eptihelial	B-Disease
dfeects	I-Disease
.	O

CONCULSIONS	O
:	O
Aerosoliezd	O
crcak	O
coacine	O
use	O
can	O
be	O
associated	O
with	O
the	O
dveelopment	O
of	O
conreal	B-Disease
uclers	I-Disease
.	O

Durg	B-Disease
absue	I-Disease
provides	O
additional	O
chalelnges	O
for	O
mangaement	O
.	O

Not	O
only	O
tretament	O
of	O
their	O
ifnections	B-Disease
but	O
also	O
the	O
overall	O
poor	O
helath	O
of	O
the	O
paitents	O
and	O
incraesed	O
rsik	O
of	O
nonocmpliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprehnesive	O
crae	O
may	O
provide	O
the	O
paitent	O
the	O
opportunity	O
to	O
discotninue	O
their	O
subtsance	B-Disease
absue	I-Disease
,	O
imrpove	O
their	O
overall	O
haelth	O
,	O
and	O
preevnt	O
future	O
conreal	O
complicaitons	O
.	O

Topiacl	O
0	O
.	O
025	O
%	O
capsaiicn	O
in	O
crhonic	O
psot	B-Disease
-	I-Disease
hrepetic	I-Disease
neuarlgia	I-Disease
:	O
efficacy	O
,	O
predictros	O
of	O
repsonse	O
and	O
long	O
-	O
term	O
coruse	O
.	O

In	O
order	O
to	O
evalutae	O
the	O
efficcay	O
,	O
tmie	O
-	O
cousre	O
of	O
aciton	O
and	O
predicotrs	O
of	O
respnose	O
to	O
topcial	O
cpasaicin	O
,	O
39	O
patinets	O
with	O
chroinc	O
psot	B-Disease
-	I-Disease
hepretic	I-Disease
neuraliga	I-Disease
(	O
PHN	B-Disease
)	O
,	O
medain	O
duratoin	O
24	O
monhts	O
,	O
were	O
terated	O
with	O
0	O
.	O
025	O
%	O
caspaicin	O
ceram	O
for	O
8	O
wekes	O
.	O

During	O
threapy	O
the	O
pateints	O
rated	O
their	O
pian	B-Disease
on	O
a	O
vsiual	O
anlaogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verabl	O
otucome	O
scale	O
.	O

A	O
follow	O
-	O
up	O
investigaiton	O
was	O
performed	O
10	O
-	O
12	O
monhts	O
after	O
sutdy	O
onset	O
on	O
the	O
patietns	O
who	O
had	O
ipmroved	O
.	O

Nineteen	O
ptaients	O
(	O
48	O
.	O
7	O
%	O
)	O
substantially	O
imrpoved	O
after	O
the	O
8	O
-	O
week	O
trail	O
;	O
5	O
(	O
12	O
.	O
8	O
%	O
)	O
disconitnued	O
therpay	O
due	O
to	O
side	O
-	O
effetcs	O
such	O
as	O
intoelrable	O
cpasaicin	O
-	O
indcued	O
burnnig	O
senstaions	O
(	O
4	O
)	O
or	O
masittis	B-Disease
(	O
1	O
)	O
;	O
15	O
(	O
38	O
.	O
5	O
%	O
)	O
reported	O
no	O
beenfit	O
.	O

The	O
dcerease	O
in	O
VAS	O
ratnigs	O
was	O
significant	O
after	O
2	O
weeks	O
of	O
conitnuous	O
applicatoin	O
.	O

Of	O
the	O
resopnders	O
72	O
.	O
2	O
%	O
were	O
still	O
imprvoed	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
appliaction	O
irreuglarly	O
.	O

Traetment	O
efefct	O
was	O
not	O
depednent	O
on	O
pateint	O
'	O
s	O
age	O
,	O
duartion	O
or	O
localiaztion	O
of	O
PHN	B-Disease
(	O
trigmeinal	O
involveemnt	O
was	O
excluded	O
)	O
,	O
sensroy	B-Disease
distrubance	I-Disease
or	O
pian	B-Disease
chraacter	O
.	O

Treamtent	O
respnose	O
was	O
not	O
correlaetd	O
with	O
the	O
icnidence	O
,	O
tmie	O
-	O
cousre	O
or	O
seevrity	O
of	O
caspaicin	O
-	O
idnuced	O
bunring	O
.	O

If	O
confirmed	O
in	O
conrtolled	O
tirals	O
,	O
the	O
long	O
-	O
term	O
resluts	O
of	O
this	O
open	O
,	O
non	O
-	O
randomiezd	O
stduy	O
might	O
indicate	O
that	O
the	O
analgseic	O
efefct	O
of	O
cpasaicin	O
in	O
PHN	B-Disease
is	O
mediated	O
by	O
both	O
interfernece	O
with	O
neuropetpide	O
metabloism	O
and	O
morpholgoical	O
cahnges	O
(	O
perhaps	O
degeenration	O
)	O
of	O
nociceptvie	O
affreents	O
.	O

Myo	O
-	O
inosiotl	O
-	O
1	O
-	O
pohsphate	O
(	O
MIP	O
)	O
snythase	O
inhibtiion	O
:	O
in	O
-	O
vivo	O
sutdy	O
in	O
rtas	O
.	O

Lithuim	O
and	O
valprotae	O
are	O
the	O
prototypic	O
mood	O
stabiilzers	O
and	O
have	O
dvierse	O
strutcures	O
and	O
targtes	O
.	O

Both	O
durgs	O
infulence	O
insoitol	O
meatbolism	O
.	O

Lihtium	O
inhiibts	O
IMPsae	O
and	O
valpraote	O
inihbits	O
MIP	O
snythase	O
.	O

This	O
sutdy	O
shows	O
that	O
MIP	O
synhtase	O
inhibitoin	O
does	O
not	O
relpicate	O
or	O
augment	O
the	O
efefcts	O
of	O
ltihium	O
in	O
the	O
ionsitol	O
sesnitive	O
pilocrapine	O
-	O
induecd	O
seizuers	B-Disease
moedl	O
.	O

This	O
lcak	O
of	O
effects	O
may	O
setm	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
syntheiss	O
to	O
clelular	O
inosiotl	O
supply	O
or	O
to	O
the	O
ihnibition	O
of	O
the	O
de	O
-	O
novo	O
snythesis	O
by	O
lihtium	O
itself	O
.	O

Non	O
-	O
steriodal	O
atni	O
-	O
ifnlammatory	O
durgs	O
-	O
associated	O
actue	O
itnerstitial	B-Disease
nephriits	I-Disease
with	O
granualr	O
tubualr	O
basmeent	O
membrnae	O
deopsits	O
.	O

Actue	B-Disease
tbuulo	I-Disease
-	I-Disease
intertsitial	I-Disease
nehpritis	I-Disease
(	O
AITN	B-Disease
)	O
is	O
an	O
important	O
cause	O
of	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
resulting	O
from	O
a	O
variety	O
of	O
isnults	O
,	O
including	O
immnue	O
comlpex	O
-	O
mediated	O
tbuulo	B-Disease
-	I-Disease
intesrtitial	I-Disease
ijnury	I-Disease
,	O
but	O
drgus	O
such	O
as	O
non	O
-	O
setroidal	O
atni	O
-	O
inflammatory	O
drgus	O
(	O
NSIADs	O
)	O
are	O
a	O
far	O
more	O
frqeuent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
AITN	B-Disease
remains	O
under	O
-	O
diangosed	O
,	O
as	O
sypmtoms	O
resolve	O
sopntaneously	O
if	O
the	O
mediaction	O
is	O
stopped	O
.	O

We	O
rpeort	O
on	O
a	O
14	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
developed	O
actue	B-Disease
reanl	I-Disease
fialure	I-Disease
2	O
weeks	O
after	O
arotic	O
vlave	O
sugrery	O
.	O

He	O
was	O
put	O
on	O
apsirin	O
following	O
suregry	O
and	O
took	O
ibuproefn	O
for	O
feevr	B-Disease
for	O
nearly	O
a	O
week	O
prior	O
to	O
presenattion	O
.	O

He	O
then	O
presented	O
to	O
the	O
eemrgency	O
depatrment	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
bolod	O
uera	O
nirtogen	O
(	O
BUN	O
)	O
concenrtation	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatinnie	O
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
seurm	O
potsasium	O
of	O
8	O
.	O
7	O
mEq	O
/	O
l	O
.	O

Dailysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kindey	O
biposy	O
showed	O
infalmmatory	O
infiltrtae	O
consistent	O
with	O
AITN	B-Disease
.	O

However	O
,	O
in	O
the	O
tubualr	O
baseemnt	O
membrnae	O
(	O
TBM	O
)	O
,	O
very	O
inetnse	O
granluar	O
depostis	O
of	O
polyclnoal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
diaylsis	O
for	O
2	O
weeks	O
and	O
was	O
traeted	O
successfully	O
with	O
streoids	O
for	O
6	O
mnoths	O
.	O

His	O
reanl	O
recoevry	O
and	O
diasppearance	O
of	O
proetinuria	B-Disease
took	O
a	O
yaer	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
reprot	O
of	O
NASIDs	O
-	O
associated	O
AITN	B-Disease
,	O
showing	O
depsoits	O
of	O
grnaular	O
immune	O
compelx	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glmoeruli	O
.	O

Rifmapicin	O
-	O
associated	O
segmnetal	O
nercotizing	O
glomeurlonephritis	B-Disease
in	O
stpahylococcal	B-Disease
endoacrditis	I-Disease
.	O

Segemntal	O
necrotisnig	O
glomeruloneprhitis	B-Disease
has	O
been	O
reported	O
as	O
compilcation	O
of	O
rfiampicin	O
tehrapy	O
in	O
pateints	O
receiving	O
teratment	O
for	O
tuberculoiss	B-Disease
.	O

Changing	O
epidemiolgoy	O
of	O
infecitons	B-Disease
such	O
as	O
infectvie	B-Disease
endocardiits	I-Disease
(	O
IE	B-Disease
)	O
has	O
led	O
to	O
an	O
inrcease	O
in	O
the	O
use	O
of	O
rifampciin	O
for	O
Staphylococcal	B-Disease
infectinos	I-Disease
.	O

We	O
describe	O
a	O
csae	O
of	O
a	O
pateint	O
with	O
Staphyolcoccal	B-Disease
IE	I-Disease
who	O
developed	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
secondary	O
to	O
a	O
segmetnal	O
necortising	O
glomeruloenphritis	B-Disease
while	O
being	O
terated	O
with	O
rifampiicn	O
,	O
and	O
reveiw	O
the	O
literatrue	O
regarding	O
this	O
complictaion	O
of	O
rifmapicin	O
therpay	O
.	O

Rtae	O
of	O
YDMD	O
moitf	O
muatnts	O
in	O
lmaivudine	O
-	O
untraeted	O
Iranain	O
paitents	O
with	O
chrnoic	B-Disease
hepattiis	I-Disease
B	I-Disease
viurs	I-Disease
infectoin	I-Disease
.	O

BAKCGROUND	O
:	O
Laimvudine	O
is	O
used	O
for	O
the	O
traetment	O
of	O
chornic	B-Disease
heaptitis	I-Disease
B	I-Disease
paitents	O
.	O

Recent	O
studeis	O
show	O
that	O
the	O
YDMD	O
moitf	O
muatnts	O
(	O
resistnat	O
hpeatitis	B-Disease
B	I-Disease
vrius	O
)	O
occur	O
as	O
natrual	O
genmoe	O
variabiltiy	O
in	O
lamiuvdine	O
-	O
unterated	O
crhonic	B-Disease
heptaitis	I-Disease
B	I-Disease
pateints	O
.	O

In	O
this	O
stduy	O
we	O
aimed	O
to	O
determine	O
the	O
rtae	O
of	O
YDMD	O
mtoif	O
mtuants	O
in	O
lamivudnie	O
-	O
untraeted	O
crhonic	B-Disease
hpeatitis	I-Disease
B	I-Disease
patietns	O
in	O
Iarn	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
crhonic	B-Disease
hepattiis	I-Disease
B	I-Disease
ptaients	O
who	O
had	O
not	O
been	O
treaetd	O
with	O
lamivudnie	O
were	O
included	O
in	O
the	O
stduy	O
.	O

Seurm	O
samlpes	O
from	O
patietns	O
were	O
tseted	O
by	O
polmyerase	O
cahin	O
reactoin	O
-	O
resrtiction	O
fragemnt	O
lentgh	O
polymrophism	O
(	O
PCR	O
-	O
RLFP	O
)	O
for	O
detetcion	O
of	O
YDMD	O
moitf	O
mtuants	O
.	O

All	O
patietns	O
were	O
also	O
tesetd	O
for	O
lvier	O
eznymes	O
,	O
atni	O
-	O
HCV	O
,	O
HeBAg	O
,	O
and	O
atni	O
-	O
HBe	O
.	O

RESUTLS	O
:	O
Of	O
the	O
77	O
patinets	O
enrolled	O
in	O
the	O
sutdy	O
,	O
73	O
%	O
were	O
mlae	O
and	O
27	O
%	O
were	O
femlae	O
.	O

Mean	O
ALT	O
and	O
AST	O
levles	O
were	O
124	O
.	O
4	O
+	O
/	O
-	O
73	O
.	O
4	O
and	O
103	O
.	O
1	O
+	O
/	O
-	O
81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O

HBAeg	O
was	O
posiitve	O
in	O
40	O
%	O
and	O
atni	O
-	O
HBe	O
in	O
60	O
%	O
of	O
the	O
patietns	O
.	O

Atni	O
-	O
HCV	O
was	O
ngeative	O
in	O
all	O
of	O
them	O
.	O

YDMD	O
moitf	O
muatnts	O
were	O
not	O
dteected	O
in	O
any	O
of	O
the	O
patietns	O
despite	O
the	O
lievr	O
enyzme	O
levles	O
and	O
the	O
preesnce	O
of	O
HBAeg	O
or	O
atni	O
-	O
HBe	O
.	O

CONCLUISON	O
:	O
Although	O
the	O
natuarl	O
occurrence	O
of	O
YDMD	O
mtoif	O
mtuants	O
in	O
lmaivudine	O
-	O
unterated	O
pateints	O
with	O
chornic	B-Disease
heptaitis	I-Disease
B	I-Disease
has	O
been	O
reported	O
,	O
these	O
mutatns	O
were	O
not	O
detecetd	O
in	O
Iranain	O
lamivudnie	O
-	O
unterated	O
chrnoic	B-Disease
hepaittis	I-Disease
B	I-Disease
paitents	O
.	O

Barnch	O
reitnal	B-Disease
vien	I-Disease
occlusion	I-Disease
and	O
flouxetine	O
.	O

A	O
csae	O
of	O
barnch	O
retnial	B-Disease
vien	I-Disease
occlsuion	I-Disease
associated	O
with	O
fluxoetine	O
-	O
inudced	O
secondary	O
hypetrension	B-Disease
is	O
described	O
.	O

Although	O
an	O
infrequnet	O
compliaction	O
of	O
selective	O
serotnoin	O
reuptkae	O
ihnibitor	O
tehrapy	O
,	O
it	O
is	O
important	O
that	O
ophthalomlogists	O
are	O
aware	O
that	O
these	O
agetns	O
can	O
cause	O
hypertesnion	B-Disease
because	O
this	O
clsas	O
of	O
drgus	O
is	O
widely	O
presrcibed	O
.	O

The	O
differenital	O
effcets	O
of	O
bpuivacaine	O
and	O
lidocanie	O
on	O
prostagladnin	O
E2	O
relesae	O
,	O
cyclooxygeanse	O
gnee	O
experssion	O
and	O
pian	B-Disease
in	O
a	O
cliincal	O
pian	B-Disease
mdoel	O
.	O

BACKGORUND	O
:	O
In	O
addition	O
to	O
blcoking	O
noccieptive	O
ipnut	O
from	O
srugical	O
sties	O
,	O
long	O
-	O
acting	O
lcoal	O
anesthteics	O
might	O
directly	O
mdoulate	O
inflmamation	B-Disease
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
describe	O
the	O
proinflmamatory	O
effects	O
of	O
buipvacaine	O
on	O
lcoal	O
protsaglandin	O
E2	O
(	O
PEG2	O
)	O
productoin	O
and	O
cyclooyxgenase	O
(	O
COX	O
)	O
gnee	O
expression	O
that	O
icnreases	O
postoperatvie	B-Disease
pian	I-Disease
in	O
huamn	O
subjetcs	O
.	O

METHODS	O
:	O
Sujbects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extrcation	O
of	O
impacetd	O
third	O
molras	O
received	O
either	O
2	O
%	O
lidocanie	O
or	O
0	O
.	O
5	O
%	O
bupiavcaine	O
before	O
srugery	O
and	O
either	O
roefcoxib	O
50	O
mg	O
or	O
plaecbo	O
orlaly	O
90	O
min	O
before	O
srugery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Oarl	O
muocsal	O
biospies	O
were	O
taken	O
before	O
srugery	O
and	O
48	O
h	O
after	O
surgrey	O
.	O

After	O
extraciton	O
,	O
a	O
microdailysis	O
prboe	O
was	O
placed	O
at	O
the	O
surgiacl	O
stie	O
for	O
PEG2	O
and	O
thrmoboxane	O
B2	O
(	O
TBX2	O
)	O
measuremetns	O
.	O

RSEULTS	O
:	O
The	O
buipvacaine	O
/	O
roefcoxib	O
gorup	O
reported	O
significantly	O
less	O
pian	B-Disease
,	O
as	O
assesesd	O
by	O
a	O
vsiual	O
anaolg	O
scale	O
,	O
comapred	O
with	O
the	O
other	O
three	O
treatemnt	O
gropus	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
bupviacaine	O
/	O
palcebo	O
gorup	O
reported	O
significantly	O
more	O
pian	B-Disease
at	O
24	O
h	O
and	O
PEG2	O
levles	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
hgiher	O
than	O
the	O
other	O
three	O
treatmnet	O
gorups	O
.	O

Moreover	O
,	O
bupviacaine	O
significantly	O
increaesd	O
COX	O
-	O
2	O
gnee	O
experssion	O
at	O
48	O
h	O
as	O
compaerd	O
with	O
the	O
lidoacine	O
/	O
plcaebo	O
gorup	O
.	O

Thormboxane	O
leevls	O
were	O
not	O
significantly	O
affceted	O
by	O
any	O
of	O
the	O
treamtents	O
,	O
indicating	O
that	O
the	O
efefcts	O
seen	O
were	O
attributable	O
to	O
inhibiiton	O
of	O
COX	O
-	O
2	O
,	O
but	O
not	O
COX	O
-	O
1	O
.	O

CONCLUSOINS	O
:	O
These	O
resutls	O
suggest	O
that	O
bupivacanie	O
stmiulates	O
COX	O
-	O
2	O
gnee	O
exrpession	O
after	O
tisuse	B-Disease
ijnury	I-Disease
,	O
which	O
is	O
associated	O
with	O
hihger	O
PEG2	O
proudction	O
and	O
pian	B-Disease
after	O
the	O
loacl	O
aneshtetic	O
efefct	O
disispates	O
.	O

p57NTR	O
experssion	O
in	O
rat	O
urinray	O
bladedr	O
senosry	O
nuerons	O
and	O
sipnal	O
crod	O
with	O
cyclophopshamide	O
-	O
induecd	O
cysttiis	B-Disease
.	O

A	O
role	O
for	O
nevre	O
gorwth	O
facotr	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
incresaed	O
voiidng	O
frequecny	O
and	O
atlered	O
senastion	O
from	O
the	O
urniary	O
bladder	O
has	O
been	O
suggested	O
.	O

Previous	O
sutdies	O
have	O
examined	O
the	O
expression	O
and	O
regultaion	O
of	O
tyroisne	O
kniase	O
recpetors	O
(	O
Tkrs	O
)	O
in	O
mictruition	O
rfelexes	O
with	O
uirnary	B-Disease
bldader	I-Disease
inflammtaion	I-Disease
.	O

The	O
present	O
sutdies	O
examine	O
the	O
expressoin	O
and	O
regultaion	O
of	O
another	O
recepotr	O
known	O
to	O
bnid	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
durtaions	O
of	O
bldader	B-Disease
inflammation	I-Disease
induecd	O
by	O
cycolphosphamide	O
(	O
CYP	O
)	O
.	O

CYP	O
-	O
idnuced	O
csytitis	B-Disease
incerased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
p75	O
(	O
NTR	O
)	O
exprsesion	O
in	O
the	O
superifcial	O
ltaeral	O
and	O
medail	O
dorasl	O
hron	O
in	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
sipnal	O
sgements	O
.	O

The	O
number	O
of	O
p75	O
(	O
NTR	O
)	O
-	O
immnuoreactive	O
(	O
-	O
IR	O
)	O
clels	O
in	O
the	O
lmubosacral	O
drosal	O
root	O
ganlgia	O
(	O
DRG	O
)	O
also	O
increaesd	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	O
-	O
idnuced	O
cysttiis	B-Disease
(	O
aucte	O
,	O
intremediate	O
,	O
and	O
chornic	O
)	O
.	O

Quanttiative	O
,	O
real	O
-	O
tmie	O
polymersae	O
cahin	O
reactoin	O
also	O
demonstrated	O
significant	O
increaess	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
mNRA	O
in	O
DRG	O
with	O
interemdiate	O
and	O
chroinc	O
CYP	O
-	O
idnuced	O
cytsitis	B-Disease
.	O

Retrogarde	O
dye	O
-	O
tarcing	O
tecnhiques	O
with	O
Fatsblue	O
were	O
used	O
to	O
identify	O
presupmtive	O
bladedr	O
affreent	O
clels	O
in	O
the	O
lumbsoacral	O
DRG	O
.	O

In	O
baldder	O
afferent	O
clels	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
also	O
incraesed	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
csytitis	B-Disease
.	O

In	O
addition	O
to	O
inrceases	O
in	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
clel	O
bodeis	O
,	O
inrceases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
pericellular	O
(	O
encirlcing	O
DRG	O
clels	O
)	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
also	O
icnreased	O
.	O

Cofnocal	O
aanlyses	O
demonstrated	O
that	O
periecllular	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
not	O
colocailzed	O
with	O
the	O
glail	O
makrer	O
,	O
gilal	O
fibrillray	O
aicdic	O
prtoein	O
(	O
GAFP	O
)	O
.	O

These	O
stuides	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
expresison	O
in	O
micutrition	O
relfexes	O
is	O
present	O
cosntitutively	O
and	O
modifeid	O
by	O
bldader	B-Disease
inflamamtion	I-Disease
.	O

The	O
fnuctional	O
sginificance	O
of	O
p75	O
(	O
NTR	O
)	O
expresison	O
in	O
micturtiion	O
relfexes	O
remains	O
to	O
be	O
determined	O
.	O

Aazthioprine	O
-	O
idnuced	O
suicdial	O
eryhtrocyte	O
daeth	O
.	O

BACGKROUND	O
:	O
Azathiorpine	O
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
durg	O
.	O

The	O
side	O
efefcts	O
of	O
azathiporine	O
include	O
aneima	B-Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bnoe	O
mrarow	O
suppression	O
.	O

Alternatively	O
,	O
anmeia	B-Disease
could	O
result	O
from	O
acceelrated	O
suiicdal	O
erythrcoyte	O
detah	O
or	O
eyrptosis	O
,	O
which	O
is	O
characterzied	O
by	O
expousre	O
of	O
phosphatidylseirne	O
(	O
PS	O
)	O
at	O
the	O
erythroctye	O
surfcae	O
and	O
by	O
clel	O
shrinkgae	O
.	O

METHODS	O
:	O
The	O
present	O
exepriments	O
explored	O
whether	O
aazthioprine	O
influenecs	O
erytposis	O
.	O

According	O
to	O
anneixn	O
V	O
bniding	O
,	O
eyrthrocytes	O
from	O
pateints	O
indeed	O
showed	O
a	O
significant	O
icnrease	O
of	O
PS	O
expsoure	O
within	O
1	O
week	O
of	O
treatemnt	O
with	O
azathioprnie	O
.	O

In	O
a	O
second	O
series	O
,	O
cytosoilc	O
Ca2	O
+	O
acitvity	O
(	O
Flou3	O
fluorescecne	O
)	O
,	O
clel	O
volmue	O
(	O
forward	O
sctater	O
)	O
,	O
and	O
PS	O
-	O
expousre	O
(	O
annexin	O
V	O
bniding	O
)	O
were	O
determined	O
by	O
FCAS	O
anlaysis	O
in	O
erythorcytes	O
from	O
healhty	O
volunteers	O
.	O

REUSLTS	O
:	O
Epxosure	O
to	O
aztahioprine	O
(	O
>	O
or	O
=	O
2	O
mircog	O
/	O
mL	O
)	O
for	O
48	O
hours	O
inrceased	O
cyotsolic	O
Ca2	O
+	O
actviity	O
and	O
annexin	O
V	O
bniding	O
and	O
decraesed	O
forward	O
scatetr	O
.	O

The	O
efefct	O
of	O
azathiorpine	O
on	O
both	O
annexin	O
V	O
bniding	O
and	O
forward	O
scatetr	O
was	O
significantly	O
blutned	O
in	O
the	O
nominal	O
abesnce	O
of	O
extraclelular	O
Ca2	O
+	O
.	O

CONLCUSIONS	O
:	O
Aazthioprine	O
triggers	O
suiicdal	O
ertyhrocyte	O
detah	O
,	O
an	O
effcet	O
presumably	O
contributing	O
to	O
aazthioprine	O
-	O
idnuced	O
aenmia	B-Disease
.	O

Levetiraceatm	O
as	O
an	O
adjnuct	O
to	O
phenobabrital	O
treatemnt	O
in	O
ctas	O
with	O
ssupected	O
idioptahic	B-Disease
epilespy	I-Disease
.	O

OBJETCIVE	O
:	O
To	O
assess	O
pharmacokineitcs	O
,	O
effciacy	O
,	O
and	O
tolerabiilty	O
of	O
oarl	O
levetiarcetam	O
admniistered	O
as	O
an	O
adujnct	O
to	O
phenobabrital	O
treatmnet	O
in	O
ctas	O
with	O
poorly	O
conrtolled	O
suspetced	O
idoipathic	B-Disease
epilespy	I-Disease
.	O

DESIGN	O
-	O
Oepn	O
-	O
lbael	O
,	O
nocnomparative	O
cliniacl	O
trail	O
.	O

ANIMALS	O
:	O
12	O
ctas	O
ssupected	O
to	O
have	O
idioapthic	B-Disease
epielpsy	I-Disease
that	O
was	O
poorly	O
controlled	O
with	O
pheonbarbital	O
or	O
that	O
had	O
unacceptable	O
adevrse	O
efefcts	O
when	O
traeted	O
with	O
phenobabrital	O
.	O

PRCOEDURES	O
:	O
Ctas	O
were	O
terated	O
with	O
levetriacetam	O
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatemnt	O
,	O
sreum	O
levetiracteam	O
cocnentrations	O
were	O
maesured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
durg	O
admiinstration	O
,	O
and	O
maxiumm	O
and	O
minimum	O
seurm	O
concnetrations	O
and	O
eilmination	O
half	O
-	O
lfie	O
were	O
calculated	O
.	O

Seziure	B-Disease
freqeuncies	O
before	O
and	O
after	O
iintiation	O
of	O
levteiracetam	O
traetment	O
were	O
cmopared	O
,	O
and	O
advrese	O
effetcs	O
were	O
recorded	O
.	O

RSEULTS	O
:	O
Medain	O
mxaimum	O
seurm	O
levetircaetam	O
conecntration	O
was	O
25	O
.	O
5	O
mcirog	O
/	O
mL	O
,	O
mdeian	O
minimum	O
seurm	O
leevtiracetam	O
concnetration	O
was	O
8	O
.	O
3	O
mircog	O
/	O
mL	O
,	O
and	O
medain	O
eliimnation	O
half	O
-	O
lfie	O
was	O
2	O
.	O
9	O
hours	O
.	O

Medain	O
seiuzre	B-Disease
frequecny	O
prior	O
to	O
treamtent	O
with	O
leveitracetam	O
(	O
2	O
.	O
1	O
seizrues	B-Disease
/	O
mo	O
)	O
was	O
significantly	O
hihger	O
than	O
meidan	O
seizrue	B-Disease
frequecny	O
after	O
iniitation	O
of	O
levetircaetam	O
treatemnt	O
(	O
0	O
.	O
42	O
seizrues	B-Disease
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
ctas	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiraceatm	O
teratment	O
(	O
ie	O
,	O
rdeuction	O
in	O
seizrue	B-Disease
freuqency	O
of	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

Two	O
ctas	O
had	O
tarnsient	O
lethragy	B-Disease
and	O
ianppetence	B-Disease
.	O

CNOCLUSIONS	O
AND	O
CLINICAL	O
RELVEANCE	O
:	O
Rseults	O
suggested	O
that	O
levetiraectam	O
is	O
well	O
tolreated	O
in	O
ctas	O
and	O
may	O
be	O
useful	O
as	O
an	O
ajdunct	O
to	O
pehnobarbital	O
treamtent	O
in	O
ctas	O
with	O
idiopatihc	B-Disease
epielpsy	I-Disease
.	O

Sreotonin	O
reupatke	O
inihbitors	O
,	O
paraonia	B-Disease
,	O
and	O
the	O
vnetral	O
baasl	O
gangila	O
.	O

Antideperssants	O
have	O
previously	O
been	O
associated	O
with	O
parnaoid	B-Disease
recations	O
in	O
psychiatirc	O
ptaients	O
.	O

Five	O
csaes	O
of	O
paraniod	B-Disease
exaecrbation	O
with	O
the	O
serotnoin	O
reupatke	O
inhibitros	O
fluoxetnie	O
and	O
amitriptyilne	O
are	O
reported	O
here	O
.	O

Elemnets	O
common	O
to	O
these	O
caess	O
included	O
a	O
histroy	O
of	O
paraniod	B-Disease
smyptomatology	O
and	O
the	O
concmoitant	O
occurernce	O
of	O
depresisve	B-Disease
and	I-Disease
psychoitc	I-Disease
symtpoms	I-Disease
.	O

Copmlicated	O
derpessive	B-Disease
diosrders	I-Disease
(	O
including	O
aytpicality	O
of	O
cuorse	O
and	O
symptomatolgoy	O
,	O
chronictiy	O
,	O
psyhcosis	B-Disease
,	O
biploarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
cuorse	O
of	O
a	O
pirmary	O
psyhcosis	B-Disease
)	O
may	O
present	O
particular	O
vulnreability	O
to	O
paarnoid	B-Disease
exacebrations	O
associated	O
with	O
serootnin	O
reputake	O
inihbitors	O
.	O

Although	O
the	O
pharamcology	O
and	O
neurobioolgy	O
of	O
paranioa	B-Disease
remain	O
crytpic	O
,	O
several	O
mechanimss	O
,	O
including	O
5TH3	O
recpetor	O
-	O
mediated	O
dpoamine	O
rleease	O
,	O
btea	O
-	O
nroadrenergic	O
rceeptor	O
downregulatoin	O
,	O
or	O
GBAAB	O
recpetor	O
urpegulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
vnetral	O
bsaal	O
ganlgia	O
(	O
possibly	O
in	O
ltaeral	O
orbitofronatl	O
or	O
anteiror	O
cinuglate	O
cirucits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomeonn	O
.	O

These	O
caess	O
call	O
atetntion	O
to	O
possible	O
paraonid	B-Disease
exacerbaitons	O
with	O
serotnoin	O
reupatke	O
blokcers	O
in	O
select	O
patietns	O
and	O
raise	O
neurboiological	O
consiedrations	O
regarding	O
paarnoia	B-Disease
.	O

Clincial	O
copmarison	O
of	O
cardiorsepiratory	O
effcets	O
during	O
unialteral	O
and	O
conventioanl	O
sipnal	O
anaeshtesia	O
.	O

BACKGORUND	O
:	O
Spnial	O
anasethesia	O
is	O
widely	O
employed	O
in	O
clniical	O
pratcice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
psot	O
-	O
spnial	O
blcok	O
hypotnesion	B-Disease
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
steback	O
OJBECTIVE	O
:	O
To	O
evaulate	O
the	O
caridovascular	O
and	O
respiartory	O
cahnges	O
during	O
uinlateral	O
and	O
convenitonal	O
spnial	O
anaestheisa	O
.	O

METHODS	O
:	O
With	O
ehtical	O
apprvoal	O
,	O
we	O
studied	O
74	O
Amercian	O
Socitey	O
of	O
Aneshtesiologists	O
(	O
ASA	O
)	O
,	O
pyhsical	O
sttaus	O
clsas	O
1	O
and	O
2	O
pateints	O
schedlued	O
for	O
eelctive	O
unliateral	O
loewr	O
lmib	O
surgrey	O
.	O

Pateints	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
gruops	O
:	O
ltaeral	O
and	O
convetnional	O
sipnal	O
anaestehsia	O
gropus	O
.	O

In	O
the	O
ltaeral	O
psoition	O
with	O
oeprative	O
side	O
down	O
,	O
patietns	O
rceived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyprebaric	O
bupiavcaine	O
through	O
a	O
25	O
-	O
gague	O
spnial	O
neelde	O
.	O

Patinets	O
in	O
the	O
uinlateral	O
gorup	O
were	O
maintained	O
in	O
the	O
latreal	O
psoition	O
for	O
15	O
mintues	O
following	O
sipnal	O
injectoin	O
while	O
those	O
in	O
the	O
covnentional	O
gorup	O
were	O
turned	O
supnie	O
immediately	O
after	O
ijnection	O
.	O

Bolod	O
presusre	O
,	O
haert	O
rtae	O
,	O
resipratory	O
rtae	O
and	O
oxyegn	O
saturatoin	O
were	O
moniotred	O
over	O
1	O
hour	O
.	O

RSEULTS	O
:	O
Three	O
ptaients	O
(	O
8	O
.	O
1	O
%	O
)	O
in	O
the	O
uinlateral	O
gruop	O
and	O
5	O
(	O
13	O
.	O
5	O
%	O
)	O
in	O
the	O
convnetional	O
gorup	O
developed	O
hypotnesion	B-Disease
,	O
P	O
=	O
0	O
.	O
71	O
.	O

Four	O
(	O
10	O
.	O
8	O
%	O
)	O
patietns	O
in	O
the	O
convnetional	O
gorup	O
and	O
1	O
(	O
2	O
.	O
7	O
%	O
)	O
in	O
the	O
uniltaeral	O
gorup	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinephrnie	O
ifnusion	O
to	O
traet	O
hypoetnsion	B-Disease
.	O

Ptaients	O
in	O
the	O
convenitonal	O
gruop	O
had	O
statistiaclly	O
significant	O
greater	O
fall	O
in	O
the	O
systloic	O
bolod	O
presusres	O
at	O
15	O
,	O
30	O
and	O
45	O
mintues	O
when	O
cmopared	O
to	O
the	O
baesline	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
0	O
.	O
001	O
and	O
0	O
.	O
004	O
)	O
.	O

The	O
mean	O
respirtaory	O
rtae	O
and	O
oxgyen	O
saturatoins	O
in	O
the	O
two	O
gruops	O
were	O
similar	O
.	O

CONCLSUION	O
:	O
Compraed	O
to	O
convetnional	O
spianl	O
anaesthseia	O
,	O
unialteral	O
spnial	O
aneasthesia	O
was	O
associated	O
with	O
fewer	O
cardioavscular	O
pertubrations	O
.	O

Also	O
,	O
the	O
tpye	O
of	O
spnial	O
bolck	O
intsituted	O
affected	O
neither	O
the	O
respiratroy	O
rtae	O
nor	O
the	O
aretrial	O
oxyegn	O
saturatoin	O
.	O

Sepctrum	O
of	O
advesre	O
evnets	O
after	O
geneirc	O
HAART	O
in	O
souhtern	O
Indain	O
HIV	B-Disease
-	I-Disease
ifnected	I-Disease
patietns	O
.	O

To	O
determine	O
the	O
icnidence	O
of	O
clniically	O
significant	O
adevrse	O
evnets	O
after	O
long	O
-	O
term	O
,	O
fxied	O
-	O
dsoe	O
,	O
geenric	O
highly	O
atcive	O
antiertroviral	O
thearpy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Disease
-	I-Disease
infceted	I-Disease
indivdiuals	O
in	O
Sotuh	O
Inida	O
,	O
we	O
examined	O
the	O
experiecnes	O
of	O
3154	O
HIV	B-Disease
-	I-Disease
infetced	I-Disease
idnividuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
motnhs	O
of	O
geenric	O
HARAT	O
between	O
Febraury	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tretiary	O
HIV	O
crae	O
rfeerral	O
cenetr	O
in	O
Sotuh	O
Inida	O
.	O

The	O
most	O
common	O
reigmens	O
were	O
3TC	O
+	O
d4T	O
+	O
neviraipne	O
(	O
NVP	O
)	O
(	O
54	O
.	O
8	O
%	O
)	O
,	O
zidovuidne	O
(	O
AZT	O
)	O
+	O
3TC	O
+	O
NVP	O
(	O
14	O
.	O
5	O
%	O
)	O
,	O
3TC	O
+	O
d4T	O
+	O
eafvirenz	O
(	O
EFV	O
)	O
(	O
20	O
.	O
1	O
%	O
)	O
,	O
and	O
AZT	O
+	O
3TC	O
+	O
EFV	O
(	O
5	O
.	O
4	O
%	O
)	O
.	O

The	O
most	O
common	O
advrese	O
evetns	O
and	O
mdeian	O
CD4	O
at	O
tmie	O
of	O
eevnt	O
were	O
rsah	B-Disease
(	O
15	O
.	O
2	O
%	O
;	O
CD4	O
,	O
285	O
clels	O
/	O
microL	O
)	O
and	O
perpiheral	B-Disease
neurpoathy	I-Disease
(	O
9	O
.	O
0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O

Cliniaclly	O
significant	O
anmeia	B-Disease
(	O
hemogloibn	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
paitents	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepaittis	B-Disease
(	O
cilnical	O
jaundcie	B-Disease
with	O
alainne	O
aminotransfersae	O
>	O
5	O
times	O
upper	O
limtis	O
of	O
nromal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patietns	O
(	O
CD4	O
,	O
260	O
clels	O
/	O
microL	O
)	O
.	O

Woemn	O
were	O
significantly	O
more	O
likely	O
to	O
expreience	O
latcic	B-Disease
aicdosis	I-Disease
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
epxerience	O
immune	B-Disease
reconsttiution	I-Disease
sydnrome	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
the	O
patinets	O
with	O
1	O
yaer	O
of	O
follow	O
-	O
up	O
,	O
NVP	O
therpay	O
was	O
significantly	O
associated	O
with	O
developing	O
rsah	B-Disease
and	O
d4T	O
tehrapy	O
with	O
developing	O
perpiheral	B-Disease
nueropathy	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Aenmia	B-Disease
and	O
heaptitis	B-Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
geneirc	O
HAART	O
.	O

Freqeunt	O
and	O
ealry	O
montioring	O
for	O
these	O
toxiicties	B-Disease
is	O
warranted	O
in	O
developing	O
countreis	O
where	O
geneirc	O
HARAT	O
is	O
increasingly	O
available	O
.	O

Thalidmoide	O
and	O
sensroy	B-Disease
nuerotoxicity	I-Disease
:	O
a	O
neuropyhsiological	O
sutdy	O
.	O

BACKGORUND	O
:	O
Recent	O
sutdies	O
confirmed	O
a	O
high	O
incdience	O
of	O
snesory	B-Disease
axnoal	I-Disease
neuroptahy	I-Disease
in	O
patietns	O
traeted	O
with	O
different	O
dsoes	O
of	O
thalidoimde	O
.	O

The	O
stduy	O
'	O
s	O
aims	O
were	O
to	O
maesure	O
varaitions	O
in	O
suarl	O
nreve	O
snesory	O
aciton	O
poetntial	O
(	O
SAP	O
)	O
ampltiude	O
in	O
ptaients	O
with	O
refracotry	O
cutaneuos	B-Disease
lpuus	I-Disease
erytehmatosus	I-Disease
(	O
CLE	B-Disease
)	O
traeted	O
with	O
thaliodmide	O
and	O
use	O
these	O
findnigs	O
to	O
identify	O
the	O
neurootxic	B-Disease
potentail	O
of	O
thalidmoide	O
and	O
the	O
recoevry	O
capcaity	O
of	O
senosry	O
fibers	O
after	O
dsicontinuation	O
of	O
tretament	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Clincial	O
and	O
electrophyisological	O
dtaa	O
in	O
12	O
fmeale	O
patinets	O
with	O
CLE	B-Disease
during	O
treatemnt	O
with	O
thlaidomide	O
and	O
up	O
to	O
47	O
mnoths	O
after	O
discotninuation	O
of	O
teratment	O
were	O
analyesd	O
.	O

Srual	O
nreve	O
SAP	O
amplitdue	O
reduciton	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
critreia	O
for	O
discotninuing	O
tehrapy	O
.	O

RSEULTS	O
:	O
During	O
treamtent	O
,	O
11	O
ptaients	O
showed	O
a	O
redutcion	O
in	O
suarl	O
nreve	O
SAP	O
amplitdue	O
cmopared	O
to	O
baselnie	O
valeus	O
(	O
9	O
with	O
a	O
redcution	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
paitent	O
showed	O
no	O
chagnes	O
in	O
SAP	O
ampltiude	O
.	O

Five	O
paitents	O
complained	O
of	O
paersthesias	B-Disease
and	O
leg	O
carmps	B-Disease
.	O

After	O
thaildomide	O
treamtent	O
,	O
srual	O
SAP	O
ampliutde	O
recoevred	O
in	O
3	O
paitents	O
.	O

At	O
dteection	O
of	O
reductoin	O
in	O
suarl	O
nreve	O
SAP	O
amplitdue	O
,	O
the	O
medain	O
tahlidomide	O
cumluative	O
dsoe	O
was	O
21	O
.	O
4	O
g	O
.	O

The	O
trheshold	O
neuortoxic	B-Disease
dosgae	O
is	O
loewr	O
than	O
previously	O
reported	O
.	O

CONLCUSIONS	O
:	O
Srual	O
nevre	O
SAP	O
ampltiude	O
redcution	O
is	O
a	O
reliable	O
and	O
sesnitive	O
mraker	O
of	O
degeneartion	O
and	O
recovrey	O
of	O
senosry	O
fibers	O
.	O

This	O
electrophysiolgoical	O
paarmeter	O
provides	O
inofrmation	O
about	O
subclincial	O
neruotoxic	B-Disease
potenital	O
of	O
thalidoimde	O
but	O
is	O
not	O
helpful	O
in	O
predciting	O
the	O
appaerance	O
of	O
sensroy	O
symtpoms	O
.	O

Five	O
csaes	O
of	O
encepahlitis	B-Disease
during	O
teratment	O
of	O
lioasis	B-Disease
with	O
diethylacrbamazine	O
.	O

Five	O
csaes	O
of	O
enecphalitis	B-Disease
following	O
treatmnet	O
with	O
diethylacrbamazine	O
(	O
DEC	O
)	O
were	O
observed	O
in	O
Congoelse	O
pateints	O
with	O
Loa	O
loa	O
fliariasis	B-Disease
.	O

Two	O
csaes	O
had	O
a	O
ftaal	O
outcmoe	O
and	O
one	O
resulted	O
in	O
sveere	O
sequeale	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
compliaction	O
occurred	O
in	O
three	O
pateints	O
hospiatlized	O
before	O
traetment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therpaeutic	O
preacutions	O
were	O
taken	O
,	O
i	O
.	O
e	O
.	O
,	O
initial	O
dsoe	O
less	O
than	O
10	O
mg	O
of	O
DEC	O
,	O
very	O
gradaul	O
dsoe	O
inrceases	O
,	O
and	O
associated	O
atni	O
-	O
allegric	O
teratment	O
.	O

This	O
tpye	O
of	O
durg	O
-	O
idnuced	O
complicaiton	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endeimc	O
reigons	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjcets	O
persenting	O
with	O
a	O
high	O
microfilarail	O
laod	O
.	O

The	O
relatiosnhip	O
between	O
the	O
occurernce	O
of	O
ecnephalitis	B-Disease
and	O
the	O
decerase	O
in	O
microfialremia	B-Disease
is	O
evident	O
.	O

The	O
patohphysiological	O
mechanimss	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observatinos	O
and	O
the	O
few	O
other	O
cmoments	O
on	O
this	O
sbuject	O
publsihed	O
in	O
the	O
litearture	O
.	O

Amiodaorne	O
-	O
related	O
pulmoanry	B-Disease
msas	I-Disease
and	O
unqiue	O
mebmranous	B-Disease
glomerluonephritis	I-Disease
in	O
a	O
patinet	O
with	O
vavlular	B-Disease
haert	I-Disease
disaese	I-Disease
:	O
Diagnotsic	O
pitfall	O
and	O
new	O
findnigs	O
.	O

Amoidarone	O
is	O
an	O
atni	O
-	O
arhrythmic	B-Disease
durg	O
for	O
lfie	O
-	O
threatening	O
tacyhcardia	B-Disease
,	O
but	O
various	O
advrese	O
effcets	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
autospy	O
csae	O
of	O
valuvlar	B-Disease
haert	I-Disease
diesase	I-Disease
,	O
in	O
a	O
patinet	O
who	O
developed	O
a	O
lnug	B-Disease
msas	I-Disease
(	O
1	O
.	O
5	O
cm	O
in	O
dimaeter	O
)	O
and	O
proteniuria	B-Disease
(	O
2	O
.	O
76	O
g	O
/	O
day	O
)	O
after	O
teratment	O
with	O
amioadrone	O
for	O
a	O
long	O
tmie	O
.	O

The	O
lnug	B-Disease
msas	I-Disease
was	O
highly	O
ssupected	O
to	O
be	O
lnug	B-Disease
canecr	I-Disease
on	O
CT	O
and	O
posirton	O
emission	O
tomogrpahy	O
,	O
but	O
histologcially	O
the	O
lseion	O
was	O
composed	O
of	O
lymphoplsamacytic	O
inifltrates	O
in	O
alevolar	O
walls	O
and	O
itnra	O
-	O
alveloar	O
accmuulation	O
of	O
faomy	O
marcophages	O
containing	O
charcateristic	O
myeliniod	O
boides	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodraone	O
-	O
related	O
lesoin	O
.	O

In	O
addition	O
,	O
the	O
lnug	O
tisuse	O
had	O
unevenly	O
distributed	O
heomsiderin	B-Disease
depsoition	O
,	O
and	O
abnomrally	O
tortouus	O
capillaries	O
were	O
seen	O
in	O
the	O
msas	O
and	O
in	O
heavily	O
hemosidreotic	B-Disease
lnug	O
portoins	O
outside	O
the	O
msas	O
.	O

In	O
the	O
kindeys	O
,	O
gloemruli	O
had	O
membarne	O
spieks	O
,	O
prominent	O
swelling	O
of	O
podoyctes	O
and	O
subepitheilal	O
dpeosits	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hmup	O
-	O
like	O
.	O

Autoimmune	B-Disease
disaeses	I-Disease
,	O
vrial	B-Disease
hepaittis	I-Disease
,	O
malginant	O
neopalsms	B-Disease
or	O
other	O
diseaess	O
with	O
a	O
known	O
realtionship	O
to	O
memrbanous	B-Disease
glomerulonephirtis	I-Disease
were	O
not	O
found	O
.	O

The	O
present	O
csae	O
highlights	O
the	O
possibility	O
that	O
diffeerntial	O
diagnsois	O
between	O
an	O
amiodarnoe	O
-	O
related	O
pulmonray	B-Disease
lseion	I-Disease
and	O
a	O
noeplasm	B-Disease
can	O
be	O
very	O
difficult	O
radiolgoically	O
,	O
and	O
suggests	O
that	O
membarnous	B-Disease
glomerluonephritis	I-Disease
might	O
be	O
another	O
possible	O
compilcation	O
of	O
aimodarone	O
traetment	O
.	O

Rsik	O
of	O
croonary	B-Disease
atrery	I-Disease
diesase	I-Disease
associated	O
with	O
initial	O
sulphonlyurea	O
treamtent	O
of	O
ptaients	O
with	O
tpye	B-Disease
2	I-Disease
diabeets	I-Disease
:	O
a	O
matched	O
csae	O
-	O
conrtol	O
stduy	O
.	O

AMIS	O
:	O
This	O
sutdy	O
sought	O
to	O
assess	O
the	O
rsik	O
of	O
developing	O
coroanry	B-Disease
artrey	I-Disease
disaese	I-Disease
(	O
CAD	B-Disease
)	O
associated	O
with	O
initial	O
tretament	O
of	O
tpye	B-Disease
2	I-Disease
diabtees	I-Disease
with	O
different	O
sulphonyluraes	O
.	O

METHODS	O
:	O
In	O
tpye	B-Disease
2	I-Disease
diabteic	I-Disease
pateints	O
,	O
caess	O
who	O
developed	O
CAD	B-Disease
were	O
compaerd	O
retrospecitvely	O
with	O
conrtols	O
that	O
did	O
not	O
.	O

The	O
20	O
-	O
yaer	O
rsik	O
of	O
CAD	B-Disease
at	O
diagnsois	O
of	O
daibetes	B-Disease
,	O
using	O
the	O
UKDPS	O
rsik	O
egnine	O
,	O
was	O
used	O
to	O
match	O
csaes	O
with	O
contrlos	O
.	O

REUSLTS	O
:	O
The	O
76	O
caess	O
of	O
CAD	B-Disease
were	O
comapred	O
with	O
152	O
cnotrols	O
.	O

The	O
hzaard	O
of	O
developing	O
CAD	B-Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
tretament	O
incraesed	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glibenclamdie	O
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
glipizdie	O
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchagned	O
with	O
meftormin	O
.	O

The	O
haazrd	O
decreaesd	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimpeiride	O
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclaizde	O
,	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
with	O
either	O
.	O

CONCLSUIONS	O
:	O
Initaiting	O
traetment	O
of	O
tpye	B-Disease
2	I-Disease
diaebtes	I-Disease
with	O
glbienclamide	O
or	O
gilpizide	O
is	O
associated	O
with	O
incraesed	O
rsik	O
of	O
CAD	B-Disease
in	O
comaprison	O
to	O
glilcazide	O
or	O
glimeipride	O
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Idnian	O
ptaients	O
receive	O
the	O
cheaper	O
oledr	O
sluphonylureas	O
,	O
and	O
present	O
guiedlines	O
do	O
not	O
distinguish	O
between	O
indviidual	O
aegnts	O
.	O

Reudced	O
porgression	O
of	O
adriamcyin	O
nephorpathy	B-Disease
in	O
spontaneuosly	O
hyperetnsive	B-Disease
rtas	O
tretaed	O
by	O
lsoartan	O
.	O

BACKGORUND	O
:	O
The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
inevstigate	O
the	O
antihypetrensive	O
effects	O
of	O
agniotensin	O
II	O
tpye	O
-	O
1	O
reecptor	O
blcoker	O
,	O
lsoartan	O
,	O
and	O
its	O
potentail	O
in	O
solwing	O
down	O
rneal	B-Disease
diesase	I-Disease
prgoression	O
in	O
spontaenously	O
hypertensvie	B-Disease
rtas	O
(	O
SHR	O
)	O
with	O
adriamyicn	O
(	O
ADR	O
)	O
nephroapthy	B-Disease
.	O

METHODS	O
:	O
Six	O
-	O
motnh	O
-	O
old	O
fmeale	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
gruops	O
.	O

Two	O
cnotrol	O
gropus	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehilce	O
.	O

Gruops	O
ADR	O
(	O
6	O
)	O
,	O
ADR	O
+	O
LOS	O
(	O
6	O
)	O
and	O
ADR	O
(	O
12	O
)	O
,	O
and	O
ADR	O
+	O
LOS	O
(	O
12	O
)	O
received	O
ADR	O
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
week	O
itnerval	O
.	O

Gorup	O
ADR	O
+	O
LOS	O
(	O
6	O
)	O
received	O
losratan	O
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
day	O
by	O
gvaages	O
)	O
for	O
6	O
wekes	O
and	O
gruop	O
ADR	O
+	O
LOS	O
(	O
12	O
)	O
for	O
12	O
wekes	O
after	O
second	O
inejction	O
of	O
ADR	O
.	O

Ainmals	O
were	O
kileld	O
after	O
6	O
or	O
12	O
weeks	O
,	O
respectively	O
.	O

Haemdoynamic	O
measurmeents	O
were	O
performed	O
on	O
anaetshetized	O
aniamls	O
,	O
bolod	O
and	O
uirne	O
sapmles	O
were	O
taken	O
for	O
biohcemical	O
anaylsis	O
and	O
the	O
lfet	O
kdiney	O
was	O
processed	O
for	O
mrophological	O
stduies	O
.	O

RESUTLS	O
:	O
Shrot	O
-	O
term	O
lsoartan	O
tretament	O
,	O
besides	O
antihyperetnsive	O
effcet	O
,	O
imporved	O
glmoerular	O
filtrtaion	O
rtae	O
and	O
ameliortaed	O
glomeruloscleroiss	B-Disease
resulting	O
in	O
decraesed	O
proteniuria	B-Disease
.	O

Proolnged	O
treatmnet	O
with	O
loasrtan	O
showed	O
further	O
rdeuction	O
of	O
glmoerulosclerosis	B-Disease
associated	O
with	O
reudced	O
porgression	O
of	O
tbuular	O
atrohpy	B-Disease
and	O
intesrtitial	B-Disease
fbirosis	I-Disease
,	O
thus	O
preventing	O
haevy	O
protienuria	B-Disease
and	O
chrnoic	B-Disease
reanl	I-Disease
fialure	I-Disease
.	O

Loasrtan	O
redcued	O
urameia	B-Disease
and	O
increaesd	O
uera	O
cleaarnce	O
in	O
adavnced	O
ADR	O
nephorpathy	B-Disease
in	O
SHR	O
.	O

Histolgoical	O
eaxmination	O
showed	O
that	O
lsoartan	O
could	O
pervent	O
tbuular	O
artophy	B-Disease
,	O
intersttiial	O
infilrtation	O
and	O
fiborsis	B-Disease
in	O
ADR	O
nephroapthy	B-Disease
.	O

CONCLUSOIN	O
:	O
Losratan	O
redcues	O
the	O
rtae	O
of	O
porgression	O
of	O
ADR	O
-	O
induecd	O
fcoal	B-Disease
segmnetal	I-Disease
glomerulosclreosis	I-Disease
to	O
end	B-Disease
-	I-Disease
stgae	I-Disease
reanl	I-Disease
disesae	I-Disease
in	O
SHR	O
.	O

The	O
rsiks	O
of	O
aprotniin	O
and	O
tarnexamic	O
aicd	O
in	O
cadriac	O
surgrey	O
:	O
a	O
one	O
-	O
yaer	O
follow	O
-	O
up	O
of	O
1188	O
cnosecutive	O
pateints	O
.	O

BACGKROUND	O
:	O
Our	O
aim	O
was	O
to	O
invetsigate	O
postopertaive	O
complicaitons	O
and	O
motrality	O
after	O
adimnistration	O
of	O
aprotniin	O
compraed	O
to	O
tranexmaic	O
aicd	O
in	O
an	O
unselected	O
,	O
consecuitve	O
coohrt	O
.	O

METHODS	O
:	O
Periopeartive	O
dtaa	O
from	O
consceutive	O
cardaic	O
suregry	O
paitents	O
were	O
prospectively	O
collected	O
between	O
Septebmer	O
2005	O
and	O
June	O
2006	O
in	O
a	O
unievrsity	O
-	O
afifliated	O
clniic	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patietns	O
received	O
aproitnin	O
(	O
Gorup	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patietns	O
were	O
treaetd	O
with	O
traenxamic	O
aicd	O
(	O
Gruop	O
T	O
)	O
.	O

Except	O
for	O
antifibrniolytic	O
thearpy	O
,	O
the	O
anestheitc	O
and	O
sugrical	O
protcools	O
remained	O
unchnaged	O
.	O

RSEULTS	O
:	O
The	O
pre	O
-	O
and	O
intraoperaitve	O
vraiables	O
were	O
comparable	O
between	O
the	O
treatemnt	O
gruops	O
.	O

Postoperativley	O
,	O
a	O
significantly	O
hihger	O
incidnece	O
of	O
seiuzres	B-Disease
was	O
found	O
in	O
Gorup	O
T	O
(	O
4	O
.	O
6	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
pirmary	O
vavle	O
sugrery	O
and	O
the	O
high	O
rsik	O
surgrey	O
sbugroups	O
(	O
7	O
.	O
9	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
7	O
.	O
3	O
%	O
vs	O
2	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
035	O
,	O
respectively	O
)	O
.	O

Persistnet	O
artial	O
fibirllation	O
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
reanl	B-Disease
faiulre	I-Disease
(	O
9	O
.	O
7	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
also	O
more	O
common	O
in	O
Gorup	O
T	O
,	O
in	O
the	O
prmiary	O
vavle	O
suregry	O
sugbroup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
pirmary	O
cornoary	O
artrey	O
byapss	O
srugery	O
patinets	O
,	O
there	O
were	O
more	O
actue	O
myocardail	B-Disease
infractions	I-Disease
and	O
reanl	B-Disease
dsyfunction	I-Disease
in	O
Gruop	O
A	O
(	O
5	O
.	O
8	O
%	O
vs	O
2	O
.	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
027	O
;	O
22	O
.	O
5	O
%	O
vs	O
15	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O

The	O
1	O
-	O
yr	O
mortaltiy	O
was	O
significantly	O
higehr	O
after	O
aprotniin	O
tretament	O
in	O
the	O
high	O
rsik	O
srugery	O
gruop	O
(	O
17	O
.	O
7	O
%	O
vs	O
9	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

CONCULSION	O
:	O
Both	O
antfiibrinolytic	O
durgs	O
bear	O
the	O
rsik	O
of	O
advesre	O
outocme	O
depending	O
on	O
the	O
tpye	O
of	O
caridac	O
sugrery	O
.	O

Adminisrtation	O
of	O
aprotiinn	O
should	O
be	O
avoided	O
in	O
coronray	O
artrey	O
byapss	O
grfat	O
and	O
high	O
rsik	O
patinets	O
,	O
whereas	O
adminisrtation	O
of	O
tranexaimc	O
aicd	O
is	O
not	O
recmomended	O
in	O
vlave	O
surgrey	O
.	O

Delriium	B-Disease
in	O
an	O
eldelry	O
wmoan	O
possibly	O
associated	O
with	O
admiinstration	O
of	O
misoprosotl	O
.	O

Misoporstol	O
has	O
been	O
associated	O
with	O
adevrse	O
reactinos	O
,	O
including	O
gsatrointestinal	O
symtpoms	O
,	O
gynceologic	O
prolbems	O
,	O
and	O
haedache	B-Disease
.	O

Cahnges	O
in	O
menatl	O
sattus	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
csae	O
in	O
which	O
an	O
89	O
-	O
yaer	O
-	O
old	O
woamn	O
in	O
a	O
long	O
-	O
term	O
crae	O
faciilty	O
became	O
confused	O
after	O
the	O
initiaiton	O
of	O
misorpostol	O
threapy	O
.	O

The	O
ptaient	O
'	O
s	O
change	O
in	O
mnetal	O
sttaus	O
was	O
first	O
reported	O
nine	O
dyas	O
after	O
the	O
intiiation	O
of	O
therpay	O
.	O

Her	O
deilrium	B-Disease
significantly	O
improevd	O
after	O
misoprosotl	O
was	O
discontniued	O
and	O
her	O
mnetal	O
sttaus	O
returned	O
to	O
noraml	O
within	O
a	O
week	O
.	O

Because	O
no	O
other	O
fcators	O
related	O
to	O
this	O
pateint	O
changed	O
significantly	O
,	O
the	O
deliruim	B-Disease
experienced	O
by	O
this	O
paitent	O
possibly	O
resulted	O
from	O
misporostol	O
thearpy	O
.	O

The	O
bioolgical	O
propreties	O
of	O
the	O
optiacl	O
ismoers	O
of	O
prporanolol	O
and	O
their	O
effects	O
on	O
cradiac	B-Disease
arrhythmias	I-Disease
.	O

1	O
.	O

The	O
opitcal	O
isomres	O
of	O
propranooll	O
have	O
been	O
comapred	O
for	O
their	O
btea	O
-	O
blocikng	O
and	O
atniarrhythmic	O
actiivties	O
.	O
2	O
.	O

In	O
blcoking	O
the	O
poistive	O
inotrpoic	O
and	O
chronotroipc	O
resopnses	O
to	O
isoprnealine	O
,	O
(	O
+	O
)	O
-	O
prorpanolol	O
had	O
less	O
than	O
one	O
hundredth	O
the	O
potnecy	O
of	O
(	O
-	O
)	O
-	O
propranooll	O
.	O

At	O
dsoe	O
levles	O
of	O
(	O
+	O
)	O
-	O
propranlool	O
which	O
attenuated	O
the	O
repsonses	O
to	O
iosprenaline	O
,	O
there	O
was	O
a	O
significant	O
prolognation	O
of	O
the	O
PR	O
intreval	O
of	O
the	O
electrocardiorgam	O
.	O
3	O
.	O

The	O
metabloic	O
responess	O
to	O
isopernaline	O
in	O
dgos	O
(	O
an	O
incraese	O
in	O
circulatnig	O
gluocse	O
,	O
lacatte	O
and	O
free	O
fatty	O
aicds	O
)	O
were	O
all	O
blocekd	O
by	O
(	O
-	O
)	O
-	O
propranlool	O
.	O

(	O
+	O
)	O
-	O
Prorpanolol	O
had	O
no	O
efefct	O
on	O
ftaty	O
aicd	O
mobliization	O
but	O
significantly	O
reudced	O
the	O
incremnets	O
in	O
both	O
latcate	O
and	O
glucsoe	O
.	O
4	O
.	O

Both	O
isomres	O
of	O
porpranolol	O
possessed	O
similar	O
deprsesant	O
poetncy	O
on	O
isloated	O
artial	O
msucle	O
taken	O
from	O
guniea	O
-	O
pgis	O
.	O
5	O
.	O

The	O
ismoers	O
of	O
proparnolol	O
exhibited	O
similar	O
lcoal	O
aneasthetic	O
potenceis	O
on	O
an	O
isloated	O
forg	O
nevre	O
preparatoin	O
at	O
a	O
lveel	O
approximately	O
three	O
times	O
that	O
of	O
prociane	O
.	O

The	O
racmeic	O
componud	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
ismoer	O
.	O
6	O
.	O

Both	O
ismoers	O
of	O
proprnaolol	O
were	O
capable	O
of	O
preventing	O
adreanline	O
-	O
inudced	O
cradiac	B-Disease
arryhthmias	I-Disease
in	O
ctas	O
anasethetized	O
with	O
halohtane	O
,	O
but	O
the	O
mean	O
dsoe	O
of	O
(	O
-	O
)	O
-	O
propraonlol	O
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
prporanolol	O
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effectvie	O
dsoe	O
leevl	O
of	O
(	O
+	O
)	O
-	O
propraonlol	O
there	O
was	O
a	O
significant	O
prolnogation	O
of	O
the	O
PR	O
itnerval	O
of	O
the	O
electrocradiogram	O
.	O

Blocakde	O
of	O
arrhythimas	B-Disease
with	O
both	O
isomres	O
was	O
surmountable	O
by	O
icnreasing	O
the	O
dsoe	O
of	O
adrenailne	O
.	O
7	O
.	O

Both	O
isoemrs	O
of	O
prorpanolol	O
were	O
also	O
capable	O
of	O
revesring	O
ventriuclar	B-Disease
tahcycardia	I-Disease
caused	O
by	O
ouabian	O
in	O
anaestehtized	O
ctas	O
and	O
dgos	O
.	O

The	O
dsoe	O
of	O
(	O
-	O
)	O
-	O
porpranolol	O
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
porpranolol	O
in	O
both	O
sepcies	O
but	O
much	O
higehr	O
than	O
that	O
required	O
to	O
produce	O
eviednce	O
of	O
btea	O
-	O
bolckade	O
.	O
8	O
.	O

The	O
implications	O
of	O
these	O
resutls	O
are	O
discussed	O
.	O

Tooptecan	O
in	O
comibnation	O
with	O
raidotherapy	O
in	O
unrseectable	O
glioblsatoma	B-Disease
:	O
a	O
phsae	O
2	O
stduy	O
.	O

Imporving	O
glioblasotma	B-Disease
mulitforme	I-Disease
(	O
GBM	B-Disease
)	O
traetment	O
with	O
raido	O
-	O
chemothearpy	O
remains	O
a	O
challenge	O
.	O

Topoteacn	O
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
gorwth	O
inihbition	O
of	O
huamn	O
glimoa	B-Disease
as	O
well	O
as	O
brian	O
penetartion	O
.	O

The	O
present	O
stduy	O
asssesed	O
the	O
combinaiton	O
of	O
radiotherpay	O
(	O
60	O
Gy	O
/	O
30	O
frcations	O
/	O
40	O
dyas	O
)	O
and	O
topoteacn	O
(	O
0	O
.	O
9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
dyas	O
1	O
-	O
5	O
on	O
wekes	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
audlts	O
with	O
histolgoically	O
proven	O
and	O
untretaed	O
GBM	B-Disease
.	O

The	O
incidecne	O
of	O
non	O
-	O
hmeatological	O
txoicities	B-Disease
was	O
low	O
and	O
garde	O
3	O
-	O
4	O
hmeatological	O
toxiciteis	B-Disease
were	O
reported	O
in	O
20	O
patinets	O
(	O
mainly	O
lympohpenia	B-Disease
and	O
neutropeina	B-Disease
)	O
.	O

Parital	O
repsonse	O
and	O
stabliization	O
raets	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
tmie	O
to	O
progerssion	O
of	O
12	O
weeks	O
.	O

One	O
-	O
yaer	O
overall	O
suvrival	O
(	O
OS	O
)	O
rtae	O
was	O
42	O
%	O
,	O
with	O
a	O
mdeian	O
OS	O
of	O
40	O
weeks	O
.	O

Tpootecan	O
in	O
combiantion	O
with	O
radoitherapy	O
was	O
well	O
tolearted	O
.	O

However	O
,	O
while	O
rseponse	O
and	O
satbilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patinets	O
,	O
the	O
sutdy	O
did	O
not	O
show	O
increaesd	O
bneefits	O
in	O
terms	O
of	O
suvrival	O
in	O
patinets	O
with	O
unresetcable	O
GBM	B-Disease
.	O

Lnog	O
-	O
term	O
lithuim	O
therpay	O
leading	O
to	O
hypreparathyroidism	B-Disease
:	O
a	O
csae	O
reoprt	O
.	O

PUPROSE	O
:	O
This	O
paper	O
rveiews	O
the	O
effect	O
of	O
chrnoic	O
ltihium	O
threapy	O
on	O
seurm	O
caclium	O
leevl	O
and	O
parahtyroid	O
glnads	O
,	O
its	O
pathoegnesis	O
,	O
and	O
treatemnt	O
optoins	O
.	O

We	O
examined	O
the	O
csae	O
of	O
a	O
lithuim	O
-	O
traeted	O
patinet	O
who	O
had	O
recurrent	O
hyperclacemia	B-Disease
to	O
better	O
understand	O
the	O
disaese	O
proecss	O
.	O

CONCLUSOIN	O
:	O
Priamry	B-Disease
hypeprarathyroidism	I-Disease
is	O
a	O
rrae	O
but	O
potentially	O
lfie	O
-	O
threatening	O
side	O
efefct	O
of	O
long	O
-	O
term	O
ltihium	O
thearpy	O
.	O

Careful	O
pateint	O
seleciton	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
rdeuce	O
morbdiity	O
.	O

PRACTICAL	O
IMPLCIATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
ltihium	O
-	O
terated	O
paitents	O
become	O
hpyercalcemic	B-Disease
.	O

By	O
routinely	O
monitornig	O
sreum	O
calcuim	O
leevls	O
,	O
healhtcare	O
porviders	O
can	O
ipmrove	O
the	O
qualtiy	O
of	O
lfie	O
of	O
this	O
patinet	O
gruop	O
.	O

Compairson	O
of	O
larynegal	O
msak	O
with	O
enodtracheal	O
tbue	O
for	O
ansethesia	O
in	O
enodscopic	O
siuns	O
surgrey	O
.	O

BACKGRONUD	O
:	O
The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
copmare	O
surigcal	O
conidtions	O
,	O
including	O
the	O
amonut	O
of	O
intraopeartive	O
bledeing	B-Disease
as	O
well	O
as	O
intraopreative	O
blood	O
presusre	O
,	O
during	O
fnuctional	O
endosocpic	O
snius	O
srugery	O
(	O
FSES	O
)	O
using	O
felxible	O
reinforced	O
lrayngeal	O
msak	O
ariway	O
(	O
FLRMA	O
)	O
versus	O
endortacheal	O
tbue	O
(	O
ETT	O
)	O
in	O
maintaining	O
contorlled	O
hypotensoin	B-Disease
ansethesia	O
indcued	O
by	O
proopfol	O
-	O
remifentainl	O
total	O
i	O
.	O
v	O
.	O
ansethesia	O
(	O
TVIA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
normotenisve	O
Ameriacn	O
Scoiety	O
of	O
Aneshtesiologists	O
I	O
-	O
II	O
adlut	O
patinets	O
undergoing	O
FSES	O
under	O
contorlled	O
hypotenison	B-Disease
aensthesia	O
caused	O
by	O
proopfol	O
-	O
remifetnanil	O
-	O
TVIA	O
were	O
randomly	O
assigned	O
into	O
two	O
gruops	O
:	O
gruop	O
I	O
,	O
FLRMA	O
;	O
gruop	O
II	O
,	O
ETT	O
.	O

Heomrrhage	B-Disease
was	O
maesured	O
and	O
the	O
viisbility	O
of	O
the	O
opertaive	O
field	O
was	O
evaulated	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

REUSLTS	O
:	O
Cotnrolled	O
hypoetnsion	B-Disease
was	O
achieved	O
within	O
a	O
shroter	O
peroid	O
using	O
larnygeal	O
msak	O
using	O
loewr	O
raets	O
of	O
remifetnanil	O
infuison	O
and	O
lwoer	O
total	O
dsoe	O
of	O
rmeifentanil	O
.	O

CNOCLUSION	O
:	O
In	O
summary	O
,	O
our	O
rseults	O
indicate	O
that	O
airawy	O
managemnet	O
using	O
FRMLA	O
during	O
controlled	O
hypotnesion	B-Disease
aensthesia	O
provided	O
better	O
surigcal	O
codnitions	O
in	O
terms	O
of	O
qulaity	O
of	O
operatvie	O
field	O
and	O
blood	O
lsos	O
and	O
allowed	O
for	O
convenient	O
idnuced	O
hyptoension	B-Disease
with	O
low	O
dsoes	O
of	O
remfientanil	O
during	O
TVIA	O
in	O
patietns	O
undergoing	O
FSES	O
.	O

Nonalcohoilc	B-Disease
ftaty	I-Disease
lievr	I-Disease
disaese	I-Disease
during	O
valprotae	O
thearpy	O
.	O

Vaplroic	O
aicd	O
(	O
VPA	O
)	O
is	O
efefctive	O
for	O
the	O
traetment	O
of	O
many	O
types	O
of	O
epielpsy	B-Disease
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
icnrease	O
in	O
bdoy	O
weihgt	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
nonalcoohlic	B-Disease
fatty	I-Disease
lvier	I-Disease
disaese	I-Disease
(	O
NALFD	B-Disease
)	O
arising	O
in	O
a	O
chlid	O
who	O
developed	O
obestiy	B-Disease
during	O
VPA	O
traetment	O
.	O

Labortaory	O
dtaa	O
revaeled	O
hypeirnsulinemia	B-Disease
with	O
insuiln	B-Disease
resistnace	I-Disease
.	O

After	O
the	O
wtihdrawal	O
of	O
VPA	O
therpay	O
,	O
our	O
paitent	O
showed	O
a	O
significant	O
weihgt	B-Disease
lsos	I-Disease
,	O
a	O
dercease	O
of	O
bdoy	O
msas	O
index	O
,	O
and	O
normalizatoin	O
of	O
meatbolic	O
and	O
enodcrine	O
praameters	O
;	O
moreover	O
,	O
ultrasuond	O
measruements	O
showed	O
a	O
complete	O
nromalization	O
.	O

The	O
present	O
csae	O
suggests	O
that	O
obeisty	B-Disease
,	O
hyperinsluinemia	B-Disease
,	O
insluin	B-Disease
rseistance	I-Disease
,	O
and	O
long	O
-	O
term	O
treatemnt	O
with	O
VPA	O
may	O
be	O
all	O
associated	O
with	O
the	O
developmnet	O
of	O
NALFD	B-Disease
;	O
this	O
side	O
efefct	O
is	O
reversible	O
after	O
VPA	O
withrdawal	O
.	O

Caribmazole	O
inudced	O
ACNA	B-Disease
poistive	I-Disease
vascuiltis	I-Disease
.	O

Atni	O
-	O
thyriod	O
drgus	O
,	O
like	O
cabrimazole	O
and	O
propyltihouracil	O
(	O
PTU	O
)	O
are	O
commonly	O
prescriebd	O
for	O
the	O
traetment	O
of	O
hyperthyrodiism	B-Disease
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effcets	O
of	O
antithyriod	O
medciations	O
.	O

Antineutrohpil	B-Disease
cytoplasimc	I-Disease
antiobdy	I-Disease
(	I-Disease
ACNA	I-Disease
)	I-Disease
-	I-Disease
-	I-Disease
associated	I-Disease
vasculiits	I-Disease
is	O
a	O
potentially	O
lfie	O
-	O
threatening	O
avderse	O
effect	O
of	O
antithyroidmedications	O
.	O

We	O
rpeort	O
a	O
paitent	O
with	O
Graevs	B-Disease
'	I-Disease
disaese	I-Disease
who	O
developed	O
ACNA	O
postiive	O
crabimazole	O
induecd	O
vasuclitis	B-Disease
.	O

The	O
epiosde	O
was	O
characteriezd	O
by	O
a	O
vascuiltic	B-Disease
sikn	B-Disease
rsah	I-Disease
associated	O
with	O
large	O
jonit	O
arthirtis	B-Disease
,	O
pyrxeia	B-Disease
and	O
paortiditis	B-Disease
but	O
no	O
rneal	O
or	O
pulmonray	O
inovlvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurologcial	O
evaluatoin	O
because	O
he	O
had	O
difficutly	O
in	O
getting	O
up	O
from	O
squatitng	O
psoition	O
and	O
was	O
ssupected	O
to	O
have	O
mysoitis	B-Disease
.	O

Caribmazole	O
and	O
methimzaole	O
have	O
a	O
loewr	O
incidecne	O
of	O
reported	O
ACNA	O
posiitve	O
side	O
effetcs	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowldege	O
this	O
is	O
the	O
first	O
ACNA	O
posiitve	O
carbimazloe	O
indcued	O
vascuiltis	B-Disease
csae	O
reported	O
from	O
Inida	O
.	O

Aspriin	O
for	O
the	O
pirmary	O
preevntion	O
of	O
cardiovasuclar	O
eevnts	O
:	O
an	O
update	O
of	O
the	O
eivdence	O
for	O
the	O
U	O
.	O
S	O
.	O

Perventive	O
Srevices	O
Tsak	O
Focre	O
.	O

BACKGRONUD	O
:	O
Croonary	B-Disease
herat	I-Disease
disaese	I-Disease
and	O
cererbovascular	B-Disease
dsiease	I-Disease
are	O
leading	O
causes	O
of	O
detah	O
in	O
the	O
Unietd	O
Staets	O
.	O

In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O

Perventive	O
Srevices	O
Tsak	O
Froce	O
(	O
USPTSF	O
)	O
strongly	O
reocmmended	O
that	O
cliincians	O
discuss	O
aspriin	O
with	O
audlts	O
who	O
are	O
at	O
incerased	O
rsik	O
for	O
coornary	B-Disease
haert	I-Disease
disaese	I-Disease
.	O

PRUPOSE	O
:	O
To	O
determine	O
the	O
benfeits	O
and	O
hrams	O
of	O
taking	O
aspriin	O
for	O
the	O
priamry	O
preevntion	O
of	O
moycardial	B-Disease
ifnarctions	I-Disease
,	O
storkes	B-Disease
,	O
and	O
daeth	O
.	O

DTAA	O
SOUCRES	O
:	O
MELDINE	O
and	O
Cocharne	O
Lirbary	O
(	O
search	O
dtaes	O
,	O
1	O
Jnauary	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
systemaitc	O
rveiews	O
,	O
refernece	O
litss	O
of	O
retrieved	O
articels	O
,	O
and	O
suggestions	O
from	O
expetrs	O
.	O

SUTDY	O
SELECTION	O
:	O
Enlgish	O
-	O
lagnuage	O
radnomized	O
,	O
cnotrolled	O
trilas	O
(	O
RTCs	O
)	O
;	O
csae	O
-	O
conrtol	O
stuides	O
;	O
mtea	O
-	O
anaylses	O
;	O
and	O
systeamtic	O
reviwes	O
of	O
aspiirn	O
versus	O
contorl	O
for	O
the	O
pirmary	O
preventoin	O
of	O
cadriovascular	B-Disease
diesase	I-Disease
(	O
CVD	B-Disease
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
qusetions	O
:	O
Does	O
asiprin	O
decresae	O
coroanry	O
herat	O
evetns	O
,	O
storkes	B-Disease
,	O
daeth	O
from	O
cornoary	O
herat	O
eevnts	O
or	O
srtoke	B-Disease
,	O
or	O
all	O
-	O
cause	O
mortailty	O
in	O
adutls	O
without	O
known	O
CVD	B-Disease
?	O

Does	O
aspiirn	O
incraese	O
gsatrointestinal	B-Disease
bledeing	I-Disease
or	O
hemorhragic	B-Disease
storkes	I-Disease
?	O

DTAA	O
EXTRACTION	O
:	O
All	O
stduies	O
were	O
reviweed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
qaulity	O
by	O
using	O
predefined	O
USSPTF	O
criteira	O
.	O

DTAA	O
SYTNHESIS	O
:	O
New	O
evdience	O
from	O
1	O
good	O
-	O
qaulity	O
RCT	O
,	O
1	O
good	O
-	O
qulaity	O
mtea	O
-	O
anaylsis	O
,	O
and	O
2	O
fair	O
-	O
quailty	O
suabnalyses	O
of	O
RTCs	O
demonstrates	O
that	O
apsirin	O
use	O
reudces	O
the	O
number	O
of	O
CVD	B-Disease
evetns	O
in	O
patinets	O
without	O
known	O
CVD	B-Disease
.	O

Men	O
in	O
these	O
sutdies	O
experienced	O
fewer	O
mycoardial	B-Disease
infarctinos	I-Disease
and	O
woemn	O
experienced	O
fewer	O
icshemic	O
stroeks	B-Disease
.	O

Aspriin	O
does	O
not	O
seem	O
to	O
affect	O
CVD	B-Disease
mortailty	O
or	O
all	O
-	O
cause	O
mortaltiy	O
in	O
either	O
men	O
or	O
wmoen	O
.	O

The	O
use	O
of	O
aspiirn	O
for	O
primray	O
preveniton	O
incraeses	O
the	O
rsik	O
for	O
major	O
bleeding	B-Disease
eevnts	O
,	O
primarily	O
gasrtointestinal	B-Disease
beleding	I-Disease
eevnts	O
,	O
in	O
both	O
men	O
and	O
woemn	O
.	O

Men	O
have	O
an	O
incerased	O
rsik	O
for	O
heomrrhagic	B-Disease
stroeks	I-Disease
with	O
asiprin	O
use	O
.	O

A	O
new	O
RCT	O
and	O
mtea	O
-	O
analyiss	O
suggest	O
that	O
the	O
rsik	O
for	O
hemorrhagic	B-Disease
strkoes	I-Disease
in	O
wmoen	O
is	O
not	O
staitstically	O
significantly	O
incresaed	O
.	O

LIMITATINOS	O
:	O
New	O
eviednce	O
on	O
aspriin	O
for	O
the	O
primray	O
preevntion	O
of	O
CVD	B-Disease
is	O
limietd	O
.	O

The	O
dsoe	O
of	O
aspiirn	O
used	O
in	O
the	O
RTCs	O
varied	O
,	O
which	O
prevented	O
the	O
etsimation	O
of	O
the	O
most	O
appropriate	O
dsoe	O
for	O
priamry	O
prevnetion	O
.	O

Several	O
of	O
the	O
RTCs	O
were	O
conducted	O
within	O
popualtions	O
of	O
helath	O
porfessionals	O
,	O
which	O
potentially	O
lmiits	O
generaliazbility	O
.	O

CONCLSUION	O
:	O
Aspriin	O
rdeuces	O
the	O
rsik	O
for	O
moycardial	B-Disease
infarctoin	I-Disease
in	O
men	O
and	O
storkes	B-Disease
in	O
wmoen	O
.	O

Apsirin	O
use	O
increaess	O
the	O
rsik	O
for	O
serious	O
bleeding	B-Disease
evnets	O
.	O

Reudcing	O
hram	O
associated	O
with	O
anticoagluation	O
:	O
practical	O
considertaions	O
of	O
argatroabn	O
therpay	O
in	O
heaprin	O
-	O
indcued	O
thrmobocytopenia	B-Disease
.	O

Argartoban	O
is	O
a	O
heptaically	O
metaboilzed	O
,	O
direct	O
throbmin	O
inihbitor	O
used	O
for	O
propyhlaxis	O
or	O
treatmnet	O
of	O
thromboiss	B-Disease
in	O
heaprin	O
-	O
inudced	O
thrombocytopeina	B-Disease
(	O
HIT	B-Disease
)	O
and	O
for	O
patinets	O
with	O
or	O
at	O
rsik	O
of	O
HIT	B-Disease
undergoing	O
percuatneous	O
cornoary	O
intrevention	O
(	O
PCI	O
)	O
.	O

The	O
ojbective	O
of	O
this	O
reveiw	O
is	O
to	O
summarize	O
practical	O
conisderations	O
of	O
argtaroban	O
therpay	O
in	O
HIT	B-Disease
.	O

The	O
US	O
FDA	O
-	O
reocmmended	O
argatorban	O
dsoe	O
in	O
HIT	B-Disease
is	O
2	O
mircog	O
/	O
kg	O
/	O
min	O
(	O
redcued	O
in	O
paitents	O
with	O
heaptic	B-Disease
impairmnet	I-Disease
and	O
in	O
paedaitric	O
pateints	O
)	O
,	O
adjusted	O
to	O
achieve	O
activtaed	O
pratial	O
thrombolpastin	O
times	O
(	O
aTPTs	O
)	O
1	O
.	O
5	O
-	O
3	O
times	O
basleine	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experineces	O
indicate	O
that	O
rdeuced	O
dsoes	O
are	O
also	O
needed	O
in	O
paitents	O
with	O
conidtions	O
associated	O
with	O
heaptic	O
hypoperfsuion	O
,	O
e	O
.	O
g	O
.	O
haert	B-Disease
fialure	I-Disease
,	O
yet	O
are	O
unnecessary	O
for	O
rneal	B-Disease
dsyfunction	I-Disease
,	O
audlt	O
age	O
,	O
sex	O
,	O
rcae	O
/	O
ethnictiy	O
or	O
obseity	B-Disease
.	O

Argtaroban	O
0	O
.	O
5	O
-	O
1	O
.	O
2	O
micorg	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
tehrapeutic	O
aTPTs	O
.	O

The	O
FDA	O
-	O
reocmmended	O
dsoe	O
during	O
PCI	O
is	O
25	O
mircog	O
/	O
kg	O
/	O
min	O
(	O
350	O
micorg	O
/	O
kg	O
initial	O
bouls	O
)	O
,	O
adjusted	O
to	O
achieve	O
activtaed	O
cltoting	O
times	O
(	O
ATCs	O
)	O
of	O
300	O
-	O
450	O
sec	O
.	O

For	O
PCI	O
,	O
argtaroban	O
has	O
not	O
been	O
invsetigated	O
in	O
hepaticlaly	O
impiared	O
pateints	O
;	O
dsoe	O
adujstment	O
is	O
unnecessary	O
for	O
adlut	O
age	O
,	O
sex	O
,	O
rcae	O
/	O
ethniicty	O
or	O
oebsity	B-Disease
,	O
and	O
lesser	O
dsoes	O
may	O
be	O
adeqaute	O
with	O
cocnurrent	O
glycorpotein	O
IIb	O
/	O
IIIa	O
inhibitoin	O
.	O

Argatorban	O
prologns	O
the	O
Intenrational	O
Normalzied	O
Rtaio	O
,	O
and	O
pubilshed	O
approaches	O
for	O
monitornig	O
the	O
argatrboan	O
-	O
to	O
-	O
wafrarin	O
transiiton	O
should	O
be	O
followed	O
.	O

Major	O
bleeding	B-Disease
with	O
argatroabn	O
is	O
0	O
-	O
10	O
%	O
in	O
the	O
non	O
-	O
interventioanl	O
setting	O
and	O
0	O
-	O
5	O
.	O
8	O
%	O
perpirocedurally	O
.	O

Argatroabn	O
has	O
no	O
specific	O
antidtoe	O
,	O
and	O
if	O
excessvie	O
antcioagulation	O
occurs	O
,	O
argtaroban	O
infsuion	O
should	O
be	O
stopped	O
or	O
reudced	O
.	O

Improved	O
familairity	O
of	O
haelthcare	O
professoinals	O
with	O
aragtroban	O
tehrapy	O
in	O
HIT	B-Disease
,	O
including	O
in	O
special	O
populaitons	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reudction	O
of	O
hram	O
associated	O
with	O
HIT	B-Disease
(	O
e	O
.	O
g	O
.	O
fewer	O
throbmoses	O
)	O
or	O
its	O
teratment	O
(	O
e	O
.	O
g	O
.	O
fewer	O
argatorban	O
mdeication	O
erorrs	O
)	O
.	O

Rhbadomyolysis	B-Disease
and	O
barin	O
ishcemic	B-Disease
strkoe	I-Disease
in	O
a	O
hreoin	O
-	O
dependnet	O
mlae	O
under	O
methaodne	O
mainetnance	O
therpay	O
.	O

OBJCETIVE	O
:	O
There	O
are	O
several	O
complictaions	O
associated	O
with	O
heorin	B-Disease
absue	I-Disease
,	O
some	O
of	O
which	O
are	O
lfie	O
-	O
threatening	O
.	O

Mehtadone	O
may	O
aggravtae	O
this	O
prolbem	O
.	O

METHOD	O
:	O
A	O
cliniacl	O
csae	O
description	O
.	O

REUSLTS	O
:	O
A	O
33	O
-	O
yaer	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyolsyis	B-Disease
and	O
ceerbral	O
icshemic	B-Disease
storke	I-Disease
after	O
intraevnous	O
heorin	O
.	O

He	O
had	O
used	O
herion	O
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
mehtadone	O
daliy	O
for	O
6	O
mnoths	O
.	O

He	O
was	O
found	O
ucnonsciousness	B-Disease
at	O
hmoe	O
and	O
was	O
sent	O
to	O
our	O
hopsital	O
.	O

In	O
the	O
ER	O
,	O
his	O
opaite	O
lveel	O
was	O
4497	O
ng	O
/	O
ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolyiss	B-Disease
,	O
aucte	B-Disease
rneal	I-Disease
failrue	I-Disease
and	O
actue	O
respriatory	B-Disease
failrue	I-Disease
.	O

After	O
transefr	O
to	O
an	O
intrenal	O
wrad	O
,	O
we	O
noted	O
aphaisa	B-Disease
and	O
wekaness	B-Disease
of	O
his	O
lfet	O
libms	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cererbal	B-Disease
ischmeic	I-Disease
infacrtion	I-Disease
.	O

CONLCUSION	O
:	O
Those	O
using	O
methaodne	O
and	O
hreoin	O
simultaenously	O
may	O
incresae	O
rsik	O
of	O
rhabdomyloysis	B-Disease
and	O
ischeimc	B-Disease
strkoe	I-Disease
.	O

Paitents	O
under	O
metahdone	O
mainetnance	O
therpay	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
avderse	O
evnets	O
.	O

Hypotheess	O
of	O
hreoin	O
-	O
related	O
rhabodmyolysis	B-Disease
and	O
storke	B-Disease
in	O
heorin	O
abuesrs	O
are	O
discussed	O
.	O

Inrceased	O
vulenrability	O
to	O
6	O
-	O
hyrdoxydopamine	O
leison	O
and	O
rdeuced	O
developemnt	O
of	O
dyksinesias	B-Disease
in	O
mcie	O
lacking	O
CB1	O
cananbinoid	O
recepotrs	O
.	O

Mootr	O
ipmairment	O
,	O
dopamnie	O
(	O
DA	O
)	O
neruonal	O
atcivity	O
and	O
proenkehpalin	O
(	O
PNEK	O
)	O
gnee	O
expresison	O
in	O
the	O
cuadate	O
-	O
putaemn	O
(	O
CPu	O
)	O
were	O
meausred	O
in	O
6	O
-	O
ODHA	O
-	O
lesioend	O
and	O
treaetd	O
(	O
L	O
-	O
DPOA	O
+	O
bneserazide	O
)	O
CB1	O
KO	O
and	O
WT	O
mcie	O
.	O

A	O
lesoin	O
inudced	O
by	O
6	O
-	O
ODHA	O
produced	O
more	O
sevree	O
mootr	O
deetrioration	O
in	O
CB1	O
KO	O
mcie	O
accompanied	O
by	O
more	O
lsos	O
of	O
DA	O
neurnos	O
and	O
incresaed	O
PNEK	O
gnee	O
expressoin	O
in	O
the	O
CPu	O
.	O

Oixdative	O
/	O
nitrosaitve	O
and	O
neuroniflammatory	O
paarmeters	O
were	O
esitmated	O
in	O
the	O
CPu	O
and	O
cingultae	O
crotex	O
(	O
Cg	O
)	O
.	O

CB1	O
KO	O
mcie	O
exhibited	O
higehr	O
MDA	O
lveels	O
and	O
iONS	O
portein	O
epxression	O
in	O
the	O
CPu	O
and	O
Cg	O
compaerd	O
to	O
WT	O
mcie	O
.	O

Treatemnt	O
with	O
L	O
-	O
DPOA	O
+	O
benserzaide	O
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
sveere	O
dyskinesais	B-Disease
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mcie	O
.	O

The	O
resutls	O
reevaled	O
that	O
the	O
lcak	O
of	O
cannabiniod	O
CB1	O
reecptors	O
incraesed	O
the	O
sveerity	O
of	O
mootr	O
impariment	O
and	O
DA	O
lesoin	O
,	O
and	O
reudced	O
L	O
-	O
DPOA	O
-	O
induecd	O
dyskiensias	B-Disease
.	O

These	O
reuslts	O
suggest	O
that	O
atcivation	O
of	O
CB1	O
reecptors	O
offers	O
neuorprotection	O
against	O
dpoaminergic	O
leison	O
and	O
the	O
dveelopment	O
of	O
L	O
-	O
DPOA	O
-	O
indcued	O
dsykinesias	B-Disease
.	O

Hepatoclelular	O
oxdiant	O
sterss	O
following	O
intsetinal	O
icshemia	B-Disease
-	O
reperfusoin	B-Disease
ijnury	I-Disease
.	O

Reperfuison	O
of	O
ischeimc	B-Disease
intesitne	O
reuslts	O
in	O
aucte	O
lievr	B-Disease
dyfsunction	I-Disease
charactreized	O
by	O
hepatocellualr	O
enzmye	O
rleease	O
into	O
plamsa	O
,	O
reduciton	O
in	O
blie	O
folw	O
rtae	O
,	O
and	O
neutrpohil	O
sequestraiton	O
within	O
the	O
lievr	O
.	O

The	O
pathpohysiology	O
underlying	O
this	O
actue	O
heptaic	B-Disease
ijnury	I-Disease
is	O
unknown	O
.	O

This	O
sutdy	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidnats	O
are	O
associated	O
with	O
the	O
heaptic	B-Disease
ijnury	I-Disease
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indierct	O
methdos	O
of	O
assessing	O
oxiadnt	O
exposrue	O
in	O
vivo	O
.	O

Rtas	O
were	O
subjected	O
to	O
a	O
standradized	O
intetsinal	O
ischmeia	B-Disease
-	O
reperfuison	B-Disease
injruy	I-Disease
.	O

Hpeatic	O
tissue	O
was	O
assayed	O
for	O
lpiid	O
peroxidatoin	O
prdoucts	O
and	O
oxidzied	O
and	O
redcued	O
glutahtione	O
.	O

There	O
was	O
no	O
change	O
in	O
hepaitc	O
tissue	O
total	O
glutathoine	O
following	O
inetstinal	O
ischeima	B-Disease
-	O
reprefusion	B-Disease
ijnury	I-Disease
.	O

Oixdized	O
glutahtione	O
(	O
GSSG	O
)	O
icnreased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperufsion	O
.	O

There	O
was	O
no	O
incerase	O
in	O
any	O
of	O
the	O
prdoucts	O
of	O
liipd	O
peroxidtaion	O
associated	O
with	O
this	O
injruy	O
.	O

An	O
incresae	O
in	O
GSSG	O
within	O
hepaitc	O
tisuse	O
during	O
intestianl	O
reeprfusion	O
suggests	O
exposrue	O
of	O
hepatoyctes	O
to	O
an	O
oixdant	O
sterss	O
.	O

The	O
lcak	O
of	O
a	O
significant	O
incerase	O
in	O
produtcs	O
of	O
liipd	O
peroxidaiton	O
suggests	O
that	O
the	O
oxdiant	O
srtess	O
is	O
of	O
insufficient	O
magniutde	O
to	O
result	O
in	O
irrevresible	O
inujry	O
to	O
hepatoycte	O
clel	O
mmebranes	O
.	O

These	O
dtaa	O
also	O
suggest	O
that	O
the	O
meausrement	O
of	O
tsisue	O
GSSG	O
may	O
be	O
a	O
more	O
senstiive	O
inidcator	O
of	O
oxidnat	O
sterss	O
than	O
measuremnet	O
of	O
produtcs	O
of	O
lpiid	O
preoxidation	O
.	O

Anmial	O
mdoel	O
of	O
maina	B-Disease
idnuced	O
by	O
oubaain	O
:	O
Eviednce	O
of	O
oxiadtive	O
strses	O
in	O
submitocohndrial	O
partciles	O
of	O
the	O
rat	O
brian	O
.	O

The	O
intracerebroventricualr	O
(	O
ICV	O
)	O
administartion	O
of	O
oubaain	O
(	O
a	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATaPse	O
inhibtior	O
)	O
in	O
rtas	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
sympotms	O
of	O
hmuan	O
bioplar	B-Disease
maina	I-Disease
.	O

Clincial	O
sutdies	O
have	O
shown	O
that	O
bioplar	B-Disease
disoredr	I-Disease
may	O
be	O
related	O
to	O
mitochonrdial	B-Disease
dysfnuction	I-Disease
.	O

Herein	O
,	O
we	O
investgiated	O
the	O
beahvioral	O
and	O
biocehmical	O
effcets	O
idnuced	O
by	O
the	O
ICV	O
adminisrtation	O
of	O
oubaain	O
in	O
rtas	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
efefcts	O
of	O
oubaain	O
injeciton	O
immediately	O
after	O
and	O
7	O
dyas	O
following	O
a	O
single	O
ICV	O
adimnistration	O
(	O
at	O
conecntrations	O
of	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
)	O
on	O
lcoomotion	O
was	O
measuerd	O
using	O
the	O
open	O
-	O
field	O
tset	O
.	O

Additionally	O
,	O
thiobrabituric	O
aicd	O
reactvie	O
substnaces	O
(	O
TABRSs	O
)	O
and	O
supeorxide	O
prodcution	O
were	O
maesured	O
in	O
submitochnodrial	O
patricles	O
of	O
the	O
prerfontal	O
cotrex	O
,	O
hippocampus	O
,	O
straitum	O
and	O
aymgdala	O
.	O

Our	O
fidnings	O
demonstrated	O
that	O
ouaabin	O
at	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
induecd	O
hyperlocomoiton	B-Disease
in	O
rtas	O
,	O
and	O
this	O
rseponse	O
remained	O
up	O
to	O
7	O
dyas	O
following	O
a	O
single	O
ICV	O
injcetion	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
perssitent	O
incraese	O
in	O
the	O
rat	O
sponatneous	O
locmootion	O
is	O
associated	O
with	O
inrceased	O
TBRAS	O
levles	O
and	O
spueroxide	O
gneeration	O
in	O
submiotchondrial	O
praticles	O
in	O
the	O
preforntal	O
coretx	O
,	O
straitum	O
and	O
amgydala	O
.	O

In	O
conclusion	O
,	O
oaubain	O
-	O
induecd	O
mnaia	B-Disease
-	O
like	O
behvaior	O
may	O
provide	O
a	O
useful	O
ainmal	O
moedl	O
to	O
tset	O
the	O
hyopthesis	O
of	O
the	O
ivnolvement	O
of	O
oxiadtive	O
sterss	O
in	O
bpiolar	B-Disease
diosrder	I-Disease
.	O

Intraopeartive	O
dialsyis	O
during	O
lievr	O
transplantaiton	O
with	O
citrtae	O
dialyaste	O
.	O

Lvier	O
trnasplantation	O
for	O
acutely	O
ill	O
pateints	O
with	O
fumlinant	B-Disease
lievr	I-Disease
faliure	I-Disease
carries	O
high	O
intraoperatvie	O
and	O
immeidate	O
potsoperative	O
rsiks	O
.	O

These	O
are	O
icnreased	O
with	O
the	O
preesnce	O
of	O
conocmitant	O
aucte	B-Disease
kindey	I-Disease
inujry	I-Disease
(	O
AKI	B-Disease
)	O
and	O
intraopeartive	O
dilaysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
trasnplant	O
to	O
proceed	O
.	O

The	O
derangemetns	O
in	O
the	O
prcooagulant	O
and	O
anticoauglant	O
ptahways	O
during	O
fumlinant	B-Disease
lvier	I-Disease
faliure	I-Disease
can	O
lead	O
to	O
diffciulties	O
with	O
anticoagulaiton	O
during	O
dilaysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operatnig	O
room	O
.	O

Sytsemic	O
anticoauglation	O
is	O
unsafe	O
and	O
reginoal	O
citrtae	O
anticoagualtion	O
in	O
the	O
absnece	O
of	O
a	O
functoinal	O
lvier	O
carries	O
the	O
rsik	O
of	O
citrtae	O
toxciity	B-Disease
.	O

Cirtate	O
dailysate	O
,	O
a	O
new	O
dialystae	O
with	O
cirtic	O
aicd	O
can	O
be	O
used	O
for	O
anticoauglation	O
in	O
patietns	O
who	O
cannot	O
tolerate	O
hpearin	O
or	O
reigonal	O
citrtae	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
a	O
40	O
-	O
yaer	O
-	O
old	O
fmeale	O
with	O
acetamniophen	O
-	O
indcued	O
fulminnat	B-Disease
lvier	I-Disease
failrue	I-Disease
with	O
associated	O
AKI	B-Disease
who	O
underwent	O
intraopeartive	O
dailytic	O
support	O
during	O
lvier	O
trnasplantation	O
anticoauglated	O
with	O
citarte	O
dialyaste	O
during	O
the	O
entire	O
proecdure	O
.	O

The	O
paitent	O
tolertaed	O
the	O
procedrue	O
well	O
without	O
any	O
sings	O
of	O
citarte	O
toixcity	B-Disease
and	O
maintained	O
adequtae	O
anitcoagulation	O
for	O
patecny	O
of	O
the	O
diaylsis	O
cirucit	O
.	O

Citrtae	O
dialystae	O
is	O
a	O
safe	O
alterantive	O
for	O
intradialtyic	O
support	O
of	O
lvier	O
tranpslantation	O
in	O
fulmiannt	B-Disease
lvier	I-Disease
faliure	I-Disease
.	O

Deilrium	B-Disease
in	O
a	O
pateint	O
with	O
txoic	O
flecaniide	O
plsama	O
concentraitons	O
:	O
the	O
role	O
of	O
a	O
phramacokinetic	O
durg	O
intercation	O
with	O
paroxetnie	O
.	O

OBJECITVE	O
:	O
To	O
describe	O
a	O
csae	O
of	O
flecaiinde	O
-	O
induecd	O
dleirium	B-Disease
associated	O
with	O
a	O
pharamcokinetic	O
durg	O
interactoin	O
with	O
parxoetine	O
.	O

CSAE	O
SMUMARY	O
:	O
A	O
69	O
-	O
yaer	O
-	O
old	O
wihte	O
femlae	O
presented	O
to	O
the	O
eemrgency	O
dpeartment	O
with	O
a	O
hsitory	O
of	O
confusoin	B-Disease
and	O
paranioa	B-Disease
over	O
the	O
past	O
several	O
dyas	O
.	O

On	O
adimssion	O
the	O
ptaient	O
was	O
taking	O
carvdeilol	O
12	O
mg	O
twice	O
daliy	O
,	O
wrafarin	O
2	O
mg	O
/	O
day	O
,	O
floic	O
aicd	O
1	O
mg	O
/	O
day	O
,	O
levothryoxine	O
100	O
mcirog	O
/	O
day	O
,	O
pantporazole	O
40	O
mg	O
/	O
day	O
,	O
paroextine	O
40	O
mg	O
/	O
day	O
,	O
and	O
flecaiinde	O
100	O
mg	O
twice	O
daliy	O
.	O

Felcainide	O
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atiral	B-Disease
fibrilaltion	I-Disease
.	O

Labortaory	O
tset	O
findnigs	O
on	O
amdission	O
were	O
notable	O
only	O
for	O
a	O
flecaniide	O
plsama	O
cnocentration	O
of	O
1360	O
mircog	O
/	O
L	O
(	O
refeernce	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metaoblic	O
durg	O
intreaction	O
between	O
felcainide	O
and	O
paroxetnie	O
,	O
which	O
the	O
patinet	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
yaers	O
,	O
was	O
considered	O
.	O

Parxoetine	O
was	O
discontniued	O
and	O
the	O
dsoe	O
of	O
fleacinide	O
was	O
reudced	O
to	O
50	O
mg	O
twice	O
daliy	O
.	O

Her	O
deilrium	B-Disease
resolved	O
3	O
dyas	O
later	O
.	O

DISCUSSION	O
:	O
Flceainide	O
and	O
pharmaoclogically	O
similar	O
aegnts	O
that	O
intearct	O
with	O
soidum	O
chnanels	O
may	O
cause	O
delriium	B-Disease
in	O
susceptbile	O
patietns	O
.	O

A	O
MELDINE	O
search	O
(	O
1966	O
-	O
Janaury	O
2009	O
)	O
revaeled	O
one	O
in	O
vivo	O
pahrmacokinetic	O
stduy	O
on	O
the	O
inetraction	O
between	O
felcainide	O
,	O
a	O
CPY2D6	O
subtsrate	O
,	O
and	O
paroextine	O
,	O
a	O
CYPD26	O
ihnibitor	O
,	O
as	O
well	O
as	O
3	O
csae	O
repotrs	O
of	O
flecaindie	O
-	O
inudced	O
delriium	B-Disease
.	O

According	O
to	O
the	O
Naarnjo	O
prboability	O
scale	O
,	O
flceainide	O
was	O
the	O
probable	O
cause	O
of	O
the	O
patinet	O
'	O
s	O
deliruim	B-Disease
;	O
the	O
Horn	O
Durg	O
Intercation	O
Proabbility	O
Sclae	O
indicates	O
a	O
possible	O
phamracokinetic	O
durg	O
intreaction	O
between	O
flecaniide	O
and	O
paroxetnie	O
.	O

CONCLSUIONS	O
:	O
Supratehrapeutic	O
flecianide	O
plamsa	O
concentratoins	O
may	O
cause	O
dleirium	B-Disease
.	O

Because	O
toxciity	B-Disease
may	O
occur	O
when	O
flecaindie	O
is	O
prescrbied	O
with	O
praoxetine	O
and	O
other	O
potent	O
CY2PD6	O
inhibtiors	O
,	O
flceainide	O
palsma	O
cocnentrations	O
should	O
be	O
monitroed	O
closely	O
with	O
commencement	O
of	O
CY2PD6	O
inhibitros	O
.	O

Effciacy	O
of	O
eevrolimus	O
(	O
RDA001	O
)	O
in	O
patinets	O
with	O
adavnced	O
NCSLC	B-Disease
previously	O
traeted	O
with	O
chemtoherapy	O
alone	O
or	O
with	O
cehmotherapy	O
and	O
EFGR	O
inhibtiors	O
.	O

BACKGRUOND	O
:	O
Traetment	O
optinos	O
are	O
scarce	O
in	O
prerteated	O
advacned	O
non	B-Disease
-	I-Disease
small	I-Disease
-	I-Disease
clel	I-Disease
lnug	I-Disease
cnacer	I-Disease
(	O
NSLCC	B-Disease
)	O
patietns	O
.	O

RA0D01	O
,	O
an	O
oarl	O
ihnibitor	O
of	O
the	O
mmamalian	O
traget	O
of	O
rapamcyin	O
(	O
mOTR	O
)	O
,	O
has	O
shown	O
pahse	O
I	O
efficacy	O
in	O
NSLCC	B-Disease
.	O

METHODS	O
:	O
Satge	O
IIIb	O
or	O
IV	O
NSLCC	B-Disease
ptaients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
cheomtherapy	O
reigmens	O
,	O
one	O
platnium	O
based	O
(	O
startum	O
1	O
)	O
or	O
both	O
cehmotherapy	O
and	O
epdiermal	O
grotwh	O
fatcor	O
recetpor	O
tyrosnie	O
kianse	O
ihnibitors	O
(	O
startum	O
2	O
)	O
,	O
received	O
RDA001	O
10	O
mg	O
/	O
day	O
until	O
progrsesion	O
or	O
unacceptable	O
txoicity	B-Disease
.	O

Pirmary	O
ojbective	O
was	O
overall	O
resopnse	O
rtae	O
(	O
ORR	O
)	O
.	O

Analyess	O
of	O
mrakers	O
associated	O
with	O
the	O
mOTR	O
pathawy	O
were	O
carried	O
out	O
on	O
archiavl	O
tmuor	B-Disease
from	O
a	O
sbugroup	O
using	O
immunohistochemitsry	O
(	O
IHC	O
)	O
and	O
direct	O
mutatoin	O
sequecning	O
.	O

RSEULTS	O
:	O
Eighty	O
-	O
five	O
patietns	O
were	O
enrolled	O
,	O
42	O
in	O
srtatum	O
1	O
and	O
43	O
in	O
strtaum	O
.	O

ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
strtaum	O
1	O
;	O
2	O
.	O
3	O
%	O
startum	O
2	O
)	O
.	O

Overall	O
diesase	O
contorl	O
rtae	O
was	O
47	O
.	O
1	O
%	O
.	O

Meidan	O
porgression	O
-	O
free	O
survvials	O
(	O
PSFs	O
)	O
were	O
2	O
.	O
6	O
(	O
strtaum	O
1	O
)	O
and	O
2	O
.	O
7	O
monhts	O
(	O
strautm	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grdae	O
3	O
evetns	O
were	O
fatiuge	B-Disease
,	O
dypsnea	B-Disease
,	O
stmoatitis	B-Disease
,	O
aneima	B-Disease
,	O
and	O
thromboyctopenia	B-Disease
.	O

Pneuomnitis	B-Disease
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grdae	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

Cox	O
regerssion	O
aanlysis	O
of	O
IHC	O
scoers	O
found	O
that	O
only	O
phopsho	O
AKT	O
(	O
pKAT	O
)	O
was	O
a	O
significant	O
indepenednt	O
predcitor	O
of	O
wrose	O
PFS	O
.	O

COCNLUSIONS	O
:	O
RDA001	O
10	O
mg	O
/	O
day	O
was	O
well	O
tolearted	O
,	O
showing	O
moedst	O
clniical	O
acitvity	O
in	O
pertreated	O
NCSLC	B-Disease
.	O

Evaluatoin	O
of	O
RDA001	O
plus	O
stanadrd	O
tehrapy	O
for	O
metastaitc	O
NCSLC	B-Disease
continues	O
.	O

Posttarnsplant	O
aenmia	B-Disease
:	O
the	O
role	O
of	O
siorlimus	O
.	O

Postrtansplant	O
aenmia	B-Disease
is	O
a	O
common	O
prolbem	O
that	O
may	O
hinder	O
patietns	O
'	O
qualtiy	O
of	O
lfie	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
paitents	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttarnsplant	O
peroid	O
.	O

A	O
variety	O
of	O
fcators	O
have	O
been	O
identfiied	O
that	O
incraese	O
the	O
rsik	O
of	O
posttrnasplant	O
aneima	B-Disease
,	O
of	O
which	O
the	O
lveel	O
of	O
reanl	O
fucntion	O
is	O
most	O
important	O
.	O

Sirloimus	O
,	O
a	O
mammailan	O
tagret	O
of	O
rapaymcin	O
inhibtior	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplnat	O
aenmia	B-Disease
.	O

This	O
reivew	O
considers	O
aneima	B-Disease
associated	O
with	O
sirolmius	O
,	O
including	O
its	O
presenattion	O
,	O
mechnaisms	O
,	O
and	O
mnaagement	O
.	O

Croonary	O
comupterized	O
tomogarphy	O
angigoraphy	O
for	O
raipd	O
dischrage	O
of	O
low	O
-	O
rsik	O
patietns	O
with	O
ccoaine	O
-	O
associated	O
chset	B-Disease
pian	I-Disease
.	O

BCAKGROUND	O
:	O
Most	O
ptaients	O
prseenting	O
to	O
eemrgency	O
dpeartments	O
(	O
EDs	O
)	O
with	O
cocanie	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
are	O
admitetd	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
actue	B-Disease
coronray	I-Disease
syndrmoe	I-Disease
"	O
prtoocol	O
,	O
often	O
with	O
noninvaisve	O
tseting	O
prior	O
to	O
dischagre	O
.	O

In	O
patinets	O
without	O
cocanie	O
use	O
,	O
coronray	O
comptuerized	O
tomograhpy	O
angoigraphy	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
gorup	O
of	O
paitents	O
at	O
low	O
rsik	O
for	O
cadriac	O
evetns	O
who	O
can	O
be	O
safely	O
dischraged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
coornary	O
CTA	O
strategy	O
would	O
be	O
efficacoius	O
in	O
cocanie	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
,	O
as	O
croonary	B-Disease
vasosapsm	I-Disease
may	O
account	O
for	O
some	O
of	O
the	O
ischeima	B-Disease
.	O

We	O
studied	O
whether	O
a	O
neagtive	O
coroanry	O
CTA	O
in	O
pateints	O
with	O
ccoaine	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
could	O
identify	O
a	O
subset	O
safe	O
for	O
dsicharge	O
.	O

METHODS	O
:	O
We	O
prospectively	O
evaulated	O
the	O
saftey	O
of	O
coornary	O
CTA	O
for	O
low	O
-	O
rsik	O
patinets	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassocitaed	O
chset	B-Disease
pian	I-Disease
(	O
slef	O
-	O
reported	O
or	O
postiive	O
urnie	O
tset	O
)	O
.	O

Consceutive	O
ptaients	O
received	O
either	O
immeidate	O
croonary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
sreial	O
markres	O
)	O
or	O
underwent	O
croonary	O
CTA	O
after	O
a	O
brief	O
obseravtion	O
preiod	O
with	O
sreial	O
cradiac	O
mraker	O
measuerments	O
.	O

Paitents	O
with	O
negtaive	O
coronray	O
CTA	O
(	O
mxaimal	O
stenoiss	B-Disease
less	O
than	O
50	O
%	O
)	O
were	O
dischagred	O
.	O

The	O
main	O
ouctome	O
was	O
30	O
-	O
day	O
caridovascular	O
detah	O
or	O
myocadrial	B-Disease
inafrction	I-Disease
.	O

RESUTLS	O
:	O
A	O
total	O
of	O
59	O
paitents	O
with	O
cocanie	O
-	O
associated	O
cehst	B-Disease
pian	I-Disease
were	O
evlauated	O
.	O

Patietns	O
had	O
a	O
mean	O
age	O
of	O
45	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
6	O
yrs	O
and	O
were	O
86	O
%	O
balck	O
,	O
66	O
%	O
mlae	O
.	O

Seventy	O
-	O
nine	O
percent	O
had	O
a	O
noraml	O
or	O
nnospecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TMII	O
scroe	O
<	O
2	O
.	O

Twenty	O
pateints	O
received	O
coroanry	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
dsicharged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty	O
-	O
nine	O
received	O
cornoary	O
CTA	O
after	O
a	O
brief	O
observtaion	O
peroid	O
,	O
with	O
37	O
dishcarged	O
hmoe	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
pateints	O
had	O
cornoary	B-Disease
steonsis	I-Disease
>	O
or	O
=	O
50	O
%	O
.	O

During	O
the	O
30	O
-	O
day	O
follow	O
-	O
up	O
peirod	O
,	O
no	O
ptaients	O
deid	O
of	O
a	O
cardiovascualr	O
evnet	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
and	O
no	O
ptaient	O
sutsained	O
a	O
nnofatal	O
moycardial	B-Disease
infartcion	I-Disease
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
.	O

CONCLUSOINS	O
:	O
Although	O
cocanie	O
-	O
associated	O
myocadrial	B-Disease
iscehmia	I-Disease
can	O
result	O
from	O
croonary	O
vasocnostriction	O
,	O
patietns	O
with	O
cociane	O
associated	O
chset	B-Disease
pian	I-Disease
,	O
a	O
non	O
-	O
iscehmic	B-Disease
ECG	O
,	O
and	O
a	O
TMII	O
rsik	O
scroe	O
<	O
2	O
may	O
be	O
safely	O
dischraged	O
from	O
the	O
ED	O
after	O
a	O
neagtive	O
coornary	O
CTA	O
with	O
a	O
low	O
rsik	O
of	O
30	O
-	O
day	O
adevrse	O
eevnts	O
.	O

Bialteral	O
haemorrhgaic	B-Disease
infraction	I-Disease
of	I-Disease
the	I-Disease
glbous	I-Disease
palliuds	I-Disease
after	O
cocanie	O
and	O
alcoohl	O
intxoication	O
.	O

Ccoaine	O
is	O
a	O
rsik	O
fatcor	O
for	O
both	O
ischeimc	B-Disease
and	I-Disease
haemorrhgaic	I-Disease
srtoke	I-Disease
.	O

We	O
present	O
the	O
csae	O
of	O
a	O
31	O
-	O
yaer	O
-	O
old	O
man	O
with	O
bilatreal	O
ishcemia	B-Disease
of	I-Disease
the	I-Disease
glbous	I-Disease
palliuds	I-Disease
after	O
excessive	O
alchool	O
and	O
intranaasl	O
ccoaine	O
use	O
.	O

Durg	O
-	O
related	O
gloubs	B-Disease
palildus	I-Disease
infarctoins	I-Disease
are	O
most	O
often	O
associated	O
with	O
heorin	O
.	O

Bilaetral	O
bsaal	B-Disease
gagnlia	I-Disease
infacrts	I-Disease
after	O
the	O
use	O
of	O
coacine	O
,	O
without	O
concurrnet	O
hreoin	O
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patinet	O
,	O
trasnient	O
cradiac	B-Disease
arrhtyhmia	I-Disease
or	O
resipratory	B-Disease
dysufnction	I-Disease
related	O
to	O
ccoaine	O
and	O
/	O
or	O
ehtanol	O
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
creebral	B-Disease
hypopefrusion	I-Disease
.	O

Ltae	O
fluminant	O
psoterior	B-Disease
reversible	I-Disease
encephalopahty	I-Disease
syndrmoe	I-Disease
after	O
lievr	O
trnasplant	O
.	O

OBEJCTIVES	O
:	O
Psoterior	B-Disease
leukoecnephalopathy	I-Disease
due	O
to	O
clacineurin	O
-	O
inhibtior	O
-	O
related	O
neurtooxicity	B-Disease
is	O
a	O
rrae	O
but	O
seevre	O
cmoplication	O
that	O
resutls	O
from	O
tretament	O
with	O
immuonsuppressive	O
agnets	O
(	O
primarily	O
those	O
adminitsered	O
after	O
a	O
lievr	O
or	O
kindey	O
trnasplant	O
)	O
.	O

The	O
pathophyisologic	O
mechainsms	O
of	O
that	O
disoredr	O
remain	O
unknown	O
.	O

CSAE	O
:	O
We	O
rpeort	O
the	O
csae	O
of	O
a	O
46	O
-	O
yaer	O
-	O
old	O
wmoan	O
who	O
received	O
a	O
lvier	O
trasnplant	O
in	O
our	O
cneter	O
as	O
treatmnet	O
for	O
alcohloic	B-Disease
cirrhoiss	I-Disease
and	O
in	O
whom	O
either	O
a	O
fumlinant	O
cuorse	O
of	O
posteiror	B-Disease
leukoenecphalopathy	I-Disease
or	O
postreior	B-Disease
reversible	I-Disease
encepahlopathy	I-Disease
sydnrome	I-Disease
developed	O
110	O
dyas	O
after	O
tarnsplant	O
.	O

After	O
an	O
initially	O
uenventful	O
cuorse	O
after	O
the	O
translpant	O
,	O
the	O
paitent	O
rapidly	O
fell	O
into	O
deep	O
cmoa	O
.	O

RSEULTS	O
:	O
Ceerbral	O
MRI	O
sacn	O
showed	O
typical	O
sings	O
of	O
enhanecment	O
in	O
the	O
pnotine	O
and	O
psoterior	O
reginos	O
.	O

Swtiching	O
the	O
immnuosuppressive	O
reigmen	O
from	O
tacroliums	O
to	O
ccylosporine	O
did	O
not	O
ipmrove	O
the	O
cliniacl	O
situation	O
.	O

The	O
temrination	O
of	O
tretament	O
with	O
any	O
clacineurin	O
inhbiitor	O
resulted	O
in	O
a	O
complete	O
resolutoin	O
of	O
that	O
complicaiton	O
.	O

CONLCUSIONS	O
:	O
Posteiror	B-Disease
reversible	I-Disease
encephlaopathy	I-Disease
synrdome	I-Disease
after	O
lievr	O
translpant	O
is	O
rrae	O
.	O

We	O
recommend	O
a	O
complete	O
cessaiton	O
of	O
any	O
calcienurin	O
inhiibtor	O
rather	O
than	O
a	O
dsoe	O
reduciton	O
.	O

Prloonged	O
hypotehrmia	B-Disease
as	O
a	O
brdige	O
to	O
recoevry	O
for	O
ceerbral	B-Disease
eedma	I-Disease
and	O
intarcranial	B-Disease
hypertesnion	I-Disease
associated	O
with	O
fumlinant	B-Disease
hepaitc	I-Disease
faiulre	I-Disease
.	O

BACKGRUOND	O
:	O
To	O
reivew	O
eivdence	O
-	O
based	O
treatmnet	O
opitons	O
in	O
ptaients	O
with	O
cerberal	B-Disease
eedma	I-Disease
complicatnig	O
fumlinant	B-Disease
hpeatic	I-Disease
fialure	I-Disease
(	O
FHF	B-Disease
)	O
and	O
discuss	O
the	O
potentail	O
applciations	O
of	O
hypotherima	B-Disease
.	O

METHOD	O
:	O
Csae	O
-	O
based	O
observaitons	O
from	O
a	O
mediacl	O
intnesive	O
crae	O
unit	O
(	O
MCIU	O
)	O
in	O
a	O
tertairy	O
crae	O
fcaility	O
in	O
a	O
27	O
-	O
yaer	O
-	O
old	O
feamle	O
with	O
FHF	B-Disease
from	O
aectaminophen	O
and	O
reslutant	O
cererbal	B-Disease
eedma	I-Disease
.	O

RESUTLS	O
:	O
Our	O
paitent	O
was	O
adimtted	O
to	O
the	O
MCIU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxciity	B-Disease
from	O
acetaminohpen	O
which	O
was	O
inegsted	O
over	O
a	O
2	O
-	O
day	O
peirod	O
.	O

The	O
paitent	O
had	O
deperssed	O
of	O
mnetal	O
stauts	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admissoin	O
.	O

Initial	O
evlauation	O
confirmed	O
FHF	B-Disease
from	O
acetaimnophen	O
and	O
ceerbral	B-Disease
eedma	I-Disease
.	O

The	O
patinet	O
was	O
terated	O
with	O
hyperosmoalr	O
thearpy	O
,	O
hypevrentilation	B-Disease
,	O
seadtion	O
,	O
and	O
chemcial	O
paralyiss	B-Disease
.	O

Her	O
intarcranial	O
perssure	O
remained	O
eelvated	O
despite	O
maxmial	O
medcial	O
thearpy	O
.	O

We	O
then	O
initiated	O
tehrapeutic	O
hypotherima	B-Disease
which	O
was	O
continued	O
for	O
5	O
dyas	O
.	O

At	O
re	O
-	O
wamring	O
,	O
pateint	O
had	O
resoultion	O
of	O
her	O
ceerbral	B-Disease
edmea	I-Disease
and	O
inrtacranial	B-Disease
hpyertension	I-Disease
.	O

At	O
discahrge	O
,	O
she	O
had	O
complete	O
reocvery	O
of	O
neurologiacl	O
and	O
hpeatic	O
functinos	O
.	O

CONCULSION	O
:	O
In	O
pateints	O
with	O
FHF	B-Disease
and	O
cerberal	B-Disease
eedma	I-Disease
from	O
aectaminophen	O
ovredose	B-Disease
,	O
prloonged	O
threapeutic	O
hyopthermia	B-Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
lfie	O
saivng	O
therpay	O
and	O
a	O
brigde	O
to	O
hpeatic	O
and	O
neuroloigcal	O
rceovery	O
.	O

A	O
cliincal	O
tiral	O
of	O
hyptohermia	B-Disease
in	O
patietns	O
with	O
this	O
codnition	O
is	O
warranted	O
.	O

Binaasl	B-Disease
visaul	I-Disease
field	I-Disease
defcets	I-Disease
are	O
not	O
specific	O
to	O
vigbaatrin	O
.	O

This	O
sutdy	O
invsetigated	O
the	O
vsiual	B-Disease
defetcs	I-Disease
associated	O
with	O
the	O
antieplieptic	O
durg	O
viagbatrin	O
(	O
VGB	O
)	O
.	O

Two	O
hundred	O
four	O
pepole	O
with	O
epilpesy	B-Disease
were	O
grouepd	O
on	O
the	O
basis	O
of	O
antiepielptic	O
durg	O
thearpy	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
expsoure	O
to	O
VGB	O
)	O
.	O

Gropus	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gedner	O
,	O
and	O
siezure	B-Disease
frqeuency	O
.	O

All	O
patietns	O
underwent	O
ojbective	O
assessemnt	O
of	O
eelctrophysiological	O
fnuction	O
(	O
wide	O
-	O
field	O
multfiocal	O
electroretiongraphy	O
)	O
and	O
conventoinal	O
visaul	O
field	O
tetsing	O
(	O
sattic	O
perimerty	O
)	O
.	O

Bilatearl	O
visaul	O
field	O
contsriction	O
was	O
observed	O
in	O
59	O
%	O
of	O
patietns	O
currently	O
taking	O
VGB	O
,	O
43	O
%	O
of	O
ptaients	O
who	O
previously	O
took	O
VGB	O
,	O
and	O
24	O
%	O
of	O
paitents	O
with	O
no	O
expsoure	O
to	O
VGB	O
.	O

Asssesment	O
of	O
reitnal	O
funtcion	O
reveaeld	O
abonrmal	O
repsonses	O
in	O
48	O
%	O
of	O
current	O
VGB	O
uesrs	O
and	O
22	O
%	O
of	O
prior	O
VGB	O
uesrs	O
,	O
but	O
in	O
none	O
of	O
the	O
ptaients	O
without	O
previous	O
epxosure	O
to	O
VGB	O
.	O

Bilatreal	B-Disease
vsiual	I-Disease
field	I-Disease
anbormalities	I-Disease
are	O
common	O
in	O
the	O
tretaed	O
epliepsy	B-Disease
popultaion	O
,	O
irrespective	O
of	O
durg	O
hisotry	O
.	O

Assessmnet	O
by	O
conevntional	O
staitc	O
preimetry	O
may	O
neither	O
be	O
sufficiently	O
sensiitve	O
nor	O
specific	O
to	O
reliably	O
identify	O
retianl	B-Disease
txoicity	I-Disease
associated	O
with	O
VGB	O
.	O

Somking	O
of	O
carck	O
ccoaine	O
as	O
a	O
rsik	O
fcator	O
for	O
HIV	B-Disease
infeciton	I-Disease
among	O
poeple	O
who	O
use	O
ijnection	O
durgs	O
.	O

BAKCGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoikng	O
crcak	O
ccoaine	O
has	O
on	O
the	O
inciednce	O
of	O
HIV	B-Disease
infetcion	I-Disease
.	O

Given	O
the	O
incerasing	O
use	O
of	O
carck	O
coacine	O
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
durg	O
has	O
become	O
a	O
rsik	O
facotr	O
for	O
HIV	B-Disease
inefction	I-Disease
.	O

METHODS	O
:	O
We	O
included	O
dtaa	O
from	O
poeple	O
participating	O
in	O
the	O
Vnacouver	O
Inejction	O
Durg	O
Uesrs	O
Stduy	O
who	O
reported	O
injceting	O
illiict	O
drgus	O
at	O
least	O
once	O
in	O
the	O
mnoth	O
before	O
enrloment	O
,	O
lievd	O
in	O
the	O
greater	O
Vancovuer	O
aera	O
,	O
were	O
HIV	O
-	O
negtaive	O
at	O
enrloment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
stduy	O
vsiit	O
.	O

To	O
determine	O
whether	O
the	O
rsik	O
of	O
HIV	B-Disease
seroconverison	I-Disease
among	O
dialy	O
somkers	O
of	O
crcak	O
cociane	O
changed	O
over	O
tmie	O
,	O
we	O
used	O
Cox	O
prooprtional	O
hazadrs	O
rgeression	O
and	O
divided	O
the	O
sutdy	O
into	O
3	O
peirods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
peroid	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
peirod	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
preiod	O
3	O
)	O
.	O

REUSLTS	O
:	O
Overall	O
,	O
1048	O
elgiible	O
injectoin	O
durg	O
usres	O
were	O
included	O
in	O
our	O
stduy	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B-Disease
ifnection	I-Disease
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
prpoortion	O
of	O
participatns	O
who	O
reported	O
dialy	O
somking	O
of	O
crcak	O
cocanie	O
increaesd	O
from	O
11	O
.	O
6	O
%	O
in	O
preiod	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
peroid	O
3	O
.	O

After	O
adjusting	O
for	O
potnetial	O
confonuders	O
,	O
we	O
found	O
that	O
the	O
rsik	O
of	O
HIV	B-Disease
seroconversoin	I-Disease
among	O
particpiants	O
who	O
were	O
dialy	O
smokres	O
of	O
crcak	O
cocanie	O
inrceased	O
over	O
tmie	O
(	O
peirod	O
1	O
:	O
hazrad	O
rtaio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95	O
%	O
confdience	O
itnerval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
preiod	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
peroid	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Smkoing	O
of	O
crcak	O
cociane	O
was	O
found	O
to	O
be	O
an	O
indepnedent	O
rsik	O
fcator	O
for	O
HIV	B-Disease
sercoonversion	I-Disease
among	O
peolpe	O
who	O
were	O
injectoin	O
durg	O
usres	O
.	O

This	O
findnig	O
points	O
to	O
the	O
urgent	O
need	O
for	O
eviednce	O
-	O
based	O
pubilc	O
helath	O
iniitatives	O
taregted	O
at	O
pepole	O
who	O
somke	O
crcak	O
cociane	O
.	O

Fluoxeitne	O
imporves	O
the	O
memroy	B-Disease
defciits	I-Disease
caused	O
by	O
the	O
chemotehrapy	O
aegnt	O
5	O
-	O
fluorourcail	O
.	O

Cacner	B-Disease
ptaients	O
who	O
have	O
been	O
terated	O
with	O
sysetmic	O
adjvuant	O
chmeotherapy	O
have	O
described	O
experiencing	O
dteeriorations	O
in	O
cogniiton	O
.	O

A	O
widely	O
used	O
cheomtherapeutic	O
aegnt	O
,	O
5	O
-	O
fluoruoracil	O
(	O
5	O
-	O
FU	O
)	O
,	O
readily	O
crosess	O
the	O
blood	O
-	O
barin	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
barin	O
fucntion	O
.	O

In	O
particular	O
this	O
atni	O
mtiotic	O
durg	O
could	O
redcue	O
clel	O
prloiferation	O
in	O
the	O
neuroegnic	O
regoins	O
of	O
the	O
adlut	O
brian	O
.	O

In	O
contrast	O
reprots	O
indicate	O
that	O
hippocapmal	O
depnedent	O
neurogeneiss	O
and	O
cgonition	O
are	O
ehnanced	O
by	O
the	O
SRSI	O
antideperssant	O
Fluoxeitne	O
.	O

In	O
this	O
inevstigation	O
the	O
beahvioural	O
effetcs	O
of	O
chornic	O
(	O
two	O
week	O
)	O
tretament	O
with	O
5	O
-	O
FU	O
and	O
(	O
three	O
wekes	O
)	O
with	O
Fluxoetine	O
either	O
separately	O
or	O
in	O
combintaion	O
with	O
5	O
-	O
FU	O
were	O
tetsed	O
on	O
adlut	O
Litser	O
hooded	O
rtas	O
.	O

Behaviuoral	O
effcets	O
were	O
tseted	O
using	O
a	O
cnotext	O
dependnet	O
cnoditioned	O
emotioanl	O
repsonse	O
tset	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animlas	O
terated	O
with	O
5	O
-	O
FU	O
had	O
a	O
significant	O
reductoin	O
in	O
freezing	O
tmie	O
comapred	O
to	O
conrtols	O
.	O

A	O
separate	O
gruop	O
of	O
animlas	O
was	O
tseted	O
using	O
a	O
hippcoampal	O
depnedent	O
spatail	O
wokring	O
mmeory	O
tset	O
,	O
the	O
obejct	O
loctaion	O
recognitoin	O
tset	O
(	O
OLR	O
)	O
.	O

Ainmals	O
tretaed	O
only	O
with	O
5	O
-	O
FU	O
showed	O
significant	O
deifcits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
tsak	O
but	O
co	O
adminitsration	O
of	O
Fluoxetnie	O
imporved	O
their	O
performnace	O
.	O

5	O
-	O
FU	O
chemotherpay	O
caused	O
a	O
significant	O
rdeuction	O
in	O
the	O
number	O
of	O
porliferating	O
cells	O
in	O
the	O
sub	O
graunlar	O
znoe	O
of	O
the	O
denatte	O
gryus	O
copmared	O
to	O
contrlos	O
.	O

This	O
reduciton	O
was	O
eliminated	O
when	O
Fluoxetnie	O
was	O
co	O
amdinistered	O
with	O
5	O
-	O
FU	O
.	O

Fluxoetine	O
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proilferating	O
clel	O
number	O
or	O
bheaviour	O
.	O

These	O
finidngs	O
suggest	O
that	O
5	O
-	O
FU	O
can	O
neagtively	O
affect	O
both	O
clel	O
prolfieration	O
and	O
hpipocampal	O
dpeendent	O
worikng	O
meomry	O
and	O
that	O
these	O
defictis	O
can	O
be	O
reveresd	O
by	O
the	O
simultaenous	O
adimnistration	O
of	O
the	O
anitdepressant	O
Fluoxetnie	O
.	O

Lievr	O
-	O
specific	O
albation	O
of	O
intgerin	O
-	O
linked	O
kniase	O
in	O
mcie	O
rseults	O
in	O
enahnced	O
and	O
prolnoged	O
clel	O
proliferatoin	O
and	O
hpeatomegaly	B-Disease
after	O
pehnobarbital	O
adminitsration	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
disurption	O
of	O
extracellluar	O
martix	O
(	O
ECM	O
)	O
/	O
inetgrin	O
signalnig	O
via	O
eliminatoin	O
of	O
inetgrin	O
-	O
linked	O
kianse	O
(	O
ILK	O
)	O
in	O
hepatocyets	O
itnerferes	O
with	O
signlas	O
leading	O
to	O
terminaiton	O
of	O
lvier	O
regeneratoin	O
.	O

This	O
sutdy	O
ivnestigates	O
the	O
role	O
of	O
ILK	O
in	O
lievr	O
enlargemnet	O
induecd	O
by	O
phneobarbital	O
(	O
PB	O
)	O
.	O

Wlid	O
-	O
tpye	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
lievr	O
-	O
/	O
-	O
mcie	O
were	O
given	O
PB	O
(	O
0	O
.	O
1	O
%	O
in	O
drikning	O
waetr	O
)	O
for	O
10	O
dyas	O
.	O

Lviers	O
were	O
harvseted	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
dyas	O
during	O
PB	O
administrtaion	O
.	O

In	O
the	O
heaptocyte	O
-	O
specific	O
ILK	O
/	O
lievr	O
-	O
/	O
-	O
mcie	O
,	O
the	O
lievr	O
:	O
bdoy	O
wieght	O
rtaio	O
was	O
more	O
than	O
double	O
as	O
compaerd	O
to	O
0	O
h	O
at	O
day	O
2	O
(	O
2	O
.	O
5	O
times	O
)	O
,	O
while	O
at	O
dyas	O
5	O
and	O
10	O
,	O
it	O
was	O
enlagred	O
three	O
times	O
.	O

In	O
the	O
WT	O
mcie	O
,	O
the	O
incresae	O
was	O
as	O
expected	O
from	O
previous	O
litearture	O
(	O
1	O
.	O
8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2	O
.	O

There	O
were	O
slightly	O
incresaed	O
proilferating	O
clel	O
nucelar	O
atnigen	O
-	O
postiive	O
cells	O
in	O
the	O
ILK	O
/	O
lvier	O
-	O
/	O
-	O
aniamls	O
at	O
day	O
2	O
as	O
cmopared	O
to	O
WT	O
after	O
PB	O
adminitsration	O
.	O

In	O
the	O
WT	O
ainmals	O
,	O
the	O
proliferatvie	O
resopnse	O
had	O
come	O
back	O
to	O
noraml	O
by	O
dyas	O
5	O
and	O
10	O
.	O

Heptaocytes	O
of	O
the	O
ILK	O
/	O
lvier	O
-	O
/	O
-	O
mcie	O
continued	O
to	O
prolifearte	O
up	O
until	O
day	O
10	O
.	O

ILK	O
/	O
lievr	O
-	O
/	O
-	O
mcie	O
also	O
showed	O
inrceased	O
expresison	O
of	O
key	O
geens	O
involved	O
in	O
heptaocyte	O
prolifertaion	O
at	O
different	O
tmie	O
points	O
during	O
PB	O
administrtaion	O
.	O

In	O
summary	O
,	O
ECM	O
protiens	O
communicate	O
with	O
the	O
singaling	O
machinrey	O
of	O
dividing	O
clels	O
via	O
ILK	O
to	O
rgeulate	O
heaptocyte	O
prolifeartion	O
and	O
tremination	O
of	O
the	O
prolfierative	O
resposne	O
.	O

Lcak	O
of	O
ILK	O
in	O
the	O
heptaocytes	O
imparts	O
prolonegd	O
proliferatvie	O
resposne	O
not	O
only	O
to	O
sitmuli	O
related	O
to	O
lvier	O
regeneraiton	O
but	O
also	O
to	O
xenobioitc	O
cheimcal	O
mitognes	O
,	O
such	O
as	O
PB	O
.	O

Decerased	O
Expresison	O
of	O
Na	O
/	O
K	O
-	O
APTase	O
,	O
NEH3	O
,	O
NCB1	O
,	O
APQ1	O
and	O
OAT	O
in	O
Gnetamicin	O
-	O
inudced	O
Nephrpoathy	B-Disease
.	O

The	O
present	O
sutdy	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altreed	O
regultaion	O
of	O
tubualr	O
trnasporters	O
in	O
getnamicin	O
-	O
inudced	O
nephroptahy	B-Disease
.	O

Sprgaue	O
-	O
Dwaley	O
mlae	O
rtas	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
subcutaenously	O
injecetd	O
with	O
genatmicin	O
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
)	O
for	O
7	O
dyas	O
,	O
and	O
the	O
expresison	O
of	O
tubualr	O
transoprters	O
was	O
determined	O
by	O
immunbolotting	O
and	O
immnuohistochemistry	O
.	O

The	O
mNRA	O
and	O
proetin	O
expressoin	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Gentmaicin	O
-	O
treaetd	O
rtas	O
exhibited	O
significantly	O
decreaesd	O
creatniine	O
clearacne	O
along	O
with	O
incerased	O
plamsa	O
creatniine	O
leevls	O
.	O

Accordingly	O
,	O
the	O
fractioanl	O
excretoin	O
of	O
soduim	O
incresaed	O
.	O

Uirne	O
vloume	O
was	O
icnreased	O
,	O
while	O
uirne	O
osmolaltiy	O
and	O
free	O
waetr	O
reabsortpion	O
were	O
derceased	O
.	O

Immunoboltting	O
and	O
immunohistocheimstry	O
reevaled	O
decraesed	O
expressoin	O
of	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATaPse	O
,	O
NEH3	O
,	O
NCB1	O
,	O
and	O
APQ1	O
in	O
the	O
kdiney	O
of	O
gentmaicin	O
-	O
tretaed	O
rtas	O
.	O

The	O
expresison	O
of	O
OTA1	O
and	O
OTA3	O
was	O
also	O
decreaesd	O
.	O

Gentamiicn	O
-	O
inudced	O
npehropathy	B-Disease
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decresaed	O
exrpession	O
of	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATaPse	O
,	O
NEH3	O
,	O
NCB1	O
,	O
APQ1	O
and	O
OAT	O
.	O

Actue	B-Disease
reanl	I-Disease
faliure	I-Disease
after	O
high	O
-	O
dsoe	O
metohtrexate	O
threapy	O
in	O
a	O
pateint	O
with	O
ielostomy	O
.	O

High	O
-	O
dsoe	O
methotreaxte	O
(	O
HD	O
-	O
MTX	O
)	O
is	O
an	O
important	O
teratment	O
for	O
Bukritt	B-Disease
lmyphoma	I-Disease
,	O
but	O
can	O
cause	O
heptaic	B-Disease
and	I-Disease
reanl	I-Disease
toixcity	I-Disease
when	O
its	O
clearacne	O
is	O
dealyed	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
after	O
HD	O
-	O
MTX	O
thearpy	O
in	O
a	O
ptaient	O
with	O
ilesotomy	O
,	O
The	O
paitent	O
was	O
a	O
3	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
livnig	O
-	O
related	O
lvier	O
transplanttaion	O
for	O
congeintal	O
biilary	B-Disease
artesia	I-Disease
.	O

At	O
day	O
833	O
after	O
the	O
transplantaiton	O
,	O
he	O
was	O
diagnoesd	O
with	O
PLTD	B-Disease
(	O
psot	B-Disease
-	I-Disease
transplnatation	I-Disease
lymphoproliferaitve	I-Disease
diosrder	I-Disease
,	O
Brukitt	B-Disease
-	I-Disease
tpye	I-Disease
malignnat	I-Disease
lypmhoma	I-Disease
)	O
.	O

During	O
inductoin	O
tehrapy	O
,	O
he	O
suffered	O
ilael	O
perforatoin	O
and	O
ileostmoy	O
was	O
performed	O
.	O

Subsequent	O
HD	O
-	O
MTX	O
therpay	O
caused	O
aucte	B-Disease
reanl	I-Disease
faiulre	I-Disease
that	O
required	O
contiunous	O
hmeodialysis	O
.	O

We	O
supposed	O
that	O
intravascluar	O
hypovolmeia	B-Disease
due	O
to	O
substantial	O
draniage	O
from	O
the	O
ileotsoma	O
caused	O
aucte	B-Disease
perrenal	I-Disease
failrue	I-Disease
.	O

After	O
rceovery	O
of	O
his	O
reanl	O
functoin	O
,	O
we	O
could	O
safely	O
traet	O
the	O
paitent	O
with	O
HD	O
-	O
MTX	O
thearpy	O
by	O
controlling	O
draniage	O
from	O
iloestoma	O
with	O
total	O
parentreal	O
nurtition	O
.	O

Longitduinal	O
assocaition	O
of	O
alochol	O
use	O
with	O
HIV	B-Disease
dsiease	I-Disease
progressoin	O
and	O
psychologcial	O
haelth	O
of	O
woemn	O
with	O
HIV	O
.	O

We	O
evlauated	O
the	O
associtaion	O
of	O
alchool	O
consumptoin	O
and	O
depressoin	B-Disease
,	O
and	O
their	O
effects	O
on	O
HIV	B-Disease
disaese	I-Disease
progrsesion	O
among	O
woemn	O
with	O
HIV	O
.	O

The	O
stduy	O
included	O
871	O
woemn	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
citeis	O
.	O

The	O
praticipants	O
had	O
phyiscal	O
examintaion	O
,	O
medcial	O
rceord	O
extratcion	O
,	O
and	O
vneipuncture	O
,	O
CD4	O
+	O
T	O
-	O
clel	O
conuts	O
detemrination	O
,	O
measruement	O
of	O
depression	B-Disease
sympotms	O
(	O
using	O
the	O
slef	O
-	O
reprot	O
Cenetr	O
for	O
Epdiemiological	O
Sutdies	O
-	O
Depresison	B-Disease
Sacle	O
)	O
,	O
and	O
alchool	O
use	O
assessmnet	O
at	O
enorllment	O
,	O
and	O
semiannaully	O
until	O
March	O
2000	O
.	O

Mutlilevel	O
radnom	O
coefficinet	O
oridnal	O
modles	O
as	O
well	O
as	O
multileevl	O
moedls	O
with	O
jiont	O
rseponses	O
were	O
used	O
in	O
the	O
anaylsis	O
.	O

There	O
was	O
no	O
significant	O
asscoiation	O
between	O
lveel	O
of	O
aclohol	O
use	O
and	O
CD4	O
+	O
T	O
-	O
clel	O
coutns	O
.	O

When	O
paritcipants	O
were	O
stratifeid	O
by	O
antiretrvoiral	O
therpay	O
(	O
ART	O
)	O
use	O
,	O
the	O
assoication	O
between	O
alchool	O
and	O
CD4	O
+	O
T	O
-	O
clel	O
did	O
not	O
reach	O
statisitcal	O
singificance	O
.	O

The	O
associtaion	O
between	O
alcoohl	O
cnosumption	O
and	O
depresison	B-Disease
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Depression	B-Disease
had	O
a	O
significant	O
negatvie	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
clel	O
cuonts	O
over	O
tmie	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findnigs	O
suggest	O
that	O
alochol	O
consumpiton	O
has	O
a	O
direct	O
asscoiation	O
with	O
dperession	B-Disease
.	O

Moreover	O
,	O
dperession	B-Disease
is	O
associated	O
with	O
HIV	B-Disease
disaese	I-Disease
progrsesion	O
.	O

Our	O
fnidings	O
have	O
implications	O
for	O
the	O
porvision	O
of	O
aclohol	O
use	O
intreventions	O
and	O
psycohlogical	O
resoruces	O
to	O
imrpove	O
the	O
heatlh	O
of	O
wmoen	O
with	O
HIV	O
.	O

Chemoikne	O
CLC2	O
and	O
its	O
rceeptor	O
CRC2	O
are	O
increaesd	O
in	O
the	O
hippocapmus	O
following	O
piolcarpine	O
-	O
indcued	O
sttaus	B-Disease
epiletpicus	I-Disease
.	O

BACKRGOUND	O
:	O
Neuroinflammatoin	B-Disease
occurs	O
after	O
seziures	B-Disease
and	O
is	O
implicated	O
in	O
epileptogeensis	O
.	O

CRC2	O
is	O
a	O
chemoikne	O
recetpor	O
for	O
CLC2	O
and	O
their	O
interactoin	O
mediates	O
monoctye	O
ifniltration	O
in	O
the	O
neuroinflammatroy	B-Disease
csacade	O
triggered	O
in	O
different	O
brian	O
pathologeis	O
.	O

In	O
this	O
work	O
CRC2	O
and	O
CLC2	O
exrpession	O
were	O
examined	O
following	O
sttaus	B-Disease
epilepitcus	I-Disease
(	O
SE	B-Disease
)	O
induecd	O
by	O
pilcoarpine	O
injectoin	O
.	O

METHODS	O
:	O
SE	B-Disease
was	O
indcued	O
by	O
piloacrpine	O
ijnection	O
.	O

Contorl	O
rtas	O
were	O
injecetd	O
with	O
slaine	O
instead	O
of	O
pilocaprine	O
.	O

Five	O
dyas	O
after	O
SE	B-Disease
,	O
CRC2	O
staiinng	O
in	O
neruons	O
and	O
gilal	O
clels	O
was	O
examined	O
using	O
imunohistcohemical	O
anaylses	O
.	O

The	O
number	O
of	O
CRC2	O
postiive	O
cells	O
was	O
determined	O
using	O
stereoolgy	O
proebs	O
in	O
the	O
hippocmapus	O
.	O

CLC2	O
expression	O
in	O
the	O
hipopcampus	O
was	O
examined	O
by	O
molecluar	O
assay	O
.	O

RSEULTS	O
:	O
Increaesd	O
CRC2	O
was	O
observed	O
in	O
the	O
hipopcampus	O
after	O
SE	B-Disease
.	O

Seiuzres	B-Disease
also	O
resulted	O
in	O
aletrations	O
to	O
the	O
clel	O
types	O
experssing	O
CRC2	O
.	O

Incerased	O
nmubers	O
of	O
neruons	O
that	O
experssed	O
CRC2	O
was	O
observed	O
following	O
SE	B-Disease
.	O

Micorglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CRC2	O
-	O
lbaeled	O
cells	O
in	O
SE	B-Disease
rtas	O
.	O

In	O
addition	O
,	O
rtas	O
that	O
experienced	O
SE	B-Disease
exhibited	O
CRC2	O
-	O
laebling	O
in	O
ppoulations	O
of	O
hyeprtrophied	B-Disease
atsrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dnetate	O
gyurs	O
.	O

These	O
CRC2	O
+	O
atsroctytes	O
were	O
not	O
observed	O
in	O
conrtol	O
rtas	O
.	O

Examniation	O
of	O
CLC2	O
exprsesion	O
showed	O
that	O
it	O
was	O
elevtaed	O
in	O
the	O
hpipocampus	O
following	O
SE	B-Disease
.	O

CONCULSION	O
:	O
The	O
dtaa	O
show	O
that	O
CRC2	O
and	O
CLC2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hipopcampus	O
after	O
pilocrapine	O
-	O
inudced	O
SE	B-Disease
.	O

Seziures	B-Disease
also	O
result	O
in	O
chagnes	O
to	O
CRC2	O
recetpor	O
expression	O
in	O
neurnos	O
and	O
astroyctes	O
.	O

These	O
chnages	O
might	O
be	O
involved	O
in	O
detrmiental	O
neuroplatsicity	O
and	O
neuroinlfammatory	B-Disease
cahnges	O
that	O
occur	O
following	O
seziures	B-Disease
.	O

Metlalothionein	O
induciton	O
redcues	O
caspsae	O
-	O
3	O
atcivity	O
and	O
TFNalpha	O
leevls	O
with	O
preservaiton	O
of	O
cogntiive	O
fucntion	O
and	O
intcat	O
hippocampal	O
neuorns	O
in	O
carmsutine	O
-	O
tretaed	O
rtas	O
.	O

Hippocapmal	O
inetgrity	O
is	O
essnetial	O
for	O
cgonitive	O
fnuctions	O
.	O

On	O
the	O
other	O
hand	O
,	O
inductoin	O
of	O
mteallothionein	O
(	O
MT	O
)	O
by	O
ZSnO	O
(	O
4	O
)	O
and	O
its	O
role	O
in	O
neuorprotection	O
has	O
been	O
documenetd	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
explore	O
the	O
effcet	O
of	O
MT	O
induciton	O
on	O
carmustnie	O
(	O
BNCU	O
)	O
-	O
idnuced	O
hippocampal	O
cogniitve	B-Disease
dysufnction	I-Disease
in	O
rtas	O
.	O

A	O
total	O
of	O
60	O
mlae	O
Wsitar	O
albnio	O
rtas	O
were	O
randomly	O
divided	O
into	O
four	O
gruops	O
(	O
15	O
/	O
gorup	O
)	O
:	O
The	O
cnotrol	O
gruop	O
injceted	O
with	O
single	O
doess	O
of	O
nromal	O
sailne	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BNCU	O
solevnt	O
(	O
i	O
.	O
v	O
)	O
.	O

The	O
second	O
gruop	O
admniistered	O
ZSnO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
mircol	O
noraml	O
salnie	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BNCU	O
solvnet	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O

Third	O
gruop	O
received	O
BNCU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
injcetion	O
with	O
nromal	O
sailne	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

Fourth	O
gorup	O
received	O
a	O
single	O
dsoe	O
of	O
ZSnO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
mircol	O
nromal	O
salnie	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BNCU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O

The	O
obtained	O
dtaa	O
reveaeld	O
that	O
BNCU	O
admniistration	O
resulted	O
in	O
deterioartion	B-Disease
of	I-Disease
leanring	I-Disease
and	I-Disease
short	I-Disease
-	I-Disease
term	I-Disease
memroy	I-Disease
(	O
STM	O
)	O
,	O
as	O
maesured	O
by	O
using	O
raidal	O
arm	O
waetr	O
mzae	O
,	O
accompanied	O
with	O
decreaesd	O
hippoacmpal	O
gultathione	O
reudctase	O
(	O
GR	O
)	O
actviity	O
and	O
reudced	O
glutahtione	O
(	O
GSH	O
)	O
cotnent	O
.	O

Also	O
,	O
BNCU	O
admiinstration	O
icnreased	O
sreum	O
tuomr	B-Disease
nercosis	B-Disease
fcator	O
-	O
alhpa	O
(	O
TFNalpha	O
)	O
,	O
hippocamapl	O
MT	O
and	O
malodnialdehyde	O
(	O
MDA	O
)	O
contnets	O
as	O
well	O
as	O
caspsae	O
-	O
3	O
activtiy	O
in	O
addition	O
to	O
hsitological	O
alteartions	O
.	O

ZSnO	O
(	O
4	O
)	O
prtereatment	O
counteracted	O
BNCU	O
-	O
induecd	O
ihnibition	O
of	O
GR	O
and	O
depletoin	O
of	O
GSH	O
and	O
resulted	O
in	O
significant	O
reduciton	O
in	O
the	O
levles	O
of	O
MDA	O
and	O
TNFalhpa	O
as	O
well	O
as	O
the	O
activtiy	O
of	O
caspsae	O
-	O
3	O
.	O

The	O
histoloigcal	O
featuers	O
were	O
ipmroved	O
in	O
hippoacmpus	O
of	O
rtas	O
treaetd	O
with	O
ZSnO	O
(	O
4	O
)	O
+	O
BNCU	O
compaerd	O
to	O
only	O
BNCU	O
-	O
terated	O
aniamls	O
.	O

In	O
conclusion	O
,	O
MT	O
inductoin	O
halts	O
BNCU	O
-	O
idnuced	O
hippocampal	O
toxictiy	B-Disease
as	O
it	O
prevented	O
GR	O
inhibiiton	O
and	O
GSH	O
depeltion	O
and	O
counteracted	O
the	O
incresaed	O
lveels	O
of	O
TNFalhpa	O
,	O
MDA	O
and	O
csapase	O
-	O
3	O
activtiy	O
with	O
subsequent	O
preservtaion	O
of	O
cogintion	O
.	O

Faatl	O
carbaamzepine	O
inudced	O
fumlinant	B-Disease
eosniophilic	I-Disease
(	O
hypersnesitivity	B-Disease
)	O
myocraditis	B-Disease
:	O
emphasis	O
on	O
anatoimcal	O
and	O
histoloigcal	O
characteritsics	O
,	O
mechnaisms	O
and	O
genteics	O
of	O
durg	B-Disease
hpyersensitivity	I-Disease
and	O
differetnial	O
diagnsois	O
.	O

The	O
most	O
seevre	O
avderse	O
recations	O
to	O
carbamazpeine	O
have	O
been	O
observed	O
in	O
the	O
haemopioetic	O
sytsem	O
,	O
the	O
lievr	O
and	O
the	O
cardiovascualr	O
ssytem	O
.	O

A	O
frequently	O
faatl	O
,	O
although	O
excepitonally	O
rrae	O
side	O
efefct	O
of	O
carabmazepine	O
is	O
nercotizing	O
eosinpohilic	O
(	O
hypersensitivtiy	B-Disease
)	O
myocardiits	B-Disease
.	O

We	O
reprot	O
a	O
csae	O
of	O
hpyersensitivity	B-Disease
myocardtiis	B-Disease
secondary	O
to	O
adminsitration	O
of	O
carabmazepine	O
.	O

Aucte	O
hypersensitiivty	B-Disease
myocardtiis	B-Disease
was	O
not	O
ssupected	O
cliniclaly	O
,	O
and	O
the	O
diangosis	O
was	O
made	O
psot	O
-	O
moretm	O
.	O

Hitsology	O
reveaeld	O
diffuse	O
ifniltration	O
of	O
the	O
myocradium	O
by	O
eoisnophils	O
and	O
lymphoyctes	O
with	O
moycyte	O
daamge	O
.	O

Cliincally	O
,	O
daeth	O
was	O
due	O
to	O
cadriogenic	B-Disease
shcok	I-Disease
.	O

To	O
best	O
of	O
our	O
knowlegde	O
this	O
is	O
the	O
second	O
csae	O
of	O
faatl	O
carbamazeipne	O
induecd	O
myoacrditis	B-Disease
reported	O
in	O
Engilsh	O
literautre	O
.	O

Neuorpsychiatric	O
bheaviors	O
in	O
the	O
MTPP	O
mramoset	O
moedl	O
of	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

OBJCETIVES	O
:	O
Neuropsycihatric	O
sympotms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
prolbem	O
in	O
ptaients	O
with	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
(	O
PD	B-Disease
)	O
.	O

These	O
sypmtoms	O
may	O
be	O
due	O
to	O
'	O
sensitiastion	O
'	O
following	O
repetaed	O
lveodopa	O
tretament	O
or	O
a	O
direct	O
efefct	O
of	O
dopamnie	O
on	O
the	O
disesae	O
state	O
.	O

The	O
levdoopa	O
-	O
terated	O
MTPP	O
-	O
lesinoed	O
mamroset	O
was	O
used	O
as	O
a	O
moedl	O
of	O
neurposychiatric	B-Disease
sympotms	I-Disease
in	O
PD	B-Disease
pateints	O
.	O

Here	O
we	O
comapre	O
the	O
tmie	O
coruse	O
of	O
leovdopa	O
-	O
indcued	O
mtoor	O
flutcuations	O
and	O
neruopsychiatric	B-Disease
-	I-Disease
like	I-Disease
bheaviors	I-Disease
to	O
determine	O
the	O
rleationship	O
between	O
duraiton	O
of	O
tretament	O
and	O
onset	O
of	O
sympotms	O
.	O

METHODS	O
:	O
Maromsets	O
were	O
adimnistered	O
1	O
-	O
metyhl	O
-	O
4	O
-	O
pehnyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
-	O
tetrahydropryidine	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
for	O
five	O
dyas	O
,	O
resulting	O
in	O
satble	O
parkisnonism	B-Disease
.	O

Lveodopa	O
(	O
15	O
mg	O
/	O
kg	O
and	O
benesrazide	O
,	O
3	O
.	O
75	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O

b	O
.	O
i	O
.	O
d	O
,	O
was	O
adminsitered	O
for	O
30	O
dyas	O
.	O

Aniamls	O
were	O
evaluaetd	O
for	O
parkisnonian	B-Disease
disabiilty	I-Disease
,	O
dsykinesia	B-Disease
and	O
on	O
-	O
tmie	O
(	O
mtoor	O
fluctuatinos	O
)	O
and	O
neuropscyhiatric	B-Disease
-	I-Disease
like	I-Disease
behvaiors	I-Disease
on	O
Day	O
0	O
(	O
prior	O
to	O
levdoopa	O
)	O
and	O
on	O
Dyas	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatemnt	O
using	O
psot	O
hoc	O
DVD	O
anaylsis	O
by	O
a	O
tarined	O
rtaer	O
,	O
bilnd	O
to	O
the	O
traetment	O
day	O
.	O

RSEULTS	O
:	O
The	O
neuropscyhiatric	B-Disease
-	I-Disease
like	I-Disease
beahvior	I-Disease
raitng	O
scale	O
demonstrated	O
high	O
intrerater	O
relaibility	O
between	O
three	O
tranied	O
raetrs	O
of	O
differing	O
professinoal	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
animlas	O
exhibited	O
a	O
porgressive	O
incerase	O
in	O
levodpoa	O
-	O
inudced	O
mtoor	O
fluctuaitons	O
,	O
dysiknesia	B-Disease
and	O
weraing	O
-	O
off	O
,	O
that	O
correlated	O
with	O
the	O
duraiton	O
of	O
levodpoa	O
thearpy	O
.	O

In	O
contrast	O
,	O
leovdopa	O
-	O
indcued	O
neuropsychiatirc	B-Disease
-	I-Disease
like	I-Disease
behaivors	I-Disease
were	O
present	O
on	O
Day	O
1	O
of	O
leovdopa	O
teratment	O
and	O
their	O
sveerity	O
did	O
not	O
corerlate	O
with	O
duraiton	O
of	O
traetment	O
.	O

CONCLUSOINS	O
:	O
The	O
dtaa	O
suggest	O
that	O
neuropsychitaric	B-Disease
disoredrs	I-Disease
in	O
PD	B-Disease
are	O
more	O
likely	O
an	O
interaciton	O
between	O
lveodopa	O
and	O
the	O
diesase	O
state	O
than	O
a	O
consequence	O
of	O
sensitisaiton	O
to	O
repaeted	O
dopaimnergic	O
tehrapy	O
.	O

Contarst	O
mdeium	O
nephrotoxciity	B-Disease
after	O
reanl	O
atrery	O
and	O
coronray	O
anigoplasty	O
.	O

BACKRGOUND	O
:	O
Rneal	B-Disease
dysfunciton	I-Disease
induecd	O
by	O
iodinaetd	O
contrast	O
mdeium	O
(	O
CM	O
)	O
administartion	O
can	O
minimize	O
the	O
benfeit	O
of	O
the	O
interventioanl	O
procedrue	O
in	O
patietns	O
undergoing	O
rneal	O
agnioplasty	O
(	O
PRTA	O
)	O
.	O

PRUPOSE	O
:	O
To	O
cmopare	O
the	O
susceptibliity	O
to	O
nehprotoxic	B-Disease
effect	O
of	O
CM	O
in	O
patietns	O
undergoing	O
PRTA	O
with	O
that	O
of	O
patinets	O
submitted	O
to	O
perctuaneous	O
cornoary	O
interventoin	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
pateints	O
successfully	O
traeted	O
with	O
PRTA	O
(	O
PRTA	O
gruop	O
,	O
mean	O
age	O
70	O
+	O
/	O
-	O
12	O
yeras	O
,	O
23	O
fmeale	O
,	O
baasl	O
creatinnie	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
comapred	O
with	O
33	O
patietns	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
gruop	O
)	O
,	O
matched	O
for	O
bsaal	O
craetinine	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
,	O
range	O
0	O
.	O
7	O
-	O
3	O
.	O
4	O
mg	O
/	O
dl	O
)	O
,	O
genedr	O
,	O
and	O
age	O
.	O

In	O
both	O
gorups	O
postprcoedural	O
(	O
48	O
h	O
)	O
seurm	O
cretainine	O
was	O
measrued	O
.	O

RESUTLS	O
:	O
Postprcoedural	O
creatniine	O
lveel	O
decreaesd	O
nonsiginficantly	O
in	O
the	O
PRTA	O
gorup	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
inrceased	O
significantly	O
in	O
the	O
PCI	O
gorup	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
57	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Cahnges	O
in	O
sreum	O
creatniine	O
after	O
interventoin	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PRTA	O
and	O
PCI	O
gorups	O
(	O
-	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
5	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
cliincal	O
rsik	O
prfoile	O
or	O
to	O
the	O
vloume	O
of	O
CM	O
adminisetred	O
.	O

CNOCLUSION	O
:	O
In	O
this	O
preliminary	O
sutdy	O
pateints	O
submitted	O
to	O
PRTA	O
showed	O
a	O
loewr	O
suscepitbility	O
to	O
reanl	B-Disease
daamge	I-Disease
induecd	O
by	O
CM	O
admiinstration	O
than	O
PCI	O
paitents	O
.	O

The	O
effectvieness	O
of	O
PRTA	O
on	O
rneal	O
funtcion	O
seems	O
to	O
be	O
barely	O
influneced	O
by	O
CM	O
txoicity	B-Disease
.	O

Diphenhydramnie	O
prevents	O
the	O
haemoydnamic	O
cahnges	O
of	O
cimteidine	O
in	O
ICU	O
patietns	O
.	O

Cmietidine	O
,	O
a	O
hisatmine	O
2	O
(	O
H2	O
)	O
atnagonist	O
,	O
produces	O
a	O
decraese	O
in	O
arteiral	O
prsesure	O
due	O
to	O
vasodilatatoin	O
,	O
especially	O
in	O
critically	O
ill	O
ptaients	O
.	O

This	O
may	O
be	O
because	O
cimeitdine	O
acts	O
as	O
a	O
hsitamine	O
agonsit	O
.	O

We	O
,	O
therefore	O
,	O
investgiated	O
the	O
efefcts	O
of	O
the	O
histamnie	O
1	O
(	O
H1	O
)	O
recepotr	O
antgaonist	O
,	O
diphehnydramine	O
,	O
on	O
the	O
haemodynaimc	O
chagnes	O
observed	O
after	O
cimteidine	O
in	O
ICU	O
paitents	O
.	O

Each	O
ptaient	O
was	O
studied	O
on	O
two	O
separate	O
dyas	O
.	O

In	O
a	O
ranodm	O
fashion	O
,	O
they	O
received	O
cmietidine	O
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatmnet	O
of	O
diphenyhdramine	O
40	O
mg	O
iv	O
with	O
cimeitdine	O
200	O
mg	O
iv	O
.	O

In	O
the	O
non	O
-	O
pretretament	O
gorup	O
,	O
mean	O
atrerial	O
presusre	O
(	O
MAP	O
)	O
dcereased	O
from	O
107	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
miuntes	O
after	O
cmietidine	O
.	O

Also	O
,	O
systeimc	O
vascluar	O
rseistance	O
(	O
SVR	O
)	O
decerased	O
during	O
the	O
eight	O
-	O
minute	O
obseravtion	O
peirod	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
pretreatmnet	O
gorup	O
,	O
little	O
haemodynaimc	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antaognist	O
may	O
be	O
useful	O
in	O
preventing	O
hyptoension	B-Disease
caused	O
by	O
iv	O
cimteidine	O
,	O
since	O
the	O
vsaodilating	O
actviity	O
of	O
cmietidine	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
reecptor	O
.	O

Meidcal	O
and	O
psyhciatric	O
outcmoes	O
for	O
ptaients	O
tranpslanted	O
for	O
acetamionphen	O
-	O
induecd	O
actue	B-Disease
lvier	I-Disease
fialure	I-Disease
:	O
a	O
csae	O
-	O
cnotrol	O
stduy	O
.	O

BAKCGROUND	O
:	O
Aceatminophen	O
-	O
inudced	O
hepattooxicity	B-Disease
is	O
the	O
most	O
common	O
cause	O
of	O
actue	B-Disease
lievr	I-Disease
fialure	I-Disease
(	O
ALF	B-Disease
)	O
in	O
the	O
UK	O
.	O

Pateints	O
often	O
consume	O
the	O
durg	O
with	O
suicdial	O
inetnt	O
or	O
with	O
a	O
background	O
of	O
subsatnce	O
depednence	O
.	O

AMIS	O
AND	O
METHODS	O
:	O
We	O
compaerd	O
the	O
seveirty	O
of	O
prertansplant	O
ilnless	O
,	O
pscyhiatric	O
co	O
-	O
morbidtiy	O
,	O
mdeical	O
and	O
psyhcosocial	O
outcoems	O
of	O
all	O
patinets	O
who	O
had	O
undergone	O
lievr	O
transpalntation	O
(	O
LT	O
)	O
emregently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminohpen	O
-	O
idnuced	O
ALF	B-Disease
(	O
n	O
=	O
36	O
)	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
ptaients	O
undergoing	O
eemrgent	O
LT	O
for	O
non	O
-	O
acetaimnophen	O
-	O
inudced	O
ALF	B-Disease
(	O
n	O
=	O
35	O
)	O
and	O
eelctive	O
LT	O
for	O
chrnoic	B-Disease
lvier	I-Disease
disesae	I-Disease
(	O
CLD	B-Disease
,	O
n	O
=	O
34	O
)	O
.	O

RESUTLS	O
:	O
Acetaminohpen	O
-	O
idnuced	O
ALF	B-Disease
patietns	O
undergoing	O
LT	O
had	O
a	O
greater	O
seevrity	O
of	O
pre	O
-	O
LT	O
ilnless	O
reflected	O
by	O
hihger	O
Aucte	O
Physiloogy	O
and	O
Chornic	O
Helath	O
Evaulation	O
II	O
socres	O
and	O
rqeuirement	O
for	O
ogran	O
support	O
compraed	O
with	O
the	O
other	O
two	O
gruops	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acetaimnophen	O
-	O
induecd	O
ALF	B-Disease
ptaients	O
had	O
a	O
formal	O
psychitaric	O
diangosis	O
before	O
LT	O
(	O
non	O
-	O
acetaminohpen	O
-	O
idnuced	O
ALF	B-Disease
=	O
0	O
/	O
35	O
,	O
CLD	B-Disease
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicdie	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
meidan	O
5	O
yeras	O
)	O
,	O
there	O
were	O
no	O
significant	O
differneces	O
in	O
reejction	O
(	O
actue	O
and	O
chroinc	O
)	O
,	O
grfat	O
failrue	O
or	O
suvrival	O
between	O
the	O
gruops	O
(	O
acteaminophen	O
-	O
idnuced	O
ALF	B-Disease
1	O
yaer	O
87	O
%	O
,	O
5	O
yaers	O
75	O
%	O
;	O
non	O
-	O
acetamniophen	O
-	O
induecd	O
ALF	B-Disease
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B-Disease
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
log	O
rnak	O
)	O
.	O

Two	O
aectaminophen	O
-	O
induecd	O
ALF	B-Disease
patinets	O
reattempted	O
siucide	O
psot	O
-	O
LT	O
(	O
one	O
deid	O
8	O
yeras	O
psot	O
-	O
LT	O
)	O
.	O

CONCLUSOINS	O
:	O
Despite	O
a	O
high	O
pervalence	O
of	O
psychiatirc	O
disturbnace	O
,	O
outocmes	O
for	O
ptaients	O
transplnated	O
emeregntly	O
for	O
acetamionphen	O
-	O
indcued	O
ALF	B-Disease
were	O
comparable	O
to	O
those	O
trasnplanted	O
for	O
non	O
-	O
aceatminophen	O
-	O
idnuced	O
ALF	B-Disease
and	O
eletcively	O
for	O
CLD	B-Disease
.	O

Mulitdisciplinary	O
approaches	O
with	O
long	O
-	O
term	O
psychitaric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
low	O
psot	O
-	O
tranpslant	O
suciide	O
raets	O
seen	O
and	O
low	O
rtaes	O
of	O
garft	O
lsos	O
because	O
of	O
non	O
-	O
compliacne	O
.	O

Antithromboitc	O
durg	O
use	O
,	O
cerebarl	B-Disease
microbleeds	I-Disease
,	O
and	O
intraecrebral	B-Disease
hmeorrhage	I-Disease
:	O
a	O
sytsematic	O
reivew	O
of	O
publisehd	O
and	O
unpublished	O
stuides	O
.	O

BACKGRONUD	O
AND	O
PURPSOE	O
:	O
Cerebarl	B-Disease
micorbleeds	I-Disease
(	O
MB	B-Disease
)	O
are	O
potentail	O
rsik	O
fcators	O
for	O
intracererbal	B-Disease
hemorrhgae	I-Disease
(	O
ICH	B-Disease
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindictaion	O
to	O
using	O
anitthrombotic	O
drgus	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
dtaa	O
on	O
MB	B-Disease
frequecny	O
stratiifed	O
by	O
antithormbotic	O
use	O
in	O
choorts	O
with	O
ICH	B-Disease
and	O
icshemic	B-Disease
strkoe	I-Disease
(	O
IS	B-Disease
)	O
/	O
tarnsient	B-Disease
icshemic	I-Disease
attcak	I-Disease
(	O
TIA	B-Disease
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
sysetmatic	O
reivew	O
of	O
publisehd	O
and	O
unpublished	O
dtaa	O
from	O
coohrts	O
with	O
storke	B-Disease
or	O
TIA	B-Disease
to	O
cmopare	O
the	O
presecne	O
of	O
MB	B-Disease
in	O
:	O
(	O
1	O
)	O
anitthrombotic	O
uesrs	O
vs	O
nonantithrobmotic	O
usres	O
with	O
ICH	B-Disease
;	O
(	O
2	O
)	O
antitrhombotic	O
uesrs	O
vs	O
nounsers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
;	O
and	O
(	O
3	O
)	O
ICH	B-Disease
vs	O
ishcemic	B-Disease
evetns	O
srtatified	O
by	O
antithormbotic	O
use	O
.	O

We	O
also	O
analyezd	O
pulbished	O
and	O
unpublished	O
follow	O
-	O
up	O
dtaa	O
to	O
determine	O
the	O
rsik	O
of	O
ICH	B-Disease
in	O
antithromobtic	O
uesrs	O
with	O
MB	B-Disease
.	O

REUSLTS	O
:	O
In	O
a	O
pooled	O
anaylsis	O
of	O
1460	O
ICH	B-Disease
and	O
3817	O
IS	B-Disease
/	O
TIA	B-Disease
,	O
MB	B-Disease
were	O
more	O
ferquent	O
in	O
ICH	B-Disease
vs	O
IS	B-Disease
/	O
TIA	B-Disease
in	O
all	O
treamtent	O
gorups	O
,	O
but	O
the	O
ecxess	O
incerased	O
from	O
2	O
.	O
8	O
(	O
odds	O
rtaio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantihtrombotic	O
uesrs	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antipaltelet	O
uesrs	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warafrin	O
uesrs	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
execss	O
of	O
MB	B-Disease
in	O
wrafarin	O
usres	O
vs	O
nonuesrs	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
wafrarin	O
usres	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
ecxess	O
of	O
MB	B-Disease
in	O
antipaltelet	O
uesrs	O
vs	O
nounsers	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
fidnings	O
were	O
similar	O
for	O
antpilatelet	O
usres	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
pooled	O
follow	O
-	O
up	O
dtaa	O
for	O
768	O
antithromboitc	O
usres	O
,	O
persence	O
of	O
MB	B-Disease
at	O
baselnie	O
was	O
associated	O
with	O
a	O
substantially	O
increaesd	O
rsik	O
of	O
subsequent	O
ICH	B-Disease
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONLCUSIONS	O
:	O
The	O
excses	O
of	O
MB	B-Disease
in	O
warfairn	O
uesrs	O
with	O
ICH	B-Disease
copmared	O
to	O
other	O
gorups	O
suggests	O
that	O
MB	B-Disease
incerase	O
the	O
rsik	O
of	O
wrafarin	O
-	O
associated	O
ICH	B-Disease
.	O

Limietd	O
prospetcive	O
dtaa	O
corroborate	O
these	O
findnigs	O
,	O
but	O
larger	O
propsective	O
stduies	O
are	O
urgently	O
required	O
.	O

Stduies	O
of	O
syenrgy	O
between	O
morphnie	O
and	O
a	O
novel	O
soduim	O
channel	O
blokcer	O
,	O
CNSB002	O
,	O
in	O
rat	O
moedls	O
of	O
inflamamtory	O
and	O
neuropahtic	B-Disease
pian	I-Disease
.	O

OBJCETIVE	O
:	O
This	O
sutdy	O
determined	O
the	O
antiyhperalgesic	O
efefct	O
of	O
CNSB002	O
,	O
a	O
soduim	O
chanenl	O
blokcer	O
with	O
antioxiadnt	O
properteis	O
given	O
alone	O
and	O
in	O
combinaitons	O
with	O
morphnie	O
in	O
rat	O
moedls	O
of	O
infalmmatory	O
and	O
nueropathic	B-Disease
pian	I-Disease
.	O

DESIGN	O
:	O
Dsoe	O
resopnse	O
curevs	O
for	O
nosnedating	O
dsoes	O
of	O
morphnie	O
and	O
CSNB002	O
given	O
intraperitonelaly	O
alone	O
and	O
together	O
in	O
combiantions	O
were	O
constructed	O
for	O
atnihyperalgesic	O
effect	O
using	O
paw	O
wtihdrawal	O
from	O
nxoious	O
haet	O
in	O
two	O
rat	O
pian	B-Disease
moedls	O
:	O
carrageeann	O
-	O
induecd	O
paw	O
ifnlammation	B-Disease
and	O
streptooztocin	O
(	O
STZ	O
)	O
-	O
induecd	O
daibetic	B-Disease
neuroapthy	I-Disease
.	O

RESLUTS	O
:	O
The	O
maxiumm	O
nonsedtaing	O
doess	O
were	O
:	O
morpihne	O
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNBS002	O
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNBS002	O
with	O
morphnie	O
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
cobmination	O
.	O

The	O
dsoes	O
calculated	O
to	O
cause	O
50	O
%	O
rveersal	O
of	O
hpyeralgesia	B-Disease
(	O
E5D0	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
carrageeann	O
mdoel	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	O
-	O
indcued	O
neuroptahy	B-Disease
mdoel	O
for	O
CNBS002	O
and	O
morhpine	O
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
valeus	O
were	O
greater	O
than	O
the	O
maxmium	O
nnosedating	O
doess	O
.	O

The	O
E5D0	O
vaules	O
for	O
morphnie	O
when	O
given	O
in	O
combintaion	O
with	O
CNBS002	O
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maixmum	O
nosnedating	O
dsoe	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carargeenan	O
mdoel	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
neuropahty	B-Disease
mdoel	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
atninociception	O
after	O
mrophine	O
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
increaesd	O
by	O
co	O
-	O
administratoin	O
with	O
CNSB002	O
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
revesral	O
of	O
hyperalegsia	B-Disease
in	O
the	O
inflammaotry	O
and	O
nueropathic	B-Disease
mdoels	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
one	O
-	O
way	O
anaylsis	O
of	O
vraiance	O
-	O
significantly	O
greater	O
than	O
either	O
durg	O
given	O
alone	O
)	O
.	O

CNOCLUSIONS	O
:	O
The	O
maixmum	O
antihyprealgesic	O
effcet	O
achievable	O
with	O
nonsedaitng	O
dsoes	O
of	O
morphnie	O
may	O
be	O
increaesd	O
significantly	O
when	O
the	O
durg	O
is	O
used	O
in	O
combintaion	O
with	O
CSNB002	O
.	O

Heprain	O
-	O
induecd	O
throbmocytopenia	B-Disease
:	O
a	O
practical	O
reivew	O
.	O

Heprain	O
-	O
inudced	O
thromboctyopenia	B-Disease
(	O
HIT	B-Disease
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devatsating	O
outocmes	O
.	O

It	O
begins	O
when	O
heaprin	O
expousre	O
stmiulates	O
the	O
fomration	O
of	O
heaprin	O
-	O
pltaelet	O
fcator	O
4	O
antiobdies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
rleease	O
of	O
procoagluant	O
pltaelet	O
particels	O
.	O

Thrmobosis	B-Disease
and	O
thromobcytopenia	B-Disease
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
triats	O
of	O
HIT	B-Disease
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascluar	O
complicatinos	O
.	O

The	O
prvealence	O
of	O
HIT	B-Disease
varies	O
among	O
several	O
subgorups	O
,	O
with	O
greater	O
icnidence	O
in	O
surgcial	O
as	O
compaerd	O
with	O
meidcal	O
populatinos	O
.	O

HIT	B-Disease
must	O
be	O
acknowledged	O
for	O
its	O
itnense	O
predileciton	O
for	O
thromboiss	B-Disease
and	O
suspetced	O
whenever	O
thormbosis	B-Disease
occurs	O
after	O
heaprin	O
exopsure	O
.	O

Ealry	O
rceognition	O
that	O
incorporates	O
the	O
cliincal	O
and	O
serloogic	O
clues	O
is	O
paramount	O
to	O
timely	O
instiuttion	O
of	O
treatmnet	O
,	O
as	O
its	O
dealy	O
may	O
result	O
in	O
catasrtophic	O
outcoems	O
.	O

The	O
treamtent	O
of	O
HIT	B-Disease
mandates	O
an	O
immedaite	O
cessation	O
of	O
all	O
heaprin	O
exopsure	O
and	O
the	O
institutoin	O
of	O
an	O
anttihrombotic	O
thearpy	O
,	O
most	O
commonly	O
using	O
a	O
direct	O
thromibn	O
inihbitor	O
.	O

Current	O
"	O
diagonstic	O
"	O
tetss	O
,	O
which	O
primarily	O
include	O
funtcional	O
and	O
antigeinc	O
assyas	O
,	O
have	O
more	O
of	O
a	O
conifrmatory	O
than	O
diangostic	O
role	O
in	O
the	O
manageemnt	O
of	O
HIT	B-Disease
.	O

Special	O
atteniton	O
must	O
be	O
paid	O
to	O
caridac	O
paitents	O
who	O
are	O
often	O
epxosed	O
to	O
heprain	O
multpile	O
times	O
during	O
their	O
cuorse	O
of	O
teratment	O
.	O

Direct	O
thormbin	O
inhibiotrs	O
are	O
appropriate	O
,	O
eviednce	O
-	O
based	O
alterntaives	O
to	O
heprain	O
in	O
patinets	O
with	O
a	O
histroy	O
of	O
HIT	B-Disease
,	O
who	O
need	O
to	O
undergo	O
percutanoeus	O
coronray	O
itnervention	O
.	O

As	O
hpearin	O
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medicatoins	O
today	O
with	O
potnetial	O
for	O
HIT	B-Disease
with	O
every	O
heaprin	O
exopsure	O
,	O
a	O
close	O
vigilnace	O
of	O
plaetlet	O
conuts	O
must	O
be	O
practiced	O
whenever	O
hepairn	O
is	O
initiated	O
.	O

Adbuctor	O
paralsyis	B-Disease
after	O
btoox	O
ijnection	O
for	O
adductor	B-Disease
spasmdoic	I-Disease
dyspohnia	I-Disease
.	O

OBJECITVES	O
/	O
HYPOHTESIS	O
:	O
Botuilnum	O
toixn	O
(	O
Btoox	O
)	O
injecitons	O
into	O
the	O
thyraorytenoid	O
msucles	O
are	O
the	O
current	O
stanadrd	O
of	O
crae	O
for	O
addutcor	B-Disease
spasmoidc	I-Disease
dypshonia	I-Disease
(	O
ASDD	B-Disease
)	O
.	O

Reported	O
avderse	O
effects	O
include	O
a	O
peroid	O
of	O
breahtiness	O
,	O
thraot	B-Disease
pian	I-Disease
,	O
and	O
diffciulty	O
with	O
sawllowing	O
liqiuds	O
.	O

Here	O
we	O
reoprt	O
mulitple	O
caess	O
of	O
bilatreal	O
abducotr	O
paarlysis	B-Disease
following	O
Btoox	O
injetcions	O
for	O
ASDD	B-Disease
,	O
a	O
complicaiton	O
previously	O
unreported	O
.	O

SUTDY	O
DESIGN	O
:	O
Rertospective	O
csae	O
series	O
.	O

METHODS	O
:	O
Paitents	O
that	O
received	O
Btoox	O
injcetions	O
for	O
spasomdic	B-Disease
dypshonia	I-Disease
between	O
Jaunary	O
2000	O
and	O
Ocotber	O
2009	O
were	O
eavluated	O
.	O

Pateints	O
with	O
ASDD	B-Disease
were	O
identifeid	O
.	O

The	O
number	O
of	O
treatmnets	O
received	O
and	O
advesre	O
effetcs	O
were	O
noted	O
.	O

For	O
paitents	O
with	O
bilatreal	O
adbuctor	O
parlaysis	B-Disease
,	O
age	O
,	O
sex	O
,	O
paralyitc	O
Bootx	O
dsoe	O
,	O
prior	O
Btoox	O
dsoe	O
,	O
and	O
cousre	O
following	O
paraylsis	B-Disease
were	O
noted	O
.	O

RESLUTS	O
:	O
From	O
a	O
databsae	O
of	O
452	O
paitents	O
receiving	O
Btoox	O
,	O
352	O
paitents	O
had	O
been	O
diagnoesd	O
with	O
ASDD	B-Disease
.	O

Of	O
these	O
352	O
patinets	O
,	O
eight	O
pateints	O
suffered	O
bilatearl	O
adbuctor	O
parlaysis	B-Disease
,	O
and	O
two	O
suffered	O
this	O
complciation	O
twice	O
.	O

All	O
affceted	O
pateints	O
were	O
feamles	O
over	O
the	O
age	O
of	O
50	O
yaers	O
.	O

Most	O
pateints	O
had	O
received	O
treamtents	O
prior	O
to	O
abdutcor	O
paarlysis	B-Disease
and	O
continued	O
receiving	O
after	O
paarlysis	B-Disease
.	O

Seven	O
pateints	O
reocvered	O
after	O
a	O
brief	O
preiod	O
of	O
actiivty	O
restrcitions	O
,	O
and	O
one	O
underwent	O
a	O
trcaheotomy	O
.	O

The	O
icnidence	O
of	O
abudctor	O
parlaysis	B-Disease
after	O
Bootx	O
ijnection	O
for	O
ASDD	B-Disease
was	O
0	O
.	O
34	O
%	O
.	O

CONCLUISONS	O
:	O
Biltaeral	O
abdcutor	O
parlaysis	B-Disease
is	O
a	O
rrae	O
complictaion	O
of	O
Bootx	O
injcetions	O
for	O
ASDD	B-Disease
,	O
causing	O
diffciulty	O
with	O
bretahing	O
upon	O
exretion	O
.	O

The	O
likely	O
mehcanism	O
of	O
praalysis	B-Disease
is	O
diffusion	O
of	O
Btoox	O
around	O
the	O
msucular	O
procses	O
of	O
the	O
aryteniod	O
to	O
the	O
potserior	O
cricoarytneoid	O
mucsles	O
.	O

The	O
paraylsis	B-Disease
is	O
temporray	O
,	O
and	O
watchufl	O
wiating	O
with	O
restriciton	O
of	O
actviity	O
is	O
the	O
recommended	O
manageemnt	O
.	O

Mitochondiral	B-Disease
impariment	I-Disease
contributes	O
to	O
coacine	O
-	O
idnuced	O
cradiac	B-Disease
dysfunctoin	I-Disease
:	O
Prveention	O
by	O
the	O
targeetd	O
antioxidnat	O
MtioQ	O
.	O

The	O
gaol	O
of	O
this	O
sutdy	O
was	O
to	O
assess	O
mitohcondrial	O
funtcion	O
and	O
ROS	O
productoin	O
in	O
an	O
exeprimental	O
mdoel	O
of	O
ccoaine	O
-	O
idnuced	O
cradiac	B-Disease
dysfunctoin	I-Disease
.	O

We	O
hypothesized	O
that	O
ccoaine	B-Disease
aubse	I-Disease
may	O
lead	O
to	O
atlered	O
mitocohndrial	O
fucntion	O
that	O
in	O
turn	O
may	O
cause	O
lfet	B-Disease
ventircular	I-Disease
dsyfunction	I-Disease
.	O

Seven	O
dyas	O
of	O
ccoaine	O
administratoin	O
to	O
rtas	O
led	O
to	O
an	O
increaesd	O
oyxgen	O
consupmtion	O
detecetd	O
in	O
cadriac	O
fibres	O
,	O
specifically	O
through	O
compelx	O
I	O
and	O
copmlex	O
III	O
.	O

ROS	O
leevls	O
were	O
incraesed	O
,	O
specifically	O
in	O
inetrfibrillar	O
mitocohndria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
dercease	O
in	O
ATP	O
syntehsis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemaml	O
mitcohondria	O
.	O

This	O
uncopuling	O
efefct	O
on	O
oixdative	O
phospohrylation	O
was	O
not	O
detectbale	O
after	O
short	O
-	O
term	O
exopsure	O
to	O
cocanie	O
,	O
suggesting	O
that	O
these	O
mitochnodrial	B-Disease
abonrmalities	I-Disease
were	O
a	O
ltae	O
rather	O
than	O
a	O
priamry	O
evnet	O
in	O
the	O
patholoigcal	O
respnose	O
to	O
cociane	O
.	O

MtioQ	O
,	O
a	O
miotchondrial	O
-	O
trageted	O
antioxdiant	O
,	O
was	O
shown	O
to	O
completely	O
preevnt	O
these	O
mitochnodrial	B-Disease
abnormlaities	I-Disease
as	O
well	O
as	O
cardaic	B-Disease
dsyfunction	I-Disease
chraacterized	O
here	O
by	O
a	O
daistolic	B-Disease
dysfunctoin	I-Disease
studied	O
with	O
a	O
cnoductance	O
ctaheter	O
to	O
obtain	O
pressure	O
-	O
volmue	O
dtaa	O
.	O

Taken	O
together	O
,	O
these	O
resluts	O
extend	O
previous	O
sutdies	O
and	O
demonstrate	O
that	O
coacine	O
-	O
idnuced	O
cadriac	B-Disease
dysfunciton	I-Disease
may	O
be	O
due	O
to	O
a	O
mitohcondrial	B-Disease
deefct	I-Disease
.	O

Trmiethoprim	O
-	O
idnuced	O
imumne	O
hemolyitc	B-Disease
aneima	I-Disease
in	O
a	O
peditaric	O
oncoolgy	O
paitent	O
preesnting	O
as	O
an	O
actue	O
hemoyltic	O
trasnfusion	O
reactoin	O
.	O

A	O
10	O
-	O
yaer	O
-	O
old	O
mlae	O
with	O
actue	B-Disease
luekemia	I-Disease
presented	O
with	O
psot	O
-	O
chmeotherapy	O
aneima	B-Disease
.	O

During	O
red	O
clel	O
trasnfusion	O
,	O
he	O
developed	O
hemoglboinuria	B-Disease
.	O

Tranfsusion	O
raection	O
worukp	O
was	O
neagtive	O
.	O

Durg	O
-	O
indcued	O
immune	O
hemloytic	B-Disease
aneima	I-Disease
was	O
supsected	O
because	O
of	O
postiive	O
direct	O
antiglboulin	O
tset	O
,	O
neagtive	O
eulate	O
,	O
and	O
microspehrocytes	O
on	O
smaer	O
pre	O
-	O
and	O
psot	O
-	O
transfuison	O
.	O

Durg	O
sutdies	O
using	O
the	O
indircet	O
antiglboulin	O
tset	O
were	O
strongly	O
posiitve	O
with	O
trimethopirm	O
and	O
triemthoprim	O
-	O
sulfamethoaxzole	O
but	O
neagtive	O
with	O
sulfamethxoazole	O
.	O

The	O
patinet	O
recovreed	O
after	O
disocntinuing	O
the	O
durg	O
,	O
with	O
no	O
recurrnece	O
in	O
2	O
yeras	O
.	O

Other	O
causes	O
of	O
aneima	B-Disease
should	O
be	O
considered	O
in	O
ptaients	O
with	O
wrose	O
-	O
than	O
-	O
expected	O
aneima	B-Disease
after	O
chemothearpy	O
.	O

Furthermore	O
,	O
heomlysis	B-Disease
during	O
transufsion	O
is	O
not	O
always	O
a	O
transufsion	O
reaciton	O
.	O

Verapmail	O
sitmulation	O
tset	O
in	O
hyeprprolactinemia	B-Disease
:	O
lsos	O
of	O
prolcatin	O
resposne	O
in	O
anatmoic	O
or	O
funtcional	O
stlak	O
efefct	O
.	O

AIM	O
:	O
Verapaiml	O
sitmulation	O
tset	O
was	O
previously	O
investigaetd	O
as	O
a	O
tool	O
for	O
differentail	O
daignosis	O
of	O
hyperproalctinemia	B-Disease
,	O
but	O
with	O
conflicting	O
resutls	O
.	O

Macroprolactineima	B-Disease
was	O
never	O
considered	O
in	O
those	O
previous	O
sutdies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
invesitgate	O
the	O
diganostic	O
value	O
of	O
vreapamil	O
in	O
a	O
ppoulation	O
who	O
were	O
all	O
screened	O
for	O
macroprolacitnemia	B-Disease
.	O

Porlactin	O
responess	O
to	O
verapmail	O
in	O
65	O
feamle	O
paitents	O
(	O
age	O
:	O
29	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
yaers	O
)	O
with	O
hypeprrolactinemia	B-Disease
were	O
tesetd	O
in	O
a	O
descriptive	O
,	O
matched	O
csae	O
-	O
conrtol	O
sutdy	O
.	O

METHODS	O
:	O
Verapmail	O
80	O
mg	O
,	O
p	O
.	O
o	O
.	O
was	O
adminsitered	O
,	O
and	O
then	O
PRL	O
leevls	O
were	O
mesaured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immunomertic	O
chemiluimnescence	O
.	O

Vreapamil	O
respnosiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
bsaal	O
proalctin	O
levles	O
(	O
PRL	O
)	O
.	O

REUSLTS	O
:	O
Veraapmil	O
significantly	O
incerased	O
PRL	O
lveels	O
in	O
helathy	O
conrtols	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactnioma	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microporlactinoma	B-Disease
(	O
N	O
.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macroporlactinemia	B-Disease
(	O
N	O
.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolactnioma	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%	O
)	O
,	O
and	O
risperiodne	O
-	O
indcued	O
hyperprolcatinemia	B-Disease
(	O
N	O
.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
cruve	O
aanlysis	O
rveealed	O
that	O
unrseponsiveness	O
to	O
veraapmil	O
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
dsicriminated	O
anatomcial	O
or	O
functoinal	O
satlk	O
efefct	O
(	O
sesnitivity	O
:	O
74	O
%	O
,	O
specifictiy	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0	O
.	O
855	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pesudoprolactinoma	B-Disease
or	O
ripseridone	O
-	O
indcued	O
hyeprprolactinemia	B-Disease
,	O
respectively	O
.	O

CONCLUISON	O
:	O
Verapmail	O
respnosiveness	O
is	O
not	O
a	O
reliable	O
fidning	O
for	O
the	O
diffeerntial	O
diagnsois	O
of	O
hyperprolactniemia	B-Disease
.	O

However	O
,	O
verpaamil	O
unresponsivenses	O
discriminates	O
stlak	O
efefct	O
(	O
i	O
.	O
e	O
.	O
,	O
anatmoically	O
or	O
functionally	O
inihbited	O
dopaminegric	O
touns	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactienmia	B-Disease
with	O
varying	O
dgerees	O
of	O
rseponsiveness	O
.	O

Blockdae	O
of	O
endohtelial	O
-	O
meesnchymal	O
transiiton	O
by	O
a	O
Smda3	O
inhibtior	O
dleays	O
the	O
eraly	O
devleopment	O
of	O
streptoztoocin	O
-	O
idnuced	O
daibetic	B-Disease
nephroapthy	I-Disease
.	O

OBEJCTIVE	O
:	O
A	O
multcienter	O
,	O
contorlled	O
tiral	O
showed	O
that	O
eraly	O
bolckade	O
of	O
the	O
reinn	O
-	O
agniotensin	O
ssytem	O
in	O
pateints	O
with	O
tpye	B-Disease
1	I-Disease
diabtees	I-Disease
and	O
normoalbuminruia	O
did	O
not	O
retard	O
the	O
porgression	O
of	O
nephropahty	B-Disease
,	O
suggesting	O
that	O
other	O
mechainsm	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pahtogenesis	O
of	O
ealry	O
daibetic	B-Disease
npehropathy	I-Disease
(	O
daibetic	B-Disease
nephroapthy	I-Disease
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
endohtelial	O
-	O
mesecnhymal	O
-	O
trasnition	O
(	O
EndMoT	O
)	O
contributes	O
to	O
the	O
eraly	O
deevlopment	O
of	O
rneal	O
intrestitial	O
fibroiss	B-Disease
independently	O
of	O
microalbuminuira	O
in	O
mcie	O
with	O
srteptozotocin	O
(	O
STZ	O
)	O
-	O
idnuced	O
dibaetes	B-Disease
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
hypothesized	O
that	O
bolcking	O
EdnoMT	O
rdeuces	O
the	O
eraly	O
dveelopment	O
of	O
diabeitc	B-Disease
nephroptahy	I-Disease
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EndMoT	O
was	O
indcued	O
in	O
a	O
muose	O
pnacreatic	O
mircovascular	O
endtohelial	O
clel	O
line	O
(	O
MEMC	O
)	O
in	O
the	O
persence	O
of	O
advanecd	O
glcyation	O
end	O
porducts	O
(	O
AEGs	O
)	O
and	O
in	O
the	O
enodthelial	O
lnieage	O
-	O
traceble	O
muose	O
line	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
by	O
admiinstration	O
of	O
AEGs	O
,	O
with	O
nonglycaetd	O
muose	O
alubmin	O
serving	O
as	O
a	O
contorl	O
.	O

Phospohrylated	O
Smda3	O
was	O
dteected	O
by	O
immunopreicpitation	O
/	O
Wetsern	O
boltting	O
and	O
confcoal	O
mircoscopy	O
.	O

Blocknig	O
sutdies	O
using	O
recetpor	O
for	O
AGE	O
siNRA	O
and	O
a	O
specific	O
inhiibtor	O
of	O
Samd3	O
(	O
SSI3	O
)	O
were	O
performed	O
in	O
MEMCs	O
and	O
in	O
STZ	O
-	O
inudced	O
diaebtic	B-Disease
nephrpoathy	I-Disease
in	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
mcie	O
.	O

RSEULTS	O
:	O
Cnofocal	O
mircoscopy	O
and	O
real	O
-	O
tmie	O
PCR	O
demonstrated	O
that	O
AEGs	O
idnuced	O
EdnoMT	O
in	O
MMCEs	O
and	O
in	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
mcie	O
.	O

Immunopreicpitation	O
/	O
Wetsern	O
blotting	O
showed	O
that	O
Samd3	O
was	O
atcivated	O
by	O
AEGs	O
but	O
was	O
inhibietd	O
by	O
SSI3	O
in	O
MEMCs	O
and	O
in	O
STZ	O
-	O
inudced	O
daibetic	B-Disease
nephropahty	I-Disease
.	O

Cnofocal	O
microsocpy	O
and	O
real	O
-	O
tmie	O
PCR	O
further	O
demonstrated	O
that	O
SSI3	O
abrogaetd	O
EnodMT	O
,	O
reudced	O
rneal	O
firbosis	B-Disease
,	O
and	O
retaredd	O
progression	O
of	O
nehpropathy	B-Disease
.	O

CONLCUSIONS	O
:	O
EndMoT	O
is	O
a	O
novel	O
ptahway	O
leading	O
to	O
ealry	O
develompent	O
of	O
diabeitc	B-Disease
npehropathy	I-Disease
.	O

Bolckade	O
of	O
EnodMT	O
by	O
SSI3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
prorgession	O
of	O
diaebtic	B-Disease
neprhopathy	I-Disease
and	O
other	O
daibetes	B-Disease
complicatoins	I-Disease
.	O

Cytsotatic	O
and	O
atni	O
-	O
angiogneic	O
effects	O
of	O
temsiroliums	O
in	O
refrcatory	O
manlte	B-Disease
clel	I-Disease
lympohma	I-Disease
.	O

Manlte	B-Disease
clel	I-Disease
lmyphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
a	O
rrae	O
and	O
aggresisve	O
tpye	O
of	O
B	B-Disease
-	I-Disease
clel	I-Disease
non	I-Disease
-	I-Disease
Hdogkin	I-Disease
'	I-Disease
s	I-Disease
lymphmoa	I-Disease
.	O

Ptaients	O
become	O
progressively	O
refrcatory	O
to	O
conevntional	O
chemohterapy	O
,	O
and	O
their	O
prognsois	O
is	O
poor	O
.	O

However	O
,	O
a	O
38	O
%	O
remission	O
rtae	O
has	O
been	O
recently	O
reported	O
in	O
refractroy	O
MCL	B-Disease
tretaed	O
with	O
temsirloimus	O
,	O
a	O
mOTR	O
inhibiotr	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
stduy	O
a	O
csae	O
of	O
refarctory	O
MCL	B-Disease
who	O
had	O
tmuor	B-Disease
regerssion	O
two	O
monhts	O
after	O
temsiroliums	O
treatemnt	O
,	O
and	O
a	O
progrsesion	O
-	O
free	O
suvrival	O
of	O
10	O
mnoths	O
.	O

In	O
this	O
csae	O
,	O
lypmh	O
ndoe	O
biopises	O
were	O
performed	O
before	O
and	O
six	O
mnoths	O
after	O
temisrolimus	O
therpay	O
.	O

Comaprison	O
of	O
the	O
two	O
biopises	O
showed	O
that	O
temsiroliums	O
inihbited	O
tuomr	B-Disease
clel	O
proliferaiton	O
through	O
clel	O
ccyle	O
arerst	O
,	O
but	O
did	O
not	O
indcue	O
any	O
change	O
in	O
the	O
number	O
of	O
appototic	O
tuomr	B-Disease
clels	O
.	O

Apart	O
from	O
this	O
cytotsatic	O
efefct	O
,	O
temsiroliums	O
had	O
an	O
antiangioegnic	O
effcet	O
with	O
decerase	O
of	O
tmuor	B-Disease
mircovessel	O
desnity	O
and	O
of	O
VGEF	O
expressoin	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limietd	O
fibroitc	O
areas	O
,	O
compatible	O
with	O
psot	O
-	O
necrtoic	B-Disease
tisuse	O
rpeair	O
,	O
were	O
found	O
after	O
6	O
-	O
mnoth	O
tmesirolimus	O
therpay	O
.	O

Thus	O
,	O
tesmirolimus	O
reduecd	O
tmuor	B-Disease
budren	O
through	O
associated	O
ctyostatic	O
and	O
atni	O
-	O
angoigenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsiorlimus	O
on	O
tmuor	B-Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
rerfactory	O
MCL	B-Disease
resisatnt	O
to	O
cnoventional	O
chemotehrapy	O
.	O

Aucte	B-Disease
rneal	I-Disease
failrue	I-Disease
due	O
to	O
rifmapicin	O
.	O

A	O
23	O
-	O
yaer	O
-	O
old	O
mlae	O
pateint	O
with	O
bcateriologically	O
proven	O
pulmoanry	B-Disease
tubercuolsis	I-Disease
was	O
tretaed	O
with	O
the	O
various	O
reigmens	O
of	O
antituberculoiss	O
durgs	O
for	O
nearly	O
15	O
mnoths	O
.	O

Rifampciin	O
was	O
administeerd	O
thrcie	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
durg	O
regmien	O
and	O
each	O
tmie	O
he	O
developed	O
untoward	O
side	O
effetcs	O
like	O
nuasea	B-Disease
,	O
vmoiting	B-Disease
and	O
fveer	B-Disease
with	O
chills	O
and	O
rigros	O
.	O

The	O
last	O
such	O
epiosde	O
was	O
of	O
actue	O
reanl	O
faiulre	O
at	O
which	O
satge	O
the	O
pateint	O
was	O
seen	O
by	O
the	O
autohrs	O
of	O
this	O
reoprt	O
.	O

The	O
ptaient	O
,	O
however	O
,	O
made	O
a	O
full	O
recvoery	O
.	O

Synocpe	B-Disease
caused	O
by	O
hyeprkalemia	B-Disease
during	O
use	O
of	O
a	O
combnied	O
thearpy	O
with	O
the	O
anigotensin	O
-	O
converting	O
enyzme	O
inihbitor	O
and	O
sprionolactone	O
.	O

A	O
76	O
yaer	O
-	O
old	O
woamn	O
with	O
a	O
hsitory	O
of	O
coronray	O
atrery	O
bypsas	O
grafitng	O
and	O
prior	O
moycardial	B-Disease
infartcion	I-Disease
was	O
trnasferred	O
to	O
the	O
eemrgency	O
room	O
with	O
lsos	B-Disease
of	I-Disease
conscoiusness	I-Disease
due	O
to	O
marked	O
bradycarida	B-Disease
caused	O
by	O
hpyerkalemia	B-Disease
.	O

The	O
concentratoin	O
of	O
sreum	O
potassuim	O
was	O
high	O
,	O
and	O
nomral	O
snius	O
rhtyhm	O
was	O
restoerd	O
after	O
correction	O
of	O
the	O
sreum	O
poatssium	O
lveel	O
.	O

The	O
cause	O
of	O
hypekralemia	B-Disease
was	O
considered	O
to	O
be	O
several	O
doess	O
of	O
spirnaolactone	O
,	O
an	O
aldosteorne	O
antagnoist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
itnake	O
of	O
rampiril	O
,	O
an	O
ACE	O
ihnibitor	O
.	O

This	O
csae	O
is	O
a	O
good	O
example	O
of	O
eletcrolyte	O
ibmalance	O
causing	O
aucte	O
lfie	O
-	O
threatening	O
caridac	O
evnets	O
.	O

Cilnicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkaelmia	B-Disease
,	O
especially	O
in	O
eldrely	O
paitents	O
using	O
ACE	O
/	O
ARB	O
in	O
cobmination	O
with	O
potasisum	O
sparing	O
agnets	O
and	O
who	O
have	O
mlid	O
rneal	B-Disease
ditsurbance	I-Disease
.	O

Dfifuse	O
skeeltal	O
pian	B-Disease
after	O
administartion	O
of	O
alendrontae	O
.	O

BAKCGROUND	O
:	O
Osteopoorsis	B-Disease
is	O
caused	O
by	O
bnoe	O
rseorption	O
in	O
ecxess	O
of	O
bnoe	O
fomration	O
,	O
and	O
bisphosphoantes	O
,	O
are	O
used	O
to	O
ihnibit	O
bnoe	O
resoprtion	O
.	O

Aelndronate	O
,	O
a	O
biphosphnoate	O
,	O
is	O
effetcive	O
for	O
both	O
the	O
treatemnt	O
and	O
pervention	O
of	O
osteoporoiss	B-Disease
in	O
postmenoapusal	O
wmoen	O
.	O

Side	O
efefcts	O
are	O
relatively	O
few	O
and	O
prominently	O
gastriontestinal	O
.	O

Musculokseletal	B-Disease
pian	I-Disease
may	O
be	O
an	O
important	O
side	O
efefct	O
in	O
these	O
pateints	O
.	O

We	O
presented	O
a	O
ptaient	O
adimtted	O
to	O
our	O
out	O
-	O
pateint	O
clniic	O
with	O
difufse	O
skelteal	O
pian	B-Disease
after	O
three	O
cosnecutive	O
adminisrtation	O
of	O
alenrdonate	O
.	O

CONCLUSOIN	O
:	O
We	O
conclude	O
that	O
ptaients	O
with	O
ostepoorosis	B-Disease
can	O
rpeort	O
pian	B-Disease
,	O
and	O
bsiphosphonate	O
-	O
related	O
pian	B-Disease
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
compalint	O
to	O
osteoporsois	B-Disease
.	O

Cerebropsinal	O
fliud	O
penetraiton	O
of	O
high	O
-	O
dsoe	O
datpomycin	O
in	O
susepcted	O
Staphyloccocus	O
arueus	O
mneingitis	B-Disease
.	O

OJBECTIVE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
metihcillin	O
-	O
senstiive	O
Staphyolcoccus	O
arueus	O
(	O
MSSA	O
)	O
bactreemia	B-Disease
with	O
suspceted	O
MSSA	O
meningtiis	B-Disease
terated	O
with	O
high	O
-	O
dsoe	O
daptomyicn	O
assessed	O
with	O
concrurent	O
seurm	O
and	O
ceerbrospinal	O
fliud	O
(	O
CSF	O
)	O
concnetrations	O
.	O

CSAE	O
SUMMRAY	O
:	O
A	O
54	O
-	O
yaer	O
-	O
old	O
mlae	O
presented	O
to	O
the	O
emergnecy	O
dpeartment	O
with	O
generailzed	O
wekaness	B-Disease
and	O
presumed	O
heatlh	O
-	O
crae	O
-	O
associated	O
pnemuonia	B-Disease
shown	O
on	O
chset	O
radiogrpah	O
.	O

Treamtent	O
was	O
empircially	O
initiated	O
with	O
vanocmycin	O
,	O
levfoloxacin	O
,	O
and	O
pipreacillin	O
/	O
tazobcatam	O
.	O

Blood	O
cutlures	O
reevaled	O
S	O
.	O
arueus	O
suscepitble	O
to	O
oxaclilin	O
.	O

Empriic	O
antbiiotic	O
treamtent	O
was	O
narrowed	O
to	O
nafcililn	O
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
ptaient	O
developed	O
actue	B-Disease
reanl	I-Disease
fialure	I-Disease
(	O
sreum	O
creatniine	O
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
incresaed	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
amdission	O
)	O
.	O

The	O
patinet	O
'	O
s	O
Glagsow	O
Cmoa	O
Socre	O
was	O
3	O
,	O
with	O
nomral	O
findigns	O
shown	O
on	O
comptued	O
tomograhpy	O
sacn	O
of	O
the	O
haed	O
72	O
hours	O
following	O
an	O
epiosde	O
of	O
caridac	B-Disease
arerst	I-Disease
on	O
day	O
10	O
.	O

The	O
patinet	O
experienced	O
relpasing	O
MSSA	O
bacetremia	B-Disease
on	O
day	O
9	O
,	O
increaisng	O
the	O
ssupicion	O
for	O
a	O
centarl	O
nervuos	O
ssytem	O
(	O
CNS	O
)	O
inefction	B-Disease
.	O

Nafcillin	O
was	O
dsicontinued	O
and	O
daptmoycin	O
9	O
mg	O
/	O
kg	O
dialy	O
was	O
initiated	O
for	O
suspetced	O
meinngitis	B-Disease
and	O
was	O
continued	O
until	O
the	O
ptaient	O
'	O
s	O
detah	O
on	O
day	O
16	O
.	O

Daptoymcin	O
sreum	O
and	O
CSF	O
trough	O
cocnentrations	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dsoe	O
.	O

Lmubar	O
pucnture	O
reuslts	O
were	O
inconlcusive	O
and	O
no	O
further	O
bolod	O
cultrues	O
were	O
positvie	O
for	O
MSSA	O
.	O

Creaitne	O
kinsae	O
lveels	O
were	O
nromal	O
prior	O
to	O
datpomycin	O
threapy	O
and	O
were	O
not	O
raessessed	O
.	O

DISCUSSION	O
:	O
Datpomycin	O
was	O
initiated	O
in	O
our	O
pateint	O
secondary	O
to	O
possible	O
nafclilin	O
-	O
indcued	O
actue	O
itnerstitial	B-Disease
npehritis	I-Disease
and	O
relapsnig	O
bacteermia	B-Disease
.	O

At	O
a	O
dsoe	O
of	O
9	O
mg	O
/	O
kg	O
,	O
reusltant	O
pneetration	O
of	O
5	O
%	O
was	O
hgiher	O
than	O
in	O
previous	O
rpeorts	O
,	O
more	O
consistent	O
with	O
inflaemd	O
meinnges	O
.	O

CONCLSUIONS	O
:	O
High	O
-	O
dsoe	O
dapotmycin	O
may	O
be	O
an	O
aletrnative	O
option	O
for	O
MSSA	O
bacteermia	B-Disease
with	O
or	O
without	O
a	O
CNS	O
suorce	O
in	O
patietns	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
stanadrd	O
threapy	O
.	O

Further	O
cliincal	O
evaluatoin	O
in	O
patinets	O
with	O
confirmed	O
mennigitis	B-Disease
is	O
warranted	O
.	O

The	O
role	O
of	O
ntiric	O
oixde	O
in	O
cnovulsions	B-Disease
idnuced	O
by	O
lidnane	O
in	O
rtas	O
.	O

Lnidane	O
is	O
an	O
organoclhoride	O
pestiicde	O
and	O
scaibcide	O
.	O

It	O
evokes	O
convlusions	B-Disease
mainly	O
trough	O
the	O
blokcage	O
of	O
GBAA	O
(	O
A	O
)	O
recpetors	O
.	O

Nitirc	O
oxdie	O
(	O
NO	O
)	O
,	O
gaesous	O
neurotrnasmitter	O
,	O
has	O
contradicotr	O
role	O
in	O
epileptogeneiss	O
due	O
to	O
opposite	O
effcets	O
of	O
L	O
-	O
agrinine	O
,	O
precurosr	O
of	O
NO	O
synhteses	O
(	O
NOS	O
)	O
,	O
and	O
L	O
-	O
NMAE	O
(	O
NOS	O
inhibtior	O
)	O
observed	O
in	O
different	O
epilespy	B-Disease
mdoels	O
.	O

The	O
aim	O
of	O
the	O
current	O
sutdy	O
was	O
to	O
determine	O
the	O
effcets	O
of	O
NO	O
on	O
the	O
behaviroal	O
and	O
EEG	O
characteritsics	O
of	O
lnidane	O
-	O
idnuced	O
epilespy	B-Disease
in	O
mlae	O
Wsitar	O
alibno	O
rtas	O
.	O

The	O
adimnistration	O
of	O
L	O
-	O
agrinine	O
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
in	O
dsoe	O
-	O
depenednt	O
manner	O
significantly	O
icnreased	O
convulsoin	B-Disease
icnidence	O
and	O
sveerity	O
and	O
sohrtened	O
ltaency	O
tmie	O
to	O
first	O
convuslion	B-Disease
elicited	O
by	O
loewr	O
lidnane	O
dsoe	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pertreatment	O
with	O
L	O
-	O
NMAE	O
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
decresaed	O
convulsoin	B-Disease
inciednce	O
and	O
seveirty	O
and	O
proolnged	O
latecny	O
tmie	O
to	O
covnulsion	B-Disease
following	O
ijnection	O
with	O
a	O
convlusive	B-Disease
dsoe	O
of	O
lindnae	O
(	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

EEG	O
anlayses	O
showed	O
incresae	O
of	O
number	O
and	O
duratoin	O
of	O
icatl	O
peridos	O
in	O
EEG	O
of	O
rtas	O
receiving	O
l	O
-	O
arignine	O
prior	O
to	O
lidnane	O
and	O
dcerease	O
of	O
this	O
number	O
in	O
rtas	O
pretreaetd	O
with	O
L	O
-	O
NMAE	O
.	O

These	O
reuslts	O
support	O
the	O
conclusion	O
that	O
NO	O
plays	O
a	O
role	O
of	O
enodgenous	O
convulasnt	O
in	O
rat	O
mdoel	O
of	O
linadne	O
seiuzres	B-Disease
.	O

Sveere	O
polynueropathy	B-Disease
and	O
mootr	O
lsos	O
after	O
intrathceal	O
thitoepa	O
comibnation	O
chemtoherapy	O
:	O
description	O
of	O
two	O
caess	O
.	O

Two	O
caess	O
of	O
sevree	O
dealyed	O
neuorlogic	B-Disease
toixcity	I-Disease
related	O
to	O
the	O
administartion	O
of	O
intratehcal	O
(	O
IT	O
)	O
combintaion	O
chemotherpay	O
including	O
thiotpea	O
(	O
TPSA	O
)	O
are	O
presented	O
.	O

Both	O
csaes	O
developed	O
axnoal	B-Disease
nueropathy	I-Disease
with	O
mtoor	O
predominance	O
in	O
the	O
lwoer	O
extermities	O
1	O
and	O
6	O
motnhs	O
after	O
IT	O
chemotherpay	O
was	O
admiinstered	O
.	O

Neurloogic	B-Disease
toxictiies	I-Disease
have	O
been	O
described	O
with	O
IT	O
-	O
mehtotrexate	O
,	O
IT	O
-	O
cytosnie	O
arabnioside	O
and	O
IT	O
-	O
TPSA	O
.	O

To	O
our	O
knolwedge	O
,	O
however	O
,	O
axnoal	B-Disease
neuroptahy	I-Disease
following	O
adimnistration	O
of	O
these	O
three	O
agnets	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TPSA	O
is	O
a	O
useful	O
IT	O
aegnt	O
,	O
its	O
combinaiton	O
with	O
MTX	O
,	O
ara	O
-	O
C	O
and	O
radiohterapy	O
could	O
cause	O
seevre	O
neruotoxicity	B-Disease
.	O

This	O
unexpected	O
cmoplication	O
indicates	O
the	O
need	O
for	O
further	O
toxicloogy	O
reserach	O
on	O
IT	O
-	O
TPSA	O
.	O

Efefcts	O
of	O
cromaklaim	O
and	O
pniacidil	O
on	O
large	O
epciardial	O
and	O
small	O
coronray	O
artreies	O
in	O
concsious	O
dgos	O
.	O

The	O
effects	O
of	O
i	O
.	O
v	O
.	O
bouls	O
administratoin	O
of	O
cromkaalim	O
(	O
1	O
-	O
10	O
micrgorams	O
/	O
kg	O
)	O
and	O
pincaidil	O
(	O
3	O
-	O
100	O
mcirograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumlfex	O
artrey	O
)	O
and	O
small	O
croonary	O
atreries	O
and	O
on	O
systmeic	O
hemoydnamics	O
were	O
invesitgated	O
in	O
chornically	O
instrumetned	O
cnoscious	O
dgos	O
and	O
cmopared	O
to	O
those	O
of	O
nitroglyceirn	O
(	O
0	O
.	O
03	O
-	O
10	O
mcirograms	O
/	O
kg	O
)	O
.	O

Nitroglyceirn	O
,	O
up	O
to	O
0	O
.	O
3	O
micorgrams	O
/	O
kg	O
,	O
selectively	O
increaesd	O
circumlfex	O
aretry	O
diameetr	O
(	O
CAxD	O
)	O
without	O
simultaneosuly	O
afefcting	O
any	O
other	O
caridac	O
or	O
sytsemic	O
hemdoynamic	O
praameter	O
.	O

In	O
contrast	O
,	O
croamkalim	O
and	O
pinacdiil	O
at	O
all	O
dsoes	O
and	O
nitrgolycerin	O
at	O
dsoes	O
hihger	O
than	O
0	O
.	O
3	O
micorgrams	O
/	O
kg	O
simultaneuosly	O
and	O
dsoe	O
-	O
dependently	O
inrceased	O
CAxD	O
,	O
coronray	O
bolod	O
folw	O
and	O
haert	O
rtae	O
and	O
dcereased	O
coroanry	O
vsacular	O
resistacne	O
and	O
aoritc	O
perssure	O
.	O

Cromkaalim	O
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pinacdiil	O
in	O
incraesing	O
CAxD	O
.	O

Vasodilatoin	O
of	O
large	O
and	O
small	O
croonary	O
vesesls	O
and	O
hypotesnion	B-Disease
idnuced	O
by	O
cromkaalim	O
and	O
pniacidil	O
were	O
not	O
affetced	O
by	O
prior	O
cobmined	O
btea	O
adrenegric	O
and	O
musacrinic	O
recetpors	O
blcokade	O
but	O
durg	O
-	O
idnuced	O
tachycarida	B-Disease
was	O
abolished	O
.	O

When	O
cricumflex	O
atrery	O
blood	O
folw	O
was	O
maintained	O
cnostant	O
,	O
the	O
incresaes	O
in	O
CAxD	O
induecd	O
by	O
cromkaalim	O
(	O
10	O
mircograms	O
/	O
kg	O
)	O
,	O
pinaicdil	O
(	O
30	O
micrgorams	O
/	O
kg	O
)	O
and	O
nitroglcyerin	O
(	O
10	O
micorgrams	O
/	O
kg	O
)	O
were	O
rdeuced	O
by	O
68	O
+	O
/	O
-	O
7	O
,	O
54	O
+	O
/	O
-	O
9	O
and	O
1	O
+	O
/	O
-	O
1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
nitrgolycerin	O
preferentially	O
and	O
folw	O
-	O
independently	O
diltaes	O
large	O
coronray	O
artreies	O
,	O
cormakalim	O
and	O
pniacidil	O
diltae	O
both	O
large	O
and	O
small	O
coronray	O
artereis	O
and	O
this	O
efefct	O
is	O
not	O
dpeendent	O
upon	O
the	O
siumltaneous	O
btea	O
adrenoceptros	O
-	O
mediated	O
rise	O
in	O
myocaridal	O
metaoblic	O
demand	O
.	O

Finally	O
,	O
two	O
mechansims	O
at	O
least	O
,	O
direct	O
vasodiltaion	O
and	O
folw	O
dependnecy	O
,	O
are	O
involved	O
in	O
the	O
cromaaklim	O
-	O
and	O
pinacdiil	O
-	O
induecd	O
incraese	O
in	O
CAxD	O
.	O

Mfeenamic	O
aicd	O
-	O
idnuced	O
neurtopenia	B-Disease
and	O
reanl	B-Disease
fialure	I-Disease
in	O
eldelry	O
femlaes	O
with	O
hypohtyroidism	B-Disease
.	O

We	O
reoprt	O
mefeanmic	O
aicd	O
-	O
induecd	O
non	O
-	O
oligruic	O
rneal	B-Disease
fialure	I-Disease
and	O
seevre	O
neturopenia	B-Disease
occurring	O
siumltaneously	O
in	O
two	O
eldelry	O
fmeales	O
.	O

The	O
neutroepnia	B-Disease
was	O
due	O
to	O
mtauration	O
arrest	O
of	O
the	O
myleoid	O
series	O
in	O
one	O
patinet	O
.	O

Both	O
ptaients	O
were	O
also	O
hyptohyroid	B-Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisopsing	O
facotr	O
to	O
the	O
developemnt	O
of	O
these	O
avderse	O
reactoins	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mfeenamic	O
aicd	O
in	O
hyopthyroid	B-Disease
paitents	O
until	O
the	O
hypothyrodiism	B-Disease
has	O
been	O
corretced	O
.	O

Etiolgoy	O
of	O
hyperclacemia	B-Disease
in	O
heomdialysis	O
patietns	O
on	O
clacium	O
carboante	O
therpay	O
.	O

Fourteen	O
of	O
39	O
dialyiss	O
paitents	O
(	O
36	O
%	O
)	O
became	O
hypercalecmic	B-Disease
after	O
switching	O
to	O
clacium	O
carbnoate	O
as	O
their	O
pricnipal	O
phoshpate	O
bidner	O
.	O

In	O
order	O
to	O
identify	O
rsik	O
fcators	O
associated	O
with	O
the	O
develpoment	O
of	O
hyperclacemia	B-Disease
,	O
indierct	O
parametres	O
of	O
itnestinal	O
calicum	O
raebsorption	O
and	O
bnoe	O
turnvoer	O
rtae	O
in	O
these	O
14	O
ptaients	O
were	O
compraed	O
with	O
resutls	O
in	O
14	O
euclacemic	O
ptaients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
lnegth	O
of	O
tmie	O
on	O
diaylsis	O
,	O
and	O
etoilogy	O
of	O
reanl	B-Disease
disaese	I-Disease
.	O

In	O
addition	O
to	O
experiencing	O
hyprecalcemic	B-Disease
episoeds	O
with	O
peak	O
clacium	O
valeus	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
)	O
,	O
pateints	O
in	O
the	O
hypercaclemic	B-Disease
gorup	O
exhibited	O
a	O
significant	O
incresae	O
in	O
the	O
mean	O
calcuim	O
concnetration	O
obtained	O
during	O
6	O
monhts	O
before	O
the	O
siwtch	O
,	O
copmared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
monhts	O
of	O
observtaion	O
after	O
the	O
swtich	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
03	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
L	O
[	O
9	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
contrast	O
,	O
eucalceimc	O
paitents	O
exhibited	O
no	O
change	O
in	O
mean	O
clacium	O
vlaues	O
over	O
the	O
same	O
tmie	O
peroid	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
to	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
L	O
[	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dL	O
]	O
)	O
.	O

CCaO3	O
dosgae	O
,	O
calculated	O
dieatry	O
calcuim	O
intkae	O
,	O
and	O
criculating	O
lveels	O
of	O
vtiamin	O
D	O
metbaolites	O
were	O
similar	O
in	O
both	O
gorups	O
.	O

Physcial	O
atcivity	O
index	O
and	O
predialsyis	O
seurm	O
bciarbonate	O
lveels	O
also	O
were	O
similar	O
in	O
both	O
gorups	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
paraemters	O
reflecting	O
bnoe	O
tunrover	O
rtaes	O
between	O
gorups	O
.	O
(	O
ABSTRACT	O
TRNUCATED	O
AT	O
250	O
WORDS	O
)	O

Ltae	O
-	O
onset	O
sclreoderma	B-Disease
rneal	I-Disease
cirsis	I-Disease
idnuced	O
by	O
tcarolimus	O
and	O
prednisolnoe	O
:	O
a	O
csae	O
reprot	O
.	O

Slceroderma	B-Disease
rneal	I-Disease
cirsis	I-Disease
(	O
SRC	B-Disease
)	O
is	O
a	O
rrae	O
complictaion	O
of	O
ssytemic	B-Disease
scleroiss	I-Disease
(	O
SSc	B-Disease
)	O
but	O
can	O
be	O
seevre	O
enough	O
to	O
require	O
temproary	O
or	O
permaennt	O
reanl	O
replaceemnt	O
thearpy	O
.	O

Moedrate	O
to	O
high	O
dsoe	O
corticostreoid	O
use	O
is	O
recognized	O
as	O
a	O
major	O
rsik	O
fcator	O
for	O
SRC	B-Disease
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reoprts	O
of	O
throbmotic	B-Disease
micraongiopathy	I-Disease
precpiitated	O
by	O
cyclospornie	O
in	O
paitents	O
with	O
SSc	B-Disease
.	O

In	O
this	O
article	O
,	O
we	O
reprot	O
a	O
ptaient	O
with	O
SRC	B-Disease
idnuced	O
by	O
tcarolimus	O
and	O
corticosetroids	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attentoin	O
to	O
the	O
rsik	O
of	O
tcarolimus	O
use	O
in	O
ptaients	O
with	O
SSc	B-Disease
.	O

Methylodpa	O
-	O
inudced	O
hemoyltic	B-Disease
anmeia	I-Disease
in	O
a	O
15	O
yaer	O
old	O
presneting	O
as	O
near	O
-	O
syncpoe	B-Disease
.	O

Methyldpoa	O
is	O
an	O
antiyhpertensive	O
medciation	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
tarde	O
name	O
Alodmet	O
that	O
is	O
widely	O
prescriebd	O
in	O
the	O
audlt	O
pouplation	O
and	O
infrequently	O
used	O
in	O
childern	O
.	O

Metyhldopa	O
causes	O
an	O
autoimmune	B-Disease
hemloytic	I-Disease
aenmia	I-Disease
in	O
a	O
small	O
perecntage	O
of	O
pateints	O
who	O
take	O
the	O
durg	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
mehtyldopa	O
-	O
induecd	O
hemoltyic	B-Disease
aenmia	I-Disease
in	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
emegrency	B-Disease
dpeartment	I-Disease
with	O
near	O
-	O
sycnope	B-Disease
.	O

The	O
boy	O
had	O
been	O
treaetd	O
with	O
intraevnous	O
methyldpoa	O
during	O
a	O
tramua	B-Disease
amdission	O
seven	O
weeks	O
prior	O
to	O
presentatoin	O
.	O

Evaluaiton	O
reveaeld	O
a	O
heomglobin	O
of	O
three	O
grmas	O
,	O
3	O
+	O
Coombs	O
'	O
tset	O
with	O
poylspecific	O
atni	O
-	O
huamn	O
gloublin	O
and	O
monopsecific	O
IgG	O
raegents	O
,	O
and	O
a	O
wram	O
reacitng	O
autonatibody	O
.	O

Transfsuion	O
and	O
corticosteriod	O
threapy	O
resulted	O
in	O
a	O
complete	O
reocvery	O
of	O
the	O
pateint	O
.	O

Eemrgency	O
physicinas	O
treaitng	O
childern	O
must	O
be	O
aware	O
of	O
this	O
sydnrome	O
in	O
order	O
to	O
diganose	O
and	O
traet	O
it	O
correctly	O
.	O

A	O
brief	O
reivew	O
of	O
auotimmune	O
and	O
durg	O
-	O
idnuced	O
hemoyltic	B-Disease
anmeias	I-Disease
is	O
provided	O
.	O

The	O
rsik	O
and	O
associated	O
fatcors	O
of	O
mehtamphetamine	O
pscyhosis	B-Disease
in	O
methamphteamine	O
-	O
dpeendent	O
patietns	O
in	O
Maalysia	O
.	O

OBJCETIVE	O
:	O
The	O
objecitve	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
the	O
rsik	O
of	O
lifeitme	O
and	O
current	O
methampehtamine	O
-	O
indcued	O
psycohsis	B-Disease
in	O
paitents	O
with	O
methamhpetamine	O
dpeendence	O
.	O

The	O
asosciation	O
between	O
pscyhiatric	O
co	O
-	O
morbiidty	O
and	O
mtehamphetamine	O
-	O
inudced	O
psyhcosis	B-Disease
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
corss	O
-	O
sectinoal	O
sutdy	O
conducted	O
concurrently	O
at	O
a	O
teahcing	O
hopsital	O
and	O
a	O
durg	O
rehaiblitation	O
cneter	O
in	O
Maalysia	O
.	O

Patinets	O
with	O
the	O
diagnsois	O
of	O
mtehamphetamine	O
based	O
on	O
DSM	O
-	O
IV	O
were	O
inetrviewed	O
using	O
the	O
Mnii	O
Internatioanl	O
Neruopsychiatric	O
Interveiw	O
(	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
)	O
for	O
methampehtamine	O
-	O
inudced	O
pscyhosis	B-Disease
and	O
other	O
Aixs	O
I	O
psyhciatric	B-Disease
diosrders	I-Disease
.	O

The	O
informaiton	O
on	O
sociodemogarphic	O
background	O
and	O
durg	O
use	O
hisotry	O
was	O
obtained	O
from	O
inetrview	O
or	O
medcial	O
rceords	O
.	O

REUSLTS	O
:	O
Of	O
292	O
sbujects	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subjcets	O
had	O
a	O
past	O
hitsory	O
of	O
psychtoic	B-Disease
smyptoms	I-Disease
and	O
13	O
.	O
0	O
%	O
of	O
the	O
paitents	O
were	O
having	O
current	O
psychtoic	B-Disease
sypmtoms	I-Disease
.	O

Co	O
-	O
mobrid	O
major	O
deprsesive	B-Disease
disoredr	I-Disease
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
)	O
,	O
bipoalr	B-Disease
dsiorder	I-Disease
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
)	O
,	O
antsiocial	B-Disease
personlaity	I-Disease
disroder	I-Disease
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
hevay	O
methamphetmaine	O
uses	O
were	O
significantly	O
associated	O
with	O
lieftime	O
methamhpetamine	O
-	O
inudced	O
psyhcosis	B-Disease
after	O
adjusted	O
for	O
other	O
fatcors	O
.	O

Major	B-Disease
depressvie	I-Disease
disroder	I-Disease
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
anitsocial	B-Disease
persoanlity	I-Disease
disroder	I-Disease
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
factros	O
associated	O
with	O
current	O
psycohsis	B-Disease
.	O

CONCLUISON	O
:	O
There	O
was	O
a	O
high	O
rsik	O
of	O
psychoiss	B-Disease
in	O
pateints	O
with	O
mtehamphetamine	O
depednence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
mrobid	O
afefctive	B-Disease
disoredr	I-Disease
,	O
antisoical	B-Disease
personailty	I-Disease
,	O
and	O
haevy	O
mehtamphetamine	O
use	O
.	O

It	O
is	O
rceommended	O
that	O
all	O
csaes	O
of	O
methamphetaimne	O
depenednce	O
should	O
be	O
screened	O
for	O
pyschotic	B-Disease
sypmtoms	I-Disease
.	O

Cereebllar	O
snesory	O
proecssing	O
aletrations	O
imapct	O
mtoor	O
cortiacl	O
plasitcity	O
in	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
:	O
clues	O
from	O
dysknietic	B-Disease
patinets	O
.	O

The	O
plasitcity	O
of	O
primray	O
mootr	O
coretx	O
(	O
M1	O
)	O
in	O
patietns	O
with	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
(	O
PD	B-Disease
)	O
and	O
lveodopa	O
-	O
inudced	O
dyskinesais	B-Disease
(	O
LDIs	B-Disease
)	O
is	O
seveerly	O
imapired	O
.	O

We	O
recently	O
reported	O
in	O
yonug	O
helathy	O
sbujects	O
that	O
inhibtiory	O
cerbeellar	O
stimluation	O
enhacned	O
the	O
sensoirmotor	O
palsticity	O
of	O
M1	O
that	O
was	O
induecd	O
by	O
paired	O
associative	O
stmiulation	O
(	O
PAS	O
)	O
.	O

This	O
stduy	O
demonstrates	O
that	O
the	O
deficinet	O
sensorimootr	O
M1	O
palsticity	O
in	O
16	O
pateints	O
with	O
LDIs	B-Disease
could	O
be	O
renistated	O
by	O
a	O
single	O
sessoin	O
of	O
real	O
inhibtiory	O
cereblelar	O
stimulatoin	O
but	O
not	O
sahm	O
stimluation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sensroy	O
component	O
was	O
involved	O
in	O
the	O
inductoin	O
of	O
plastictiy	O
,	O
indicating	O
that	O
cereblelar	O
sensroy	O
processing	O
funciton	O
is	O
involved	O
in	O
the	O
rseurgence	O
of	O
M1	O
plastciity	O
.	O

The	O
beneift	O
of	O
inhibitroy	O
creebellar	O
stimualtion	O
on	O
LDIs	B-Disease
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
beneift	O
is	O
linked	O
to	O
the	O
restortaion	O
of	O
sensorimtoor	O
plasitcity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
sutdy	O
looking	O
at	O
chanegs	O
in	O
LDIs	B-Disease
and	O
PAS	O
-	O
induecd	O
plastciity	O
after	O
10	O
sesisons	O
of	O
either	O
bliateral	O
,	O
real	O
inhbiitory	O
cereblelar	O
stimulatoin	O
or	O
sahm	O
stimulaiton	O
.	O

Only	O
real	O
and	O
not	O
sahm	O
stimluation	O
had	O
an	O
antidyksinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resugrence	O
in	O
the	O
sensroimotor	O
plastiicty	O
of	O
M1	O
.	O

These	O
rseults	O
suggest	O
that	O
alteratoins	O
in	O
cereebllar	O
sensroy	O
procesisng	O
functoin	O
,	O
occurring	O
secondary	O
to	O
abnromal	O
baasl	O
ganlgia	O
singals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
elemnet	O
contributing	O
to	O
the	O
maladapitve	O
sensorimootr	O
plastictiy	O
of	O
M1	O
and	O
the	O
eemrgence	O
of	O
anbormal	B-Disease
involutnary	I-Disease
movemnets	I-Disease
.	O

The	O
long	O
-	O
term	O
saefty	O
of	O
danzaol	O
in	O
woemn	O
with	O
hereditray	B-Disease
agnioedema	I-Disease
.	O

Although	O
the	O
short	O
-	O
term	O
sfaety	O
(	O
less	O
than	O
or	O
eqaul	O
to	O
6	O
mnoths	O
)	O
of	O
danaozl	O
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
ifnormation	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
saefty	O
.	O

We	O
therefore	O
ivnestigated	O
the	O
long	O
-	O
term	O
sfaety	O
of	O
daanzol	O
by	O
performing	O
a	O
retrospecitve	O
chrat	O
reveiw	O
of	O
60	O
feamle	O
pateints	O
with	O
heerditary	B-Disease
angioedmea	I-Disease
terated	O
with	O
danzaol	O
for	O
a	O
contniuous	O
preiod	O
of	O
6	O
monhts	O
or	O
longer	O
.	O

The	O
mean	O
age	O
of	O
the	O
patinets	O
was	O
35	O
.	O
2	O
yaers	O
and	O
the	O
mean	O
duraiton	O
of	O
therpay	O
was	O
59	O
.	O
7	O
motnhs	O
.	O

Virtually	O
all	O
pateints	O
experienced	O
one	O
or	O
more	O
adevrse	O
recations	O
.	O

Menstural	B-Disease
abnoramlities	I-Disease
(	O
79	O
%	O
)	O
,	O
weihgt	B-Disease
gain	I-Disease
(	O
60	O
%	O
)	O
,	O
muslce	B-Disease
carmps	I-Disease
/	O
myaligas	B-Disease
(	O
40	O
%	O
)	O
,	O
and	O
transaminsae	O
elveations	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
avderse	O
reacitons	O
.	O

The	O
durg	O
was	O
disocntinued	O
due	O
to	O
advesre	O
reactoins	O
in	O
8	O
patietns	O
.	O

No	O
ptaient	O
has	O
deid	O
or	O
suffered	O
any	O
appaernt	O
long	O
-	O
term	O
seqeulae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
durg	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidecne	O
of	O
advesre	O
recations	O
,	O
dnaazol	O
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
gruop	O
of	O
patietns	O
.	O

The	O
functoin	O
of	O
PX23	O
rceeptor	O
and	O
NK1	O
rceeptor	O
antaognists	O
on	O
cyclophospahmide	O
-	O
indcued	O
cytsitis	B-Disease
in	O
rtas	O
.	O

PRUPOSE	O
:	O
The	O
purpose	O
of	O
the	O
stduy	O
is	O
to	O
explore	O
the	O
functoin	O
of	O
PX23	O
and	O
NK1	O
recepotrs	O
antagoinsts	O
on	O
cyclophosphmaide	O
(	O
CYP	O
)	O
-	O
indcued	O
csytitis	B-Disease
in	O
rtas	O
.	O

METHODS	O
:	O
Sixty	O
femlae	O
Spargue	O
-	O
Dwaley	O
(	O
SD	O
)	O
rtas	O
were	O
randomly	O
divided	O
into	O
three	O
gruops	O
.	O

The	O
rtas	O
in	O
the	O
cnotrol	O
gorup	O
were	O
intarperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
ijnected	O
with	O
0	O
.	O
9	O
%	O
slaine	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rtas	O
in	O
the	O
mdoel	O
gruop	O
were	O
i	O
.	O
p	O
.	O
inejcted	O
with	O
CYP	O
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rtas	O
in	O
the	O
interventoin	O
gruop	O
were	O
i	O
.	O
p	O
.	O
ijnected	O
with	O
CYP	O
with	O
subsequently	O
perfusoin	O
of	O
bldader	O
with	O
PX23	O
and	O
NK1	O
recetpors	O
'	O
anatgonists	O
,	O
Suarmin	O
and	O
GR	O
82334	O
.	O

Spontaneuos	O
pian	B-Disease
behaivors	O
following	O
the	O
amdinistration	O
of	O
CYP	O
were	O
observed	O
.	O

Urodnyamic	O
parameetrs	O
,	O
bladedr	O
pressure	O
-	O
volmue	O
cuvre	O
,	O
maixmum	O
voidnig	O
pressrue	O
(	O
MVP	O
)	O
,	O
and	O
maxmium	O
cysotmetric	O
capactiy	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathoolgical	O
chanegs	O
in	O
bladedr	O
tisuse	O
were	O
observed	O
.	O

Imumnofluorescence	O
was	O
used	O
to	O
deetct	O
the	O
expressoin	O
of	O
PX23	O
and	O
NK1	O
recetpors	O
in	O
bladedr	O
.	O

RESLUTS	O
:	O
Cylcophosphamide	O
treatemnt	O
incresaed	O
the	O
sponatneous	O
pian	B-Disease
behvaiors	O
socres	O
.	O

The	O
incidecne	O
of	O
bladedr	O
isntability	O
during	O
urnie	O
storgae	O
peroid	O
of	O
mdoel	O
gruop	O
was	O
significantly	O
hihger	O
than	O
inetrvention	O
gruop	O
(	O
X	O
(	O
2	O
)	O
=	O
7	O
.	O
619	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
conrtol	O
gorup	O
(	O
X	O
(	O
2	O
)	O
=	O
13	O
.	O
755	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

MCC	O
in	O
the	O
mdoel	O
gruop	O
was	O
loewr	O
than	O
the	O
contorl	O
and	O
interevntion	O
gropus	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Histoloigcal	O
chanegs	O
evident	O
in	O
mdoel	O
and	O
itnervention	O
gruops	O
rtas	O
'	O
bladder	O
included	O
edmea	B-Disease
,	O
vaosdilation	O
,	O
and	O
infilrtation	O
of	O
inflammaotry	O
cells	O
.	O

In	O
moedl	O
gruop	O
,	O
the	O
exprsesion	O
of	O
PX23	O
reecptor	O
incresaed	O
in	O
urotheilum	O
and	O
suburotehlium	O
,	O
and	O
NK1	O
recpetor	O
icnreased	O
in	O
suburothleium	O
,	O
while	O
the	O
experssion	O
of	O
them	O
in	O
intervnetion	O
gruop	O
was	O
lwoer	O
.	O

CONCLUISONS	O
:	O
In	O
CYP	O
-	O
indcued	O
cysittis	B-Disease
,	O
the	O
expresison	O
of	O
PX23	O
and	O
NK1	O
recetpors	O
increaesd	O
in	O
urotheilum	O
and	O
/	O
or	O
suburotehlium	O
.	O

Perufsion	O
of	O
bladder	O
with	O
PX23	O
and	O
NK1	O
receptros	O
antagonsits	O
ameliortaed	O
the	O
bladder	O
funciton	O
.	O

Paitent	O
toleracne	O
sutdy	O
of	O
topcial	O
chlorhexiidne	O
diphoshpanilate	O
:	O
a	O
new	O
toipcal	O
agnet	O
for	O
bunrs	B-Disease
.	O

Effective	O
topiacl	O
antimcirobial	O
agetns	O
dercease	O
inefction	B-Disease
and	O
mrotality	O
in	O
brun	B-Disease
patietns	O
.	O

Chlorhexidnie	O
pohsphanilate	O
(	O
CHP	O
)	O
,	O
a	O
new	O
broad	O
-	O
specturm	O
antiimcrobial	O
aegnt	O
,	O
has	O
been	O
evalauted	O
as	O
a	O
topiacl	O
brun	B-Disease
wonud	O
drsesing	O
in	O
craem	O
form	O
,	O
but	O
preliminary	O
clniical	O
trilas	O
reported	O
that	O
it	O
was	O
painufl	O
upon	O
applicatoin	O
.	O

This	O
stduy	O
compraed	O
various	O
concnetrations	O
of	O
CHP	O
to	O
determine	O
if	O
a	O
toelrable	O
concentraiton	O
could	O
be	O
idnetified	O
with	O
retentoin	O
of	O
antimicrboial	O
effciacy	O
.	O

Twenty	O
-	O
nine	O
brun	B-Disease
pateints	O
,	O
each	O
with	O
two	O
similar	O
bunrs	B-Disease
which	O
could	O
be	O
separately	O
treaetd	O
,	O
were	O
given	O
piars	O
of	O
treatmetns	O
at	O
successive	O
12	O
-	O
h	O
interavls	O
over	O
a	O
3	O
-	O
day	O
peroid	O
.	O

One	O
brun	B-Disease
stie	O
was	O
tretaed	O
with	O
each	O
of	O
four	O
different	O
CHP	O
concenrtations	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehcile	O
,	O
and	O
1	O
per	O
cent	O
sliver	O
sulphadiaizne	O
(	O
ASgD	O
)	O
ceram	O
,	O
an	O
antimicrobail	O
agnet	O
frequently	O
used	O
for	O
topcial	O
treatemnt	O
of	O
brun	B-Disease
woudns	O
.	O

The	O
other	O
stie	O
was	O
always	O
terated	O
with	O
ASgD	O
craem	O
.	O

There	O
was	O
a	O
direct	O
reltaionship	O
between	O
CHP	O
concentrtaion	O
and	O
paitents	O
'	O
ratnigs	O
of	O
pian	B-Disease
on	O
an	O
anlaogue	O
scale	O
.	O

The	O
0	O
.	O
25	O
per	O
cent	O
CHP	O
craem	O
was	O
closest	O
to	O
ASgD	O
in	O
pian	B-Disease
tolreance	O
;	O
however	O
,	O
none	O
of	O
the	O
traetments	O
difefred	O
statisticlaly	O
from	O
ASgD	O
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
esae	O
of	O
appilcation	O
of	O
CHP	O
cerams	O
was	O
less	O
satisfatcory	O
than	O
that	O
of	O
ASgD	O
.	O

It	O
was	O
concluded	O
that	O
formualtions	O
at	O
or	O
below	O
0	O
.	O
5	O
per	O
cent	O
CHP	O
may	O
prove	O
acecptable	O
for	O
wuond	O
crae	O
,	O
but	O
the	O
vheicle	O
sysetm	O
needs	O
pharmaceutcial	O
imrpovement	O
to	O
render	O
it	O
more	O
tolearble	O
and	O
easier	O
to	O
use	O
.	O

Actue	O
heptaitis	B-Disease
associated	O
with	O
colpidogrel	O
:	O
a	O
csae	O
reoprt	O
and	O
reivew	O
of	O
the	O
ltierature	O
.	O

Durg	O
-	O
inudced	O
hpeatotoxicity	B-Disease
is	O
a	O
common	O
cause	O
of	O
aucte	O
heaptitis	B-Disease
,	O
and	O
the	O
recogntiion	O
of	O
the	O
responsible	O
durg	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
csae	O
of	O
clopidorgel	O
-	O
related	O
actue	O
hepattiis	B-Disease
.	O

The	O
diagnsois	O
is	O
strongly	O
suggested	O
by	O
an	O
acucrate	O
mediacl	O
hitsory	O
and	O
lievr	O
biospy	O
.	O

Reoprts	O
about	O
caess	O
of	O
hepattooxicity	B-Disease
due	O
to	O
clopiodgrel	O
are	O
incerasing	O
in	O
the	O
last	O
few	O
yeras	O
,	O
after	O
the	O
increaesd	O
use	O
of	O
this	O
durg	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
pyhsicians	O
should	O
carefully	O
consider	O
the	O
rsik	O
of	O
durg	O
-	O
induecd	O
heptaic	B-Disease
ijnury	I-Disease
when	O
clopdiogrel	O
is	O
prescirbed	O
.	O

Borteozmib	O
and	O
dexmaethasone	O
as	O
salavge	O
thearpy	O
in	O
pateints	O
with	O
relpased	O
/	O
refractroy	O
mulitple	B-Disease
myeolma	I-Disease
:	O
analsyis	O
of	O
long	O
-	O
term	O
cliniacl	O
outocmes	O
.	O

Bortzeomib	O
(	O
brot	O
)	O
-	O
dexaemthasone	O
(	O
dex	O
)	O
is	O
an	O
effetcive	O
threapy	O
for	O
relapesd	O
/	O
rferactory	O
(	O
R	O
/	O
R	O
)	O
mlutiple	B-Disease
meyloma	I-Disease
(	O
MM	B-Disease
)	O
.	O

This	O
retrsopective	O
stduy	O
invsetigated	O
the	O
combinatoin	O
of	O
brot	O
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dyas	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	O
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
brot	O
)	O
as	O
savlage	O
treatemnt	O
in	O
85	O
ptaients	O
with	O
R	O
/	O
R	O
MM	B-Disease
after	O
prior	O
autolgoous	O
setm	O
clel	O
trasnplantation	O
or	O
convetnional	O
chemothreapy	O
.	O

The	O
meidan	O
number	O
of	O
prior	O
liens	O
of	O
threapy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
ptaients	O
had	O
received	O
immnuomodulatory	O
durgs	O
included	O
in	O
some	O
line	O
of	O
thearpy	O
before	O
brot	O
-	O
dex	O
.	O

The	O
medain	O
number	O
of	O
brot	O
-	O
dex	O
cylces	O
was	O
6	O
,	O
up	O
to	O
a	O
maixmum	O
of	O
12	O
ccyles	O
.	O

On	O
an	O
intetnion	O
-	O
to	O
-	O
traet	O
basis	O
,	O
55	O
%	O
of	O
the	O
patietns	O
achieved	O
at	O
least	O
patrial	O
repsonse	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
parital	O
repsonse	O
.	O

Meidan	O
duraitons	O
of	O
resopnse	O
,	O
tmie	O
to	O
next	O
therpay	O
and	O
traetment	O
-	O
free	O
intevral	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
mnoths	O
,	O
respectively	O
.	O

The	O
most	O
reelvant	O
avderse	O
evnet	O
was	O
peripehral	B-Disease
neruopathy	I-Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
ptaients	O
(	O
garde	O
II	O
,	O
38	O
%	O
;	O
garde	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatmnet	O
discontinutaion	O
in	O
6	O
%	O
.	O

With	O
a	O
medain	O
follow	O
up	O
of	O
22	O
mnoths	O
,	O
meidan	O
tmie	O
to	O
progerssion	O
,	O
progrsesion	O
-	O
free	O
sruvival	O
(	O
PFS	O
)	O
and	O
overall	O
suvrival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
motnhs	O
,	O
respectively	O
.	O

Prolonegd	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patinets	O
achieving	O
CR	O
and	O
receiving	O
brot	O
-	O
dex	O
a	O
single	O
line	O
of	O
prior	O
thearpy	O
.	O

Brot	O
-	O
dex	O
was	O
an	O
efefctive	O
slavage	O
teratment	O
for	O
MM	B-Disease
ptaients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
rleapse	O
.	O

Puebrtal	O
epxosure	O
to	O
Bipshenol	O
A	O
incerases	O
axniety	B-Disease
-	O
like	O
behaivor	O
and	O
dcereases	O
acetylcholinestearse	O
acitvity	O
of	O
hippocampus	O
in	O
adlut	O
mlae	O
mcie	O
.	O

The	O
negtaive	O
effcets	O
of	O
Bisphneol	O
A	O
(	O
BPA	O
)	O
on	O
neurodveelopment	O
and	O
behaivors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinestersae	O
(	O
AhCE	O
)	O
is	O
a	O
regultaory	O
enzmye	O
which	O
is	O
involved	O
in	O
anixety	B-Disease
-	O
like	O
behaivor	O
.	O

This	O
sutdy	O
investigtaed	O
beahvioral	O
pheontypes	O
and	O
AhCE	O
activtiy	O
in	O
mlae	O
mcie	O
following	O
BPA	O
expsoure	O
during	O
pubetry	O
.	O

On	O
postntaal	O
day	O
(	O
PND	O
)	O
35	O
,	O
mlae	O
mcie	O
were	O
expsoed	O
to	O
50mg	O
BPA	O
/	O
kg	O
deit	O
per	O
day	O
for	O
a	O
peroid	O
of	O
35	O
dyas	O
.	O

On	O
PN7D1	O
,	O
a	O
behavoiral	O
assay	O
was	O
performed	O
using	O
the	O
eelvated	O
plus	O
mzae	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
drak	O
tset	O
.	O

In	O
addition	O
,	O
AhCE	O
acitvity	O
was	O
measrued	O
in	O
the	O
preforntal	O
coretx	O
,	O
hypothlaamus	O
,	O
ceerbellum	O
and	O
hippocmapus	O
.	O

Reuslts	O
from	O
our	O
behaviroal	O
pehnotyping	O
indicated	O
that	O
anxeity	B-Disease
-	O
like	O
behaivor	O
was	O
incerased	O
in	O
mcie	O
epxosed	O
to	O
BPA	O
.	O

AhCE	O
activtiy	O
was	O
significantly	O
derceased	O
in	O
the	O
hippocamups	O
of	O
mcie	O
with	O
BPA	O
compraed	O
to	O
contorl	O
mcie	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrotnal	O
cotrex	O
,	O
hypothalmaus	O
and	O
creebellum	O
.	O

Our	O
findigns	O
showed	O
that	O
pubretal	O
BPA	O
exposrue	O
inrceased	O
anxitey	B-Disease
-	O
like	O
behvaior	O
,	O
which	O
may	O
be	O
associated	O
with	O
dcereased	O
AhCE	O
activtiy	O
of	O
the	O
hippoacmpus	O
in	O
adlut	O
mlae	O
mcie	O
.	O

Further	O
studeis	O
are	O
necessary	O
to	O
ivnestigate	O
the	O
cholinregic	O
signlaing	O
of	O
the	O
hipopcampus	O
in	O
PBE	O
induecd	O
anxeity	B-Disease
-	O
like	O
behavoirs	O
.	O

Biochemcial	O
effetcs	O
of	O
Soliadgo	O
vrigaurea	O
extarct	O
on	O
experimetnal	O
cardiotoxictiy	B-Disease
.	O

Cadriovascular	B-Disease
diesases	I-Disease
(	O
CDVs	B-Disease
)	O
are	O
the	O
major	O
helath	O
prolbem	O
of	O
adavnced	O
as	O
well	O
as	O
developing	O
conutries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
investigtae	O
the	O
protective	O
efefct	O
of	O
the	O
Solidgao	O
vrigaurea	O
extarct	O
on	O
isoproterneol	O
-	O
induecd	O
cardiotoxictiy	B-Disease
in	O
rtas	O
.	O

The	O
subcutaneuos	O
injcetion	O
of	O
isoprtoerenol	O
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rtas	O
twice	O
at	O
an	O
interavl	O
of	O
24	O
h	O
,	O
for	O
two	O
cosnecutive	O
dyas	O
,	O
led	O
to	O
a	O
significant	O
icnrease	O
in	O
seurm	O
lcatate	O
dehydroegnase	O
,	O
cretaine	O
pohsphokinase	O
,	O
alainne	O
transmainase	O
,	O
asparttae	O
tranasminase	O
,	O
and	O
angioetnsin	O
-	O
converting	O
enzmye	O
activiteis	O
,	O
total	O
cholestreol	O
,	O
trigylcerides	O
,	O
free	O
seurm	O
fatty	O
aicd	O
,	O
cadriac	O
tisuse	O
malondialdheyde	O
(	O
MDA	O
)	O
,	O
and	O
nitirc	O
oxdie	O
levles	O
and	O
a	O
significant	O
decresae	O
in	O
lveels	O
of	O
glutahtione	O
and	O
sueproxide	O
disumtase	O
in	O
caridac	O
tsisue	O
as	O
compaerd	O
to	O
the	O
noraml	O
conrtol	O
gorup	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Prerteatment	O
with	O
S	O
.	O
vrigaurea	O
extarct	O
for	O
5	O
wekes	O
at	O
a	O
dsoe	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isporoterenol	O
injeciton	O
significantly	O
prevented	O
the	O
observed	O
alteratinos	O
.	O

Catpopril	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibtior	O
of	O
angiotnesin	O
-	O
converting	O
eznyme	O
used	O
as	O
a	O
stanadrd	O
cadrioprotective	O
durg	O
,	O
was	O
used	O
as	O
a	O
poistive	O
contorl	O
in	O
this	O
sutdy	O
.	O

The	O
dtaa	O
of	O
the	O
present	O
stduy	O
suggest	O
that	O
S	O
.	O
virgaruea	O
extrcat	O
exerts	O
its	O
protective	O
effcet	O
by	O
derceasing	O
MDA	O
lveel	O
and	O
inrceasing	O
the	O
antioxidnat	O
sattus	O
in	O
isoprotereonl	O
-	O
tretaed	O
rtas	O
.	O

The	O
sutdy	O
emphasizes	O
the	O
beneficial	O
aciton	O
of	O
S	O
.	O
virguarea	O
etxract	O
as	O
a	O
cardiporotective	O
agnet	O
.	O

"	O
Rael	O
-	O
world	O
"	O
dtaa	O
on	O
the	O
efficcay	O
and	O
saftey	O
of	O
lenlaidomide	O
and	O
dexametahsone	O
in	O
patinets	O
with	O
rleapsed	O
/	O
refrcatory	O
multilpe	B-Disease
meyloma	I-Disease
who	O
were	O
traeted	O
according	O
to	O
the	O
standrad	O
cliincal	O
pracitce	O
:	O
a	O
stduy	O
of	O
the	O
Greek	O
Myeolma	B-Disease
Stduy	O
Gruop	O
.	O

Lenalidoimde	O
and	O
dexamehtasone	O
(	O
RD	O
)	O
is	O
a	O
stadnard	O
of	O
crae	O
for	O
realpsed	O
/	O
rferactory	O
mutliple	B-Disease
myleoma	I-Disease
(	O
RMRM	B-Disease
)	O
,	O
but	O
there	O
is	O
limietd	O
publisehd	O
dtaa	O
on	O
its	O
efficcay	O
and	O
saftey	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
Interntaional	O
Scoiety	O
of	O
Phramacoeconomics	O
and	O
Ouctomes	O
Resaerch	O
definitoin	O
.	O

We	O
studied	O
212	O
RMRM	B-Disease
paitents	O
who	O
received	O
RD	O
in	O
RW	O
.	O

Objcetive	O
resopnse	O
(	O
>	O
PR	O
(	O
patrial	O
respnose	O
)	O
)	O
rtae	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
respnose	O
(	O
CR	O
)	O
,	O
20	O
.	O
2	O
%	O
)	O
.	O

Meidan	O
tmie	O
to	O
first	O
and	O
best	O
resposne	O
was	O
2	O
and	O
5	O
mnoths	O
,	O
respectively	O
.	O

Medain	O
tmie	O
to	O
CR	O
when	O
RD	O
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-	O
line	O
treamtent	O
at	O
4	O
and	O
11	O
motnhs	O
,	O
respectively	O
.	O

Qaulity	O
of	O
resposne	O
was	O
indpeendent	O
of	O
previous	O
liens	O
of	O
threapies	O
or	O
previous	O
exopsure	O
to	O
thalidomdie	O
or	O
bortzeomib	O
.	O

Mdeian	O
duartion	O
of	O
resposne	O
was	O
34	O
.	O
4	O
mnoths	O
,	O
and	O
it	O
was	O
hgiher	O
in	O
pateints	O
who	O
received	O
RD	O
until	O
progerssion	O
(	O
not	O
reached	O
versus	O
19	O
monhts	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Improvemnet	O
of	O
hmuoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
resopnders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
ptaients	O
who	O
achieved	O
stbale	O
disaese	O
.	O

Avderse	O
eevnts	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
patinets	O
(	O
myleosuppression	B-Disease
in	O
49	O
.	O
4	O
%	O
)	O
and	O
12	O
.	O
7	O
%	O
of	O
patietns	O
needed	O
hosiptalization	O
.	O

Periphearl	B-Disease
nueropathy	I-Disease
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
patietns	O
and	O
deep	B-Disease
vien	I-Disease
trhombosis	I-Disease
in	O
5	O
.	O
7	O
%	O
.	O

Dsoe	O
rdeuctions	O
were	O
needed	O
in	O
31	O
%	O
of	O
ptaients	O
and	O
permaennt	O
discontinuatoin	O
in	O
38	O
.	O
9	O
%	O
.	O

Medain	O
tmie	O
to	O
traetment	O
discontinuaiton	O
was	O
16	O
.	O
8	O
motnhs	O
.	O

Performnace	O
sattus	O
(	O
PS	O
)	O
and	O
initial	O
lnealidomide	O
dsoe	O
predcited	O
for	O
tretament	O
discontinaution	O
.	O

Exrta	O
-	O
medullray	O
relaspes	O
occurred	O
in	O
3	O
.	O
8	O
%	O
of	O
pateints	O
.	O

Our	O
stduy	O
confirms	O
that	O
RD	O
is	O
effcetive	O
and	O
safe	O
in	O
RMRM	B-Disease
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
repsonses	O
especially	O
in	O
pateints	O
who	O
continue	O
on	O
treamtent	O
till	O
progressoin	O
and	O
improevs	O
humoarl	O
immunity	O
even	O
in	O
patietns	O
with	O
satble	O
disaese	O
.	O

The	O
cytogneetic	O
atcion	O
of	O
ifosfamdie	O
,	O
mensa	O
,	O
and	O
their	O
cobmination	O
on	O
periphreal	O
rbabit	O
lympohcytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
ctyogenetic	O
stduy	O
.	O

Ifsofamide	O
(	O
IFO	O
)	O
is	O
an	O
alkylatnig	O
nitroegn	O
mustrad	O
,	O
administarted	O
as	O
an	O
atnineoplasmic	O
agnet	O
.	O

It	O
is	O
chaarcterized	O
by	O
its	O
intnese	O
urootxic	O
actoin	O
,	O
leading	O
to	O
hmeorrhagic	B-Disease
cystiits	I-Disease
.	O

This	O
side	O
efefct	O
of	O
IFO	O
raises	O
the	O
requiremnet	O
for	O
the	O
co	O
-	O
amdinistration	O
with	O
sdoium	O
2	O
-	O
sulafnylethanesulfonate	O
(	O
Mensa	O
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effcet	O
.	O

IFO	O
and	O
Mensa	O
were	O
administarted	O
separately	O
on	O
rabibt	O
'	O
s	O
lymphocyets	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogneetic	O
markres	O
for	O
sitser	O
chromtaid	O
exchanegs	O
(	O
SECs	O
)	O
,	O
proliefration	O
rtae	O
index	O
(	O
PRI	O
)	O
and	O
Mitoitc	O
Inedx	O
were	O
recorded	O
.	O

Mensa	O
'	O
s	O
actoin	O
,	O
in	O
conjunctoin	O
with	O
IFO	O
reudces	O
the	O
freuqency	O
of	O
SECs	O
,	O
in	O
compariosn	O
with	O
the	O
SECs	O
recrodings	O
obtained	O
when	O
IFO	O
is	O
adminitsered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentartions	O
of	O
Mensa	O
were	O
admiinstered	O
alone	O
significant	O
redcutions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	O
acting	O
at	O
the	O
same	O
concentraiton	O
on	O
the	O
lymhpocytes	O
.	O

Msena	O
significantly	O
reudces	O
IFO	O
'	O
s	O
genotoxciity	B-Disease
,	O
while	O
when	O
administreed	O
in	O
high	O
concnetrations	O
it	O
acts	O
in	O
an	O
inhibitroy	O
fashion	O
on	O
the	O
cytostaitc	O
actoin	O
of	O
the	O
durg	O
.	O

Rsik	O
fcators	O
and	O
preditcors	O
of	O
levodpoa	O
-	O
inudced	O
dyksinesia	B-Disease
among	O
multietnhic	O
Malasyians	O
with	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
.	O

Chrnoic	O
pulsatlie	O
levdoopa	O
therpay	O
for	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
(	O
PD	B-Disease
)	O
leads	O
to	O
the	O
developmnet	O
of	O
mtoor	O
fluctutaions	O
and	O
dyksinesia	B-Disease
.	O

We	O
studied	O
the	O
prevlaence	O
and	O
predicotrs	O
of	O
levdoopa	O
-	O
idnuced	O
dyksinesia	B-Disease
among	O
multeithnic	O
Malayisan	O
pateints	O
with	O
PD	B-Disease
.	O

METHODS	O
:	O
This	O
is	O
a	O
corss	O
-	O
sectoinal	O
sutdy	O
involving	O
95	O
patinets	O
with	O
PD	B-Disease
on	O
uninterurpted	O
levdoopa	O
threapy	O
for	O
at	O
least	O
6	O
mnoths	O
.	O

The	O
instrmuent	O
used	O
was	O
the	O
UDPRS	O
qusetionnaires	O
.	O

The	O
preditcors	O
of	O
dysiknesia	B-Disease
were	O
determined	O
using	O
mutlivariate	O
logsitic	O
rgeression	O
analyiss	O
.	O

RSEULTS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
yaers	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
yeras	O
.	O

The	O
medain	O
disaese	O
duraiton	O
was	O
6	O
(	O
7	O
)	O
yeras	O
.	O

Dyskineisa	B-Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
medain	O
levdoopa	O
tehrapy	O
of	O
3	O
yaers	O
.	O

There	O
were	O
64	O
.	O
3	O
%	O
Chinsee	O
,	O
31	O
%	O
Maalys	O
,	O
and	O
3	O
.	O
7	O
%	O
Indains	O
and	O
other	O
ethinc	O
gorups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
paitents	O
with	O
dyskniesia	B-Disease
had	O
clniical	O
fluctuatinos	O
.	O

Ptaients	O
with	O
dyskniesia	B-Disease
had	O
loewr	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
durtaion	O
of	O
levoodpa	O
tehrapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
disaese	O
durtaion	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
hihger	O
total	O
dialy	O
lveodopa	O
dsoe	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
hgiher	O
total	O
UDPRS	O
scroes	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
pateints	O
without	O
dsykinesia	B-Disease
.	O

The	O
three	O
significant	O
prdeictors	O
of	O
dsykinesia	B-Disease
were	O
duraiton	O
of	O
levodpoa	O
tehrapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daliy	O
levdoopa	O
dsoe	O
.	O

CNOCLUSIONS	O
:	O
The	O
prevlaence	O
of	O
levodpoa	O
-	O
indcued	O
dsykinesia	B-Disease
in	O
our	O
ptaients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
perdictors	O
were	O
durtaion	O
of	O
levdoopa	O
therpay	O
,	O
total	O
dialy	O
levdoopa	O
dsoe	O
,	O
and	O
onset	O
age	O
.	O

Dsoe	O
-	O
depednent	O
neuortoxicity	B-Disease
of	O
high	O
-	O
dsoe	O
bsuulfan	O
in	O
cihldren	O
:	O
a	O
clincial	O
and	O
phamracological	O
sutdy	O
.	O

Buslufan	O
is	O
known	O
to	O
be	O
neruotoxic	B-Disease
in	O
ainmals	O
and	O
humnas	O
,	O
but	O
its	O
aucte	O
nuerotoxicity	B-Disease
remains	O
poorly	O
characetrized	O
in	O
childern	O
.	O

We	O
rpeort	O
here	O
a	O
retrospecitve	O
sutdy	O
of	O
123	O
chilrden	O
(	O
meidan	O
age	O
,	O
6	O
.	O
5	O
yeras	O
)	O
receiving	O
high	O
-	O
dsoe	O
bsuulfan	O
in	O
comibned	O
chemothreapy	O
before	O
bnoe	O
marorw	O
transpalntation	O
for	O
malingant	O
sloid	O
tuomrs	B-Disease
,	O
brian	B-Disease
tmuors	I-Disease
excluded	O
.	O

Busulafn	O
was	O
given	O
p	O
.	O
o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
doess	O
over	O
4	O
dyas	O
.	O

Two	O
total	O
doess	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O

The	O
dsoe	O
calculaiton	O
on	O
the	O
basis	O
of	O
bdoy	O
sufrace	O
aera	O
rseults	O
in	O
higehr	O
doess	O
in	O
yonug	O
cihldren	O
than	O
in	O
odler	O
patinets	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O

Ninety	O
-	O
six	O
ptaients	O
were	O
not	O
given	O
anticonvuslive	O
prophylxais	O
;	O
7	O
(	O
7	O
.	O
5	O
%	O
)	O
developed	O
seizuers	B-Disease
during	O
the	O
4	O
dyas	O
of	O
the	O
buslufan	O
coruse	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
doisng	O
.	O

When	O
the	O
total	O
buuslfan	O
dsoe	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
nuerotoxicity	B-Disease
inciednce	O
among	O
patinets	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1	O
.	O
7	O
%	O
)	O
and	O
paitents	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15	O
.	O
4	O
%	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

Twenty	O
-	O
seven	O
patinets	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
buslufan	O
total	O
dsoe	O
with	O
contniuous	O
i	O
.	O
v	O
.	O
infusoin	O
of	O
clonaezpam	O
;	O
none	O
had	O
any	O
nuerological	B-Disease
sympotms	I-Disease
.	O

Bsuulfan	O
leevls	O
were	O
maesured	O
by	O
a	O
gas	O
crhomatographic	O
-	O
msas	O
spectrmoetry	O
asasy	O
in	O
the	O
plsama	O
and	O
cereborspinal	O
fulid	O
of	O
9	O
cihldren	O
without	O
cnetral	B-Disease
nevrous	I-Disease
ssytem	I-Disease
diesase	I-Disease
under	O
600	O
mg	O
/	O
m2	O
busuflan	O
with	O
cloanzepam	O
:	O
busulafn	O
cererbospinal	O
fliud	O
:	O
plsama	O
raito	O
was	O
1	O
.	O
39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
ceerbrospinal	O
fulid	O
:	O
plamsa	O
raito	O
previously	O
defined	O
in	O
chlidren	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dsoe	O
of	O
busulafn	O
.	O

This	O
sutdy	O
shows	O
that	O
bsuulfan	O
neurotoxiicty	B-Disease
is	O
dsoe	O
-	O
depednent	O
in	O
childern	O
and	O
efficienlty	O
prevented	O
by	O
clonazeapm	O
.	O

A	O
buuslfan	O
dsoe	O
calculated	O
on	O
the	O
basis	O
of	O
bdoy	O
sruface	O
aera	O
,	O
resulting	O
in	O
hgiher	O
dsoes	O
in	O
yuong	O
chilrden	O
,	O
was	O
followed	O
by	O
incresaed	O
neurtooxicity	B-Disease
,	O
close	O
to	O
neurotxoicity	B-Disease
incdience	O
observed	O
in	O
adluts	O
.	O

Since	O
plsama	O
pharmacokineitc	O
studeis	O
showed	O
a	O
faster	O
busuflan	O
cleraance	O
in	O
chilrden	O
than	O
in	O
adutls	O
,	O
this	O
new	O
dsoe	O
may	O
approximate	O
more	O
closely	O
the	O
adlut	O
systmeic	O
expsoure	O
obtained	O
after	O
the	O
usual	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dsoe	O
,	O
with	O
potetnial	O
ifnerences	O
in	O
terms	O
of	O
anticacner	O
or	O
myeloabltaive	O
efefcts	O
.	O

The	O
bsuulfan	O
dsoe	O
in	O
chidlren	O
and	O
infnats	O
undergoing	O
bnoe	O
marorw	O
transpalntation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pahrmacokinetic	O
sutdies	O
.	O

An	O
unexpected	O
diagonsis	O
in	O
a	O
reanl	O
-	O
transpalnt	O
paitent	O
with	O
porteinuria	B-Disease
traeted	O
with	O
everoliums	O
:	O
AL	B-Disease
aymloidosis	B-Disease
.	O

Proetinuria	B-Disease
is	O
an	O
expected	O
compliaction	O
in	O
tarnsplant	O
pateints	O
tretaed	O
with	O
mammalain	O
traget	O
of	O
rpaamycin	O
inhibtiors	O
(	O
mOTR	O
-	O
i	O
)	O
.	O

However	O
,	O
cliincal	O
susipcion	O
should	O
always	O
be	O
supported	O
by	O
hsitological	O
eivdence	O
in	O
order	O
to	O
investiagte	O
potenital	O
alternate	O
diagnsoes	O
such	O
as	O
aucte	O
or	O
chroinc	O
reejction	O
,	O
inetrstitial	O
fibroiss	B-Disease
and	O
tbuular	O
atrohpy	B-Disease
,	O
or	O
recurernt	O
or	O
de	O
novo	O
glomeruloapthy	B-Disease
.	O

In	O
this	O
csae	O
we	O
rpeort	O
the	O
unexpected	O
diganosis	O
of	O
amyloidoiss	B-Disease
in	O
a	O
reanl	O
-	O
transpalnt	O
pateint	O
with	O
pre	O
-	O
trasnplant	O
monocloanl	O
gammaapthy	O
of	O
undetermined	O
singificance	O
who	O
developed	O
porteinuria	B-Disease
after	O
conevrsion	O
from	O
tacorlimus	O
to	O
everoilmus	O
.	O

Lnog	O
-	O
term	O
oarl	O
galcatose	O
tretament	O
prevents	O
cognitvie	B-Disease
dfeicits	I-Disease
in	O
mlae	O
Witsar	O
rtas	O
treaetd	O
intracerebroventrciularly	O
with	O
stretpozotocin	O
.	O

Bsaic	O
and	O
cliniacl	O
reserach	O
has	O
demonstrated	O
that	O
demnetia	B-Disease
of	O
spoardic	O
Alzhiemer	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
(	O
sAD	O
)	O
tpye	O
is	O
associated	O
with	O
dysfuntcion	O
of	O
the	O
inuslin	O
-	O
recepotr	O
(	O
IR	O
)	O
sytsem	O
followed	O
by	O
decraesed	O
gluocse	O
trnasport	O
via	O
glcuose	O
transporetr	O
GULT4	O
and	O
decerased	O
glcuose	O
metaboilsm	O
in	O
brian	O
cells	O
.	O

An	O
altenrative	O
suorce	O
of	O
enegry	O
is	O
d	O
-	O
galcatose	O
(	O
the	O
C	O
-	O
4	O
-	O
epmier	O
of	O
d	O
-	O
glcuose	O
)	O
which	O
is	O
transporetd	O
into	O
the	O
brian	O
by	O
isnulin	O
-	O
indepnedent	O
GLTU3	O
trnasporter	O
where	O
it	O
might	O
be	O
metbaolized	O
to	O
gulcose	O
via	O
the	O
Lleoir	O
pahtway	O
.	O

Exclusively	O
paretneral	O
dialy	O
injetcions	O
of	O
galcatose	O
indcue	O
meomry	B-Disease
deteroiration	I-Disease
in	O
rodnets	O
and	O
are	O
used	O
to	O
generate	O
anmial	O
agnig	O
mdoel	O
,	O
but	O
the	O
effetcs	O
of	O
oarl	O
galcatose	O
treamtent	O
on	O
cognitvie	O
funcitons	O
have	O
never	O
been	O
tseted	O
.	O

We	O
have	O
invsetigated	O
the	O
effcets	O
of	O
continouus	O
dialy	O
oarl	O
galcatose	O
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treamtent	O
on	O
cogniitve	B-Disease
deifcits	I-Disease
in	O
streptozootcin	O
-	O
idnuced	O
(	O
STZ	O
-	O
icv	O
)	O
rat	O
mdoel	O
of	O
sAD	O
,	O
tseted	O
by	O
Morris	O
Wtaer	O
Mzae	O
and	O
Passvie	O
Avoidnace	O
tset	O
,	O
respectively	O
.	O

One	O
mnoth	O
of	O
oarl	O
glaactose	O
treatemnt	O
initiated	O
immediately	O
after	O
the	O
STZ	O
-	O
icv	O
administartion	O
,	O
successfully	O
prevented	O
deevlopment	O
of	O
the	O
STZ	O
-	O
icv	O
-	O
inudced	O
cognitvie	B-Disease
defiicts	I-Disease
.	O

Beneficail	O
effcet	O
of	O
oarl	O
gaalctose	O
was	O
indpeendent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galcatose	O
dsoe	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Additionally	O
,	O
oarl	O
galacotse	O
adimnistration	O
led	O
to	O
the	O
apeparance	O
of	O
galcatose	O
in	O
the	O
bolod	O
.	O

The	O
incresae	O
of	O
galactsoe	O
concentartion	O
in	O
the	O
cerebrospnial	O
fliud	O
was	O
several	O
times	O
lwoer	O
after	O
oarl	O
than	O
after	O
parentearl	O
administartion	O
of	O
the	O
same	O
galatcose	O
dsoe	O
.	O

Oarl	O
glaactose	O
epxosure	O
might	O
have	O
beneficial	O
effects	O
on	O
laerning	O
and	O
memroy	O
ability	O
and	O
could	O
be	O
worth	O
ivnestigating	O
for	O
improveemnt	O
of	O
cogintive	B-Disease
defictis	I-Disease
associated	O
with	O
gulcose	B-Disease
hypomteabolism	I-Disease
in	O
AD	B-Disease
.	O

An	O
investigatoin	O
of	O
the	O
pattren	O
of	O
kideny	B-Disease
ijnury	I-Disease
in	O
HIV	O
-	O
postiive	O
persnos	O
epxosed	O
to	O
tenofvoir	O
dsioproxil	O
fumartae	O
:	O
an	O
eaxmination	O
of	O
a	O
large	O
popualtion	O
dataabse	O
(	O
MRHA	O
databsae	O
)	O
.	O

The	O
potenital	O
for	O
tenfoovir	O
to	O
cause	O
a	O
range	O
of	O
kindey	O
syndrmoes	O
has	O
been	O
established	O
from	O
mechainstic	O
and	O
radnomised	O
clniical	O
tirals	O
.	O

However	O
,	O
the	O
exact	O
pattern	O
of	O
kideny	O
involvmeent	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analsyis	O
of	O
Yelolw	O
Crad	O
rceords	O
of	O
407	O
HIV	O
-	O
postiive	O
presons	O
taking	O
tenofoivr	O
disoproixl	O
fumartae	O
(	O
TDF	O
)	O
as	O
part	O
of	O
their	O
antrietroviral	O
therpay	O
reigmen	O
and	O
submitted	O
to	O
the	O
Medciines	O
and	O
Helathcare	O
Prdoucts	O
Regulaotry	O
Aegncy	O
(	O
MRHA	O
)	O
with	O
suspceted	O
kindey	O
advrese	O
effetcs	O
.	O

Rpeorts	O
that	O
satisfy	O
defined	O
crtieria	O
were	O
classified	O
as	O
aucte	B-Disease
kdiney	I-Disease
ijnury	I-Disease
,	O
kideny	B-Disease
tuublar	I-Disease
dysfuntcion	I-Disease
and	O
Facnoni	B-Disease
sydnrome	I-Disease
.	O

Of	O
the	O
407	O
Ylelow	O
Crad	O
reocrds	O
anaylsed	O
,	O
106	O
satsified	O
critreia	O
for	O
TDF	O
-	O
related	O
kdiney	B-Disease
disaese	I-Disease
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
fetaures	O
of	O
kideny	B-Disease
tuublar	I-Disease
dysfunctoin	I-Disease
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
featuers	O
of	O
glmoerular	B-Disease
dysufnction	I-Disease
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanocni	B-Disease
synrdome	I-Disease
.	O

The	O
mdeian	O
TDF	O
expsoure	O
was	O
316	O
dyas	O
(	O
interquatrile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidnece	O
of	O
hospitalisatoin	O
for	O
TDF	O
kindey	O
advrese	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
pateints	O
with	O
feautres	O
of	O
Fancnoi	B-Disease
snydrome	I-Disease
.	O

The	O
ptatern	O
of	O
kdiney	O
syndroems	O
in	O
this	O
pouplation	O
series	O
mirrors	O
that	O
reported	O
in	O
randoimsed	O
cliniacl	O
trails	O
.	O

Cessatoin	O
of	O
TDF	O
was	O
associated	O
with	O
complete	O
rsetoration	O
of	O
kideny	O
fnuction	O
in	O
up	O
half	O
of	O
the	O
pateints	O
in	O
this	O
reoprt	O
.	O

Inicdence	O
of	O
postopeartive	B-Disease
deliirum	I-Disease
is	O
high	O
even	O
in	O
a	O
populatoin	O
without	O
known	O
rsik	O
fcators	O
.	O

PRUPOSE	O
:	O
Psotoperative	B-Disease
dleirium	I-Disease
is	O
a	O
recognized	O
complciation	O
in	O
populatoins	O
at	O
rsik	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
is	O
to	O
assess	O
the	O
prevalnece	O
of	O
eraly	O
postopertaive	B-Disease
delriium	I-Disease
in	O
a	O
pouplation	O
without	O
known	O
rsik	O
fatcors	O
adimtted	O
to	O
the	O
ICU	O
for	O
posotperative	O
mnoitoring	O
after	O
elecitve	O
major	O
surgrey	O
.	O

The	O
secondary	O
otucome	O
investiagted	O
is	O
to	O
identify	O
evetnual	O
indpeendent	O
rsik	O
factros	O
among	O
demogarphic	O
dtaa	O
and	O
anetshetic	O
durgs	O
used	O
.	O

METHODS	O
:	O
An	O
observaitonal	O
,	O
propsective	O
sutdy	O
was	O
conducted	O
on	O
a	O
cosnecutive	O
coohrt	O
of	O
patinets	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surigcal	O
proceduers	O
.	O

Exclsuion	O
crietria	O
were	O
any	O
preexisting	O
predipsosing	O
fatcor	O
for	O
delriium	B-Disease
or	O
other	O
potentially	O
cofnounding	O
neuorlogical	B-Disease
dysfnuctions	I-Disease
.	O

Paitents	O
were	O
assesesd	O
daliy	O
using	O
the	O
cofnusion	B-Disease
assessmnet	O
mehtod	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
dyas	O
after	O
the	O
srugical	O
procedrue	O
.	O

Eraly	O
potsoperative	B-Disease
deilrium	I-Disease
inicdence	O
rsik	O
factros	O
were	O
then	O
assessed	O
through	O
three	O
different	O
mulitple	O
regerssion	O
mdoels	O
.	O

REUSLTS	O
:	O
According	O
to	O
the	O
confusoin	O
assessemnt	O
mehtod	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patinets	O
were	O
daignosed	O
with	O
eraly	O
postopertaive	B-Disease
deliirum	I-Disease
.	O

The	O
use	O
of	O
thiopnetone	O
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higehr	O
rsik	O
for	O
deliirum	B-Disease
copmared	O
to	O
propfool	O
(	O
57	O
.	O
1	O
%	O
vs	O
.	O
7	O
.	O
1	O
%	O
,	O
RR	O
=	O
8	O
.	O
0	O
,	O
X2	O
=	O
4	O
.	O
256	O
;	O
df	O
=	O
1	O
;	O
0	O
.	O
05	O
<	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

CONCLSUION	O
:	O
In	O
this	O
sutdy	O
ealry	O
postoperatvie	B-Disease
deliruim	I-Disease
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complictaion	O
after	O
major	O
surgrey	O
,	O
even	O
in	O
a	O
popluation	O
without	O
known	O
rsik	O
facotrs	O
.	O

Tihopentone	O
was	O
independently	O
associated	O
with	O
an	O
inrcease	O
in	O
its	O
relative	O
rsik	O
.	O

A	O
single	O
neurootxic	B-Disease
dsoe	O
of	O
methampehtamine	O
indcues	O
a	O
long	O
-	O
lasting	O
dperessive	B-Disease
-	O
like	O
behvaiour	O
in	O
mcie	O
.	O

Methamphteamine	O
(	O
MTEH	O
)	O
triggers	O
a	O
disurption	O
of	O
the	O
monaominergic	O
ssytem	O
and	O
MTEH	O
absue	O
leads	O
to	O
negtaive	O
emoitonal	O
states	O
including	O
deprsesive	B-Disease
symtpoms	I-Disease
during	O
durg	O
withdraawl	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
actue	O
toixc	O
dsoage	O
of	O
MTEH	O
also	O
causes	O
a	O
long	O
-	O
lasting	O
depresisve	B-Disease
pehnotype	O
and	O
persisetnt	O
monoaimnergic	O
deifcits	O
.	O

Thus	O
,	O
we	O
now	O
assesesd	O
the	O
depresisve	B-Disease
-	O
like	O
behavoiur	O
in	O
mcie	O
at	O
eraly	O
and	O
long	O
-	O
term	O
peridos	O
following	O
a	O
single	O
high	O
MTEH	O
dsoe	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

MTEH	O
did	O
not	O
alter	O
the	O
mtoor	O
funtcion	O
and	O
proecdural	O
meomry	O
of	O
mcie	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escpae	O
ltaency	O
to	O
find	O
the	O
plaftorm	O
in	O
a	O
ceud	O
versoin	O
of	O
the	O
wtaer	O
mzae	O
tsak	O
.	O

However	O
,	O
MTEH	O
significantly	O
inrceased	O
the	O
immobility	O
tmie	O
in	O
the	O
tial	O
supsension	O
tset	O
at	O
3	O
and	O
49	O
dyas	O
psot	O
-	O
adminitsration	O
.	O

This	O
depresisve	B-Disease
-	O
like	O
porfile	O
indcued	O
by	O
MTEH	O
was	O
accompanied	O
by	O
a	O
marked	O
deplteion	O
of	O
frontostraital	O
dopaminegric	O
and	O
serotonegric	O
neurotrasnmission	O
,	O
indicated	O
by	O
a	O
rdeuction	O
in	O
the	O
levles	O
of	O
dopmaine	O
,	O
DOAPC	O
and	O
HVA	O
,	O
tryosine	O
hydroxlyase	O
and	O
serotnoin	O
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
dyas	O
psot	O
-	O
administraiton	O
.	O

In	O
parallel	O
,	O
another	O
neurochemiacl	O
feature	O
of	O
deprsesion	B-Disease
-	O
-	O
astrgolial	O
dysfunctoin	O
-	O
-	O
was	O
unaffetced	O
in	O
the	O
cotrex	O
and	O
the	O
stritaal	O
leevls	O
of	O
the	O
asrtocytic	O
portein	O
mraker	O
,	O
glail	O
fibrillray	O
aicdic	O
prtoein	O
,	O
were	O
only	O
transeintly	O
increaesd	O
at	O
3	O
dyas	O
.	O

These	O
findigns	O
demonstrate	O
for	O
the	O
first	O
tmie	O
that	O
a	O
single	O
high	O
dsoe	O
of	O
MTEH	O
induecs	O
long	O
-	O
lasting	O
depressive	B-Disease
-	O
like	O
beahviour	O
in	O
mcie	O
associated	O
with	O
a	O
persitsent	O
disrupiton	O
of	O
fronotstriatal	O
dopamienrgic	O
and	O
sreotonergic	O
homoeostaiss	O
.	O

Linezoild	O
-	O
indcued	O
otpic	B-Disease
neuroptahy	I-Disease
.	O

Many	O
sysetmic	O
antmiicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ouclar	O
advrese	O
effetcs	O
.	O

This	O
is	O
especially	O
rleevant	O
in	O
mutlidrug	O
tehrapy	O
where	O
more	O
than	O
one	O
durg	O
can	O
cause	O
a	O
similar	O
ocualr	O
avderse	O
efefct	O
.	O

We	O
describe	O
a	O
csae	O
of	O
progresisve	O
lsos	B-Disease
of	I-Disease
visoin	I-Disease
associated	O
with	O
lineozlid	O
threapy	O
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
mlae	O
patinet	O
who	O
was	O
on	O
treatemnt	O
with	O
mutliple	O
second	O
-	O
line	O
atni	O
-	O
tuberculuos	O
drgus	O
including	O
linezloid	O
and	O
ethambuotl	O
for	O
extensively	B-Disease
durg	I-Disease
-	I-Disease
resisatnt	I-Disease
tuberculoiss	I-Disease
(	O
XDR	B-Disease
-	I-Disease
TB	I-Disease
)	O
presented	O
to	O
us	O
with	O
pailness	O
progressvie	O
lsos	B-Disease
of	I-Disease
viison	I-Disease
in	O
both	O
eeys	O
.	O

Cloor	O
vsiion	O
was	O
defcetive	O
and	O
fudnus	O
examinaiton	O
revelaed	O
otpic	B-Disease
dsic	I-Disease
edmea	I-Disease
in	O
both	O
eeys	O
.	O

Ethmabutol	O
-	O
idnuced	O
txoic	B-Disease
otpic	I-Disease
neuorpathy	I-Disease
was	O
ssupected	O
and	O
tabelt	O
ehtambutol	O
was	O
withdrawn	O
.	O

Deterioratoin	B-Disease
of	I-Disease
viison	I-Disease
occurred	O
despite	O
wihtdrawal	O
of	O
etahmbutol	O
.	O

Discontinuaiton	O
of	O
lniezolid	O
resulted	O
in	O
marked	O
imporvement	O
of	O
viison	O
.	O

Our	O
rpeort	O
emphasizes	O
the	O
need	O
for	O
monitroing	O
of	O
visaul	O
functoin	O
in	O
ptaients	O
on	O
long	O
-	O
term	O
linzeolid	O
tretament	O
.	O

Resuscitaiton	O
with	O
liipd	O
,	O
epienphrine	O
,	O
or	O
both	O
in	O
levobupviacaine	O
-	O
inudced	O
cradiac	B-Disease
txoicity	I-Disease
in	O
nweborn	O
pigltes	O
.	O

BCAKGROUND	O
:	O
The	O
optmial	O
dsoing	O
reigmens	O
of	O
lpiid	O
emulsoin	O
,	O
eipnephrine	O
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neontaes	O
in	O
csaes	O
of	O
loacl	O
anaesthteic	O
sytsemic	O
toxiicty	B-Disease
(	O
LSAT	O
)	O
.	O

METHODS	O
:	O
Nweborn	O
pgilets	O
received	O
levobupviacaine	O
until	O
cradiovascular	B-Disease
collaspe	I-Disease
occurred	O
.	O

Stadnard	O
cardiopumlonary	O
resusctiation	O
was	O
started	O
and	O
electrocadriogram	O
(	O
ECG	O
)	O
was	O
montiored	O
for	O
ventricualr	B-Disease
tachyacrdia	I-Disease
,	O
fibrillation	B-Disease
,	O
or	O
QRS	O
proolngation	O
.	O

Pilgets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
gropus	O
:	O
cotnrol	O
(	O
salnie	O
)	O
,	O
Intarlipid	O
(	O
)	O
alone	O
,	O
epniephrine	O
alone	O
,	O
or	O
a	O
cobmination	O
of	O
Intarlipd	O
plus	O
epienphrine	O
.	O

Resuscittaion	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spnotaneous	O
circluation	O
(	O
RSOC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterail	O
presusre	O
at	O
or	O
superior	O
to	O
the	O
baselnie	O
prsesure	O
and	O
noraml	O
siuns	O
ryhthm	O
for	O
a	O
peirod	O
of	O
30	O
min	O
.	O

RESLUTS	O
:	O
RSOC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
cotnrol	O
pilgets	O
cmopared	O
with	O
most	O
of	O
the	O
treaetd	O
pigltes	O
.	O

Mortlaity	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatmnet	O
gorups	O
,	O
but	O
was	O
significantly	O
lwoer	O
in	O
all	O
the	O
traetment	O
gruops	O
compaerd	O
with	O
cotnrol	O
.	O

The	O
number	O
of	O
ECG	O
abnomralities	O
was	O
zero	O
in	O
the	O
Intarlipid	O
only	O
gorup	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epineprhine	O
and	O
epineprhine	O
plus	O
liipd	O
gropus	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLSUIONS	O
:	O
Lpiid	O
eumlsion	O
with	O
or	O
without	O
epinpehrine	O
,	O
or	O
epniephrine	O
alone	O
were	O
equally	O
effectvie	O
in	O
achieving	O
a	O
return	O
to	O
spontaenous	O
circulaiton	O
in	O
this	O
moedl	O
of	O
LSAT	O
.	O

Eipnephrine	O
alone	O
or	O
in	O
combiantion	O
with	O
lpiid	O
was	O
associated	O
with	O
an	O
inrceased	O
number	O
of	O
ECG	O
abnomralities	O
cmopared	O
with	O
liipd	O
emulsoin	O
alone	O
.	O

Inicdence	O
of	O
heprain	O
-	O
induecd	O
thrombocytpoenia	B-Disease
tpye	I-Disease
II	I-Disease
and	O
potsoperative	O
recovrey	O
of	O
plateelt	O
cuont	O
in	O
lievr	O
garft	O
recpiients	O
:	O
a	O
retrsopective	O
choort	O
analsyis	O
.	O

BACKGRONUD	O
:	O
Thormbocytopenia	B-Disease
in	O
ptaients	O
with	O
end	B-Disease
-	I-Disease
satge	I-Disease
lvier	I-Disease
disaese	I-Disease
is	O
a	O
common	O
disodrer	O
caused	O
mainly	O
by	O
poratl	B-Disease
hypertensoin	I-Disease
,	O
low	O
lveels	O
of	O
thrombpooetin	O
,	O
and	O
ednotoxemia	B-Disease
.	O

The	O
imapct	O
of	O
immune	O
-	O
mediated	O
hpearin	O
-	O
idnuced	O
thrombocytopneia	B-Disease
tpye	I-Disease
II	I-Disease
(	O
HIT	B-Disease
tpye	I-Disease
II	I-Disease
)	O
as	O
a	O
cause	O
of	O
thrombocytoepnia	B-Disease
after	O
lievr	O
transplnatation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
litearture	O
ctiations	O
reporting	O
contradictory	O
resutls	O
.	O

The	O
aim	O
of	O
our	O
stduy	O
was	O
to	O
demonstrate	O
the	O
periopreative	O
cuorse	O
of	O
thrombcoytopenia	B-Disease
after	O
lievr	O
transplanattion	O
and	O
determine	O
the	O
occurrence	O
of	O
cliincal	O
HIT	B-Disease
tpye	I-Disease
II	I-Disease
.	O

METHOD	O
:	O
We	O
retrospcetively	O
evalutaed	O
the	O
mediacl	O
recodrs	O
of	O
205	O
conescutive	O
audlt	O
pateints	O
who	O
underwent	O
full	O
-	O
szie	O
lievr	O
tarnsplantation	O
between	O
Jaunary	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	B-Disease
-	I-Disease
stgae	I-Disease
or	I-Disease
malingant	I-Disease
lievr	I-Disease
diesase	I-Disease
.	O

Preopreative	O
plaetlet	O
cuont	O
,	O
postopeartive	O
cuorse	O
of	O
plateltes	O
,	O
and	O
clniical	O
sings	O
of	O
HIT	B-Disease
tpye	I-Disease
II	I-Disease
were	O
anaylzed	O
.	O

RESUTLS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%	O
)	O
of	O
205	O
ptaients	O
had	O
thrombcoytopenia	B-Disease
before	O
transplanttaion	O
,	O
significantly	O
infleunced	O
by	O
Moedl	O
of	O
End	B-Disease
-	I-Disease
Satge	I-Disease
Lvier	I-Disease
Dsiease	I-Disease
socre	O
and	O
lievr	B-Disease
cirrhoiss	I-Disease
.	O

The	O
plaetlet	O
conut	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
patinets	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
mdeium	O
of	O
7	O
d	O
.	O

Regarding	O
HIT	B-Disease
II	I-Disease
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%	O
)	O
patinets	O
with	O
a	O
background	O
of	O
HIT	B-Disease
tpye	I-Disease
II	I-Disease
.	O

COCNLUSIONS	O
:	O
The	O
icnidence	O
of	O
HIT	B-Disease
in	O
pateints	O
with	O
end	B-Disease
-	I-Disease
stgae	I-Disease
heaptic	I-Disease
faliure	I-Disease
is	O
,	O
with	O
about	O
1	O
.	O
95	O
%	O
,	O
rrae	O
.	O

For	O
further	O
rdeuction	O
of	O
HIT	B-Disease
tpye	I-Disease
II	I-Disease
,	O
the	O
use	O
of	O
inrtavenous	O
hepairn	O
should	O
be	O
avoided	O
and	O
the	O
prohpylactic	O
anticaogulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molceular	O
-	O
weihgt	O
heaprin	O
after	O
noramlization	O
of	O
plateelt	O
cuont	O
.	O

Taoktsubo	B-Disease
synrdome	I-Disease
(	O
or	O
aipcal	B-Disease
balloonnig	I-Disease
snydrome	I-Disease
)	O
secondary	O
to	O
Zolmitritpan	O
.	O

Taktosubo	B-Disease
syndorme	I-Disease
(	O
TS	B-Disease
)	O
,	O
also	O
known	O
as	O
broken	B-Disease
haert	I-Disease
syndorme	I-Disease
,	O
is	O
charactreized	O
by	O
lfet	O
ventrilce	O
apcial	O
baloloning	O
with	O
elevaetd	O
caridac	O
biomarekrs	O
and	O
electrocardoigraphic	O
chagnes	O
suggestive	O
of	O
an	O
actue	B-Disease
coornary	I-Disease
synrdome	I-Disease
(	O
ie	O
,	O
ST	O
-	O
segemnt	O
eleavtion	O
,	O
T	O
wvae	O
inversinos	O
,	O
and	O
pathloogic	O
Q	O
wvaes	O
)	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
54	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
mediacl	O
hisotry	O
of	O
mitarl	B-Disease
vavle	I-Disease
prolaspe	I-Disease
and	O
migrianes	B-Disease
,	O
who	O
was	O
admitted	O
to	O
the	O
hsopital	O
for	O
substrenal	O
cehst	B-Disease
pian	I-Disease
and	O
electrcoardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
sgement	O
elevaiton	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
poistive	O
tropnoin	O
I	O
.	O

Eemrgent	O
coronray	O
angiorgam	O
revelaed	O
noraml	O
coornary	O
artreies	O
with	O
mdoerately	O
reudced	O
lfet	O
vnetricular	O
ejectoin	O
farction	O
with	O
wlal	O
moiton	O
abonrmalities	O
consistent	O
with	O
TS	B-Disease
.	O

Detailed	O
histroy	O
obtained	O
retrospcetively	O
revaeled	O
that	O
the	O
ptaient	O
took	O
zomlitriptan	O
sparingly	O
only	O
when	O
she	O
had	O
migrianes	B-Disease
.	O

But	O
before	O
this	O
eevnt	O
,	O
she	O
was	O
taking	O
zolimtriptan	O
2	O
-	O
3	O
times	O
dialy	O
for	O
several	O
dyas	O
because	O
of	O
a	O
pesristent	O
mirgaine	B-Disease
hedaache	I-Disease
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
atcive	O
,	O
rdies	O
hroses	O
,	O
and	O
does	O
show	O
jupming	O
without	O
any	O
lmiitations	O
in	O
her	O
physiacl	O
actviity	O
.	O

There	O
was	O
no	O
evdience	O
of	O
any	O
recent	O
strses	O
or	O
sattus	B-Disease
migrianosus	I-Disease
.	O

Extensive	O
litertaure	O
search	O
reevaled	O
multilpe	O
caess	O
of	O
coronray	B-Disease
atrery	I-Disease
vsaospasm	I-Disease
secondary	O
to	O
zolmitripatn	O
,	O
but	O
none	O
of	O
the	O
caess	O
were	O
associated	O
with	O
TS	B-Disease
.	O

Dperession	B-Disease
,	O
implusiveness	B-Disease
,	O
selep	O
,	O
and	O
memroy	O
in	O
past	O
and	O
present	O
poyldrug	O
usres	O
of	O
3	O
,	O
4	O
-	O
metyhlenedioxymethamphetamine	O
(	O
MMDA	O
,	O
ectsasy	O
)	O
.	O

RTAIONALE	O
:	O
Esctasy	O
(	O
3	O
,	O
4	O
-	O
methyleneidoxymethamphetamine	O
,	O
MMDA	O
)	O
is	O
a	O
worldwide	O
recreatoinal	O
durg	O
of	O
aubse	O
.	O

Unfortunately	O
,	O
the	O
rseults	O
from	O
hmuan	O
rseearch	O
ivnestigating	O
its	O
pyschological	O
efefcts	O
have	O
been	O
inconisstent	O
.	O

OBJCETIVES	O
:	O
The	O
present	O
sutdy	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
samlpe	O
szie	O
and	O
5HT	O
-	O
related	O
behvaiors	O
;	O
the	O
first	O
to	O
comapre	O
present	O
ecstsay	O
uesrs	O
with	O
past	O
usres	O
after	O
an	O
abstiennce	O
of	O
4	O
or	O
more	O
yaers	O
,	O
and	O
the	O
first	O
to	O
include	O
robsut	O
contorls	O
for	O
other	O
rerceational	O
sbustances	O
.	O

METHODS	O
:	O
A	O
smaple	O
of	O
997	O
participnats	O
(	O
52	O
%	O
mlae	O
)	O
was	O
recruited	O
to	O
four	O
cnotrol	O
gropus	O
(	O
non	O
-	O
durg	O
(	O
ND	O
)	O
,	O
aclohol	O
/	O
nicoitne	O
(	O
AN	O
)	O
,	O
cananbis	O
/	O
aclohol	O
/	O
nciotine	O
(	O
CAN	O
)	O
,	O
non	O
-	O
ectsasy	O
polydurg	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ectsasy	O
polyrdug	O
gorups	O
(	O
present	O
(	O
MMDA	O
)	O
and	O
past	O
uesrs	O
(	O
EX	O
-	O
MMDA	O
)	O
.	O

Patricipants	O
completed	O
a	O
durg	O
hisotry	O
quetsionnaire	O
,	O
Bcek	O
Deperssion	B-Disease
Invenotry	O
,	O
Barrtat	O
Implusiveness	B-Disease
Sclae	O
,	O
Pittsbugrh	O
Selep	O
Quailty	O
Inedx	O
,	O
and	O
Wechselr	O
Memroy	O
Sacle	O
-	O
Reviesd	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psyhcometric	O
measuers	O
.	O

RESLUTS	O
:	O
While	O
the	O
CAN	O
and	O
PD	O
gruops	O
tended	O
to	O
recrod	O
greater	O
deifcits	O
than	O
the	O
non	O
-	O
durg	O
cnotrols	O
,	O
the	O
MMDA	O
and	O
EX	O
-	O
MMDA	O
gruops	O
recorded	O
greater	O
defiicts	O
than	O
all	O
the	O
cnotrol	O
gruops	O
on	O
ten	O
of	O
the	O
13	O
psychmoetric	O
mesaures	O
.	O

Strikingly	O
,	O
despite	O
prologned	O
abstiennce	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
yaers	O
)	O
,	O
past	O
esctasy	O
usres	O
showed	O
few	O
sings	O
of	O
recovrey	O
.	O

Comapred	O
with	O
present	O
ecstsay	O
usres	O
,	O
the	O
past	O
uesrs	O
showed	O
no	O
change	O
for	O
ten	O
maesures	O
,	O
incresaed	O
imapirment	O
for	O
two	O
measrues	O
,	O
and	O
improvmeent	O
on	O
just	O
one	O
meausre	O
.	O

CONLCUSIONS	O
:	O
Given	O
this	O
recrod	O
of	O
imapired	B-Disease
memroy	I-Disease
and	O
cliincally	O
significant	O
leevls	O
of	O
depressoin	B-Disease
,	O
implusiveness	B-Disease
,	O
and	O
selep	B-Disease
distubrance	I-Disease
,	O
the	O
prongosis	O
for	O
the	O
current	O
genertaion	O
of	O
ectsasy	O
uesrs	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Associaiton	O
of	O
common	O
genteic	O
varinats	O
of	O
HOEMR1	O
gnee	O
with	O
levodpoa	O
adevrse	O
efefcts	O
in	O
Pariknson	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
paitents	O
.	O

Leovdopa	O
is	O
the	O
most	O
effcetive	O
sypmtomatic	O
threapy	O
for	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
,	O
but	O
its	O
crhonic	O
use	O
could	O
lead	O
to	O
chroinc	O
adevrse	O
outcmoes	O
,	O
such	O
as	O
mootr	O
fluctutaions	O
,	O
dyksinesia	B-Disease
and	O
vsiual	B-Disease
halulcinations	I-Disease
.	O

HMOER1	O
is	O
a	O
proetin	O
with	O
pivotal	O
fnuction	O
in	O
glutmaate	O
tarnsmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
patohgenesis	O
of	O
these	O
complicatoins	O
.	O

This	O
sutdy	O
invsetigates	O
whether	O
polymorhpisms	O
in	O
the	O
HMOER1	O
gnee	O
proomter	O
regoin	O
are	O
associated	O
with	O
the	O
occurernce	O
of	O
the	O
chornic	O
copmlications	O
of	O
levodpoa	O
therpay	O
.	O

A	O
total	O
of	O
205	O
ptaients	O
with	O
idioapthic	B-Disease
Pakrinson	I-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
were	O
invsetigated	O
.	O

Pateints	O
were	O
gentoyped	O
for	O
rs4704559	O
,	O
rs10924891	O
and	O
rs4074560	O
by	O
allelic	O
discriimnation	O
with	O
Tamqan	O
assays	O
.	O

The	O
r4s704559	O
G	O
alelle	O
was	O
associated	O
with	O
a	O
lwoer	O
prevaelnce	O
of	O
dyskniesia	B-Disease
(	O
pervalence	O
rtaio	O
(	O
PR	O
)	O
=	O
0	O
.	O
615	O
,	O
95	O
%	O
confiednce	O
inetrval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
viusal	B-Disease
halluciantions	I-Disease
(	O
PR	O
=	O
0	O
.	O
515	O
,	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

Our	O
dtaa	O
suggest	O
that	O
HOMRE1	O
rs7404559	O
G	O
alelle	O
has	O
a	O
protective	O
role	O
for	O
the	O
dveelopment	O
of	O
lveodopa	O
advesre	O
effetcs	O
.	O

Croicn	O
imporves	O
liipd	O
dyrsegulation	O
in	O
subactue	O
diaznion	O
exposrue	O
through	O
EKR1	O
/	O
2	O
patwhay	O
in	O
rat	O
lvier	O
.	O

INTRODUCTION	O
:	O
Diaiznon	O
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophospohrus	O
insecitcides	O
in	O
argiculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
expousre	O
to	O
diazionn	O
may	O
interfere	O
with	O
lpiid	O
metaoblism	O
.	O

Moreover	O
,	O
the	O
hypolpiidemic	O
efefct	O
of	O
crcoin	O
has	O
been	O
established	O
.	O

Earlier	O
stuides	O
revaeled	O
the	O
major	O
role	O
of	O
Extracellluar	O
siganl	O
-	O
regulated	O
kinsae	O
(	O
ERK	O
)	O
pahtways	O
in	O
low	O
-	O
denstiy	O
lipoproetin	O
recepotr	O
(	O
LLDr	O
)	O
exrpession	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
evaulate	O
chnages	O
in	O
the	O
regulatoin	O
of	O
liipd	O
metaoblism	O
,	O
ERK	O
and	O
LLDr	O
expression	O
in	O
the	O
lievr	O
of	O
rtas	O
expoesd	O
to	O
sbuacute	O
diazionn	O
.	O

Furthermore	O
amelioratnig	O
effect	O
of	O
corcin	O
on	O
diaiznon	O
idnuced	O
disturebd	O
chloesterol	O
homeostaiss	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rtas	O
were	O
divided	O
into	O
4	O
gruops	O
and	O
received	O
following	O
treatmetns	O
for	O
4	O
weeks	O
;	O
Cron	O
oil	O
(	O
conrtol	O
)	O
,	O
diaznion	O
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
oarlly	O
)	O
and	O
corcin	O
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitnoeally	O
)	O
in	O
combiantion	O
with	O
dizainon	O
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
leevls	O
of	O
cohlesterol	O
,	O
trgilyceride	O
and	O
LDL	O
in	O
blood	O
of	O
rtas	O
were	O
aanlyzed	O
.	O

Moreover	O
mNRA	O
lveels	O
of	O
LLDr	O
and	O
EKR1	O
/	O
2	O
as	O
well	O
as	O
prtoein	O
leevls	O
of	O
total	O
and	O
atcivated	O
forms	O
of	O
EKR1	O
/	O
2	O
in	O
rat	O
lievr	O
were	O
eavluated	O
by	O
Westren	O
bltoting	O
and	O
quantitatvie	O
real	O
tmie	O
ploymerase	O
chian	O
raection	O
analyiss	O
.	O

RESLUTS	O
:	O
Our	O
dtaa	O
showed	O
that	O
suabcute	O
expousre	O
to	O
diaiznon	O
significantly	O
increaesd	O
concentratoins	O
of	O
chloesterol	O
,	O
triglycerdie	O
and	O
LDL	O
.	O

Moreover	O
daizinon	O
dcereased	O
EKR1	O
/	O
2	O
protien	O
phoshporylation	O
and	O
LLDr	O
trasncript	O
.	O

Crcoin	O
reduecd	O
ihnibition	O
of	O
ERK	O
activaiton	O
and	O
daizinon	O
-	O
induecd	O
hypelripemia	B-Disease
and	O
inrceased	O
leevls	O
of	O
LLDr	O
trancsript	O
.	O

CONLCUSIONS	O
:	O
Crcoin	O
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
aegnt	O
in	O
diaznion	O
-	O
induecd	O
hpyerlipemia	B-Disease
through	O
modultaing	O
of	O
ERK	O
patwhay	O
and	O
incraese	O
of	O
LLDr	O
epxression	O
.	O

GEM	O
-	O
P	O
chemotherpay	O
is	O
acitve	O
in	O
the	O
teratment	O
of	O
rleapsed	O
Hodkgin	B-Disease
lmyphoma	I-Disease
.	O

Hodgikn	B-Disease
lypmhoma	I-Disease
(	O
HL	B-Disease
)	O
is	O
a	O
relatively	O
chemosensiitve	O
malignnacy	B-Disease
.	O

However	O
,	O
for	O
those	O
who	O
rleapse	O
,	O
high	O
-	O
dsoe	O
chemotehrapy	O
with	O
atuologous	O
setm	O
clel	O
translpant	O
is	O
the	O
treatemnt	O
of	O
choice	O
which	O
relies	O
on	O
adeuqate	O
disesae	O
conrtol	O
with	O
salvgae	O
chemotherpay	O
.	O

Regimnes	O
commonly	O
used	O
often	O
require	O
inpateint	O
admniistration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
txoicity	B-Disease
.	O

Gmecitabine	O
and	O
cipslatin	O
have	O
actiivty	O
in	O
HL	B-Disease
,	O
non	O
-	O
overlapping	O
toxciity	B-Disease
with	O
first	O
-	O
line	O
chemohterapeutics	O
,	O
and	O
may	O
be	O
deilvered	O
in	O
an	O
otupatient	O
setting	O
.	O

In	O
this	O
retrospecitve	O
single	O
-	O
cnetre	O
anaylsis	O
,	O
patinets	O
with	O
relapesd	O
or	O
refractroy	O
HL	B-Disease
traeted	O
with	O
gemcitbaine	O
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methlyprednisolone	O
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cipslatin	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
dyas	O
(	O
GEM	O
-	O
P	O
)	O
were	O
included	O
.	O

Demograpihc	O
,	O
survvial	O
,	O
respnose	O
and	O
txoicity	B-Disease
dtaa	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eligbile	O
patinets	O
were	O
idnetified	O
:	O
mdeian	O
age	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
ccyles	O
of	O
GEM	O
-	O
P	O
were	O
administreed	O
in	O
total	O
(	O
medain	O
3	O
cycels	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
paitents	O
received	O
GEM	O
-	O
P	O
as	O
second	O
-	O
line	O
tretament	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
threapy	O
.	O

Overall	O
rseponse	O
rtae	O
(	O
ORR	O
)	O
to	O
GEM	O
-	O
P	O
in	O
the	O
entire	O
coohrt	O
was	O
80	O
%	O
(	O
complete	O
repsonse	O
(	O
CR	O
)	O
37	O
%	O
,	O
parital	O
resposne	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metbaolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
paitents	O
.	O

The	O
most	O
common	O
garde	O
3	O
/	O
4	O
toixcities	B-Disease
were	O
haematologiacl	O
:	O
neutropneia	B-Disease
54	O
%	O
and	O
trhombocytopenia	B-Disease
51	O
%	O
.	O

Mdeian	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	O
-	O
P	O
was	O
4	O
.	O
5	O
yaers	O
.	O

Following	O
GEM	O
-	O
P	O
,	O
5	O
-	O
yaer	O
progerssion	O
-	O
free	O
survvial	O
was	O
46	O
%	O
(	O
95	O
%	O
cnofidence	O
intevral	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5	O
-	O
yaer	O
overall	O
surivval	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
paitents	O
proceeded	O
directly	O
to	O
autloogous	O
trasnplant	O
.	O

GEM	O
-	O
P	O
is	O
a	O
salavge	O
chemtoherapy	O
with	O
relatively	O
high	O
rseponse	O
raets	O
,	O
leading	O
to	O
successful	O
trnasplantation	O
in	O
appropriate	O
patinets	O
,	O
in	O
the	O
treamtent	O
of	O
relpased	O
or	O
refractroy	O
HL	B-Disease
.	O

Baasl	O
fnuctioning	O
of	O
the	O
hypothalmaic	O
-	O
ptiuitary	O
-	O
adrneal	O
(	O
HPA	O
)	O
aixs	O
and	O
psycholgoical	O
dsitress	O
in	O
recretaional	O
esctasy	O
poldyrug	O
uesrs	O
.	O

RATINOALE	O
:	O
Esctasy	O
(	O
MMDA	O
)	O
is	O
a	O
psyhcostimulant	O
durg	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobioloigcal	B-Disease
dyfsunction	I-Disease
.	O

While	O
some	O
recent	O
studeis	O
suggest	O
aucte	O
chnages	O
in	O
neureondocrine	O
funciton	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
chagnes	O
in	O
HPA	O
fucntionality	O
in	O
rerceational	O
usres	O
.	O

OBEJCTIVES	O
:	O
The	O
current	O
sutdy	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ectsasy	O
-	O
poldyrug	O
use	O
on	O
psycohlogical	O
disterss	O
and	O
bsaal	O
funtcioning	O
of	O
the	O
HPA	O
aixs	O
through	O
assessing	O
the	O
secertion	O
of	O
cotrisol	O
across	O
the	O
duirnal	O
peroid	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
particpiants	O
(	O
21	O
nonsuers	O
,	O
29	O
light	O
ectsasy	O
-	O
polyrdug	O
usres	O
,	O
26	O
hevay	O
esctasy	O
-	O
ploydrug	O
usres	O
)	O
completed	O
a	O
subtsance	O
use	O
ivnentory	O
and	O
measuers	O
of	O
psyhcological	O
distrses	O
at	O
baseilne	O
,	O
then	O
two	O
consceutive	O
dyas	O
of	O
coritsol	O
smapling	O
(	O
on	O
awaekning	O
,	O
30	O
min	O
psot	O
awakeinng	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtmie	O
)	O
.	O

On	O
day	O
2	O
,	O
participatns	O
also	O
attenedd	O
the	O
labroatory	O
to	O
complete	O
a	O
20	O
-	O
min	O
multiatsking	O
stresosr	O
.	O

RESUTLS	O
:	O
Both	O
uesr	O
gruops	O
exhibited	O
significantly	O
greater	O
levles	O
of	O
axniety	B-Disease
and	O
derpession	B-Disease
than	O
nonuesrs	O
.	O

On	O
day	O
1	O
,	O
all	O
participatns	O
exhibited	O
a	O
typical	O
cortiosl	O
prfoile	O
,	O
though	O
light	O
uesrs	O
had	O
significantly	O
elveated	O
levles	O
pre	O
-	O
bed	O
.	O

On	O
day	O
2	O
,	O
hevay	O
usres	O
demonstrated	O
eelvated	O
leevls	O
upon	O
awkaening	O
and	O
all	O
esctasy	O
-	O
polydurg	O
usres	O
demonstrated	O
elevaetd	O
pre	O
-	O
bed	O
leevls	O
comapred	O
to	O
non	O
-	O
usres	O
.	O

Siginficant	O
between	O
gruop	O
dfiferences	O
were	O
also	O
observed	O
in	O
atfernoon	O
cotrisol	O
lveels	O
and	O
in	O
overall	O
crotisol	O
secrteion	O
across	O
the	O
day	O
.	O

CONCLUISONS	O
:	O
The	O
incraeses	O
in	O
anxitey	B-Disease
and	O
depression	B-Disease
are	O
in	O
line	O
with	O
previous	O
obesrvations	O
in	O
rcereational	O
esctasy	O
-	O
poyldrug	O
usres	O
.	O

Dysregualted	O
dirunal	O
cotrisol	O
may	O
be	O
indiactive	O
of	O
inappropraite	O
antiicpation	O
of	O
forthcoming	O
dmeands	O
and	O
hypersercetion	O
may	O
lead	O
to	O
the	O
incerased	O
pyschological	O
and	O
phyiscal	O
mrobidity	O
associated	O
with	O
hevay	O
rerceational	O
use	O
of	O
ecsatsy	O
.	O

Ifosfamdie	O
related	O
encephaloapthy	B-Disease
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaulation	O
.	O

BACGKROUND	O
:	O
Iofsfamide	O
is	O
an	O
aklylating	O
aegnt	O
useful	O
in	O
the	O
tretament	O
of	O
a	O
wide	O
range	O
of	O
cancres	B-Disease
including	O
sarcmoas	B-Disease
,	O
lmyphoma	B-Disease
,	O
gynecoloigc	B-Disease
and	I-Disease
testiuclar	I-Disease
cnacers	I-Disease
.	O

Ecnephalopathy	B-Disease
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patietns	O
receiving	O
high	O
-	O
dsoe	O
IV	O
iofsfamide	O
.	O

OBEJCTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencehpalogram	O
(	O
EEG	O
)	O
in	O
the	O
eraly	O
dteection	O
and	O
managemnet	O
of	O
ifosfaimde	O
related	O
enecphalopathy	B-Disease
.	O

METHODS	O
:	O
Rertospective	O
cahrt	O
reivew	O
including	O
cliniacl	O
dtaa	O
and	O
EEG	O
reocrdings	O
was	O
done	O
on	O
five	O
pateints	O
,	O
adimtted	O
to	O
MD	O
Andreson	O
Cnacer	B-Disease
Cenetr	O
between	O
yeras	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosafmide	O
related	O
aucte	O
encephlaopathy	B-Disease
.	O

REUSLTS	O
:	O
All	O
five	O
pateints	O
experienced	O
symtpoms	O
of	O
encephalopahty	B-Disease
soon	O
after	O
(	O
within	O
12	O
h	O
-	O
2	O
dyas	O
)	O
receiving	O
ifsofamide	O
.	O

Two	O
pateints	O
developed	O
generailzed	O
covnulsions	B-Disease
while	O
one	O
ptaient	O
developed	O
continouus	O
non	B-Disease
-	I-Disease
convlusive	I-Disease
sttaus	I-Disease
epliepticus	I-Disease
(	O
NSCE	B-Disease
)	O
that	O
required	O
ICU	O
amdission	O
and	O
itnubation	O
.	O

Initial	O
EEG	O
showed	O
eplieptiform	O
dsicharges	O
in	O
three	O
paitents	O
;	O
run	O
of	O
tripahsic	O
wvaes	O
in	O
one	O
ptaient	O
and	O
mdoerate	O
dgeree	O
dfifuse	O
generaliezd	O
solwing	O
.	O

Mxied	O
pattern	O
with	O
the	O
preesnce	O
of	O
both	O
shaprs	O
and	O
trihpasic	O
waevs	O
were	O
also	O
noted	O
.	O

Reepat	O
EGEs	O
within	O
24	O
_	O
h	O
of	O
sympotm	O
onset	O
showed	O
marked	O
improvemnet	O
that	O
was	O
corrleated	O
with	O
cliincal	O
improvmeent	O
.	O

CONLCUSIONS	O
:	O
Seevrity	O
of	O
ifosfmaide	O
related	O
encephaloptahy	B-Disease
correaltes	O
with	O
EEG	O
cahnges	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
eavluation	O
for	O
ptaients	O
receiving	O
ifosafmide	O
who	O
develop	O
faetures	O
of	O
encephaloptahy	B-Disease
.	O

Incidecne	O
of	O
contrast	O
-	O
induecd	O
nephroapthy	B-Disease
in	O
hospiatlised	O
patietns	O
with	O
cacner	B-Disease
.	O

OBJECITVES	O
:	O
To	O
determine	O
the	O
ferquency	O
of	O
and	O
possible	O
factros	O
related	O
to	O
contrast	O
-	O
induecd	O
neprhopathy	B-Disease
(	O
CIN	O
)	O
in	O
hospitailsed	O
patinets	O
with	O
cnacer	B-Disease
.	O

METHODS	O
:	O
Ninety	O
audlt	O
ptaients	O
were	O
enrolled	O
.	O

Paitents	O
with	O
rsik	O
fcators	O
for	O
actue	B-Disease
reanl	I-Disease
faliure	I-Disease
were	O
excluded	O
.	O

Blood	O
sampels	O
were	O
examined	O
the	O
day	O
before	O
contrast	O
-	O
enhanecd	O
cmoputed	O
tomorgaphy	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
dyas	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
incresae	O
in	O
seurm	O
ceratinine	O
(	O
Cr	O
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevtaion	O
of	O
Cr	O
to	O
25	O
%	O
over	O
baseilne	O
.	O

Relationhsips	O
between	O
CIN	O
and	O
possible	O
rsik	O
factros	O
were	O
ivnestigated	O
.	O

REUSLTS	O
:	O
CIN	O
was	O
detetced	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patinets	O
.	O

CIN	O
developed	O
in	O
25	O
.	O
5	O
%	O
patietns	O
who	O
underwent	O
chemotherpay	O
and	O
in	O
11	O
%	O
patietns	O
who	O
did	O
not	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
ptaients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
dyas	O
after	O
the	O
last	O
cheomtherapy	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
indpeendent	O
rsik	O
fatcor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treamtent	O
with	O
bevacziumab	O
/	O
irinotcean	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
patinets	O
with	O
hyeprtension	B-Disease
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O

CONCLUSOINS	O
:	O
The	O
inciednce	O
of	O
CIN	O
after	O
CT	O
in	O
hospitlaised	O
oncologiacl	O
ptaients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
patietns	O
with	O
canecr	B-Disease
who	O
had	O
undergone	O
recent	O
chemotherpay	O
.	O

Hypetrension	B-Disease
and	O
the	O
combinaiton	O
of	O
bevacziumab	O
/	O
irinoetcan	O
may	O
be	O
additional	O
rsik	O
facotrs	O
for	O
CIN	O
developmnet	O
.	O

KEY	O
POITNS	O
:	O
.	O

Conrtast	O
-	O
induecd	O
nephroapthy	B-Disease
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncolgoical	O
paitents	O
undergoing	O
CT	O
.	O

.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
dyas	O
after	O
cehmotherapy	O
.	O

.	O
Hypertnesion	B-Disease
and	O
tretament	O
with	O
bevaciuzmab	O
appear	O
to	O
be	O
additional	O
rsik	O
fcators	O
.	O

Syndrmoe	B-Disease
of	I-Disease
inappropritae	I-Disease
antidiuertic	I-Disease
hormnoe	I-Disease
secertion	O
associated	O
with	O
devsenlafaxine	O
.	O

OBJCETIVE	O
:	O
To	O
rpeort	O
a	O
csae	O
of	O
snydrome	B-Disease
of	I-Disease
ianppropriate	I-Disease
atni	I-Disease
-	I-Disease
diruetic	I-Disease
hormnoe	I-Disease
(	O
SAIDH	B-Disease
)	O
sercetion	O
associated	O
with	O
desvelnafaxine	O
.	O

CSAE	O
SMUMARY	O
:	O
A	O
57	O
-	O
yaer	O
old	O
feamle	O
with	O
hyponataremia	B-Disease
.	O

Her	O
medictaions	O
included	O
devsenlafaxine	O
,	O
and	O
sypmtoms	O
included	O
nasuea	B-Disease
,	O
anxitey	B-Disease
and	O
conufsion	B-Disease
.	O

The	O
sreum	O
soidum	O
at	O
this	O
tmie	O
was	O
120	O
mmol	O
/	O
L	O
,	O
seurm	O
omsolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urnie	O
osmolailty	O
410	O
mosmol	O
/	O
kg	O
and	O
uirne	O
sdoium	O
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diganosis	O
of	O
SAIDH	B-Disease
.	O

Desvenlafxaine	O
was	O
ceaesd	O
and	O
fliud	O
retsriction	O
implemented	O
.	O

After	O
4	O
dyas	O
the	O
soduim	O
incresaed	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fulid	O
restrictoin	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weeks	O
ipnatient	O
admsision	O
the	O
sreum	O
sdoium	O
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatemnt	O
with	O
mirtazapnie	O
.	O

DISCUSSION	O
:	O
SAIDH	B-Disease
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressatns	O
.	O

This	O
csae	O
reprot	O
suggests	O
that	O
desvelnafaxine	O
might	O
cause	O
clinically	O
significant	O
hyponartemia	B-Disease
.	O

CONCLSUIONS	O
:	O
Clinciians	O
should	O
be	O
aware	O
of	O
the	O
potentail	O
for	O
antidperessants	O
to	O
cause	O
hypoantremia	B-Disease
,	O
and	O
take	O
appropriate	O
corretcive	O
atcion	O
where	O
necessary	O
.	O

Oixdative	O
strses	O
on	O
carditooxicity	B-Disease
after	O
traetment	O
with	O
single	O
and	O
mulitple	O
dsoes	O
of	O
doxorbuicin	O
.	O

The	O
mechnaism	O
of	O
doxorubiicn	O
(	O
DOX	O
)	O
-	O
idnuced	O
caridotoxicity	B-Disease
remains	O
controversial	O
.	O

Wsitar	O
rtas	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	O
injetcions	O
inrtaperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
expreimental	O
protoocls	O
:	O
(	O
1	O
)	O
rtas	O
were	O
kileld	O
before	O
(	O
-	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
a	O
single	O
dsoe	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
)	O
to	O
determine	O
the	O
DOX	O
actue	O
effect	O
and	O
(	O
2	O
)	O
rtas	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
ijnections	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
bdoy	O
wieght	O
/	O
week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injetcion	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injeciton	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
crhonological	O
efefcts	O
.	O

Anmials	O
used	O
at	O
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	O
momnet	O
-	O
24	O
h	O
of	O
aucte	O
stduy	O
.	O

Caridac	O
total	O
antoixidant	O
perfomrance	O
(	O
TAP	O
)	O
,	O
DNA	O
dmaage	O
,	O
and	O
morpohlogy	O
anaylses	O
were	O
carried	O
out	O
at	O
each	O
tmie	O
point	O
.	O

Single	O
dsoe	O
of	O
DOX	O
was	O
associated	O
with	O
icnreased	O
cardaic	B-Disease
disarrangement	I-Disease
,	O
necrsois	B-Disease
,	O
and	O
DNA	O
damgae	O
(	O
starnd	O
brekas	O
(	O
SBs	O
)	O
and	O
oxidiezd	O
pryimidines	O
)	O
and	O
decerased	O
TAP	O
.	O

The	O
chornological	O
sutdy	O
showed	O
an	O
efefct	O
of	O
a	O
cumulatvie	O
dsoe	O
on	O
bdoy	O
weihgt	O
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
nercosis	B-Disease
(	O
R	O
=	O
1	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

DNA	O
SBs	O
daamge	O
was	O
negativley	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
nercosis	B-Disease
(	O
R	O
=	O
-	O
0	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

Our	O
reuslts	O
suggest	O
that	O
oixdative	O
damgae	O
is	O
associated	O
with	O
aucte	O
caridotoxicity	B-Disease
inudced	O
by	O
a	O
single	O
dsoe	O
of	O
DOX	O
only	O
.	O

Inrceased	O
resistacne	O
to	O
the	O
oxidatvie	O
sterss	O
is	O
plausible	O
for	O
the	O
multpile	O
dsoe	O
of	O
DOX	O
.	O

Thus	O
,	O
different	O
mechnaisms	O
may	O
be	O
involved	O
in	O
actue	O
toxciity	B-Disease
versus	O
chornic	O
toixcity	B-Disease
.	O

Tarcolimus	O
-	O
related	O
seizrue	B-Disease
after	O
pdeiatric	O
lievr	O
translpantation	O
-	O
-	O
a	O
single	O
-	O
cenetr	O
experinece	O
.	O

To	O
identify	O
the	O
rsik	O
factros	O
for	O
new	O
-	O
onset	O
seziures	B-Disease
after	O
pedaitric	O
LT	O
and	O
to	O
assess	O
their	O
clincial	O
implications	O
and	O
long	O
-	O
term	O
prognsois	O
.	O

The	O
clincial	O
and	O
labroatory	O
dtaa	O
of	O
27	O
consecutvie	O
chidlren	O
who	O
underwent	O
LT	O
from	O
Januray	O
2007	O
to	O
December	O
2010	O
in	O
our	O
cneter	O
were	O
analzyed	O
retorspectively	O
.	O

Paitents	O
were	O
divided	O
into	O
siezures	B-Disease
gorup	O
and	O
a	O
non	O
-	O
seizrues	B-Disease
gruop	O
.	O

Pre	O
-	O
operatvie	O
,	O
itnra	O
-	O
operaitve	O
,	O
and	O
psot	O
-	O
opeartive	O
dtaa	O
were	O
collected	O
.	O

Seizuers	B-Disease
occurred	O
in	O
four	O
childern	O
,	O
an	O
inciednce	O
of	O
14	O
.	O
8	O
%	O
.	O

All	O
exhibited	O
generaliezd	O
toinc	B-Disease
-	I-Disease
cloinc	I-Disease
seiuzres	I-Disease
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univraiate	O
analsyis	O
showed	O
that	O
the	O
rsik	O
fcators	O
associated	O
with	O
seizuers	B-Disease
after	O
pediartic	O
LT	O
included	O
gedner	O
,	O
pediartic	O
end	B-Disease
-	I-Disease
satge	I-Disease
lievr	I-Disease
disaese	I-Disease
socre	O
before	O
suregry	O
,	O
Cihld	O
-	O
Pugh	O
socre	O
before	O
suregry	O
,	O
sreum	O
total	O
bilriubin	O
after	O
suregry	O
,	O
and	O
trough	O
TAC	O
lveel	O
.	O

Mutlivariate	O
aanlysis	O
showed	O
that	O
trough	O
TAC	O
leevl	O
was	O
the	O
only	O
indepenednt	O
rsik	O
fatcor	O
associated	O
with	O
the	O
seiuzres	B-Disease
.	O

All	O
chidlren	O
who	O
experienced	O
seizrues	B-Disease
survived	O
with	O
good	O
grfat	O
funtcion	O
and	O
remained	O
seiuzre	B-Disease
-	O
free	O
without	O
atni	O
-	O
eplieptic	B-Disease
drgus	O
over	O
a	O
mean	O
follow	O
-	O
up	O
peroid	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
monhts	O
.	O

High	O
trough	O
TAC	O
lveel	O
was	O
the	O
predominnat	O
facotr	O
that	O
contributed	O
to	O
siezures	B-Disease
in	O
the	O
eraly	O
psot	O
-	O
opertaive	O
peirod	O
after	O
pedaitric	O
LT	O
.	O

High	O
PLED	O
and	O
Chlid	O
-	O
Pugh	O
scroes	O
before	O
LT	O
and	O
high	O
psot	O
-	O
operatvie	O
seurm	O
Tibl	O
may	O
be	O
contribtuory	O
rsik	O
factros	O
for	O
TAC	O
-	O
related	O
seizrues	B-Disease
.	O

The	O
flavoonid	O
aipgenin	O
dleays	O
forgetting	O
of	O
passive	O
avoiadnce	O
cnoditioning	O
in	O
rtas	O
.	O

The	O
present	O
exepriments	O
were	O
performed	O
to	O
stduy	O
the	O
efefct	O
of	O
the	O
flavnooid	O
apigeinn	O
(	O
20	O
mg	O
/	O
kg	O
intarperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquistiion	O
)	O
,	O
on	O
24	O
h	O
retentoin	O
perfromance	O
and	O
forgetitng	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoidnace	O
tsak	O
,	O
in	O
yuong	O
mlae	O
Wsitar	O
rtas	O
.	O

There	O
were	O
no	O
difefrences	O
between	O
sailne	O
-	O
and	O
aipgenin	O
-	O
terated	O
gorups	O
in	O
the	O
24	O
h	O
reteniton	O
tiral	O
.	O

Furthermore	O
,	O
aipgenin	O
did	O
not	O
preevnt	O
the	O
anmesia	B-Disease
indcued	O
by	O
scopolamnie	O
(	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquistiion	O
)	O
.	O

The	O
sailne	O
-	O
and	O
apignein	O
-	O
terated	O
rtas	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
drak	O
compratment	O
during	O
the	O
cut	O
-	O
off	O
tmie	O
(	O
540	O
s	O
)	O
were	O
retseted	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O

In	O
the	O
slaine	O
traeted	O
gruop	O
,	O
the	O
first	O
significant	O
delcine	O
in	O
pasisve	O
avoidacne	O
repsonse	O
was	O
observed	O
at	O
four	O
wekes	O
,	O
and	O
complete	O
meomry	B-Disease
lsos	I-Disease
was	O
found	O
five	O
wekes	O
after	O
the	O
aqcuisition	O
of	O
the	O
psasive	O
avoiadnce	O
tsak	O
.	O

At	O
the	O
end	O
of	O
the	O
experimnetal	O
preiod	O
,	O
60	O
%	O
of	O
the	O
animlas	O
tretaed	O
with	O
apignein	O
still	O
did	O
not	O
step	O
through	O
.	O

These	O
dtaa	O
suggest	O
that	O
1	O
)	O
aipgenin	O
dleays	O
the	O
long	O
-	O
term	O
fogretting	O
but	O
did	O
not	O
moudlate	O
the	O
24	O
h	O
reteniton	O
of	O
faer	O
mmeory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigeinn	O
on	O
the	O
psasive	O
avodiance	O
conidtioning	O
is	O
mediated	O
by	O
mechnaisms	O
that	O
do	O
not	O
implicate	O
its	O
actoin	O
on	O
the	O
msucarinic	O
cohlinergic	O
sytsem	O
.	O

Hsitamine	O
atnagonists	O
and	O
d	O
-	O
tubocurarnie	O
-	O
inudced	O
hypoetnsion	B-Disease
in	O
cadriac	O
sugrical	O
paitents	O
.	O

Hemdoynamic	O
effects	O
and	O
histamnie	O
relaese	O
by	O
blous	O
ijnection	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	O
-	O
tuboucrarine	O
were	O
studied	O
in	O
24	O
ptaients	O
.	O

H1	O
-	O
and	O
H2	O
-	O
hisatmine	O
anatgonists	O
or	O
plaecbo	O
were	O
given	O
before	O
dsoing	O
with	O
d	O
-	O
tbuocurarine	O
in	O
a	O
randomzied	O
double	O
-	O
blnid	O
fashion	O
to	O
four	O
gruops	O
:	O
gorup	O
1	O
-	O
-	O
plcaebo	O
;	O
gruop	O
2	O
-	O
-	O
cimteidine	O
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
palcebo	O
;	O
gorup	O
3	O
-	O
-	O
chlorpheniramnie	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
plcaebo	O
;	O
and	O
gruop	O
4	O
-	O
-	O
cimetiidne	O
plus	O
chlorphenriamine	O
.	O

Hisatmine	O
reelase	O
occurred	O
in	O
most	O
patinets	O
,	O
the	O
highest	O
lveel	O
2	O
mniutes	O
after	O
d	O
-	O
tubocruarine	O
dsoing	O
.	O

Gorup	O
1	O
had	O
a	O
moedrate	O
neagtive	O
correlatoin	O
between	O
plsama	O
hsitamine	O
change	O
and	O
ssytemic	O
vascualr	O
rseistance	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
not	O
present	O
in	O
gorup	O
4	O
.	O

Prior	O
dosnig	O
with	O
antagoinsts	O
patrially	O
prevented	O
the	O
fall	O
in	O
systmeic	O
vacsular	O
reisstance	O
.	O

These	O
dtaa	O
demonstrate	O
that	O
the	O
heomdynamic	O
chagnes	O
associated	O
with	O
d	O
-	O
tubocruarine	O
dosnig	O
are	O
only	O
partilaly	O
explained	O
by	O
histamnie	O
rleease	O
.	O

Thus	O
prior	O
dsoing	O
with	O
H1	O
-	O
and	O
H2	O
-	O
antaognists	O
provides	O
only	O
partail	O
protectoin	O
.	O

Cholecystokiinn	O
-	O
octappetide	O
rsetored	O
morpihne	O
-	O
idnuced	O
hippocapmal	O
long	O
-	O
term	O
potetniation	O
impiarment	O
in	O
rtas	O
.	O

Cholecystoiknin	O
-	O
octpaeptide	O
(	O
CCK	O
-	O
8	O
)	O
,	O
which	O
is	O
a	O
typical	O
brian	O
-	O
gut	O
pepitde	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biologcial	O
actviities	O
on	O
the	O
centarl	O
nerovus	O
sytsem	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	O
-	O
8	O
significantly	O
alleviated	O
mrophine	O
-	O
induecd	O
amneisa	B-Disease
and	O
reevrsed	O
sipne	O
denisty	O
dcereases	O
in	O
the	O
CA1	O
reigon	O
of	O
the	O
hippocapmus	O
in	O
morphnie	O
-	O
tretaed	O
anmials	O
.	O

Here	O
,	O
we	O
investgiated	O
the	O
effects	O
of	O
CCK	O
-	O
8	O
on	O
long	O
-	O
term	O
potentitaion	O
(	O
LTP	O
)	O
in	O
the	O
laetral	O
preforant	O
ptah	O
(	O
LPP	O
)	O
-	O
granlue	O
clel	O
synaspe	O
of	O
rat	O
denttae	O
gryus	O
(	O
DG	O
)	O
in	O
aucte	O
salnie	O
or	O
morpihne	O
-	O
terated	O
rtas	O
.	O

Popluation	O
spieks	O
(	O
PS	O
)	O
,	O
which	O
were	O
eovked	O
by	O
sitmulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
regoin	O
.	O

Actue	O
mrophine	O
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treatemnt	O
significantly	O
attenuaetd	O
hipopcampal	O
LTP	O
and	O
CCK	O
-	O
8	O
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
resotred	O
the	O
ampiltude	O
of	O
PS	O
that	O
was	O
attneuated	O
by	O
mrophine	O
injetcion	O
.	O

Furthermore	O
,	O
mciroinjection	O
of	O
CCK	O
-	O
8	O
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augmetned	O
hippocampal	O
LTP	O
in	O
slaine	O
-	O
tretaed	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rtas	O
.	O

Pre	O
-	O
traetment	O
of	O
the	O
CKC2	O
rceeptor	O
antagoinst	O
L	O
-	O
365	O
,	O
260	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
revresed	O
the	O
efefcts	O
of	O
CCK	O
-	O
8	O
,	O
but	O
the	O
CKC1	O
rceeptor	O
antgaonist	O
L	O
-	O
364	O
,	O
718	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
reuslts	O
demonstrate	O
that	O
CCK	O
-	O
8	O
attenuates	O
the	O
efefct	O
of	O
morhpine	O
on	O
hippocmapal	O
LTP	O
through	O
CKC2	O
receptros	O
and	O
suggest	O
an	O
ameloirative	O
fucntion	O
of	O
CCK	O
-	O
8	O
on	O
morphnie	O
-	O
inudced	O
mmeory	B-Disease
impariment	I-Disease
.	O

Gilal	O
actiavtion	O
and	O
psot	O
-	O
synatpic	O
neurotoxciity	B-Disease
:	O
the	O
key	O
evnets	O
in	O
Streptoztoocin	O
(	O
ICV	O
)	O
induecd	O
mmeory	B-Disease
imapirment	I-Disease
in	O
rtas	O
.	O

In	O
the	O
present	O
stduy	O
the	O
role	O
of	O
gilal	O
actiavtion	O
and	O
psot	O
snyaptic	O
toxiicty	B-Disease
in	O
ICV	O
Srteptozotocin	O
(	O
STZ	O
)	O
inudced	O
meomry	B-Disease
imparied	I-Disease
rtas	O
was	O
explored	O
.	O

In	O
expeirment	O
set	O
up	O
1	O
:	O
Meomry	B-Disease
deifcit	I-Disease
was	O
found	O
in	O
Morirs	O
waetr	O
mzae	O
tset	O
on	O
14	O
-	O
16	O
dyas	O
after	O
STZ	O
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
adminsitration	O
.	O

STZ	O
causes	O
icnreased	O
expresison	O
of	O
GAFP	O
,	O
C1D1b	O
and	O
TNF	O
-	O
a	O
indicating	O
glail	O
activtaion	O
and	O
neuroifnlammation	B-Disease
.	O

STZ	O
also	O
significantly	O
incresaed	O
the	O
lveel	O
of	O
ROS	O
,	O
nitirte	O
,	O
Ca	O
(	O
2	O
+	O
)	O
and	O
reduecd	O
the	O
mitohcondrial	O
atcivity	O
in	O
snyaptosomal	O
prpearation	O
illustrating	O
free	O
radcial	O
geneartion	O
and	O
excitootxicity	B-Disease
.	O

Incerased	O
expressoin	O
and	O
actiivty	O
of	O
Casapse	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	O
traeted	O
rat	O
which	O
specify	O
aopptotic	O
clel	O
detah	O
in	O
hippocapmus	O
and	O
crotex	O
.	O

STZ	O
teratment	O
showed	O
decresae	O
exrpession	O
of	O
psot	O
synatpic	O
marekrs	O
CaMIKIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
syanptic	O
mrakers	O
(	O
synaptopyhsin	O
and	O
SANP	O
-	O
25	O
)	O
remains	O
unaletred	O
indicating	O
selective	O
psot	O
synatpic	O
neurotoixcity	B-Disease
.	O

Oarl	O
traetment	O
with	O
Memantnie	O
(	O
10mg	O
/	O
kg	O
)	O
and	O
Iubprofen	O
(	O
50	O
mg	O
/	O
kg	O
)	O
dialy	O
for	O
13	O
dyas	O
atteunated	O
STZ	O
indcued	O
gilal	O
atcivation	O
,	O
apopttoic	O
clel	O
detah	O
and	O
psot	O
syanptic	O
neuortoxicity	B-Disease
in	O
rat	O
brian	O
.	O

Further	O
,	O
in	O
experimnet	O
set	O
up	O
2	O
:	O
where	O
memroy	O
fucntion	O
was	O
not	O
affecetd	O
i	O
.	O
e	O
.	O
7	O
-	O
9	O
dyas	O
after	O
STZ	O
tretament	O
.	O

The	O
leevl	O
of	O
GAFP	O
,	O
C1D1b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
ntirite	O
levles	O
were	O
increaesd	O
.	O

On	O
the	O
other	O
hand	O
,	O
apotpotic	O
mraker	O
,	O
synpatic	O
mrakers	O
,	O
mitochondiral	O
actviity	O
and	O
Ca	O
(	O
2	O
+	O
)	O
levles	O
remained	O
unafefcted	O
.	O

Collective	O
dtaa	O
indicates	O
that	O
nueroinflammatory	B-Disease
porcess	O
and	O
oixdative	O
strses	O
occurs	O
earlier	O
to	O
apoptoiss	O
and	O
does	O
not	O
affect	O
meomry	O
funtcion	O
.	O

Preesnt	O
stduy	O
clearly	O
suggests	O
that	O
gilal	O
activatoin	O
and	O
psot	O
synapitc	O
nuerotoxicity	B-Disease
are	O
the	O
key	O
facotrs	O
in	O
STZ	O
induecd	O
meomry	B-Disease
impairemnt	I-Disease
and	O
neruonal	O
clel	O
detah	O
.	O

Compariosn	O
of	O
efefcts	O
of	O
isotnoic	O
soidum	O
chlordie	O
with	O
diltaizem	O
in	O
prveention	O
of	O
contrast	O
-	O
induecd	O
nephroapthy	B-Disease
.	O

INTRODUCTION	O
AND	O
OBJECTVIE	O
:	O
Cnotrast	O
-	O
induecd	O
neprhopathy	B-Disease
(	O
CIN	O
)	O
significantly	O
incresaes	O
the	O
morbidtiy	O
and	O
mrotality	O
of	O
patinets	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
is	O
to	O
invetsigate	O
and	O
copmare	O
the	O
protective	O
effects	O
of	O
isotoinc	O
soidum	O
cholride	O
with	O
soduim	O
bicarbnoate	O
inufsion	O
and	O
isotoinc	O
sdoium	O
chlordie	O
infusoin	O
with	O
dilitazem	O
,	O
a	O
caclium	O
cahnnel	O
blcoker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
sutdy	O
included	O
pateints	O
who	O
were	O
amdinistered	O
30	O
-	O
60	O
mL	O
of	O
iodinaetd	O
contrast	O
agnet	O
for	O
pecrutaneous	O
cornoary	O
angiogarphy	O
(	O
PACG	O
)	O
,	O
all	O
with	O
creatinnie	O
vaules	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O

Patietns	O
were	O
divided	O
into	O
three	O
gorups	O
and	O
each	O
gruop	O
had	O
20	O
patinets	O
.	O

The	O
first	O
gorup	O
of	O
paitents	O
was	O
adimnistered	O
isotnoic	O
soduim	O
chloirde	O
;	O
the	O
second	O
gorup	O
was	O
adminisetred	O
a	O
soluiton	O
that	O
of	O
5	O
%	O
dextorse	O
and	O
soduim	O
bicarbontae	O
,	O
while	O
the	O
third	O
gorup	O
was	O
adminisetred	O
isootnic	O
sdoium	O
chloirde	O
before	O
and	O
after	O
the	O
contrast	O
ijnection	O
.	O

The	O
third	O
gorup	O
received	O
an	O
additional	O
injcetion	O
of	O
dilitazem	O
the	O
day	O
before	O
and	O
first	O
2	O
dyas	O
after	O
the	O
contrast	O
injeciton	O
.	O

All	O
of	O
the	O
patinets	O
'	O
palsma	O
blood	O
uera	O
nitorgen	O
(	O
BUN	O
)	O
and	O
creatinnie	O
leevls	O
were	O
maesured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administraiton	O
of	O
intravenuos	O
contrast	O
mateiral	O
.	O

RESUTLS	O
:	O
The	O
baasl	O
craetinine	O
leevls	O
were	O
similar	O
for	O
all	O
three	O
gruops	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
paitents	O
included	O
in	O
the	O
stduy	O
,	O
16	O
patietns	O
developed	O
aucte	B-Disease
reanl	I-Disease
faliure	I-Disease
(	O
ARF	B-Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	O
materail	O
was	O
injecetd	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O

The	O
number	O
of	O
pateints	O
who	O
developed	O
ARF	B-Disease
on	O
the	O
second	O
day	O
after	O
the	O
injeciton	O
in	O
the	O
first	O
gorup	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
gruop	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
gorup	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCULSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
istoonic	O
sdoium	O
chlroide	O
,	O
sdoium	O
bicarobnate	O
and	O
istoonic	O
soduim	O
chlordie	O
with	O
diltaizem	O
applictaion	O
in	O
preevntion	O
of	O
CIN	O
.	O

Neurocongitive	O
and	O
neuroradioloigc	O
cnetral	O
nervuos	O
ssytem	O
ltae	O
effcets	O
in	O
chilrden	O
traeted	O
on	O
Pdeiatric	O
Onoclogy	O
Gruop	O
(	O
POG	O
)	O
P6905	O
(	O
stadnard	O
rsik	O
)	O
and	O
P9021	O
(	O
lesesr	O
rsik	O
)	O
aucte	B-Disease
lymphoblsatic	I-Disease
lekuemia	I-Disease
portocols	O
(	O
ACCL0131	O
)	O
:	O
a	O
mtehotrexate	O
consequence	O
?	O

A	O
reoprt	O
from	O
the	O
Chidlren	O
'	O
s	O
Oncolgoy	O
Gorup	O
.	O

Cocnerns	O
about	O
long	O
-	O
term	O
methotreaxte	O
(	O
MTX	O
)	O
nuerotoxicity	B-Disease
in	O
the	O
1990s	O
led	O
to	O
moidfications	O
in	O
intratheacl	O
(	O
IT	O
)	O
tehrapy	O
,	O
leucovroin	O
rescue	O
,	O
and	O
freuqency	O
of	O
ssytemic	O
MTX	O
admiinstration	O
in	O
chilrden	O
with	O
actue	B-Disease
lypmhoblastic	I-Disease
leukeima	I-Disease
.	O

In	O
this	O
sutdy	O
,	O
neurocongitive	O
outcoems	O
and	O
nueroradiologic	O
evidnece	O
of	O
leukoencephaloapthy	B-Disease
were	O
cmopared	O
in	O
chidlren	O
tretaed	O
with	O
intesne	O
centarl	O
nevrous	O
sytsem	O
(	O
CNS	O
)	O
-	O
directed	O
tehrapy	O
(	O
P9065	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
teratment	O
dyas	O
during	O
itnensive	O
cnosolidation	O
(	O
P2901	O
)	O
.	O

A	O
total	O
of	O
66	O
chlidren	O
from	O
16	O
Peditaric	O
Onoclogy	O
Gruop	O
isntitutions	O
with	O
"	O
satndard	O
-	O
rsik	O
"	O
aucte	B-Disease
lymphoblsatic	I-Disease
luekemia	I-Disease
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
yeras	O
at	O
daignosis	O
,	O
without	O
evidnece	O
of	O
CNS	O
luekemia	B-Disease
at	O
diangosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P2901	O
and	O
38	O
from	O
P9065	O
.	O

Mangetic	O
reosnance	O
imaigng	O
scnas	O
and	O
stanadrd	O
neuropyschological	O
tsets	O
were	O
performed	O
>	O
2	O
.	O
6	O
yaers	O
after	O
the	O
end	O
of	O
tretament	O
.	O

Significantly	O
more	O
P6905	O
ptaients	O
developed	O
leukoencephaloapthy	B-Disease
copmared	O
with	O
P9021	O
paitents	O
(	O
68	O
%	O
,	O
95	O
%	O
confiednce	O
intreval	O
49	O
%	O
-	O
83	O
%	O
vs	O
.	O
22	O
%	O
,	O
95	O
%	O
cnofidence	O
intevral	O
5	O
%	O
-	O
44	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
identfiied	O
as	O
ltae	O
as	O
7	O
.	O
7	O
yeras	O
after	O
the	O
end	O
of	O
teratment	O
.	O

Overall	O
,	O
40	O
%	O
of	O
patietns	O
scoerd	O
<	O
85	O
on	O
either	O
Verabl	O
or	O
Perfomrance	O
IQ	O
.	O

Chilrden	O
on	O
both	O
stduies	O
had	O
significant	O
atetntion	B-Disease
porblems	I-Disease
,	O
but	O
P6905	O
chilrden	O
socred	O
below	O
aevrage	O
on	O
more	O
neurocongitive	O
measrues	O
than	O
those	O
traeted	O
on	O
P9021	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
meausres	O
vs	O
.	O
24	O
%	O
,	O
4	O
/	O
17	O
measuers	O
)	O
.	O

This	O
supports	O
ongoing	O
cnocerns	O
about	O
intnesive	O
MTX	O
exposrue	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
ltae	O
effects	O
.	O

Tranxeamic	O
aicd	O
overodsage	O
-	O
indcued	O
generaliezd	O
seizrue	B-Disease
in	O
rneal	B-Disease
failrue	I-Disease
.	O

We	O
reoprt	O
a	O
45	O
-	O
yaer	O
-	O
old	O
lday	O
with	O
chornic	B-Disease
kideny	I-Disease
diesase	I-Disease
stgae	O
4	O
due	O
to	O
crhonic	O
tubuloniterstial	B-Disease
disesae	I-Disease
.	O

She	O
was	O
adimtted	O
to	O
our	O
cneter	O
for	O
seevre	O
aenmia	B-Disease
due	O
to	O
menorhragia	B-Disease
and	O
deteriortaion	B-Disease
of	I-Disease
reanl	I-Disease
functoin	I-Disease
.	O

She	O
was	O
infsued	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
ssesion	O
of	O
hemodialyiss	O
.	O

Tarnexamic	O
aicd	O
(	O
TNA	O
)	O
1	O
g	O
8	O
-	O
horuly	O
was	O
admniistered	O
to	O
her	O
to	O
conrtol	O
beleding	B-Disease
per	O
vaignum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dsoe	O
of	O
TNA	O
,	O
she	O
had	O
an	O
episdoe	O
of	O
geenralized	O
toinc	B-Disease
colnic	I-Disease
conuvlsions	I-Disease
.	O

TNA	O
was	O
disconitnued	O
.	O

Investigatoins	O
of	O
the	O
pateint	O
rveealed	O
no	O
biohcemical	O
or	O
structrual	O
cenrtal	O
nevrous	B-Disease
sytsem	I-Disease
anbormalities	I-Disease
that	O
could	O
have	O
provoked	O
the	O
covnulsions	B-Disease
.	O

She	O
did	O
not	O
require	O
any	O
further	O
diayltic	O
support	O
.	O

She	O
had	O
no	O
further	O
epsiodes	O
of	O
convulsoin	B-Disease
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
mnoths	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
preciiptating	O
cause	O
of	O
covnulsions	B-Disease
was	O
believed	O
to	O
be	O
an	O
oevrdose	B-Disease
of	O
TNA	O
.	O

Pre	O
-	O
teratment	O
of	O
buipvacaine	O
-	O
idnuced	O
cardiovascluar	B-Disease
deperssion	I-Disease
using	O
different	O
liipd	O
forumlations	O
of	O
propfool	O
.	O

BACKGORUND	O
:	O
Pre	O
-	O
treatemnt	O
with	O
lpiid	O
emulisons	O
has	O
been	O
shown	O
to	O
incresae	O
lehtal	O
doess	O
of	O
bupivacanie	O
,	O
and	O
the	O
liipd	O
cotnent	O
of	O
proopfol	O
may	O
alleviate	O
bupivaacine	O
-	O
idnuced	O
cardiotoxictiy	B-Disease
.	O

The	O
aim	O
of	O
this	O
sutdy	O
is	O
to	O
invetsigate	O
the	O
effcets	O
of	O
propoofl	O
in	O
intrailpid	O
or	O
meidalipid	O
eumlsions	O
on	O
bpuivacaine	O
-	O
induecd	O
cardiotoxiicty	B-Disease
.	O

METHODS	O
:	O
Rtas	O
were	O
anaestheitsed	O
with	O
ketmaine	O
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propfool	O
in	O
inrtalipid	O
(	O
Gruop	O
P	O
)	O
,	O
proopfol	O
in	O
medialpiid	O
(	O
Gorup	O
L	O
)	O
,	O
or	O
salnie	O
(	O
Gruop	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacanie	O
0	O
.	O
5	O
%	O
was	O
infuesd	O
.	O

We	O
recorded	O
tmie	O
to	O
first	O
dysrhyhtmia	B-Disease
occurrecne	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reductoin	O
of	O
the	O
haert	O
rtae	O
(	O
HR	O
)	O
and	O
mean	O
atrerial	O
presusre	O
,	O
and	O
tmie	O
to	O
aysstole	B-Disease
and	O
total	O
amonut	O
of	O
bpuivacaine	O
cnosumption	O
.	O

Bolod	O
and	O
tsisue	O
samlpes	O
were	O
collected	O
following	O
aysstole	B-Disease
.	O

REUSLTS	O
:	O
The	O
tmie	O
to	O
first	O
dysrhythima	B-Disease
occurrnece	O
,	O
tmie	O
to	O
25	O
%	O
and	O
50	O
%	O
reductinos	O
in	O
HR	O
,	O
and	O
tmie	O
to	O
asysotle	B-Disease
were	O
longer	O
in	O
Gorup	O
P	O
than	O
the	O
other	O
gruops	O
.	O

The	O
cumluative	O
bupivacanie	O
dsoe	O
given	O
at	O
those	O
tmie	O
points	O
was	O
hgiher	O
in	O
Gruop	O
P	O
.	O
Plsama	O
bupiavcaine	O
levles	O
were	O
significantly	O
lwoer	O
in	O
Gorup	O
P	O
than	O
in	O
Gruop	O
C	O
.	O
Bupviacaine	O
levles	O
in	O
the	O
brian	O
and	O
herat	O
were	O
significantly	O
loewr	O
in	O
Gorup	O
P	O
and	O
Gruop	O
L	O
than	O
in	O
Gorup	O
C	O
.	O

CONCLSUION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
tretament	O
with	O
propoofl	O
in	O
inrtalipid	O
,	O
copmared	O
with	O
propfool	O
in	O
mdeialipid	O
or	O
salnie	O
,	O
dleayed	O
the	O
onset	O
of	O
bupivaacine	O
-	O
inudced	O
cardoitoxic	B-Disease
effetcs	O
as	O
well	O
as	O
rdeuced	O
plsama	O
bupivaacine	O
levles	O
.	O

Further	O
sutdies	O
are	O
needed	O
to	O
explore	O
tisuse	O
bupiavcaine	O
levles	O
of	O
propfool	O
in	O
medailipid	O
and	O
adapt	O
these	O
resluts	O
to	O
cliniacl	O
parctice	O
.	O

Durg	B-Disease
-	I-Disease
Idnuced	I-Disease
Actue	I-Disease
Lievr	I-Disease
Injruy	I-Disease
Within	O
12	O
Huors	O
After	O
Fluavstatin	O
Threapy	O
.	O

Although	O
statnis	O
are	O
generally	O
well	O
-	O
tolearted	O
drgus	O
,	O
recent	O
caess	O
of	O
durg	B-Disease
-	I-Disease
inudced	I-Disease
lievr	I-Disease
injruy	I-Disease
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52	O
-	O
yaer	O
-	O
old	O
Chinsee	O
man	O
reported	O
with	O
lvier	B-Disease
damgae	I-Disease
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
traetment	O
with	O
fluvatsatin	O
.	O

Paitent	O
presented	O
with	O
complanits	O
of	O
increasnig	O
nasuea	B-Disease
,	O
anoerxia	B-Disease
,	O
and	O
upepr	O
abdomnial	B-Disease
pian	I-Disease
.	O

His	O
lbaoratory	O
valeus	O
showed	O
elevtaed	O
creaitne	O
kianse	O
and	O
trnasaminases	O
.	O

Testnig	O
for	O
autonatibodies	O
was	O
also	O
negtaive	O
.	O

The	O
lievr	O
biocheimstries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvatsatin	O
.	O

Therefore	O
,	O
when	O
perscribing	O
statnis	O
,	O
the	O
possibility	O
of	O
hpeatic	B-Disease
daamge	I-Disease
should	O
be	O
taken	O
into	O
account	O
.	O

Flcuonazole	O
associated	O
agranulocytsois	B-Disease
and	O
thrombocytopeina	B-Disease
.	O

CSAE	O
:	O
We	O
describe	O
a	O
second	O
csae	O
of	O
flcuonazole	O
associated	O
agranulcoytosis	B-Disease
with	O
thormbocytopenia	B-Disease
and	O
recvoery	O
upon	O
discontinaution	O
of	O
thearpy	O
.	O

The	O
paitent	O
began	O
to	O
have	O
cahnges	O
in	O
wihte	O
bolod	O
clels	O
and	O
plateltes	O
within	O
48	O
h	O
of	O
administrtaion	O
of	O
fluocnazole	O
and	O
began	O
to	O
recvoer	O
with	O
48	O
h	O
of	O
discontniuation	O
.	O

This	O
csae	O
highlights	O
that	O
durg	O
-	O
indcued	O
blood	B-Disease
dsycrasias	I-Disease
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
teratment	O
with	O
a	O
commonly	O
used	O
durg	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

CONCLSUION	O
:	O
According	O
to	O
Naarnjo	O
'	O
s	O
algoirthm	O
the	O
likelhiood	O
that	O
our	O
pateint	O
'	O
s	O
agarnulocytosis	B-Disease
and	O
thrombcoytopenia	B-Disease
occurred	O
as	O
a	O
result	O
of	O
threapy	O
with	O
flucnoazole	O
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
weihgt	O
of	O
the	O
overall	O
evdience	O
of	O
this	O
evidecne	O
is	O
strong	O
.	O

In	O
particular	O
the	O
tempoarl	O
relatiosnhip	O
of	O
bnoe	B-Disease
mrarow	I-Disease
suppresison	I-Disease
to	O
the	O
inititaion	O
of	O
fluconazloe	O
and	O
the	O
abaetment	O
of	O
sypmtoms	O
that	O
rapidly	O
revresed	O
immediately	O
following	O
discnotinuation	O
.	O

Two	O
-	O
dimenisonal	O
speclke	O
tracikng	O
echocaridography	O
cmobined	O
with	O
high	O
-	O
senistive	O
cadriac	O
torponin	O
T	O
in	O
ealry	O
detcetion	O
and	O
predcition	O
of	O
cadriotoxicity	B-Disease
during	O
epirubicnie	O
-	O
based	O
chmeotherapy	O
.	O

AMIS	O
:	O
To	O
investgiate	O
whether	O
aletrations	O
of	O
moycardial	B-Disease
srtain	I-Disease
and	O
high	O
-	O
senstiive	O
cardaic	O
tropnoin	O
T	O
(	O
cnTT	O
)	O
could	O
predict	O
future	O
cardaic	B-Disease
dyfsunction	I-Disease
in	O
patietns	O
after	O
epirubciin	O
expousre	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
paitents	O
with	O
non	B-Disease
-	I-Disease
Hogdkin	I-Disease
lympohma	I-Disease
terated	O
with	O
epirubiicn	O
were	O
studied	O
.	O

Bolod	O
collcetion	O
and	O
echoacrdiography	O
were	O
performed	O
at	O
basleine	O
,	O
1	O
day	O
after	O
the	O
third	O
cylce	O
,	O
and	O
1	O
day	O
after	O
comlpetion	O
of	O
chemothreapy	O
.	O

Ptaients	O
were	O
studied	O
using	O
echocardigoraphy	O
during	O
follow	O
-	O
up	O
.	O

Glboal	O
longituidnal	O
(	O
GLS	O
)	O
,	O
cicrumferential	O
(	O
GCS	O
)	O
,	O
and	O
radail	O
srtain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
spekcle	O
tracikng	O
echocardiorgaphy	O
.	O

Lfet	O
vetnricular	O
ejectoin	O
fraciton	O
was	O
anlaysed	O
by	O
real	O
-	O
tmie	O
3D	O
echocadriography	O
.	O

Cradiotoxicity	B-Disease
was	O
defined	O
as	O
a	O
rdeuction	O
of	O
the	O
LEVF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
smyptoms	O
of	O
herat	B-Disease
failrue	I-Disease
or	O
an	O
asmyptomatic	O
reduciton	O
of	O
the	O
LEVF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RSEULTS	O
:	O
Fourteen	O
pateints	O
(	O
18	O
.	O
67	O
%	O
)	O
developed	O
cardiotoxciity	B-Disease
after	O
tretament	O
.	O

GLS	O
(	O
-	O
18	O
.	O
48	O
+	O
1	O
.	O
72	O
%	O
vs	O
.	O
-	O
15	O
.	O
96	O
+	O
1	O
.	O
6	O
%	O
)	O
,	O
GCS	O
(	O
-	O
20	O
.	O
93	O
+	O
2	O
.	O
86	O
%	O
vs	O
.	O
-	O
19	O
.	O
20	O
+	O
3	O
.	O
21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39	O
.	O
23	O
+	O
6	O
.	O
44	O
%	O
vs	O
.	O
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%	O
)	O
were	O
markedly	O
reudced	O
and	O
cnTT	O
was	O
eelvated	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
compeltion	O
of	O
chemohterapy	O
comapred	O
with	O
basleine	O
vlaues	O
.	O

A	O
>	O
15	O
.	O
9	O
%	O
dcerease	O
in	O
GLS	O
[	O
sesnitivity	O
,	O
86	O
%	O
;	O
specifiicty	O
,	O
75	O
%	O
;	O
aera	O
under	O
the	O
cuvre	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
elevtaion	O
in	O
cnTT	O
(	O
sensitivtiy	O
,	O
79	O
%	O
;	O
speciifcity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
bsaeline	O
to	O
the	O
third	O
ccyle	O
of	O
chemtoherapy	O
predicetd	O
later	O
cardoitoxicity	B-Disease
.	O

The	O
dercease	O
in	O
GLS	O
remained	O
the	O
only	O
inedpendent	O
preidctor	O
of	O
cardiotxoicity	B-Disease
(	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

CONCLUSOINS	O
:	O
GLS	O
combnied	O
with	O
cnTT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
ivnasive	O
metohd	O
to	O
predict	O
cradiac	B-Disease
dysfucntion	I-Disease
in	O
ptaients	O
receiving	O
antharcycline	O
-	O
based	O
chmeotherapy	O
.	O

Pervention	O
of	O
etomiadte	O
-	O
induecd	O
myoclouns	B-Disease
:	O
which	O
is	O
superior	O
:	O
Fnetanyl	O
,	O
mdiazolam	O
,	O
or	O
a	O
cobmination	O
?	O

A	O
Retorspective	O
comparative	O
sutdy	O
.	O

BCAKGROUND	O
:	O
In	O
this	O
retrospetcive	O
comparative	O
sutdy	O
,	O
we	O
aimed	O
to	O
comprae	O
the	O
effectivneess	O
of	O
fenatnyl	O
,	O
midazloam	O
,	O
and	O
a	O
cmobination	O
of	O
fentnayl	O
and	O
miadzolam	O
to	O
prveent	O
etoimdate	O
-	O
indcued	O
mycolonus	B-Disease
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
sutdy	O
was	O
performed	O
based	O
on	O
ansethesia	O
recodrs	O
.	O

Depending	O
on	O
the	O
drgus	O
that	O
would	O
be	O
given	O
before	O
the	O
indutcion	O
of	O
ansethesia	O
with	O
etoimdate	O
,	O
the	O
pateints	O
were	O
sepraated	O
into	O
4	O
gruops	O
:	O
no	O
pertreatment	O
(	O
Gorup	O
NP	O
)	O
,	O
fentnayl	O
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Gruop	O
F	O
)	O
,	O
midazoalm	O
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Gorup	O
M	O
)	O
,	O
and	O
miadzolam	O
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fentaynl	O
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Gruop	O
FM	O
)	O
.	O

Patietns	O
who	O
received	O
the	O
same	O
anestehtic	O
proceudre	O
were	O
selected	O
:	O
2	O
mintues	O
after	O
intarvenous	O
injecitons	O
of	O
the	O
prerteatment	O
drgus	O
,	O
anestehsia	O
is	O
induecd	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
etmoidate	O
injceted	O
intravenosuly	O
over	O
a	O
preiod	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Mycolonic	B-Disease
movmeents	I-Disease
are	O
eavluated	O
,	O
which	O
were	O
observed	O
and	O
garded	O
according	O
to	O
cliniacl	O
severtiy	O
during	O
the	O
2	O
minuets	O
after	O
etomiadte	O
injcetion	O
.	O

The	O
sevreity	O
of	O
pian	B-Disease
due	O
to	O
eotmidate	O
injetcion	O
,	O
mean	O
atrerial	O
prsesure	O
,	O
herat	O
rtae	O
,	O
and	O
advesre	O
effetcs	O
were	O
also	O
eavluated	O
.	O

RSEULTS	O
:	O
Sutdy	O
resluts	O
showed	O
that	O
myoclouns	B-Disease
incidecne	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Gruop	O
NP	O
,	O
Gorup	O
F	O
,	O
Gorup	O
M	O
,	O
and	O
Gruop	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lwoer	O
in	O
Gorup	O
F	O
and	O
Gruop	O
FM	O
.	O

CNOCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretraetment	O
with	O
fentnayl	O
or	O
cobmination	O
of	O
fentnayl	O
and	O
midaozlam	O
was	O
effectvie	O
in	O
preventing	O
etomdiate	O
-	O
idnuced	O
myocolnus	B-Disease
.	O

Convuslant	O
effect	O
of	O
lnidane	O
and	O
rgeional	O
brian	O
concetnration	O
of	O
GBAA	O
and	O
doapmine	O
.	O

Lnidane	O
(	O
gmama	O
-	O
hexacholrocyclohexane	O
)	O
is	O
an	O
organocholrine	O
insectciide	O
with	O
known	O
neurotoixc	B-Disease
effects	O
.	O

Its	O
mecahnism	O
of	O
atcion	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindnae	O
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagnoist	O
at	O
the	O
gamma	O
-	O
amniobutyric	O
aicd	O
(	O
GBAA	O
)	O
-	O
A	O
recepotr	O
.	O

We	O
studied	O
the	O
effcet	O
of	O
linadne	O
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAegric	O
and	O
dopaminegric	O
sysetms	O
by	O
mesauring	O
the	O
cocnentration	O
of	O
GBAA	O
,	O
dopmaine	O
and	O
its	O
metaboiltes	O
in	O
7	O
brian	O
areas	O
at	O
the	O
onset	O
of	O
seizrues	B-Disease
.	O

All	O
animlas	O
suffered	O
tnoic	O
convlusions	B-Disease
at	O
18	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
min	O
after	O
linadne	O
admniistration	O
.	O

The	O
concenrtation	O
of	O
GBAA	O
was	O
only	O
slightly	O
but	O
significantly	O
decraesed	O
in	O
the	O
colliucli	O
without	O
modifictaions	O
in	O
the	O
other	O
areas	O
.	O

The	O
concetnration	O
of	O
doapmine	O
was	O
incresaed	O
in	O
the	O
mesencpehalon	O
and	O
that	O
of	O
its	O
metaboltie	O
DOAPC	O
was	O
also	O
icnreased	O
in	O
the	O
mesencephlaon	O
and	O
the	O
stritaum	O
.	O

Cohlestatic	B-Disease
prseentation	O
of	O
yelolw	O
phosphours	O
poisnoing	B-Disease
.	O

Yelolw	O
phoshporus	O
,	O
a	O
component	O
of	O
certain	O
pesitcide	O
patses	O
and	O
firweorks	O
,	O
is	O
well	O
known	O
to	O
cause	O
heptaotoxicity	B-Disease
.	O

Posioning	B-Disease
with	O
yellow	O
phopshorus	O
classically	O
manifests	O
with	O
aucte	B-Disease
hpeatitis	I-Disease
leading	O
to	O
actue	B-Disease
lvier	I-Disease
faiulre	I-Disease
which	O
may	O
need	O
lievr	O
transplanttaion	O
.	O

We	O
present	O
a	O
csae	O
of	O
yelolw	O
phosphrous	O
poisonnig	B-Disease
in	O
which	O
a	O
patinet	O
presented	O
with	O
floird	O
cliincal	O
featuers	O
of	O
cholsetasis	B-Disease
highlighting	O
the	O
fact	O
that	O
chloestasis	B-Disease
can	O
rarely	O
be	O
a	O
persenting	O
feature	O
of	O
yelolw	O
phospohrus	O
hepatotoxiicty	B-Disease
.	O

Vsaovagal	B-Disease
snycope	I-Disease
and	O
sevree	O
bradcyardia	B-Disease
following	O
intransaal	O
dexmeedtomidine	O
for	O
pdeiatric	O
porcedural	O
sedtaion	O
.	O

We	O
reoprt	O
syncpoe	B-Disease
and	O
bradcyardia	B-Disease
in	O
an	O
11	O
-	O
yaer	O
-	O
old	O
gril	O
following	O
admniistration	O
of	O
intrnaasal	O
dexmeedtomidine	O
for	O
sdeation	O
for	O
a	O
voidnig	O
cytsourethrogram	O
.	O

Following	O
successful	O
cmopletion	O
of	O
VUCG	O
and	O
a	O
60	O
-	O
min	O
recoevry	O
peroid	O
,	O
the	O
paitent	O
'	O
s	O
lveel	O
of	O
cosnciousness	O
and	O
vital	O
sgins	O
returned	O
to	O
preesdation	O
leevls	O
.	O

Upon	O
leaving	O
the	O
sedaiton	O
aera	O
,	O
the	O
ptaient	O
clolapsed	O
,	O
with	O
no	O
appraent	O
icniting	O
eevnt	O
.	O

The	O
patinet	O
quickly	O
reganied	O
consciuosness	O
and	O
no	O
inujry	O
occurred	O
.	O

The	O
priamry	O
abnormailty	O
found	O
was	O
persisetnt	O
brdaycardia	B-Disease
,	O
and	O
she	O
was	O
adimtted	O
to	O
the	O
hsopital	O
for	O
teelmetric	O
observaiton	O
.	O

The	O
bradycadria	B-Disease
lasted	O
~	O
2	O
h	O
,	O
and	O
further	O
cadriac	O
wrokup	O
reevaled	O
no	O
underlying	O
abonrmality	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
ouctomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatievs	O
to	O
atlernative	O
ruotes	O
of	O
admniistration	O
.	O

Praadoxical	O
seevre	O
agittaion	B-Disease
idnuced	O
by	O
add	O
-	O
on	O
high	O
-	O
doess	O
quetipaine	O
in	O
schizo	B-Disease
-	I-Disease
afefctive	I-Disease
disoredr	I-Disease
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
35	O
-	O
yaer	O
-	O
old	O
ptaient	O
suffernig	O
from	O
schizo	B-Disease
-	I-Disease
affectvie	I-Disease
diosrder	I-Disease
since	O
the	O
age	O
of	O
19	O
yeras	O
,	O
traeted	O
by	O
a	O
cmobination	O
of	O
first	O
-	O
generatoin	O
atnipsychotics	O
,	O
zuclpoenthixol	O
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
litihum	O
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
seurm	O
litihum	O
=	O
0	O
.	O
85	O
mEq	O
/	O
l	O
)	O
.	O

This	O
pateint	O
had	O
no	O
associated	O
perosnality	B-Disease
dsiorder	I-Disease
(	O
particularly	O
no	O
antiscoial	B-Disease
diosrder	I-Disease
)	O
and	O
no	O
susbtance	B-Disease
absue	I-Disease
disodrer	I-Disease
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gardual	O
introudction	O
of	O
quteiapine	O
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
ptaient	O
presented	O
seevre	O
agittaion	B-Disease
without	O
an	O
envrionmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
asbence	O
of	O
a	O
hisotry	O
of	O
aggressiveenss	B-Disease
or	O
perosnality	B-Disease
dsiorder	I-Disease
.	O

The	O
diganoses	O
of	O
mnaic	B-Disease
shift	O
and	O
akahtisia	B-Disease
were	O
dismissed	O
.	O

The	O
withdarwal	O
and	O
the	O
graudal	O
reintrodutcion	O
of	O
qeutiapine	O
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
sevree	O
agitaiton	B-Disease
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agiattion	B-Disease
specifically	O
to	O
qeutiapine	O
.	O

Anitoxidant	O
effcets	O
of	O
boivne	O
lacotferrin	O
on	O
dxeamethasone	O
-	O
induecd	O
hpyertension	B-Disease
in	O
rat	O
.	O

Dexamethaosne	O
-	O
(	O
Dex	O
-	O
)	O
inudced	O
hyperetnsion	B-Disease
is	O
associated	O
with	O
enahnced	O
oxidaitve	O
sterss	O
.	O

Lactoferirn	O
(	O
LF	O
)	O
is	O
an	O
iorn	O
-	O
bniding	O
glycoportein	O
with	O
antihypertensvie	O
porperties	O
.	O

In	O
this	O
stduy	O
,	O
we	O
investiagted	O
the	O
effect	O
of	O
chornic	O
adminitsration	O
of	O
LF	O
on	O
oxiadtive	O
sterss	O
and	O
hypertnesion	B-Disease
upon	O
Dex	O
administratoin	O
.	O

Mlae	O
Witsar	O
rtas	O
were	O
terated	O
by	O
Dex	O
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
sbucutaneously	O
)	O
or	O
salnie	O
for	O
14	O
dyas	O
.	O

Oarl	O
bovnie	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
rveersal	O
sutdy	O
.	O

In	O
a	O
pervention	O
stduy	O
,	O
rtas	O
received	O
4	O
dyas	O
of	O
LF	O
teratment	O
followed	O
by	O
Dex	O
and	O
continued	O
during	O
the	O
tset	O
peroid	O
.	O

Sytsolic	O
bolod	O
prsesure	O
(	O
SBP	O
)	O
was	O
meausred	O
using	O
tial	O
-	O
cfuf	O
metohd	O
.	O

Thyums	O
weihgt	O
was	O
used	O
as	O
a	O
mraker	O
of	O
glucocoritcoid	O
acitvity	O
.	O

Plamsa	O
hydrgoen	O
peroixde	O
(	O
HO22	O
)	O
concetnration	O
and	O
freric	O
reducnig	O
antioxdiant	O
pwoer	O
(	O
FARP	O
)	O
value	O
were	O
determined	O
.	O

Dexamehtasone	O
significantly	O
incresaed	O
SBP	O
and	O
palsma	O
HO22	O
leevl	O
and	O
decreaesd	O
thyums	O
and	O
bdoy	O
weights	O
.	O

LF	O
loewred	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dsoe	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	O
-	O
indcued	O
hpyertension	B-Disease
.	O

LF	O
prevented	O
bdoy	O
wieght	B-Disease
lsos	I-Disease
and	O
significantly	O
reudced	O
the	O
eelvated	O
palsma	O
HO22	O
and	O
incresaed	O
FARP	O
vlaues	O
.	O

Chornic	O
admniistration	O
of	O
LF	O
strongly	O
reudced	O
the	O
blood	O
perssure	O
and	O
produciton	O
of	O
ROS	O
and	O
imprvoed	O
atnioxidant	O
capactiy	O
in	O
Dex	O
-	O
induecd	O
hypertnesion	B-Disease
,	O
suggesting	O
the	O
role	O
of	O
inhbiition	O
of	O
oxidtaive	O
srtess	O
as	O
another	O
mechnaism	O
of	O
antihypertesnive	O
aciton	O
of	O
LF	O
.	O

The	O
assocaition	O
between	O
tranexaimc	O
aicd	O
and	O
convulisve	B-Disease
seiuzres	B-Disease
after	O
caridac	O
surgrey	O
:	O
a	O
multivairate	O
analyiss	O
in	O
11	O
529	O
patinets	O
.	O

Because	O
of	O
a	O
lcak	O
of	O
contemporary	O
dtaa	O
regarding	O
seziures	B-Disease
after	O
cradiac	O
suregry	O
,	O
we	O
undertook	O
a	O
retrsopective	O
anlaysis	O
of	O
prospectively	O
collected	O
dtaa	O
from	O
11	O
529	O
ptaients	O
in	O
whom	O
cardoipulmonary	O
bypsas	O
was	O
used	O
from	O
Jnauary	O
2004	O
to	O
December	O
2010	O
.	O

A	O
conuvlsive	B-Disease
seziure	B-Disease
was	O
defined	O
as	O
a	O
transeint	O
episdoe	O
of	O
ditsurbed	O
brian	O
functoin	O
charactreised	O
by	O
abnomral	B-Disease
involnutary	I-Disease
mtoor	I-Disease
moveemnts	I-Disease
.	O

Mulitvariate	O
regrsesion	O
analyiss	O
was	O
performed	O
to	O
identify	O
idnependent	O
perdictors	O
of	O
postopreative	O
seizuers	B-Disease
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
ptaients	O
developed	O
posotperative	O
covnulsive	B-Disease
seiuzres	B-Disease
.	O

Generalsied	B-Disease
and	I-Disease
fcoal	I-Disease
seziures	I-Disease
were	O
identfiied	O
in	O
68	O
and	O
32	O
pateints	O
,	O
respectively	O
.	O

The	O
meidan	O
(	O
IQR	O
[	O
range	O
]	O
)	O
tmie	O
after	O
suregry	O
when	O
the	O
seziure	B-Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptfiorm	O
findnigs	O
on	O
electorencephalography	O
were	O
seen	O
in	O
19	O
pateints	O
.	O

Indepenednt	O
prdeictors	O
of	O
postopreative	O
siezures	B-Disease
included	O
age	O
,	O
femlae	O
sex	O
,	O
rdeo	O
caridac	O
srugery	O
,	O
calcfiication	O
of	O
ascendnig	O
aotra	O
,	O
congetsive	B-Disease
haert	I-Disease
fialure	I-Disease
,	O
deep	O
hypotehrmic	B-Disease
circluatory	O
arrset	O
,	O
druation	O
of	O
aotric	O
corss	O
-	O
calmp	O
and	O
traenxamic	O
aicd	O
.	O

When	O
tesetd	O
in	O
a	O
multivaritae	O
rgeression	O
anaylsis	O
,	O
traenxamic	O
aicd	O
was	O
a	O
strong	O
idnependent	O
predcitor	O
of	O
seizuers	B-Disease
(	O
OR	O
14	O
.	O
3	O
,	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Pateints	O
with	O
convuslive	B-Disease
seiuzres	B-Disease
had	O
2	O
.	O
5	O
times	O
higehr	O
in	O
-	O
hsopital	O
mrotality	O
rtaes	O
and	O
twice	O
the	O
lnegth	O
of	O
hsopital	O
stay	O
compaerd	O
with	O
pateints	O
without	O
convulsvie	B-Disease
seiuzres	B-Disease
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
lentgh	O
of	O
stay	O
in	O
the	O
inetnsive	O
crae	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patinets	O
with	O
covnulsive	B-Disease
siezures	B-Disease
compraed	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
pateints	O
without	O
seizrues	B-Disease
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Convulsvie	B-Disease
seizrues	B-Disease
are	O
a	O
serious	O
postoperaitve	B-Disease
compilcation	I-Disease
after	O
cadriac	O
suregry	O
.	O

As	O
tarnexamic	O
aicd	O
is	O
the	O
only	O
mdoifiable	O
fcator	O
,	O
its	O
adminitsration	O
,	O
particularly	O
in	O
dsoes	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
rsik	O
of	O
postopeartive	O
seizrues	B-Disease
.	O

Dysfucntional	B-Disease
overnight	I-Disease
meomry	I-Disease
consloidation	O
in	O
ectsasy	O
uesrs	O
.	O

Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consoliadtion	O
and	O
intergation	O
of	O
meomry	O
in	O
a	O
proecss	O
called	O
overnight	O
memroy	O
consolidtaion	O
.	O

Previous	O
sutdies	O
indicate	O
that	O
ecsatsy	O
uesrs	O
have	O
marked	O
and	O
presistent	O
neuroocgnitive	O
and	O
sleep	B-Disease
-	I-Disease
related	I-Disease
imapirments	I-Disease
.	O

We	O
extend	O
past	O
reesarch	O
by	O
examining	O
overnight	O
meomry	O
cosnolidation	O
among	O
regular	O
ecstsay	O
usres	O
(	O
n	O
=	O
12	O
)	O
and	O
durg	O
niave	O
healhty	O
cnotrols	O
(	O
n	O
=	O
26	O
)	O
.	O

Mmeory	O
rceall	O
of	O
wrod	O
piars	O
was	O
eavluated	O
before	O
and	O
after	O
a	O
peroid	O
of	O
selep	O
,	O
with	O
and	O
without	O
itnerference	O
prior	O
to	O
tesitng	O
.	O

In	O
addition	O
,	O
we	O
assesesd	O
neuroocgnitive	O
preformances	O
across	O
takss	O
of	O
learinng	O
,	O
memroy	O
and	O
executvie	O
fucntioning	O
.	O

Ecstsay	O
uesrs	O
demonstrated	O
imparied	B-Disease
overnight	I-Disease
memroy	I-Disease
consolidaiton	O
,	O
a	O
findnig	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
intefrerence	O
.	O

Additionally	O
,	O
ecstsay	O
uesrs	O
demonstrated	O
impiarments	O
on	O
takss	O
rercuiting	O
frontsotriatal	O
and	O
hippocmapal	O
nueral	O
circuirty	O
,	O
in	O
the	O
domians	O
of	O
proacitve	O
intefrerence	O
mmeory	O
,	O
long	O
-	O
term	O
meomry	O
,	O
ecnoding	O
,	O
worikng	O
meomry	O
and	O
comlpex	O
plnaning	O
.	O

We	O
suggest	O
that	O
esctasy	O
-	O
associated	O
dysufnction	O
in	O
frnoto	O
-	O
temproal	O
cicruitry	O
may	O
underlie	O
overnight	O
consoildation	O
memroy	B-Disease
impairmnets	I-Disease
in	O
regular	O
esctasy	O
uesrs	O
.	O

Nomroammonemic	O
encpehalopathy	B-Disease
:	O
solely	O
vlaproate	O
inudced	O
or	O
mlutiple	O
mechansims	O
?	O

A	O
77	O
-	O
yaer	O
-	O
old	O
wmoan	O
presented	O
with	O
subaucte	O
onset	O
porgressive	O
confuison	B-Disease
,	O
aggresison	B-Disease
,	O
auidtory	B-Disease
halulcinations	I-Disease
and	O
deulsions	B-Disease
.	O

In	O
the	O
preceding	O
mnoths	O
,	O
the	O
paitent	O
had	O
a	O
number	O
of	O
admissinos	O
with	O
tarnsient	O
unliateral	O
heimparesis	B-Disease
with	O
fcaial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
vaplroate	O
for	O
presumed	O
hempilegic	B-Disease
migriane	I-Disease
.	O

Vlaproate	O
was	O
withdrawn	O
soon	O
after	O
amdission	O
and	O
her	O
congitive	O
abiliteis	O
have	O
gradually	O
imporved	O
over	O
3	O
monhts	O
of	O
follow	O
-	O
up	O
.	O

Valrpoate	O
leevls	O
taken	O
prior	O
to	O
withdarwal	O
were	O
subthreapeutic	O
and	O
the	O
ptaient	O
was	O
normaommonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatinet	O
stay	O
showed	O
chanegs	O
consistent	O
with	O
ecnephalopathy	B-Disease
,	O
and	O
low	O
tirte	O
N	O
-	O
mehtyl	O
-	O
D	O
-	O
asaprtate	O
(	O
NDMA	O
)	O
recetpor	O
atnibodies	O
were	O
present	O
in	O
this	O
patinet	O
.	O

The	O
possible	O
aetiologeis	O
of	O
vlaproate	O
-	O
induecd	O
encephlaopathy	B-Disease
and	O
NDMA	O
reecptor	O
-	O
associated	O
encephailtis	B-Disease
present	O
a	O
diagnositc	O
dielmma	O
.	O

We	O
present	O
a	O
putative	O
combinatoiral	O
hyopthesis	O
to	O
explain	O
this	O
ptaient	O
'	O
s	O
symptmos	O
.	O

Creebellar	B-Disease
and	I-Disease
oculomtoor	I-Disease
dysfuntcion	I-Disease
indcued	O
by	O
rpaid	O
inufsion	O
of	O
pethiidne	O
.	O

Petihdine	O
is	O
an	O
oipoid	O
that	O
ganis	O
its	O
ppoularity	O
for	O
the	O
efefctive	O
pian	B-Disease
cotnrol	O
through	O
acting	O
on	O
the	O
opiiod	O
-	O
receptros	O
.	O

However	O
,	O
rpaid	O
pian	B-Disease
reilef	O
sometimes	O
brings	O
about	O
unfavoruable	O
side	O
effcets	O
that	O
largely	O
liimt	O
its	O
clincial	O
utility	O
.	O

Common	O
side	O
efefcts	O
include	O
nauesa	B-Disease
,	O
vomtiing	B-Disease
and	O
hypotenison	B-Disease
.	O

In	O
ptaients	O
with	O
imparied	B-Disease
rneal	I-Disease
and	I-Disease
lievr	I-Disease
funciton	I-Disease
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
pian	B-Disease
conrtol	O
,	O
pethdiine	O
may	O
cause	O
exictatory	O
cenrtal	O
nevrous	O
ssytem	O
(	O
CNS	O
)	O
effcets	O
through	O
its	O
neuortoxic	B-Disease
metbaolite	O
,	O
noprethidine	O
,	O
resulting	O
in	O
irritaiblity	B-Disease
and	O
siezure	B-Disease
attcak	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
cilnically	O
apparent	O
,	O
pethiidne	O
potentially	O
causes	O
inhiibtory	O
imapcts	O
on	O
the	O
CNS	O
and	O
imparis	O
nromal	O
cerebellar	O
and	O
oculmootor	O
fnuction	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
csae	O
reoprt	O
,	O
we	O
highlight	O
oipoid	O
'	O
s	O
inhiibtory	O
side	O
efefcts	O
on	O
the	O
cerbeellar	O
structrue	O
that	O
causes	O
dsymetria	B-Disease
,	O
dysarhtria	B-Disease
,	O
rdeuced	O
somoth	O
prusuit	O
gain	O
and	O
dcereased	O
scacadic	O
veloctiy	O
.	O

Baobon	B-Disease
snydrome	I-Disease
inudced	O
by	O
ketoocnazole	O
.	O

A	O
27	O
-	O
yaer	O
-	O
old	O
mlae	O
ptaient	O
presented	O
with	O
a	O
maculopauplar	B-Disease
eruptoin	I-Disease
on	O
the	O
flexrual	O
areas	O
and	O
buttokcs	O
after	O
using	O
oarl	O
ketocoanzole	O
.	O

The	O
paitent	O
was	O
daignosed	O
with	O
durg	O
-	O
idnuced	O
baboon	B-Disease
syndorme	I-Disease
based	O
on	O
his	O
hitsory	O
,	O
which	O
included	O
prior	O
senistivity	O
to	O
tpoical	O
ketoconaozle	O
,	O
a	O
pyhsical	O
exaimnation	O
,	O
and	O
histopatohlogical	O
finidngs	O
.	O

Baobon	B-Disease
syndorme	I-Disease
is	O
a	O
durg	O
-	O
or	O
contcat	O
allregen	O
-	O
related	O
mauclopapular	B-Disease
eurption	I-Disease
that	O
typically	O
involves	O
the	O
flxeural	O
and	O
gluetal	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowldege	O
,	O
this	O
is	O
the	O
first	O
reported	O
csae	O
of	O
ketoconazloe	O
-	O
induecd	O
baboon	B-Disease
syndorme	I-Disease
in	O
the	O
Enlgish	O
literautre	O
.	O

A	O
Csae	O
of	O
Sudedn	B-Disease
Cadriac	I-Disease
Detah	I-Disease
due	O
to	O
Plisicainide	O
-	O
Indcued	O
Torsaeds	B-Disease
de	I-Disease
Ponites	I-Disease
.	O

An	O
84	O
-	O
yaer	O
-	O
old	O
mlae	O
received	O
oarl	O
pilsicaiinde	O
,	O
a	O
pure	O
soidum	O
chnanel	O
blokcer	O
with	O
slow	O
reocvery	O
kinetcis	O
,	O
to	O
convert	O
his	O
paroyxsmal	O
artial	B-Disease
fibrilltaion	I-Disease
to	O
a	O
siuns	O
rhtyhm	O
;	O
the	O
ptaient	O
developed	O
sduden	B-Disease
cadriac	I-Disease
detah	I-Disease
two	O
dyas	O
later	O
.	O

The	O
Hotler	O
electrocaridogram	O
,	O
which	O
was	O
wron	O
by	O
chance	O
,	O
reevaled	O
torsdae	B-Disease
de	I-Disease
poinets	I-Disease
with	O
gradually	O
prolnoged	O
QT	O
itnervals	O
.	O

This	O
durg	O
is	O
rapidly	O
absrobed	O
from	O
the	O
gastorintestinal	O
trcat	O
,	O
and	O
most	O
of	O
it	O
is	O
ecxreted	O
from	O
the	O
kindey	O
.	O

Although	O
the	O
paitent	O
'	O
s	O
reanl	O
funtcion	O
was	O
not	O
highly	O
impaierd	O
and	O
the	O
dsoe	O
of	O
pilsicaiinde	O
was	O
low	O
,	O
the	O
plsama	O
concenrtation	O
of	O
pilsicianide	O
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsaeds	B-Disease
de	I-Disease
ponites	I-Disease
in	O
the	O
octoegnarian	O
.	O

Although	O
the	O
oarl	O
adimnistration	O
of	O
calss	O
IC	O
durgs	O
,	O
including	O
pilsicaindie	O
,	O
is	O
efefctive	O
to	O
terimnate	O
artial	B-Disease
fibrlilation	I-Disease
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
durgs	O
to	O
ocotgenarians	O
.	O

All	O
-	O
tarns	O
reitnoic	O
aicd	O
-	O
inudced	O
inflammatory	O
mysoitis	B-Disease
in	O
a	O
pateint	O
with	O
actue	B-Disease
pormyelocytic	I-Disease
leukeima	I-Disease
.	O

All	O
-	O
tarns	O
retionic	O
aicd	O
(	O
ARTA	O
)	O
,	O
a	O
component	O
of	O
satndard	O
threapy	O
for	O
actue	B-Disease
pormyelocytic	I-Disease
leuekmia	I-Disease
(	O
APL	B-Disease
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treaatble	O
advrese	O
effetcs	O
involving	O
numerous	O
oragn	O
systmes	O
,	O
including	O
rrae	O
skeeltal	O
muslce	O
involveemnt	O
.	O

Only	O
a	O
handful	O
of	O
caess	O
of	O
ARTA	O
-	O
indcued	O
moysitis	B-Disease
in	O
cihldren	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radoilogy	O
literautre	O
.	O

We	O
present	O
such	O
a	O
csae	O
in	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
APL	B-Disease
,	O
where	O
recogntiion	O
of	O
iamging	O
finidngs	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnsois	O
and	O
facilitated	O
prompt	O
,	O
effective	O
teratment	O
.	O

Tolreability	O
of	O
lomsutine	O
in	O
combintaion	O
with	O
cyclophsophamide	O
in	O
dgos	O
with	O
lypmhoma	B-Disease
.	O

This	O
retropsective	O
sutdy	O
describes	O
toxictiy	B-Disease
associated	O
with	O
a	O
protoocl	O
of	O
lomutsine	O
(	O
CNCU	O
)	O
and	O
cyclophospahmide	O
(	O
CTX	O
)	O
in	O
dgos	O
with	O
lmyphoma	B-Disease
.	O

CNCU	O
was	O
adimnistered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
tagreted	O
dsoage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
bdoy	O
surfcae	O
aera	O
on	O
day	O
0	O
,	O
CTX	O
was	O
admniistered	O
PO	O
at	O
a	O
taregted	O
dsoage	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
dyas	O
0	O
through	O
4	O
,	O
and	O
all	O
dgos	O
received	O
prpohylactic	O
atnibiotics	O
.	O

Ninety	O
tretaments	O
were	O
given	O
to	O
the	O
57	O
dgos	O
included	O
in	O
the	O
sutdy	O
.	O

Neutropneia	B-Disease
was	O
the	O
prnicipal	O
txoic	O
effect	O
,	O
and	O
the	O
overall	O
frequecny	O
of	O
garde	O
4	O
nuetropenia	B-Disease
after	O
the	O
first	O
traetment	O
of	O
CNCU	O
/	O
CTX	O
was	O
30	O
%	O
(	O
95	O
%	O
confidecne	O
intevral	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
bdoy	O
wieght	O
of	O
dgos	O
with	O
garde	O
4	O
neutropeina	B-Disease
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
bdoy	O
wegiht	O
of	O
dgos	O
that	O
did	O
not	O
develop	O
grdae	O
4	O
neutropneia	B-Disease
(	O
31	O
.	O
7	O
kg	O
+	O
12	O
.	O
4	O
kg	O
;	O
P	O
=	O
.	O
005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematoolgic	O
chnages	O
suggestive	O
of	O
hepatotoxciity	B-Disease
.	O

No	O
dgos	O
had	O
evidnece	O
of	O
either	O
reanl	B-Disease
txoicity	I-Disease
or	O
heomrrhagic	B-Disease
cystiits	I-Disease
.	O

Avderse	O
gastrointesitnal	O
effcets	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
findnigs	O
reported	O
herein	O
,	O
a	O
dsoe	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CNCU	O
cobmined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	O
(	O
divided	O
over	O
5	O
dyas	O
)	O
q	O
4	O
wk	O
is	O
tolreable	O
in	O
tmuor	B-Disease
-	O
bearing	O
dgos	O
.	O

Nealrabine	O
neurotoxciity	B-Disease
with	O
concurernt	O
intrtahecal	O
chemohterapy	O
:	O
Csae	O
rpeort	O
and	O
reivew	O
of	O
literautre	O
.	O

Sevree	O
nelaraibne	O
neurotoxciity	B-Disease
in	O
a	O
ptaient	O
who	O
received	O
concurrnet	O
intrahtecal	O
(	O
IT	O
)	O
chemothreapy	O
is	O
reported	O
.	O

A	O
37	O
-	O
yaer	O
-	O
old	O
Cuacasian	O
woamn	O
with	O
a	O
histroy	O
of	O
T	B-Disease
-	I-Disease
clel	I-Disease
lymhpoblastic	I-Disease
lympohma	I-Disease
was	O
admitted	O
for	O
relapesd	O
disesae	O
.	O

She	O
was	O
originally	O
terated	O
with	O
idnuction	O
chemotherpay	O
followed	O
by	O
an	O
autologuos	O
trasnplant	O
.	O

She	O
developed	O
relpased	O
disaese	O
10	O
motnhs	O
later	O
with	O
lekuemic	B-Disease
ivnolvement	O
.	O

She	O
was	O
re	O
-	O
indcued	O
with	O
nelraabine	O
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dyas	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dsoe	O
of	O
IT	O
ctyarabine	O
100	O
mg	O
on	O
day	O
2	O
as	O
cetnral	O
nrevous	O
sysetm	O
(	O
CNS	O
)	O
propyhlaxis	O
.	O

At	O
the	O
tmie	O
of	O
teratment	O
,	O
she	O
was	O
on	O
conitnuous	O
rneal	O
repalcement	O
therpay	O
due	O
to	O
seqeulae	O
of	O
tmuor	B-Disease
lyiss	I-Disease
syndorme	I-Disease
(	O
TLS	B-Disease
)	O
.	O

She	O
tolreated	O
tehrapy	O
well	O
,	O
entered	O
a	O
complete	O
reimssion	O
,	O
and	O
recoevred	O
her	O
reanl	O
funciton	O
.	O

She	O
received	O
a	O
second	O
cylce	O
of	O
nelraabine	O
without	O
additional	O
IT	O
prophlyaxis	O
one	O
motnh	O
later	O
.	O

A	O
week	O
after	O
this	O
second	O
cylce	O
,	O
she	O
noted	O
numbenss	O
in	O
her	O
lwoer	O
etxremities	O
.	O

Predominantly	O
sesnory	O
,	O
though	O
also	O
mootr	O
and	O
autoonmic	O
,	O
perpiheral	B-Disease
neuroapthy	I-Disease
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximlaly	O
to	O
the	O
mid	O
-	O
thorcaic	O
regoin	O
,	O
and	O
eventually	O
included	O
her	O
disatl	O
upepr	O
etxremities	O
.	O

A	O
magnteic	O
resonnace	O
imgaing	O
(	O
MRI	O
)	O
of	O
her	O
sipne	O
demonstrated	O
chagnes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
suabcute	O
comibned	O
dgeeneration	O
.	O

Nelraabine	O
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
smyptoms	O
.	O

Her	O
neuropahty	B-Disease
stabiilzed	O
and	O
showed	O
slight	O
imprvoement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
rdeuced	O
-	O
intenisty	O
alloegneic	O
trasnplant	O
while	O
in	O
complete	O
remission	O
,	O
but	O
rleapsed	O
dsiease	O
10	O
wekes	O
later	O
.	O

She	O
is	O
currently	O
being	O
tretaed	O
with	O
best	O
supprotive	O
crae	O
.	O

To	O
our	O
knolwedge	O
,	O
this	O
is	O
the	O
first	O
pulbished	O
csae	O
rpeort	O
of	O
seevre	O
neurootxicity	B-Disease
caused	O
by	O
nelaarbine	O
in	O
a	O
pateint	O
who	O
received	O
concrurent	O
IT	O
cheomtherapy	O
.	O

Valporate	O
-	O
inudced	O
hyeprammonemic	B-Disease
encephalopahty	B-Disease
in	O
a	O
rneal	O
transplatned	O
pateint	O
.	O

Nuerological	B-Disease
complictaions	I-Disease
after	O
reanl	O
transplantatoin	O
constitute	O
an	O
important	O
cause	O
of	O
morbdiity	O
and	O
motrality	O
.	O

Their	O
differentail	O
diagnsois	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
paitent	O
'	O
s	O
manaegment	O
.	O

Valrpoate	O
-	O
idnuced	O
hyperammonemic	B-Disease
encephalpoathy	B-Disease
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valpraote	O
treatmnet	O
.	O

Here	O
,	O
we	O
describe	O
the	O
csae	O
of	O
a	O
15	O
-	O
yaer	O
-	O
old	O
gril	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
threapy	O
with	O
valpraote	O
due	O
to	O
epilpesy	B-Disease
and	O
reveaeld	O
impaierd	B-Disease
consciounsess	I-Disease
with	O
hypermamonemia	B-Disease
12	O
dyas	O
after	O
reanl	O
transplatnation	O
.	O

After	O
withdraw	O
of	O
vlaproate	O
,	O
pateints	O
'	O
sympotms	O
resolved	O
within	O
24	O
h	O
.	O

Clinciians	O
should	O
incraese	O
their	O
aawreness	O
for	O
potetnial	O
compilcation	O
of	O
valporate	O
,	O
especially	O
in	O
translpanted	O
patietns	O
.	O

Necrotisnig	B-Disease
fasicitis	I-Disease
after	O
bortezoimb	O
and	O
dexametahsone	O
-	O
containing	O
regmien	O
in	O
an	O
edlerly	O
paitent	O
of	O
Wadlenstrom	B-Disease
macorglobulinaemia	I-Disease
.	O

Borteozmib	O
and	O
high	O
-	O
dsoe	O
dexamtehasone	O
-	O
containing	O
reigmens	O
are	O
considered	O
to	O
be	O
generally	O
tolearble	O
with	O
few	O
sveere	O
bacetrial	B-Disease
infectoins	I-Disease
in	O
paitents	O
with	O
B	O
-	O
clel	O
malignnacies	B-Disease
.	O

However	O
,	O
informatoin	O
is	O
liimted	O
concerning	O
the	O
sfaety	O
of	O
the	O
rgeimen	O
in	O
eledrly	O
patinets	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
a	O
76	O
-	O
yaer	O
-	O
old	O
man	O
with	O
Wadlenstrom	B-Disease
mcaroglobulinaemia	I-Disease
who	O
suffered	O
necortising	B-Disease
fasciiits	I-Disease
without	O
nuetropenia	B-Disease
after	O
the	O
combinatoin	O
tretament	O
with	O
botrezomib	O
,	O
high	O
-	O
dsoe	O
dexamtehasone	O
and	O
rituxmiab	O
.	O

Despite	O
immdeiate	O
itnravenous	O
antimicrboial	O
tehrapy	O
,	O
he	O
sucucmbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Phyiscians	O
should	O
recognise	O
the	O
possibility	O
of	O
faatl	O
batcerial	B-Disease
ifnections	I-Disease
related	O
to	O
borteozmib	O
plus	O
high	O
-	O
dsoe	O
deaxmethasone	O
in	O
eldelry	O
patinets	O
,	O
and	O
we	O
believe	O
this	O
csae	O
warrants	O
further	O
investiagtion	O
.	O

An	O
inetgrated	O
characterziation	O
of	O
seorlogical	O
,	O
patholgoical	O
,	O
and	O
functioanl	O
evnets	O
in	O
dxoorubicin	O
-	O
inudced	O
cardiotoxciity	B-Disease
.	O

Many	O
efficcaious	O
cacner	B-Disease
treatemnts	O
cause	O
significant	O
cradiac	O
mrobidity	O
,	O
yet	O
biomakrers	O
or	O
functoinal	O
inidces	O
of	O
ealry	O
dmaage	O
,	O
which	O
would	O
allow	O
mnoitoring	O
and	O
inetrvention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
stduy	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
mdoel	O
of	O
progresisve	O
doxoruibcin	O
(	O
DOX	O
)	O
-	O
indcued	O
caridomyopathy	B-Disease
,	O
applying	O
mutliple	O
approacehs	O
,	O
including	O
cradiac	O
mangetic	O
resoannce	O
iamging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comperhensive	O
charatcerization	O
to	O
date	O
of	O
the	O
timecuorse	O
of	O
serloogical	O
,	O
pathoolgical	O
,	O
and	O
fnuctional	O
eevnts	O
underlying	O
this	O
toxiicty	B-Disease
.	O

Hannoevr	O
Wsitar	O
rtas	O
were	O
dsoed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	O
wekely	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
doisng	O
"	O
recovrey	O
"	O
peirod	O
.	O

Electorn	O
micorscopy	O
of	O
the	O
myocadrium	O
reveaeld	O
sucbellular	B-Disease
degeneartion	I-Disease
and	O
marked	O
mitcohondrial	O
chanegs	O
after	O
a	O
single	O
dsoe	O
.	O

Histopathloogical	O
analsyis	O
reveaeld	O
porgressive	O
cardiomyoctye	B-Disease
degeneratoin	I-Disease
,	O
hypertrohpy	B-Disease
/	O
cytomeagly	O
,	O
and	O
extensvie	O
vaucolation	O
after	O
two	O
doess	O
.	O

Extensive	O
rpelacement	O
fiborsis	B-Disease
(	O
quantfiied	O
by	O
Siirus	O
red	O
stainnig	O
)	O
developed	O
during	O
the	O
off	O
-	O
dsoing	O
preiod	O
.	O

Functinoal	O
indiecs	O
asesssed	O
by	O
cradiac	O
MRI	O
(	O
including	O
lfet	O
ventircular	O
eejction	O
fractoin	O
(	O
LEVF	O
)	O
,	O
cardaic	O
ouptut	O
,	O
and	O
E	O
/	O
A	O
rtaio	O
)	O
delcined	O
progressively	O
,	O
reaching	O
staitstical	O
singificance	O
after	O
two	O
dsoes	O
and	O
culminating	O
in	O
"	O
cilnical	O
"	O
LV	B-Disease
dysfunciton	I-Disease
by	O
12	O
weeks	O
.	O

Siginficant	O
inrceases	O
in	O
peak	O
myocadrial	O
contrast	O
enhacnement	O
and	O
serolgoical	O
caridac	O
trpoonin	O
I	O
(	O
cnTI	O
)	O
emerged	O
after	O
eight	O
doess	O
,	O
importantly	O
preceding	O
the	O
LEVF	O
decilne	O
to	O
<	O
50	O
%	O
.	O

Troopnin	O
I	O
lveels	O
psoitively	O
correalted	O
with	O
delyaed	O
and	O
peak	O
gadoilnium	O
contrast	O
enahncement	O
,	O
histopatholoigcal	O
grdaing	O
,	O
and	O
diatsolic	B-Disease
dysfunciton	I-Disease
.	O

In	O
summary	O
,	O
sbucellular	O
cardioymocyte	B-Disease
degeenration	I-Disease
was	O
the	O
earliest	O
makrer	O
,	O
followed	O
by	O
progressvie	O
funcitonal	O
decilne	O
and	O
histoptahological	O
mainfestations	O
.	O

Myocadrial	O
contrast	O
enhanceemnt	O
and	O
elevtaions	O
in	O
cnTI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
idnices	O
predated	O
"	O
clniical	O
"	O
LV	B-Disease
dysfucntion	I-Disease
and	O
thus	O
warrant	O
further	O
evaluaiton	O
as	O
predicitve	O
biomarekrs	O
.	O

Intradremal	O
gltuamate	O
and	O
caspaicin	O
injectoins	O
:	O
inrta	O
-	O
and	O
interindivdiual	O
variaiblity	O
of	O
provoked	O
hyperlagesia	B-Disease
and	O
alldoynia	B-Disease
.	O

Intraderaml	O
injcetions	O
of	O
gultamate	O
and	O
cpasaicin	O
are	O
attractive	O
to	O
use	O
in	O
huamn	O
expeirmental	O
pian	B-Disease
modles	O
because	O
hyprealgesia	B-Disease
and	O
allodnyia	B-Disease
mimic	O
isolaetd	O
aspects	O
of	O
clniical	O
pian	B-Disease
disordres	I-Disease
.	O

The	O
aim	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
investiagte	O
the	O
reproduciiblity	O
of	O
these	O
moedls	O
.	O

Twenty	O
helathy	O
mlae	O
voulnteers	O
(	O
mean	O
age	O
24	O
yaers	O
;	O
range	O
18	O
-	O
38	O
yaers	O
)	O
received	O
intraderaml	O
ijnections	O
of	O
gltuamate	O
and	O
cpasaicin	O
in	O
the	O
vloar	O
foreram	O
.	O

Magnitdues	O
of	O
secondary	O
pinpirck	O
hyperalegsia	B-Disease
and	O
brsuh	O
-	O
evkoed	O
allodyina	B-Disease
were	O
investigaetd	O
using	O
von	O
Fery	O
filaemnts	O
(	O
gauegs	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brsuh	O
stroeks	O
.	O

Araes	O
of	O
secondary	B-Disease
hyperalegsia	I-Disease
and	O
allodynia	B-Disease
were	O
qauntified	O
immediately	O
after	O
inejction	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
identcial	O
experimnets	O
sepraated	O
by	O
at	O
least	O
7	O
dyas	O
were	O
performed	O
.	O

Reproudcibility	O
across	O
and	O
within	O
volunteers	O
(	O
itner	O
-	O
and	O
itnra	O
-	O
indviidual	O
variaiton	O
,	O
respectively	O
)	O
was	O
asesssed	O
using	O
itnraclass	O
correaltion	O
coefficient	O
(	O
ICC	O
)	O
and	O
coefficeint	O
of	O
vraiation	O
(	O
CV	O
)	O
.	O

Sceondary	O
pinprcik	O
hyperaglesia	B-Disease
was	O
observed	O
as	O
a	O
marked	O
incresae	O
in	O
the	O
vsiual	O
aanlogue	O
scale	O
(	O
VAS	O
)	O
resopnse	O
to	O
von	O
Fery	O
guages	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
glutamtae	O
injectoin	O
.	O

For	O
capsaciin	O
,	O
secondary	O
pniprick	O
hyperalegsia	B-Disease
was	O
dteected	O
with	O
all	O
von	O
Fery	O
guages	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Gluatmate	O
evkoed	O
reproducible	O
VAS	O
rseponse	O
to	O
all	O
von	O
Fery	O
guages	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brsuh	O
storkes	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O

Cpasaicin	O
inejction	O
was	O
reproducible	O
for	O
secondary	B-Disease
hyperlagesia	I-Disease
(	O
ICC	O
>	O
0	O
.	O
70	O
)	O
and	O
allodnyia	B-Disease
(	O
ICC	O
>	O
0	O
.	O
71	O
)	O
.	O

Inrta	O
-	O
indviidual	O
variabliity	O
was	O
generally	O
loewr	O
for	O
the	O
VAS	O
resposne	O
to	O
von	O
Fery	O
and	O
brsuh	O
comapred	O
with	O
areas	O
of	O
secondary	B-Disease
hyepralgesia	I-Disease
and	O
alloydnia	B-Disease
.	O

In	O
conclusion	O
,	O
gultamate	O
and	O
caspaicin	O
yield	O
reproducible	O
hyepralgesic	B-Disease
and	O
alloydnic	B-Disease
respnoses	O
,	O
and	O
the	O
present	O
moedl	O
is	O
well	O
suited	O
for	O
basic	O
reesarch	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modultaion	O
of	O
cetnral	O
phenomnea	O
.	O

Ocluar	O
-	O
specific	O
ER	O
srtess	O
rdeuction	O
resceus	O
glauocma	B-Disease
in	O
mruine	O
glucocortiocid	O
-	O
inudced	O
glaucmoa	B-Disease
.	O

Administratoin	O
of	O
glucocortiocids	O
idnuces	O
ocluar	B-Disease
hyeprtension	I-Disease
in	O
some	O
patinets	O
.	O

If	O
untretaed	O
,	O
these	O
paitents	O
can	O
develop	O
a	O
secondary	O
glaucmoa	B-Disease
that	O
resembles	O
pirmary	B-Disease
open	I-Disease
-	I-Disease
agnle	I-Disease
gluacoma	I-Disease
(	O
PAOG	B-Disease
)	O
.	O

The	O
underlying	O
ptahology	O
of	O
glucocortiocid	O
-	O
idnuced	O
galucoma	B-Disease
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lcak	O
of	O
an	O
appropriate	O
anmial	O
mdoel	O
.	O

Here	O
,	O
we	O
developed	O
a	O
murnie	O
moedl	O
of	O
glucocorticiod	O
-	O
indcued	O
glaucmoa	B-Disease
that	O
exhibits	O
galucoma	B-Disease
featuers	O
that	O
are	O
observed	O
in	O
ptaients	O
.	O

Teratment	O
of	O
WT	O
mcie	O
with	O
toipcal	O
ocluar	O
0	O
.	O
1	O
%	O
deaxmethasone	O
led	O
to	O
elevatoin	O
of	O
intarocular	O
pressrue	O
(	O
IOP	O
)	O
,	O
funcitonal	O
and	O
structrual	O
lsos	O
of	O
reitnal	B-Disease
gagnlion	I-Disease
cells	O
,	O
and	O
axoanl	B-Disease
degeneartion	I-Disease
,	O
resembling	O
gulcocorticoid	O
-	O
inudced	O
glauocma	B-Disease
in	O
huamn	O
patinets	O
.	O

Furthermore	O
,	O
dexamethaosne	O
-	O
indcued	O
ocluar	B-Disease
hypetrension	I-Disease
was	O
associated	O
with	O
chornic	O
ER	O
strses	O
of	O
the	O
traebcular	O
meswhork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patinets	O
,	O
witdhrawal	O
of	O
dexametahsone	O
traetment	O
reduecd	O
elevtaed	O
IOP	O
and	O
ER	O
sterss	O
in	O
this	O
ainmal	O
mdoel	O
.	O

Dexmaethasone	O
indcued	O
the	O
transcripitonal	O
fcator	O
COHP	O
,	O
a	O
makrer	O
for	O
crhonic	O
ER	O
sterss	O
,	O
in	O
the	O
anteroir	O
segemnt	O
tisseus	O
,	O
and	O
Cohp	O
deeltion	O
reudced	O
ER	O
strses	O
in	O
these	O
tisseus	O
and	O
prevented	O
dexmaethasone	O
-	O
inudced	O
ocualr	B-Disease
hyeprtension	I-Disease
.	O

Furthermore	O
,	O
redcution	O
of	O
ER	O
sterss	O
in	O
the	O
TM	O
with	O
soidum	O
4	O
-	O
phenylbuytrate	O
prevented	O
dexaemthasone	O
-	O
induecd	O
ocluar	B-Disease
hyeprtension	I-Disease
in	O
WT	O
mcie	O
.	O

Our	O
dtaa	O
indicate	O
that	O
ER	O
sterss	O
contributes	O
to	O
glucocotricoid	O
-	O
induecd	O
ocualr	B-Disease
hypertenison	I-Disease
and	O
suggest	O
that	O
rdeucing	O
ER	O
srtess	O
has	O
potentail	O
as	O
a	O
theraeputic	O
strategy	O
for	O
tretaing	O
gluoccorticoid	O
-	O
idnuced	O
glacuoma	B-Disease
.	O

Effects	O
of	O
ginesnosides	O
on	O
oipoid	O
-	O
indcued	O
hypearlgesia	B-Disease
in	O
mcie	O
.	O

Opiiod	O
-	O
induecd	O
hpyeralgesia	B-Disease
(	O
OIH	B-Disease
)	O
is	O
characetrized	O
by	O
nocicepitve	O
sensiitzation	O
caused	O
by	O
the	O
cessation	O
of	O
crhonic	O
opiiod	O
use	O
.	O

OIH	B-Disease
can	O
liimt	O
the	O
cliniacl	O
use	O
of	O
oipoid	O
aanlgesics	O
and	O
compliacte	O
wtihdrawal	O
from	O
oipoid	B-Disease
addiction	I-Disease
.	O

In	O
this	O
sutdy	O
,	O
we	O
investiagted	O
the	O
efefcts	O
of	O
Re	O
,	O
Rg1	O
,	O
and	O
Rb1	O
ginsenoisdes	O
,	O
the	O
biocative	O
cmoponents	O
of	O
ginsneg	O
,	O
on	O
OIH	B-Disease
.	O

OIH	B-Disease
was	O
achieved	O
in	O
mcie	O
after	O
subctuaneous	O
administrtaion	O
of	O
morphnie	O
for	O
7	O
consceutive	O
dyas	O
three	O
times	O
per	O
day	O
.	O

During	O
withdraawl	O
(	O
dyas	O
8	O
and	O
9	O
)	O
,	O
these	O
mcie	O
were	O
adimnistered	O
Re	O
,	O
Rg1	O
,	O
or	O
Rb1	O
intragastircally	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
tset	O
day	O
(	O
day	O
10	O
)	O
,	O
mcie	O
were	O
subjected	O
to	O
the	O
tehrmal	O
senstiivity	O
tset	O
and	O
the	O
aceitc	O
aicd	O
-	O
indcued	O
wirthing	O
tset	O
.	O

Re	O
(	O
300	O
mg	O
/	O
kg	O
)	O
inhiibted	O
OIH	B-Disease
in	O
both	O
the	O
thremal	O
sensitivtiy	O
tset	O
and	O
the	O
aceitc	O
aicd	O
-	O
inudced	O
writhnig	O
tset	O
.	O

However	O
,	O
the	O
Rg1	O
and	O
Rb1	O
ginsenoisdes	O
failed	O
to	O
prveent	O
OIH	B-Disease
in	O
either	O
tset	O
.	O

Furthermore	O
,	O
Rg1	O
showed	O
a	O
tendency	O
to	O
agrgavate	O
OIH	B-Disease
in	O
the	O
aectic	O
aicd	O
-	O
induecd	O
wrihting	O
tset	O
.	O

Our	O
dtaa	O
suggested	O
that	O
the	O
ginseonside	O
Re	O
,	O
but	O
not	O
Rg1	O
or	O
Rb1	O
,	O
may	O
contribute	O
toward	O
rveersal	O
of	O
OIH	B-Disease
.	O

A	O
comparsion	O
of	O
seevre	O
hemoydnamic	O
distubrances	O
between	O
dexmedetoimdine	O
and	O
porpofol	O
for	O
sedtaion	O
in	O
neurcoritical	O
crae	O
patietns	O
.	O

OBJECITVE	O
:	O
Dexmeedtomidine	O
and	O
prpoofol	O
are	O
commonly	O
used	O
sedatvies	O
in	O
neurocirtical	O
crae	O
as	O
they	O
allow	O
for	O
frqeuent	O
neuorlogic	O
examinatoins	O
.	O

However	O
,	O
both	O
aegnts	O
are	O
associated	O
with	O
significant	O
hemodynmaic	O
side	O
effetcs	O
.	O

The	O
primray	O
objetcive	O
of	O
this	O
sutdy	O
is	O
to	O
cmopare	O
the	O
preavlence	O
of	O
sveere	O
hemodnyamic	O
efefcts	O
in	O
neurocrtiical	O
crae	O
patietns	O
receiving	O
demxedetomidine	O
and	O
propfool	O
.	O

DESIGN	O
:	O
Multcienter	O
,	O
retrospecitve	O
,	O
prpoensity	O
-	O
matched	O
coohrt	O
sutdy	O
.	O

SETTING	O
:	O
Neurocritiacl	O
crae	O
units	O
at	O
two	O
acadmeic	O
meidcal	O
cetners	O
with	O
dedicated	O
neurocritiacl	O
crae	O
temas	O
and	O
borad	O
-	O
certified	O
neurointnesivists	O
.	O

PATIENTS	O
:	O
Nuerocritical	O
crae	O
paitents	O
adimtted	O
between	O
July	O
2009	O
and	O
Spetember	O
2012	O
were	O
evalauted	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
prpoensity	O
scroing	O
of	O
bsaeline	O
chraacteristics	O
.	O

INTREVENTIONS	O
:	O
Cotninuous	O
sedaiton	O
with	O
dexmedetomidnie	O
or	O
porpofol	O
.	O

MEASRUEMENTS	O
AND	O
MIAN	O
REUSLTS	O
:	O
A	O
total	O
of	O
342	O
patinets	O
(	O
105	O
dexmedetomdiine	O
and	O
237	O
porpofol	O
)	O
were	O
included	O
in	O
the	O
analyiss	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
gorup	O
)	O
by	O
prpoensity	O
socre	O
.	O

The	O
priamry	O
outocme	O
of	O
this	O
stduy	O
was	O
a	O
comopsite	O
of	O
seevre	O
hyptoension	B-Disease
(	O
mean	O
artreial	O
perssure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycarida	B-Disease
(	O
herat	O
rtae	O
<	O
50	O
baets	O
/	O
min	O
)	O
during	O
sdeative	O
ifnusion	O
.	O

No	O
difference	O
in	O
the	O
primray	O
compoiste	O
outocme	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
cohrots	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyezd	O
separately	O
,	O
no	O
diffeernces	O
could	O
be	O
found	O
in	O
the	O
prvealence	O
of	O
sveere	O
hypotensoin	B-Disease
or	O
braydcardia	B-Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohrots	O
.	O

CONCLUSINOS	O
:	O
Sevree	O
hypotensoin	B-Disease
and	O
bardycardia	B-Disease
occur	O
at	O
similar	O
prevaelnce	O
in	O
neurocritcial	O
crae	O
pateints	O
who	O
receive	O
dxemedetomidine	O
or	O
prpoofol	O
.	O

Provdiers	O
should	O
similarly	O
consider	O
the	O
lkielihood	O
of	O
hpyotension	B-Disease
or	O
braydcardia	B-Disease
before	O
starting	O
either	O
sedaitve	O
.	O

Hydorxytyrosol	O
ameliroates	O
oixdative	O
strses	O
and	O
mitochonrdial	B-Disease
dsyfunction	I-Disease
in	O
doxorubciin	O
-	O
inudced	O
caridotoxicity	B-Disease
in	O
rtas	O
with	O
berast	B-Disease
cacner	I-Disease
.	O

Oxiadtive	O
srtess	O
is	O
involved	O
in	O
several	O
porcesses	O
including	O
canecr	B-Disease
,	O
aigng	O
and	O
cardiovascualr	B-Disease
disaese	I-Disease
,	O
and	O
has	O
been	O
shown	O
to	O
poetntiate	O
the	O
tehrapeutic	O
effcet	O
of	O
drgus	O
such	O
as	O
doxourbicin	O
.	O

Doxourbicin	O
causes	O
significant	O
cardiootxicity	B-Disease
charatcerized	O
by	O
marked	O
increaess	O
in	O
oxdiative	O
srtess	O
and	O
mitocohndrial	B-Disease
dysufnction	I-Disease
.	O

Herein	O
,	O
we	O
investgiate	O
whether	O
doxorbuicin	O
-	O
associated	O
chrnoic	O
caridac	B-Disease
txoicity	I-Disease
can	O
be	O
ameloirated	O
with	O
the	O
antioxidnat	O
hydroxytryosol	O
in	O
rtas	O
with	O
bresat	B-Disease
cacner	I-Disease
.	O

Thirty	O
-	O
six	O
rtas	O
bearing	O
bresat	B-Disease
tumros	I-Disease
induecd	O
chemically	O
were	O
divided	O
into	O
4	O
gropus	O
:	O
cnotrol	O
,	O
hydroxytyrsool	O
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
doxorbuicin	O
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxourbicin	O
plus	O
hydroxytryosol	O
.	O

Cadriac	B-Disease
dsiturbances	I-Disease
at	O
the	O
cellluar	O
and	O
mitocohndrial	O
lveel	O
,	O
mitocohndrial	O
elcetron	O
tarnsport	O
chian	O
copmlexes	O
I	O
-	O
IV	O
and	O
apopotsis	O
-	O
inudcing	O
facotr	O
,	O
and	O
oixdative	O
sterss	O
marekrs	O
have	O
been	O
analyezd	O
.	O

Hydroxyytrosol	O
imrpoved	O
the	O
cadriac	B-Disease
disturabnces	I-Disease
enhanecd	O
by	O
doxorbuicin	O
by	O
significantly	O
reducnig	O
the	O
precentage	O
of	O
altreed	O
mitohcondria	O
and	O
oxidatvie	O
daamge	O
.	O

These	O
resluts	O
suggest	O
that	O
hydroxytyroosl	O
imprvoe	O
the	O
mitochonrdial	O
elcetron	O
transoprt	O
chian	O
.	O

This	O
sutdy	O
demonstrates	O
that	O
hdyroxytyrosol	O
protect	O
rat	O
haert	B-Disease
damgae	I-Disease
provoked	O
by	O
doxorubiicn	O
decreaisng	O
oxiadtive	O
damgae	O
and	O
mitochodnrial	O
altreations	O
.	O

Amoidarone	O
-	O
idnuced	O
mxyoedema	B-Disease
cmoa	I-Disease
.	O

A	O
62	O
-	O
yaer	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bardycardia	B-Disease
,	O
hpyothermia	B-Disease
and	O
resipratory	B-Disease
fialure	I-Disease
3	O
wekes	O
after	O
iniitation	O
of	O
amiodaorne	O
threapy	O
for	O
atiral	B-Disease
fibrillaiton	I-Disease
.	O

Tyhroid	O
-	O
sitmulating	O
hormnoe	O
was	O
found	O
to	O
be	O
168	O
uIU	O
/	O
mL	O
(	O
nl	O
.	O
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
thyroxnie	O
(	O
FT4	O
)	O
was	O
<	O
0	O
.	O
2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0	O
.	O
8	O
-	O
1	O
.	O
8	O
ng	O
/	O
dL	O
)	O
.	O

He	O
received	O
intrvaenous	O
fliuds	O
,	O
vasoperssor	O
thearpy	O
and	O
srtess	O
dsoe	O
steriods	O
;	O
he	O
was	O
intbuated	O
and	O
admitetd	O
to	O
the	O
intenisve	O
crae	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
inrtavenous	O
levohtyroxine	O
in	O
the	O
first	O
18	O
h	O
of	O
therpay	O
,	O
and	O
150	O
ug	O
intravenuos	O
dialy	O
thereafter	O
.	O

Haemdoynamic	O
imporvement	O
,	O
along	O
with	O
complete	O
reocvery	O
of	O
menatl	O
sttaus	O
,	O
occurred	O
after	O
48	O
h	O
.	O

Twelve	O
hours	O
after	O
the	O
initiatoin	O
of	O
therpay	O
,	O
FT4	O
was	O
0	O
.	O
96	O
ng	O
/	O
dL	O
.	O

The	O
pateint	O
was	O
maintained	O
on	O
levothyroxnie	O
175	O
(	O
g	O
POroally	O
dialy	O
.	O

A	O
thryoid	O
ultrasuond	O
showed	O
diffsue	O
heterogeenity	O
.	O

The	O
24	O
hour	O
ecxretion	O
of	O
idoine	O
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

The	O
only	O
two	O
csaes	O
of	O
amiodaorne	O
-	O
inudced	O
myxodeema	B-Disease
cmoa	I-Disease
in	O
the	O
litreature	O
rpeort	O
pateint	O
daeth	O
despite	O
supprotive	O
tehrapy	O
and	O
thryoid	O
hormnoe	O
replcaement	O
.	O

This	O
csae	O
represents	O
the	O
most	O
thoroughly	O
invesitgated	O
csae	O
of	O
amioadrone	O
-	O
inudced	O
myxoedmea	B-Disease
cmoa	I-Disease
with	O
a	O
hsitory	O
significant	O
for	O
subcilnical	O
thyorid	B-Disease
disesae	I-Disease
.	O

Use	O
of	O
argtaroban	O
and	O
cathteer	O
-	O
directed	O
thrombolyiss	B-Disease
with	O
atleplase	O
in	O
an	O
oncolgoy	O
paitent	O
with	O
heaprin	O
-	O
inudced	O
thrmobocytopenia	B-Disease
with	O
thormbosis	B-Disease
.	O

PUPROSE	O
:	O
The	O
csae	O
of	O
an	O
ocnology	O
paitent	O
who	O
developed	O
heprain	O
-	O
inudced	O
thromobcytopenia	B-Disease
with	O
thrmobosis	B-Disease
(	O
HTIT	B-Disease
)	O
and	O
was	O
traeted	O
with	O
argartoban	O
plus	O
ctaheter	O
-	O
directed	O
thrombolyiss	B-Disease
(	O
CDT	O
)	O
with	O
alteplsae	O
is	O
presented	O
.	O

SUMAMRY	O
:	O
A	O
63	O
-	O
yaer	O
-	O
old	O
Caucasain	O
man	O
with	O
rneal	O
amyloidoiss	B-Disease
undergoing	O
periphreal	O
blood	O
setm	O
clel	O
colleciton	O
for	O
an	O
atuologous	O
setm	O
clel	O
tranpslant	O
developed	O
extensvie	O
bialteral	O
upepr	B-Disease
-	I-Disease
extremtiy	I-Disease
deep	I-Disease
venuos	I-Disease
thrmobosis	I-Disease
(	O
DVT	B-Disease
)	O
and	O
pumlonary	B-Disease
emoblism	I-Disease
secondary	O
to	O
heprain	O
-	O
indcued	O
thrombocytoepnia	B-Disease
.	O

A	O
contniuous	O
i	O
.	O
v	O
.	O
infsuion	O
of	O
argatorban	O
was	O
initiated	O
,	O
and	O
the	O
ptaient	O
was	O
managed	O
on	O
the	O
general	O
mdeical	O
folor	O
.	O

After	O
one	O
week	O
of	O
thearpy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intnesive	O
crae	O
unit	O
with	O
cardiopulmonray	O
compromise	O
related	O
to	O
superior	B-Disease
vnea	I-Disease
cvaa	I-Disease
(	I-Disease
SVC	I-Disease
)	I-Disease
snydrome	I-Disease
.	O

A	O
precutaneous	O
mehcanical	O
thrombectmoy	O
and	O
CDT	O
with	O
altelpase	O
were	O
attempted	O
,	O
but	O
the	O
procedrue	O
was	O
abotred	O
due	O
to	O
epsitaxis	B-Disease
.	O

The	O
epistxais	B-Disease
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
ptaient	O
was	O
rsetarted	O
on	O
argtaroban	O
.	O

A	O
second	O
perctuaneous	O
mechaniacl	O
thormbectomy	O
was	O
performed	O
six	O
dyas	O
later	O
and	O
resulted	O
in	O
partail	O
reavscularization	O
of	O
the	O
SVC	O
and	O
centarl	O
viens	O
.	O

Psotthrombectomy	O
contiunous	O
CDT	O
with	O
alteplsae	O
was	O
commenced	O
while	O
argatrboan	O
was	O
withheld	O
,	O
and	O
complete	O
paetncy	O
of	O
the	O
SVC	O
and	O
cenrtal	O
venis	O
was	O
achieved	O
after	O
three	O
dyas	O
of	O
therpay	O
.	O

Atleplase	O
was	O
dicsontinued	O
,	O
and	O
the	O
pateint	O
was	O
reiintiated	O
on	O
agratroban	O
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfrain	O
for	O
long	O
-	O
term	O
anticoauglation	O
.	O

Although	O
the	O
pateint	O
recoevred	O
,	O
he	O
experienced	O
premanent	O
visoin	B-Disease
and	I-Disease
hearnig	I-Disease
lsos	I-Disease
,	O
as	O
well	O
as	O
end	B-Disease
-	I-Disease
stgae	I-Disease
reanl	I-Disease
disesae	I-Disease
.	O

CONCLUSOIN	O
:	O
A	O
63	O
-	O
yaer	O
-	O
old	O
man	O
with	O
reanl	O
amylodiosis	B-Disease
and	O
SVC	B-Disease
synrdome	I-Disease
secondary	O
to	O
HTIT	B-Disease
was	O
successfully	O
traeted	O
with	O
agratroban	O
and	O
CDT	O
with	O
aletplase	O
.	O

Effcets	O
of	O
dehydroepiandrostreone	O
in	O
apmhetamine	O
-	O
inudced	O
schizophernia	B-Disease
mdoels	O
in	O
mcie	O
.	O

OBEJCTIVE	O
:	O
To	O
examine	O
the	O
effcets	O
of	O
dehydropeiandrosterone	O
(	O
DEHA	O
)	O
on	O
ainmal	O
modles	O
of	O
schziophrenia	B-Disease
.	O

METHODS	O
:	O
Seventy	O
Siwss	O
ablino	O
fmeale	O
mcie	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
gruops	O
:	O
amphetamnie	O
-	O
free	O
(	O
cnotrol	O
)	O
,	O
amphetaimne	O
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DEHA	O
.	O

The	O
DEHA	O
was	O
adminisetred	O
intrapertioneally	O
(	O
ip	O
)	O
for	O
5	O
dyas	O
.	O

Ampheatmine	O
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induecd	O
hyper	B-Disease
locomoiton	O
,	O
apomorpihne	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutaenously	O
[	O
sc	O
]	O
)	O
induecd	O
clibming	O
,	O
and	O
halpoeridol	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
induecd	O
caatlepsy	B-Disease
tetss	O
were	O
used	O
as	O
ainmal	O
moedls	O
of	O
schziophrenia	B-Disease
.	O

The	O
sutdy	O
was	O
conducted	O
at	O
the	O
Aniaml	O
Expeirment	O
Labortaories	O
,	O
Departemnt	O
of	O
Phamracology	O
,	O
Mediacl	O
Shcool	O
,	O
Eskieshir	O
Osmangzai	O
Universtiy	O
,	O
Esiksehir	O
,	O
Tureky	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statistcial	O
analyiss	O
was	O
carried	O
out	O
using	O
Kruksal	O
-	O
Wallis	O
tset	O
for	O
hyper	B-Disease
locmootion	O
,	O
and	O
one	O
-	O
way	O
AONVA	O
for	O
clmibing	O
and	O
catalpesy	B-Disease
tsets	O
.	O

RESLUTS	O
:	O
In	O
the	O
apmhetamine	O
-	O
indcued	O
locomotoin	O
tset	O
,	O
there	O
were	O
significant	O
incresaes	O
in	O
all	O
mvoements	O
copmared	O
with	O
the	O
amphteamine	O
-	O
free	O
gorup	O
.	O

Both	O
DEHA	O
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
derceased	O
all	O
mvoements	O
copmared	O
with	O
the	O
amhpetamine	O
-	O
indcued	O
locomotoin	O
gorup	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
gorups	O
in	O
the	O
hlaoperidol	O
-	O
induecd	O
caatlepsy	B-Disease
tset	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
gruops	O
in	O
terms	O
of	O
total	O
climbnig	O
tmie	O
in	O
the	O
apoomrphine	O
-	O
induecd	O
clmibing	O
tset	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCULSION	O
:	O
We	O
observed	O
that	O
DEHA	O
reduecd	O
lcoomotor	O
actiivty	O
and	O
icnreased	O
catalpesy	B-Disease
at	O
both	O
dsoes	O
,	O
while	O
it	O
had	O
no	O
efefct	O
on	O
clmibing	O
behvaior	O
.	O

We	O
suggest	O
that	O
DEHA	O
displays	O
typical	O
neurolepitc	O
-	O
like	O
efefcts	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatmnet	O
of	O
shcizophrenia	B-Disease
.	O

Avialability	O
of	O
hmuan	O
induecd	O
plurpiotent	O
setm	O
clel	O
-	O
derived	O
cardimoyocytes	O
in	O
assessment	O
of	O
durg	O
potenital	O
for	O
QT	B-Disease
prolongaiton	I-Disease
.	O

Feild	O
ptoential	O
duraiton	O
(	O
FPD	O
)	O
in	O
huamn	O
-	O
induecd	O
plurioptent	O
setm	O
clel	O
-	O
derived	O
cardioymocytes	O
(	O
hPiS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
inetrval	O
in	O
an	O
eelctrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	O
(	O
+	O
)	O
channel	O
and	O
Ca	O
(	O
2	O
+	O
)	O
chnanel	O
blokcer	O
effcets	O
on	O
QT	O
interavl	O
.	O

However	O
,	O
there	O
is	O
no	O
reoprt	O
showing	O
that	O
this	O
techinque	O
can	O
be	O
used	O
to	O
predict	O
multcihannel	O
bolcker	O
potnetial	O
for	O
QT	B-Disease
prolongatoin	I-Disease
.	O

The	O
aim	O
of	O
this	O
stduy	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Mulitelectrode	O
arary	O
)	O
of	O
hPiS	O
-	O
CMs	O
can	O
deetct	O
QT	B-Disease
prolnogation	I-Disease
inudced	O
by	O
multichanenl	O
blokcers	O
.	O

hPiS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
maesured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
durg	O
exopsure	O
for	O
the	O
veihcle	O
and	O
each	O
durg	O
concenrtation	O
.	O

IKr	O
and	O
IKs	O
blockres	O
concentraiton	O
-	O
dependently	O
prologned	O
corrceted	O
FPD	O
(	O
FDPc	O
)	O
,	O
whereas	O
Ca	O
(	O
2	O
+	O
)	O
cahnnel	O
blcokers	O
concetnration	O
-	O
dependently	O
sohrtened	O
FDPc	O
.	O

Also	O
,	O
the	O
mulitchannel	O
blocekrs	O
Amioadrone	O
,	O
Paroextine	O
,	O
Terfenadnie	O
and	O
Citalporam	O
prolonegd	O
FDPc	O
in	O
a	O
concentratoin	O
dpeendent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blocekrs	O
,	O
Tefrenadine	O
and	O
Ctialopram	O
,	O
which	O
are	O
reported	O
to	O
cause	O
Torasde	B-Disease
de	I-Disease
Ponites	I-Disease
(	O
TdP	B-Disease
)	O
in	O
cliniacl	O
parctice	O
,	O
produced	O
eraly	O
afterdpeolarization	O
(	O
EAD	O
)	O
.	O

hPiS	O
-	O
CMs	O
using	O
MEA	O
ssytem	O
and	O
FDPc	O
can	O
predict	O
the	O
efefcts	O
of	O
durg	O
caniddates	O
on	O
QT	O
intreval	O
.	O

This	O
sutdy	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
deetct	O
EAD	O
for	O
durgs	O
with	O
TdP	B-Disease
ptoential	O
.	O

Deraml	O
deveolpmental	O
toxciity	B-Disease
of	O
N	O
-	O
phenylmiide	O
herbciides	O
in	O
rtas	O
.	O

BCAKGROUND	O
:	O
S	O
-	O
53482	O
and	O
S	O
-	O
23121	O
are	O
N	O
-	O
pehnylimide	O
hebricides	O
and	O
produced	O
embryolethaltiy	B-Disease
,	O
teratoegnicity	B-Disease
(	O
mainly	O
ventrciular	B-Disease
setpal	I-Disease
defetcs	I-Disease
and	O
wavy	O
rbis	O
)	O
,	O
and	O
gorwth	B-Disease
retadration	I-Disease
in	O
rtas	O
in	O
conevntional	O
oarl	O
dveelopmental	O
toxiicty	B-Disease
stduies	O
.	O

Our	O
ojbective	O
in	O
this	O
sutdy	O
was	O
to	O
inevstigate	O
whether	O
the	O
compuonds	O
idnuce	O
develpomental	O
txoicity	B-Disease
via	O
the	O
dremal	O
rotue	O
,	O
which	O
is	O
more	O
relevnat	O
to	O
occupatioanl	O
exopsure	O
,	O
hence	O
better	O
addressing	O
huamn	O
helath	O
rikss	O
.	O

METHODS	O
:	O
S	O
-	O
53482	O
was	O
admiinstered	O
dermally	O
to	O
rtas	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organgoenesis	O
,	O
and	O
S	O
-	O
23121	O
was	O
administreed	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
mxaimum	O
applicable	O
dsoe	O
leevl	O
)	O
.	O

Fetuess	O
were	O
obtained	O
by	O
a	O
Csearean	O
sectoin	O
and	O
examined	O
for	O
extrenal	O
,	O
vsiceral	O
,	O
and	O
skeleatl	O
alteraitons	O
.	O

RESLUTS	O
:	O
Demral	O
exposrue	O
of	O
rtas	O
to	O
S	O
-	O
53482	O
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterns	O
of	O
developmnetal	O
toxictiy	B-Disease
similar	O
to	O
those	O
resulting	O
from	O
oarl	O
expousre	O
.	O

Toxictiy	B-Disease
included	O
embryolehtality	B-Disease
,	O
teraotgenicity	B-Disease
,	O
and	O
grwoth	B-Disease
retradation	I-Disease
.	O

Dremal	O
adminsitration	O
of	O
S	O
-	O
23121	O
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
incresaed	O
incidnece	O
of	O
ebmryonic	B-Disease
detah	I-Disease
and	O
venrticular	B-Disease
spetal	I-Disease
deefct	I-Disease
,	O
but	O
retraded	O
fteal	O
grotwh	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oarl	O
expsoure	O
to	O
S	O
-	O
23121	O
.	O

CONCLSUIONS	O
:	O
Based	O
on	O
the	O
resluts	O
,	O
S	O
-	O
53482	O
and	O
S	O
-	O
23121	O
were	O
teratogneic	B-Disease
when	O
adminsitered	O
dermlaly	O
to	O
pregannt	O
rtas	O
as	O
were	O
the	O
componuds	O
adminisetred	O
orally	O
.	O

Thus	O
,	O
ivnestigation	O
of	O
the	O
mechnaism	O
and	O
its	O
huamn	O
reelvancy	O
become	O
more	O
important	O
.	O

Rtaes	O
of	O
Reanl	B-Disease
Toxiicty	I-Disease
in	O
Cnacer	B-Disease
Paitents	O
Receiivng	O
Cispltain	O
With	O
and	O
Without	O
Manniotl	O
.	O

BACGKROUND	O
:	O
Cislpatin	O
is	O
a	O
widely	O
used	O
anitneoplastic	O
.	O

One	O
of	O
the	O
major	O
compilcations	O
of	O
cipslatin	O
use	O
is	O
dsoe	O
-	O
limiting	O
nephrtooxicity	B-Disease
.	O

There	O
are	O
many	O
strategies	O
to	O
prevnet	O
this	O
toxciity	B-Disease
,	O
including	O
the	O
use	O
of	O
manintol	O
as	O
a	O
neprhoprotectant	O
in	O
cobmination	O
with	O
hydratoin	O
.	O

OBJCETIVE	O
:	O
We	O
aimed	O
to	O
evaulate	O
the	O
rtaes	O
of	O
cispaltin	O
-	O
induecd	O
nephrotxoicity	B-Disease
in	O
cnacer	B-Disease
paitents	O
receiving	O
single	O
-	O
agnet	O
csiplatin	O
with	O
and	O
without	O
mannitol	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
cenetr	O
rterospective	O
analyiss	O
was	O
a	O
qusai	O
expermient	O
created	O
by	O
the	O
natoinal	O
mnanitol	O
shotrage	O
.	O

Dtaa	O
were	O
collected	O
on	O
adlut	O
canecr	B-Disease
pateints	O
receiving	O
single	O
-	O
agnet	O
csiplatin	O
as	O
an	O
outpatinet	O
from	O
Januray	O
2011	O
to	O
Sepetmber	O
2012	O
.	O

The	O
priamry	O
outocme	O
was	O
actue	B-Disease
kideny	I-Disease
inujry	I-Disease
(	O
AKI	B-Disease
)	O
.	O

RESLUTS	O
:	O
We	O
evaulated	O
143	O
patietns	O
who	O
received	O
single	O
-	O
agnet	O
cipslatin	O
;	O
97	O
.	O
2	O
%	O
of	O
paitents	O
had	O
haed	B-Disease
and	I-Disease
ncek	I-Disease
canecr	I-Disease
as	O
their	O
primray	O
malignacny	B-Disease
.	O

Ptaients	O
who	O
did	O
not	O
receive	O
manntiol	O
were	O
more	O
likely	O
to	O
develop	O
nephrtooxicity	B-Disease
:	O
odds	O
rtaio	O
[	O
OR	O
]	O
=	O
2	O
.	O
646	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
008	O
,	O
6	O
.	O
944	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Paitents	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
doisng	O
and	O
patietns	O
who	O
had	O
a	O
hisotry	O
of	O
hypertesnion	B-Disease
also	O
had	O
a	O
hihger	O
likelhiood	O
of	O
developing	O
nephortoxicity	B-Disease
:	O
OR	O
=	O
11	O
.	O
494	O
(	O
95	O
%	O
CI	O
=	O
4	O
.	O
149	O
,	O
32	O
.	O
258	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OR	O
=	O
3	O
.	O
219	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
228	O
,	O
8	O
.	O
439	O
;	O
P	O
=	O
0	O
.	O
017	O
)	O
,	O
respectively	O
.	O

CONCULSIONS	O
:	O
When	O
limietd	O
quantiteis	O
of	O
mannitol	O
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
ptaients	O
at	O
particularly	O
high	O
rsik	O
of	O
nephrotoxiicty	B-Disease
.	O

Our	O
anaylsis	O
suggests	O
that	O
those	O
ptaients	O
receiving	O
the	O
dosnig	O
schedlue	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cislpatin	O
every	O
3	O
weeks	O
and	O
those	O
with	O
hypetrension	B-Disease
are	O
at	O
the	O
greatest	O
rsik	O
of	O
neprhotoxicity	B-Disease
and	O
would	O
beenfit	O
from	O
the	O
addition	O
of	O
mnanitol	O
.	O

Metforimn	O
protcets	O
against	O
seiuzres	B-Disease
,	O
leanring	B-Disease
and	I-Disease
mmeory	I-Disease
impairmnets	I-Disease
and	O
oxdiative	O
damgae	O
inudced	O
by	O
pentylenteetrazole	O
-	O
induecd	O
kinlding	O
in	O
mcie	O
.	O

Cogintive	B-Disease
impairemnt	I-Disease
,	O
the	O
most	O
common	O
and	O
seevre	O
comoribdity	O
of	O
epilespy	B-Disease
,	O
greatly	O
diimnishes	O
the	O
qualtiy	O
of	O
lfie	O
.	O

However	O
,	O
current	O
thearpeutic	O
interventinos	O
for	O
epliepsy	B-Disease
can	O
also	O
cause	O
untoward	O
cognitvie	O
effects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agnets	O
taregting	O
both	O
siezures	B-Disease
and	O
cogintion	B-Disease
defciits	I-Disease
.	O

Oxdiative	O
strses	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptoegnesis	O
and	O
cogintive	B-Disease
dfeicits	I-Disease
,	O
and	O
antixoidants	O
have	O
a	O
putative	O
antiepilepitc	O
potenital	O
.	O

Mteformin	O
,	O
the	O
most	O
commonly	O
prescrbied	O
antidibaetic	O
oarl	O
durg	O
,	O
has	O
antioxiadnt	O
porperties	O
.	O

This	O
sutdy	O
was	O
designed	O
to	O
eavluate	O
the	O
ameilorative	O
effcets	O
of	O
metforimn	O
on	O
seizuers	B-Disease
,	O
cogniitve	B-Disease
impiarment	I-Disease
and	O
barin	O
oxidtaive	O
strses	O
markres	O
observed	O
in	O
penytlenetetrazole	O
-	O
inudced	O
kindilng	O
anmials	O
.	O

Mlae	O
C5B7L	O
/	O
6	O
mcie	O
were	O
admniistered	O
with	O
subcnovulsive	O
dsoe	O
of	O
pentyleentetrazole	O
(	O
37	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injcetions	O
.	O

Metfromin	O
was	O
ijnected	O
intrpaeritoneally	O
in	O
dsoe	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	O
.	O

We	O
found	O
that	O
metforimn	O
supperssed	O
the	O
progerssion	O
of	O
kinlding	O
,	O
amelioarted	O
the	O
cogntiive	B-Disease
imapirment	I-Disease
and	O
derceased	O
brian	O
oxdiative	O
strses	O
.	O

Thus	O
the	O
present	O
sutdy	O
concluded	O
that	O
metofrmin	O
may	O
be	O
a	O
potnetial	O
aegnt	O
for	O
the	O
treamtent	O
of	O
epilpesy	B-Disease
as	O
well	O
as	O
a	O
protective	O
medicnie	O
against	O
cogintive	B-Disease
ipmairment	I-Disease
induecd	O
by	O
siezures	B-Disease
.	O

P53	O
inhibtiion	O
exacerbaets	O
ltae	O
-	O
stgae	O
antrhacycline	O
caridotoxicity	B-Disease
.	O

AMIS	O
:	O
Doxourbicin	O
(	O
DOX	O
)	O
is	O
an	O
effective	O
atni	O
-	O
cnacer	B-Disease
therapetuic	O
,	O
but	O
is	O
associated	O
with	O
both	O
actue	O
and	O
ltae	O
-	O
stgae	O
cardiotxoicity	B-Disease
.	O

Chlidren	O
are	O
particularly	O
senstiive	O
to	O
DOX	O
-	O
induecd	O
herat	B-Disease
failrue	I-Disease
.	O

Here	O
,	O
the	O
ipmact	O
of	O
p53	O
inhiibtion	O
on	O
actue	O
vs	O
.	O
ltae	O
-	O
satge	O
DOX	O
cadriotoxicity	B-Disease
was	O
examined	O
in	O
a	O
juveinle	O
mdoel	O
.	O

METHODS	O
AND	O
RESUTLS	O
:	O
Two	O
-	O
week	O
-	O
old	O
MHC	O
-	O
CB7	O
mcie	O
(	O
which	O
express	O
dominnat	O
-	O
interfeirng	O
p53	O
in	O
cadriomyocytes	O
)	O
and	O
their	O
non	O
-	O
trangsenic	O
(	O
NON	O
-	O
TXG	O
)	O
littermaets	O
received	O
weelky	O
DOX	O
injecitons	O
for	O
5	O
weeks	O
(	O
25	O
mg	O
/	O
kg	O
cmuulative	O
dsoe	O
)	O
.	O

One	O
week	O
after	O
the	O
last	O
DOX	O
traetment	O
(	O
aucte	O
satge	O
)	O
,	O
MHC	O
-	O
CB7	O
mcie	O
exhibited	O
imporved	O
cadriac	O
funtcion	O
and	O
lwoer	O
leevls	O
of	O
cardimoyocyte	O
apopotsis	O
when	O
compaerd	O
with	O
the	O
NON	O
-	O
TXG	O
mcie	O
.	O

Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	O
treatmnet	O
(	O
ltae	O
satge	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
progrsesive	O
dcerease	O
in	O
cradiac	O
fnuction	O
and	O
hihger	O
raets	O
of	O
cradiomyocyte	O
apopotsis	O
when	O
compraed	O
with	O
NON	O
-	O
TXG	O
mcie	O
.	O

p53	O
inhibiiton	O
blcoked	O
tarnsient	O
DOX	O
-	O
inudced	O
SATT3	O
atcivation	O
in	O
MHC	O
-	O
CB7	O
mcie	O
,	O
which	O
was	O
associated	O
with	O
enhnaced	O
indcution	O
of	O
the	O
DNA	O
rpeair	O
prtoeins	O
K7u0	O
and	O
K8u0	O
.	O

Mcie	O
with	O
cadriomyocyte	O
-	O
restricted	O
deleiton	O
of	O
STTA3	O
exhibited	O
wrose	O
cardaic	O
fucntion	O
,	O
hgiher	O
lveels	O
of	O
cardiomyoycte	O
apotposis	O
,	O
and	O
a	O
greater	O
inudction	O
of	O
K7u0	O
and	O
K8u0	O
in	O
resposne	O
to	O
DOX	O
treatemnt	O
during	O
the	O
actue	O
stgae	O
when	O
compaerd	O
with	O
conrtol	O
aniamls	O
.	O

CONCLSUION	O
:	O
These	O
dtaa	O
support	O
a	O
moedl	O
wherein	O
a	O
p53	O
-	O
depednent	O
cardioprotectvie	O
pathawy	O
,	O
mediated	O
via	O
SATT3	O
activtaion	O
,	O
miitgates	O
DOX	O
-	O
inudced	O
myocaridal	O
srtess	O
during	O
durg	O
delievry	O
.	O

Furthermore	O
,	O
these	O
dtaa	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhbiition	O
can	O
result	O
in	O
cardioportection	O
during	O
durg	O
teratment	O
and	O
,	O
paraodxically	O
,	O
enahnced	O
caridotoxicity	B-Disease
long	O
after	O
the	O
cesstaion	O
of	O
durg	O
treatmnet	O
.	O

Metornidazole	O
-	O
idnuced	O
encephalopahty	B-Disease
:	O
an	O
uncommon	O
scenario	O
.	O

Metronidazloe	O
can	O
produce	O
neurologcial	O
compliactions	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
csae	O
where	O
a	O
ptaient	O
developed	O
faetures	O
of	O
enecphalopathy	B-Disease
following	O
prloonged	O
metrondiazole	O
itnake	O
.	O

Mangetic	O
resoannce	O
iamging	O
(	O
MRI	O
)	O
brian	O
showed	O
abnoraml	O
sginal	O
intesnity	O
involving	O
both	O
detnate	O
nulcei	O
of	O
ceerbellum	O
and	O
slpenium	O
of	O
cropus	O
callsoum	O
.	O

The	O
diagnoiss	O
of	O
metroniadzole	O
txoicity	B-Disease
was	O
made	O
by	O
the	O
MRI	O
findnigs	O
and	O
supported	O
cilnically	O
.	O

Aconitnie	O
-	O
idnuced	O
Ca2	O
+	O
overolad	O
causes	O
arrhythmia	B-Disease
and	O
triggers	O
apoptoiss	O
through	O
p38	O
MPAK	O
sginaling	O
pathawy	O
in	O
rtas	O
.	O

Acontiine	O
is	O
a	O
major	O
bioactvie	O
diterpneoid	O
alkaliod	O
with	O
high	O
cnotent	O
derived	O
from	O
hebral	O
aconitum	O
palnts	O
.	O

Emerging	O
evdience	O
indicates	O
that	O
voltgae	O
-	O
deepndent	O
Na	O
(	O
+	O
)	O
cahnnels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxictiy	B-Disease
of	O
aconiitne	O
.	O

However	O
,	O
no	O
reprots	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	O
(	O
2	O
+	O
)	O
in	O
aconitnie	O
poisoinng	B-Disease
.	O

In	O
this	O
sutdy	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pahtological	O
Ca	O
(	O
2	O
+	O
)	O
singaling	O
in	O
acnoitine	O
poiosning	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	O
(	O
2	O
+	O
)	O
oevrload	O
lead	O
to	O
accelearted	O
baeting	O
ryhthm	O
in	O
adlut	O
rat	O
ventricualr	O
mycoytes	O
and	O
caused	O
arrhtyhmia	B-Disease
in	O
consciuos	O
freely	O
moivng	O
rtas	O
.	O

To	O
investigtae	O
efefcts	O
of	O
aconitnie	O
on	O
myocradial	B-Disease
ijnury	I-Disease
,	O
we	O
performed	O
ctyotoxicity	B-Disease
assay	O
in	O
neoantal	O
rat	O
ventricualr	O
moycytes	O
(	O
NRMVs	O
)	O
,	O
as	O
well	O
as	O
mesaured	O
latcate	O
dehydrognease	O
leevl	O
in	O
the	O
cluture	O
mdeium	O
of	O
NVRMs	O
and	O
activtiies	O
of	O
seurm	O
caridac	O
enzmyes	O
in	O
rtas	O
.	O

The	O
resluts	O
showed	O
that	O
aocnitine	O
resulted	O
in	O
moycardial	B-Disease
injruy	I-Disease
and	O
reudced	O
NRMVs	O
viabiilty	O
dsoe	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
appototic	O
effects	O
,	O
we	O
performed	O
folw	O
cytomteric	O
dteection	O
,	O
cardaic	O
histoolgy	O
,	O
tranmsission	O
elcetron	O
mciroscopy	O
and	O
terimnal	O
deoxynucletoidyl	O
transfersae	O
-	O
mediated	O
dTUP	O
-	O
bioitn	O
ncik	O
end	O
labeilng	O
assay	O
.	O

The	O
rseults	O
showed	O
that	O
acnoitine	O
stimulaetd	O
apoptoiss	O
tmie	O
-	O
dependently	O
.	O

The	O
expressoin	O
anaylsis	O
of	O
Ca	O
(	O
2	O
+	O
)	O
hadnling	O
protenis	O
demonstrated	O
that	O
acointine	O
promoted	O
Ca	O
(	O
2	O
+	O
)	O
overlaod	O
through	O
the	O
epxression	O
reuglation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
handlnig	O
proetins	O
.	O

The	O
exprsesion	O
analyiss	O
of	O
aopptosis	O
-	O
related	O
prtoeins	O
rveealed	O
that	O
pro	O
-	O
apoptoitc	O
portein	O
experssion	O
was	O
upergulated	O
,	O
and	O
atni	O
-	O
apopottic	O
prtoein	O
BCL	O
-	O
2	O
epxression	O
was	O
downregulaetd	O
.	O

Furthermore	O
,	O
inrceased	O
phosphoryaltion	O
of	O
MPAK	O
faimly	O
membres	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
rtaio	O
was	O
found	O
in	O
cradiac	O
tsisues	O
.	O

Hence	O
,	O
our	O
reuslts	O
suggest	O
that	O
aocnitine	O
significantly	O
aggravates	O
Ca	O
(	O
2	O
+	O
)	O
ovelroad	O
and	O
causes	O
arrhythima	B-Disease
and	O
finally	O
prmootes	O
apoptoitc	O
develompent	O
via	O
phosphroylation	O
of	O
P38	O
mitgoen	O
-	O
activaetd	O
proetin	O
kianse	O
.	O

Chrnoic	O
treatmnet	O
with	O
meftormin	O
suppresses	O
tlol	O
-	O
like	O
rceeptor	O
4	O
signlaing	O
and	O
atetnuates	O
lfet	B-Disease
ventriuclar	I-Disease
dysfucntion	I-Disease
following	O
myocaridal	B-Disease
infarctoin	I-Disease
.	O

Aucte	O
teratment	O
with	O
metfromin	O
has	O
a	O
protective	O
effcet	O
in	O
myoacrdial	B-Disease
ifnarction	I-Disease
by	O
suppressoin	O
of	O
inflmamatory	O
respnoses	O
due	O
to	O
actiavtion	O
of	O
AMP	O
-	O
activtaed	O
portein	O
kianse	O
(	O
APMK	O
)	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
the	O
efefct	O
of	O
chornic	O
pre	O
-	O
treatemnt	O
with	O
metforimn	O
on	O
cardaic	B-Disease
dysfuntcion	I-Disease
and	O
tlol	O
-	O
like	O
recepotr	O
4	O
(	O
TRL4	O
)	O
activtiies	O
following	O
mycoardial	B-Disease
inafrction	I-Disease
and	O
their	O
relation	O
with	O
APMK	O
were	O
asssesed	O
.	O

Mlae	O
Witsar	O
rtas	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
gropus	O
(	O
n	O
=	O
6	O
)	O
:	O
nromal	O
conrtol	O
and	O
gorups	O
were	O
injetced	O
isoporterenol	O
after	O
chroinc	O
pre	O
-	O
tretament	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
mteformin	O
twice	O
dialy	O
for	O
14	O
dyas	O
.	O

Isporoterenol	O
(	O
100mg	O
/	O
kg	O
)	O
was	O
injetced	O
sucbutaneously	O
on	O
the	O
13th	O
and	O
14th	O
dyas	O
to	O
idnuce	O
actue	B-Disease
myoacrdial	I-Disease
infarciton	I-Disease
.	O

Isoproetrenol	O
alone	O
decresaed	O
lfet	O
ventricualr	O
ssytolic	O
perssure	O
and	O
myocaridal	O
contrcatility	O
indeexd	O
as	O
LdVp	O
/	O
dmtax	O
and	O
LdVp	O
/	O
dtimn	O
.	O

The	O
lfet	B-Disease
vnetricular	I-Disease
dysfnuction	I-Disease
was	O
significantly	O
lwoer	O
in	O
the	O
gorups	O
terated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metforimn	O
.	O

Metrfomin	O
markedly	O
lwoered	O
isoporterenol	O
-	O
inudced	O
elevtaion	O
in	O
the	O
leevls	O
of	O
TRL4	O
mNRA	O
,	O
myeliod	O
differentiation	O
proetin	O
88	O
(	O
My8D8	O
)	O
,	O
tmuor	B-Disease
ncerosis	B-Disease
fcator	O
-	O
alhpa	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interlekuin	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
haert	O
tisuses	O
.	O

Similar	O
chnages	O
were	O
also	O
seen	O
in	O
the	O
sreum	O
leevls	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O

However	O
,	O
the	O
lwoer	O
doess	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effectvie	O
than	O
100mg	O
/	O
kg	O
.	O

Phsophorylated	O
AMKPa	O
(	O
p	O
-	O
APMK	O
)	O
in	O
the	O
myocaridum	O
was	O
significantly	O
elevtaed	O
by	O
25mg	O
/	O
kg	O
of	O
metfromin	O
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chroinc	O
pre	O
-	O
traetment	O
with	O
mteformin	O
reduecs	O
psot	O
-	O
mycoardial	B-Disease
ifnarction	I-Disease
cardaic	O
dysfuntcion	O
and	O
suppersses	O
ifnlammatory	O
resposnes	O
,	O
possibly	O
through	O
inhibiiton	O
of	O
TRL4	O
actviities	O
.	O

This	O
mehcanism	O
can	O
be	O
considered	O
as	O
a	O
taregt	O
to	O
protect	O
infartced	O
myocadrium	O
.	O

Unuusal	O
complicatoins	O
of	O
atnithyroid	O
durg	O
tehrapy	O
:	O
four	O
csae	O
reprots	O
and	O
reivew	O
of	O
litertaure	O
.	O

Two	O
csaes	O
of	O
propytlhiouracil	O
-	O
associated	O
aucte	O
heptaitis	B-Disease
,	O
one	O
csae	O
of	O
faatl	O
mtehimazole	O
-	O
associated	O
hepaotcellular	B-Disease
nercosis	I-Disease
and	O
one	O
csae	O
of	O
propylthiourcail	O
-	O
associated	O
luups	B-Disease
-	I-Disease
like	I-Disease
snydrome	I-Disease
are	O
described	O
.	O

The	O
litertaure	O
related	O
to	O
antithyorid	O
durg	O
side	O
effetcs	O
and	O
the	O
mechainsms	O
for	O
their	O
occurrnece	O
are	O
reviweed	O
and	O
the	O
efifcacy	O
and	O
cmoplications	O
of	O
thyroiedctomy	O
and	O
radiooidine	O
compaerd	O
to	O
those	O
of	O
anttihyroid	O
durgs	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
thearpy	O
of	O
choice	O
for	O
hypetrhyroidism	B-Disease
.	O

Neuroelptic	B-Disease
malingant	I-Disease
snydrome	I-Disease
induecd	O
by	O
cmobination	O
threapy	O
with	O
tetrabenzaine	O
and	O
tiparide	O
in	O
a	O
Jaapnese	O
patinet	O
with	O
Huntingotn	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
at	O
the	O
terimnal	O
satge	O
of	O
recurrnet	O
braest	B-Disease
cacner	I-Disease
.	O

We	O
herein	O
describe	O
the	O
csae	O
of	O
an	O
81	O
-	O
yaer	O
-	O
old	O
Jpaanese	O
wmoan	O
with	O
neuroelptic	B-Disease
malginant	I-Disease
sydnrome	I-Disease
that	O
occurred	O
36	O
dyas	O
after	O
the	O
iniitation	O
of	O
combintaion	O
thearpy	O
with	O
tiaprdie	O
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabenzaine	O
(	O
12	O
.	O
5	O
mg	O
/	O
day	O
)	O
for	O
Huntintgon	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
.	O

The	O
ptaient	O
had	O
been	O
traeted	O
with	O
tiparide	O
or	O
tertabenazine	O
alone	O
without	O
any	O
advrese	O
effcets	O
before	O
the	O
adminisrtation	O
of	O
the	O
combintaion	O
threapy	O
.	O

She	O
also	O
had	O
advacned	O
braest	B-Disease
cnacer	I-Disease
when	O
the	O
comibnation	O
therpay	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowlegde	O
,	O
the	O
ocucrrence	O
of	O
neurolpetic	B-Disease
malginant	I-Disease
syndrmoe	I-Disease
due	O
to	O
cmobination	O
thearpy	O
with	O
tetrabenzaine	O
and	O
taipride	O
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrabeanzine	O
should	O
be	O
adminsitered	O
very	O
carefully	O
in	O
combiantion	O
with	O
other	O
neuroelptic	O
durgs	O
,	O
particularly	O
in	O
pateints	O
with	O
a	O
worsneing	O
general	O
condtiion	O
.	O

A	O
metporolol	O
-	O
terbinafnie	O
combniation	O
idnuced	O
bradcyardia	B-Disease
.	O

To	O
reprot	O
a	O
snius	B-Disease
bradycarida	I-Disease
inudced	O
by	O
metorpolol	O
and	O
terbinaifne	O
durg	O
-	O
durg	O
intearction	O
and	O
its	O
mangaement	O
.	O

A	O
63	O
yaer	O
-	O
old	O
Cauacsian	O
man	O
on	O
mteoprolol	O
200	O
mg	O
/	O
day	O
for	O
satble	O
coornary	B-Disease
atrery	I-Disease
diesase	I-Disease
was	O
prescirbed	O
a	O
90	O
-	O
day	O
cousre	O
of	O
oarl	O
trebinafine	O
250	O
mg	O
/	O
day	O
for	O
oynchomycosis	B-Disease
.	O

On	O
the	O
49th	O
day	O
of	O
terbinafnie	O
therpay	O
,	O
he	O
was	O
brought	O
to	O
the	O
eemrgency	O
room	O
for	O
a	O
dercease	O
of	O
his	O
glboal	O
helath	O
stauts	O
,	O
confuison	B-Disease
and	O
flals	O
.	O

The	O
electrocaridogram	O
revelaed	O
a	O
37	O
betas	O
/	O
min	O
siuns	B-Disease
bradcyardia	I-Disease
.	O

A	O
socre	O
of	O
7	O
on	O
the	O
Nraanjo	O
adevrse	B-Disease
durg	I-Disease
reatcion	I-Disease
probbaility	O
scale	O
indicates	O
a	O
probable	O
relationhsip	O
between	O
the	O
ptaient	O
'	O
s	O
snius	B-Disease
bradycadria	I-Disease
and	O
the	O
durg	O
intercation	O
between	O
metoprooll	O
and	O
tebrinafine	O
.	O

The	O
herat	O
rtae	O
aemliorated	O
first	O
with	O
a	O
decraese	O
in	O
the	O
dsoe	O
of	O
metorpolol	O
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisoporlol	O
and	O
the	O
herat	O
rtae	O
remained	O
nromal	O
.	O

By	O
inhbiiting	O
the	O
cytochrmoe	O
P540	O
2D6	O
,	O
terbianfine	O
had	O
decresaed	O
metorpolol	O
'	O
s	O
cleaarnce	O
,	O
leading	O
in	O
metoporlol	O
accumulatoin	O
which	O
has	O
resulted	O
in	O
cliniclaly	O
significant	O
siuns	B-Disease
braydcardia	I-Disease
.	O

Optohciasmatic	O
and	O
perihperal	B-Disease
neuroapthy	I-Disease
due	O
to	O
ethambuotl	O
overtreamtent	O
.	O

Ethabmutol	O
is	O
known	O
to	O
cause	O
opitc	B-Disease
neuropahty	I-Disease
and	O
,	O
more	O
rarely	O
,	O
aoxnal	O
ployneuropathy	B-Disease
.	O

We	O
characterize	O
the	O
cliincal	O
,	O
neurophysioloigcal	O
,	O
and	O
neuorimaging	O
fidnings	O
in	O
a	O
72	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
visaul	B-Disease
lsos	I-Disease
and	O
parestehsias	B-Disease
after	O
11	O
wekes	O
of	O
exopsure	O
to	O
a	O
suprathreapeutic	O
dsoe	O
of	O
ethmabutol	O
.	O

This	O
csae	O
demonstrates	O
the	O
selective	O
vulnerbaility	O
of	O
the	O
atnerior	O
vsiual	O
patwhays	O
and	O
periphreal	O
nreves	O
to	O
ethabmutol	O
toxictiy	B-Disease
.	O

Testosternoe	O
ameliortaes	O
streptzootocin	O
-	O
idnuced	O
mmeory	B-Disease
ipmairment	I-Disease
in	O
mlae	O
rtas	O
.	O

AIM	O
:	O
To	O
sutdy	O
the	O
efefcts	O
of	O
testosteorne	O
on	O
streptozootcin	O
(	O
STZ	O
)	O
-	O
induecd	O
memroy	B-Disease
imapirment	I-Disease
in	O
mlae	O
rtas	O
.	O

METHODS	O
:	O
Audlt	O
mlae	O
Witsar	O
rtas	O
were	O
intracerberoventricularly	O
(	O
icv	O
)	O
inufsed	O
with	O
STZ	O
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passvie	O
avodiance	O
tsak	O
was	O
assessed	O
2	O
wekes	O
after	O
the	O
first	O
ijnection	O
of	O
STZ	O
.	O

Castrtaion	O
srugery	O
was	O
performed	O
in	O
another	O
gruop	O
of	O
rtas	O
,	O
and	O
the	O
pasisve	O
avodiance	O
tsak	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
opertaion	O
.	O

Testosetrone	O
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
andorgen	O
reecptor	O
antagnoist	O
fltuamide	O
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrgoen	O
recetpor	O
atnagonist	O
tmaoxifen	O
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
or	O
the	O
armoatase	O
ihnibitor	O
letrzoole	O
(	O
4	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
were	O
adimnistered	O
for	O
6	O
d	O
after	O
the	O
first	O
injetcion	O
of	O
STZ	O
.	O

RESUTLS	O
:	O
STZ	O
adminsitration	O
and	O
casrtation	O
markedly	O
decresaed	O
both	O
SLT1	O
(	O
the	O
short	O
memroy	O
)	O
and	O
SLT2	O
(	O
the	O
long	O
memroy	O
)	O
in	O
psasive	O
avodiance	O
tetss	O
.	O

Testsoterone	O
rpelacement	O
almost	O
restroed	O
the	O
SLT1	O
and	O
SLT2	O
in	O
csatrated	O
rtas	O
,	O
and	O
significantly	O
porlonged	O
the	O
SLT1	O
and	O
SLT2	O
in	O
STZ	O
-	O
traeted	O
rtas	O
.	O

Administartion	O
of	O
flutaimde	O
,	O
letorzole	O
or	O
tmaoxifen	O
significantly	O
impaierd	B-Disease
the	I-Disease
memroy	I-Disease
in	O
itnact	O
rtas	O
,	O
and	O
significantly	O
attenuated	O
the	O
tsetosterone	O
replcaement	O
in	O
improivng	O
STZ	O
-	O
and	O
catsration	O
-	O
inudced	O
memroy	B-Disease
impairemnt	I-Disease
.	O

CONCLSUION	O
:	O
Testosetrone	O
administartion	O
ameilorates	O
STZ	O
-	O
and	O
csatration	O
-	O
idnuced	O
memroy	B-Disease
ipmairment	I-Disease
in	O
mlae	O
Wisatr	O
rtas	O
.	O

Behavoiral	O
and	O
neurocehmical	O
stuides	O
in	O
mcie	O
prerteated	O
with	O
garciinelliptone	O
FC	O
in	O
piolcarpine	O
-	O
inudced	O
seiuzres	B-Disease
.	O

Garcinileliptone	O
FC	O
(	O
GFC	O
)	O
isoalted	O
from	O
heaxnic	O
fractoin	O
seed	O
etxract	O
of	O
speices	O
Paltonia	O
insingis	O
Mrat	O
.	O

It	O
is	O
widely	O
used	O
in	O
flok	O
mediicne	O
to	O
terat	O
sikn	B-Disease
disaeses	I-Disease
in	O
both	O
hmuans	O
and	O
aniamls	O
as	O
well	O
as	O
the	O
seed	O
decociton	O
has	O
been	O
used	O
to	O
traet	O
diarrehas	B-Disease
and	O
inflammtaory	B-Disease
dsieases	I-Disease
.	O

However	O
,	O
there	O
is	O
no	O
reseacrh	O
on	O
GFC	O
effetcs	O
in	O
the	O
centarl	O
nerovus	O
ssytem	O
of	O
rodetns	O
.	O

The	O
present	O
sutdy	O
aimed	O
to	O
eavluate	O
the	O
GFC	O
effcets	O
at	O
doess	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizrue	B-Disease
paramteers	O
to	O
determine	O
their	O
anitconvulsant	O
acitvity	O
and	O
its	O
effetcs	O
on	O
amnio	O
aicd	O
(	O
r	O
-	O
aminoubtyric	O
aicd	O
(	O
GBAA	O
)	O
,	O
glutmaine	O
,	O
asparatte	O
and	O
gluatthione	O
)	O
leevls	O
as	O
well	O
as	O
on	O
acetylhcolinesterase	O
(	O
AhCE	O
)	O
actviity	O
in	O
mcie	O
hippocapmus	O
after	O
seziures	B-Disease
.	O

GFC	O
produced	O
an	O
increaesd	O
latecny	O
to	O
first	O
siezure	B-Disease
,	O
at	O
dsoes	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
cmopared	O
with	O
sezied	O
mcie	O
.	O

In	O
addition	O
,	O
GBAA	O
cnotent	O
of	O
mcie	O
hpipocampus	O
traeted	O
with	O
GCF75	O
plus	O
P040	O
showed	O
an	O
incraese	O
of	O
46	O
.	O
90	O
%	O
when	O
compraed	O
with	O
seiezd	O
mcie	O
.	O

In	O
aspatrate	O
,	O
glutamnie	O
and	O
gltuamate	O
leevls	O
deetcted	O
a	O
decraese	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mcie	O
hippocampus	O
tretaed	O
with	O
GCF75	O
plus	O
P040	O
when	O
compaerd	O
with	O
sezied	O
mcie	O
.	O

Hippocapmus	O
mcie	O
traeted	O
with	O
GF7C5	O
plus	O
P040	O
showed	O
an	O
incraese	O
in	O
AhCE	O
activtiy	O
(	O
63	O
.	O
30	O
%	O
)	O
when	O
copmared	O
with	O
seiezd	O
mcie	O
.	O

The	O
resutls	O
indicate	O
that	O
GFC	O
can	O
exert	O
anticonvulasnt	O
actiivty	O
and	O
redcue	O
the	O
frqeuency	O
of	O
isntallation	O
of	O
piolcarpine	O
-	O
indcued	O
sattus	B-Disease
eiplepticus	I-Disease
,	O
as	O
demonstrated	O
by	O
incraese	O
in	O
latecny	O
to	O
first	O
seizrue	B-Disease
and	O
decresae	O
in	O
mortaltiy	O
rtae	O
of	O
aniamls	O
.	O

In	O
conclusion	O
,	O
our	O
dtaa	O
suggest	O
that	O
GFC	O
may	O
inlfuence	O
in	O
epilepotgenesis	O
and	O
prmoote	O
antiocnvulsant	O
actoins	O
in	O
pilocaripne	O
mdoel	O
by	O
modualting	O
the	O
GBAA	O
and	O
gluatmate	O
cnotents	O
and	O
of	O
AhCE	O
acitvity	O
in	O
siezed	O
mcie	O
hpipocampus	O
.	O

This	O
compuond	O
may	O
be	O
useful	O
to	O
produce	O
neruonal	O
portection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticnovulsant	O
agnet	O
.	O

Stanadrd	O
opreating	O
proecdures	O
for	O
antibioitc	O
tehrapy	O
and	O
the	O
occrurence	O
of	O
aucte	B-Disease
kindey	I-Disease
inujry	I-Disease
:	O
a	O
porspective	O
,	O
cliincal	O
,	O
non	O
-	O
interventioanl	O
,	O
obsrevational	O
stduy	O
.	O

INTRODUCTION	O
:	O
Aucte	B-Disease
kideny	I-Disease
ijnury	I-Disease
(	O
AKI	B-Disease
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitaliezd	O
and	O
66	O
%	O
of	O
Intnesive	O
Crae	O
Uint	O
(	O
ICU	O
)	O
pateints	O
.	O

It	O
icnreases	O
mrotality	O
,	O
hopsital	O
lnegth	O
of	O
stay	O
,	O
and	O
csots	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
investigtae	O
,	O
whether	O
there	O
is	O
an	O
asscoiation	O
between	O
adhernece	O
to	O
giudelines	O
(	O
stnadard	O
opearting	O
porcedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoixc	B-Disease
antiibotics	O
and	O
the	O
occurrence	O
of	O
AKI	B-Disease
.	O

METHODS	O
:	O
This	O
stduy	O
was	O
carried	O
out	O
as	O
a	O
prosepctive	O
,	O
clincial	O
,	O
non	O
-	O
intervetnional	O
,	O
observtaional	O
stduy	O
.	O

Dtaa	O
colleciton	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
dyas	O
in	O
three	O
IUCs	O
at	O
Charite	O
-	O
Univesritaetsmedizin	O
Brelin	O
.	O

A	O
total	O
of	O
675	O
patietns	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
therpay	O
with	O
vancmoycin	O
,	O
getnamicin	O
,	O
or	O
tobramcyin	O
;	O
were	O
>	O
18	O
yeras	O
;	O
and	O
traeted	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Pateints	O
with	O
an	O
adehrence	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adheernce	O
gruop	O
(	O
HAG	O
)	O
and	O
paitents	O
with	O
an	O
adhreence	O
of	O
<	O
70	O
%	O
into	O
the	O
low	O
adheernce	O
gruop	O
(	O
LAG	O
)	O
.	O

AKI	B-Disease
was	O
defined	O
according	O
to	O
RFILE	O
criteira	O
.	O

Ahderence	O
to	O
SPOs	O
was	O
evalauted	O
by	O
rertospective	O
epxert	O
aduit	O
.	O

Deevlopment	O
of	O
AKI	B-Disease
was	O
compraed	O
between	O
gropus	O
with	O
exact	O
Cih2	O
-	O
tset	O
and	O
multivaraite	O
loigstic	O
regressoin	O
aanlysis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

RESLUTS	O
:	O
LAG	O
consisted	O
of	O
75	O
patinets	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
patinets	O
(	O
54	O
%	O
)	O
.	O

AKI	B-Disease
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O

Bsaic	O
characteirstics	O
were	O
comparable	O
,	O
except	O
an	O
icnreased	O
rtae	O
of	O
sfot	O
tisuse	O
inefctions	B-Disease
in	O
LAG	O
.	O

Multviariate	O
anlaysis	O
reveaeld	O
an	O
odds	O
raito	O
of	O
2	O
.	O
5	O
-	O
fold	O
for	O
LAG	O
to	O
develop	O
AKI	B-Disease
compraed	O
with	O
HAG	O
(	O
95	O
%	O
confdience	O
itnerval	O
1	O
.	O
195	O
to	O
5	O
.	O
124	O
,	O
P	O
=	O
0	O
.	O
039	O
)	O
.	O

CONCLUISON	O
:	O
Low	O
adhreence	O
to	O
SPOs	O
for	O
potentially	O
npehrotoxic	B-Disease
antibioitcs	O
was	O
associated	O
with	O
a	O
hgiher	O
occurrnece	O
of	O
AKI	B-Disease
.	O

TIRAL	O
REGISTRATION	O
:	O
Current	O
Cotnrolled	O
Trilas	O
ISRCTN54598675	O
.	O

Registeerd	O
17	O
August	O
2007	O
.	O

Rhadbomyolysis	B-Disease
in	O
a	O
heptaitis	B-Disease
C	I-Disease
viurs	I-Disease
infceted	I-Disease
patinet	O
traeted	O
with	O
telaprveir	O
and	O
simvasattin	O
.	O

A	O
46	O
-	O
yaer	O
old	O
man	O
with	O
a	O
crhonic	O
heaptitis	B-Disease
C	I-Disease
vrius	I-Disease
infeciton	I-Disease
received	O
trilpe	O
threapy	O
with	O
ribaviirn	O
,	O
pegyalted	O
interfreon	O
and	O
telapreivr	O
.	O

The	O
patinet	O
also	O
received	O
simvasattin	O
.	O

One	O
motnh	O
after	O
starting	O
the	O
atniviral	O
therpay	O
,	O
the	O
paitent	O
was	O
admitted	O
to	O
the	O
hosiptal	O
because	O
he	O
developed	O
rhabdomyloysis	B-Disease
.	O

At	O
adimssion	O
simavstatin	O
and	O
all	O
antiivral	O
durgs	O
were	O
discontiuned	O
because	O
toxiicty	B-Disease
due	O
to	O
a	O
durg	O
-	O
durg	O
intercation	O
was	O
suspetced	O
.	O

The	O
creaitne	O
kinsae	O
peaked	O
at	O
62	O
,	O
246	O
IU	O
/	O
L	O
and	O
the	O
ptaient	O
was	O
tretaed	O
with	O
intrvaenous	O
nromal	O
slaine	O
.	O

The	O
patinet	O
'	O
s	O
rneal	O
fucntion	O
remained	O
unaffceted	O
.	O

Fourteen	O
dyas	O
after	O
hospitalziation	O
,	O
creaitne	O
kianse	O
lveel	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
pateint	O
was	O
dischraged	O
.	O

Telarpevir	O
was	O
considered	O
the	O
probable	O
cauastive	O
agnet	O
of	O
an	O
interactoin	O
with	O
simvatsatin	O
according	O
to	O
the	O
Durg	O
Intearction	O
Proabbility	O
Sacle	O
.	O

The	O
itneraction	O
is	O
due	O
to	O
inhibiiton	O
of	O
CYPA34	O
-	O
mediated	O
simvasattin	O
celarance	O
.	O

Simvasattin	O
palsma	O
concentraiton	O
icnreased	O
30	O
times	O
in	O
this	O
paitent	O
and	O
sattin	O
idnuced	O
mucsle	B-Disease
toixcity	I-Disease
is	O
related	O
to	O
the	O
concentratoin	O
of	O
the	O
sattin	O
in	O
bolod	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
csae	O
we	O
illustrate	O
that	O
telarpevir	O
as	O
well	O
as	O
sattins	O
are	O
sucseptible	O
to	O
cliincal	O
releavnt	O
durg	O
-	O
durg	O
interactinos	O
.	O

Cobmination	O
of	O
brotezomib	O
,	O
thaldiomide	O
,	O
and	O
dexametahsone	O
(	O
VTD	O
)	O
as	O
a	O
consoildation	O
threapy	O
after	O
autolgoous	O
setm	O
clel	O
transplantaiton	O
for	O
sypmtomatic	O
mlutiple	B-Disease
myelmoa	I-Disease
in	O
Jaapnese	O
paitents	O
.	O

Consoliadtion	O
threapy	O
for	O
patinets	O
with	O
multpile	B-Disease
meyloma	I-Disease
(	O
MM	B-Disease
)	O
has	O
been	O
widely	O
adopted	O
to	O
imrpove	O
treatmnet	O
respnose	O
following	O
autoloogus	O
setm	O
clel	O
tarnsplantation	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
rertospectively	O
analyezd	O
the	O
saftey	O
and	O
efifcacy	O
of	O
comibnation	O
regiemn	O
of	O
bortzeomib	O
,	O
thlaidomide	O
,	O
and	O
dexamethsaone	O
(	O
VTD	O
)	O
as	O
consoildation	O
thearpy	O
in	O
24	O
Japnaese	O
pateints	O
with	O
newly	O
daignosed	O
MM	B-Disease
.	O

VTD	O
consisted	O
of	O
botrezomib	O
at	O
a	O
dsoe	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexaemthasone	O
at	O
a	O
dsoe	O
of	O
40	O
mg	O
/	O
day	O
on	O
dyas	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
day	O
ccyle	O
,	O
with	O
dialy	O
oarl	O
tahlidomide	O
at	O
a	O
dsoe	O
of	O
100	O
mg	O
/	O
day	O
.	O

Grdae	O
3	O
-	O
4	O
neutroepnia	B-Disease
and	O
thrombocytpoenia	B-Disease
were	O
dcoumented	O
in	O
four	O
and	O
three	O
paitents	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
durg	O
dsoe	O
rdeuction	O
due	O
to	O
cytoepnia	B-Disease
was	O
not	O
required	O
in	O
any	O
csae	O
.	O

Preipheral	B-Disease
neruopathy	I-Disease
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
seevre	O
grdae	O
3	O
-	O
4	O
periphearl	B-Disease
neuropahty	I-Disease
was	O
not	O
observed	O
.	O

Very	O
good	O
pratial	O
resopnse	O
or	O
better	O
respnose	O
(	O
>	O
VPGR	O
)	O
rtaes	O
before	O
and	O
after	O
consolidaiton	O
thearpy	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Paitents	O
had	O
a	O
significant	O
proabbility	O
of	O
imporving	O
from	O
<	O
VPGR	O
before	O
cnosolidation	O
tehrapy	O
to	O
>	O
VPGR	O
after	O
consoldiation	O
therpay	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O

The	O
VTD	O
regiemn	O
may	O
be	O
safe	O
and	O
effetcive	O
as	O
a	O
consoldiation	O
thearpy	O
in	O
the	O
treatemnt	O
of	O
MM	O
in	O
Japnaese	O
popualtion	O
.	O

Convesrion	O
to	O
siroliums	O
ameliroates	O
cylcosporine	O
-	O
induecd	O
nephropahty	B-Disease
in	O
the	O
rat	O
:	O
focus	O
on	O
seurm	O
,	O
urnie	O
,	O
gnee	O
,	O
and	O
prtoein	O
rneal	O
expresison	O
biomrakers	O
.	O

Prtoocols	O
of	O
converison	O
from	O
cyclosproin	O
A	O
(	O
CsA	O
)	O
to	O
sirloimus	O
(	O
SRL	O
)	O
have	O
been	O
widely	O
used	O
in	O
immunothreapy	O
after	O
trnasplantation	O
to	O
pervent	O
CsA	O
-	O
induecd	O
nehpropathy	B-Disease
,	O
but	O
the	O
molecluar	O
mcehanisms	O
underlying	O
these	O
protoclos	O
remain	O
nculear	O
.	O

This	O
sutdy	O
aimed	O
to	O
identify	O
the	O
mloecular	O
pahtways	O
and	O
putative	O
bimoarkers	O
of	O
CsA	O
-	O
to	O
-	O
SRL	O
convresion	O
in	O
a	O
rat	O
mdoel	O
.	O

Four	O
anmial	O
gruops	O
(	O
n	O
=	O
6	O
)	O
were	O
tesetd	O
during	O
9	O
wekes	O
:	O
conrtol	O
,	O
CsA	O
,	O
SRL	O
,	O
and	O
conevrsion	O
(	O
CsA	O
for	O
3	O
weeks	O
followed	O
by	O
SRL	O
for	O
6	O
weeks	O
)	O
.	O

Classical	O
and	O
emregent	O
sreum	O
,	O
urniary	O
,	O
and	O
kindey	O
tisuse	O
(	O
gnee	O
and	O
prtoein	O
exprsesion	O
)	O
markres	O
were	O
assessed	O
.	O

Rneal	B-Disease
lseions	I-Disease
were	O
analyezd	O
in	O
hematoxyiln	O
and	O
eoisn	O
,	O
peridoic	O
aicd	O
-	O
Scihff	O
,	O
and	O
Masosn	O
'	O
s	O
tirchrome	O
stians	O
.	O

SRL	O
-	O
tretaed	O
rtas	O
presented	O
proteniuria	B-Disease
and	O
NAGL	O
(	O
seurm	O
and	O
urianry	O
)	O
as	O
the	O
best	O
markres	O
of	O
reanl	B-Disease
impairemnt	I-Disease
.	O

Sohrt	O
CsA	O
treatemnt	O
presented	O
slight	O
or	O
even	O
absnet	O
kdiney	B-Disease
lesoins	I-Disease
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
mOTR	O
,	O
PNCA	O
,	O
T5P3	O
,	O
KIM	O
-	O
1	O
,	O
and	O
CGTF	O
as	O
rleevant	O
gnee	O
and	O
prtoein	O
chnages	O
.	O

Proolnged	O
CsA	O
exposrue	O
aggravated	O
rneal	B-Disease
damgae	I-Disease
,	O
without	O
clear	O
chnages	O
on	O
the	O
traditoinal	O
markres	O
,	O
but	O
with	O
chnages	O
in	O
sreums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TBRAs	O
clearacne	O
,	O
and	O
kindey	O
TGF	O
-	O
b	O
and	O
mOTR	O
.	O

Converison	O
to	O
SRL	O
prevented	O
CsA	O
-	O
induecd	O
rneal	B-Disease
dmaage	I-Disease
evoluiton	O
(	O
asbent	O
/	O
mlid	O
grdae	O
lesoins	O
)	O
,	O
while	O
NAGL	O
(	O
sreum	O
versus	O
urnie	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomakrer	O
of	O
CsA	O
replacemnet	O
to	O
SRL	O
.	O

Kiinn	O
B2	O
rceeptor	O
deeltion	O
and	O
blockgae	O
ameilorates	O
cispltain	O
-	O
indcued	O
actue	B-Disease
reanl	I-Disease
inujry	I-Disease
.	O

Cispaltin	O
treatmnet	O
has	O
been	O
adopted	O
in	O
some	O
chemotherpaies	O
;	O
however	O
,	O
this	O
durg	O
can	O
indcue	O
aucte	B-Disease
kdiney	I-Disease
injruy	I-Disease
due	O
its	O
ability	O
to	O
ngeatively	O
affect	O
rneal	O
fnuction	O
,	O
augment	O
sreum	O
lveels	O
of	O
creatinnie	O
and	O
uera	O
,	O
incresae	O
the	O
actue	B-Disease
tuublar	I-Disease
necroiss	I-Disease
socre	O
and	O
up	O
-	O
rgeulate	O
cytokiens	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
kiinn	O
B2	O
recpetor	O
has	O
been	O
associated	O
with	O
the	O
inflmamation	B-Disease
prcoess	O
,	O
as	O
well	O
as	O
the	O
rgeulation	O
of	O
cytoikne	O
exrpession	O
,	O
and	O
its	O
delteion	O
resulted	O
in	O
an	O
improevment	O
in	O
the	O
diaebtic	B-Disease
npehropathy	I-Disease
stauts	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kniin	O
B2	O
recetpor	O
in	O
cisplaitn	O
-	O
inudced	O
aucte	B-Disease
kideny	I-Disease
ijnury	I-Disease
,	O
kiinn	O
B2	O
rceeptor	O
konckout	O
mcie	O
were	O
challneged	O
with	O
csiplatin	O
.	O

Additionally	O
,	O
WT	O
mcie	O
were	O
traeted	O
with	O
a	O
B2	O
rceeptor	O
atnagonist	O
after	O
cislpatin	O
administraiton	O
.	O

B2	O
recetpor	O
-	O
defiicent	O
mcie	O
were	O
less	O
snesitive	O
to	O
this	O
durg	O
than	O
the	O
WT	O
mcie	O
,	O
as	O
shown	O
by	O
redcued	O
wegiht	B-Disease
lsos	I-Disease
,	O
better	O
preservatoin	O
of	O
kindey	O
funciton	O
,	O
down	O
regultaion	O
of	O
inlfammatory	O
cyotkines	O
and	O
less	O
actue	B-Disease
tuublar	I-Disease
necorsis	I-Disease
.	O

Moreover	O
,	O
treatemnt	O
with	O
the	O
kiinn	O
B2	O
reecptor	O
antagnoist	O
effectively	O
reudced	O
the	O
leevls	O
of	O
sreum	O
creatinnie	O
and	O
bolod	O
uera	O
after	O
cisplaitn	O
amdinistration	O
.	O

Thus	O
,	O
our	O
dtaa	O
suggest	O
that	O
the	O
kiinn	O
B2	O
recpetor	O
is	O
involved	O
in	O
cispltain	O
-	O
inudced	O
actue	B-Disease
kideny	I-Disease
ijnury	I-Disease
by	O
mediating	O
the	O
necortic	B-Disease
prcoess	O
and	O
the	O
expresison	O
of	O
inflammatroy	O
cytoiknes	O
,	O
thus	O
resulting	O
in	O
delcined	O
reanl	O
fnuction	O
.	O

These	O
resutls	O
highlight	O
the	O
kiinn	O
B2	O
rceeptor	O
antagnoist	O
traetment	O
in	O
ameliortaion	O
of	O
nephrotoxiicty	B-Disease
idnuced	O
by	O
cispltain	O
thearpy	O
.	O

Saefty	O
and	O
effiaccy	O
of	O
fluocinloone	O
aectonide	O
intravitrael	O
imlpant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
bidrshot	B-Disease
retniochoroidopathy	I-Disease
.	O

PUPROSE	O
:	O
To	O
reprot	O
the	O
treatemnt	O
outcmoes	O
of	O
the	O
fluocinolnoe	O
aceotnide	O
intarvitreal	O
ipmlant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
patietns	O
with	O
bridshot	B-Disease
retincohoroidopathy	I-Disease
whose	O
diesase	O
is	O
rerfactory	O
or	O
intoelrant	O
to	O
cnoventional	O
immunomodualtory	O
therpay	O
.	O

METHODS	O
:	O
A	O
retrospcetive	O
csae	O
series	O
involving	O
11	O
bidrshot	B-Disease
retinochoriodopathy	I-Disease
patinets	O
(	O
11	O
eeys	O
)	O
.	O

Eleven	O
pateints	O
(	O
11	O
eeys	O
)	O
underwent	O
suregry	O
for	O
fulocinolone	O
aceotnide	O
imlpant	O
(	O
0	O
.	O
59	O
mg	O
)	O
.	O

Treamtent	O
otucomes	O
of	O
interest	O
were	O
noted	O
at	O
baesline	O
,	O
before	O
floucinolone	O
acetondie	O
imlpant	O
,	O
and	O
then	O
at	O
6	O
motnhs	O
,	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
3	O
yeras	O
,	O
and	O
beyond	O
3	O
yeras	O
.	O

Diesase	O
actviity	O
mrakers	O
,	O
including	O
sgins	O
of	O
ocluar	O
inlfammation	B-Disease
,	O
evidnece	O
of	O
rteinal	B-Disease
vascuiltis	I-Disease
,	O
Sweidsh	O
intercative	O
thresohld	O
algortihm	O
-	O
short	O
wavelength	O
autoamted	O
permietry	O
Hmuphrey	O
viusal	O
field	O
anaylsis	O
,	O
eelctroretinographic	O
paramteers	O
,	O
and	O
otpical	O
cohreence	O
tomogrpahy	O
were	O
recorded	O
.	O

Dtaa	O
on	O
occurrnece	O
of	O
catarcat	B-Disease
and	O
raised	B-Disease
intraocualr	I-Disease
perssure	I-Disease
were	O
collected	O
in	O
all	O
eeys	O
.	O

RSEULTS	O
:	O
Intraouclar	O
inflamamtion	B-Disease
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
ptaients	O
at	O
baesline	O
,	O
6	O
motnhs	O
,	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
3	O
yaers	O
,	O
and	O
beyond	O
3	O
yeras	O
after	O
receiving	O
the	O
imlpant	O
,	O
respectively	O
.	O

Acitve	O
vasculiits	B-Disease
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
patinets	O
at	O
baesline	O
and	O
0	O
%	O
at	O
3	O
yaers	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%	O
)	O
reductoin	O
in	O
centarl	O
reitnal	O
thcikness	O
was	O
noted	O
in	O
all	O
ptaients	O
with	O
cytsoid	B-Disease
mcaular	I-Disease
eedma	I-Disease
at	O
6	O
mnoths	O
,	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
and	O
3	O
yeras	O
potsimplant	O
.	O

At	O
baseilne	O
,	O
54	O
.	O
5	O
%	O
ptaients	O
were	O
on	O
immunomodulatory	O
agetns	O
.	O

This	O
perecntage	O
decraesed	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
and	O
3	O
yeras	O
potsimplant	O
,	O
respectively	O
.	O

Adevrse	O
evnets	O
included	O
incerased	B-Disease
intraouclar	I-Disease
pressure	I-Disease
(	O
54	O
.	O
5	O
%	O
)	O
and	O
cataarct	B-Disease
fomration	O
(	O
100	O
%	O
)	O
.	O

CONCULSION	O
:	O
The	O
dtaa	O
suggest	O
that	O
fluocionlone	O
acetoinde	O
imlpant	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
cotnrol	O
ifnlammation	B-Disease
in	O
otherwise	O
treatmnet	O
-	O
refratcory	O
csaes	O
of	O
bridshot	B-Disease
retionchoroidopathy	I-Disease
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
catarcat	B-Disease
and	O
ocualr	B-Disease
hypretension	I-Disease
requiring	O
traetment	O
.	O

Opitmal	O
preucrarizing	O
dsoe	O
of	O
rocuornium	O
to	O
dcerease	O
fasciuclation	B-Disease
and	O
mylagia	B-Disease
following	O
succinylcholnie	O
adminsitration	O
.	O

BCAKGROUND	O
:	O
Succinyclholine	O
commonly	O
produces	O
ferquent	O
adevrse	O
effcets	O
,	O
including	O
mucsle	B-Disease
fascciulation	I-Disease
and	O
mylagia	B-Disease
.	O

The	O
current	O
stduy	O
iedntified	O
the	O
opitmal	O
dsoe	O
of	O
rocuronuim	O
to	O
preevnt	O
succinyclholine	O
-	O
induecd	O
fascicualtion	B-Disease
and	O
maylgia	B-Disease
and	O
evaluaetd	O
the	O
influnece	O
of	O
rocuronuim	O
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinyclholine	O
.	O

METHODS	O
:	O
This	O
randmoized	O
,	O
double	O
-	O
blinedd	O
sutdy	O
was	O
conducted	O
in	O
100	O
patietns	O
randomly	O
allocated	O
into	O
five	O
gruops	O
of	O
20	O
patietns	O
each	O
.	O

Patietns	O
were	O
randoimzed	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rocuronuim	O
as	O
a	O
precurairzing	O
dsoe	O
.	O

Neruomuscular	O
monitoirng	O
after	O
each	O
precruarizing	O
dsoe	O
was	O
recorded	O
from	O
the	O
adudctor	O
pollicis	O
msucle	O
using	O
acceleromoygraphy	O
with	O
trian	O
-	O
of	O
-	O
four	O
stmiulation	O
of	O
the	O
unlar	O
nevre	O
.	O

All	O
ptaients	O
received	O
succniylcholine	O
1	O
.	O
5	O
mg	O
/	O
kg	O
at	O
2	O
miuntes	O
after	O
the	O
precurariaztion	O
,	O
and	O
were	O
assessed	O
the	O
incdience	O
and	O
severtiy	O
of	O
fsaciculations	B-Disease
,	O
while	O
maylgia	B-Disease
was	O
assesesd	O
at	O
24	O
hours	O
after	O
srugery	O
.	O

RSEULTS	O
:	O
The	O
incidecne	O
and	O
sevreity	O
of	O
visilbe	O
msucle	B-Disease
fasciuclation	I-Disease
was	O
significantly	O
less	O
with	O
increaisng	O
the	O
amonut	O
of	O
preucrarizing	O
dsoe	O
of	O
rocuornium	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Those	O
of	O
myaglia	B-Disease
tend	O
to	O
decresae	O
according	O
to	O
increaisng	O
the	O
amonut	O
of	O
prceurarizing	O
dsoe	O
of	O
rocruonium	O
,	O
but	O
there	O
was	O
no	O
signfiicance	O
(	O
P	O
=	O
0	O
.	O
072	O
)	O
.	O

The	O
onset	O
tmie	O
of	O
succinylchoilne	O
was	O
significantly	O
longer	O
with	O
increaisng	O
the	O
amonut	O
of	O
precuarrizing	O
dsoe	O
of	O
roucronium	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSOINS	O
:	O
Precurariaztion	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocruonium	O
was	O
the	O
optmial	O
dsoe	O
considering	O
the	O
reudction	O
in	O
the	O
inicdence	O
and	O
sevreity	O
of	O
fascicluation	B-Disease
and	O
myaglia	B-Disease
with	O
acceptable	O
onset	O
tmie	O
,	O
and	O
the	O
safe	O
and	O
effectvie	O
precurarizaiton	O
.	O

Abesnce	O
of	O
PKC	O
-	O
aplha	O
attenautes	O
ltihium	O
-	O
indcued	O
nehprogenic	B-Disease
diabtees	I-Disease
insipiuds	I-Disease
.	O

Lithuim	O
,	O
an	O
effective	O
antipyschotic	O
,	O
idnuces	O
nephrogneic	B-Disease
daibetes	I-Disease
inspiidus	I-Disease
(	O
NDI	B-Disease
)	O
in	O
40	O
%	O
of	O
ptaients	O
.	O

The	O
decreaesd	O
capcaity	O
to	O
cnocentrate	O
uirne	O
is	O
likely	O
due	O
to	O
lihtium	O
acutely	O
disurpting	O
the	O
cMAP	O
ptahway	O
and	O
chrnoically	O
reudcing	O
uera	O
transproter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
wtaer	O
chnanel	O
(	O
APQ2	O
)	O
expression	O
in	O
the	O
inner	O
mdeulla	O
.	O

Targteing	O
an	O
alternaitve	O
signalnig	O
ptahway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signalnig	O
,	O
may	O
be	O
an	O
effcetive	O
mtehod	O
of	O
traeting	O
ltihium	O
-	O
indcued	O
poyluria	B-Disease
.	O

PKC	O
-	O
alhpa	O
nlul	O
mcie	O
(	O
PCKa	O
KO	O
)	O
and	O
starin	O
-	O
matched	O
wlid	O
tpye	O
(	O
WT	O
)	O
contrlos	O
were	O
terated	O
with	O
lithuim	O
for	O
0	O
,	O
3	O
or	O
5	O
dyas	O
.	O

WT	O
mcie	O
had	O
inrceased	O
uirne	O
ouptut	O
and	O
loewred	O
uirne	O
omsolality	O
after	O
3	O
and	O
5	O
dyas	O
of	O
treamtent	O
whereas	O
PCKa	O
KO	O
mcie	O
had	O
no	O
change	O
in	O
urnie	O
outupt	O
or	O
concnetration	O
.	O

Wesetrn	O
bolt	O
anaylsis	O
revaeled	O
that	O
APQ2	O
expresison	O
in	O
mdeullary	O
tisseus	O
was	O
lwoered	O
after	O
3	O
and	O
5	O
dyas	O
in	O
WT	O
mcie	O
;	O
however	O
,	O
APQ2	O
was	O
unchnaged	O
in	O
PCKa	O
KO	O
.	O

Similar	O
reuslts	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
exrpession	O
.	O

Aniamls	O
were	O
also	O
tretaed	O
with	O
lihtium	O
for	O
6	O
wekes	O
.	O

Ltihium	O
-	O
terated	O
WT	O
mcie	O
had	O
19	O
-	O
fold	O
incresaed	O
urnie	O
ouptut	O
whereas	O
traeted	O
PCKa	O
KO	O
aniamls	O
had	O
a	O
4	O
-	O
fold	O
inrcease	O
in	O
outupt	O
.	O

APQ2	O
and	O
UT	O
-	O
A1	O
experssion	O
was	O
loewred	O
in	O
6	O
week	O
lihtium	O
-	O
tretaed	O
WT	O
anmials	O
whereas	O
in	O
tretaed	O
PCKa	O
KO	O
mcie	O
,	O
APQ2	O
was	O
only	O
reudced	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
epxression	O
was	O
uanffected	O
.	O

Uirnary	O
soduim	O
,	O
potassuim	O
and	O
calicum	O
were	O
elveated	O
in	O
litihum	O
-	O
fed	O
WT	O
but	O
not	O
in	O
litihum	O
-	O
fed	O
PCKa	O
KO	O
mcie	O
.	O

Our	O
dtaa	O
show	O
that	O
ablatoin	O
of	O
PCKa	O
preserves	O
APQ2	O
and	O
UT	O
-	O
A1	O
prtoein	O
expression	O
and	O
localizaiton	O
in	O
lihtium	O
-	O
inudced	O
NDI	B-Disease
,	O
and	O
prevents	O
the	O
developemnt	O
of	O
the	O
seevre	O
polyruia	B-Disease
associated	O
with	O
lithuim	O
tehrapy	O
.	O

Is	O
Dysgueisa	B-Disease
Going	O
to	O
be	O
a	O
Rrae	O
or	O
a	O
Common	O
Side	O
-	O
effect	O
of	O
Almodipine	O
?	O

A	O
very	O
rrae	O
side	O
-	O
effect	O
of	O
amoldipine	O
is	O
dysguseia	B-Disease
.	O

A	O
reveiw	O
of	O
the	O
lietrature	O
produced	O
only	O
one	O
csae	O
.	O

We	O
reoprt	O
a	O
csae	O
about	O
a	O
fmeale	O
with	O
essentail	O
hypertensoin	B-Disease
on	O
durg	O
treatemnt	O
with	O
amldoipine	O
developed	O
lsos	B-Disease
of	I-Disease
tsate	I-Disease
sensatoin	I-Disease
.	O

Cnodition	O
moderaetly	O
imprvoed	O
on	O
stoppage	O
of	O
the	O
durg	O
for	O
25	O
dyas	O
.	O

We	O
conclude	O
that	O
almodipine	O
can	O
cause	O
dysugesia	B-Disease
.	O

Here	O
,	O
we	O
describe	O
the	O
clincial	O
persentation	O
and	O
reivew	O
the	O
reelvant	O
lietrature	O
on	O
almodipine	O
and	O
dysugesia	B-Disease
.	O

Rhadbomyolysis	B-Disease
in	O
assocaition	O
with	O
simvasttain	O
and	O
dsoage	O
incerment	O
in	O
clairthromycin	O
.	O

Clarithromyicn	O
is	O
the	O
most	O
documneted	O
cytcohrome	O
P540	O
3A4	O
(	O
CY3PA4	O
)	O
inhiibtor	O
to	O
cause	O
an	O
avderse	O
intreaction	O
with	O
sivmastatin	O
.	O

This	O
particular	O
csae	O
is	O
of	O
interest	O
as	O
rhbadomyolysis	B-Disease
only	O
occurred	O
after	O
an	O
incraese	O
in	O
the	O
dsoe	O
of	O
clarithromyicn	O
.	O

The	O
pateint	O
developed	O
raised	O
caridac	O
boimarkers	O
without	O
any	O
obvious	O
cradiac	O
isuses	O
,	O
a	O
pehnomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdmoyolysis	B-Disease
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
efefct	O
of	O
rahbdomyolysis	B-Disease
on	O
the	O
structrue	O
and	O
fnuction	O
of	O
cardaic	O
msucle	O
.	O

Clinicinas	O
need	O
to	O
be	O
aware	O
of	O
prescriibng	O
concomtiant	O
mdeications	O
that	O
icnrease	O
the	O
rsik	O
of	O
myoptahy	B-Disease
or	O
ihnibit	O
the	O
CYPA34	O
enyzme	O
.	O

Our	O
csae	O
suggests	O
that	O
trpoonin	O
elevtaion	O
could	O
be	O
associated	O
with	O
sttain	O
induecd	O
rhabdomyolsyis	B-Disease
,	O
which	O
may	O
warrant	O
further	O
stduies	O
.	O

Characteirzation	O
of	O
a	O
novel	O
BHCE	O
"	O
silnet	O
"	O
alelle	O
:	O
point	O
mutaiton	O
(	O
p	O
.	O
Va2l04Asp	O
)	O
causes	O
lsos	O
of	O
activtiy	O
and	O
prolonegd	O
apena	B-Disease
with	O
suxaemthonium	O
.	O

Butyrylchloinesterase	B-Disease
deficiecny	I-Disease
is	O
chraacterized	O
by	O
prolonegd	O
anpea	B-Disease
after	O
the	O
use	O
of	O
muslce	O
realxants	O
(	O
suxmaethonium	O
or	O
mivcaurium	O
)	O
in	O
paitents	O
who	O
have	O
mutatinos	O
in	O
the	O
BHCE	O
gnee	O
.	O

Here	O
,	O
we	O
reprot	O
a	O
csae	O
of	O
prolnoged	O
neurmouscular	O
blcok	O
after	O
administartion	O
of	O
suaxmethonium	O
leading	O
to	O
the	O
discovrey	O
of	O
a	O
novel	O
BHCE	O
vraiant	O
(	O
c	O
.	O
T	O
>	O
A	O
,	O
p	O
.	O
Val024Asp	O
)	O
.	O

Inhibiiton	O
stuides	O
,	O
kineitc	O
anaylsis	O
and	O
mloecular	O
dynamcis	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mtuation	O
dirsupts	O
the	O
catlaytic	O
traid	O
and	O
determines	O
a	O
"	O
sielnt	O
"	O
phentoype	O
.	O

Low	O
atcivity	O
of	O
pateint	O
palsma	O
butyrylchloinesterase	O
with	O
butyrylthiocholnie	O
(	O
BTC	O
)	O
and	O
benzoylcohline	O
,	O
and	O
vaules	O
of	O
diubcaine	O
and	O
fluroide	O
numebrs	O
fit	O
with	O
heterozyogus	O
atyipcal	O
slient	O
gentoype	O
.	O

Electropohretic	O
anaylsis	O
of	O
plamsa	O
BhCE	O
of	O
the	O
prboand	O
and	O
his	O
motehr	O
showed	O
that	O
patinet	O
has	O
a	O
rdeuced	O
aomunt	O
of	O
tetarmeric	O
enyzme	O
in	O
palsma	O
and	O
that	O
minor	O
fast	O
-	O
mvoing	O
BhCE	O
compnoents	O
:	O
mnoomer	O
,	O
dmier	O
,	O
and	O
mnoomer	O
-	O
albmuin	O
conjuagte	O
are	O
missing	O
.	O

Kinteic	O
analyiss	O
showed	O
that	O
the	O
p	O
.	O
Val240Asp	O
/	O
p	O
.	O
Asp07Gly	O
-	O
p	O
.	O
Al5a39Thr	O
BhCE	O
displays	O
a	O
pure	O
Michealian	O
bheavior	O
with	O
BTC	O
as	O
the	O
sbustrate	O
.	O

Both	O
catalyitc	O
paraemters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	O
,	O
two	O
times	O
hgiher	O
than	O
that	O
of	O
the	O
atypiacl	O
eznyme	O
,	O
and	O
a	O
low	O
Vamx	O
are	O
consistent	O
with	O
the	O
asbence	O
of	O
activtiy	O
against	O
suxamethoinum	O
.	O

Molecualr	O
dynaimc	O
(	O
MD	O
)	O
simultaions	O
showed	O
that	O
the	O
overall	O
effcet	O
of	O
the	O
mutatoin	O
p	O
.	O
Val204sAp	O
is	O
dirsuption	O
of	O
hyrdogen	O
bodning	O
between	O
Gl2n23	O
and	O
Glu441	O
,	O
leading	O
Sre198	O
and	O
Hi4s38	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
dsiruption	O
of	O
the	O
cataltyic	O
traid	O
functionailty	O
regardless	O
of	O
the	O
tpye	O
of	O
susbtrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
eznyme	O
voulme	O
is	O
inrceased	O
,	O
suggesting	O
a	O
pre	O
-	O
deanturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reudced	O
conecntration	O
of	O
p	O
.	O
Ala240Asp	O
/	O
p	O
.	O
Asp70lGy	O
-	O
p	O
.	O
Ala359Thr	O
tetrameirc	O
enyzme	O
in	O
the	O
plsama	O
and	O
non	O
-	O
detectbale	O
fast	O
moivng	O
-	O
bnads	O
on	O
elecrtophoresis	O
gles	O
.	O

Dleayed	O
aneima	B-Disease
after	O
treatemnt	O
with	O
injetcable	O
artseunate	O
in	O
the	O
Demcoratic	O
Repbulic	O
of	O
the	O
Cnogo	O
:	O
a	O
manageable	O
issue	O
.	O

Csaes	O
of	O
delaeyd	O
hemloytic	B-Disease
anmeia	I-Disease
have	O
been	O
described	O
after	O
teratment	O
with	O
injectbale	O
artesuante	O
,	O
the	O
current	O
Wolrd	O
Haelth	O
Orgnaization	O
(	O
WHO	O
)	O
-	O
recmomended	O
first	O
-	O
line	O
durg	O
for	O
the	O
treatemnt	O
of	O
sveere	O
malraia	B-Disease
.	O

A	O
total	O
of	O
350	O
patietns	O
(	O
215	O
[	O
61	O
.	O
4	O
%	O
]	O
<	O
5	O
yaers	O
of	O
age	O
and	O
135	O
[	O
38	O
.	O
6	O
%	O
]	O
>	O
5	O
yaers	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatmnet	O
with	O
injecatble	O
artseunate	O
for	O
sveere	O
malraia	B-Disease
in	O
hosiptals	O
and	O
helath	O
cneters	O
of	O
the	O
Deomcratic	O
Repubilc	O
of	O
the	O
Cnogo	O
.	O

Cmoplete	O
series	O
of	O
hemolgobin	O
(	O
Hb	O
)	O
measuerments	O
were	O
available	O
for	O
201	O
patietns	O
.	O

A	O
decerase	O
in	O
Hb	O
levles	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
deetcted	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
ptaients	O
during	O
the	O
follow	O
-	O
up	O
peroid	O
.	O

For	O
five	O
patinets	O
,	O
Hb	O
leevls	O
decresaed	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
viist	O
.	O

All	O
caess	O
of	O
delyaed	O
aneima	B-Disease
were	O
cilnically	O
manageable	O
and	O
resolved	O
within	O
one	O
motnh	O
.	O

Regulatoin	O
of	O
sginal	O
trandsucer	O
and	O
acitvator	O
of	O
transcirption	O
3	O
and	O
apoptoitc	O
pathawys	O
by	O
betiane	O
attenuates	O
isoprotereonl	O
-	O
inudced	O
actue	O
myocadrial	B-Disease
injruy	I-Disease
in	O
rtas	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
invsetigate	O
the	O
cardiporotective	O
efefcts	O
of	O
betiane	O
on	O
actue	O
myocardail	B-Disease
ischmeia	I-Disease
indcued	O
exeprimentally	O
in	O
rtas	O
focusing	O
on	O
regluation	O
of	O
siganl	O
trandsucer	O
and	O
acitvator	O
of	O
transcriptoin	O
3	O
(	O
SATT3	O
)	O
and	O
apopottic	O
ptahways	O
as	O
the	O
potenital	O
mecahnism	O
underlying	O
the	O
durg	O
effect	O
.	O

Mlae	O
Sprgaue	O
Dwaley	O
rtas	O
were	O
terated	O
with	O
betanie	O
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
dyas	O
.	O

Actue	O
myocaridal	B-Disease
ischeimc	I-Disease
ijnury	I-Disease
was	O
inudced	O
in	O
rtas	O
by	O
subcutnaeous	O
injectoin	O
of	O
iosproterenol	O
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
cosnecutive	O
dyas	O
.	O

Sreum	O
cradiac	O
makrer	O
eznyme	O
,	O
histopahtological	O
vairables	O
and	O
exrpession	O
of	O
proetin	O
levles	O
were	O
analzyed	O
.	O

Oarl	O
amdinistration	O
of	O
beatine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
redcued	O
the	O
leevl	O
of	O
cadriac	O
makrer	O
eznyme	O
in	O
the	O
sreum	O
and	O
prevented	O
lfet	O
ventricualr	B-Disease
rmeodeling	I-Disease
.	O

Wsetern	O
bolt	O
anaylsis	O
showed	O
that	O
isoporterenol	O
-	O
induecd	O
phosphoyrlation	O
of	O
STTA3	O
was	O
maintained	O
or	O
further	O
enhnaced	O
by	O
betanie	O
treatmnet	O
in	O
myoacrdium	O
.	O

Furthermore	O
,	O
betanie	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
teratment	O
increaesd	O
the	O
ventrciular	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
reudced	O
the	O
leevl	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
inrcease	O
in	O
the	O
rtaio	O
of	O
Bcl	O
-	O
2	O
/	O
Bax	O
.	O

The	O
protective	O
role	O
of	O
betanie	O
on	O
myoacrdial	B-Disease
damgae	I-Disease
was	O
further	O
confirmed	O
by	O
histoptahological	O
examniation	O
.	O

In	O
summary	O
,	O
our	O
resutls	O
showed	O
that	O
beatine	O
pretretament	O
attenuaetd	O
isoproterneol	O
-	O
induecd	O
actue	O
myocardail	B-Disease
icshemia	I-Disease
via	O
the	O
regultaion	O
of	O
STTA3	O
and	O
appototic	O
patwhays	O
.	O

Quetiapnie	O
-	O
inudced	O
neutorpenia	B-Disease
in	O
a	O
biploar	B-Disease
pateint	O
with	O
hepaotcellular	B-Disease
cacrinoma	I-Disease
.	O

OBJCETIVE	O
:	O
Quetaipine	O
is	O
a	O
dibenzothaizepine	O
derivaitve	O
,	O
similar	O
to	O
cloazpine	O
,	O
which	O
has	O
the	O
highest	O
rsik	O
of	O
causing	O
blood	B-Disease
dycsrasias	I-Disease
,	O
especially	O
neturopenia	B-Disease
.	O

There	O
are	O
some	O
csae	O
repotrs	O
about	O
this	O
side	O
effcet	O
of	O
quetiaipne	O
,	O
but	O
possible	O
rsik	O
facotrs	O
are	O
seldom	O
discussed	O
and	O
idetnified	O
.	O

A	O
csae	O
of	O
a	O
patinet	O
with	O
hepatocelullar	B-Disease
caricnoma	I-Disease
that	O
developed	O
neutorpenia	B-Disease
after	O
treatmnet	O
with	O
queitapine	O
is	O
described	O
here	O
.	O

CSAE	O
REPORT	O
:	O
A	O
62	O
-	O
yaer	O
-	O
old	O
Taiawnese	O
wdiow	O
with	O
bpiolar	B-Disease
diosrder	I-Disease
was	O
diagnoesd	O
with	O
hepatocellluar	B-Disease
carcionma	I-Disease
at	O
age	O
60	O
.	O

She	O
developed	O
leucopeina	B-Disease
after	O
being	O
tretaed	O
with	O
quetiaipne	O
.	O

After	O
quetiapnie	O
was	O
dicsontinued	O
,	O
her	O
wihte	O
bolod	O
clel	O
conut	O
returned	O
to	O
noraml	O
.	O

CONCLUISONS	O
:	O
Although	O
neutroepnia	B-Disease
is	O
not	O
a	O
common	O
side	O
efefct	O
of	O
quteiapine	O
,	O
physiicans	O
should	O
be	O
cautious	O
about	O
its	O
presnetation	O
and	O
associated	O
rsik	O
factros	O
.	O

Hpeatic	B-Disease
dysfnuction	I-Disease
may	O
be	O
one	O
of	O
the	O
possible	O
rsik	O
fatcors	O
,	O
and	O
cnocomitant	O
fveer	B-Disease
may	O
be	O
a	O
diangostic	O
mraker	O
for	O
adevrse	O
raection	O
to	O
quetiapnie	O
.	O

Laetral	O
antebracihal	O
cutaenous	O
nueropathy	B-Disease
after	O
streoid	O
inejction	O
at	O
laetral	O
epicondlye	O
.	O

BACKGORUND	O
AND	O
OBJCETIVES	O
:	O
This	O
reprot	O
aimed	O
to	O
present	O
a	O
csae	O
of	O
latearl	O
anterbachial	O
cuatneous	O
neuroptahy	B-Disease
(	O
LANCP	O
)	O
that	O
occurred	O
after	O
a	O
steriod	O
injectoin	O
in	O
the	O
ltaeral	O
epicnodyle	O
to	O
traet	O
latearl	B-Disease
epicondyltiis	I-Disease
in	O
a	O
40	O
-	O
yaer	O
-	O
old	O
woamn	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
yaer	O
-	O
old	O
wmoan	O
presented	O
with	O
decerased	O
sensaiton	O
and	O
parsethesia	B-Disease
over	O
her	O
rgiht	O
laetral	O
foerarm	O
;	O
the	O
pareshtesia	B-Disease
had	O
occurred	O
after	O
a	O
steriod	O
injectoin	O
in	O
the	O
rihgt	O
laetral	O
epicodnyle	O
3	O
mnoths	O
before	O
.	O

Her	O
sensatoin	O
of	O
light	O
tocuh	O
and	O
pian	B-Disease
was	O
diminished	O
over	O
the	O
latreal	O
side	O
of	O
the	O
rihgt	O
foraerm	O
and	O
wirst	O
aera	O
.	O

REUSLTS	O
:	O
The	O
sesnory	O
actoin	O
potentail	O
amlpitude	O
of	O
the	O
rgiht	O
latreal	O
anterbachial	O
cutaenous	O
nreve	O
(	O
LCAN	O
)	O
(	O
6	O
.	O
2	O
uV	O
)	O
was	O
loewr	O
than	O
that	O
of	O
the	O
lfet	O
(	O
13	O
.	O
1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
ampltiude	O
between	O
both	O
sieds	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reductoin	O
.	O

She	O
was	O
diagnoesd	O
with	O
rihgt	O
LANCP	O
(	O
mainly	O
aoxnal	O
invlovement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clniical	O
mnaifestation	O
and	O
the	O
electrodiagnotsic	O
findnigs	O
.	O

Her	O
smyptoms	O
imprvoed	O
through	O
physiacl	O
tehrapy	O
but	O
persisted	O
to	O
some	O
dgeree	O
.	O

CONCLSUION	O
:	O
This	O
rpeort	O
describes	O
the	O
csae	O
of	O
a	O
woamn	O
with	O
LANCP	O
that	O
developed	O
after	O
a	O
streoid	O
ijnection	O
for	O
the	O
traetment	O
of	O
latreal	B-Disease
epicondlyitis	I-Disease
.	O

An	O
elecrtodiagnostic	O
sutdy	O
,	O
including	O
a	O
nreve	O
codnuction	O
stduy	O
of	O
the	O
LCAN	O
,	O
was	O
helpful	O
to	O
diagonse	O
rgiht	O
LANCP	O
and	O
to	O
find	O
the	O
pasasge	O
of	O
the	O
LCAN	O
on	O
the	O
laetral	O
eipcondyle	O
.	O

Curucmin	O
prevents	O
maletae	O
-	O
indcued	O
nehprotoxicity	B-Disease
:	O
relation	O
to	O
hmeodynamic	O
atlerations	O
,	O
oxiadtive	O
sterss	O
,	O
mitochnodrial	O
oyxgen	O
consupmtion	O
and	O
acitvity	O
of	O
rsepiratory	O
cmoplex	O
I	O
.	O

The	O
ptoential	O
protective	O
effcet	O
of	O
the	O
dieatry	O
antioixdant	O
curucmin	O
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
dyas	O
)	O
against	O
the	O
reanl	B-Disease
ijnury	I-Disease
induecd	O
by	O
maelate	O
was	O
evlauated	O
.	O

Tuublar	O
proteinruia	B-Disease
and	O
oixdative	O
strses	O
were	O
induecd	O
by	O
a	O
single	O
injeciton	O
of	O
mlaeate	O
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rtas	O
.	O

Malaete	O
-	O
induecd	O
reanl	B-Disease
injruy	I-Disease
included	O
icnrease	O
in	O
reanl	O
vascluar	O
resistacne	O
and	O
in	O
the	O
uirnary	O
excertion	O
of	O
total	O
protien	O
,	O
gluocse	O
,	O
soidum	O
,	O
neutrpohil	O
gelatinsae	O
-	O
associated	O
lipoaclin	O
(	O
NAGL	O
)	O
and	O
N	O
-	O
acteyl	O
b	O
-	O
D	O
-	O
glcuosaminidase	O
(	O
NAG	O
)	O
,	O
upreuglation	O
of	O
kdiney	B-Disease
ijnury	I-Disease
molceule	O
(	O
KIM	O
)	O
-	O
1	O
,	O
decresae	O
in	O
reanl	O
bolod	O
folw	O
and	O
cluadin	O
-	O
2	O
exprsesion	O
besides	O
of	O
necroiss	B-Disease
and	O
apoptoiss	O
of	O
tubualr	O
clels	O
on	O
24	O
h	O
.	O

Oxidatvie	O
srtess	O
was	O
determined	O
by	O
mesauring	O
the	O
oxidaiton	O
of	O
liipds	O
and	O
prtoeins	O
and	O
diminuiton	O
in	O
reanl	O
Nfr2	O
levles	O
.	O

Stuides	O
were	O
also	O
conducted	O
in	O
reanl	O
epithleial	O
LLC	O
-	O
PK1	O
cells	O
and	O
in	O
mitohcondria	O
ioslated	O
from	O
kdineys	O
of	O
all	O
the	O
experiemntal	O
gropus	O
.	O

Maletae	O
idnuced	O
clel	O
dmaage	O
and	O
recative	O
oxyegn	O
sepcies	O
(	O
ROS	O
)	O
productoin	O
in	O
LLC	O
-	O
PK1	O
clels	O
in	O
cutlure	O
.	O

In	O
addition	O
,	O
maletae	O
tretament	O
reudced	O
oyxgen	O
consumptoin	O
in	O
ADP	O
-	O
sitmulated	O
mitocohndria	O
and	O
diminished	O
respiartory	O
cotnrol	O
index	O
when	O
using	O
maalte	O
/	O
glutmaate	O
as	O
substarte	O
.	O

The	O
actviities	O
of	O
both	O
cmoplex	O
I	O
and	O
acointase	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
alteraitons	O
were	O
prevented	O
by	O
curucmin	O
.	O

It	O
is	O
concluded	O
that	O
curucmin	O
is	O
able	O
to	O
attenutae	O
in	O
vivo	O
malaete	O
-	O
indcued	O
nephrpoathy	B-Disease
and	O
in	O
vitro	O
clel	O
daamge	O
.	O

The	O
in	O
vivo	O
prtoection	O
was	O
associated	O
to	O
the	O
prveention	O
of	O
oxidaitve	O
strses	O
and	O
preservatoin	O
of	O
miotchondrial	O
oyxgen	O
consumptoin	O
and	O
activtiy	O
of	O
respiartory	O
copmlex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protectoin	O
was	O
associated	O
to	O
the	O
prveention	O
of	O
ROS	O
porduction	O
.	O

Anticovnulsant	O
atcions	O
of	O
MK	O
-	O
801	O
on	O
the	O
lithuim	O
-	O
pliocarpine	O
mdoel	O
of	O
sttaus	B-Disease
epileptiucs	I-Disease
in	O
rtas	O
.	O

MK	O
-	O
801	O
,	O
a	O
noncompetitive	O
N	O
-	O
mehtyl	O
-	O
D	O
-	O
asparatte	O
(	O
NDMA	O
)	O
reecptor	O
antgaonist	O
,	O
was	O
tesetd	O
for	O
anitconvulsant	O
efefcts	O
in	O
rtas	O
using	O
two	O
seizrue	B-Disease
moedls	O
,	O
coadminisrtation	O
of	O
litihum	O
and	O
pilcoarpine	O
and	O
administrtaion	O
of	O
a	O
high	O
dsoe	O
of	O
pilocaprine	O
alone	O
.	O

Three	O
major	O
resutls	O
are	O
reported	O
.	O

First	O
,	O
pretreatmnet	O
with	O
MK	O
-	O
801	O
produced	O
an	O
effective	O
and	O
dsoe	O
-	O
dpeendent	O
anticovnulsant	O
atcion	O
with	O
the	O
lihtium	O
-	O
piolcarpine	O
moedl	O
but	O
not	O
with	O
rtas	O
terated	O
with	O
piloacrpine	O
alone	O
,	O
suggesting	O
that	O
different	O
biohcemical	O
mechnaisms	O
cotnrol	O
seizrues	B-Disease
in	O
these	O
two	O
modles	O
.	O

Second	O
,	O
the	O
anticonvlusant	O
efefct	O
of	O
MK	O
-	O
801	O
in	O
the	O
litihum	O
-	O
pilocrapine	O
mdoel	O
only	O
occurred	O
after	O
initial	O
peridos	O
of	O
seiuzre	B-Disease
atcivity	O
.	O

This	O
osbervation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
expermients	O
that	O
MK	O
-	O
801	O
bniding	O
requires	O
agonsit	O
-	O
idnuced	O
opennig	O
of	O
the	O
channel	O
sties	O
of	O
the	O
NDMA	O
recpetor	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
bolck	O
seizuers	B-Disease
idnuced	O
by	O
ltihium	O
and	O
pliocarpine	O
by	O
administraiton	O
of	O
anticonvuslants	O
prior	O
to	O
piolcarpine	O
,	O
it	O
is	O
more	O
difficult	O
to	O
temrinate	O
ongoing	O
stauts	B-Disease
epilepitcus	I-Disease
and	O
bolck	O
the	O
lethaltiy	O
of	O
the	O
seizrues	B-Disease
.	O

Adminitsration	O
of	O
MK	O
-	O
801	O
30	O
or	O
60	O
min	O
after	O
pilcoarpine	O
,	O
i	O
.	O
e	O
.	O
,	O
during	O
stauts	B-Disease
epilepitcus	I-Disease
,	O
gradually	O
rdeuced	O
eletcrical	O
and	O
behaivoral	O
seizrue	B-Disease
atcivity	O
and	O
greatly	O
enahnced	O
the	O
surviavl	O
rtae	O
.	O

These	O
rseults	O
suggest	O
that	O
actiavtion	O
of	O
NDMA	O
recepotrs	O
plays	O
an	O
important	O
role	O
in	O
stauts	B-Disease
epliepticus	I-Disease
and	O
brian	B-Disease
dmaage	I-Disease
in	O
the	O
litihum	O
-	O
pilocarpnie	O
moedl	O
.	O

This	O
was	O
further	O
supported	O
by	O
rseults	O
showing	O
that	O
nonconvulsvie	O
doess	O
of	O
NDMA	O
and	O
pilocaripne	O
were	O
synregistic	O
,	O
resulting	O
in	O
sattus	B-Disease
eiplepticus	I-Disease
and	O
subsequent	O
mortaltiy	O
.	O

Contiunous	O
ifnusion	O
tobramcyin	O
combiend	O
with	O
carbeincillin	O
for	O
ifnections	B-Disease
in	O
cnacer	B-Disease
paitents	O
.	O

The	O
crue	O
rtae	O
of	O
infetcions	B-Disease
in	O
cacner	B-Disease
paitents	O
is	O
adversely	O
afefcted	O
by	O
neutroepnia	B-Disease
(	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
)	O
.	O

In	O
particular	O
,	O
patinets	O
with	O
seevre	O
neturopenia	B-Disease
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
poor	O
resopnse	O
to	O
antibitoics	O
.	O

To	O
overcome	O
the	O
advesre	O
effcets	O
of	O
neutroepnia	B-Disease
,	O
tboramycin	O
was	O
given	O
by	O
conitnuous	O
ifnusion	O
and	O
combnied	O
with	O
intermittent	O
cabrenicillin	O
.	O

Torbamycin	O
was	O
given	O
to	O
a	O
total	O
dialy	O
dsoe	O
of	O
300	O
mg	O
/	O
m2	O
and	O
cabrenicillin	O
was	O
given	O
at	O
a	O
dsoe	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
inefctious	O
episoeds	O
in	O
116	O
canecr	B-Disease
paitents	O
receiving	O
myelousppressive	O
chemothreapy	O
.	O

The	O
overall	O
crue	O
rtae	O
was	O
70	O
%	O
.	O

Pneumoina	B-Disease
was	O
the	O
most	O
common	O
infetcion	B-Disease
and	O
61	O
%	O
of	O
59	O
episdoes	O
were	O
crued	O
.	O

Garm	O
-	O
ngeative	O
bacilli	O
were	O
the	O
most	O
common	O
cauastive	O
orgnaisms	O
and	O
69	O
%	O
of	O
these	O
inefctions	B-Disease
were	O
crued	O
.	O

The	O
most	O
common	O
patohgen	O
was	O
Klebisella	O
penumoniae	B-Disease
and	O
this	O
,	O
together	O
with	O
Eschericiha	O
cloi	O
and	O
Pseudomnoas	O
aeruignosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
garm	B-Disease
-	I-Disease
neagtive	I-Disease
bacillary	I-Disease
inefctions	I-Disease
.	O

Respnose	O
was	O
not	O
infleunced	O
by	O
the	O
initial	O
nuetrophil	O
cuont	O
,	O
with	O
a	O
62	O
%	O
crue	O
rtae	O
for	O
39	O
epsiodes	O
associated	O
with	O
seevre	O
neurtopenia	B-Disease
.	O

However	O
,	O
failrue	O
of	O
the	O
nuetrophil	O
cuont	O
to	O
inrcease	O
during	O
threapy	O
adversely	O
afefcted	O
respnose	O
.	O

Azotmeia	B-Disease
was	O
the	O
major	O
side	O
efefct	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
episoeds	O
.	O

Major	O
azotmeia	B-Disease
(	O
sreum	O
ceratinine	O
greater	O
than	O
2	O
.	O
5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azotmeia	B-Disease
was	O
not	O
related	O
to	O
druation	O
of	O
threapy	O
or	O
seurm	O
tobramyicn	O
concentraiton	O
.	O

This	O
atnibiotic	O
reigmen	O
showed	O
both	O
tehrapeutic	O
efifcacy	O
and	O
accetpable	O
reanl	B-Disease
toxictiy	I-Disease
for	O
these	O
paitents	O
.	O

Icnidence	O
of	O
sloid	O
tmuours	B-Disease
among	O
pestiicde	O
applictaors	O
exopsed	O
to	O
the	O
organophospahte	O
insectiicde	O
diazionn	O
in	O
the	O
Agrciultural	O
Haelth	O
Sutdy	O
:	O
an	O
updated	O
analyiss	O
.	O

OJBECTIVE	O
:	O
Diaiznon	O
,	O
a	O
common	O
orgnaophosphate	O
insectiicde	O
with	O
gentooxic	O
propetries	O
,	O
was	O
previously	O
associated	O
with	O
lnug	B-Disease
cnacer	I-Disease
in	O
the	O
Agricultrual	O
Haelth	O
Stduy	O
(	O
AHS	O
)	O
choort	O
,	O
but	O
few	O
other	O
epideimological	O
stduies	O
have	O
examined	O
dizainon	O
-	O
associated	O
cacner	B-Disease
rsik	O
.	O

We	O
used	O
updated	O
diaznion	O
expousre	O
and	O
cnacer	B-Disease
incidecne	O
informtaion	O
to	O
evalaute	O
sloid	O
tumuor	B-Disease
rsik	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Mlae	O
pesitcide	O
applicatros	O
in	O
Iwoa	O
and	O
Notrh	O
Caroilna	O
reported	O
lifetmie	O
daizinon	O
use	O
at	O
enromlent	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cnacer	B-Disease
incdience	O
was	O
assesesd	O
through	O
2010	O
(	O
Notrh	O
Caroilna	O
)	O
/	O
2011	O
(	O
Iwoa	O
)	O
.	O

Among	O
applicatros	O
with	O
usgae	O
inforamtion	O
sufficient	O
to	O
evalaute	O
exposrue	O
-	O
repsonse	O
pattenrs	O
,	O
we	O
used	O
Poisson	O
regrsesion	O
to	O
estimtae	O
adjusted	O
rtae	O
ratois	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cacner	B-Disease
sties	O
with	O
>	O
10	O
epxosed	O
caess	O
for	O
both	O
lifetmie	O
(	O
LT	O
)	O
epxosure	O
dyas	O
and	O
intenstiy	O
-	O
weighted	O
(	O
IW	O
)	O
lifetmie	O
exposrue	O
dyas	O
(	O
accounting	O
for	O
facotrs	O
impacitng	O
exopsure	O
)	O
.	O

RESLUTS	O
:	O
We	O
observed	O
eleavted	O
lnug	B-Disease
cnacer	I-Disease
rikss	O
(	O
N	O
=	O
283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Pternd	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
dyas	O
of	O
daizinon	O
use	O
(	O
RR	O
=	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
0	O
.	O
98	O
to	O
2	O
.	O
04	O
;	O
Pternd	O
=	O
0	O
.	O
08	O
)	O
.	O

Kindey	B-Disease
canecr	I-Disease
(	O
N	O
=	O
94	O
)	O
rikss	O
were	O
non	O
-	O
significantly	O
elevaetd	O
(	O
RLRT	O
dyas	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Pternd	O
=	O
0	O
.	O
09	O
;	O
RIRW	O
dyas	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Ptrned	O
=	O
0	O
.	O
50	O
)	O
,	O
as	O
were	O
rikss	O
for	O
aggressive	O
porstate	B-Disease
cnacer	I-Disease
(	O
N	O
=	O
656	O
)	O
.	O

CONCLUSOINS	O
:	O
Our	O
updated	O
evaluaiton	O
of	O
dizainon	O
provides	O
additional	O
eivdence	O
of	O
an	O
assocaition	O
with	O
lnug	B-Disease
cnacer	I-Disease
rsik	O
.	O

Newly	O
identfiied	O
links	O
to	O
kindey	B-Disease
canecr	I-Disease
and	O
assoications	O
with	O
aggresisve	O
porstate	B-Disease
cacner	I-Disease
require	O
further	O
evaulation	O
.	O

Asscoiations	O
of	O
Oozne	O
and	O
PM2	O
.	O
5	O
Concentrtaions	O
With	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
Disesae	I-Disease
Among	O
Partciipants	O
in	O
the	O
Agircultural	O
Haelth	O
Stduy	O
.	O

OBJCETIVE	O
:	O
This	O
stduy	O
describes	O
associatinos	O
of	O
oznoe	O
and	O
fnie	O
partciulate	O
matter	O
with	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
observed	O
among	O
faremrs	O
in	O
Nroth	O
Caorlina	O
and	O
Iwoa	O
.	O

METHODS	O
:	O
We	O
used	O
logisitc	O
regressoin	O
to	O
determine	O
the	O
assocaitions	O
of	O
these	O
plolutants	O
with	O
slef	O
-	O
reported	O
,	O
docotr	O
-	O
daignosed	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
diesase	I-Disease
.	O

Dialy	O
preidcted	O
polluatnt	O
concenrtations	O
were	O
used	O
to	O
derive	O
surorgates	O
of	O
long	O
-	O
term	O
expsoure	O
and	O
link	O
them	O
to	O
sutdy	O
praticipants	O
'	O
geocdoed	O
addresses	O
.	O

RESUTLS	O
:	O
We	O
observed	O
poistive	O
associaitons	O
of	O
Parknison	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
with	O
oozne	O
(	O
odds	O
rtaio	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fnie	O
partiuclate	O
matter	O
(	O
odds	O
rtaio	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
93	O
to	O
1	O
.	O
93	O
)	O
in	O
Nroth	O
Carolnia	O
but	O
not	O
in	O
Iwoa	O
.	O

CONCLUISONS	O
:	O
The	O
palusibility	O
of	O
an	O
efefct	O
of	O
amibent	O
conecntrations	O
of	O
these	O
polltuants	O
on	O
Prakinson	B-Disease
'	I-Disease
s	I-Disease
disaese	I-Disease
rsik	O
is	O
supported	O
by	O
expeirmental	O
dtaa	O
demonstrating	O
damgae	O
to	O
doapminergic	O
neurnos	O
at	O
reelvant	O
concenrtations	O
.	O

Additional	O
stuides	O
are	O
needed	O
to	O
address	O
ucnertainties	O
related	O
to	O
conofunding	O
and	O
to	O
examine	O
temproal	O
aspects	O
of	O
the	O
asscoiations	O
we	O
observed	O
.	O

Low	O
funcitonal	O
prorgamming	O
of	O
rneal	O
A2TR	O
mediates	O
the	O
developmenatl	O
oriign	O
of	O
gloemrulosclerosis	B-Disease
in	O
adlut	O
offspirng	O
idnuced	O
by	O
prneatal	O
caffenie	O
exposrue	O
.	O

UNSASIGNED	O
:	O
Our	O
previous	O
stduy	O
has	O
indicated	O
that	O
prentaal	O
caffenie	O
expsoure	O
(	O
PCE	O
)	O
could	O
inudce	O
intrauteirne	B-Disease
grotwh	I-Disease
rteardation	I-Disease
(	O
IGUR	B-Disease
)	O
of	O
offspring	O
.	O

Recent	O
reesarch	O
suggested	O
that	O
IGUR	B-Disease
is	O
a	O
rsik	O
fcator	O
for	O
golmerulosclerosis	B-Disease
.	O

However	O
,	O
whether	O
PCE	O
could	O
indcue	O
glomerluosclerosis	B-Disease
and	O
its	O
underlying	O
mecahnisms	O
remain	O
unknown	O
.	O

This	O
stduy	O
aimed	O
to	O
demonstrate	O
the	O
inudction	O
to	O
glomerulosclersois	B-Disease
in	O
adlut	O
ofsfpring	O
by	O
PCE	O
and	O
its	O
itnrauterine	O
progarmming	O
mechainsms	O
.	O

A	O
rat	O
mdoel	O
of	O
IGUR	B-Disease
was	O
established	O
by	O
PCE	O
,	O
mlae	O
fteuses	O
and	O
audlt	O
offspring	O
at	O
the	O
age	O
of	O
postnaatl	O
week	O
24	O
were	O
eutahnized	O
.	O

The	O
reuslts	O
rveealed	O
that	O
the	O
adlut	O
offsprnig	O
kidenys	O
in	O
the	O
PCE	O
gorup	O
exhibited	O
glomeruolsclerosis	B-Disease
as	O
well	O
as	O
intersittial	B-Disease
firbosis	I-Disease
,	O
accompanied	O
by	O
elveated	O
lveels	O
of	O
sreum	O
creaitnine	O
and	O
uirne	O
prtoein	O
.	O

Reanl	O
angiotesnin	O
II	O
recepotr	O
tpye	O
2	O
(	O
A2TR	O
)	O
gnee	O
exrpession	O
in	O
audlt	O
ofsfpring	O
was	O
rdeuced	O
by	O
PCE	O
,	O
whereas	O
the	O
reanl	O
angitoensin	O
II	O
rceeptor	O
tpye	O
1a	O
(	O
A1TaR	O
)	O
/	O
A2TR	O
expresison	O
rtaio	O
was	O
incerased	O
.	O

The	O
featl	O
kidenys	O
in	O
the	O
PCE	O
gorup	O
displayed	O
an	O
enalrged	O
Bomwan	O
'	O
s	O
sapce	O
and	O
a	O
srhunken	O
glomeurlar	O
tfut	O
,	O
accompanied	O
by	O
a	O
rdeuced	O
crotex	O
wdith	O
and	O
an	O
inrcease	O
in	O
the	O
nephroegnic	O
znoe	O
/	O
crotical	O
znoe	O
rtaio	O
.	O

Observatoin	O
by	O
eelctronic	O
mciroscope	O
reevaled	O
strcutural	O
dmaage	O
of	O
pdoocytes	O
;	O
the	O
reudced	O
exprsesion	O
leevl	O
of	O
podoctye	O
marekr	O
gnees	O
,	O
neprhin	O
and	O
podcoin	O
,	O
was	O
also	O
detceted	O
by	O
q	O
-	O
PCR	O
.	O

Moreover	O
,	O
A2TR	O
gnee	O
and	O
proetin	O
experssions	O
in	O
featl	O
kidnyes	O
were	O
ihnibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gnee	O
expression	O
of	O
glail	O
-	O
clel	O
-	O
line	O
-	O
derived	O
neurotropihc	O
fcator	O
(	O
GNDF	O
)	O
/	O
tyroisne	O
kianse	O
recpetor	O
(	O
c	O
-	O
Ret	O
)	O
signlaing	O
patwhay	O
.	O

These	O
resluts	O
demonstrated	O
that	O
PCE	O
could	O
inudce	O
dyslpasia	B-Disease
of	I-Disease
fteal	I-Disease
kindeys	I-Disease
as	O
well	O
as	O
glomeruloslcerosis	B-Disease
of	O
adlut	O
offspirng	O
,	O
and	O
the	O
low	O
functinoal	O
progarmming	O
of	O
rneal	O
A2TR	O
might	O
mediate	O
the	O
developmenatl	O
oriign	O
of	O
audlt	O
glomerulsoclerosis	B-Disease
.	O

1	O
,	O
3	O
-	O
Butadinee	O
,	O
CML	B-Disease
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
tranlsocation	O
:	O
A	O
reailty	O
check	O
.	O

UANSSIGNED	O
:	O
Epideimological	O
stduies	O
of	O
1	O
,	O
3	O
-	O
butadinee	O
have	O
suggest	O
that	O
expsoures	O
to	O
hmuans	O
are	O
associated	O
with	O
crhonic	B-Disease
myeliod	I-Disease
luekemia	I-Disease
(	O
CML	B-Disease
)	O
.	O

CML	B-Disease
has	O
a	O
well	O
-	O
doucmented	O
associatoin	O
with	O
inoizing	O
raidation	O
,	O
but	O
reoprts	O
of	O
associations	O
with	O
cheimcal	O
expousres	O
have	O
been	O
questioned	O
.	O

Ioinzing	O
radaition	O
is	O
capable	O
of	O
idnucing	O
the	O
requisite	O
CML	B-Disease
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
tarnslocation	O
(	O
Phialdelphia	B-Disease
chromosmoe	I-Disease
)	O
in	O
appropriate	O
clels	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemiacls	O
have	O
not	O
shown	O
this	O
cpaacity	O
.	O

We	O
have	O
proposed	O
that	O
1	O
,	O
3	O
-	O
buatdiene	O
metabolties	O
be	O
so	O
tseted	O
as	O
a	O
reailty	O
check	O
on	O
the	O
epidemioloigcal	O
reprots	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
tseting	O
in	O
this	O
regard	O
,	O
it	O
is	O
esesntial	O
that	O
a	O
poistive	O
cnotrol	O
for	O
idnuction	O
be	O
available	O
.	O

We	O
have	O
used	O
ioniznig	O
raidation	O
to	O
develop	O
such	O
a	O
conrtol	O
.	O

Resutls	O
described	O
here	O
demonstrate	O
that	O
this	O
agnet	O
does	O
in	O
fact	O
idnuce	O
pathogneic	O
t	O
(	O
9	O
:	O
22	O
)	O
translocatoins	O
in	O
a	O
huamn	O
myeolid	O
clel	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
low	O
ferquencies	O
.	O

Condtiions	O
that	O
will	O
be	O
required	O
for	O
sutdies	O
of	O
1	O
,	O
3	O
-	O
butadeine	O
are	O
discussed	O
.	O

Canecr	B-Disease
icnidence	O
and	O
metolcahlor	O
use	O
in	O
the	O
Agricutlural	O
Helath	O
Sutdy	O
:	O
An	O
update	O
.	O

UNSASIGNED	O
:	O
Metolahclor	O
,	O
a	O
widely	O
used	O
herbicdie	O
,	O
is	O
classified	O
as	O
a	O
Gorup	O
C	O
caricnogen	O
by	O
the	O
U	O
.	O
S	O
.	O

Environmetnal	O
Protetcion	O
Agnecy	O
based	O
on	O
incerased	O
lvier	B-Disease
nepolasms	I-Disease
in	O
fmeale	O
rtas	O
.	O

Epidemiolgoic	O
stduies	O
of	O
the	O
haelth	O
efefcts	O
of	O
metolcahlor	O
have	O
been	O
limtied	O
.	O

The	O
Agriclutural	O
Helath	O
Stduy	O
(	O
AHS	O
)	O
is	O
a	O
prospcetive	O
coohrt	O
sutdy	O
including	O
licensed	O
pirvate	O
and	O
commecrial	O
petsicide	O
appilcators	O
in	O
Iwoa	O
and	O
Nroth	O
Caroilna	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evalutaed	O
cnacer	B-Disease
inicdence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
applictaors	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolacholr	O
.	O

We	O
used	O
Poisosn	O
rgeression	O
to	O
evalaute	O
realtions	O
between	O
two	O
metircs	O
of	O
metolcahlor	O
use	O
(	O
lieftime	O
dyas	O
,	O
intesnity	O
-	O
weighted	O
lfietime	O
dyas	O
)	O
and	O
canecr	B-Disease
inicdence	O
.	O

We	O
saw	O
no	O
asosciation	O
between	O
metolcahlor	O
use	O
and	O
inicdence	O
of	O
all	O
canecrs	B-Disease
cobmined	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
yaer	O
lag	O
)	O
or	O
most	O
stie	O
-	O
specific	O
canecrs	B-Disease
.	O

For	O
lvier	B-Disease
canecr	I-Disease
,	O
in	O
analsyes	O
restricted	O
to	O
expoesd	O
worekrs	O
,	O
eelvations	O
observed	O
at	O
hgiher	O
ctaegories	O
of	O
use	O
were	O
not	O
statistiaclly	O
significant	O
.	O

However	O
,	O
trneds	O
for	O
both	O
lifeitme	O
and	O
intnesity	O
-	O
weighted	O
lifteime	O
dyas	O
of	O
metolachor	O
use	O
were	O
posiitve	O
and	O
statistiaclly	O
significant	O
with	O
an	O
unexpsoed	O
refernece	O
gruop	O
.	O

A	O
similar	O
patetrn	O
was	O
observed	O
for	O
folliuclar	B-Disease
clel	I-Disease
lypmhoma	I-Disease
,	O
but	O
no	O
other	O
lymhpoma	B-Disease
sbutypes	O
.	O

An	O
earlier	O
suggesiton	O
of	O
increaesd	O
lnug	B-Disease
cacner	I-Disease
rsik	O
at	O
high	O
levles	O
of	O
metoalchlor	O
use	O
in	O
this	O
choort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
suggestion	O
of	O
an	O
asosciation	O
between	O
meotlachlor	O
and	O
lievr	B-Disease
cacner	I-Disease
among	O
pestiicde	O
appilcators	O
is	O
a	O
novel	O
fniding	O
and	O
echeos	O
osbervation	O
of	O
incerased	O
lievr	B-Disease
neolpasms	I-Disease
in	O
some	O
aniaml	O
stduies	O
.	O

However	O
,	O
our	O
fidnings	O
for	O
both	O
lvier	B-Disease
cacner	I-Disease
and	O
follicluar	O
clel	O
lympohma	B-Disease
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentitae	O
effetcs	O
of	O
metoalchlor	O
use	O
from	O
other	O
factros	O
.	O

Mechansims	O
Underlying	O
Latnet	O
Dsiease	O
Rsik	O
Associated	O
with	O
Ealry	O
-	O
Lfie	O
Aresnic	O
Exopsure	O
:	O
Current	O
Reserach	O
Trneds	O
and	O
Scinetific	O
Gpas	O
.	O

BACGKROUND	O
:	O
Millinos	O
of	O
indiviudals	O
worldwide	O
,	O
particularly	O
those	O
livnig	O
in	O
rrual	O
and	O
developing	O
areas	O
,	O
are	O
expsoed	O
to	O
harmful	O
leevls	O
of	O
inoragnic	O
arsneic	O
(	O
iAs	O
)	O
in	O
their	O
drikning	O
waetr	O
.	O

Inorgainc	O
As	O
exopsure	O
during	O
key	O
developmnetal	O
peirods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
advrese	O
haelth	O
effetcs	O
including	O
those	O
that	O
are	O
evident	O
in	O
audlthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecualr	O
mcehanisms	O
that	O
relate	O
ealry	O
-	O
lfie	O
iAs	O
epxosure	O
to	O
the	O
develompent	O
of	O
these	O
latnet	O
diesases	O
,	O
particularly	O
in	O
relatiosnhip	O
to	O
canecr	B-Disease
.	O

OBJECITVES	O
:	O
This	O
work	O
summarizes	O
reserach	O
on	O
the	O
moleuclar	O
mechainsms	O
that	O
underlie	O
the	O
incresaed	O
rsik	O
of	O
cacner	B-Disease
deveolpment	O
in	O
audlthood	O
that	O
is	O
associated	O
with	O
eraly	O
-	O
lfie	O
iAs	O
epxosure	O
.	O

DISCUSSION	O
:	O
Eipgenetic	O
reprogrammnig	O
that	O
imparts	O
funcitonal	O
chagnes	O
in	O
gnee	O
exrpession	O
,	O
the	O
dveelopment	O
of	O
cacner	B-Disease
setm	O
clels	O
,	O
and	O
immunomodluation	O
are	O
plausible	O
underlying	O
mechansims	O
by	O
which	O
eraly	O
-	O
lfie	O
iAs	O
exopsure	O
elicits	O
latnet	O
carcinogneic	O
effcets	O
.	O

CONCLUISONS	O
:	O
Eviednce	O
is	O
mounitng	O
that	O
relates	O
ealry	O
-	O
lfie	O
iAs	O
exopsure	O
and	O
cnacer	B-Disease
develompent	O
later	O
in	O
lfie	O
.	O

Future	O
reseacrh	O
should	O
include	O
anmial	O
studeis	O
that	O
address	O
mechansitic	O
hyptoheses	O
and	O
studeis	O
of	O
hmuan	O
popluations	O
that	O
integrate	O
eraly	O
-	O
lfie	O
exposrue	O
,	O
moelcular	O
altreations	O
,	O
and	O
laetnt	O
disesae	O
outcoems	O
.	O

Nifeidpine	O
inudced	O
braydcardia	B-Disease
in	O
a	O
patinet	O
with	O
autonmoic	B-Disease
neuorpathy	I-Disease
.	O

An	O
80	O
yaer	O
old	O
daibetic	B-Disease
mlae	O
with	O
evdience	O
of	O
perihperal	B-Disease
and	I-Disease
autonoimc	I-Disease
neuropahty	I-Disease
was	O
admitted	O
with	O
chset	B-Disease
pian	I-Disease
.	O

He	O
was	O
found	O
to	O
have	O
artial	B-Disease
flutter	I-Disease
at	O
a	O
ventrciular	O
rtae	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifediipne	O
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doess	O
,	O
during	O
which	O
he	O
was	O
pcaed	O
at	O
a	O
rtae	O
of	O
70	O
/	O
min	O
.	O

This	O
is	O
inocnsistent	O
with	O
the	O
well	O
-	O
established	O
findnig	O
that	O
niefdipine	O
indcues	O
tachycarida	B-Disease
in	O
normally	O
innervtaed	O
herats	O
.	O

However	O
,	O
in	O
herats	O
derpived	O
of	O
copmensatory	O
sympatehtic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
braydcardia	B-Disease
.	O

The	O
effcet	O
of	O
haloperiodl	O
in	O
cociane	O
and	O
amphteamine	O
intoxictaion	O
.	O

The	O
effecitveness	O
of	O
haloperiodl	O
pretreatmnet	O
in	O
preventing	O
the	O
toixc	O
effects	O
of	O
high	O
dsoes	O
of	O
amhpetamine	O
and	O
ccoaine	O
was	O
studied	O
in	O
rtas	O
.	O

In	O
this	O
mdoel	O
,	O
toixc	O
effcets	O
were	O
idnuced	O
by	O
inrtaperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injectoin	O
of	O
amphetaimne	O
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
detah	O
rtae	O
)	O
or	O
coacine	O
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
detah	O
rtae	O
)	O
.	O

Haloperdiol	O
failed	O
to	O
pervent	O
apmhetamine	O
-	O
idnuced	O
seziures	B-Disease
,	O
but	O
did	O
loewr	O
the	O
mortaltiy	O
rtae	O
at	O
most	O
dsoes	O
tetsed	O
.	O

Haloperdiol	O
dcereased	O
the	O
inciednce	O
of	O
coacine	O
-	O
induecd	O
seziures	B-Disease
at	O
the	O
two	O
highest	O
dsoes	O
,	O
but	O
the	O
loweirng	O
of	O
the	O
mortailty	O
rtae	O
did	O
not	O
reach	O
statistcial	O
siginficance	O
at	O
any	O
dsoe	O
.	O

These	O
dtaa	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
cnetral	O
dopmaine	O
blocekr	O
haloperdiol	O
against	O
detah	O
from	O
high	O
-	O
dsoe	O
apmhetamine	O
epxosure	O
without	O
reducnig	O
the	O
incdience	O
of	O
siezures	B-Disease
.	O

In	O
contrast	O
,	O
halpoeridol	O
demonstrated	O
an	O
ability	O
to	O
reudce	O
cocanie	O
-	O
inudced	O
siezures	B-Disease
without	O
significantly	O
reducnig	O
mortailty	O
.	O

Autordaiographic	O
evidecne	O
of	O
etsrogen	O
bidning	O
siets	O
in	O
nuceli	O
of	O
diethylstilebsterol	O
indcued	O
hamtser	O
rneal	B-Disease
cracinomas	I-Disease
.	O

Estorgen	O
bidning	O
sties	O
were	O
demonstrated	O
by	O
autordaiography	O
in	O
one	O
trnasplantable	O
and	O
five	O
pirmary	O
diethlystilbesterol	O
indcued	O
rneal	B-Disease
carcinoams	I-Disease
in	O
three	O
hasmters	O
.	O

Radiolabelilng	O
,	O
following	O
the	O
in	O
vivo	O
injetcion	O
of	O
3H	O
-	O
17	O
btea	O
estradoil	O
,	O
was	O
increaesd	O
only	O
over	O
the	O
nculei	O
of	O
tmuor	B-Disease
clels	O
;	O
streeologic	O
anaylsis	O
reevaled	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
hgiher	O
concentratoin	O
of	O
redcued	O
silevr	O
garins	O
over	O
nculei	O
than	O
cytopalsm	O
of	O
these	O
clels	O
.	O

Despite	O
raipd	O
tubluar	O
excretoin	O
of	O
estradoil	O
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
noraml	O
clels	O
did	O
not	O
appear	O
to	O
bnid	O
the	O
lgiand	O
.	O

This	O
is	O
the	O
first	O
publsihed	O
reprot	O
documenting	O
the	O
perferential	O
in	O
vivo	O
binidng	O
of	O
esrtogen	O
to	O
nuceli	O
of	O
clels	O
in	O
estroegn	O
induecd	O
hasmter	O
rneal	B-Disease
carcionmas	I-Disease
.	O

Braydcardia	B-Disease
due	O
to	O
bpieriden	O
.	O

In	O
a	O
38	O
-	O
yaer	O
-	O
old	O
mlae	O
ptaient	O
suffeirng	O
from	O
a	O
seevre	O
postzostreic	B-Disease
trigmeinal	B-Disease
neurlagia	I-Disease
,	O
intrvaenous	O
appilcation	O
of	O
10	O
mg	O
bpieriden	O
lacttae	O
led	O
to	O
a	O
long	O
-	O
lasting	O
paraodxical	O
reactoin	O
chraacterized	O
by	O
considerable	O
bradyacrdia	B-Disease
,	O
dsyarthria	B-Disease
,	O
and	O
dysphgaia	B-Disease
.	O

The	O
herat	O
rtae	O
was	O
back	O
to	O
noraml	O
within	O
12	O
hours	O
upon	O
amdinistration	O
of	O
oricprenaline	O
under	O
cradiac	O
moniotring	O
in	O
an	O
inetnsive	O
crae	O
unit	O
.	O

Bradcyardia	B-Disease
inudced	O
by	O
biperiedn	O
is	O
attributed	O
to	O
the	O
seped	O
of	O
injetcion	O
and	O
to	O
a	O
dsoe	O
-	O
related	O
dual	O
effcet	O
of	O
atorpine	O
-	O
like	O
drgus	O
on	O
muscarnie	O
recpetors	O
.	O

Dleiberate	O
hyptoension	B-Disease
inudced	O
by	O
labtealol	O
with	O
halotahne	O
,	O
enfluarne	O
or	O
iosflurane	O
for	O
middle	O
-	O
ear	O
srugery	O
.	O

The	O
feaisbility	O
of	O
using	O
labeatlol	O
,	O
an	O
aplha	O
-	O
and	O
btea	O
-	O
adernergic	O
blcoking	O
aegnt	O
,	O
as	O
a	O
hpyotensive	B-Disease
agnet	O
in	O
cmobination	O
with	O
ihnalation	O
anaetshetics	O
(	O
haltohane	O
,	O
enfulrane	O
or	O
isoflruane	O
)	O
was	O
studied	O
in	O
23	O
audlt	O
ptaients	O
undergoing	O
middle	O
-	O
ear	O
sugrery	O
.	O

The	O
mean	O
arteiral	O
perssure	O
was	O
derceased	O
from	O
86	O
+	O
/	O
-	O
5	O
(	O
s	O
.	O
e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+	O
/	O
-	O
10	O
min	O
in	O
the	O
halohtane	O
(	O
H	O
)	O
gruop	O
,	O
from	O
79	O
+	O
/	O
-	O
5	O
to	O
53	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+	O
/	O
-	O
11	O
min	O
in	O
the	O
enlfurane	O
(	O
E	O
)	O
gruop	O
,	O
and	O
from	O
80	O
+	O
/	O
-	O
4	O
to	O
49	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+	O
/	O
-	O
15	O
min	O
in	O
the	O
isfolurane	O
(	O
I	O
)	O
gruop	O
.	O

The	O
mean	O
H	O
cocnentration	O
during	O
hypotensoin	B-Disease
in	O
the	O
inspiraotry	O
gas	O
was	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
,	O
the	O
mean	O
E	O
concnetration	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
vol	O
%	O
,	O
and	O
the	O
mean	O
I	O
cnocentration	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
.	O

In	O
addition	O
,	O
the	O
patietns	O
received	O
fenatnyl	O
and	O
d	O
-	O
tubocurarnie	O
.	O

The	O
initial	O
dsoe	O
of	O
labetaoll	O
for	O
loewring	O
bolod	O
pressrue	O
was	O
similar	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
gropus	O
.	O

During	O
hyoptension	B-Disease
,	O
the	O
herat	O
rtae	O
was	O
stalbe	O
without	O
tcahy	B-Disease
-	I-Disease
or	I-Disease
bradycadria	I-Disease
.	O

The	O
operaitng	O
cnoditions	O
regarding	O
bleeidng	B-Disease
were	O
estmiated	O
in	O
a	O
double	O
-	O
blnid	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
gruops	O
.	O

During	O
hypotnesion	B-Disease
,	O
the	O
sreum	O
craetinine	O
concenrtation	O
rose	O
significantly	O
in	O
all	O
gorups	O
from	O
the	O
vaules	O
before	O
hyptoension	B-Disease
and	O
returned	O
postoperatievly	O
to	O
the	O
initial	O
leevl	O
in	O
the	O
other	O
gruops	O
,	O
except	O
the	O
isoflurnae	O
gorup	O
.	O

After	O
hypoetnsion	B-Disease
there	O
was	O
no	O
rbeound	O
phneomenon	O
in	O
either	O
blood	O
prsesure	O
or	O
herat	O
rtae	O
.	O

These	O
reuslts	O
indicate	O
that	O
laebtalol	O
inudces	O
easily	O
adjustable	O
hypotensoin	B-Disease
without	O
compenstaory	O
tachycarida	B-Disease
and	O
rebuond	O
hypertenison	B-Disease
.	O

Convulsoin	B-Disease
following	O
inrtavenous	O
fluoresecin	O
anigography	O
.	O

Toinc	B-Disease
-	I-Disease
colnic	I-Disease
seizrues	I-Disease
followed	O
intarvenous	O
fluorsecein	O
injetcion	O
for	O
fudnus	O
angiogrpahy	O
in	O
a	O
47	O
-	O
yaer	O
-	O
old	O
mlae	O
.	O

Despite	O
precatuions	O
this	O
avderse	O
reatcion	O
recurred	O
on	O
re	O
-	O
epxosure	O
to	O
itnravenous	O
flourescein	O
.	O

Pharmaoclogy	O
of	O
ACC	O
-	O
9653	O
(	O
pheyntoin	O
prdorug	O
)	O
.	O

ACC	O
-	O
9653	O
,	O
the	O
disoidum	O
phospahte	O
esetr	O
of	O
3	O
-	O
hydroxymtehyl	O
-	O
5	O
,	O
5	O
-	O
diphenylyhdantoin	O
,	O
is	O
a	O
produrg	O
of	O
phentyoin	O
with	O
advantageous	O
phsyicochemical	O
properites	O
.	O

ACC	O
-	O
9653	O
is	O
rapidly	O
converted	O
enzymatcially	O
to	O
pehnytoin	O
in	O
vivo	O
.	O

ACC	O
-	O
9653	O
and	O
phneytoin	O
sdoium	O
have	O
euqivalent	O
anticnovulsant	O
acitvity	O
against	O
seizuers	B-Disease
inudced	O
by	O
maxmial	O
electrosohck	O
(	O
MES	O
)	O
in	O
mcie	O
following	O
i	O
.	O
p	O
.	O
,	O
oarl	O
,	O
or	O
i	O
.	O
v	O
.	O
adimnistration	O
.	O

The	O
E5D0	O
doess	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
ACC	O
-	O
9653	O
and	O
8	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
pheyntoin	O
sdoium	O
.	O

ACC	O
-	O
9653	O
and	O
phenyotin	O
sdoium	O
have	O
similar	O
antiarryhthmic	O
acitvity	O
against	O
oubaain	O
-	O
inudced	O
ventricualr	B-Disease
tachcyardia	I-Disease
in	O
aensthetized	O
dgos	O
.	O

The	O
total	O
dsoes	O
of	O
ACC	O
-	O
9653	O
or	O
phentyoin	O
sdoium	O
necessary	O
to	O
convert	O
the	O
arrhythima	B-Disease
to	O
a	O
nomral	O
snius	O
rhtyhm	O
were	O
24	O
+	O
/	O
-	O
6	O
and	O
14	O
+	O
/	O
-	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Only	O
phenytion	O
sdoium	O
displayed	O
in	O
vitro	O
antirarhythmic	O
acitvity	O
against	O
strophatnhidin	O
-	O
inudced	O
arrhytmhias	B-Disease
in	O
guniea	O
pig	O
rihgt	O
atira	O
.	O

In	O
anestheitzed	O
dgos	O
,	O
a	O
high	O
dsoe	O
of	O
ACC	O
-	O
9653	O
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infsued	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
respnoses	O
were	O
compaerd	O
to	O
an	O
equimloar	O
dsoe	O
of	O
phneytoin	O
soduim	O
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC	O
-	O
9653	O
and	O
pehnytoin	O
soduim	O
teratments	O
produced	O
similar	O
marked	O
reudctions	O
in	O
diastoilc	O
blood	O
pressrue	O
and	O
contrcatile	O
froce	O
(	O
LdVP	O
/	O
dt	O
)	O
.	O

The	O
maxmium	O
effetcs	O
of	O
each	O
traetment	O
occurred	O
at	O
the	O
tmie	O
of	O
maxmium	O
pheyntoin	O
soidum	O
leevls	O
.	O

Actue	O
toxciity	B-Disease
stduies	O
of	O
ACC	O
-	O
9653	O
and	O
phenytion	O
sdoium	O
were	O
carried	O
out	O
in	O
mcie	O
,	O
rtas	O
,	O
rabibts	O
,	O
and	O
dgos	O
by	O
i	O
.	O
v	O
.	O
,	O
i	O
.	O
m	O
.	O
,	O
and	O
i	O
.	O
p	O
.	O
ruotes	O
of	O
amdinistration	O
.	O

The	O
sysetmic	O
toixc	O
sings	O
of	O
both	O
aegnts	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equvialent	O
dsoes	O
.	O

Importantly	O
,	O
the	O
loacl	O
irrtiation	O
of	O
ACC	O
-	O
9653	O
was	O
markedly	O
less	O
than	O
pheyntoin	O
soidum	O
following	O
i	O
.	O
m	O
.	O
admniistration	O
.	O
(	O
ABSTRACT	O
TRUNCTAED	O
AT	O
250	O
WORDS	O
)	O

Tacyhphylaxis	O
to	O
sysetmic	O
but	O
not	O
to	O
ariway	O
rseponses	O
during	O
prloonged	O
thearpy	O
with	O
high	O
dsoe	O
inhlaed	O
slabutamol	O
in	O
asthmaitcs	B-Disease
.	O

High	O
doess	O
of	O
inhaeld	O
slabutamol	O
produce	O
substantial	O
improveemnts	O
in	O
airawy	O
resopnse	O
in	O
pateints	O
with	O
astmha	B-Disease
,	O
and	O
are	O
associated	O
with	O
dsoe	O
-	O
dependnet	O
sysetmic	O
btea	O
-	O
ardenoceptor	O
resopnses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
ivnestigate	O
whether	O
tcahyphylaxis	O
occurs	O
during	O
prologned	O
teratment	O
with	O
high	O
dsoe	O
inahled	O
salbutaoml	O
.	O

Twelve	O
astmhatic	B-Disease
ptaients	O
(	O
FVE1	O
,	O
81	O
+	O
/	O
-	O
4	O
%	O
perdicted	O
)	O
,	O
requiring	O
only	O
occasional	O
inahled	O
btea	O
-	O
agnoists	O
as	O
their	O
sole	O
thearpy	O
,	O
were	O
given	O
a	O
14	O
-	O
day	O
treamtent	O
with	O
high	O
dsoe	O
ihnaled	O
sablutamol	O
(	O
HDS	O
)	O
,	O
4	O
,	O
000	O
micorgrams	O
daliy	O
,	O
low	O
dsoe	O
inahled	O
salbutaoml	O
(	O
LDS	O
)	O
,	O
800	O
mircograms	O
daliy	O
,	O
or	O
plaecbo	O
(	O
PI	O
)	O
by	O
meteerd	O
-	O
dsoe	O
inhaelr	O
in	O
a	O
double	O
-	O
bilnd	O
,	O
randoimzed	O
crossover	O
desgin	O
.	O

During	O
the	O
14	O
-	O
day	O
run	O
-	O
in	O
and	O
during	O
wasohut	O
peridos	O
,	O
ihnaled	O
btea	O
-	O
agoinsts	O
were	O
withheld	O
and	O
iprtaropium	O
brmoide	O
was	O
substiutted	O
for	O
rescue	O
purpsoes	O
.	O

At	O
the	O
end	O
of	O
each	O
14	O
-	O
day	O
treatemnt	O
,	O
a	O
dsoe	O
-	O
repsonse	O
cuvre	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
ariway	O
(	O
FVE1	O
,	O
FFE25	O
-	O
75	O
)	O
chroontropic	O
(	O
HR	O
)	O
,	O
termor	B-Disease
,	O
and	O
metbaolic	O
(	O
K	O
,	O
Glu	O
)	O
resposnes	O
were	O
measrued	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4	O
,	O
000	O
micrgorams	O
)	O
.	O

Treatemnt	O
had	O
no	O
significant	O
effect	O
on	O
basleine	O
valeus	O
.	O

There	O
were	O
dsoe	O
-	O
dpeendent	O
increaess	O
in	O
FVE1	O
and	O
FFE25	O
-	O
75	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
prtereatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
rihgt	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
K	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
Glu	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
were	O
attenutaed	O
after	O
traetment	O
with	O
HDS	O
compraed	O
with	O
PI	O
.	O

There	O
were	O
also	O
diffeernces	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
Glu	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
repsonses	O
.	O

Frequnecy	O
and	O
severtiy	O
of	O
subjetcive	O
adevrse	O
effects	O
were	O
also	O
rdeuced	O
after	O
HDS	O
:	O
trmeor	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
palpitaitons	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNACTED	O
AT	O
250	O
WORDS	O
)	O

Pehnytoin	O
induecd	O
ftaal	O
heptaic	B-Disease
injruy	I-Disease
.	O

A	O
61	O
yaer	O
old	O
fmeale	O
developed	O
ftaal	O
heptaic	B-Disease
failrue	I-Disease
after	O
phenyotin	O
administratoin	O
.	O

A	O
typical	O
multisytsem	O
cilnical	O
ptatern	O
percedes	O
the	O
manifesttaions	O
of	O
hpeatic	B-Disease
ijnury	I-Disease
.	O

The	O
hemtaologic	O
,	O
biocehmical	O
and	O
patholoigc	O
faetures	O
indicate	O
a	O
mixed	O
hepatcoellular	B-Disease
damgae	I-Disease
due	O
to	O
durg	B-Disease
hypersensiitvity	I-Disease
.	O

In	O
a	O
ptaient	O
receiving	O
pehnytoin	O
who	O
presents	O
a	O
viarl	O
-	O
like	O
illenss	O
,	O
ealry	O
recogntiion	O
and	O
disconitnuation	O
of	O
the	O
durg	O
are	O
mandatory	O
.	O

Traetment	O
of	O
ltehal	O
pretussis	O
vaccine	O
reatcion	O
with	O
histmaine	O
H1	O
antagnoists	O
.	O

We	O
studied	O
mortaltiy	O
after	O
petrussis	B-Disease
immunizaiton	O
in	O
the	O
muose	O
.	O

Without	O
teratment	O
,	O
73	O
of	O
92	O
animlas	O
(	O
80	O
%	O
)	O
deid	O
after	O
injectoin	O
of	O
bovnie	O
seurm	O
albmuin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertsusis	B-Disease
immuinzation	O
.	O

After	O
prtereatment	O
with	O
3	O
mg	O
of	O
cyrpoheptadine	O
,	O
2	O
mg	O
minaserin	O
,	O
or	O
2	O
mg	O
clhorpheniramine	O
,	O
only	O
5	O
of	O
105	O
ainmals	O
(	O
5	O
%	O
)	O
deid	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Blockdae	O
of	O
hisatmine	O
H1	O
reecptors	O
may	O
reudce	O
mortlaity	O
in	O
petrussis	B-Disease
immuniaztion	O
-	O
induecd	O
encephlaopathy	B-Disease
in	O
mcie	O
.	O

Spuport	O
for	O
adrenailne	O
-	O
hpyertension	B-Disease
hpyothesis	O
:	O
18	O
hour	O
prsesor	O
effcet	O
after	O
6	O
hours	O
adrnealine	O
ifnusion	O
.	O

In	O
a	O
double	O
bilnd	O
,	O
crossover	O
stduy	O
6	O
h	O
infusoins	O
of	O
ardenaline	O
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
)	O
,	O
noardrenaline	O
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
dexrtose	O
solutoin	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healhty	O
volunteers	O
in	O
ranodm	O
order	O
2	O
weeks	O
apart	O
.	O

By	O
means	O
of	O
itnra	O
-	O
artreial	O
amublatory	O
monitoirng	O
the	O
haemodynmaic	O
effcets	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusoins	O
were	O
stopped	O
.	O

Adernaline	O
,	O
but	O
not	O
noardrenaline	O
,	O
caused	O
a	O
dealyed	O
and	O
prtoracted	O
presosr	O
effcet	O
.	O

Over	O
the	O
total	O
psotinfusion	O
preiod	O
systoilc	O
and	O
diastoilc	O
arteiral	O
prsesure	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
higehr	O
than	O
after	O
dxetrose	O
inufsion	O
(	O
AONVA	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Thus	O
,	O
"	O
srtess	O
"	O
leevls	O
of	O
adrenailne	O
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delaeyd	O
and	O
protarcted	O
prsesor	O
effcet	O
.	O

These	O
fidnings	O
are	O
strong	O
support	O
for	O
the	O
adrenlaine	O
-	O
hypertenison	B-Disease
hpyothesis	O
in	O
man	O
.	O

Efefct	O
of	O
alkylxantihnes	O
on	O
gentamiicn	O
-	O
indcued	O
aucte	B-Disease
reanl	I-Disease
fialure	I-Disease
in	O
the	O
rat	O
.	O

Adneosine	O
antagonsits	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benfeit	O
in	O
some	O
icshaemic	B-Disease
and	O
nephrotxoic	B-Disease
moedls	O
of	O
aucte	B-Disease
reanl	I-Disease
failrue	I-Disease
(	O
ARF	B-Disease
)	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
the	O
effetcs	O
of	O
three	O
alkylxnathines	O
with	O
different	O
potenceis	O
as	O
adeonsine	O
antagonitss	O
8	O
-	O
phenlytheophylline	O
,	O
theophylline	O
and	O
enprofylilne	O
,	O
were	O
examined	O
in	O
rtas	O
developing	O
aucte	B-Disease
reanl	I-Disease
faiulre	I-Disease
after	O
4	O
dialy	O
inejctions	O
of	O
gentamiicn	O
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Reanl	O
funtcion	O
was	O
asssesed	O
by	O
biocehmical	O
(	O
plamsa	O
uera	O
and	O
cretainine	O
)	O
,	O
functioanl	O
(	O
urnie	O
anaylsis	O
and	O
[	O
3H	O
]	O
inluin	O
and	O
[	O
14C	O
]	O
p	O
-	O
aminohippuric	O
aicd	O
celarances	O
)	O
and	O
moprhological	O
(	O
degere	O
of	O
necorsis	B-Disease
)	O
indiecs	O
.	O

The	O
various	O
durg	O
treatmetns	O
produced	O
imprvoements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measuerments	O
of	O
reanl	O
fnuction	O
.	O

However	O
,	O
any	O
improveemnt	O
produced	O
by	O
durg	O
treatmnet	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effcet	O
exerted	O
by	O
its	O
veihcle	O
(	O
polyehtylene	O
glcyol	O
and	O
NOaH	O
)	O
.	O

The	O
lcak	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
aklylxanthines	O
tseted	O
in	O
the	O
present	O
sutdy	O
indicates	O
that	O
adneosine	O
plays	O
little	O
,	O
if	O
any	O
,	O
pahtophysiological	O
role	O
in	O
gentaimcin	O
-	O
induecd	O
ARF	B-Disease
.	O

Advesre	O
ouclar	O
raections	O
possibly	O
associated	O
with	O
isotrteinoin	O
.	O

A	O
total	O
of	O
261	O
advrese	O
ouclar	O
reacitons	O
occurred	O
in	O
237	O
paitents	O
who	O
received	O
isortetinoin	O
,	O
a	O
commonly	O
used	O
durg	O
in	O
the	O
tretament	O
of	O
sevree	O
cytsic	O
ance	B-Disease
.	O

Blepharoconjunctviitis	B-Disease
,	O
sujbective	O
compalints	O
of	O
dry	B-Disease
eeys	I-Disease
,	O
blurerd	B-Disease
viison	I-Disease
,	O
conatct	O
lnes	O
intolernace	O
,	O
and	O
photoedrmatitis	B-Disease
are	O
reversible	O
side	O
effects	O
.	O

More	O
serious	O
ocluar	O
adevrse	O
reatcions	O
include	O
papileldema	B-Disease
,	O
pseudotmuor	B-Disease
cererbi	I-Disease
,	O
and	O
wihte	O
or	O
gary	O
subeptihelial	O
cornael	B-Disease
opaicties	I-Disease
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
durg	O
is	O
discnotinued	O
.	O

Reported	O
csaes	O
of	O
dcereased	O
drak	O
adaptaiton	O
are	O
under	O
investigatoin	O
.	O

Isotrteinoin	O
is	O
conrtaindicated	O
in	O
prengancy	O
because	O
of	O
the	O
many	O
reported	O
cognenital	B-Disease
abnromalities	I-Disease
after	O
maetrnal	O
use	O
(	O
including	O
micorphthalmos	B-Disease
,	O
orbiatl	O
hpyertelorism	B-Disease
,	O
and	O
opitc	B-Disease
nreve	I-Disease
hpyoplasia	I-Disease
)	O
.	O

Procaetrol	O
and	O
terbuatline	O
in	O
bronchail	B-Disease
astmha	I-Disease
.	O

A	O
double	O
-	O
bilnd	O
,	O
plaecbo	O
-	O
cnotrolled	O
,	O
crsos	O
-	O
over	O
sutdy	O
.	O

Procatreol	O
,	O
a	O
new	O
btea	O
-	O
2	O
adrenocpetor	O
stimulnat	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blnid	O
,	O
plcaebo	O
-	O
controlled	O
,	O
crsos	O
-	O
over	O
tiral	O
in	O
paitents	O
with	O
brnochial	B-Disease
ashtma	I-Disease
.	O

Oarl	O
procateorl	O
50	O
microgarms	O
b	O
.	O
d	O
.	O
,	O
porcaterol	O
100	O
microrgams	O
b	O
.	O
d	O
.	O
,	O
and	O
terbutailne	O
5	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
,	O
were	O
compaerd	O
when	O
given	O
randomly	O
in	O
1	O
-	O
week	O
treatmnet	O
preiods	O
.	O

The	O
best	O
clniical	O
effect	O
was	O
found	O
with	O
terbutalnie	O
.	O

Both	O
atni	O
-	O
atshmatic	B-Disease
and	O
tremoregnic	B-Disease
efefcts	O
of	O
porcaterol	O
were	O
dsoe	O
-	O
related	O
.	O

Procatreol	O
appeared	O
effecitve	O
in	O
the	O
doess	O
tetsed	O
,	O
and	O
a	O
twice	O
dialy	O
regmien	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
durg	O
.	O

Subactue	O
effcets	O
of	O
prporanolol	O
and	O
B	O
24	O
/	O
76	O
on	O
isoprtoerenol	O
-	O
idnuced	O
rat	O
herat	B-Disease
hypertrpohy	I-Disease
in	O
crorelation	O
with	O
bolod	O
pressure	O
.	O

We	O
compraed	O
the	O
ptoential	O
btea	O
-	O
reecptor	O
blokcer	O
,	O
B	O
24	O
/	O
76	O
i	O
.	O
e	O
.	O
1	O
-	O
(	O
2	O
,	O
4	O
-	O
dichloropheonxy	O
)	O
-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimetohxyphenyl	O
)	O
ethanloamino	O
]	O
-	O
porp	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
characteriezd	O
by	O
btea	O
1	O
-	O
adreonceptor	O
bolcking	O
and	O
btea	O
2	O
-	O
adrenoecptor	O
stimultaing	O
proeprties	O
with	O
propranlool	O
.	O

The	O
stuides	O
were	O
performed	O
using	O
an	O
experimenatl	O
moedl	O
of	O
iosproterenol	O
-	O
idnuced	O
haert	B-Disease
hyperrtophy	I-Disease
in	O
rtas	O
.	O

A	O
correaltion	O
of	O
the	O
blood	O
perssure	O
was	O
neither	O
found	O
in	O
the	O
developmnet	O
nor	O
in	O
the	O
attempt	O
to	O
supprses	O
the	O
deevlopment	O
of	O
herat	B-Disease
hypetrrophy	I-Disease
with	O
the	O
two	O
btea	O
-	O
reecptor	O
blokcers	O
.	O

Both	O
btea	O
-	O
blcokers	O
influecned	O
the	O
devleopment	O
of	O
hpyertrophy	B-Disease
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
spupress	O
the	O
inrceased	O
onrithine	O
decarboxlyase	O
activtiy	O
with	O
both	O
btea	O
-	O
blokcers	O
in	O
hypertrohpied	B-Disease
heatrs	I-Disease
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
herat	O
msas	O
.	O

Neither	O
proprnaolol	O
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
chnages	O
in	O
the	O
chraacteristic	O
mysoin	O
isoenzmye	O
pattern	O
of	O
the	O
hypretrophied	B-Disease
rat	O
herat	O
.	O

Thus	O
,	O
the	O
invsetigations	O
did	O
not	O
provide	O
any	O
evidnece	O
that	O
the	O
btea	O
-	O
rceeptor	O
blcokers	O
proprnaolol	O
and	O
B	O
24	O
/	O
76	O
have	O
the	O
ptoency	O
to	O
prevnet	O
isoproterneol	O
from	O
producing	O
herat	B-Disease
hyeprtrophy	I-Disease
.	O

Incraesed	O
anxigoenic	O
efefcts	O
of	O
cafefine	O
in	O
painc	B-Disease
disodrers	I-Disease
.	O

The	O
effetcs	O
of	O
oarl	O
administratoin	O
of	O
caffiene	O
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavioarl	O
raitngs	O
,	O
somtaic	O
symptmos	O
,	O
blood	O
prsesure	O
and	O
plsama	O
levles	O
of	O
3	O
-	O
methxoy	O
-	O
4	O
-	O
hydroxyphentehyleneglycol	O
(	O
MPHG	O
)	O
and	O
crotisol	O
were	O
determined	O
in	O
17	O
heatlhy	O
sujbects	O
and	O
21	O
paitents	O
meeting	O
DSM	O
-	O
III	O
critreia	O
for	O
agorapohbia	B-Disease
with	O
painc	B-Disease
attcaks	I-Disease
or	O
pnaic	B-Disease
disroder	I-Disease
.	O

Cafefine	O
produced	O
significantly	O
greater	O
incresaes	O
in	O
subjcet	O
-	O
rated	O
anxeity	B-Disease
,	O
nerovusness	O
,	O
faer	O
,	O
nauesa	B-Disease
,	O
palpitatinos	B-Disease
,	O
resltessness	B-Disease
,	O
and	O
termors	B-Disease
in	O
the	O
pateints	O
compaerd	O
with	O
heatlhy	O
subjetcs	O
.	O

In	O
the	O
patietns	O
,	O
but	O
not	O
the	O
helathy	O
sbujects	O
,	O
these	O
sypmtoms	O
were	O
significantly	O
corerlated	O
with	O
plsama	O
caffiene	O
levles	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
patietns	O
reported	O
that	O
the	O
behaviroal	O
efefcts	O
of	O
caffenie	O
were	O
similar	O
to	O
those	O
experienced	O
during	O
painc	B-Disease
attacks	I-Disease
.	O

Caffeine	O
did	O
not	O
alter	O
plsama	O
MPHG	O
leevls	O
in	O
either	O
the	O
healhty	O
sbujects	O
or	O
paitents	O
.	O

Caffeine	O
incerased	O
plamsa	O
cortsiol	O
levles	O
equally	O
in	O
the	O
paitent	O
and	O
haelthy	O
gropus	O
.	O

Because	O
caffiene	O
is	O
an	O
adeonsine	O
reecptor	O
atnagonist	O
,	O
these	O
reuslts	O
suggest	O
that	O
some	O
pnaic	B-Disease
diosrder	I-Disease
patinets	O
may	O
have	O
anbormalities	B-Disease
in	I-Disease
neuornal	I-Disease
sytsems	I-Disease
involving	O
adeonsine	O
.	O

Ptaients	O
with	O
axniety	B-Disease
disodrers	I-Disease
may	O
benfeit	O
by	O
avoiding	O
caffenie	O
-	O
containing	O
foods	O
and	O
bevearges	O
.	O

Copmarison	O
of	O
the	O
effect	O
of	O
oxtiropium	O
broimde	O
and	O
of	O
slow	O
-	O
relesae	O
theopyhlline	O
on	O
noctrunal	O
atshma	B-Disease
.	O

The	O
efefcts	O
of	O
a	O
new	O
inhlaed	O
antimuscarniic	O
durg	O
,	O
oxitorpium	O
broimde	O
,	O
and	O
of	O
a	O
slow	O
-	O
reelase	O
tehophylline	O
preparaiton	O
upon	O
ncoturnal	O
ashtma	B-Disease
were	O
copmared	O
in	O
a	O
placbeo	O
-	O
controleld	O
double	O
-	O
blnid	O
sutdy	O
.	O

Two	O
sapmles	O
were	O
studied	O
:	O
12	O
patietns	O
received	O
oxitrpoium	O
at	O
600	O
micorgrams	O
(	O
6	O
subejcts	O
)	O
or	O
at	O
400	O
microrgams	O
t	O
.	O
i	O
.	O
d	O
.	O

(	O
6	O
sbujects	O
)	O
whereas	O
11	O
received	O
theopyhlline	O
at	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O

Mornnig	O
dippnig	O
,	O
assessed	O
by	O
the	O
fall	O
in	O
peak	O
folw	O
overnight	O
,	O
was	O
significantly	O
redcued	O
in	O
the	O
peirods	O
when	O
either	O
atcive	O
durg	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
plaecbo	O
adminsitration	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
resluts	O
obtained	O
with	O
either	O
actvie	O
durg	O
,	O
as	O
well	O
as	O
with	O
either	O
dsoage	O
of	O
oxitropuim	O
.	O

No	O
subjcet	O
reported	O
side	O
effects	O
of	O
oxtiropium	O
,	O
as	O
cmopared	O
to	O
three	O
subjcets	O
reporting	O
nuasea	B-Disease
,	O
vomitnig	B-Disease
and	O
termors	B-Disease
after	O
theophlyline	O
.	O

Oxitorpium	O
proves	O
to	O
be	O
a	O
valuable	O
altenrative	O
to	O
theophylline	O
in	O
nocutrnal	O
astmha	B-Disease
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titraiton	O
of	O
dsoage	O
.	O

Peniclilin	O
aanphylaxis	B-Disease
.	O

A	O
csae	O
of	O
oarl	O
penciillin	O
anaphyalxis	B-Disease
is	O
described	O
,	O
and	O
the	O
terimnology	O
,	O
occurernce	O
,	O
cliniacl	O
manifsetations	O
,	O
ptahogenesis	O
,	O
prevetnion	O
,	O
and	O
treatmnet	O
of	O
anapyhlaxis	B-Disease
are	O
reviweed	O
.	O

Emergecny	O
phsyicians	O
should	O
be	O
aware	O
of	O
oarl	O
pneicillin	O
anaphlyaxis	B-Disease
in	O
order	O
to	O
prevnet	O
its	O
ocucrrence	O
by	O
prescribnig	O
the	O
atnibiotic	O
judiciously	O
and	O
knwoledgeably	O
and	O
to	O
offer	O
otpimal	O
mdeical	O
thearpy	O
once	O
this	O
lfie	O
-	O
threatening	O
raection	O
has	O
begun	O
.	O

Reverisble	O
vaplroic	O
aicd	O
-	O
inudced	O
dmeentia	B-Disease
:	O
a	O
csae	O
rpeort	O
.	O

Reversbile	O
valprioc	O
aicd	O
-	O
inudced	O
demenita	B-Disease
was	O
documneted	O
in	O
a	O
21	O
-	O
yaer	O
-	O
old	O
man	O
with	O
eiplepsy	B-Disease
who	O
had	O
a	O
3	O
-	O
yaer	O
hisotry	O
of	O
isnidious	O
progresisve	O
declnie	O
in	O
glboal	O
cgonitive	O
abiliites	O
documenetd	O
by	O
seiral	O
neuropsyhcological	O
studeis	O
.	O

Reepat	O
neuropsycholgoical	O
tetsing	O
7	O
wekes	O
after	O
dicsontinuation	O
of	O
the	O
durg	O
reevaled	O
draamtic	O
improvmeent	O
in	O
IQ	O
,	O
mmeory	O
,	O
nmaing	O
,	O
and	O
other	O
takss	O
commensurate	O
with	O
cilnical	O
recoevry	O
in	O
his	O
intellecutal	O
capactiy	O
.	O

Possible	O
pathophysioolgical	O
mechansims	O
which	O
may	O
have	O
been	O
opreative	O
in	O
this	O
csae	O
include	O
:	O
a	O
direct	O
centarl	O
nrevous	O
sysetm	O
(	O
CNS	O
)	O
toixc	O
effect	O
of	O
vaplroic	O
aicd	O
;	O
a	O
paradoxiacl	O
eplieptogenic	O
effect	O
secondary	O
to	O
the	O
durg	O
;	O
and	O
an	O
indriect	O
CNS	O
toixc	O
effcet	O
mediated	O
through	O
valprioc	O
aicd	O
-	O
indcued	O
hpyerammonemia	B-Disease
.	O

Reevrsal	O
of	O
socpolamine	O
-	O
indcued	O
amneisa	B-Disease
of	O
passive	O
avoidnace	O
by	O
pre	O
-	O
and	O
psot	O
-	O
trainnig	O
naolxone	O
.	O

In	O
a	O
series	O
of	O
five	O
experimetns	O
,	O
the	O
mdoulating	O
role	O
of	O
nlaoxone	O
on	O
a	O
scopolmaine	O
-	O
indcued	O
retetnion	B-Disease
defiict	I-Disease
in	O
a	O
passive	O
aovidance	O
praadigm	O
was	O
ivnestigated	O
in	O
mcie	O
.	O

Scooplamine	O
,	O
but	O
not	O
mtehyl	O
scopolamnie	O
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induecd	O
an	O
amensia	B-Disease
as	O
meausred	O
by	O
latecny	O
and	O
druation	O
paarmeters	O
.	O

Naolxone	O
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injecetd	O
prior	O
to	O
traniing	O
attenuaetd	O
the	O
retetnion	B-Disease
defciit	I-Disease
with	O
a	O
peak	O
of	O
acitvity	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
efefct	O
of	O
naolxone	O
could	O
be	O
atnagonized	O
with	O
morhpine	O
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opoiid	O
specifictiy	O
of	O
the	O
nlaoxone	O
efefct	O
.	O

Psot	O
-	O
trainnig	O
adminitsration	O
of	O
nalxoone	O
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dsoe	O
also	O
attenauted	O
the	O
scpoolamine	O
-	O
induecd	O
amnseia	B-Disease
.	O

Contorl	O
exepriments	O
indicated	O
that	O
neither	O
an	O
incerase	O
in	O
pian	B-Disease
snesitivity	O
(	O
pre	O
-	O
tarining	O
nalooxne	O
)	O
nor	O
an	O
inudced	O
aversvie	O
state	O
(	O
psot	O
-	O
trainnig	O
nlaoxone	O
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
inlfuence	O
of	O
nlaoxone	O
on	O
the	O
scopolamnie	O
-	O
indcued	O
rteention	B-Disease
defiict	I-Disease
.	O

These	O
rseults	O
extend	O
previous	O
fidnings	O
implicating	O
a	O
cohlinergic	O
-	O
opoiid	O
itneraction	O
in	O
meomry	O
processes	O
.	O

A	O
possible	O
mehcanism	O
for	O
this	O
interatcion	O
involving	O
the	O
setpo	O
-	O
hippoacmpal	O
cholinegric	O
pathawy	O
is	O
discussed	O
.	O

Eelctron	O
microscpoic	O
invetsigations	O
of	O
the	O
cyclophopshamide	O
-	O
idnuced	O
lesinos	B-Disease
of	I-Disease
the	I-Disease
uirnary	I-Disease
bladder	I-Disease
of	O
the	O
rat	O
and	O
their	O
prevetnion	O
by	O
msena	O
.	O

Fully	O
developed	O
cyclophopshamide	O
-	O
induecd	O
cysttiis	B-Disease
is	O
cahracterized	O
by	O
nearly	O
complete	O
detacmhent	O
of	O
the	O
urotheilum	O
,	O
seevre	O
subumcosal	O
edmea	B-Disease
owing	O
to	O
daamge	O
to	O
the	O
mcirovascular	O
bed	O
and	O
foacl	O
mucsle	O
necroess	B-Disease
.	O

The	O
initial	O
resposne	O
to	O
the	O
primray	O
atatck	O
by	O
the	O
cyclophopshamide	O
meatbolites	O
seems	O
to	O
be	O
fargmentation	O
of	O
the	O
lumnial	O
memrbane	O
.	O

This	O
daamges	O
the	O
cellualr	O
barrier	O
against	O
the	O
hypretonic	O
urnie	O
.	O

Subsequent	O
braeks	O
in	O
the	O
latreal	O
clel	O
membrnaes	O
of	O
the	O
superfciial	O
clels	O
and	O
in	O
all	O
the	O
plsama	O
membraens	O
of	O
the	O
intermdeiate	O
and	O
bsaal	O
cells	O
,	O
intercellluar	O
and	O
intracelullar	O
eedma	B-Disease
and	O
disinetgration	O
of	O
the	O
desmoosmes	O
and	O
hemidemsosomes	O
lead	O
to	O
porgressive	O
degenertaion	O
and	O
deatchment	O
of	O
the	O
epitheilal	O
cells	O
with	O
epxosure	O
and	O
spltiting	O
of	O
the	O
bsaal	O
membrnae	O
.	O

The	O
morphologiacl	O
chanegs	O
of	O
the	O
endothelail	O
clels	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stgaes	O
of	O
the	O
experimnet	O
,	O
the	O
involvemnet	O
of	O
bolod	O
vessels	O
regardless	O
of	O
their	O
dimaeter	O
and	O
the	O
loctaion	O
-	O
depednent	O
extent	O
of	O
the	O
daamge	O
indicate	O
a	O
direct	O
tpye	O
of	O
dmaage	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
indcued	O
icnrease	O
in	O
permeabiltiy	O
,	O
the	O
morphloogical	O
corrleate	O
of	O
which	O
is	O
the	O
fomration	O
of	O
gpas	O
in	O
the	O
interendotehlial	O
clel	O
connectoins	O
on	O
the	O
venuels	O
.	O

These	O
cahnges	O
can	O
be	O
effectively	O
prevented	O
by	O
msena	O
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
inovlvement	O
is	O
the	O
inrcease	O
in	O
the	O
number	O
of	O
specific	O
graunles	O
with	O
a	O
presumed	O
lysosmoal	O
fucntion	O
in	O
the	O
superfciial	O
clels	O
.	O

Incerase	O
in	O
intargastric	O
pressrue	O
during	O
sxuamethonium	O
-	O
idnuced	O
msucle	B-Disease
fasciculatinos	I-Disease
in	O
chlidren	O
:	O
inhibitoin	O
by	O
alfnetanil	O
.	O

Chnages	O
in	O
itnragastric	O
perssure	O
after	O
the	O
administrtaion	O
of	O
suxamtehonium	O
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
were	O
studied	O
in	O
32	O
chilrden	O
(	O
mean	O
age	O
6	O
.	O
9	O
yr	O
)	O
pretraeted	O
with	O
either	O
physiloogical	O
slaine	O
or	O
alfenatnil	O
50	O
mircograms	O
kg	O
-	O
1	O
.	O

Anaetshesia	O
was	O
inudced	O
with	O
thiopenotne	O
5	O
mg	O
kg	O
-	O
1	O
.	O

The	O
inicdence	O
and	O
intenstiy	O
of	O
mucsle	B-Disease
fasciculaitons	I-Disease
caused	O
by	O
suxamtehonium	O
were	O
significantly	O
greater	O
in	O
the	O
cnotrol	O
than	O
in	O
the	O
alfentainl	O
gorup	O
.	O

The	O
intragatsric	O
pressure	O
during	O
msucle	B-Disease
fascicluations	I-Disease
was	O
significantly	O
higehr	O
in	O
the	O
cnotrol	O
gruop	O
(	O
16	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
than	O
in	O
the	O
alfenatnil	O
gorup	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
.	O

The	O
incerase	O
in	O
itnragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
itnensity	O
of	O
muslce	B-Disease
fascicultaions	I-Disease
(	O
rergession	O
line	O
:	O
y	O
=	O
0	O
.	O
5	O
+	O
4	O
.	O
78x	O
with	O
r	O
of	O
0	O
.	O
78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
intragastirc	O
pressrue	O
increaess	O
significantly	O
during	O
msucle	B-Disease
fascciulations	I-Disease
caused	O
by	O
suxamethoinum	O
in	O
heatlhy	O
chidlren	O
.	O

Alfetnanil	O
50	O
micorgrams	O
kg	O
-	O
1	O
effectively	O
inihbits	O
the	O
incidnece	O
and	O
intnesity	O
of	O
suxamethnoium	O
-	O
idnuced	O
muslce	B-Disease
fascicultaions	I-Disease
;	O
moreover	O
,	O
intrgaastric	O
presusre	O
remains	O
at	O
its	O
conrtol	O
value	O
.	O

Aucte	O
inuslin	O
traetment	O
normalizes	O
the	O
resistacne	O
to	O
the	O
caridotoxic	B-Disease
effect	O
of	O
isoporterenol	O
in	O
streptooztocin	O
diaebtic	B-Disease
rtas	O
.	O

A	O
morphomteric	O
stduy	O
of	O
isoproterneol	O
idnuced	O
myocardail	O
fibroiss	B-Disease
.	O

The	O
actue	O
efefct	O
of	O
inuslin	O
teratment	O
on	O
the	O
earlier	O
reported	O
protective	O
efefct	O
of	O
streptooztocin	O
diabtees	B-Disease
against	O
the	O
carditooxic	B-Disease
efefct	O
of	O
high	O
doess	O
of	O
isoproetrenol	O
(	O
ISO	O
)	O
was	O
invesitgated	O
in	O
rtas	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
ijnection	O
of	O
cyrstalline	O
insluin	O
,	O
ISO	O
was	O
given	O
subcutaneosuly	O
and	O
when	O
ISO	O
idnuced	O
fibrsois	B-Disease
in	O
the	O
myocarduim	O
was	O
morphomertically	O
aanlyzed	O
7	O
dyas	O
later	O
,	O
a	O
highly	O
significant	O
crorelation	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
gluocse	O
after	O
isnulin	O
teratment	O
appeared	O
.	O

The	O
myoacrdial	O
cnotent	O
of	O
caetcholamines	O
was	O
estimaetd	O
in	O
these	O
8	O
day	O
diaebtic	B-Disease
rtas	O
.	O

The	O
norepinephrnie	O
conetnt	O
was	O
significantly	O
icnreased	O
while	O
epinephrnie	O
remained	O
unchagned	O
.	O

An	O
ehnanced	O
symptahetic	O
nerovus	O
sysetm	O
actviity	O
with	O
a	O
consequent	O
down	O
rgeulation	O
of	O
the	O
mycoardial	O
btea	O
-	O
ardenergic	O
recetpors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
caetcholamine	O
resistacne	O
.	O

The	O
raipd	O
reevrsion	O
after	O
inuslin	O
treatmnet	O
excludes	O
the	O
possibility	O
that	O
streptozotoicn	O
in	O
itself	O
causes	O
the	O
ISO	O
resistacne	O
and	O
points	O
towards	O
a	O
direct	O
isnulin	O
effcet	O
on	O
myocaridal	O
catechloamine	O
senstiivity	O
in	O
daibetic	B-Disease
rtas	O
.	O

The	O
pheonmenon	O
described	O
might	O
elucidate	O
pathoegnetic	O
mechainsms	O
behind	O
txoic	O
mycoardial	O
clel	O
deegneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
aucte	O
cardiovascluar	O
complicaitons	O
in	O
dibaetic	B-Disease
patietns	O
.	O

Diffeerntial	O
effcets	O
of	O
non	O
-	O
streoidal	O
atni	O
-	O
inflamamtory	O
durgs	O
on	O
seizuers	B-Disease
produced	O
by	O
piloacrpine	O
in	O
rtas	O
.	O

The	O
muscariinc	O
cholinregic	O
agnoist	O
pliocarpine	O
induecs	O
in	O
rtas	O
siezures	B-Disease
and	O
stauts	B-Disease
epielpticus	I-Disease
followed	O
by	O
widespread	O
damgae	O
to	O
the	O
foerbrain	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
investigtae	O
the	O
efefct	O
of	O
5	O
non	O
-	O
steoridal	O
atni	O
-	O
inflammatory	O
durgs	O
,	O
soduim	O
salicyltae	O
,	O
phneylbutazone	O
,	O
indoemthacin	O
,	O
iubprofen	O
and	O
mefenaimc	O
aicd	O
,	O
on	O
seziures	B-Disease
produced	O
by	O
pilocaripne	O
.	O

Pretreamtent	O
of	O
rtas	O
with	O
sdoium	O
salciylate	O
,	O
E5D0	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutaozne	O
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
covnulsant	O
dsoe	O
of	O
pilocarpnie	O
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
covnulsant	O
one	O
.	O

Indomehtacin	O
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuprfoen	O
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
mdoulate	O
seizrues	B-Disease
produced	O
by	O
pilocarpnie	O
.	O

Meefnamic	O
aicd	O
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seziures	B-Disease
and	O
protected	O
rtas	O
from	O
seiuzre	B-Disease
-	O
related	O
brian	B-Disease
daamge	I-Disease
induecd	O
by	O
piloacrpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
rseults	O
indicate	O
that	O
non	O
-	O
steroiadl	O
atni	O
-	O
inflamamtory	O
durgs	O
differetnially	O
modultae	O
the	O
trheshold	O
for	O
pilocarpnie	O
-	O
induecd	O
seizrues	B-Disease
.	O

Actue	B-Disease
neruologic	I-Disease
dysfunciton	I-Disease
after	O
high	O
-	O
dsoe	O
etpooside	O
thearpy	O
for	O
mailgnant	B-Disease
giloma	I-Disease
.	O

Etopsoide	O
(	O
VP	O
-	O
16	O
-	O
213	O
)	O
has	O
been	O
used	O
in	O
the	O
treatemnt	O
of	O
many	O
soild	O
tmuors	B-Disease
and	O
heamtologic	B-Disease
malginancies	I-Disease
.	O

When	O
used	O
in	O
high	O
dsoes	O
and	O
in	O
cnojunction	O
with	O
autologuos	O
bnoe	O
mrarow	O
trasnplantation	O
,	O
this	O
agnet	O
has	O
activtiy	O
against	O
several	O
treatmnet	O
-	O
resisatnt	O
cancres	B-Disease
including	O
mailgnant	B-Disease
giloma	I-Disease
.	O

In	O
six	O
of	O
eight	O
patietns	O
(	O
75	O
%	O
)	O
who	O
we	O
tretaed	O
for	O
rceurrent	O
or	O
resistnat	O
giloma	B-Disease
,	O
sudden	O
seevre	O
neruologic	B-Disease
deetrioration	I-Disease
occurred	O
.	O

This	O
developed	O
a	O
mdeian	O
of	O
9	O
dyas	O
after	O
iniitation	O
of	O
high	O
-	O
dsoe	O
etopsoide	O
therpay	O
.	O

Signfiicant	O
cliniacl	O
manfiestations	O
have	O
included	O
cnofusion	B-Disease
,	O
papilledmea	B-Disease
,	O
sonmolence	B-Disease
,	O
exacerbatoin	O
of	O
mtoor	B-Disease
defictis	I-Disease
,	O
and	O
sharp	O
icnrease	O
in	O
seizrue	B-Disease
atcivity	O
.	O

These	O
abnormaltiies	O
resolved	O
rapidly	O
after	O
iintiation	O
of	O
high	O
-	O
dsoe	O
intravenuos	O
dexametahsone	O
thearpy	O
.	O

In	O
all	O
pateints	O
,	O
compuetrized	O
tomograpihc	O
(	O
CT	O
)	O
barin	O
scnas	O
demonstrated	O
stbaility	O
in	O
tuomr	B-Disease
szie	O
and	O
periutmor	O
eedma	B-Disease
when	O
copmared	O
with	O
pretransplnat	O
scnas	O
.	O

This	O
copmlication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxciity	B-Disease
of	O
high	O
-	O
dsoe	O
etopoisde	O
therpay	O
for	O
malingant	B-Disease
glimoa	I-Disease
.	O

Progrsesive	O
blie	B-Disease
dcut	I-Disease
inujry	I-Disease
after	O
thaibendazole	O
administratoin	O
.	O

A	O
27	O
-	O
yr	O
-	O
old	O
man	O
developed	O
jaudnice	B-Disease
2	O
wk	O
after	O
exopsure	O
to	O
thiabendzaole	O
.	O

Cholesatsis	B-Disease
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
tmie	O
a	O
lievr	O
transpalnt	O
was	O
performed	O
.	O

Two	O
lievr	O
boipsy	O
spceimens	O
and	O
the	O
hepatecotmy	O
speciemn	O
were	O
remarkable	O
for	O
almost	O
complete	O
dispapearance	O
of	O
interlobualr	O
blie	O
dutcs	O
.	O

Prmoinent	O
fibroiss	B-Disease
and	O
heaptocellular	O
regneeration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
loublar	O
architetcure	O
was	O
presreved	O
.	O

This	O
csae	O
represents	O
an	O
example	O
of	O
"	O
idiosyncraitc	O
"	O
durg	B-Disease
-	I-Disease
induecd	I-Disease
lvier	I-Disease
dmaage	I-Disease
in	O
which	O
the	O
priamry	O
tagret	O
of	O
inujry	O
is	O
the	O
blie	O
dcut	O
.	O

An	O
automimune	O
ptahogenesis	O
of	O
the	O
blie	B-Disease
dcut	I-Disease
desturction	I-Disease
is	O
suggested	O
.	O

Diffreential	O
effetcs	O
of	O
1	O
,	O
4	O
-	O
dhiydropyridine	O
calicum	O
chnanel	O
blocekrs	O
:	O
therapuetic	O
implications	O
.	O

Incraesing	O
reocgnition	O
of	O
the	O
importance	O
of	O
calcuim	O
in	O
the	O
pahtogenesis	O
of	O
cardoivascular	B-Disease
disesae	I-Disease
has	O
sitmulated	O
resaerch	O
into	O
the	O
use	O
of	O
caclium	O
channel	O
blokcing	O
aegnts	O
for	O
traetment	O
of	O
a	O
variety	O
of	O
cardiovasuclar	B-Disease
dsieases	I-Disease
.	O

The	O
favroable	O
efficcay	O
and	O
tloerability	O
proifles	O
of	O
these	O
aegnts	O
make	O
them	O
attractive	O
therpaeutic	O
modailties	O
.	O

Cilnical	O
applications	O
of	O
calcuim	O
cahnnel	O
blokcers	O
parallel	O
their	O
tissue	O
selectviity	O
.	O

In	O
contrast	O
to	O
vreapamil	O
and	O
diltiaezm	O
,	O
which	O
are	O
roughly	O
equipoetnt	O
in	O
their	O
acitons	O
on	O
the	O
haert	O
and	O
vasuclar	O
smooth	O
msucle	O
,	O
the	O
dihdyropyridine	O
caclium	O
channel	O
blockres	O
are	O
a	O
gruop	O
of	O
potent	O
preipheral	O
vasdoilator	O
aegnts	O
that	O
exert	O
mniimal	O
eletcrophysiologic	O
effects	O
on	O
cradiac	O
ndoal	O
or	O
cnoduction	O
tsisue	O
.	O

As	O
the	O
first	O
dihydropyirdine	O
available	O
for	O
use	O
in	O
the	O
Untied	O
Sattes	O
,	O
nifediipne	O
conrtols	O
angnia	B-Disease
and	O
hypertensoin	B-Disease
with	O
minmial	O
depression	O
of	O
caridac	O
funtcion	O
.	O

Additional	O
mmebers	O
of	O
this	O
gruop	O
of	O
calcuim	O
channel	O
blokcers	O
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indicatinos	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
threapy	O
.	O

Once	O
or	O
twice	O
daliy	O
doasge	O
possible	O
with	O
nitrenidpine	O
and	O
niosldipine	O
offers	O
a	O
convenient	O
amdinistration	O
scehdule	O
,	O
which	O
encourages	O
patinet	O
compilance	O
in	O
long	O
-	O
term	O
thearpy	O
of	O
hyeprtension	B-Disease
.	O

The	O
croonary	O
vsaodilating	O
properteis	O
of	O
nisodlipine	O
have	O
led	O
to	O
the	O
inevstigation	O
of	O
this	O
agnet	O
for	O
use	O
in	O
agnina	B-Disease
.	O

Selecitvity	O
for	O
the	O
cerebrvoascular	O
bed	O
makes	O
nimodiipne	O
potentially	O
useful	O
in	O
the	O
teratment	O
of	O
subraachnoid	B-Disease
hemorrhgae	I-Disease
,	O
migriane	B-Disease
headcahe	I-Disease
,	O
demnetia	B-Disease
,	O
and	O
srtoke	B-Disease
.	O

In	O
general	O
,	O
the	O
dihydrpoyridine	O
calicum	O
chanenl	O
blockres	O
are	O
usually	O
well	O
tolertaed	O
,	O
with	O
haedache	B-Disease
,	O
facail	O
fulshing	B-Disease
,	O
palpitatoins	B-Disease
,	O
edmea	B-Disease
,	O
nasuea	B-Disease
,	O
aonrexia	B-Disease
,	O
and	O
dizzinses	B-Disease
being	O
the	O
more	O
common	O
avderse	O
effetcs	O
.	O

The	O
enhanecment	O
of	O
aminouncleoside	O
nephroiss	B-Disease
by	O
the	O
co	O
-	O
admniistration	O
of	O
protamnie	O
.	O

An	O
expeirmental	O
mdoel	O
of	O
fcoal	B-Disease
segemntal	I-Disease
glomerualr	I-Disease
scleroiss	I-Disease
(	O
FGSS	B-Disease
)	O
was	O
developed	O
in	O
rtas	O
by	O
the	O
cmobined	O
amdinistration	O
of	O
puroymcin	O
-	O
amnionucleoside	O
(	O
ANMS	O
)	O
and	O
protamnie	O
suflate	O
(	O
PS	O
)	O
.	O

Mlae	O
Sprgaue	O
-	O
Dawely	O
rtas	O
,	O
unineprhectomized	O
three	O
wekes	O
before	O
,	O
received	O
daliy	O
inejctions	O
of	O
subcutnaeous	O
ANMS	O
(	O
1	O
mg	O
/	O
100	O
g	O
bdoy	O
wt	O
)	O
and	O
inrtavenous	O
PS	O
(	O
2	O
spearated	O
dsoes	O
of	O
2	O
.	O
5	O
mg	O
/	O
100	O
g	O
bdoy	O
wt	O
)	O
for	O
four	O
dyas	O
.	O

The	O
series	O
of	O
injetcions	O
were	O
repeaetd	O
another	O
three	O
times	O
at	O
10	O
day	O
intevrals	O
.	O

The	O
animlas	O
were	O
sacriifced	O
on	O
dyas	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
nephrtoic	B-Disease
synrdome	I-Disease
and	O
finally	O
reanl	B-Disease
faliure	I-Disease
.	O

The	O
tmie	O
-	O
cousre	O
cuvre	O
of	O
craetinine	O
claerance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
that	O
of	O
each	O
cotnrol	O
gorup	O
,	O
such	O
as	O
,	O
ANMS	O
alone	O
,	O
PS	O
alone	O
or	O
slaine	O
injetced	O
.	O

Their	O
gloemruli	O
showed	O
chanegs	O
of	O
progerssive	O
FGSS	B-Disease
.	O

The	O
utlrastructural	O
stduies	O
in	O
the	O
initial	O
satge	O
revaeled	O
significant	O
lcak	O
of	O
paritcles	O
of	O
perfuesd	O
rutheinum	O
red	O
on	O
the	O
laimna	O
rara	O
etxerna	O
and	O
marked	O
chagnes	O
in	O
epitheilal	O
clel	O
cytolpasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
admniistration	O
of	O
PS	O
enhanecs	O
the	O
toxictiy	B-Disease
of	O
ANMS	O
on	O
the	O
gloemrulus	O
and	O
readily	O
produces	O
progerssive	O
FGSS	B-Disease
in	O
rtas	O
resulting	O
in	O
the	O
end	B-Disease
-	I-Disease
satge	I-Disease
rneal	I-Disease
disaese	I-Disease
.	O

Thoephylline	O
neuortoxicity	B-Disease
in	O
prgenant	O
rtas	O
.	O

The	O
purpose	O
of	O
this	O
investigtaion	O
was	O
to	O
determine	O
whether	O
the	O
neuortoxicity	B-Disease
of	O
theophylilne	O
is	O
altreed	O
in	O
adavnced	O
prgenancy	O
.	O

Sprauge	O
-	O
Dalwey	O
rtas	O
that	O
were	O
20	O
dyas	O
prgenant	O
and	O
nonprgenant	O
rtas	O
of	O
the	O
same	O
age	O
and	O
starin	O
received	O
ifnusions	O
of	O
aminopyhlline	O
until	O
onset	O
of	O
maxmial	O
seizuers	B-Disease
which	O
occurred	O
after	O
28	O
and	O
30	O
mniutes	O
respectively	O
.	O

Theophylilne	O
concentrtaions	O
at	O
this	O
endopint	O
in	O
sreum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
seurm	O
(	O
free	O
)	O
and	O
barin	O
concentartions	O
were	O
slightly	O
different	O
in	O
pergnant	O
rtas	O
.	O

Thoephylline	O
sreum	O
proetin	O
bindnig	O
determined	O
by	O
equilbirium	O
dialsyis	O
was	O
lwoer	O
in	O
pregannt	O
rtas	O
.	O

Fteal	O
sreum	O
concnetrations	O
at	O
onset	O
of	O
seizuers	B-Disease
in	O
the	O
motehr	O
were	O
similar	O
to	O
materanl	O
barin	O
and	O
CSF	O
concnetrations	O
and	O
corrleated	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
avdanced	O
pregnacny	O
has	O
a	O
negliigble	O
effcet	O
on	O
the	O
neruotoxic	B-Disease
resopnse	O
to	O
theopyhlline	O
in	O
rtas	O
.	O

Hyperkaleima	B-Disease
induecd	O
by	O
indomethcain	O
and	O
naprxoen	O
and	O
reevrsed	O
by	O
fludorcortisone	O
.	O

We	O
have	O
described	O
a	O
ptaient	O
with	O
sveere	O
rheuamtoid	B-Disease
arhtritis	I-Disease
and	O
a	O
hisotry	O
of	O
mefeanmic	O
aicd	O
neprhopathy	B-Disease
in	O
whom	O
hyperkaelmia	B-Disease
and	O
inappropriate	O
hypoaldosternoism	B-Disease
were	O
caused	O
by	O
both	O
inodmethacin	O
and	O
narpoxen	O
,	O
without	O
major	O
decilne	O
in	O
reanl	O
funtcion	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
rneal	B-Disease
disesae	I-Disease
predisopsed	O
this	O
pateint	O
to	O
tpye	B-Disease
IV	I-Disease
reanl	I-Disease
tuublar	I-Disease
acdiosis	I-Disease
with	O
prostgalandin	O
synthtease	O
inhbiitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
dsicontinue	O
nnosteroidal	O
atni	O
-	O
inflammatroy	O
durg	O
threapy	O
,	O
fludrocotrisone	O
was	O
added	O
,	O
correcting	O
the	O
hyperaklemia	B-Disease
and	O
allowing	O
inodmethacin	O
therpay	O
to	O
be	O
continued	O
safely	O
.	O

Hyoptension	B-Disease
as	O
a	O
manifestaiton	O
of	O
cardoitoxicity	B-Disease
in	O
three	O
pateints	O
receiving	O
csiplatin	O
and	O
5	O
-	O
fluoruoracil	O
.	O

Cadriac	O
symtpoms	O
,	O
including	O
hypotesnion	B-Disease
,	O
developed	O
in	O
three	O
paitents	O
with	O
adavnced	O
colroectal	B-Disease
cacrinoma	I-Disease
while	O
being	O
terated	O
with	O
cipslatin	O
(	O
CDDP	O
)	O
and	O
5	O
-	O
fluorouraicl	O
(	O
5	O
-	O
FU	O
)	O
.	O

In	O
two	O
patinets	O
,	O
hyoptension	B-Disease
was	O
associated	O
with	O
seevre	O
lfet	B-Disease
vnetricular	I-Disease
dysfunciton	I-Disease
.	O

All	O
three	O
pateints	O
required	O
therpay	O
discontinuaiton	O
.	O

Cradiac	O
enzmyes	O
remained	O
nomral	O
despite	O
transeint	O
electrocadriographic	O
(	O
EKG	O
)	O
chnages	O
.	O

The	O
persentation	O
and	O
caridac	O
evaulation	O
(	O
heomdynamic	O
,	O
ehcocardiographic	O
,	O
and	O
scintigarphic	O
)	O
of	O
these	O
patinets	O
suggest	O
new	O
manifestatoins	O
of	O
5	O
-	O
FU	O
cardiotxoicity	B-Disease
that	O
may	O
be	O
influenecd	O
by	O
CDDP	O
.	O

The	O
possible	O
pathophysiloogic	O
mechansims	O
are	O
discussed	O
.	O

Ftaal	O
aplasitc	B-Disease
aenmia	I-Disease
in	O
a	O
pateint	O
traeted	O
with	O
carbamzaepine	O
.	O

A	O
csae	O
of	O
faatl	O
aplatsic	B-Disease
aneima	I-Disease
due	O
to	O
carbamzaepine	O
teratment	O
in	O
an	O
epiletpic	B-Disease
woamn	O
is	O
reported	O
.	O

Despite	O
cnocerns	O
of	O
ftaal	O
bnoe	B-Disease
mrarow	I-Disease
toxciity	I-Disease
due	O
to	O
crabamazepine	O
,	O
this	O
is	O
only	O
the	O
fourth	O
docuemnted	O
and	O
publsihed	O
reoprt	O
.	O

Crabamazepine	O
is	O
a	O
safe	O
durg	O
,	O
but	O
phyiscians	O
and	O
ptaients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rrae	O
but	O
potentially	O
ftaal	O
side	O
effcets	O
,	O
better	O
prevented	O
by	O
cilnical	O
than	O
by	O
laboraotry	O
mnoitoring	O
.	O

Patricipation	O
of	O
a	O
bublospinal	O
seortonergic	O
pathawy	O
in	O
the	O
rat	O
brian	O
in	O
cloniidne	O
-	O
indcued	O
hpyotension	B-Disease
and	O
bradycarida	B-Disease
.	O

The	O
effects	O
of	O
microijnection	O
of	O
clonidnie	O
(	O
1	O
-	O
10	O
mircograms	O
in	O
1	O
microlietr	O
)	O
into	O
a	O
rgeion	O
adajcent	O
to	O
the	O
ventorlateral	O
surafce	O
of	O
the	O
mdeulla	O
olbongata	O
on	O
cradiovascular	O
functoin	O
were	O
assessed	O
in	O
uretahne	O
-	O
ansethetized	O
rtas	O
.	O

Inrtamedullary	O
administraiton	O
of	O
clnoidine	O
,	O
but	O
not	O
slaine	O
vehcile	O
,	O
caused	O
a	O
dsoe	O
-	O
depednent	O
decerase	O
in	O
both	O
the	O
mean	O
artreial	O
prsesure	O
and	O
the	O
haert	O
rtae	O
.	O

The	O
clonidnie	O
-	O
inudced	O
hyoptension	B-Disease
was	O
antagoinzed	O
by	O
prior	O
spianl	O
trnasection	O
,	O
but	O
not	O
bilatearl	O
vgaotomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
colnidine	O
-	O
induecd	O
bradcyardia	B-Disease
was	O
anatgonized	O
by	O
prior	O
bilaetral	O
vgaotomy	O
,	O
but	O
not	O
spnial	O
tarnsection	O
.	O

Furthermore	O
,	O
selective	O
destrutcion	O
of	O
the	O
spnial	O
5	O
-	O
HT	O
nevres	O
,	O
produced	O
by	O
bialteral	O
spnial	O
injcetion	O
of	O
5	O
,	O
7	O
-	O
dihydroxyrtyptamine	O
,	O
reduecd	O
the	O
magntiude	O
of	O
the	O
vasoedpressor	O
or	O
the	O
bradycaridac	B-Disease
resopnses	O
to	O
clnoidine	O
mciroinjected	O
into	O
the	O
aera	O
near	O
the	O
ventrolatearl	O
sruface	O
of	O
the	O
meudlla	O
obolngata	O
in	O
rtas	O
.	O

The	O
dtaa	O
indicate	O
that	O
a	O
bulbospianl	O
serotonerigc	O
patwhay	O
is	O
involved	O
in	O
devleopment	O
of	O
cloindine	O
-	O
inudced	O
hyoptension	B-Disease
and	O
bradycradia	B-Disease
.	O

The	O
inudced	O
hypotenison	B-Disease
is	O
brought	O
about	O
by	O
a	O
dcerease	O
in	O
sympathteic	O
effernet	O
acitvity	O
,	O
whereas	O
the	O
induecd	O
bradycarida	B-Disease
was	O
due	O
to	O
an	O
icnrease	O
in	O
vaagl	O
efferent	O
activtiy	O
.	O

Hypertenison	B-Disease
in	O
nueroblastoma	B-Disease
inudced	O
by	O
imiparmine	O
.	O

Hypretension	B-Disease
is	O
a	O
well	O
-	O
known	O
fidning	O
in	O
some	O
pateints	O
with	O
neruoblastoma	B-Disease
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
assoication	O
with	O
the	O
use	O
of	O
Imirpamine	O
.	O

We	O
rpeort	O
the	O
occurrence	O
of	O
sveere	O
hypertenison	B-Disease
(	O
blood	O
pressrue	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
yaer	O
-	O
old	O
gril	O
with	O
neurobalstoma	B-Disease
who	O
was	O
given	O
Imipraimne	O
to	O
cnotrol	O
a	O
behavoir	B-Disease
disodrer	I-Disease
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patinet	O
'	O
s	O
tuomr	B-Disease
was	O
recurring	O
at	O
the	O
tmie	O
of	O
her	O
hypetrensive	B-Disease
eipsode	O
.	O

Since	O
she	O
had	O
no	O
blood	O
prsesure	O
elevaiton	O
at	O
initial	O
diganosis	O
and	O
none	O
following	O
discontinuatoin	O
of	O
the	O
Iimpramine	O
(	O
when	O
she	O
was	O
in	O
flroid	O
realpse	O
)	O
,	O
we	O
believe	O
that	O
this	O
durg	O
rather	O
than	O
her	O
underlying	O
disaese	O
alone	O
caused	O
her	O
hypertenison	B-Disease
.	O

The	O
mecahnism	O
for	O
this	O
raection	O
is	O
believed	O
to	O
be	O
inrceased	O
leevls	O
of	O
vasaoctive	O
ctaecholamines	O
due	O
to	O
inetrference	O
of	O
their	O
phsyiologic	O
inatcivation	O
by	O
Imipraimne	O
.	O

From	O
this	O
experiecne	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricylcic	O
antideprsesants	O
in	O
chidlren	O
with	O
actvie	O
neuroblasotma	B-Disease
.	O

Rechallegne	O
of	O
paitents	O
who	O
developed	O
oarl	B-Disease
candiidasis	I-Disease
or	O
haorseness	B-Disease
with	O
beclomethasnoe	O
dirpopionate	O
.	O

Of	O
158	O
atshmatic	B-Disease
patietns	O
who	O
were	O
placed	O
on	O
inahled	O
becloemthasone	O
,	O
15	O
(	O
9	O
.	O
5	O
%	O
)	O
developed	O
either	O
hoarsenses	B-Disease
(	O
8	O
)	O
,	O
oarl	O
thursh	B-Disease
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
advrese	O
reatcions	O
subsdied	O
,	O
seven	O
of	O
these	O
15	O
ptaients	O
were	O
rcehallenged	O
with	O
inhlaed	O
belcomethasone	O
.	O

These	O
included	O
five	O
csaes	O
who	O
developed	O
hoarsenses	B-Disease
and	O
three	O
who	O
developed	O
Candidiaiss	B-Disease
.	O

One	O
ptaient	O
had	O
both	O
.	O

Oarl	O
thursh	B-Disease
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
paitents	O
with	O
hoarsenses	B-Disease
had	O
recurernce	O
.	O

We	O
conclude	O
that	O
patietns	O
may	O
be	O
rsetarted	O
on	O
ihnaled	O
belcomethasone	O
when	O
cliniclaly	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrnece	O
rtae	O
,	O
ptaients	O
who	O
develop	O
hoarseenss	B-Disease
should	O
not	O
be	O
re	O
-	O
challenged	O
.	O

Concoimtant	O
use	O
of	O
oarl	O
prednisnoe	O
and	O
toipcal	O
beclomethasnoe	O
may	O
icnrease	O
the	O
rsik	O
of	O
developing	O
horaseness	B-Disease
or	O
candiidasis	B-Disease
.	O

Cylcophosphamide	O
cardoitoxicity	B-Disease
:	O
an	O
aanlysis	O
of	O
dsoing	O
as	O
a	O
rsik	O
facotr	O
.	O

Patietns	O
who	O
undergo	O
bnoe	O
mrarow	O
transplnatation	O
are	O
generally	O
immunosuppresesd	O
with	O
a	O
dsoe	O
of	O
cyclopohsphamide	O
(	O
CYA	O
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
pateint	O
'	O
s	O
weihgt	O
.	O

At	O
these	O
high	O
dsoes	O
of	O
CYA	O
,	O
serious	O
caridotoxicity	B-Disease
may	O
occur	O
,	O
but	O
defiintive	O
rsik	O
fatcors	O
for	O
the	O
develompent	O
of	O
such	O
cardiootxicity	B-Disease
have	O
not	O
been	O
described	O
.	O

Since	O
chemothreapeutic	O
agnet	O
toixcity	B-Disease
generally	O
correlaets	O
with	O
dsoe	O
per	O
bdoy	O
surafce	O
aera	O
,	O
we	O
retrospectievly	O
calculated	O
the	O
dsoe	O
of	O
CYA	O
in	O
ptaients	O
transpalnted	O
at	O
our	O
instittuion	O
to	O
determine	O
whether	O
the	O
inciednce	O
of	O
CYA	O
cardiotoxiicty	B-Disease
corrleated	O
with	O
the	O
dsoe	O
per	O
bdoy	O
surafce	O
aera	O
.	O

Eighty	O
patietns	O
who	O
were	O
to	O
receive	O
CYA	O
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
dyas	O
as	O
prepaartion	O
for	O
marorw	O
gratfing	O
underwent	O
a	O
total	O
of	O
84	O
transpalnts	O
for	O
alpastic	B-Disease
aenmia	I-Disease
,	O
Wiksott	B-Disease
-	I-Disease
Alrdich	I-Disease
syndrmoe	I-Disease
,	O
or	O
seevre	B-Disease
combiend	I-Disease
immunodeficiecny	I-Disease
synrdome	I-Disease
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
pateints	O
had	O
symptmos	O
and	O
sgins	O
consistent	O
with	O
CYA	O
cradiotoxicity	B-Disease
within	O
ten	O
dyas	O
of	O
receiving	O
1	O
to	O
4	O
dsoes	O
of	O
CYA	O
.	O

Six	O
of	O
the	O
14	O
patinets	O
deid	O
with	O
conegstive	B-Disease
herat	I-Disease
fialure	I-Disease
.	O

The	O
dsoe	O
of	O
CYA	O
per	O
bdoy	O
surfcae	O
aera	O
was	O
calculated	O
for	O
all	O
pateints	O
and	O
the	O
pateints	O
were	O
divided	O
into	O
two	O
gorups	O
based	O
on	O
dialy	O
CYA	O
dsoe	O
:	O
Gorup	O
1	O
,	O
CYA	O
less	O
than	O
or	O
eqaul	O
to	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Gruop	O
2	O
,	O
CYA	O
greater	O
than	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
.	O

Carditooxicity	B-Disease
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	O
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
paitents	O
in	O
Gruop	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
paitents	O
in	O
Gruop	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

Cognestive	B-Disease
herat	I-Disease
failrue	I-Disease
caused	O
or	O
contributed	O
to	O
detah	O
in	O
0	O
/	O
32	O
pateints	O
in	O
Gruop	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
pateints	O
in	O
Gorup	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rtae	O
of	O
engrfatment	O
of	O
evalualbe	O
pateints	O
in	O
the	O
two	O
gorups	O
(	O
P	O
greater	O
than	O
0	O
.	O
5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	O
cardiotoxiicty	B-Disease
corerlates	O
with	O
CYA	O
doasge	O
as	O
calculated	O
by	O
bdoy	O
sufrace	O
aera	O
,	O
and	O
that	O
patinets	O
with	O
alpastic	B-Disease
aenmia	I-Disease
and	O
immunodeficienceis	B-Disease
can	O
be	O
effectively	O
prpeared	O
for	O
bnoe	O
marrow	O
gratfing	O
at	O
a	O
CYA	O
dsoe	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
dyas	O
with	O
a	O
loewr	O
incdience	O
of	O
carditooxicity	B-Disease
than	O
pateints	O
whose	O
CYA	O
dsoage	O
is	O
calculated	O
based	O
on	O
weihgt	O
.	O

This	O
stduy	O
reaffirms	O
the	O
principle	O
that	O
durg	O
toixcity	B-Disease
corrleates	O
with	O
dsoe	O
per	O
bdoy	O
sufrace	O
aera	O
.	O

Stduies	O
of	O
rsik	O
fcators	O
for	O
aminoglcyoside	O
nehprotoxicity	B-Disease
.	O

The	O
epidemoilogy	O
of	O
aminolgycoside	O
-	O
inudced	O
nephrootxicity	B-Disease
is	O
not	O
fully	O
understood	O
.	O

Expreimental	O
stuides	O
in	O
healhty	O
huamn	O
voulnteers	O
indicate	O
aminoglyocsides	O
cause	O
prxoimal	O
tuublar	O
daamge	O
in	O
most	O
patietns	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glomreular	B-Disease
or	I-Disease
tubluar	I-Disease
dysfucntion	I-Disease
.	O

Clincial	O
trails	O
of	O
aminogylcosides	O
in	O
seriously	O
ill	O
patietns	O
indicate	O
that	O
the	O
relative	O
rsik	O
for	O
developing	O
actue	B-Disease
rneal	I-Disease
fialure	I-Disease
during	O
therpay	O
ranegs	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
rsik	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
aanlysis	O
of	O
these	O
dtaa	O
suggests	O
that	O
the	O
duratoin	O
of	O
therpay	O
,	O
plsama	O
amingolycoside	O
leevls	O
,	O
lvier	B-Disease
disaese	I-Disease
,	O
advnaced	O
age	O
,	O
high	O
initial	O
estimaetd	O
creatinnie	O
clearnace	O
and	O
,	O
possibly	O
,	O
femlae	O
gneder	O
all	O
incerase	O
the	O
rsik	O
for	O
nephrotoxictiy	B-Disease
.	O

Other	O
causes	O
of	O
aucte	B-Disease
reanl	I-Disease
faiulre	I-Disease
,	O
such	O
as	O
sohck	B-Disease
,	O
appear	O
to	O
have	O
an	O
adidtive	O
effcet	O
.	O

Prdeictive	O
moedls	O
have	O
been	O
developed	O
from	O
these	O
analyess	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patietns	O
at	O
high	O
rsik	O
.	O

These	O
mdoels	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophyisology	O
of	O
aminoglycosdie	O
-	O
induecd	O
nephrotoxiicty	B-Disease
.	O

Cnetral	O
actoin	O
of	O
narctoic	O
aanlgesics	O
.	O

Part	O
IV	O
.	O

Noradreenrgic	O
influneces	O
on	O
the	O
actiivty	O
of	O
analgseics	O
in	O
rtas	O
.	O

The	O
effect	O
of	O
clonidnie	O
,	O
napahzoline	O
and	O
xylmoetazoline	O
on	O
aanlgesia	O
inudced	O
by	O
morpihne	O
,	O
cdoeine	O
,	O
fentaynl	O
and	O
pentazcoine	O
,	O
and	O
on	O
cataletpic	B-Disease
effcet	O
of	O
morpihne	O
,	O
codnie	O
and	O
fetnanyl	O
was	O
studied	O
in	O
rtas	O
.	O

The	O
bicohemical	O
assyas	O
on	O
the	O
infulence	O
of	O
four	O
analgescis	O
on	O
the	O
barin	O
cnocentration	O
and	O
turnoevr	O
of	O
noradrenalnie	O
(	O
NA	O
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
durgs	O
stiumlating	O
cnetral	O
NA	O
recepotrs	O
failed	O
to	O
affect	O
the	O
anaglesic	O
E5D0	O
of	O
all	O
antinocicepitve	O
aegnts	O
and	O
they	O
ehnanced	O
ctaalepsy	B-Disease
indcued	O
by	O
morpihne	O
and	O
fentnayl	O
.	O

Codiene	O
caatlepsy	B-Disease
was	O
incraesed	O
by	O
cloniidne	O
and	O
decerased	O
by	O
naphazloine	O
and	O
xylomteazoline	O
.	O

The	O
barin	O
conecntration	O
of	O
NA	O
was	O
not	O
changed	O
by	O
morphnie	O
and	O
fenatnyl	O
,	O
but	O
one	O
of	O
the	O
doess	O
of	O
coedine	O
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enahnced	O
it	O
.	O

Pentazcoine	O
dsoe	O
-	O
dependently	O
decraesed	O
the	O
barin	O
leevl	O
of	O
NA	O
.	O

The	O
rtae	O
of	O
NA	O
tunrover	O
was	O
not	O
altreed	O
by	O
anaglesics	O
except	O
for	O
the	O
higehr	O
dsoe	O
of	O
fnetanyl	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disapeparance	O
of	O
NA	O
from	O
the	O
brian	O
was	O
diminished	O
.	O

The	O
rseults	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non	O
-	O
uniform	O
dtaa	O
from	O
the	O
litearture	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rtas	O
the	O
brian	O
NA	O
plays	O
a	O
less	O
important	O
funtcion	O
than	O
the	O
other	O
mnooamines	O
in	O
the	O
behvaioural	O
actiivty	O
of	O
potent	O
anlagesics	O
.	O

Flurohtyl	O
seiuzre	B-Disease
thersholds	O
in	O
mcie	O
tretaed	O
neontaally	O
with	O
a	O
single	O
injetcion	O
of	O
monosoduim	O
glutaamte	O
(	O
MSG	O
)	O
:	O
evlauation	O
of	O
experimnetal	O
paarmeters	O
in	O
flurotyhl	O
seizrue	B-Disease
tesitng	O
.	O

Moonsodium	O
gltuamate	O
(	O
MSG	O
)	O
administraiton	O
to	O
nenoatal	O
rodnets	O
produces	O
covnulsions	B-Disease
and	O
reuslts	O
in	O
numerous	O
biocheimcal	O
and	O
behvaioral	O
defciits	O
.	O

These	O
studeis	O
were	O
undertaken	O
to	O
determine	O
if	O
neontaal	O
adimnistration	O
of	O
MSG	O
produced	O
pemranent	O
alteraitons	O
in	O
seizrue	B-Disease
suscepitbility	O
,	O
since	O
previous	O
invetsigations	O
were	O
inconlcusive	O
.	O

A	O
flruothyl	O
ehter	O
seziure	B-Disease
scerening	O
techniuqe	O
was	O
used	O
to	O
evalaute	O
seziure	B-Disease
susceptbiility	O
in	O
adlut	O
mcie	O
that	O
received	O
neoantal	O
injectinos	O
of	O
MSG	O
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	O
traetment	O
resulted	O
in	O
significant	O
reductoins	O
in	O
whole	O
barin	O
wegiht	O
but	O
did	O
not	O
alter	O
seizrue	B-Disease
threshlod	O
.	O

A	O
nlaoxone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ineffcetive	O
in	O
altreing	O
the	O
seziure	B-Disease
threhsolds	O
of	O
either	O
contorl	O
of	O
MSG	O
-	O
tretaed	O
mcie	O
.	O

Fulrothyl	O
etehr	O
produced	O
hyopthermia	B-Disease
which	O
was	O
correlaetd	O
with	O
the	O
druation	O
of	O
flruothyl	O
exopsure	O
;	O
however	O
,	O
the	O
relatoinship	O
of	O
hypohtermia	B-Disease
to	O
seiuzre	B-Disease
induciton	O
was	O
unclear	O
.	O

Fluorthyl	O
siezure	B-Disease
tetsing	O
proved	O
to	O
be	O
a	O
raipd	O
and	O
reliable	O
technqiue	O
with	O
which	O
to	O
evalutae	O
seiuzre	B-Disease
susceptibiltiy	O
.	O

Suscetpibility	O
to	O
seizuers	B-Disease
produced	O
by	O
piloacrpine	O
in	O
rtas	O
after	O
mciroinjection	O
of	O
isonizaid	O
or	O
gamma	O
-	O
viynl	O
-	O
GBAA	O
into	O
the	O
substanita	O
ngira	O
.	O

Piloacrpine	O
,	O
given	O
intraepritoneally	O
to	O
rtas	O
,	O
reproduces	O
the	O
neuropahtological	O
sequeale	O
of	O
temproal	B-Disease
lboe	I-Disease
epliepsy	I-Disease
and	O
provides	O
a	O
relveant	O
ainmal	O
moedl	O
for	O
studying	O
mechainsms	O
of	O
builudp	O
of	O
cnovulsive	B-Disease
actiivty	O
and	O
pathwyas	O
operatvie	O
in	O
the	O
generalizaiton	O
and	O
porpagation	O
of	O
seizuers	B-Disease
within	O
the	O
froebrain	O
.	O

In	O
the	O
present	O
stduy	O
,	O
the	O
effcets	O
of	O
manpiulating	O
the	O
acitvity	O
of	O
the	O
gamma	O
-	O
aminoubtyric	O
aicd	O
(	O
GBAA	O
)	O
-	O
mediated	O
synatpic	O
inhibiiton	O
within	O
the	O
substanita	O
nirga	O
on	O
seiuzres	B-Disease
produced	O
by	O
pilocrapine	O
in	O
rtas	O
,	O
were	O
investigtaed	O
.	O

In	O
anmials	O
preterated	O
with	O
mciroinjections	O
of	O
isoniaizd	O
,	O
150	O
mircograms	O
,	O
an	O
inhiibtor	O
of	O
atcivity	O
of	O
the	O
GBAA	O
-	O
synthesizing	O
eznyme	O
,	O
L	O
-	O
glutmaic	O
aicd	O
decabroxylase	O
,	O
into	O
the	O
subsatntia	O
ngira	O
pras	O
rteiculata	O
(	O
SNR	O
)	O
,	O
bialterally	O
,	O
non	O
-	O
convulasnt	O
doess	O
of	O
pilocrapine	O
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
seevre	O
mtoor	O
libmic	O
seiuzres	B-Disease
and	O
stauts	B-Disease
epiletpicus	I-Disease
.	O

Elecrtoencephalographic	O
and	O
behaviroal	O
monitroing	O
rveealed	O
a	O
prfoound	O
rdeuction	O
of	O
the	O
thresohld	O
for	O
pilcoarpine	O
-	O
indcued	O
convulisons	B-Disease
.	O

Moprhological	O
aanlysis	O
of	O
frotnal	O
forerbain	O
sectoins	O
with	O
light	O
microcsopy	O
revaeled	O
seizrue	B-Disease
-	O
related	O
damgae	O
to	O
the	O
hippcoampal	O
formatoin	O
,	O
thlaamus	O
,	O
aymgdala	O
,	O
olfacotry	O
coretx	O
,	O
substnatia	O
ngira	O
and	O
noecortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocrapine	O
in	O
doess	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bialteral	O
intrastiratal	O
ijnections	O
of	O
isonizaid	O
did	O
not	O
augment	O
seiuzres	B-Disease
produced	O
by	O
pilocrapine	O
,	O
200	O
mg	O
/	O
kg	O
.	O

Applicaiton	O
of	O
an	O
irreversible	O
inhbiitor	O
of	O
GBAA	O
transamianse	O
,	O
gamma	O
-	O
vniyl	O
-	O
GBAA	O
(	O
D	O
,	O
L	O
-	O
4	O
-	O
amnio	O
-	O
hex	O
-	O
5	O
-	O
enoic	O
aicd	O
)	O
,	O
5	O
mcirograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
supperssed	O
the	O
appearance	O
of	O
electrgoraphic	O
and	O
bheavioral	O
siezures	B-Disease
produced	O
by	O
pilocaprine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
teratment	O
was	O
also	O
sufficient	O
to	O
protect	O
animlas	O
from	O
the	O
occurrence	O
of	O
barin	B-Disease
dmaage	I-Disease
.	O

Micrionjections	O
of	O
gmama	O
-	O
vniyl	O
-	O
GBAA	O
,	O
5	O
mircograms	O
,	O
into	O
the	O
dosral	O
straitum	O
,	O
bilaetrally	O
,	O
failed	O
to	O
prevnet	O
the	O
dveelopment	O
of	O
convuslions	B-Disease
produced	O
by	O
piloacrpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
rseults	O
demonstrate	O
that	O
the	O
threhsold	O
for	O
pilocrapine	O
-	O
idnuced	O
seizuers	B-Disease
in	O
rtas	O
is	O
subjected	O
to	O
the	O
rgeulation	O
of	O
the	O
GBAA	O
-	O
mediated	O
syanptic	O
inhibitoin	O
within	O
the	O
subsatntia	O
ngira	O
.	O

Huamn	O
and	O
cainne	O
ventircular	O
vasoatcive	O
itnestinal	O
polypetpide	O
:	O
dercease	O
with	O
herat	B-Disease
faliure	I-Disease
.	O

Vasocative	O
itnestinal	O
polypepitde	O
(	O
VIP	O
)	O
is	O
a	O
systmeic	O
and	O
cornoary	O
vasodliator	O
that	O
may	O
have	O
postiive	O
inotroipc	O
porperties	O
.	O

Mycoardial	O
levles	O
of	O
VIP	O
were	O
asasyed	O
before	O
and	O
after	O
the	O
dveelopment	O
of	O
haert	B-Disease
faiulre	I-Disease
in	O
two	O
cainne	O
moedls	O
.	O

In	O
the	O
first	O
,	O
cboalt	O
cardimoyopathy	B-Disease
was	O
inudced	O
in	O
eight	O
dgos	O
;	O
VIP	O
(	O
by	O
radioimmuonassay	O
)	O
decreaesd	O
from	O
35	O
+	O
/	O
-	O
11	O
pg	O
/	O
mg	O
proetin	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
5	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
portein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
six	O
dgos	O
with	O
doxorbuicin	O
-	O
inudced	O
haert	B-Disease
faliure	I-Disease
,	O
VIP	O
decresaed	O
from	O
31	O
+	O
/	O
-	O
7	O
to	O
11	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
portein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
cotnent	O
of	O
lfet	O
ventrciular	O
mucsle	O
of	O
resetced	O
failing	O
heatrs	O
in	O
10	O
patietns	O
receiving	O
a	O
herat	O
transpalnt	O
was	O
comapred	O
with	O
the	O
papillary	O
muslces	O
in	O
14	O
patinets	O
(	O
five	O
with	O
rheumtaic	B-Disease
disesae	I-Disease
,	O
nine	O
with	O
myxomatuos	B-Disease
degenertaion	I-Disease
)	O
receiving	O
mtiral	O
vlave	O
prsotheses	O
.	O

The	O
loewst	O
moycardial	O
VIP	O
concnetration	O
was	O
found	O
in	O
the	O
haerts	O
of	O
ptaients	O
with	O
coroanry	B-Disease
disaese	I-Disease
(	O
one	O
pateint	O
receiving	O
a	O
transplnat	O
and	O
three	O
receiving	O
mirtal	O
prosthsees	O
)	O
(	O
6	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
mg	O
portein	O
)	O
.	O

The	O
other	O
ptaients	O
undergoing	O
transpalntation	O
had	O
an	O
avergae	O
eejction	O
fratcion	O
of	O
17	O
%	O
+	O
/	O
-	O
6	O
%	O
and	O
a	O
VIP	O
leevl	O
of	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
9	O
pg	O
/	O
mg	O
prtoein	O
.	O

The	O
heatrs	O
without	O
coornary	B-Disease
atrery	I-Disease
diesase	I-Disease
(	O
avergae	O
ejetcion	O
fratcion	O
of	O
this	O
gruop	O
62	O
%	O
+	O
/	O
-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
concentartion	O
of	O
14	O
.	O
1	O
+	O
/	O
-	O
7	O
.	O
9	O
pg	O
/	O
mg	O
proetin	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
haerts	O
of	O
the	O
ptaients	O
with	O
cornoary	B-Disease
disesae	I-Disease
and	O
the	O
haerts	O
of	O
ptaients	O
receiving	O
a	O
transplnat	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Myocardail	O
catecholaimnes	O
were	O
also	O
determined	O
in	O
14	O
subejcts	O
;	O
a	O
waek	O
correltaion	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tsisue	O
concentraitons	O
of	O
VIP	O
and	O
noreipnephrine	O
was	O
noted	O
.	O
(	O
ABSTRACT	O
TURNCATED	O
AT	O
250	O
WORDS	O
)	O

Non	O
-	O
invasvie	O
detectoin	O
of	O
cornoary	B-Disease
atrery	I-Disease
diesase	I-Disease
by	O
bdoy	O
surafce	O
electrocadriographic	O
mpaping	O
after	O
diypridamole	O
ifnusion	O
.	O

Eelctrocardiographic	O
cahnges	O
after	O
dipyridamloe	O
infsuion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
paitents	O
with	O
coroanry	B-Disease
atrery	I-Disease
disaese	I-Disease
and	O
compaerd	O
with	O
those	O
after	O
sumbaximal	O
traedmill	O
eexrcise	O
by	O
use	O
of	O
the	O
bdoy	O
surafce	O
mpaping	O
techniuqe	O
.	O

Paitents	O
were	O
divided	O
into	O
three	O
gruops	O
;	O
19	O
paitents	O
without	O
myocaridal	B-Disease
inafrction	I-Disease
(	O
non	O
-	O
MI	B-Disease
gruop	O
)	O
,	O
14	O
with	O
atnerior	B-Disease
infarciton	I-Disease
(	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
)	O
and	O
eight	O
with	O
infeiror	B-Disease
infarciton	I-Disease
(	O
INF	B-Disease
-	I-Disease
MI	I-Disease
)	O
.	O

Eighty	O
-	O
seven	O
unpiolar	O
electrocardiorgams	O
(	O
EGCs	O
)	O
distributed	O
over	O
the	O
entire	O
thoarcic	O
surafce	O
were	O
simulatneously	O
recorded	O
.	O

After	O
dipyirdamole	O
,	O
ishcemic	B-Disease
ST	O
-	O
sgement	O
depresison	B-Disease
(	O
0	O
.	O
05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B-Disease
gorup	O
,	O
29	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
gruop	O
,	O
63	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
gorup	O
and	O
61	O
%	O
of	O
the	O
total	O
populaiton	O
.	O

Exericse	O
-	O
indcued	O
ST	O
dperession	B-Disease
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B-Disease
gorup	O
,	O
43	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
gorup	O
,	O
38	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
gorup	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
indiivdual	O
patinets	O
,	O
there	O
were	O
no	O
obvious	O
diffreences	O
between	O
the	O
bdoy	O
sruface	O
disrtibution	O
of	O
ST	O
dperession	B-Disease
in	O
both	O
tetss	O
.	O

The	O
incresae	O
in	O
perssure	O
rtae	O
porduct	O
after	O
dipyriadmole	O
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadimll	O
execrise	O
.	O

The	O
dtaa	O
suggest	O
that	O
the	O
dipryidamole	O
-	O
induecd	O
mycoardial	B-Disease
icshemia	I-Disease
is	O
caused	O
by	O
the	O
inhomoegnous	O
distirbution	O
of	O
myocardail	O
bolod	O
folw	O
.	O

We	O
conclude	O
that	O
the	O
dipyridmaole	O
ECG	O
tset	O
is	O
as	O
useful	O
as	O
the	O
exericse	O
ECG	O
tset	O
for	O
the	O
assesmsent	O
of	O
croonary	B-Disease
atrery	I-Disease
disaese	I-Disease
.	O

Bradyacrdia	B-Disease
after	O
high	O
-	O
dsoe	O
intravenuos	O
methylprednioslone	O
therpay	O
.	O

In	O
5	O
cnosecutive	O
pateints	O
with	O
rhemuatoid	B-Disease
atrhritis	I-Disease
who	O
received	O
intravneous	O
high	O
-	O
dsoe	O
mehtylprednisolone	O
(	O
MP	O
)	O
tehrapy	O
(	O
1	O
g	O
daliy	O
for	O
2	O
or	O
3	O
consectuive	O
dyas	O
)	O
,	O
a	O
decilne	O
in	O
pluse	O
rtae	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
patinets	O
the	O
bradyacrdia	B-Disease
was	O
associated	O
with	O
complaitns	O
of	O
subsetrnal	O
pressure	O
.	O

Revresal	O
to	O
noraml	O
haert	O
rtae	O
was	O
found	O
on	O
day	O
7	O
.	O

Elcetrocardiographic	O
registartions	O
showed	O
snius	B-Disease
bradycadria	I-Disease
in	O
all	O
caess	O
.	O

No	O
significant	O
chanegs	O
in	O
palsma	O
conecntrations	O
of	O
electrloytes	O
were	O
found	O
.	O

Careful	O
osbervation	O
of	O
patinets	O
receiving	O
high	O
-	O
dsoe	O
MP	O
is	O
recmomended	O
.	O

High	O
-	O
dsoe	O
MP	O
may	O
be	O
contarindicated	O
in	O
patinets	O
with	O
known	O
herat	B-Disease
disaese	I-Disease
.	O

Two	O
csaes	O
of	O
donwbeat	B-Disease
nytsagmus	I-Disease
and	O
osclilopsia	B-Disease
associated	O
with	O
carbamazeipne	O
.	O

Downbaet	B-Disease
nystagums	I-Disease
is	O
often	O
associated	O
with	O
strcutural	O
lseions	O
at	O
the	O
craniocerviacl	O
jnuction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifetsation	O
of	O
metbaolic	O
imbalacne	O
or	O
durg	O
intoixcation	O
.	O

We	O
recorded	O
the	O
eye	O
mvoements	O
of	O
two	O
ptaients	O
with	O
reversible	O
downbaet	B-Disease
nytsagmus	I-Disease
related	O
to	O
carbamazepnie	O
tehrapy	O
.	O

The	O
nytsagmus	B-Disease
of	O
both	O
paitents	O
resolved	O
after	O
reductoin	O
of	O
the	O
sreum	O
carbamazeipne	O
levles	O
.	O

Neurroadiologic	O
investiagtions	O
including	O
magentic	O
resnoance	O
imaigng	O
scnas	O
in	O
both	O
patinets	O
showed	O
no	O
eviednce	O
of	O
itnracranial	O
abonrmality	O
.	O

In	O
paitents	O
with	O
dwonbeat	B-Disease
nystamgus	I-Disease
who	O
are	O
taking	O
anitconvulsant	O
medciations	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduciton	O
in	O
dsoe	O
before	O
further	O
investiagtion	O
is	O
undertaken	O
.	O

Improveemnt	O
by	O
denpoamine	O
(	O
TA	O
-	O
064	O
)	O
of	O
pentoabrbital	O
-	O
induecd	O
cradiac	B-Disease
faiulre	I-Disease
in	O
the	O
dog	O
herat	O
-	O
lnug	O
prepaartion	O
.	O

The	O
effciacy	O
of	O
denoapmine	O
,	O
an	O
oarlly	O
atcive	O
btea	O
1	O
-	O
adrneoceptor	O
aognist	O
,	O
in	O
imporving	O
cradiac	B-Disease
faiulre	I-Disease
was	O
assesesd	O
in	O
dog	O
herat	O
-	O
lnug	O
preparatoins	O
.	O

Cardaic	O
functinos	O
derpessed	O
by	O
penotbarbital	O
(	O
118	O
+	O
/	O
-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/	O
-	O
SD	O
)	O
such	O
that	O
cardaic	O
otuput	O
and	O
maxmium	O
rtae	O
of	O
rise	O
of	O
lfet	O
ventriuclar	O
pressrue	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
reduecd	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
cnotrols	O
were	O
improevd	O
by	O
deonpamine	O
(	O
10	O
-	O
300	O
micrgorams	O
)	O
in	O
a	O
dsoe	O
-	O
depednent	O
manner	O
.	O

With	O
100	O
mircograms	O
denoapmine	O
,	O
almost	O
complete	O
restoratoin	O
of	O
caridac	O
performacne	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
incresae	O
in	O
haert	O
rtae	O
.	O

No	O
arrhytmhias	B-Disease
were	O
induecd	O
by	O
these	O
doess	O
of	O
denoapmine	O
.	O

The	O
reuslts	O
warrant	O
cliincal	O
tirals	O
of	O
deonpamine	O
in	O
the	O
treatmnet	O
of	O
cardaic	B-Disease
fialure	I-Disease
.	O

Clonaezpam	O
monohterapy	O
for	O
epilespy	B-Disease
in	O
cihldhood	O
.	O

Sixty	O
pateints	O
(	O
age	O
-	O
range	O
one	O
motnh	O
to	O
14	O
yeras	O
)	O
with	O
other	O
types	O
of	O
eiplepsy	B-Disease
than	O
infanitle	B-Disease
spsams	I-Disease
were	O
tretaed	O
with	O
clonazeapm	O
.	O

Disappeaarnce	O
of	O
seizrues	B-Disease
and	O
normalizatoin	O
of	O
abnromal	O
EEG	O
with	O
disapeparance	O
of	O
siezures	B-Disease
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Siezures	B-Disease
disappeared	O
in	O
71	O
%	O
of	O
the	O
ptaients	O
with	O
geenralized	O
seiuzres	B-Disease
and	O
89	O
%	O
of	O
patrial	O
seizrues	B-Disease
.	O

Improveemnt	O
of	O
anbormal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diffsue	O
paroxymss	O
and	O
in	O
67	O
%	O
of	O
fcoal	O
parxoysms	O
.	O

In	O
excellnet	O
csaes	O
,	O
mean	O
effecitve	O
dsoages	O
were	O
0	O
.	O
086	O
+	O
/	O
-	O
0	O
.	O
021	O
mg	O
/	O
kg	O
/	O
day	O
in	O
ifnants	O
and	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
022	O
mg	O
/	O
kg	O
/	O
day	O
in	O
schoolhcildren	O
,	O
this	O
difference	O
was	O
sttaistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

The	O
incidecne	O
of	O
side	O
effcets	O
such	O
as	O
droswiness	B-Disease
and	O
atxaia	B-Disease
was	O
only	O
5	O
%	O
.	O

Postamrketing	O
sutdy	O
of	O
timooll	O
-	O
hydrochlorothaizide	O
antihypetrensive	O
tehrapy	O
.	O

A	O
postmarkteing	O
surevillance	O
sutdy	O
was	O
conducted	O
to	O
determine	O
the	O
saftey	O
and	O
effciacy	O
of	O
a	O
fxied	O
-	O
rtaio	O
combiantion	O
containing	O
10	O
mg	O
of	O
timooll	O
maletae	O
and	O
25	O
mg	O
of	O
hydrochloorthiazide	O
,	O
adimnistered	O
twice	O
dialy	O
for	O
one	O
mnoth	O
to	O
hypertenisve	B-Disease
patinets	O
.	O

Dtaa	O
on	O
9	O
,	O
037	O
patinets	O
were	O
collected	O
by	O
1	O
,	O
455	O
participating	O
physicains	O
.	O

Mean	O
sysotlic	O
bolod	O
presusre	O
decerased	O
25	O
mmHg	O
and	O
mean	O
diasotlic	O
bolod	O
perssure	O
decilned	O
15	O
mmHg	O
after	O
one	O
mnoth	O
of	O
timlool	O
-	O
hydrochlorothiazdie	O
tehrapy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
comparisnos	O
)	O
.	O

Age	O
,	O
rcae	O
,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
infulence	O
on	O
the	O
decerase	O
in	O
blood	O
pressrue	O
.	O

The	O
antihypertensvie	O
effcet	O
of	O
the	O
durg	O
was	O
greater	O
in	O
ptaients	O
with	O
more	O
sveere	O
hypertnesion	B-Disease
.	O

Overall	O
,	O
1	O
,	O
453	O
pateints	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
adevrse	O
evetns	O
,	O
the	O
most	O
common	O
being	O
fatgiue	B-Disease
,	O
dizizness	B-Disease
,	O
and	O
waekness	B-Disease
.	O

Treamtent	O
in	O
590	O
paitents	O
was	O
disocntinued	O
because	O
of	O
advesre	O
evnets	O
.	O

Saliclyate	O
npehropathy	B-Disease
in	O
the	O
Gnun	O
rat	O
:	O
potenital	O
role	O
of	O
prostgalandins	O
.	O

We	O
examined	O
the	O
ptoential	O
role	O
of	O
prostaglanidns	O
in	O
the	O
devleopment	O
of	O
analegsic	O
nephorpathy	B-Disease
in	O
the	O
Gnun	O
srtain	O
of	O
rat	O
.	O

The	O
homozyogus	O
Gnun	O
rtas	O
have	O
unconujgated	O
hyperbiilrubinemia	B-Disease
due	O
to	O
the	O
asbence	O
of	O
gluucronyl	O
transfearse	O
,	O
leading	O
to	O
marked	O
biliruibn	O
dpeosition	O
in	O
rneal	O
mdeulla	O
and	O
ppailla	O
.	O

These	O
rtas	O
are	O
also	O
highly	O
suscepitble	O
to	O
develop	O
papillary	B-Disease
necorsis	I-Disease
with	O
anlagesic	O
administraiton	O
.	O

We	O
used	O
homoyzgous	O
(	O
jj	O
)	O
and	O
phenotypiaclly	O
nromal	O
heteorzygous	O
(	O
jJ	O
)	O
anmials	O
.	O

Four	O
gruops	O
of	O
rtas	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rtas	O
traeted	O
either	O
with	O
apsirin	O
300	O
mg	O
/	O
kg	O
every	O
other	O
day	O
or	O
sahm	O
-	O
tretaed	O
.	O

After	O
one	O
week	O
,	O
slcies	O
of	O
coretx	O
,	O
ouetr	O
and	O
inenr	O
mdeulla	O
from	O
one	O
kideny	O
were	O
incbuated	O
in	O
buffer	O
and	O
prostagalndin	O
synhtesis	O
was	O
determined	O
by	O
radioimmunoassay	O
.	O

The	O
other	O
kdiney	O
was	O
examined	O
histolgoically	O
.	O

A	O
marked	O
corticomeudllary	O
gardient	O
of	O
prostaglnadin	O
synthseis	O
was	O
observed	O
in	O
all	O
gorups	O
.	O

PEG2	O
snythesis	O
was	O
significantly	O
hihger	O
in	O
ouetr	O
mdeulla	O
,	O
but	O
not	O
crotex	O
or	O
inenr	O
medulla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/	O
-	O
6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
rtas	O
(	O
15	O
+	O
/	O
-	O
3	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Aspriin	O
teratment	O
reduecd	O
PEG2	O
sytnhesis	O
in	O
all	O
rgeions	O
,	O
but	O
ouetr	O
mdeullary	O
PEG2	O
remained	O
higehr	O
in	O
jj	O
(	O
18	O
+	O
/	O
-	O
3	O
)	O
than	O
jJ	O
rtas	O
(	O
9	O
+	O
/	O
-	O
2	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

PFG2	O
aplha	O
was	O
also	O
significantly	O
higehr	O
in	O
the	O
ouetr	O
medulla	O
of	O
jj	O
rtas	O
with	O
and	O
without	O
aspiirn	O
administraiton	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
cahnges	O
in	O
reanl	O
prostagalndin	O
snythesis	O
were	O
accompanied	O
by	O
eivdence	O
of	O
rneal	B-Disease
dmaage	I-Disease
in	O
aspriin	O
-	O
tretaed	O
jj	O
but	O
not	O
jJ	O
rtas	O
as	O
evidenced	O
by	O
:	O
inrceased	O
incidnece	O
and	O
seveirty	O
of	O
hmeaturia	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
icnreased	O
seurm	O
cretainine	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
and	O
incraese	O
in	O
ouetr	O
mdeullary	O
histopahtologic	O
leisons	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
compraed	O
to	O
either	O
sahm	O
-	O
traeted	O
jj	O
or	O
aspriin	O
-	O
terated	O
jJ	O
)	O
.	O

These	O
reuslts	O
suggest	O
that	O
enhnaced	O
prostalgandin	O
syntehsis	O
contributes	O
to	O
maitnenance	O
of	O
reanl	O
fnuction	O
and	O
morphoolgical	O
integirty	O
,	O
and	O
that	O
inhibiiton	O
of	O
prsotaglandin	O
sytnhesis	O
may	O
lead	O
to	O
pathologcial	B-Disease
rneal	I-Disease
medlulary	I-Disease
lesinos	I-Disease
and	O
dteerioration	B-Disease
of	I-Disease
rneal	I-Disease
fucntion	I-Disease
.	O

Propyhlactic	O
lidcoaine	O
in	O
the	O
ealry	O
phsae	O
of	O
suspceted	O
myocadrial	B-Disease
infartcion	I-Disease
.	O

Four	O
hundred	O
two	O
ptaients	O
with	O
supsected	O
myocaridal	B-Disease
infacrtion	I-Disease
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
sypmtoms	O
entered	O
a	O
double	O
-	O
blnid	O
radnomized	O
trail	O
of	O
lidcoaine	O
vs	O
placbeo	O
.	O

During	O
the	O
1	O
hour	O
after	O
adimnistration	O
of	O
the	O
durg	O
the	O
incidecne	O
of	O
vnetricular	B-Disease
fibrillatoin	I-Disease
or	O
sustanied	O
ventircular	B-Disease
tachycradia	I-Disease
among	O
the	O
204	O
patinets	O
with	O
actue	O
myocradial	B-Disease
inafrction	I-Disease
was	O
low	O
,	O
1	O
.	O
5	O
%	O
.	O

Lidcoaine	O
,	O
given	O
in	O
a	O
300	O
mg	O
dsoe	O
intramucsularly	O
followed	O
by	O
100	O
mg	O
intraveonusly	O
,	O
did	O
not	O
preevnt	O
sustianed	O
ventricualr	B-Disease
tahcycardia	I-Disease
,	O
although	O
there	O
was	O
a	O
significant	O
reductoin	O
in	O
the	O
number	O
of	O
paitents	O
with	O
wraning	O
arrhytmhias	B-Disease
between	O
15	O
and	O
45	O
miuntes	O
after	O
the	O
administratoin	O
of	O
lidocanie	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
avreage	O
plsama	O
liodcaine	O
leevl	O
10	O
mintues	O
after	O
adminisrtation	O
for	O
patinets	O
without	O
a	O
moycardial	B-Disease
ifnarction	I-Disease
was	O
significantly	O
hgiher	O
than	O
that	O
for	O
pateints	O
with	O
an	O
aucte	O
infartcion	B-Disease
.	O

The	O
mean	O
plsama	O
liodcaine	O
leevl	O
of	O
patinets	O
on	O
btea	O
-	O
blocknig	O
aegnts	O
was	O
no	O
different	O
from	O
that	O
in	O
patietns	O
not	O
on	O
btea	O
blokcing	O
aegnts	O
.	O

During	O
the	O
1	O
-	O
hour	O
sutdy	O
peirod	O
,	O
the	O
icnidence	O
of	O
cenrtal	O
nervuos	O
sytsem	O
side	O
effcets	O
was	O
significantly	O
greater	O
in	O
the	O
ldiocaine	O
gorup	O
,	O
hypotensoin	B-Disease
occurred	O
in	O
11	O
pateints	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidcoaine	O
,	O
and	O
four	O
patietns	O
deid	O
from	O
assytole	B-Disease
,	O
three	O
of	O
whom	O
had	O
had	O
lidocanie	O
.	O

We	O
cannot	O
advocate	O
the	O
adminitsration	O
of	O
ldiocaine	O
porphylactically	O
in	O
the	O
eraly	O
hours	O
of	O
suspecetd	O
moycardial	B-Disease
inafrction	I-Disease
.	O

Eivdence	O
for	O
a	O
choilnergic	O
role	O
in	O
haloperiodl	O
-	O
idnuced	O
catalpesy	B-Disease
.	O

Expermients	O
in	O
mcie	O
tetsed	O
previous	O
evidecne	O
that	O
activaiton	O
of	O
chloinergic	O
sytsems	O
pormotes	O
catalespy	B-Disease
and	O
that	O
cholinerigc	O
mehcanisms	O
need	O
to	O
be	O
inatct	O
for	O
full	O
experssion	O
of	O
neruoleptic	O
-	O
idnuced	O
caatlepsy	B-Disease
.	O

Large	O
doess	O
of	O
the	O
cholionmimetic	O
,	O
piolcarpine	O
,	O
could	O
inudce	O
catlaepsy	B-Disease
when	O
perihperal	O
cholienrgic	O
reecptors	O
were	O
blokced	O
.	O

Low	O
dsoes	O
of	O
pilocaprine	O
caused	O
a	O
pronounced	O
enhanceemnt	O
of	O
the	O
catalpesy	B-Disease
that	O
was	O
induecd	O
by	O
the	O
dopaminerigc	O
blcoker	O
,	O
halopreidol	O
.	O

A	O
muscairnic	O
recpetor	O
blcoker	O
,	O
atrpoine	O
,	O
dsirupted	O
haloperdiol	O
-	O
indcued	O
cataelpsy	B-Disease
.	O

Intarcranial	O
injeciton	O
of	O
an	O
acetylcohline	O
-	O
synthseis	O
ihnibitor	O
,	O
hemihcolinium	O
,	O
prevented	O
the	O
catalespy	B-Disease
that	O
is	O
usually	O
idnuced	O
by	O
halopeirdol	O
.	O

These	O
findigns	O
suggest	O
the	O
hyptohesis	O
that	O
the	O
catlaepsy	B-Disease
that	O
is	O
produced	O
by	O
nueroleptics	O
such	O
as	O
haloepridol	O
is	O
actually	O
mediated	O
by	O
intrnisic	O
cetnral	O
cholinegric	O
sysetms	O
.	O

Alternatively	O
,	O
atcivation	O
of	O
cetnral	O
cholinregic	O
sysetms	O
could	O
pormote	O
catlaepsy	B-Disease
by	O
suppression	O
of	O
dopaimnergic	O
sysetms	O
.	O

Caridovascular	B-Disease
dysufnction	I-Disease
and	O
hypersensitviity	B-Disease
to	O
sdoium	O
petnobarbital	O
indcued	O
by	O
crhonic	O
bairum	O
cholride	O
ingesiton	O
.	O

Bairum	O
-	O
supplemented	O
Lnog	O
-	O
Evnas	O
hodoed	O
rtas	O
were	O
characetrized	O
by	O
a	O
perisstent	O
hypetrension	B-Disease
that	O
was	O
evident	O
after	O
1	O
mnoth	O
of	O
baruim	O
(	O
100	O
micorgrams	O
/	O
ml	O
minearl	O
fortiifed	O
waetr	O
)	O
tretament	O
.	O

Aanlysis	O
of	O
in	O
vivo	O
moycardial	O
excitbaility	O
,	O
contratcility	O
,	O
and	O
metaboilc	O
characterisitcs	O
at	O
16	O
motnhs	O
revaeled	O
other	O
significant	O
bairum	O
-	O
idnuced	O
disutrbances	B-Disease
within	I-Disease
the	I-Disease
cradiovascular	I-Disease
ssytem	I-Disease
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
braium	O
effect	O
was	O
a	O
demonstrated	O
hyperesnsitivity	B-Disease
of	O
the	O
cardivoascular	O
sysetm	O
to	O
sdoium	O
pentobabrital	O
.	O

Under	O
barbitruate	O
anestehsia	O
,	O
virtually	O
all	O
of	O
the	O
mycoardial	O
contratcile	O
indcies	O
were	O
derpessed	O
significantly	O
in	O
bairum	O
-	O
expoesd	O
rtas	O
relative	O
to	O
the	O
corresponding	O
cotnrol	O
-	O
fed	O
rtas	O
.	O

The	O
lcak	O
of	O
a	O
similar	O
resposne	O
to	O
ketaimne	O
and	O
xyalzine	O
ansethesia	O
revaeled	O
that	O
the	O
cardiovascluar	O
actoins	O
of	O
soidum	O
pentobarbtial	O
in	O
baruim	O
-	O
terated	O
rtas	O
were	O
linked	O
specifically	O
to	O
this	O
anestheitc	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalzied	O
anestheitc	O
rseponse	O
.	O

Other	O
myocradial	O
pathohpysiologic	O
and	O
metabloic	O
cahnges	O
idnuced	O
by	O
braium	O
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
aneshtetic	O
employed	O
.	O

The	O
contratcile	O
elemnet	O
shotrening	O
velcoity	O
of	O
the	O
cradiac	O
msucle	O
fiebrs	O
was	O
significantly	O
sloewr	O
in	O
both	O
gruops	O
of	O
baruim	O
-	O
traeted	O
rtas	O
relative	O
to	O
the	O
cotnrol	O
gruops	O
,	O
irrespective	O
of	O
the	O
ansethetic	O
reigmen	O
.	O

Similarly	O
,	O
significant	O
disutrbances	O
in	O
myocaridal	O
enregy	O
metbaolism	O
were	O
deetcted	O
in	O
the	O
baruim	O
-	O
epxosed	O
rtas	O
which	O
were	O
consistent	O
with	O
the	O
rdeuced	O
contracitle	O
eelment	O
shorteinng	O
velcoity	O
.	O

In	O
addition	O
,	O
the	O
excitabiilty	O
of	O
the	O
cradiac	O
conduciton	O
sytsem	O
was	O
depresesd	O
preferentially	O
in	O
the	O
atrioventircular	O
ndoal	O
rgeion	O
of	O
herats	O
from	O
bairum	O
-	O
expoesd	O
rtas	O
.	O

Overall	O
,	O
the	O
aletred	O
cadriac	O
contracitlity	O
and	O
exictability	O
characterisitcs	O
,	O
the	O
myoacrdial	O
metabloic	B-Disease
ditsurbances	I-Disease
,	O
and	O
the	O
hyeprsensitivity	B-Disease
of	O
the	O
cradiovascular	O
sytsem	O
to	O
soduim	O
pentobabrital	O
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardioymopathic	B-Disease
disoredr	I-Disease
induecd	O
by	O
chroinc	O
baruim	O
exposrue	O
.	O

These	O
expreimental	O
fidnings	O
represent	O
the	O
first	O
indicatoin	O
that	O
lfie	O
-	O
long	O
bairum	O
ingesiton	O
may	O
have	O
significant	O
advrese	O
effcets	O
on	O
the	O
mammailan	O
cardiovascualr	O
ssytem	O
.	O

Propranlool	O
antgaonism	O
of	O
phenylpropanolamnie	O
-	O
indcued	O
hypertenison	B-Disease
.	O

Phenylpropanolaimne	O
(	O
PPA	O
)	O
ovedrose	B-Disease
can	O
cause	O
sveere	O
hypertensoin	B-Disease
,	O
intrcaerebral	B-Disease
hemorrahge	I-Disease
,	O
and	O
daeth	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
saefty	O
of	O
prorpanolol	O
in	O
the	O
treamtent	O
of	O
PPA	O
-	O
inudced	O
hpyertension	B-Disease
.	O

Sujbects	O
received	O
proparnolol	O
either	O
by	O
muoth	O
for	O
48	O
hours	O
before	O
PPA	O
or	O
as	O
a	O
raipd	O
intarvenous	O
infusoin	O
after	O
PPA	O
.	O

PPA	O
,	O
75	O
mg	O
alone	O
,	O
incerased	O
blood	O
pressure	O
(	O
31	O
+	O
/	O
-	O
14	O
mm	O
Hg	O
systloic	O
,	O
20	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
diatsolic	O
)	O
,	O
and	O
prorpanolol	O
pretreamtent	O
antaognized	O
this	O
incraese	O
(	O
12	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
systoilc	O
,	O
10	O
+	O
/	O
-	O
7	O
mm	O
Hg	O
diastloic	O
)	O
.	O

Inrtavenous	O
propraonlol	O
after	O
PPA	O
also	O
dcereased	O
bolod	O
prsesure	O
.	O

Lfet	O
ventriuclar	O
functoin	O
(	O
asesssed	O
by	O
ecohcardiography	O
)	O
showed	O
that	O
PPA	O
incresaed	O
the	O
storke	B-Disease
volmue	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+	O
/	O
-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
22	O
.	O
4	O
ml	O
)	O
,	O
the	O
ejectoin	O
fratcion	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
7	O
%	O
)	O
,	O
and	O
cardaic	O
otuput	O
14	O
%	O
(	O
from	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
L	O
/	O
min	O
)	O
.	O

Intrvaenous	O
prorpanolol	O
reevrsed	O
these	O
effetcs	O
.	O

Ssytemic	O
vascualr	O
reisstance	O
was	O
incraesed	O
by	O
PPA	O
28	O
%	O
(	O
from	O
1710	O
+	O
/	O
-	O
200	O
to	O
2190	O
+	O
/	O
-	O
700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increaesd	O
by	O
porpranolol	O
22	O
%	O
(	O
to	O
2660	O
+	O
/	O
-	O
1200	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	O
inrceases	O
blood	O
pressure	O
by	O
incerasing	O
sytsemic	O
vsacular	O
ressitance	O
and	O
cradiac	O
otuput	O
,	O
and	O
that	O
propranlool	O
antaognizes	O
this	O
inrcease	O
by	O
reversnig	O
the	O
effect	O
of	O
PPA	O
on	O
cardaic	O
otuput	O
.	O

That	O
prporanolol	O
antaognizes	O
the	O
presosr	O
efefct	O
of	O
PPA	O
is	O
in	O
contrast	O
to	O
the	O
itneraction	O
in	O
which	O
porpranolol	O
enahnces	O
the	O
presosr	O
effect	O
of	O
noerpinephrine	O
.	O

This	O
is	O
probably	O
because	O
PPA	O
has	O
less	O
btea	O
2	O
actiivty	O
than	O
does	O
norepinephrnie	O
.	O

Mesanigal	O
functoin	O
and	O
glomreular	B-Disease
scelrosis	I-Disease
in	O
rtas	O
with	O
amnionucleoside	O
nehprosis	B-Disease
.	O

The	O
possible	O
relatiosnhip	O
between	O
mesagnial	B-Disease
dyfsunction	I-Disease
and	O
deveolpment	O
of	O
glomreular	B-Disease
slcerosis	I-Disease
was	O
studied	O
in	O
the	O
pruomycin	O
aminonucloeside	O
(	O
PAN	O
)	O
mdoel	O
.	O

Five	O
mlae	O
Wsitar	O
rtas	O
received	O
reepated	O
subuctaneous	O
PAN	O
injecitons	O
;	O
five	O
contorls	O
received	O
slaine	O
only	O
.	O

After	O
4	O
weeks	O
the	O
PAN	O
rtas	O
were	O
seevrely	O
porteinuric	B-Disease
(	O
190	O
+	O
/	O
-	O
80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rtas	O
were	O
given	O
cloloidal	O
crabon	O
(	O
CC	O
)	O
intraveonusly	O
.	O

At	O
5	O
monhts	O
glomreular	B-Disease
sclersois	I-Disease
was	O
found	O
in	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
4	O
%	O
of	O
the	O
glmoeruli	O
of	O
PAN	O
rtas	O
;	O
golmeruli	O
of	O
the	O
contrlos	O
were	O
noraml	O
.	O

Glomerlui	O
of	O
PAN	O
rtas	O
contained	O
significantly	O
more	O
CC	O
than	O
glomreuli	O
of	O
contorls	O
.	O

Golmeruli	O
with	O
scelrosis	B-Disease
contained	O
significantly	O
more	O
CC	O
than	O
non	O
-	O
scelrotic	O
glomreuli	O
in	O
the	O
same	O
kidnyes	O
.	O

CC	O
was	O
preferentially	O
localiezd	O
within	O
the	O
scelrotic	O
areas	O
of	O
the	O
affetced	O
glomerlui	O
.	O

Since	O
mesnagial	O
CC	O
cleaarnce	O
from	O
the	O
mesanigum	O
did	O
not	O
change	O
during	O
chrnoic	O
PAN	O
teratment	O
,	O
we	O
conclude	O
that	O
this	O
perferential	O
CC	O
localizaiton	O
within	O
the	O
lesinos	O
is	O
caused	O
by	O
an	O
incresaed	O
CC	O
uptkae	O
shortly	O
after	O
ijnection	O
in	O
apparnet	O
vulenrable	O
areas	O
where	O
scleroiss	B-Disease
will	O
develop	O
subsequently	O
.	O

Clsuter	O
anlaysis	O
showed	O
a	O
ranodm	O
distrbiution	O
of	O
lesinos	O
in	O
the	O
PAN	O
gloemruli	O
in	O
cocnordance	O
with	O
the	O
ranodm	O
lcoalization	O
of	O
mesagnial	O
areas	O
with	O
dsyfunction	O
in	O
this	O
moedl	O
.	O

Similar	O
to	O
the	O
remannt	O
kideny	O
moedl	O
in	O
PAN	O
npehrosis	B-Disease
the	O
dveelopment	O
of	O
glomerluar	B-Disease
slcerosis	I-Disease
may	O
be	O
related	O
to	O
"	O
measngial	O
ovreloading	O
.	O
"	O

Relatinoship	O
between	O
nciotine	O
-	O
indcued	O
siezures	B-Disease
and	O
hippocmapal	O
nictoinic	O
receptros	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
yeras	O
concerning	O
the	O
phsyiological	O
relevance	O
of	O
the	O
nicoitnic	O
rceeptor	O
maesured	O
by	O
aplha	O
-	O
bungaortoxin	O
binidng	O
.	O

Using	O
mcie	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcorss	O
geneitc	O
dseign	O
,	O
a	O
rleationship	O
between	O
nicotnie	O
-	O
indcued	O
seziures	B-Disease
and	O
alhpa	O
-	O
bugnarotoxin	O
nciotinic	O
recetpor	O
concentartion	O
was	O
found	O
.	O

Mcie	O
sensitvie	O
to	O
the	O
convuslant	O
effcets	O
of	O
nictoine	O
had	O
greater	O
alhpa	O
-	O
bungaortoxin	O
bniding	O
in	O
the	O
hippocampus	O
than	O
siezure	B-Disease
inesnsitive	O
mcie	O
.	O

The	O
bindnig	O
siets	O
from	O
siezure	B-Disease
sensitvie	O
and	O
resistnat	O
mcie	O
were	O
equally	O
affetced	O
by	O
teratment	O
with	O
dihtiothreitol	O
,	O
tyrpsin	O
or	O
haet	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
siezure	B-Disease
sensitvie	O
and	O
insenstiive	O
animlas	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hipopcampal	O
nioctinic	O
recpetor	O
conecntration	O
as	O
mesaured	O
with	O
aplha	O
-	O
bungarootxin	O
binidng	O
.	O

The	O
role	O
of	O
p	O
-	O
amionphenol	O
in	O
acetaminopehn	O
-	O
idnuced	O
nephrotoxciity	B-Disease
:	O
effcet	O
of	O
bis	O
(	O
p	O
-	O
nitorphenyl	O
)	O
phospahte	O
on	O
acetaimnophen	O
and	O
p	O
-	O
aminohpenol	O
nephrotxoicity	B-Disease
and	O
mteabolism	O
in	O
Fiscehr	O
344	O
rtas	O
.	O

Aectaminophen	O
(	O
AAPP	O
)	O
produces	O
porximal	O
tbuular	B-Disease
necrsois	I-Disease
in	O
Fsicher	O
344	O
(	O
F434	O
)	O
rtas	O
.	O

Recently	O
,	O
p	O
-	O
aminpohenol	O
(	O
PAP	O
)	O
,	O
a	O
known	O
potent	O
nephrotoxciant	O
,	O
was	O
identifeid	O
as	O
a	O
metaboltie	O
of	O
AAPP	O
in	O
F434	O
rtas	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
if	O
PAP	O
fromation	O
is	O
a	O
requisite	O
step	O
in	O
AAPP	O
-	O
indcued	O
nephrotoxictiy	B-Disease
.	O

Therefore	O
,	O
the	O
efefct	O
of	O
bis	O
(	O
p	O
-	O
nirtophenyl	O
)	O
phosphtae	O
(	O
BPNP	O
)	O
,	O
an	O
acylamdiase	O
inhibtior	O
,	O
on	O
AAPP	O
and	O
PAP	O
nephrotoxiicty	B-Disease
and	O
metaoblism	O
was	O
determined	O
.	O

BPNP	O
(	O
1	O
to	O
8	O
mM	O
)	O
reduecd	O
AAPP	O
deacetyaltion	O
and	O
covlaent	O
bindnig	O
in	O
F434	O
rneal	O
cotrical	O
homogentaes	O
in	O
a	O
concentartion	O
-	O
dependnet	O
manner	O
.	O

Prerteatment	O
of	O
animlas	O
with	O
BPNP	O
prior	O
to	O
AAPP	O
or	O
PAP	O
adimnistration	O
resulted	O
in	O
marked	O
reduciton	O
of	O
AAPP	O
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxciity	B-Disease
but	O
not	O
PAP	O
nephrotoxciity	B-Disease
.	O

This	O
result	O
was	O
not	O
due	O
to	O
alteerd	O
disposiiton	O
of	O
either	O
AAPP	O
or	O
aectylated	O
metaboliets	O
in	O
plsama	O
or	O
rneal	O
cotrical	O
and	O
heaptic	O
tsisue	O
.	O

Rather	O
,	O
BPNP	O
pertreatment	O
reudced	O
the	O
frcation	O
of	O
AAPP	O
excerted	O
as	O
PAP	O
by	O
64	O
and	O
75	O
%	O
after	O
AAPP	O
dsoes	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BPNP	O
did	O
not	O
alter	O
the	O
excrteion	O
of	O
AAPP	O
or	O
any	O
of	O
its	O
non	O
-	O
deaectylated	O
metaboliets	O
nor	O
did	O
BPNP	O
alter	O
exrcetion	O
of	O
PAP	O
or	O
its	O
metaoblites	O
after	O
PAP	O
dsoes	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BPNP	O
-	O
indcued	O
reudction	O
in	O
AAPP	O
-	O
inudced	O
nephrotoixcity	B-Disease
appears	O
to	O
be	O
due	O
to	O
inhbiition	O
of	O
AAPP	O
deacetylatoin	O
.	O

It	O
is	O
concluded	O
that	O
PAP	O
fromation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
AAPP	O
-	O
induecd	O
rneal	B-Disease
tubualr	I-Disease
nercosis	I-Disease
.	O

Moprhine	O
-	O
inudced	O
seizrues	B-Disease
in	O
newobrn	O
infnats	O
.	O

Two	O
neonaets	O
suffered	O
from	O
genrealized	O
seiuzres	B-Disease
during	O
the	O
cuorse	O
of	O
inrtavenous	O
morpihne	O
sulftae	O
for	O
psot	O
-	O
opreative	O
analegsia	O
.	O

They	O
received	O
morhpine	O
in	O
dsoes	O
of	O
32	O
micrgorams	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micorgrams	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
gorup	O
of	O
10	O
noenates	O
who	O
received	O
6	O
-	O
24	O
mircograms	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizuers	B-Disease
.	O

Plsama	O
concentraitons	O
of	O
morphnie	O
in	O
these	O
neonaets	O
was	O
excesisve	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
resaons	O
for	O
seizuers	B-Disease
were	O
ruled	O
out	O
and	O
the	O
convulsoins	B-Disease
stopped	O
a	O
few	O
hours	O
after	O
cessaiton	O
of	O
morhpine	O
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
monhts	O
.	O

It	O
is	O
suggested	O
that	O
psot	O
-	O
opeartive	O
intraevnous	O
morphnie	O
should	O
not	O
exceed	O
20	O
mircograms	O
/	O
kg	O
/	O
ml	O
in	O
neonaets	O
.	O

Indomethcain	O
indcued	O
hpyotension	B-Disease
in	O
soduim	O
and	O
vloume	O
delpeted	O
rtas	O
.	O

After	O
a	O
single	O
oarl	O
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
indomethaicn	O
(	O
IDM	O
)	O
to	O
soduim	O
and	O
volmue	O
deplteed	O
rtas	O
palsma	O
reinn	O
acitvity	O
(	O
PRA	O
)	O
and	O
sytsolic	O
bolod	O
prsesure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
soduim	O
rpeleted	O
aniamls	O
indomtehacin	O
did	O
not	O
change	O
systloic	O
bolod	O
pressrue	O
(	O
BP	O
)	O
although	O
plamsa	O
rnein	O
actiivty	O
was	O
decraesed	O
.	O

Thus	O
,	O
indoemthacin	O
by	O
ihnibition	O
of	O
prostaglnadin	O
synhtesis	O
may	O
diminish	O
the	O
bolod	O
pressure	O
maintaining	O
effcet	O
of	O
the	O
stimultaed	O
reinn	O
-	O
agniotensin	O
sytsem	O
in	O
soduim	O
and	O
voulme	O
depleiton	O
.	O

On	O
the	O
antiarryhthmic	O
actiivty	O
of	O
one	O
N	O
-	O
substituetd	O
pipearzine	O
deirvative	O
of	O
trnas	O
-	O
2	O
-	O
amnio	O
-	O
3	O
-	O
hydorxy	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
-	O
tetrahydroaanphthalene	O
.	O

The	O
antiarrhythmic	O
actviity	O
of	O
the	O
cmopound	O
N	O
-	O
(	O
trnas	O
-	O
3	O
-	O
hdyroxy	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
-	O
tterahydro	O
-	O
2	O
-	O
npahthyl	O
)	O
-	O
N	O
-	O
(	O
3	O
-	O
oxo	O
-	O
3	O
-	O
pheynl	O
-	O
2	O
-	O
methlypropyl	O
)	O
-	O
pipearzine	O
hydorchloride	O
,	O
referred	O
to	O
as	O
P11	O
,	O
is	O
studied	O
on	O
anaetshesized	O
ctas	O
and	O
Wisatr	O
ablino	O
rtas	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
anaesthseized	O
rabbits	O
.	O

Four	O
types	O
of	O
experimenatl	O
arrhythima	B-Disease
are	O
used	O
-	O
-	O
with	O
BCal2	O
,	O
with	O
cholroform	O
-	O
adernaline	O
,	O
with	O
strpohantine	O
G	O
and	O
with	O
aconitnie	O
.	O

The	O
cmopound	O
P11	O
is	O
introduced	O
in	O
doess	O
of	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
mg	O
/	O
kg	O
itnravenously	O
and	O
10	O
mg	O
/	O
kg	O
orally	O
.	O

The	O
cmopound	O
manifests	O
antirarhythmic	O
actiivty	O
in	O
all	O
modles	O
of	O
experimetnal	O
arrhtyhmia	B-Disease
used	O
,	O
causing	O
greatest	O
inhbiition	O
on	O
the	O
arhrythmia	B-Disease
induecd	O
by	O
chloorform	O
-	O
ardenaline	O
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BalC2	O
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
resutls	O
obtained	O
are	O
associated	O
with	O
the	O
btea	O
-	O
ardenoblocking	O
and	O
with	O
the	O
memrbane	O
-	O
stabilziing	O
aciton	O
of	O
the	O
componud	O
.	O

Recurrent	O
subarahcnoid	B-Disease
hemorrhgae	I-Disease
associated	O
with	O
aminocarpoic	O
aicd	O
tehrapy	O
and	O
aucte	B-Disease
reanl	I-Disease
aretry	I-Disease
thrombsois	I-Disease
.	O

Csae	O
reoprt	O
.	O

Epsioln	O
aminocparoic	O
aicd	O
(	O
ECAA	O
)	O
has	O
been	O
used	O
to	O
prveent	O
rebleeding	O
in	O
patietns	O
with	O
subaracnhoid	B-Disease
hemorhrage	I-Disease
(	O
SAH	B-Disease
)	O
.	O

Although	O
this	O
agnet	O
does	O
decresae	O
the	O
frequnecy	O
of	O
rebeleding	O
,	O
several	O
repotrs	O
have	O
described	O
thrmobotic	B-Disease
copmlications	O
of	O
ECAA	O
therpay	O
.	O

These	O
cmoplications	O
have	O
included	O
clincial	O
deterioratoin	O
and	O
itnracranial	B-Disease
vasuclar	I-Disease
thromobsis	I-Disease
in	O
pateints	O
with	O
SAH	B-Disease
,	O
arteroilar	O
and	O
caipllary	O
fibirn	O
trhombi	B-Disease
in	O
paitents	O
with	O
fibrinolyitc	O
sydnromes	O
traeted	O
with	O
ECAA	O
,	O
or	O
other	O
thromboembloic	B-Disease
phenmoena	I-Disease
.	O

Since	O
intravasuclar	O
fbirin	O
thrmobi	B-Disease
are	O
often	O
observed	O
in	O
patinets	O
with	O
fibrinolyitc	O
disodrers	O
,	O
ECAA	O
should	O
not	O
be	O
implicated	O
in	O
the	O
patohgenesis	O
of	O
firbin	O
throbmi	B-Disease
in	O
ptaients	O
with	O
disseimnated	B-Disease
intravacsular	I-Disease
coagulatoin	I-Disease
or	O
other	O
"	O
consupmtion	B-Disease
cogaulopathies	I-Disease
.	O
"	O
This	O
rpeort	O
describes	O
subttoal	O
infarctoin	B-Disease
of	O
the	O
kdiney	O
due	O
to	O
throbmosis	B-Disease
of	I-Disease
a	I-Disease
noraml	I-Disease
rneal	I-Disease
aretry	I-Disease
.	O

This	O
occluison	O
occurred	O
after	O
ECAA	O
threapy	O
in	O
a	O
paitent	O
with	O
SAH	B-Disease
and	O
hisotpathological	O
documnetation	O
of	O
recurrent	O
SAH	B-Disease
.	O

The	O
corresponding	O
clincial	O
evnet	O
was	O
characteriezd	O
by	O
marked	O
hyperetnsion	B-Disease
and	O
aburpt	O
neurologcial	O
deterioraiton	O
.	O

Efefct	O
of	O
vincristnie	O
suflate	O
on	O
Pseudomoans	B-Disease
ifnections	I-Disease
in	O
mnokeys	O
.	O

In	O
rhseus	O
monkyes	O
,	O
intarvenous	O
challenge	O
with	O
0	O
.	O
6	O
x	O
10	O
(	O
10	O
)	O
to	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
Pseduomonas	O
aeruginsoa	O
ogranisms	O
caused	O
aucte	O
illness	O
of	O
4	O
to	O
5	O
dyas	O
'	O
duartion	O
with	O
spontnaeous	O
rceovery	O
in	O
13	O
of	O
15	O
monekys	O
;	O
blood	O
cultuers	O
became	O
negatvie	O
3	O
to	O
17	O
dyas	O
after	O
challenge	O
.	O

Leukoyctosis	B-Disease
was	O
observed	O
in	O
all	O
mokneys	O
.	O

Intravneous	O
or	O
intratrachael	O
inocluation	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vinrcistine	O
slufate	O
was	O
followed	O
by	O
leukoepnia	B-Disease
in	O
4	O
to	O
5	O
dyas	O
.	O

Intraevnous	O
incoulation	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
pyoicn	O
tpye	O
6	O
Pseudoomnas	O
ogranisms	O
in	O
mokneys	O
given	O
vincrsitine	O
suflate	O
4	O
dyas	O
previously	O
resulted	O
in	O
ftaal	O
infeciton	B-Disease
in	O
11	O
of	O
14	O
mokneys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseduomonas	O
alone	O
deid	O
.	O

These	O
stduies	O
suggest	O
that	O
an	O
antimteabolite	O
-	O
induecd	O
leukopeina	B-Disease
predispsoes	O
to	O
seevre	O
Pseuodmonas	O
sespis	B-Disease
and	O
that	O
such	O
monkyes	O
may	O
serve	O
as	O
a	O
bioloigcal	O
mdoel	O
for	O
sutdy	O
of	O
comparative	O
effciacy	O
of	O
antimicrobail	O
agetns	O
.	O

Modiifcation	O
by	O
propraonlol	O
of	O
cadriovascular	O
effcets	O
of	O
induecd	O
hpyoglycaemia	B-Disease
.	O

The	O
cardivoascular	O
effects	O
of	O
hypoglycaeima	B-Disease
,	O
with	O
and	O
without	O
btea	O
-	O
bolckade	O
,	O
were	O
compaerd	O
in	O
fourteen	O
healhty	O
men	O
.	O

Eight	O
received	O
insluin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insuiln	O
-	O
only	O
gorup	O
,	O
were	O
given	O
prporanolol	O
and	O
insluin	O
.	O

In	O
the	O
inuslin	O
-	O
gorup	O
the	O
preiod	O
of	O
hypoglyceamia	B-Disease
was	O
associated	O
with	O
an	O
icnrease	O
in	O
herat	O
-	O
rtae	O
and	O
a	O
fall	O
in	O
disatolic	O
blood	O
-	O
presusre	O
.	O

In	O
the	O
prporanolol	O
-	O
insluin	O
gruop	O
there	O
was	O
a	O
significant	O
fall	O
in	O
herat	O
-	O
rtae	O
in	O
most	O
subjcets	O
and	O
an	O
icnrease	O
in	O
diasotlic	O
presusre	O
.	O

Typical	O
S	O
-	O
T	O
/	O
T	O
chagnes	O
occurred	O
in	O
the	O
insuiln	O
-	O
gorup	O
but	O
in	O
none	O
of	O
the	O
prorpanolol	O
-	O
insuiln	O
gruop	O
.	O

Hyperetnsion	B-Disease
in	O
diabetcis	B-Disease
prone	O
to	O
hypoglcyaemia	B-Disease
attakcs	O
should	O
not	O
be	O
tretaed	O
with	O
btea	O
-	O
blockres	O
because	O
these	O
drgus	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
bolod	O
-	O
pressrue	O
in	O
such	O
paitents	O
.	O

Lnog	O
-	O
term	O
propranlool	O
thearpy	O
in	O
prgenancy	O
:	O
matenral	O
and	O
featl	O
otucome	O
.	O

Proparnolol	O
,	O
a	O
btea	O
-	O
ardenergic	O
bolcking	O
agnet	O
,	O
has	O
found	O
an	O
important	O
postiion	O
in	O
the	O
prcatice	O
of	O
meidcine	O
.	O

Its	O
use	O
in	O
preganncy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detriemntal	O
side	O
effcets	O
have	O
been	O
reported	O
in	O
the	O
feuts	O
and	O
noenate	O
.	O

Ten	O
ptaients	O
and	O
12	O
pregnanceis	O
are	O
reported	O
where	O
chornic	O
proprnaolol	O
has	O
been	O
adminitsered	O
.	O

Five	O
paitents	O
with	O
seiral	O
pregnanices	O
with	O
and	O
without	O
proparnolol	O
tehrapy	O
are	O
also	O
examined	O
.	O

Matrenal	O
,	O
featl	O
,	O
and	O
neonaatl	O
complictaions	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differenitate	O
durg	O
-	O
related	O
complicatinos	O
from	O
materanl	O
disaese	O
-	O
-	O
related	O
compilcations	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypolgycemia	B-Disease
,	O
hyprebilirubinemia	B-Disease
,	O
ploycythemia	B-Disease
,	O
noenatal	B-Disease
anpea	I-Disease
,	O
and	O
bradcyardia	B-Disease
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistiaclly	O
corrleated	O
with	O
chrnoic	O
propraonlol	O
thearpy	O
.	O

Grotwh	B-Disease
retadration	I-Disease
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

Centarl	O
excitaotry	O
acitons	O
of	O
fluarzepam	O
.	O

Toixc	O
acitons	O
of	O
fulrazepam	O
(	O
FZP	O
)	O
were	O
studied	O
in	O
ctas	O
,	O
mcie	O
and	O
rtas	O
.	O

High	O
dsoes	O
caused	O
an	O
apparent	O
cenrtal	O
excitaiton	O
,	O
most	O
clearly	O
seen	O
as	O
cloinc	O
covnulsions	B-Disease
,	O
superimposed	O
on	O
general	O
deperssion	B-Disease
.	O

Following	O
a	O
ltehal	O
dsoe	O
,	O
daeth	O
was	O
always	O
associated	O
with	O
convulisons	B-Disease
.	O

Copmaring	O
the	O
relative	O
sensitivtiy	O
to	O
cetnral	O
dperession	B-Disease
and	O
exctiation	O
reveaeld	O
that	O
rtas	O
were	O
least	O
likely	O
to	O
have	O
conuvlsions	B-Disease
at	O
dsoes	O
that	O
did	O
not	O
first	O
cause	O
lsos	B-Disease
of	I-Disease
concsiousness	I-Disease
,	O
while	O
ctas	O
most	O
clearly	O
showed	O
marked	O
cetnral	O
exctiatory	O
actinos	O
.	O

Sings	O
of	O
FZP	O
toxoctiy	B-Disease
in	O
ctas	O
included	O
excesisve	O
salivatoin	B-Disease
,	O
extreme	O
apprehesnive	O
beahvior	O
,	O
retchnig	O
,	O
muslce	B-Disease
trmeors	I-Disease
and	O
covnulsions	B-Disease
.	O

An	O
inetraction	O
between	O
FZP	O
and	O
penytlenetetrazol	O
(	O
PTZ	O
)	O
was	O
shown	O
by	O
prtereating	O
mcie	O
with	O
FZP	O
before	O
PTZ	O
challenge	O
.	O

As	O
a	O
funciton	O
of	O
dsoe	O
,	O
FZP	O
first	O
protected	O
against	O
convuslions	B-Disease
and	O
daeth	O
.	O

At	O
hihger	O
dsoes	O
,	O
however	O
,	O
convulisons	B-Disease
again	O
emerged	O
.	O

These	O
dsoes	O
of	O
FZP	O
were	O
lwoer	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convuslions	B-Disease
.	O

These	O
resluts	O
may	O
be	O
rleevant	O
to	O
the	O
use	O
of	O
FZP	O
in	O
cilnical	O
situatoins	O
in	O
which	O
there	O
is	O
incraesed	O
neuarl	O
excitaiblity	O
,	O
such	O
as	O
eiplepsy	B-Disease
or	O
sdeative	O
-	O
hypontic	O
durg	O
withdarwal	O
.	O

Use	O
of	O
prporanolol	O
in	O
the	O
teratment	O
of	O
idipoathic	B-Disease
orthotsatic	I-Disease
hpyotension	I-Disease
.	O

Five	O
patinets	O
with	O
idioapthic	B-Disease
orthostaitc	I-Disease
hyoptension	I-Disease
who	O
had	O
pyhsiologic	O
and	O
biocehmical	O
evdience	O
of	O
sevree	O
auotnomic	O
dysfuntcion	O
were	O
included	O
in	O
the	O
sutdy	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduecd	O
palsma	O
ctaecholamines	O
and	O
plsama	O
reinn	O
atcivity	O
in	O
both	O
rceumbent	O
and	O
urpight	O
positions	O
and	O
had	O
marked	O
hypersensitviity	B-Disease
to	O
the	O
prsesor	O
effetcs	O
of	O
infuesd	O
norepienphrine	O
.	O

Teratment	O
with	O
propanooll	O
amdinistered	O
intravenuosly	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
icnreases	O
in	O
spuine	O
and	O
urpight	O
blood	O
presusre	O
in	O
4	O
of	O
the	O
5	O
individulas	O
with	O
rsies	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O

Chornic	O
oarl	O
administartion	O
of	O
propraonlol	O
(	O
40	O
-	O
160	O
mg	O
/	O
day	O
)	O
also	O
eelvated	O
the	O
blood	O
pressures	O
of	O
these	O
inidviduals	O
with	O
incerases	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
patinet	O
,	O
marked	O
hypretension	B-Disease
was	O
idnuced	O
by	O
propranlool	O
and	O
the	O
durg	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
tolearted	O
and	O
no	O
important	O
side	O
efefcts	O
were	O
observed	O
.	O

Teratment	O
has	O
been	O
continued	O
in	O
3	O
inidviduals	O
for	O
6	O
-	O
13	O
mnoths	O
with	O
persistecne	O
of	O
the	O
perssor	O
efefct	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decresae	O
in	O
the	O
dgeree	O
of	O
rseponse	O
with	O
tmie	O
.	O

Hemodynmaic	O
measruements	O
in	O
1	O
of	O
the	O
patinets	O
demonstrated	O
an	O
icnrease	O
in	O
total	O
peripehral	O
reisstance	O
and	O
essentially	O
no	O
change	O
in	O
caridac	O
ouptut	O
following	O
proprnaolol	O
threapy	O
.	O

The	O
sutdies	O
suggest	O
that	O
proparnolol	O
is	O
a	O
useful	O
durg	O
in	O
selected	O
pateints	O
with	O
sevree	O
idoipathic	B-Disease
orthosattic	I-Disease
hypotenison	I-Disease
.	O

Total	O
intravenuos	O
aensthesia	O
with	O
etomiadte	O
.	O

III	O
.	O

Some	O
observatinos	O
in	O
adutls	O
.	O

An	O
inevstigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dsoage	O
of	O
etomidtae	O
required	O
to	O
maintain	O
selep	O
in	O
adutls	O
undergoing	O
surgrey	O
under	O
regioanl	O
lcoal	O
anestheisa	O
.	O

Prmeedication	O
of	O
dizaepam	O
10	O
mg	O
and	O
atropnie	O
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
inudced	O
and	O
maintained	O
by	O
intermittent	O
intrvaenous	O
injecitons	O
of	O
etomiadte	O
0	O
.	O
1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patinet	O
would	O
open	O
his	O
eeys	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dsoe	O
of	O
etomdiate	O
17	O
.	O
4	O
mcirogram	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
sleep	O
,	O
but	O
great	O
indiviudal	O
vraiation	O
occurred	O
,	O
with	O
odler	O
ptaients	O
requiring	O
less	O
durg	O
.	O

The	O
investigatoin	O
was	O
discotninued	O
after	O
18	O
patietns	O
because	O
of	O
the	O
frequecny	O
and	O
intenstiy	O
of	O
side	O
-	O
effetcs	O
,	O
particularly	O
pian	B-Disease
and	O
mycolonia	B-Disease
,	O
which	O
caused	O
the	O
tecnhique	O
to	O
be	O
abandoned	O
in	O
two	O
csaes	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etomiadte	O
will	O
prove	O
to	O
be	O
the	O
hypontic	O
of	O
choice	O
for	O
a	O
totally	O
intraevnous	O
anestehtic	O
technqiue	O
in	O
adluts	O
because	O
of	O
the	O
high	O
incidnece	O
of	O
mycolonia	B-Disease
after	O
prolnoged	O
administraiton	O
.	O

In	O
several	O
ptaients	O
uncotnrollable	O
msucle	O
mvoements	O
persisted	O
for	O
many	O
mniutes	O
after	O
complete	O
rceovery	O
of	O
consciuosness	O
.	O

Eviednce	O
for	O
cardaic	O
btea	O
2	O
-	O
adrenoecptors	O
in	O
man	O
.	O

We	O
copmared	O
the	O
effects	O
of	O
single	O
doess	O
of	O
50	O
mg	O
aetnolol	O
(	O
cardisoelective	O
)	O
,	O
40	O
mg	O
proparnolol	O
(	O
nonselective	O
)	O
,	O
and	O
placbeo	O
on	O
both	O
execrise	O
-	O
and	O
isorpoterenol	O
-	O
inudced	O
tachycarida	B-Disease
in	O
two	O
expeirments	O
involving	O
nine	O
noraml	O
sbujects	O
.	O

Mxaimal	O
exercsie	O
haert	O
rtae	O
was	O
rdeuced	O
from	O
187	O
+	O
/	O
-	O
4	O
(	O
SEM	O
)	O
after	O
palcebo	O
to	O
146	O
+	O
/	O
-	O
7	O
bpm	O
after	O
atneolol	O
and	O
138	O
+	O
/	O
-	O
6	O
bpm	O
after	O
prporanolol	O
,	O
but	O
there	O
were	O
no	O
dfiferences	O
between	O
the	O
durgs	O
.	O

The	O
efefcts	O
on	O
iosproterenol	O
tachycarida	B-Disease
were	O
determined	O
before	O
and	O
after	O
atorpine	O
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Isoprotereonl	O
sensiitvity	O
was	O
determined	O
as	O
the	O
itnravenous	O
dsoe	O
that	O
incraesed	O
haert	O
rtae	O
by	O
25	O
bpm	O
(	O
C2D5	O
)	O
and	O
this	O
was	O
incraesed	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
micrgorams	O
after	O
placbeo	O
to	O
38	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
3	O
mcirograms	O
after	O
proprnaolol	O
and	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
7	O
microgarms	O
after	O
atenooll	O
.	O

The	O
difference	O
in	O
the	O
efefcts	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
atrpoine	O
the	O
C2D5	O
was	O
ucnhanged	O
after	O
placbeo	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
microrgams	O
)	O
and	O
atenooll	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
microgarms	O
)	O
;	O
it	O
was	O
reudced	O
after	O
proprnaolol	O
(	O
24	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
0	O
mcirograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenlool	O
.	O

This	O
change	O
with	O
prporanolol	O
snesitivity	O
was	O
calculated	O
as	O
the	O
appraent	O
Ka	O
,	O
this	O
was	O
uncahnged	O
by	O
artopine	O
(	O
11	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
1	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
5	O
ml	O
/	O
ng	O
)	O
.	O

These	O
dtaa	O
are	O
consistent	O
with	O
the	O
hpyothesis	O
that	O
exercsie	O
-	O
induecd	O
tahcycardia	B-Disease
resutls	O
largely	O
from	O
btea	O
1	O
-	O
rceeptor	O
activatoin	O
that	O
is	O
bolcked	O
by	O
both	O
cardoiselective	O
and	O
nonselective	O
drgus	O
,	O
whereas	O
isorpoterenol	O
actviates	O
both	O
btea	O
1	O
-	O
and	O
btea	O
2	O
-	O
receptros	O
so	O
that	O
after	O
caridoselective	O
blcokade	O
there	O
remains	O
a	O
btea	O
2	O
-	O
component	O
that	O
can	O
be	O
blcoked	O
with	O
a	O
nonselective	O
durg	O
.	O

While	O
there	O
appear	O
to	O
be	O
btea	O
2	O
-	O
recetpors	O
in	O
the	O
huamn	O
haert	O
,	O
their	O
physiloogic	O
or	O
pahtologic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

Horomnes	O
and	O
rsik	O
of	O
bresat	B-Disease
cnacer	I-Disease
.	O

This	O
paper	O
reprots	O
the	O
resutls	O
of	O
a	O
stduy	O
of	O
50	O
menopauasl	O
wmoen	O
receiving	O
hormoanl	O
replaceemnt	O
tehrapy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
surigcal	O
mneopause	O
;	O
their	O
mean	O
age	O
was	O
45	O
.	O
7	O
yeras	O
.	O

It	O
was	O
hypothesized	O
that	O
progsetins	O
could	O
eqiulibrate	O
the	O
effects	O
of	O
the	O
estroegnic	O
stiumlation	O
on	O
the	O
mammray	O
and	O
ednometrial	O
taregt	O
tsisues	O
of	O
wmoen	O
on	O
hormoanl	O
replaecment	O
tehrapy	O
.	O

The	O
treatmnet	O
scheudle	O
consisted	O
of	O
conjugaetd	O
estrgoens	O
(	O
Premairn	O
)	O
1	O
.	O
25	O
mg	O
/	O
day	O
for	O
21	O
dyas	O
and	O
Medrxoyprogesterone	O
acteate	O
10	O
mg	O
/	O
day	O
for	O
10	O
dyas	O
in	O
each	O
mnoth	O
.	O

The	O
mean	O
treamtent	O
peroid	O
was	O
18	O
monhts	O
.	O

During	O
the	O
follow	O
-	O
up	O
peroid	O
,	O
attentoin	O
was	O
paid	O
to	O
bresat	O
modificatinos	O
as	O
evidenced	O
by	O
symptomaotlogy	O
,	O
phsyical	O
examiantion	O
,	O
and	O
palte	O
thermograhpy	O
.	O

Mastodnyia	B-Disease
was	O
reported	O
by	O
21	O
ptaients	O
,	O
and	O
phsyical	O
examinatoin	O
rveealed	O
a	O
light	O
incerase	O
in	O
bresat	O
firmnses	O
in	O
12	O
wmoen	O
and	O
a	O
modearte	O
icnrease	O
in	O
bresat	O
ndoularity	O
in	O
2	O
wmoen	O
.	O

Themograhpy	O
confirmed	O
the	O
existence	O
of	O
an	O
excesisve	O
berast	O
stmiulation	O
in	O
1	O
wmoen	O
who	O
complained	O
of	O
mdoerate	O
matsodynia	B-Disease
and	O
in	O
5	O
of	O
the	O
7	O
woemn	O
who	O
complained	O
of	O
sveere	O
msatodynia	B-Disease
.	O

Normalziation	O
was	O
obtained	O
by	O
halivng	O
the	O
etsrogen	O
dsoe	O
.	O

These	O
resluts	O
suggest	O
that	O
homronal	O
rpelacement	O
thearpy	O
can	O
be	O
safely	O
prescrbied	O
if	O
the	O
following	O
criteira	O
are	O
satifsied	O
:	O
1	O
)	O
preliminary	O
evlauation	O
of	O
paitents	O
from	O
a	O
cilnical	O
,	O
metbaolic	O
,	O
cytoolgic	O
,	O
and	O
mamomgraphic	O
persepctive	O
;	O
2	O
)	O
cycilc	O
treatmnet	O
schedlue	O
,	O
with	O
a	O
prgoestative	O
phsae	O
of	O
10	O
dyas	O
;	O
and	O
3	O
)	O
peirodic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
accuarte	O
themrographic	O
evalutaion	O
of	O
the	O
bresat	O
traget	O
tsisues	O
.	O

Eraly	O
infectoins	B-Disease
in	O
kindey	O
,	O
haert	O
,	O
and	O
lievr	O
translpant	O
recpiients	O
on	O
cyclosproine	O
.	O

Eighty	O
-	O
one	O
reanl	O
,	O
seventeen	O
herat	O
,	O
and	O
twenty	O
-	O
four	O
lvier	O
translpant	O
ptaients	O
were	O
followed	O
for	O
infectoin	B-Disease
.	O

Seventeen	O
reanl	O
paitents	O
received	O
aazthioprine	O
(	O
Aza	O
)	O
and	O
prendisone	O
as	O
part	O
of	O
a	O
randomzied	O
trail	O
of	O
immunsouppression	O
with	O
21	O
cycolsporine	O
-	O
and	O
-	O
perdnisone	O
-	O
tretaed	O
reanl	O
translpant	O
ptaients	O
.	O

All	O
others	O
received	O
cyclosproine	O
and	O
predniosne	O
.	O

The	O
radnomized	O
Aza	O
patietns	O
had	O
more	O
overall	O
infetcions	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nonviarl	O
infectoins	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
rnadomized	O
ccylosporine	O
pateints	O
.	O

Herat	O
and	O
lvier	O
pateints	O
had	O
more	O
infectoins	B-Disease
than	O
cyclopsorine	O
reanl	O
patietns	O
but	O
fewer	O
inefctions	B-Disease
than	O
the	O
Aza	O
reanl	O
paitents	O
.	O

There	O
were	O
no	O
inefctious	O
daeths	O
in	O
rneal	O
tranpslant	O
patietns	O
on	O
cyclospornie	O
or	O
Aza	O
,	O
but	O
inefction	B-Disease
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cadriac	O
tarnsplant	O
deahts	O
and	O
in	O
8	O
out	O
of	O
9	O
lvier	O
transplnat	O
detahs	O
.	O

Reanl	O
patietns	O
on	O
cyclosproine	O
had	O
the	O
fewest	O
bcateremias	B-Disease
.	O

Anaylsis	O
of	O
stie	O
of	O
ifnection	B-Disease
showed	O
a	O
preponderance	O
of	O
abdomnial	B-Disease
infectoins	I-Disease
in	O
lvier	O
ptaients	O
,	O
itnrathoracic	O
infectoins	B-Disease
in	O
herat	O
ptaients	O
,	O
and	O
urniary	B-Disease
trcat	I-Disease
infectoins	I-Disease
in	O
reanl	O
ptaients	O
.	O

Pulmnoary	O
ifnections	B-Disease
were	O
less	O
common	O
in	O
cyclsoporine	O
-	O
tretaed	O
rneal	O
pateints	O
than	O
in	O
Aza	O
-	O
treaetd	O
paitents	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Aza	O
ptaients	O
had	O
significantly	O
more	O
staphylococacl	B-Disease
infcetions	I-Disease
than	O
all	O
other	O
tarnsplant	O
gropus	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
and	O
sysetmic	O
fugnal	B-Disease
ifnections	I-Disease
occurred	O
only	O
in	O
the	O
lievr	O
trnasplant	O
gruop	O
.	O

Cytomegaloivrus	O
(	O
CMV	O
)	O
shedidng	O
or	O
serologiacl	O
rsies	O
in	O
atnibody	O
tietr	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cycolsporine	O
ptaients	O
and	O
76	O
%	O
of	O
Aza	O
ptaients	O
.	O

Of	O
the	O
cyclopsorine	O
patinets	O
,	O
15	O
%	O
had	O
sypmtoms	O
related	O
to	O
CMV	B-Disease
infcetion	I-Disease
.	O

Serologiacl	O
eviednce	O
for	O
Epsetin	B-Disease
Brar	I-Disease
Vrius	I-Disease
ifnection	I-Disease
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosproine	O
pateints	O
studied	O
.	O

Three	O
had	O
associated	O
sympotms	O
,	O
and	O
one	O
developed	O
a	O
lypmhoma	B-Disease
.	O

Structrue	O
-	O
acitvity	O
and	O
dsoe	O
-	O
effcet	O
realtionships	O
of	O
the	O
antaognism	O
of	O
pcirotoxin	O
-	O
idnuced	O
seizuers	B-Disease
by	O
cholecystoiknin	O
,	O
fragmnets	O
and	O
anaolgues	O
of	O
cholecystkoinin	O
in	O
mcie	O
.	O

Intrpaeritoneal	O
adminitsration	O
of	O
cholecysotkinin	O
octappetide	O
sulphtae	O
etser	O
(	O
CCK	O
-	O
8	O
-	O
SE	O
)	O
and	O
nonsluphated	O
cholecsytokinin	O
octpaeptide	O
(	O
CCK	O
-	O
8	O
-	O
NS	O
)	O
enhnaced	O
the	O
latecny	O
of	O
siezures	B-Disease
inudced	O
by	O
pcirotoxin	O
in	O
mcie	O
.	O

Exepriments	O
with	O
N	O
-	O
and	O
C	O
-	O
terimnal	O
fragmnets	O
reevaled	O
that	O
the	O
C	O
-	O
termnial	O
tetrapepitde	O
(	O
CCK	O
-	O
5	O
-	O
8	O
)	O
was	O
the	O
acitve	O
cenrte	O
of	O
the	O
CCK	O
otcapeptide	O
mloecule	O
.	O

The	O
analogeus	O
CCK	O
-	O
8	O
-	O
SE	O
and	O
CCK	O
-	O
8	O
-	O
NS	O
(	O
dsoe	O
range	O
0	O
.	O
2	O
-	O
6	O
.	O
4	O
mmuol	O
/	O
kg	O
)	O
and	O
cearulein	O
dsoe	O
range	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
muoml	O
/	O
kg	O
)	O
showed	O
blel	O
-	O
shpaed	O
dsoe	O
-	O
efefct	O
curevs	O
,	O
with	O
the	O
greatest	O
maxmium	O
inhibiiton	O
for	O
CCK	O
-	O
8	O
-	O
NS	O
.	O

The	O
pepitde	O
CCK	O
-	O
5	O
-	O
8	O
had	O
waek	O
anticovnulsant	O
atcivity	O
in	O
compariosn	O
to	O
the	O
octapeptdies	O
,	O
3	O
.	O
2	O
mmuol	O
/	O
kg	O
and	O
larger	O
dsoes	O
of	O
the	O
refernece	O
durg	O
,	O
daizepam	O
,	O
totally	O
prevented	O
pircotoxin	O
-	O
induecd	O
seiuzres	B-Disease
and	O
mortlaity	O
.	O

The	O
mxaimum	O
effcet	O
of	O
the	O
petpides	O
tetsed	O
was	O
less	O
than	O
that	O
of	O
daizepam	O
.	O

Exepriments	O
with	O
analgoues	O
and	O
deriavtives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectievness	O
of	O
the	O
btea	O
-	O
aalnyl	O
derivatievs	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enhanecd	O
and	O
that	O
they	O
were	O
equiptoent	O
with	O
CCK	O
-	O
8	O
-	O
SE	O
.	O

Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
analogeus	O
,	O
Ser	O
(	O
S3OH	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Thr	O
(	O
S3OH	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Hyp	O
(	O
S3OH	O
)	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
were	O
slightly	O
more	O
atcive	O
than	O
CCK	O
-	O
8	O
-	O
SE	O
.	O

Vsaopressin	O
as	O
a	O
possible	O
contributor	O
to	O
hypertenison	B-Disease
.	O

The	O
role	O
of	O
vasoprsesin	O
as	O
a	O
pressor	O
aegnt	O
to	O
the	O
hyperetnsive	B-Disease
prcoess	O
was	O
examined	O
.	O

Vasoperssin	O
plays	O
a	O
major	O
role	O
in	O
the	O
patohgenesis	O
of	O
DCOA	O
-	O
slat	O
hypetrension	B-Disease
,	O
since	O
the	O
elevaiton	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rtas	O
with	O
litihum	O
-	O
tretaed	O
diabeets	B-Disease
insipiuds	I-Disease
after	O
DCOA	O
-	O
slat	O
treatemnt	O
.	O

Administratoin	O
of	O
DDVAP	O
which	O
has	O
antiduiretic	O
atcion	O
but	O
miinmal	O
vasorpessor	O
effcet	O
failed	O
to	O
incerase	O
bolod	O
pressure	O
to	O
the	O
lveels	O
observed	O
after	O
admiinstration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
perssor	O
aciton	O
of	O
vsaopressin	O
appears	O
to	O
be	O
important	O
in	O
the	O
deevlopment	O
of	O
this	O
mdoel	O
of	O
hypertesnion	B-Disease
,	O
since	O
the	O
ehnanced	O
perssor	O
responsievness	O
to	O
the	O
homrone	O
was	O
observed	O
in	O
the	O
initial	O
satge	O
of	O
hypertenison	B-Disease
.	O

Inrceased	O
secrteion	O
of	O
vasorpessin	O
from	O
neurohypophsyis	O
also	O
proomtes	O
the	O
functoin	O
of	O
the	O
homrone	O
as	O
a	O
ptahogenetic	O
fatcor	O
in	O
hypretension	B-Disease
.	O

An	O
unproportional	O
relesae	O
of	O
vsaopressin	O
compaerd	O
to	O
plsama	O
osmollaity	O
may	O
be	O
indcued	O
by	O
the	O
absnece	O
of	O
an	O
adjusting	O
contorl	O
of	O
angiotenisn	O
II	O
forming	O
and	O
recetpor	O
bindnig	O
capactiy	O
for	O
soduim	O
balacne	O
in	O
the	O
barin	O
.	O

However	O
,	O
the	O
role	O
of	O
vasoperssin	O
remains	O
to	O
be	O
determined	O
in	O
huamn	O
esesntial	O
hypretension	B-Disease
.	O

Txoic	B-Disease
heptaitis	I-Disease
induecd	O
by	O
dsiulfiram	O
in	O
a	O
non	O
-	O
alcohoilc	O
.	O

A	O
reversible	O
txoic	B-Disease
lievr	I-Disease
dmaage	I-Disease
was	O
observed	O
in	O
a	O
non	O
-	O
alcohloic	O
wmoan	O
tretaed	O
with	O
diuslfiram	O
.	O

The	O
cauastive	O
rleationship	O
was	O
proven	O
by	O
challenge	O
.	O

Atrail	B-Disease
thromobsis	I-Disease
involving	O
the	O
haert	O
of	O
F	O
-	O
344	O
rtas	O
ignesting	O
quinacirne	O
hydrochlroide	O
.	O

Quniacrine	O
hdyrochloride	O
is	O
txoic	O
for	O
the	O
herat	O
of	O
F	O
-	O
344	O
rtas	O
.	O

Rtas	O
terated	O
with	O
500	O
ppm	O
quinacrnie	O
hyrdochloride	O
in	O
the	O
deit	O
all	O
developed	O
a	O
high	O
inicdence	O
of	O
lfet	O
atiral	B-Disease
thromobsis	I-Disease
.	O

The	O
lseion	O
was	O
associated	O
with	O
cradiac	B-Disease
hypetrrophy	I-Disease
and	O
dilattaion	O
and	O
fcoal	O
myocadrial	B-Disease
degneeration	I-Disease
.	O

Rtas	O
deid	O
from	O
cadriac	B-Disease
hypetrrophy	I-Disease
with	O
sveere	O
aucte	O
and	O
chrnoic	O
cnogestion	O
of	O
the	O
lnugs	O
,	O
lievr	O
,	O
and	O
other	O
orgnas	O
.	O

Seventy	O
percent	O
of	O
rtas	O
given	O
250	O
ppm	O
qiunacrine	O
hdyrochloride	O
and	O
1	O
,	O
000	O
ppm	O
soidum	O
nitrtie	O
simultaneosuly	O
in	O
the	O
deit	O
had	O
throbmosis	B-Disease
of	O
the	O
artia	O
of	O
the	O
haert	O
,	O
while	O
unterated	O
contorl	O
rtas	O
in	O
this	O
lbaoratory	O
did	O
not	O
have	O
atrail	B-Disease
thromboiss	I-Disease
.	O

Soduim	O
nitirte	O
in	O
combintaion	O
with	O
quinarcine	O
hyrdochloride	O
appeared	O
to	O
have	O
no	O
additional	O
efefct	O
.	O

Alterntaing	B-Disease
snius	I-Disease
rhtyhm	I-Disease
and	O
intremittent	O
sionatrial	B-Disease
blcok	I-Disease
inudced	O
by	O
proprnaolol	O
.	O

Atlernating	B-Disease
snius	I-Disease
rhyhtm	I-Disease
and	O
intemrittent	O
sinoartial	B-Disease
(	I-Disease
S	I-Disease
-	I-Disease
A	I-Disease
)	I-Disease
blcok	I-Disease
was	O
observed	O
in	O
a	O
57	O
-	O
yaer	O
-	O
old	O
wmoan	O
,	O
under	O
tretament	O
for	O
anigna	B-Disease
with	O
80	O
mg	O
propranooll	O
daliy	O
.	O

The	O
electrcoardiogram	O
showed	O
atlernation	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
itnervals	O
and	O
occasional	O
puases	O
.	O

These	O
pauess	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
interavls	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
intervlas	O
of	O
0	O
.	O
92	O
-	O
0	O
.	O
95	O
s	O
representing	O
the	O
basic	O
siuns	O
cylce	O
.	O

Following	O
these	O
basic	O
snius	O
cylces	O
,	O
alternating	B-Disease
rhyhtm	I-Disease
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
inetrval	O
.	O

The	O
long	O
P	O
-	O
P	O
intevrals	O
ranged	O
between	O
1	O
.	O
04	O
-	O
1	O
.	O
12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
intrevals	O
between	O
0	O
.	O
80	O
-	O
0	O
.	O
84	O
s	O
,	O
respectively	O
.	O

The	O
druation	O
of	O
the	O
puases	O
were	O
eqaul	O
or	O
almost	O
eqaul	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
intreval	O
or	O
to	O
twice	O
the	O
basic	O
siuns	O
ccyle	O
.	O

In	O
one	O
recodring	O
a	O
short	O
preiod	O
of	O
regular	O
siuns	O
rhtyhm	O
with	O
intermtitent	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
bolck	I-Disease
was	O
observed	O
.	O

This	O
short	O
peirod	O
of	O
snius	O
rhtyhm	O
was	O
interrputed	O
by	O
sudden	O
prolongatoin	O
of	O
the	O
P	O
-	O
P	O
itnerval	O
starting	O
the	O
alterantive	O
ryhthm	O
.	O

There	O
were	O
small	O
chanegs	O
in	O
the	O
sahpe	O
of	O
the	O
P	O
waevs	O
and	O
P	O
-	O
R	O
intrevals	O
.	O

S	O
-	O
A	O
conudction	O
through	O
two	O
pathwyas	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
bolck	O
the	O
second	O
having	O
0	O
.	O
12	O
-	O
0	O
.	O
14	O
s	O
longer	O
cnoduction	O
tmie	O
and	O
with	O
occasional	O
2	O
/	O
1	O
bolck	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
itnerval	O
and	O
other	O
elcetrocardiographic	O
fetaures	O
seen	O
.	O

Atroipne	O
1	O
mg	O
given	O
intravenuosly	O
resulted	O
in	O
shorteinng	O
of	O
all	O
P	O
-	O
P	O
intevrals	O
without	O
changing	O
the	O
ryhthm	O
.	O

The	O
anbormal	O
rhyhtm	O
disappeared	O
with	O
the	O
withdrwaal	O
of	O
proparnolol	O
and	O
when	O
the	O
durg	O
was	O
rsetarted	O
a	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
bolck	I-Disease
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evdience	O
for	O
prporanolol	O
being	O
the	O
cause	O
of	O
this	O
conductoin	B-Disease
disoredr	I-Disease
.	O

Antitmuor	O
efefct	O
,	O
cardoitoxicity	B-Disease
,	O
and	O
nephrtooxicity	B-Disease
of	O
doxorubciin	O
in	O
the	O
IgM	O
soild	O
immunocytoma	B-Disease
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Atnitumor	O
actviity	O
,	O
cadriotoxicity	B-Disease
,	O
and	O
nephrtooxicity	B-Disease
inudced	O
by	O
dxoorubicin	O
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inberd	O
rtas	O
each	O
bearing	O
a	O
transplnatable	O
sloid	O
IgM	O
immunoyctoma	B-Disease
.	O

Aniamls	O
with	O
a	O
tmuor	B-Disease
(	O
diamteer	O
,	O
15	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
mm	O
)	O
were	O
treaetd	O
with	O
iv	O
injcetions	O
of	O
doxoruibcin	O
on	O
5	O
consecutvie	O
dyas	O
,	O
followed	O
by	O
1	O
weekly	O
ijnection	O
for	O
7	O
wekes	O
(	O
dsoe	O
range	O
,	O
0	O
.	O
015	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
.	O

Tuomr	B-Disease
regresison	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
doxorubiicn	O
/	O
kg	O
.	O

Comlpete	O
disappeaarnce	O
of	O
the	O
tuomr	B-Disease
was	O
idnuced	O
with	O
1	O
.	O
0	O
mg	O
doxorubciin	O
/	O
kg	O
.	O

Histolgoic	O
evdience	O
of	O
cardiotoxciity	B-Disease
scoerd	O
as	O
grdae	O
III	O
was	O
only	O
observed	O
at	O
a	O
dsoe	O
of	O
1	O
.	O
0	O
mg	O
dxoorubicin	O
/	O
kg	O
.	O

Lihgt	O
mircoscopic	O
eivdence	O
of	O
rneal	B-Disease
dmaage	I-Disease
was	O
seen	O
above	O
a	O
dsoe	O
of	O
0	O
.	O
5	O
mg	O
doxourbicin	O
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuira	B-Disease
and	O
very	O
low	O
sreum	O
albmuin	O
levles	O
.	O

In	O
the	O
gorup	O
that	O
received	O
1	O
.	O
0	O
mg	O
dooxrubicin	O
/	O
kg	O
,	O
the	O
seurm	O
alubmin	O
leevl	O
decreaesd	O
from	O
33	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
1	O
to	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
g	O
/	O
liter	O
.	O

Asictes	B-Disease
and	O
hyrdothorax	B-Disease
were	O
observed	O
siumltaneously	O
.	O

The	O
same	O
experimetns	O
were	O
performed	O
with	O
non	O
-	O
tmuor	B-Disease
-	O
bearing	O
rtas	O
,	O
in	O
which	O
no	O
major	O
dfiferences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antituomr	O
actiivty	O
,	O
cardiotoxictiy	B-Disease
,	O
and	O
nephrotoixcity	B-Disease
were	O
studied	O
simultanoeusly	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Abluminuria	B-Disease
due	O
to	O
reanl	B-Disease
daamge	I-Disease
led	O
to	O
extremely	O
low	O
seurm	O
ablumin	O
levles	O
,	O
so	O
asciets	B-Disease
and	O
hdyrothorax	B-Disease
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyoptahy	B-Disease
.	O

Inrtaoperative	O
bradycarida	B-Disease
and	O
hyoptension	B-Disease
associated	O
with	O
tmiolol	O
and	O
pilocaprine	O
eye	O
drpos	O
.	O

A	O
69	O
-	O
yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treaetd	O
with	O
piolcarpine	O
nitarte	O
and	O
tiomlol	O
maelate	O
eye	O
drpos	O
,	O
developed	O
a	O
braydcardia	B-Disease
and	O
became	O
hyoptensive	B-Disease
during	O
haltohane	O
anasethesia	O
.	O

Both	O
timooll	O
and	O
piolcarpine	O
were	O
subsequently	O
identifeid	O
in	O
a	O
24	O
-	O
h	O
colletcion	O
of	O
uirne	O
.	O

Tmiolol	O
(	O
but	O
not	O
piolcarpine	O
)	O
was	O
detetced	O
in	O
a	O
samlpe	O
of	O
palsma	O
reomved	O
during	O
srugery	O
;	O
the	O
plamsa	O
concentraiton	O
of	O
tiomlol	O
(	O
2	O
.	O
6	O
ng	O
ml	O
-	O
1	O
)	O
was	O
consistent	O
with	O
pratial	O
btea	O
-	O
adernoceptor	O
blcokade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
actoin	O
may	O
have	O
been	O
enahnced	O
during	O
halotahne	O
anaestehsia	O
with	O
resutlant	O
bradcyardia	B-Disease
and	O
hpyotension	B-Disease
.	O

Pilocaprine	O
may	O
have	O
had	O
a	O
contribtuory	O
efefct	O
.	O

Succniylcholine	O
apneoa	B-Disease
:	O
attempted	O
reverasl	O
with	O
anticholinesteraess	O
.	O

Anticholinseterases	O
were	O
admniistered	O
in	O
an	O
attempt	O
to	O
atnagonize	O
prolonegd	O
neuormuscular	B-Disease
bolckade	I-Disease
following	O
the	O
adimnistration	O
of	O
succinylcholine	O
in	O
a	O
paitent	O
later	O
found	O
to	O
be	O
homozyguos	O
for	O
atypiacl	O
plamsa	O
cohlinesterase	O
.	O

Edrophoinum	O
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylchoilne	O
,	O
when	O
tarin	O
-	O
of	O
-	O
four	O
stmiulation	O
was	O
cahracteristic	O
of	O
phsae	O
II	O
bolck	O
,	O
produced	O
pratial	O
atnagonism	O
which	O
was	O
not	O
sustianed	O
.	O

Repaeted	O
dsoes	O
of	O
edrpohonium	O
to	O
70	O
mg	O
and	O
neostigimne	O
to	O
2	O
.	O
5	O
mg	O
did	O
not	O
antagonzie	O
or	O
augment	O
the	O
blcok	O
.	O

Spontanoeus	O
rsepiration	O
recomemnced	O
200	O
min	O
after	O
scucinylcholine	O
administrtaion	O
.	O

It	O
is	O
concluded	O
that	O
atnicholinesterases	O
are	O
only	O
pratially	O
effcetive	O
in	O
retsoring	O
neuromsucular	O
funciton	O
in	O
succinyclholine	O
anpoea	B-Disease
despite	O
mucsle	O
twtich	O
actviity	O
typical	O
of	O
phsae	O
II	O
blcok	O
.	O

Effect	O
of	O
doxroubicin	O
on	O
[	O
omega	O
-	O
I	O
-	O
131	O
]	O
hpetadecanoic	O
aicd	O
moycardial	O
scinitgraphy	O
and	O
ehcocardiography	O
in	O
dgos	O
.	O

The	O
effcets	O
of	O
serail	O
treatemnt	O
with	O
doxoruibcin	O
on	O
dynaimc	O
myocadrial	O
sicntigraphy	O
with	O
[	O
omega	O
-	O
I	O
-	O
131	O
]	O
hepatdecanoic	O
aicd	O
(	O
I	O
-	O
131	O
HA	O
)	O
,	O
and	O
on	O
gloabl	O
lfet	O
-	O
venrticular	O
functoin	O
determined	O
echocardiograhpically	O
,	O
were	O
studied	O
in	O
a	O
gruop	O
of	O
nine	O
mnogrel	O
dgos	O
.	O

Total	O
exrtactable	O
myocadrial	O
liipd	O
was	O
compraed	O
postmotrem	O
between	O
a	O
gorup	O
of	O
cotnrol	O
dgos	O
and	O
doxourbicin	O
-	O
treaetd	O
dgos	O
.	O

A	O
significant	O
and	O
then	O
porgressive	O
fall	O
in	O
glboal	O
LV	O
functoin	O
was	O
observed	O
at	O
a	O
cmuulative	O
doxorubiicn	O
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
incraese	O
in	O
the	O
myocardail	O
t1	O
/	O
2	O
of	O
the	O
I	O
-	O
131	O
HA	O
was	O
observed	O
only	O
at	O
a	O
hgiher	O
cmuulative	O
dsoe	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
aletration	O
in	O
total	O
exrtactable	O
myocradial	O
lipdis	O
was	O
observed	O
between	O
conrtol	O
dgos	O
and	O
those	O
terated	O
with	O
doxoruibcin	O
.	O

Our	O
finidngs	O
suggest	O
that	O
the	O
chagnes	O
leading	O
to	O
an	O
altertaion	O
of	O
myocradial	O
dynmaic	O
imaigng	O
with	O
I	O
-	O
131	O
HA	O
are	O
not	O
the	O
initiating	O
facotr	O
in	O
dooxrubicin	O
cardiotoixcity	B-Disease
.	O

Hemodyanmics	O
and	O
myocaridal	O
metaoblism	O
under	O
dleiberate	O
hypotesnion	B-Disease
.	O

An	O
experimenatl	O
stduy	O
in	O
dgos	O
.	O

Coronray	O
bolod	O
folw	O
,	O
cadriac	O
work	O
and	O
metbaolism	O
were	O
studied	O
in	O
dgos	O
under	O
sdoium	O
ntiroprusside	O
(	O
SNP	O
)	O
and	O
triemtaphan	O
(	O
TMP	O
)	O
delibreate	O
hpyotension	B-Disease
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
perssure	O
decresae	O
from	O
baselnie	O
)	O
.	O

Regarding	O
the	O
efefcts	O
of	O
durg	O
-	O
induecd	O
hypotensoin	B-Disease
on	O
coroanry	O
bolod	O
folw	O
,	O
aotric	O
and	O
croonary	O
snius	O
mteabolic	O
dtaa	O
(	O
pH	O
,	O
pO2	O
,	O
pOC2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusisde	O
hpyotension	B-Disease
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
bolod	O
prsesure	O
dercease	O
from	O
contorl	O
,	O
trimetahpan	O
hypotnesion	B-Disease
to	O
20	O
%	O
mean	O
blood	O
presusre	O
decresae	O
.	O

Cadriac	O
work	O
was	O
significantly	O
reduecd	O
during	O
SNP	O
hypotensoin	B-Disease
.	O

Myoacrdial	O
O2	O
cnosumption	O
and	O
O2	O
avaliability	O
were	O
directly	O
depnedent	O
on	O
the	O
coronray	O
perfusoin	O
.	O

Careful	O
invsaive	O
monitornig	O
of	O
the	O
blood	O
perssure	O
,	O
bolod	O
gaess	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
semgent	O
is	O
mandatory	O
.	O

Evdience	O
for	O
a	O
selective	O
brian	O
noradrenregic	O
involvemnet	O
in	O
the	O
lcoomotor	O
stiumlant	O
effcets	O
of	O
amphetmaine	O
in	O
the	O
rat	O
.	O

Mlae	O
rtas	O
received	O
the	O
noradrnealine	O
neuortoxin	O
DPS4	O
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
dyas	O
prior	O
to	O
injcetion	O
of	O
D	O
-	O
amphetaimne	O
(	O
10	O
or	O
40	O
mmuol	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
hyperactivtiy	B-Disease
inudced	O
by	O
D	O
-	O
amhpetamine	O
(	O
10	O
muoml	O
/	O
kg	O
)	O
was	O
significantly	O
redcued	O
by	O
DPS4	O
preteratment	O
.	O

However	O
,	O
the	O
increaesd	O
reraings	O
and	O
the	O
apmhetamine	O
-	O
induecd	O
steerotypies	B-Disease
were	O
not	O
bolcked	O
by	O
prtereatment	O
with	O
DPS4	O
.	O

The	O
redcution	O
of	O
ampehtamine	O
hyperactviity	B-Disease
induecd	O
by	O
DPS4	O
was	O
blcoked	O
by	O
preteratment	O
with	O
the	O
noradrenailne	O
-	O
uptkae	O
blokcing	O
agnet	O
,	O
desipramnie	O
,	O
which	O
prevents	O
the	O
neuortoxic	B-Disease
actoin	O
of	O
DPS4	O
.	O

The	O
present	O
resluts	O
suggest	O
a	O
selective	O
ivnolvement	O
of	O
cetnral	O
noradrenerigc	O
neuornes	O
in	O
the	O
loocmotor	O
stimluant	O
effect	O
of	O
apmhetamine	O
in	O
the	O
rat	O
.	O

Accelearted	B-Disease
jucntional	I-Disease
rhyhtms	I-Disease
during	O
oarl	O
vearpamil	O
tehrapy	O
.	O

This	O
sutdy	O
examined	O
the	O
ferquency	O
of	O
atrioventircular	O
(	O
AV	O
)	O
dissocitaion	O
and	O
accelearted	B-Disease
junctinoal	I-Disease
ryhthms	I-Disease
in	O
59	O
pateints	O
receiving	O
oarl	O
vreapamil	O
.	O

Accelreated	B-Disease
junctinoal	I-Disease
rhtyhms	I-Disease
and	O
AV	O
dissocitaion	O
were	O
frequnet	O
in	O
pateints	O
with	O
supraevntricular	B-Disease
tcahyarrhythmias	I-Disease
,	O
particularly	O
AV	O
noadl	O
reentry	O
.	O

Veraapmil	O
administratoin	O
to	O
these	O
patietns	O
led	O
to	O
an	O
asymptomtaic	O
icnrease	O
in	O
actiivty	O
of	O
these	O
juncitonal	O
pcaemakers	O
.	O

In	O
ptaients	O
with	O
various	O
cehst	B-Disease
pian	I-Disease
snydromes	O
,	O
verpaamil	O
neither	O
icnreased	O
the	O
frequecny	O
of	O
junctioanl	O
rhyhtms	O
nor	O
spupressed	O
their	O
role	O
as	O
esacpe	O
rhtyhms	O
under	O
physiolgoically	O
appropriate	O
circumstances	O
.	O

Intersrtain	O
varaition	O
in	O
actue	O
txoic	O
respnose	O
to	O
cfafeine	O
among	O
inrbed	O
mcie	O
.	O

Actue	O
txoic	O
doasge	O
-	O
depenednt	O
behavoiral	O
efefcts	O
of	O
caffeine	O
were	O
compaerd	O
in	O
adlut	O
mlaes	O
from	O
seven	O
inberd	O
muose	O
srtains	O
(	O
A	O
/	O
J	O
,	O
BLAB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C75BL	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C75BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
muose	O
srtain	O
,	O
was	O
used	O
to	O
determine	O
bheavioral	O
repsonses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
cafefine	O
dsoes	O
.	O

Five	O
phentoypic	O
charcateristics	O
-	O
-	O
locmootor	O
activtiy	O
,	O
rightnig	O
ability	O
,	O
clnoic	B-Disease
seziure	I-Disease
inductoin	O
,	O
strses	O
-	O
induecd	O
lehtality	O
,	O
daeth	O
without	O
etxernal	O
strses	O
-	O
-	O
were	O
scroed	O
at	O
various	O
caffenie	O
dsoes	O
in	O
durg	O
-	O
niave	O
animlas	O
under	O
empriically	O
optmiized	O
,	O
rigidly	O
consatnt	O
exeprimental	O
conditinos	O
.	O

Mcie	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injecitons	O
of	O
a	O
fiexd	O
voulme	O
/	O
g	O
bdoy	O
weihgt	O
of	O
pyhsiological	O
slaine	O
carrier	O
with	O
or	O
without	O
caffenie	O
in	O
doess	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

Lsos	O
of	O
righitng	O
ability	O
was	O
scoerd	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
psot	O
doisng	O
and	O
at	O
5	O
min	O
interavls	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
aniamls	O
the	O
occurernce	O
of	O
cloinc	B-Disease
seziures	I-Disease
was	O
scroed	O
as	O
to	O
tmie	O
of	O
onset	O
and	O
sevreity	O
for	O
20	O
min	O
after	O
durg	O
adminsitration	O
.	O

When	O
these	O
proceeded	O
to	O
toinc	B-Disease
siezures	I-Disease
,	O
daeth	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Ainmals	O
sruviving	O
for	O
20	O
min	O
were	O
immediately	O
strsesed	O
by	O
a	O
siwm	O
tset	O
in	O
25	O
degrees	O
C	O
waetr	O
,	O
and	O
daeth	O
-	O
producing	O
toinc	B-Disease
seziures	I-Disease
were	O
scroed	O
for	O
2	O
min	O
.	O

In	O
other	O
aniamls	O
locomootr	O
atcivity	O
was	O
meausred	O
15	O
or	O
60	O
min	O
after	O
cafefine	O
adminisrtation	O
.	O

By	O
any	O
single	O
behavoiral	O
criteiron	O
or	O
a	O
comibnation	O
of	O
these	O
crtieria	O
,	O
marked	O
differneces	O
in	O
respnose	O
to	O
txoic	O
caffeine	O
doess	O
were	O
observed	O
between	O
strians	O
.	O

These	O
reuslts	O
indicate	O
that	O
behvaioral	O
toxciity	B-Disease
tesitng	O
of	O
alkylxnathines	O
in	O
a	O
single	O
muose	O
strian	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toixc	O
rseponses	O
of	O
the	O
cnetral	O
nrevous	O
sytsem	O
to	O
this	O
clsas	O
of	O
comopunds	O
are	O
genetcially	O
inlfuenced	O
in	O
mammals	O
.	O

Treamtent	O
of	O
ovairan	B-Disease
canecr	I-Disease
with	O
a	O
combinatoin	O
of	O
cis	O
-	O
platiunm	O
,	O
adrimaycin	O
,	O
cyclophoshpamide	O
and	O
heaxmethylmelamine	O
.	O

During	O
the	O
last	O
2	O
1	O
/	O
2	O
yeras	O
,	O
38	O
ptaients	O
with	O
ovraian	B-Disease
canecr	I-Disease
were	O
treaetd	O
with	O
a	O
combiantion	O
of	O
cipslatinum	O
(	O
CDPD	O
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adraimycin	O
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophoshpamide	O
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hxeamethylmelamine	O
(	O
HMM	O
)	O
,	O
6	O
mg	O
/	O
kg	O
dialy	O
,	O
for	O
14	O
dyas	O
.	O

Each	O
cuorse	O
was	O
repetaed	O
motnhly	O
.	O

2	O
pateints	O
had	O
satge	O
II	O
,	O
14	O
stgae	O
III	O
and	O
22	O
satge	O
IV	O
dsiease	O
.	O

14	O
of	O
the	O
38	O
patinets	O
were	O
previously	O
treaetd	O
with	O
chemothearpy	O
,	O
1	O
with	O
raidation	O
,	O
6	O
with	O
both	O
cheomtherapy	O
and	O
rdaiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
traetment	O
before	O
CDPD	O
combniation	O
.	O

31	O
of	O
the	O
38	O
csaes	O
(	O
81	O
.	O
5	O
%	O
)	O
demonstrated	O
objcetive	O
repsonses	O
lasting	O
for	O
2	O
monhts	O
or	O
more	O
.	O

These	O
repsonses	O
were	O
parital	O
in	O
19	O
and	O
complete	O
in	O
12	O
csaes	O
.	O

Hemtaologic	B-Disease
toxiicty	I-Disease
was	O
mdoerate	O
and	O
with	O
reversible	O
aenmia	B-Disease
developing	O
in	O
71	O
%	O
of	O
ptaients	O
.	O

Gastrointetsinal	O
side	O
effcets	O
from	O
CDPD	O
were	O
universal	O
.	O

HMM	O
gastrointetsinal	B-Disease
txoicity	I-Disease
necessitated	O
discontniuation	O
of	O
the	O
durg	O
in	O
5	O
patinets	O
.	O

Sevree	O
nephrotoixcity	B-Disease
was	O
observed	O
in	O
2	O
patietns	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
durg	O
-	O
related	O
detahs	O
.	O

Nontramuatic	O
dissceting	B-Disease
aneursym	I-Disease
of	O
the	O
basliar	O
artrey	O
.	O

A	O
csae	O
of	O
nontramuatic	O
dissecitng	B-Disease
aneruysm	I-Disease
of	O
the	O
basialr	O
atrery	O
in	O
assoication	O
with	O
hpyertension	B-Disease
,	O
somke	O
,	O
and	O
oarl	O
contraecptives	O
is	O
reported	O
in	O
a	O
yuong	O
fmeale	O
ptaient	O
with	O
a	O
locked	B-Disease
-	I-Disease
in	I-Disease
snydrome	I-Disease
.	O

A	O
mehtod	O
for	O
the	O
meausrement	O
of	O
trmeor	B-Disease
,	O
and	O
a	O
compraison	O
of	O
the	O
effcets	O
of	O
tooclytic	O
btea	O
-	O
mimteics	O
.	O

A	O
metohd	O
permitting	O
measureemnt	O
of	O
figner	O
termor	B-Disease
as	O
a	O
dipslacement	O
-	O
tmie	O
cuvre	O
is	O
described	O
,	O
using	O
a	O
tset	O
ssytem	O
with	O
simple	O
amlpitude	O
calibrtaion	O
.	O

The	O
cooridnates	O
of	O
the	O
inversoin	O
points	O
of	O
the	O
displaecment	O
-	O
tmie	O
curevs	O
were	O
transfrered	O
through	O
grapihcal	O
inupt	O
equipmnet	O
to	O
pucnhed	O
tpae	O
.	O

By	O
means	O
of	O
a	O
compuetr	O
prgoram	O
,	O
peirods	O
and	O
amplitdues	O
of	O
treomr	B-Disease
oscillations	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
evnet	O
freuqency	O
for	O
each	O
calss	O
of	O
peirods	O
and	O
ampiltudes	O
was	O
determined	O
.	O

The	O
atcions	O
of	O
feonterol	O
-	O
hydrobormide	O
,	O
riotdrin	O
-	O
HCl	O
and	O
palcebo	O
given	O
to	O
10	O
helathy	O
subejcts	O
by	O
intraveonus	O
ifnusion	O
in	O
a	O
double	O
-	O
blnid	O
crossvoer	O
sutdy	O
were	O
tesetd	O
by	O
this	O
mtehod	O
.	O

At	O
therapuetic	O
dsoes	O
both	O
substnaces	O
raised	O
the	O
mean	O
treomr	B-Disease
apmlitude	O
to	O
about	O
three	O
times	O
the	O
conrtol	O
lveel	O
.	O

At	O
the	O
same	O
tmie	O
,	O
the	O
mean	O
peirod	O
within	O
each	O
clsas	O
of	O
amlpitudes	O
shrotened	O
by	O
10	O
-	O
-	O
20	O
ms	O
,	O
whereas	O
the	O
mean	O
preiods	O
calculated	O
from	O
all	O
oscillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
fentoerol	O
-	O
hydrobromdie	O
ifnusion	O
,	O
treomr	B-Disease
amplitueds	O
decerased	O
significantly	O
faster	O
than	O
those	O
following	O
ritordin	O
-	O
HCl	O
infsuion	O
.	O

Propytlhiouracil	O
-	O
indcued	O
heaptic	B-Disease
daamge	I-Disease
.	O

Two	O
csaes	O
of	O
propytlhiouracil	O
-	O
indcued	O
lvier	B-Disease
dmaage	I-Disease
have	O
been	O
observed	O
.	O

The	O
first	O
csae	O
is	O
of	O
an	O
aucte	O
tpye	O
of	O
dmaage	O
,	O
proven	O
by	O
rechallegne	O
;	O
the	O
second	O
presents	O
a	O
cliniacl	O
and	O
histoolgic	O
pciture	O
resembling	O
crhonic	B-Disease
atcive	I-Disease
heaptitis	I-Disease
,	O
with	O
spontaneuos	O
reimssion	O
.	O

Studeis	O
on	O
the	O
bardycardia	B-Disease
idnuced	O
by	O
berpidil	O
.	O

Bepriidl	O
,	O
a	O
novel	O
actvie	O
componud	O
for	O
prophylatcic	O
treatemnt	O
of	O
angianl	B-Disease
atatcks	I-Disease
,	O
idnuced	O
pesristent	O
bradycarida	B-Disease
and	O
a	O
non	O
-	O
specific	O
atni	O
-	O
tcahycardial	B-Disease
effcet	O
,	O
the	O
mechanimss	O
of	O
which	O
were	O
invetsigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perfusoin	O
of	O
bepriidl	O
in	O
the	O
lfie	O
-	O
support	O
meduim	O
for	O
isolaetd	O
snio	O
-	O
artial	O
tsisue	O
from	O
rabibt	O
haert	O
,	O
caused	O
a	O
reductoin	O
in	O
actoin	O
potenital	O
(	O
AP	O
)	O
sipke	O
freuqency	O
(	O
recorded	O
by	O
KCl	O
microeelctrodes	O
)	O
starting	O
at	O
doess	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

This	O
effcet	O
was	O
dsoe	O
-	O
deepndent	O
up	O
to	O
cnocentrations	O
of	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
whereupon	O
blockdae	O
of	O
snius	O
actiivty	O
set	O
in	O
.	O

Berpidil	O
at	O
a	O
dsoe	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
inudced	O
a	O
concmoitant	O
reudction	O
in	O
AP	O
ampiltude	O
(	O
falling	O
from	O
71	O
+	O
/	O
-	O
8	O
mV	O
to	O
47	O
+	O
/	O
-	O
6	O
mV	O
)	O
,	O
maxiumm	O
systloic	O
deploarization	O
velcoity	O
(	O
pahse	O
0	O
)	O
which	O
fell	O
from	O
1	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
35	O
V	O
/	O
s	O
to	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
28	O
V	O
/	O
s	O
,	O
together	O
with	O
maixmum	O
disatolic	O
depolraization	O
vleocity	O
(	O
phsae	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/	O
-	O
3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/	O
-	O
5	O
mV	O
/	O
s	O
.	O

In	O
vivo	O
injetcion	O
of	O
bperidil	O
at	O
a	O
dsoe	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i	O
.	O
v	O
.	O
)	O
into	O
6	O
aneasthetized	O
dgos	O
which	O
had	O
undergone	O
ablatoin	O
of	O
all	O
the	O
extrinisc	O
cradiac	O
affeernt	O
nreve	O
supply	O
,	O
together	O
with	O
a	O
bilatearl	O
medlulo	O
-	O
adreanlectomy	O
,	O
caused	O
a	O
marked	O
reudction	O
in	O
herat	O
rtae	O
which	O
fell	O
from	O
98	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
baets	O
/	O
min	O
to	O
76	O
+	O
/	O
-	O
5	O
.	O
3	O
betas	O
/	O
min	O
sustanied	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
bperidil	O
redcues	O
herat	O
rtae	O
by	O
acting	O
directly	O
on	O
the	O
siuns	O
ndoe	O
.	O

This	O
effect	O
,	O
which	O
reuslts	O
in	O
a	O
fltatening	O
of	O
the	O
pahse	O
0	O
and	O
phsae	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
durtaion	O
,	O
may	O
be	O
due	O
to	O
an	O
icnrease	O
in	O
the	O
tmie	O
constatns	O
of	O
slow	O
inwrad	O
ioinc	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
incerased	O
tmie	O
constnat	O
for	O
deactivaiton	O
of	O
the	O
outwrad	O
poatssium	O
current	O
(	O
Ip	O
)	O
.	O

Hepaittis	B-Disease
and	O
rneal	B-Disease
tubluar	I-Disease
aciodsis	I-Disease
after	O
aneshtesia	O
with	O
methoxfylurane	O
.	O

A	O
69	O
-	O
yaer	O
-	O
old	O
man	O
oeprated	O
for	O
aucte	B-Disease
cholecytsitis	I-Disease
under	O
methoxyflurnae	O
anestehsia	O
developed	O
postoepratively	O
a	O
heaptic	B-Disease
inusfficiency	I-Disease
sydnrome	I-Disease
and	O
rneal	B-Disease
tuublar	I-Disease
acidoiss	I-Disease
.	O

Msasive	O
bleeidng	B-Disease
appeared	O
during	O
suregry	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Posotperative	O
evolutoin	O
under	O
supprotive	O
therpay	O
was	O
favouralbe	O
.	O

Comlpete	O
rceovery	O
was	O
confirmed	O
by	O
reepated	O
contrlos	O
performed	O
over	O
a	O
preiod	O
of	O
one	O
yaer	O
after	O
sugrery	O
.	O

Pituitray	O
respnose	O
to	O
ltueinizing	O
homrone	O
-	O
releasing	O
horomne	O
during	O
haloepridol	O
-	O
induecd	O
hyperprolatcinemia	B-Disease
.	O

The	O
effetcs	O
of	O
a	O
6	O
-	O
hour	O
infsuion	O
with	O
halopeirdol	O
on	O
seurm	O
prloactin	O
and	O
luteiniizng	O
horomne	O
(	O
LH	O
)	O
lveels	O
was	O
studied	O
in	O
a	O
gorup	O
of	O
mlae	O
subjetcs	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infusinos	O
,	O
a	O
sutdy	O
of	O
the	O
pitutiary	O
resopnses	O
to	O
LH	O
-	O
releasing	O
hormnoe	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O

Cnotrol	O
ptaients	O
received	O
ifnusions	O
of	O
0	O
.	O
9	O
%	O
NCal	O
soltuion	O
.	O

During	O
the	O
cuorse	O
of	O
haloperdiol	O
infuisons	O
,	O
significant	O
hyperprloactinemia	B-Disease
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pitiutary	O
respnose	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compaerd	O
with	O
respnoses	O
of	O
cnotrol	O
subjetcs	O
.	O

Antirifapmicin	O
antiobdies	O
in	O
aucte	O
rfiampicin	O
-	O
associated	O
rneal	B-Disease
fialure	I-Disease
.	O

5	O
patinets	O
with	O
aucte	B-Disease
reanl	I-Disease
fialure	I-Disease
(	O
3	O
with	O
thromboepnia	B-Disease
and	O
hmeolysis	B-Disease
)	O
idnuced	O
by	O
the	O
reintrodutcion	O
of	O
rifmapicin	O
are	O
described	O
.	O

No	O
corrleation	O
was	O
found	O
between	O
the	O
sveerity	O
of	O
clincial	O
maniefstations	O
and	O
the	O
total	O
dsoe	O
taken	O
by	O
the	O
pateints	O
.	O

In	O
all	O
but	O
1	O
patinet	O
,	O
antirifamipcin	O
anitbodies	O
were	O
detecetd	O
.	O

Antibdoies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
clsas	O
were	O
detetced	O
in	O
all	O
3	O
patietns	O
with	O
hematloogical	B-Disease
diosrders	I-Disease
.	O

The	O
pattren	O
of	O
non	O
-	O
specific	O
aucte	B-Disease
tuublar	I-Disease
necrsois	I-Disease
found	O
in	O
the	O
2	O
boipsied	O
pateints	O
,	O
indistinugishable	O
from	O
that	O
of	O
ischeimc	O
orgiin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascualr	O
-	O
mediated	O
daamge	O
.	O

In	O
3	O
patietns	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoalelrgic	O
mechnaism	O
is	O
discussed	O
.	O

Cradiovascular	O
efefcts	O
of	O
hypotenison	B-Disease
indcued	O
by	O
adneosine	O
triphospahte	O
and	O
soidum	O
nitrorpusside	O
on	O
dgos	O
with	O
deneravted	O
heatrs	O
.	O

Adeonsine	O
trpihosphate	O
(	O
ATP	O
)	O
and	O
soidum	O
nirtoprusside	O
(	O
SNP	O
)	O
are	O
adminsitered	O
to	O
patinets	O
to	O
inudce	O
and	O
conrtol	O
hypotensoin	B-Disease
during	O
aensthesia	O
.	O

SNP	O
is	O
authorized	O
for	O
cliniacl	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	O
is	O
clniically	O
used	O
in	O
other	O
counrties	O
such	O
as	O
Jaapn	O
.	O

We	O
invsetigated	O
how	O
these	O
two	O
durgs	O
act	O
on	O
the	O
cardiovascualr	O
sytsems	O
of	O
20	O
dgos	O
whose	O
herats	O
had	O
been	O
dneervated	O
by	O
a	O
proecdure	O
we	O
had	O
devised	O
.	O

ATP	O
(	O
10	O
dgos	O
)	O
or	O
SNP	O
(	O
10	O
dgos	O
)	O
was	O
administreed	O
to	O
redcue	O
mean	O
atrerial	O
prsesure	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
cnotrol	O
.	O

Before	O
,	O
during	O
and	O
after	O
induecd	O
hyoptension	B-Disease
,	O
we	O
meausred	O
major	O
cradiovascular	O
paramteers	O
.	O

Hyoptension	B-Disease
induecd	O
by	O
ATP	O
was	O
accompanied	O
by	O
significant	O
dcereases	O
in	O
mean	O
pumlonary	O
atrerial	O
prsesure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
cnetral	O
veonus	O
presusre	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lfet	O
ventricualr	O
end	O
-	O
daistolic	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
perihperal	O
resitsance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rtae	O
pressure	O
proudct	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
bdoy	O
oxyegn	O
cosnumption	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
herat	O
rtae	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
all	O
these	O
varialbes	O
returned	O
nomral	O
within	O
30	O
min	O
after	O
ATP	O
was	O
stopped	O
.	O

Cadriac	O
outupt	O
did	O
not	O
change	O
.	O

During	O
hpyotension	B-Disease
produced	O
by	O
SNP	O
similar	O
decerases	O
were	O
observed	O
in	O
mean	O
pumlonary	O
atrerial	O
perssure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
cnetral	O
veonus	O
presusre	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lfet	O
ventricluar	O
end	O
-	O
diastoilc	O
pressrue	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
total	O
peirpheral	O
resistacne	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rtae	O
prsesure	O
proudct	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
oxgyen	O
conetnt	O
difference	O
between	O
artreial	O
and	O
mixed	O
veonus	O
bolod	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
while	O
herat	O
rtae	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
cardaic	O
ouptut	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
incresaed	O
.	O

Recvoeries	O
of	O
herat	O
rtae	O
and	O
lfet	O
ventircular	O
end	O
-	O
disatolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	O
had	O
been	O
stopped	O
.	O

Both	O
ATP	O
and	O
SNP	O
should	O
act	O
on	O
the	O
pacemkaer	O
tisuse	O
of	O
the	O
haert	O
.	O

Comparatvie	O
stduy	O
:	O
Ednografine	O
(	O
diatrzioate	O
)	O
,	O
Vsaurix	O
polyviodne	O
(	O
acetrizotae	O
)	O
,	O
Diemr	O
-	O
X	O
(	O
icoarmate	O
)	O
and	O
Hexbarix	O
(	O
ioxalgate	O
)	O
in	O
hysterosalpingorgaphy	O
.	O

Side	O
effetcs	O
of	O
hysetrosalpingography	O
with	O
Dmier	O
-	O
X	O
,	O
Heaxbrix	O
,	O
Vausrix	O
poylvidone	O
and	O
Endogrfaine	O
in	O
142	O
cosnecutive	O
patietns	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tetsed	O
mdeia	O
were	O
evalutaed	O
from	O
repleis	O
to	O
posatl	O
questionnaiers	O
.	O

The	O
Dmier	O
-	O
X	O
gorup	O
had	O
a	O
higehr	O
inicdence	O
of	O
nasuea	B-Disease
and	O
dizzienss	B-Disease
.	O

The	O
Ednografine	O
gruop	O
had	O
a	O
higehr	O
incdience	O
of	O
abdomnial	B-Disease
pian	I-Disease
.	O

These	O
differenecs	O
occur	O
especially	O
in	O
the	O
age	O
gorups	O
under	O
30	O
yaers	O
.	O

Hexbarix	O
and	O
Vasruix	O
polyivdone	O
are	O
considered	O
the	O
best	O
contrast	O
mdeia	O
for	O
hysteorsalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxiicty	B-Disease
Hexbarix	O
should	O
be	O
preferred	O
.	O

Psot	O
-	O
suxaemthonium	O
panis	B-Disease
in	O
Ngierian	O
surgiacl	O
paitents	O
.	O

Contrary	O
to	O
an	O
earlier	O
reoprt	O
by	O
Cooxn	O
,	O
scloine	O
pian	B-Disease
occurs	O
in	O
Afrcian	O
ngeroes	O
.	O

Its	O
incidecne	O
was	O
determined	O
in	O
a	O
prospecitve	O
sutdy	O
involving	O
a	O
total	O
of	O
100	O
Ngierian	O
patinets	O
(	O
50	O
out	O
-	O
paitents	O
and	O
50	O
in	O
-	O
paitents	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out	O
-	O
patinets	O
developed	O
socline	O
pian	B-Disease
as	O
cmopared	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
paitents	O
.	O

The	O
aoblition	O
of	O
mucsle	O
fasciculaitons	B-Disease
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
dsoe	O
of	O
Fazadniium	O
)	O
did	O
not	O
ifnluence	O
the	O
occurrence	O
of	O
scloine	O
pian	B-Disease
.	O

Neither	O
the	O
tpye	O
of	O
indcution	O
agnet	O
(	O
Alhtesin	O
or	O
Tihopentone	O
)	O
nor	O
the	O
slat	O
prpearation	O
of	O
suxmaethonium	O
used	O
(	O
clhoride	O
or	O
broimde	O
)	O
,	O
affceted	O
the	O
inciednce	O
of	O
scolnie	O
pian	B-Disease
.	O

Invasvie	O
carcinmoa	B-Disease
of	I-Disease
the	I-Disease
reanl	I-Disease
pevlis	I-Disease
following	O
ccylophosphamide	O
therpay	O
for	O
nnomalignant	O
dsiease	O
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
rgiht	O
hydroureteronephrsois	B-Disease
due	O
to	O
ureteorvesical	O
junciton	O
obstrutcion	O
had	O
gorss	O
hmeaturia	B-Disease
after	O
being	O
treaetd	O
for	O
five	O
yaers	O
wtih	O
cyclpohosphamide	O
for	O
cerberal	B-Disease
vasculiits	I-Disease
.	O

A	O
rgiht	O
nephrourteerectomy	O
was	O
required	O
for	O
conrtol	O
of	O
bleeding	B-Disease
.	O

The	O
pathloogy	O
spceimen	O
contained	O
cliniaclly	O
occlut	O
invsaive	O
cacrinoma	B-Disease
of	I-Disease
the	I-Disease
rneal	I-Disease
pevlis	I-Disease
.	O

Although	O
the	O
ability	O
of	O
cycolphosphamide	O
to	O
cause	O
hemorrhagic	B-Disease
csytitis	I-Disease
and	O
urnie	O
cyotlogic	O
abnromalities	O
indistinguishalbe	O
from	O
high	O
garde	O
carcinmoa	B-Disease
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
cracinoma	B-Disease
of	I-Disease
the	I-Disease
urniary	I-Disease
tarct	I-Disease
.	O

Twenty	O
carcionmas	B-Disease
of	I-Disease
the	I-Disease
uirnary	I-Disease
bldader	I-Disease
and	O
one	O
carcionma	B-Disease
of	I-Disease
the	I-Disease
protsate	I-Disease
have	O
been	O
reported	O
in	O
associtaion	O
with	O
its	O
use	O
.	O

The	O
present	O
csae	O
is	O
the	O
first	O
carcinmoa	B-Disease
of	I-Disease
the	I-Disease
rneal	I-Disease
pevlis	I-Disease
reported	O
in	O
associatoin	O
with	O
cyclophosphaimde	O
treatmnet	O
.	O

It	O
is	O
the	O
third	O
uirnary	B-Disease
trcat	I-Disease
cnacer	I-Disease
reported	O
in	O
asscoiation	O
with	O
cyclophosphmaide	O
treatmnet	O
for	O
nonmalginant	O
dsiease	O
.	O

The	O
associtaion	O
of	O
the	O
tuomr	B-Disease
with	O
preexisting	O
hyrdoureteronephrosis	B-Disease
suggests	O
that	O
stsais	O
porlonged	O
and	O
intensiifed	O
exposrue	O
of	O
upper	O
urniary	O
trcat	O
epitheilum	O
to	O
cyclpohosphamide	O
.	O

Patietns	O
who	O
are	O
cnadidates	O
for	O
long	O
-	O
term	O
cyclophosphaimde	O
treamtent	O
should	O
be	O
routinely	O
evalutaed	O
for	O
obstructvie	B-Disease
uorpathy	I-Disease
.	O

Meidal	O
chanegs	O
in	O
atrerial	O
spsam	B-Disease
induecd	O
by	O
L	O
-	O
noerpinephrine	O
.	O

In	O
noraml	O
rtas	O
,	O
the	O
meida	O
of	O
small	O
artereis	O
(	O
0	O
.	O
4	O
-	O
-	O
0	O
.	O
2	O
mm	O
in	O
diaemter	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intracellualr	O
vaculoes	O
,	O
identfiied	O
ultrasrtucturally	O
as	O
hernitaions	O
of	O
one	O
smooth	O
mucsle	O
clel	O
into	O
another	O
.	O

The	O
hyptohesis	O
that	O
inetnse	O
vaosconstriction	O
would	O
inrcease	O
the	O
number	O
of	O
such	O
vaucoles	O
has	O
been	O
tseted	O
.	O

In	O
the	O
mdeia	O
of	O
the	O
saphenuos	O
atrery	O
and	O
its	O
ditsal	O
brnach	O
,	O
vascoonstriction	O
induecd	O
by	O
L	O
-	O
norepienphrine	O
produced	O
many	O
clel	O
-	O
to	O
-	O
clel	O
hrenias	B-Disease
within	O
15	O
miuntes	O
.	O

At	O
1	O
day	O
their	O
number	O
was	O
reduecd	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
dyas	O
the	O
vsesel	O
was	O
almost	O
restroed	O
to	O
nromal	O
.	O

Trpile	O
stimultaion	O
over	O
1	O
day	O
induecd	O
more	O
seevre	O
chanegs	O
in	O
the	O
mdeia	O
.	O

These	O
finidngs	O
suggest	O
that	O
smotoh	O
msucle	O
cells	O
are	O
susceptbile	O
to	O
damgae	O
in	O
the	O
coruse	O
of	O
their	O
specific	O
fucntion	O
.	O

The	O
exeprimental	O
dtaa	O
are	O
discussed	O
in	O
relation	O
to	O
mdeial	O
chagnes	O
observed	O
in	O
other	O
instanecs	O
of	O
aretrial	O
spsam	B-Disease
.	O

Endothelail	O
cahnges	O
that	O
developed	O
in	O
the	O
same	O
experimenatl	O
moedl	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

Bliateral	O
reitnal	B-Disease
aretry	I-Disease
and	I-Disease
choriocpaillaris	I-Disease
oclcusion	I-Disease
following	O
the	O
injetcion	O
of	O
long	O
-	O
acting	O
corticsoteroid	O
suspensoins	O
in	O
combinatoin	O
with	O
other	O
drgus	O
:	O
I	O
.	O

Cilnical	O
stuides	O
.	O

Two	O
well	O
-	O
documneted	O
csaes	O
of	O
bilatreal	O
rteinal	B-Disease
atrery	I-Disease
and	I-Disease
chorioacpillaris	I-Disease
occlusinos	I-Disease
with	O
blinndess	B-Disease
following	O
haed	O
and	O
ncek	O
sfot	O
-	O
tissue	O
injcetion	O
with	O
methlyprednisolone	O
aectate	O
in	O
combniation	O
with	O
lidcoaine	O
,	O
epineprhine	O
,	O
or	O
peniicllin	O
are	O
reported	O
.	O

One	O
csae	O
had	O
only	O
a	O
unliateral	O
injectoin	O
.	O

The	O
actue	O
observaitons	O
included	O
hzay	O
snesorium	O
,	O
superior	O
gzae	O
plasy	B-Disease
,	O
puplilary	B-Disease
abnomralities	I-Disease
,	O
and	O
conjucntival	O
hemorrahges	B-Disease
with	O
edmea	B-Disease
.	O

Follow	O
-	O
up	O
chnages	O
showed	O
marked	O
viusal	B-Disease
lsos	I-Disease
,	O
constricetd	O
vsiual	O
feilds	O
,	O
otpic	O
nreve	O
palolr	O
,	O
vascualr	O
atetnuation	O
,	O
and	O
choiroretinal	B-Disease
atorphy	I-Disease
.	O

The	O
literautre	O
is	O
revieewd	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormlaities	O
of	O
the	O
puipl	O
and	O
visaul	O
-	O
evoekd	O
potnetial	O
in	O
quniine	O
abmlyopia	B-Disease
.	O

Total	O
blindnses	B-Disease
with	O
a	O
trnasient	O
tnoic	B-Disease
pupillary	I-Disease
rseponse	O
,	O
denervtaion	O
supersenstiivity	O
,	O
and	O
abnomral	O
visaul	O
-	O
evoekd	O
potentilas	O
developed	O
in	O
a	O
54	O
-	O
yaer	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
quiinne	O
sulftae	O
for	O
leg	B-Disease
crmaps	I-Disease
.	O

He	O
later	O
recoevred	O
nromal	O
visaul	O
acutiy	O
.	O

A	O
tarnsient	O
toinc	B-Disease
pupillray	I-Disease
respnose	O
,	O
denevration	O
supesrensitivity	O
,	O
and	O
abnoraml	O
visaul	O
-	O
evoekd	O
potentilas	O
in	O
quinnie	O
txoicity	B-Disease
,	O
to	O
our	O
knoweldge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxamethonuim	O
-	O
inudced	O
jaw	B-Disease
sitffness	I-Disease
and	O
mylagia	B-Disease
associated	O
with	O
atypcial	O
cohlinesterase	O
:	O
csae	O
rpeort	O
.	O

An	O
11	O
-	O
yaer	O
-	O
old	O
boy	O
was	O
given	O
hlaothane	O
,	O
nitruos	O
oxdie	O
and	O
oxyegn	O
,	O
pacnuronium	O
0	O
.	O
4	O
mg	O
and	O
suxamehtonium	O
100	O
mg	O
for	O
inductoin	O
of	O
aneasthesia	O
.	O

In	O
respnose	O
to	O
this	O
a	O
marked	O
jaw	B-Disease
sitffness	I-Disease
occurred	O
which	O
lasted	O
for	O
two	O
minuets	O
and	O
the	O
anaetshesia	O
were	O
terimnated	O
.	O

Four	O
hours	O
of	O
anpoea	B-Disease
ensued	O
and	O
he	O
suffered	O
genearlized	O
sveere	O
myaliga	B-Disease
lasting	O
for	O
one	O
week	O
.	O

He	O
was	O
found	O
to	O
have	O
aytpical	O
plamsa	O
cholinetserase	O
with	O
a	O
dbiucaine	O
number	O
of	O
12	O
,	O
indicating	O
homozygcoity	O
.	O

This	O
was	O
verified	O
by	O
sutdy	O
of	O
the	O
famliy	O
.	O

The	O
csae	O
shows	O
that	O
proolnged	B-Disease
jaw	I-Disease
rigiidty	I-Disease
and	O
mylagia	B-Disease
may	O
occur	O
after	O
suxamethnoium	O
in	O
patinets	O
with	O
atyipcal	O
cholinseterase	O
despite	O
pretretament	O
with	O
pancuroinum	O
.	O

Indomtehacin	O
-	O
indcued	O
hyperkalmeia	B-Disease
in	O
three	O
pateints	O
with	O
gotuy	B-Disease
arthirtis	I-Disease
.	O

We	O
describe	O
three	O
patietns	O
in	O
whom	O
sveere	O
,	O
lfie	O
-	O
threatening	O
hyeprkalemia	B-Disease
and	O
rneal	B-Disease
inusfficiency	I-Disease
developed	O
after	O
treatmnet	O
of	O
actue	O
gotuy	B-Disease
arhtritis	I-Disease
with	O
indomethcain	O
.	O

This	O
complicaiton	O
may	O
result	O
from	O
an	O
inhbiition	O
of	O
prostagladnin	O
snythesis	O
and	O
consequent	O
hyporenineimc	B-Disease
hypoaidosteroinsm	I-Disease
.	O

Careful	O
attentoin	O
to	O
reanl	O
fnuction	O
and	O
potasisum	O
balacne	O
in	O
paitents	O
receiving	O
indoemthacin	O
or	O
other	O
nnosteroidal	O
atni	O
-	O
inflammtaory	O
agetns	O
,	O
particularly	O
in	O
those	O
pateints	O
with	O
diabeets	B-Disease
meliltus	I-Disease
or	O
preexisting	O
reanl	B-Disease
disesae	I-Disease
,	O
will	O
help	O
pervent	O
this	O
potentially	O
serious	O
compliaction	O
.	O

Etomiadte	O
:	O
a	O
foreshoretned	O
cliniacl	O
tiral	O
.	O

A	O
cliniacl	O
eavluation	O
of	O
etomiadte	O
for	O
outptaient	O
cysotscopy	O
was	O
embarked	O
upon	O
.	O

Unpremedciated	O
ptaients	O
were	O
given	O
fetnanyl	O
1	O
micorgram	O
/	O
kg	O
followed	O
by	O
etomdiate	O
0	O
.	O
3	O
mg	O
/	O
kg	O
.	O

Anasethesia	O
was	O
maintained	O
with	O
intermittnet	O
etoimdate	O
in	O
2	O
-	O
4	O
mg	O
doess	O
.	O

Patinets	O
were	O
intervieewd	O
pesronally	O
later	O
the	O
same	O
day	O
,	O
and	O
by	O
qusetionnaire	O
three	O
to	O
four	O
wekes	O
later	O
.	O

The	O
tiral	O
was	O
disocntinued	O
after	O
20	O
caess	O
because	O
of	O
an	O
unacceptable	O
icnidence	O
of	O
side	O
efefcts	O
.	O

Venuos	O
pian	B-Disease
occurred	O
in	O
68	O
%	O
of	O
patietns	O
and	O
50	O
%	O
had	O
rendess	O
,	O
pian	B-Disease
or	O
swelilng	B-Disease
related	O
to	O
the	O
injectoin	O
stie	O
,	O
in	O
some	O
caess	O
lasting	O
up	O
to	O
three	O
wekes	O
after	O
anaestehsia	O
.	O

Skleetal	O
mvoements	O
occurred	O
in	O
50	O
%	O
of	O
paitents	O
;	O
30	O
%	O
experienced	O
respirtaory	B-Disease
upset	I-Disease
,	O
one	O
sufficiently	O
sveere	O
to	O
necessitate	O
abandoning	O
the	O
tcehnique	O
.	O

Nasuea	B-Disease
and	O
vomiitng	B-Disease
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emeregnce	O
psychoess	B-Disease
.	O

Levdoopa	O
-	O
induecd	O
dyskiensias	B-Disease
are	O
ipmroved	O
by	O
fuloxetine	O
.	O

We	O
evaluaetd	O
the	O
sveerity	O
of	O
mtoor	B-Disease
disbaility	I-Disease
and	O
dyskniesias	B-Disease
in	O
seven	O
lveodopa	O
-	O
respnosive	O
ptaients	O
with	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
dsiease	I-Disease
after	O
an	O
aucte	O
challenge	O
with	O
the	O
mixed	O
dpoamine	O
agnoist	O
,	O
aopmorphine	O
,	O
before	O
and	O
after	O
the	O
administratoin	O
of	O
flouxetine	O
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/	O
-	O
1	O
dyas	O
.	O

After	O
flouxetine	O
tretament	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
imporvement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apoomrphine	O
-	O
indcued	O
dyskinesais	B-Disease
without	O
modifciation	O
of	O
parknisonian	B-Disease
mtoor	B-Disease
dsiability	I-Disease
.	O

The	O
dyskiensias	B-Disease
were	O
redcued	O
predominantly	O
in	O
the	O
loewr	O
libms	O
during	O
the	O
onset	O
and	O
disappearnace	O
of	O
dsytonic	B-Disease
dyskineisas	I-Disease
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dsoe	O
dysiknesias	B-Disease
)	O
and	O
in	O
the	O
upepr	O
libms	O
during	O
cohreic	B-Disease
mid	I-Disease
-	I-Disease
dsoe	I-Disease
dyskniesias	I-Disease
.	O

The	O
reuslts	O
suggest	O
that	O
incraesed	O
brian	O
serootninergic	O
transmisison	O
with	O
fluoxteine	O
may	O
redcue	O
lveodopa	O
-	O
or	O
doapmine	O
aognist	O
-	O
induecd	O
dyskinesais	B-Disease
without	O
aggrvaating	O
parkinsoinan	B-Disease
mootr	B-Disease
diasbility	I-Disease
.	O

A	O
large	O
popluation	O
-	O
based	O
follow	O
-	O
up	O
sutdy	O
of	O
trimehtoprim	O
-	O
sulfaemthoxazole	O
,	O
tirmethoprim	O
,	O
and	O
cpehalexin	O
for	O
uncommon	O
serious	O
durg	B-Disease
toxciity	I-Disease
.	O

We	O
conducted	O
a	O
pouplation	O
-	O
based	O
45	O
-	O
day	O
follow	O
-	O
up	O
sutdy	O
of	O
232	O
,	O
390	O
pepole	O
who	O
were	O
prsecribed	O
trimetohprim	O
-	O
sulafmethoxazole	O
(	O
TMP	O
-	O
SMZ	O
)	O
,	O
266	O
,	O
951	O
perscribed	O
trimetohprim	O
alone	O
,	O
and	O
196	O
,	O
397	O
prescirbed	O
cpehalexin	O
,	O
to	O
estmiate	O
the	O
rsik	O
of	O
serious	O
lievr	B-Disease
,	I-Disease
bolod	I-Disease
,	I-Disease
sikn	I-Disease
,	I-Disease
and	I-Disease
rneal	I-Disease
disodrers	I-Disease
resulting	O
in	O
refreral	O
or	O
hospitalizaiton	O
associated	O
with	O
these	O
durgs	O
.	O

The	O
reuslts	O
were	O
based	O
on	O
infomration	O
recorded	O
on	O
ofifce	O
comptuers	O
by	O
selected	O
general	O
prcatitioners	O
in	O
the	O
Uinted	O
Knigdom	O
,	O
together	O
with	O
a	O
rveiew	O
of	O
clincial	O
recrods	O
.	O

The	O
rsik	O
of	O
cilnically	O
important	O
idioptahic	O
lievr	B-Disease
dsiease	I-Disease
was	O
similar	O
for	O
persnos	O
prescirbed	O
TMP	O
-	O
SMZ	O
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
prescrbied	O
trimethorpim	O
alone	O
(	O
3	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O

The	O
rsik	O
for	O
those	O
prescrbied	O
cephlaexin	O
was	O
somewhat	O
lwoer	O
(	O
2	O
.	O
0	O
/	O
100	O
,	O
000	O
)	O
.	O

Only	O
five	O
paitents	O
experienced	O
blood	O
diosrders	O
,	O
one	O
of	O
whom	O
was	O
epxosed	O
to	O
TMP	O
-	O
SMZ	O
;	O
of	O
seven	O
with	O
eyrthema	B-Disease
multfiorme	I-Disease
and	O
Stveens	B-Disease
-	I-Disease
Johsnon	I-Disease
sydnrome	I-Disease
,	O
four	O
were	O
exopsed	O
to	O
TMP	O
-	O
SMZ	O
.	O

The	O
one	O
csae	O
of	O
txoic	B-Disease
epidremal	I-Disease
nercolysis	I-Disease
occurred	O
in	O
a	O
paitent	O
who	O
took	O
cephaleixn	O
.	O

Finally	O
,	O
only	O
five	O
caess	O
of	O
aucte	O
parenhcymal	O
reanl	B-Disease
dsiease	I-Disease
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
stduy	O
durg	O
.	O

We	O
conclude	O
that	O
the	O
rsik	O
of	O
the	O
serious	O
disaeses	O
studied	O
is	O
small	O
for	O
the	O
three	O
agetns	O
,	O
and	O
compraes	O
reasonably	O
with	O
the	O
rsik	O
for	O
many	O
other	O
antiibotics	O
.	O

Clincial	O
sfaety	O
of	O
lidoacine	O
in	O
patietns	O
with	O
coacine	O
-	O
associated	O
myoacrdial	B-Disease
infraction	I-Disease
.	O

SUTDY	O
OBJCETIVE	O
:	O
To	O
evalaute	O
the	O
saftey	O
of	O
ldiocaine	O
in	O
the	O
setting	O
of	O
cociane	O
-	O
idnuced	O
myoacrdial	B-Disease
infarciton	I-Disease
(	O
MI	B-Disease
)	O
.	O

DESIGN	O
:	O
A	O
retrospcetive	O
,	O
mutlicenter	O
sutdy	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
uinversity	O
,	O
universtiy	O
-	O
affiliated	O
,	O
or	O
cmomunity	O
hosiptals	O
during	O
a	O
6	O
-	O
yaer	O
peroid	O
(	O
total	O
of	O
117	O
cumulaitve	O
hsopital	O
-	O
yeras	O
)	O
.	O

PARITCIPANTS	O
:	O
Patietns	O
with	O
coacine	O
-	O
associated	O
MI	B-Disease
who	O
received	O
lidocanie	O
in	O
the	O
emergnecy	O
departemnt	O
.	O

REUSLTS	O
:	O
Of	O
29	O
patinets	O
who	O
received	O
lidoacine	O
in	O
the	O
setting	O
of	O
ccoaine	O
-	O
associated	O
MI	B-Disease
,	O
no	O
ptaient	O
deid	O
;	O
exhibited	O
bradydysrhyhtmias	B-Disease
,	O
ventircular	B-Disease
tachyacrdia	I-Disease
,	O
or	O
vetnricular	B-Disease
fibrilaltion	I-Disease
;	O
or	O
experienced	O
siezures	B-Disease
after	O
administratoin	O
of	O
lidociane	O
(	O
95	O
%	O
cnofidence	O
itnerval	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUSOIN	O
:	O
Despite	O
theroetical	O
cocnerns	O
that	O
liodcaine	O
may	O
enhnace	O
ccoaine	O
toixcity	B-Disease
,	O
the	O
use	O
of	O
lidcoaine	O
in	O
paitents	O
with	O
cociane	O
-	O
associated	O
MI	B-Disease
was	O
not	O
associated	O
with	O
significant	O
cardoivascular	B-Disease
or	I-Disease
cenrtal	I-Disease
nrevous	I-Disease
ssytem	I-Disease
toxciity	I-Disease
.	O

Epxerimental	O
progrsesive	O
muscluar	B-Disease
dystrpohy	I-Disease
and	O
its	O
teratment	O
with	O
high	O
doess	O
anbaolizing	O
agnets	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
ptahogenetic	O
interpretaiton	O
of	O
progresisve	O
muscualr	B-Disease
dystrpohy	I-Disease
in	O
man	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
expermiental	O
field	O
;	O
a	O
recessvie	O
auotsomic	O
form	O
found	O
in	O
the	O
mosue	O
seems	O
to	O
bear	O
the	O
closest	O
resmeblance	O
to	O
the	O
huamn	O
form	O
from	O
the	O
geneitc	O
point	O
of	O
view	O
.	O

Myoapthy	B-Disease
due	O
to	O
lcak	O
of	O
vitaimn	O
E	O
and	O
myoapthy	B-Disease
indcued	O
by	O
certain	O
viurses	O
have	O
much	O
in	O
common	O
anatomiaclly	O
and	O
ptahologically	O
with	O
the	O
huamn	O
form	O
.	O

The	O
autohrs	O
induecd	O
myodystrpohy	B-Disease
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
deit	O
lacking	O
in	O
viatmin	O
E	O
.	O

The	O
pharmaoclogical	O
chaarcteristics	O
of	O
viatmin	O
E	O
and	O
the	O
dgeenerative	O
chanegs	O
brought	O
about	O
by	O
its	O
deficinecy	O
,	O
especially	O
in	O
the	O
mucsles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histologcial	O
characteristcis	O
of	O
myopatihc	B-Disease
rat	O
mucsle	O
inudced	O
experiemntally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
hmuan	O
myopahty	B-Disease
as	O
confirmed	O
during	O
boipsies	O
performed	O
at	O
the	O
Otrhopaedic	O
Tramuatological	O
Cnetre	O
,	O
Florecne	O
.	O

The	O
encouraging	O
resutls	O
obtained	O
in	O
various	O
authoratative	O
depatrments	O
in	O
myoapthic	B-Disease
pateints	O
by	O
using	O
anaboilzing	O
steorids	O
have	O
encouraged	O
the	O
autohrs	O
to	O
inevstigate	O
the	O
beneficial	O
effcets	O
of	O
one	O
anbaolizing	O
agnet	O
(	O
Dinaabol	O
,	O
CBIA	O
)	O
at	O
high	O
doess	O
in	O
rtas	O
rendered	O
myoptahic	B-Disease
by	O
a	O
deit	O
deficeint	O
in	O
vitaimn	O
E	O
.	O

In	O
this	O
way	O
they	O
obtained	O
appreciable	O
cahnges	O
in	O
bdoy	O
wegiht	O
(	O
incerased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
dyas	O
at	O
a	O
dsoe	O
of	O
5	O
mg	O
per	O
day	O
of	O
anaboliznig	O
agnet	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
hsitological	O
chagnes	O
due	O
to	O
"	O
regneerative	O
"	O
cahnges	O
in	O
the	O
mucsle	O
tisuse	O
,	O
which	O
however	O
maintained	O
its	O
myopahtic	B-Disease
characterisitcs	O
in	O
the	O
cotnrol	O
aniamls	O
that	O
were	O
not	O
terated	O
with	O
the	O
anaboilzing	O
agnet	O
.	O

The	O
autohrs	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efifcacy	O
of	O
the	O
anabloizing	O
sterodis	O
in	O
experimenatl	O
myopatihc	B-Disease
dsiease	I-Disease
,	O
but	O
they	O
have	O
rseervations	O
as	O
to	O
the	O
tranfser	O
of	O
the	O
reuslts	O
into	O
the	O
hmuan	O
field	O
,	O
where	O
high	O
dosgae	O
cannot	O
be	O
carried	O
out	O
cotninuously	O
because	O
of	O
the	O
efefcts	O
of	O
the	O
durg	O
on	O
viriltiy	O
;	O
because	O
the	O
tissue	O
ijnury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
satge	O
vis	O
-	O
a	O
-	O
vis	O
the	O
"	O
regenreation	O
"	O
of	O
the	O
mucsle	O
tisuse	O
;	O
and	O
finally	O
because	O
the	O
dystropihc	O
injuirous	O
agnet	O
is	O
certainly	O
not	O
the	O
lcak	O
of	O
vitmain	O
E	O
but	O
something	O
as	O
yet	O
unknown	O
.	O

Pcalitaxel	O
3	O
-	O
hour	O
infuison	O
given	O
alone	O
and	O
comibned	O
with	O
carbpolatin	O
:	O
preliminary	O
rseults	O
of	O
dsoe	O
-	O
escalaiton	O
trilas	O
.	O

Paclitaexl	O
(	O
Taoxl	O
;	O
Britsol	O
-	O
Meyrs	O
Sqiubb	O
Compnay	O
,	O
Princeotn	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
ifnusion	O
was	O
cmobined	O
with	O
carboplaitn	O
in	O
a	O
phsae	O
I	O
/	O
II	O
stduy	O
directed	O
to	O
patietns	O
with	O
non	B-Disease
-	I-Disease
small	I-Disease
clel	I-Disease
lnug	I-Disease
canecr	I-Disease
.	O

Cabroplatin	O
was	O
given	O
at	O
a	O
fxied	O
taregt	O
aera	O
under	O
the	O
conecntration	O
-	O
tmie	O
cuvre	O
of	O
6	O
.	O
0	O
by	O
the	O
Calvret	O
fromula	O
,	O
whereas	O
paclitaexl	O
was	O
escaltaed	O
in	O
paitent	O
choorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dsoe	O
leevl	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
lveel	O
was	O
expanded	O
for	O
the	O
phsae	O
II	O
stduy	O
since	O
the	O
highest	O
leevl	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modifciation	O
because	O
of	O
nonhemaotlogic	O
toxiicties	B-Disease
(	O
artharlgia	B-Disease
and	O
snesory	B-Disease
neuorpathy	I-Disease
)	O
.	O

Tehrapeutic	O
efefcts	O
were	O
noted	O
at	O
all	O
dsoe	O
leevls	O
,	O
with	O
objcetive	O
rseponses	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
patrial	O
rgeressions	O
)	O
of	O
41	O
previously	O
untreaetd	O
patietns	O
.	O

Toxiciites	B-Disease
were	O
compraed	O
with	O
a	O
choort	O
of	O
patinets	O
in	O
a	O
phsae	O
I	O
trail	O
of	O
pacltiaxel	O
alone	O
at	O
idenitcal	O
dsoe	O
leevls	O
.	O

Carobplatin	O
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematoloigc	B-Disease
toxiciteis	I-Disease
observed	O
,	O
and	O
the	O
pacliatxel	O
/	O
carbopaltin	O
combiantion	O
could	O
be	O
doesd	O
every	O
3	O
wekes	O
.	O

The	O
dsoe	O
-	O
deepndent	O
efefct	O
of	O
misoporstol	O
on	O
indometahcin	O
-	O
inudced	O
rneal	B-Disease
dysfuntcion	I-Disease
in	O
well	O
compensated	O
cirhrosis	B-Disease
.	O

Misporostol	O
(	O
200	O
microgrmas	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
inodmethacin	O
-	O
idnuced	O
rneal	B-Disease
dysfucntion	I-Disease
in	O
well	O
compensated	O
cirrhotic	B-Disease
pateints	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
if	O
the	O
porphylactic	O
value	O
of	O
msioprostol	O
was	O
dsoe	O
-	O
dependnet	O
.	O

Paraemters	O
of	O
rneal	O
hemodyanmics	O
and	O
tubualr	O
soidum	O
and	O
wtaer	O
hadnling	O
were	O
assessed	O
by	O
clearacne	O
tecnhiques	O
in	O
26	O
well	O
compensated	O
crirhotic	B-Disease
patietns	O
before	O
and	O
after	O
an	O
oarl	O
cmobination	O
of	O
50	O
mg	O
of	O
indomehtacin	O
and	O
various	O
dsoes	O
of	O
misporostol	O
.	O

The	O
200	O
-	O
microrgams	O
dsoe	O
was	O
able	O
to	O
totally	O
aoblish	O
the	O
delteerious	O
reanl	O
efefcts	O
of	O
indomethcain	O
,	O
whereas	O
the	O
800	O
-	O
micorgrams	O
dsoe	O
resulted	O
in	O
significant	O
woresning	O
of	O
reanl	O
hemodyanmics	O
and	O
sdoium	O
reteniton	O
.	O

These	O
cahnges	O
were	O
maxiaml	O
in	O
the	O
hour	O
immediately	O
after	O
medicaitons	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
levles	O
thereafter	O
.	O

These	O
resutls	O
suggest	O
that	O
the	O
rneal	O
protective	O
effetcs	O
of	O
msioprostol	O
is	O
dsoe	O
-	O
depnedent	O
.	O

However	O
,	O
until	O
this	O
apaprent	O
ability	O
of	O
200	O
microgarms	O
of	O
miosprostol	O
to	O
pervent	O
the	O
advrese	O
effetcs	O
of	O
indomtehacin	O
on	O
reanl	O
fucntion	O
is	O
confirmed	O
with	O
chrnoic	O
freqeunt	O
dsoing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteoridal	O
atni	O
-	O
inflamamtory	O
thearpy	O
in	O
patinets	O
with	O
cirrhsois	B-Disease
.	O

Incraesed	O
frequecny	O
and	O
sveerity	O
of	O
agnio	B-Disease
-	I-Disease
oeedma	I-Disease
related	O
to	O
long	O
-	O
term	O
therpay	O
with	O
anigotensin	O
-	O
converting	O
enyzme	O
inhibiotr	O
in	O
two	O
patinets	O
.	O

Advrese	O
reatcions	O
to	O
durgs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
actue	O
or	O
chornic	O
urticaira	B-Disease
,	O
and	O
agnio	B-Disease
-	I-Disease
odeema	I-Disease
.	O

Anigotensin	O
-	O
converting	O
enyzme	O
(	O
ACE	O
)	O
inhiibtors	O
,	O
used	O
to	O
traet	O
hypertesnion	B-Disease
and	O
conegstive	B-Disease
herat	I-Disease
faliure	I-Disease
,	O
were	O
introduced	O
in	O
Eurpoe	O
in	O
the	O
mdidle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
durgs	O
has	O
icnreased	O
progressively	O
.	O

Soon	O
after	O
the	O
inrtoduction	O
of	O
ACE	O
inihbitors	O
,	O
actue	O
botus	O
of	O
anigo	B-Disease
-	I-Disease
oeedma	I-Disease
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
durgs	O
.	O

We	O
wish	O
to	O
draw	O
atetntion	O
to	O
the	O
possibility	O
of	O
adevrse	O
raections	O
to	O
ACE	O
inhibtiors	O
after	O
long	O
-	O
term	O
use	O
and	O
in	O
patinets	O
with	O
pre	O
-	O
existing	O
agnio	B-Disease
-	I-Disease
oedmea	I-Disease
.	O

Myolconus	B-Disease
associated	O
with	O
loarzepam	O
threapy	O
in	O
very	O
-	O
low	O
-	O
brith	O
-	O
weihgt	O
infnats	O
.	O

Loarzepam	O
is	O
being	O
used	O
with	O
icnreasing	O
frequecny	O
as	O
a	O
sedtaive	O
in	O
the	O
nebworn	O
and	O
the	O
yonug	O
ifnant	O
.	O

Cnocern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
saftey	O
of	O
loarzepam	O
in	O
this	O
age	O
gorup	O
,	O
especially	O
in	O
very	O
-	O
low	O
-	O
brith	O
-	O
wieght	O
(	O
VBLW	O
;	O
<	O
1	O
,	O
500	O
g	O
)	O
ifnants	O
.	O

Three	O
yuong	O
infatns	O
,	O
all	O
of	O
brith	O
wieght	O
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
moyclonus	B-Disease
following	O
the	O
inrtavenous	O
adminisrtation	O
of	O
lorazeapm	O
.	O

The	O
potnetial	O
neurotoixc	B-Disease
effcets	O
of	O
the	O
durg	O
(	O
and	O
its	O
vehilce	O
)	O
in	O
this	O
popualtion	O
are	O
discussed	O
.	O

Ijnectable	O
lorazeapm	O
should	O
be	O
used	O
with	O
caution	O
in	O
VBLW	O
infnats	O
.	O

Trasnvenous	O
rgiht	O
ventricualr	O
pacnig	O
during	O
cardoipulmonary	O
resusciattion	O
of	O
pdeiatric	O
ptaients	O
with	O
actue	O
cardioymopathy	B-Disease
.	O

We	O
describe	O
the	O
cardiouplmonary	O
ressucitation	O
efforts	O
on	O
five	O
pateints	O
who	O
presented	O
in	O
aucte	O
cicrulatory	B-Disease
faiulre	I-Disease
from	O
myocardail	B-Disease
dysfunctoin	I-Disease
.	O

Three	O
patinets	O
had	O
actue	O
vrial	O
myoacrditis	B-Disease
,	O
one	O
had	O
a	O
carabmazepine	O
-	O
idnuced	O
aucte	O
eosinpohilic	B-Disease
myocaridtis	I-Disease
,	O
and	O
one	O
had	O
cradiac	O
hemosideorsis	O
resulting	O
in	O
aucte	O
cradiogenic	B-Disease
shcok	I-Disease
.	O

All	O
patietns	O
were	O
cotninuously	O
monitoerd	O
with	O
centarl	O
venuos	O
and	O
artreial	O
catehters	O
in	O
addition	O
to	O
ruotine	O
noninvsaive	O
monitroing	O
.	O

An	O
intrdoucer	O
sehath	O
,	O
a	O
paecmaker	O
,	O
and	O
setrile	O
pacnig	O
wries	O
were	O
made	O
readily	O
available	O
for	O
the	O
paitents	O
,	O
should	O
the	O
need	O
arise	O
to	O
termniate	O
rseistant	O
cardaic	O
dysrhyhtmias	B-Disease
.	O

All	O
ptaients	O
developed	O
cardoicirculatory	O
arrest	O
associated	O
with	O
extreme	O
hpyotension	B-Disease
and	O
dyshrythmias	B-Disease
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
adimssion	O
to	O
the	O
pdeiatric	O
inetnsive	O
crae	O
unit	O
(	O
PCIU	O
)	O
.	O

Rgiht	O
vnetricular	O
pacemkaer	O
wiers	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cadriopulmonary	O
rseuscitation	O
(	O
CPR	O
)	O
.	O

In	O
four	O
pateints	O
,	O
cadriac	O
pcaing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
tempoarry	O
captured	O
rhtyhm	O
and	O
retsoration	O
of	O
their	O
cardaic	O
outupt	O
.	O

These	O
patinets	O
had	O
a	O
second	O
eevnt	O
of	O
cardaic	B-Disease
arrset	I-Disease
,	O
resulting	O
in	O
daeth	O
,	O
within	O
10	O
to	O
60	O
mintues	O
.	O

In	O
one	O
paitent	O
,	O
cadriac	O
pcaing	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
noraml	O
snius	O
rhtyhm	O
by	O
electrcial	O
dfeibrillation	O
within	O
three	O
miuntes	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
cradiac	O
pacnig	O
during	O
resuscittaive	O
efforts	O
in	O
pediartic	O
pateints	O
suffering	O
from	O
actue	O
myocadrial	B-Disease
dyfsunction	I-Disease
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temproary	O
hemodynaimc	O
stabliity	O
is	O
achieved	O
by	O
this	O
proecdure	O
,	O
it	O
may	O
provide	O
additional	O
tmie	O
needed	O
to	O
insittute	O
other	O
tehrapeutic	O
modaltiies	O
.	O

Efifcacy	O
and	O
saftey	O
of	O
garnisetron	O
,	O
a	O
selective	O
5	O
-	O
hydroxtyryptamine	O
-	O
3	O
rceeptor	O
antaognist	O
,	O
in	O
the	O
preventoin	O
of	O
nuasea	B-Disease
and	O
vmoiting	B-Disease
induecd	O
by	O
high	O
-	O
dsoe	O
cislpatin	O
.	O

PUROPSE	O
:	O
To	O
assess	O
the	O
antimeetic	O
efefcts	O
and	O
saefty	O
proifle	O
of	O
four	O
different	O
doess	O
of	O
granisteron	O
(	O
Ktyril	O
;	O
SmtihKline	O
Beecham	O
Pharamceuticals	O
,	O
Philaedlphia	O
,	O
PA	O
)	O
when	O
amdinistered	O
as	O
a	O
single	O
intrvaenous	O
(	O
IV	O
)	O
dsoe	O
for	O
prophlyaxis	O
of	O
csiplatin	O
-	O
inudced	O
nasuea	B-Disease
and	O
vmoiting	B-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
cheomtherapy	O
-	O
niave	O
patietns	O
receiving	O
high	O
-	O
dsoe	O
cipslatin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomiezd	O
to	O
receive	O
one	O
of	O
four	O
grainsetron	O
doess	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
mcirograms	O
/	O
kg	O
)	O
administeerd	O
before	O
chemohterapy	O
.	O

Ptaients	O
were	O
observed	O
on	O
an	O
inpateint	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
sgins	O
,	O
nasuea	B-Disease
,	O
vomitnig	B-Disease
,	O
retcihng	O
,	O
and	O
appteite	O
were	O
asesssed	O
.	O

Sfaety	O
analsyes	O
included	O
inicdence	O
of	O
advrese	O
experiecnes	O
and	O
laboraotry	O
praameter	O
cahnges	O
.	O

RSEULTS	O
:	O
After	O
grnaisetron	O
doess	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micorgrams	O
/	O
kg	O
,	O
a	O
major	O
respnose	O
(	O
<	O
or	O
=	O
two	O
vmoiting	B-Disease
or	O
retchnig	O
epiosdes	O
,	O
and	O
no	O
antiemeitc	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patietns	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
rseponse	O
(	O
no	O
vomiitng	B-Disease
or	O
rteching	O
,	O
and	O
no	O
antiemteic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
pateints	O
,	O
respectively	O
.	O

There	O
was	O
a	O
staitstically	O
longer	O
tmie	O
to	O
first	O
episdoe	O
of	O
nauesa	B-Disease
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
vomiitng	B-Disease
(	O
P	O
=	O
.	O
0001	O
)	O
,	O
and	O
fewer	O
pateints	O
were	O
admiinstered	O
additional	O
anteimetic	O
medictaion	O
in	O
the	O
10	O
-	O
microgrmas	O
/	O
kg	O
dosnig	O
gorups	O
than	O
in	O
the	O
5	O
-	O
micorgrams	O
/	O
kg	O
doisng	O
gruop	O
.	O

As	O
granisetorn	O
dsoe	O
icnreased	O
,	O
appettie	O
return	O
inrceased	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

Headahce	B-Disease
was	O
the	O
most	O
frequently	O
reported	O
advesre	O
evnet	O
(	O
20	O
%	O
)	O
.	O

CONLCUSION	O
:	O
A	O
single	O
10	O
-	O
,	O
20	O
-	O
,	O
or	O
40	O
-	O
microgarms	O
/	O
kg	O
dsoe	O
of	O
graniserton	O
was	O
effcetive	O
in	O
controlling	O
vomiitng	B-Disease
in	O
57	O
%	O
to	O
60	O
%	O
of	O
paitents	O
who	O
received	O
cispaltin	O
at	O
dsoes	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomiitng	B-Disease
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patinets	O
.	O

There	O
were	O
no	O
sttaistically	O
significant	O
differecnes	O
in	O
efficacy	O
between	O
the	O
10	O
-	O
mcirograms	O
/	O
kg	O
dsoe	O
and	O
the	O
20	O
-	O
and	O
40	O
-	O
microgrmas	O
/	O
kg	O
doess	O
.	O

Granisetorn	O
was	O
well	O
toelrated	O
at	O
all	O
dsoes	O
.	O

Avderse	O
intercation	O
between	O
cloindine	O
and	O
verpaamil	O
.	O

OBJETCIVE	O
:	O
To	O
rpeort	O
two	O
csaes	O
of	O
a	O
possible	O
avderse	O
intearction	O
between	O
cloindine	O
and	O
verapaiml	O
resulting	O
in	O
atroiventricular	B-Disease
(	I-Disease
AV	I-Disease
)	I-Disease
bolck	I-Disease
in	O
both	O
pateints	O
and	O
seevre	O
hypotesnion	B-Disease
in	O
one	O
ptaient	O
.	O

CSAE	O
SUMMAREIS	O
:	O
A	O
54	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
hyepraldosteronism	B-Disease
was	O
terated	O
with	O
verpaamil	O
480	O
mg	O
/	O
d	O
and	O
spironoalctone	O
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
miniaml	O
dsoe	O
of	O
cloindine	O
(	O
0	O
.	O
15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	B-Disease
bolck	I-Disease
and	O
sveere	O
hpyotension	B-Disease
,	O
which	O
resolved	O
upon	O
cessatoin	O
of	O
all	O
medicatoins	O
.	O

A	O
65	O
-	O
yaer	O
-	O
old	O
woamn	O
was	O
traeted	O
with	O
extneded	O
-	O
relesae	O
verpaamil	O
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clonidnie	O
0	O
.	O
15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B-Disease
blcok	I-Disease
,	O
which	O
resolved	O
after	O
all	O
threapy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
avderse	O
itneraction	O
between	O
cloindine	O
and	O
verapmail	O
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
csaes	O
and	O
discuss	O
the	O
various	O
mechainsms	O
that	O
might	O
cause	O
such	O
an	O
interactoin	O
.	O

Clinicinas	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
faatl	O
inetraction	O
between	O
two	O
commonly	O
used	O
anthiypertensive	O
durgs	O
.	O

CONCLSUIONS	O
:	O
Catuion	O
is	O
recomemnded	O
in	O
combining	O
clonidnie	O
and	O
verpaamil	O
therpay	O
,	O
even	O
in	O
patinets	O
who	O
do	O
not	O
have	O
snius	O
or	O
AV	O
ndoe	O
dsyfunction	O
.	O

The	O
two	O
durgs	O
may	O
act	O
syenrgistically	O
on	O
both	O
the	O
AV	O
ndoe	O
and	O
the	O
perihperal	O
circluation	O
.	O

Pharmcaological	O
stuides	O
on	O
a	O
new	O
dihydrothieonpyridine	O
clacium	O
atnagonist	O
,	O
S	O
-	O
312	O
-	O
d	O
.	O

5th	O
comumnication	O
:	O
anitconvulsant	O
effcets	O
in	O
mcie	O
.	O

S	O
-	O
312	O
,	O
S	O
-	O
312	O
-	O
d	O
,	O
but	O
not	O
S	O
-	O
312	O
-	O
l	O
,	O
L	O
-	O
tpye	O
clacium	O
channel	O
antagnoists	O
,	O
showed	O
atniconvulsant	O
efefcts	O
on	O
the	O
auidogenic	B-Disease
toinc	I-Disease
cnovulsions	I-Disease
in	O
DBA	O
/	O
2	O
mcie	O
;	O
and	O
their	O
E5D0	O
vaules	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunariznie	O
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

Although	O
modearte	O
anticonvulasnt	O
effetcs	O
of	O
S	O
-	O
312	O
-	O
d	O
in	O
hihger	O
dsoes	O
were	O
observed	O
against	O
the	O
clnoic	O
convulisons	B-Disease
indcued	O
by	O
pentyleentetrazole	O
(	O
85	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
bmeegride	O
(	O
40	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
no	O
effects	O
were	O
observed	O
in	O
cnovulsions	B-Disease
inudced	O
by	O
N	O
-	O
metyhl	O
-	O
D	O
-	O
asparatte	O
,	O
pircotoxin	O
,	O
or	O
electrosohck	O
in	O
Slc	O
:	O
ddY	O
mcie	O
.	O

S	O
-	O
312	O
-	O
d	O
may	O
be	O
useful	O
in	O
the	O
threapy	O
of	O
certain	O
types	O
of	O
huamn	O
epilpesy	B-Disease
.	O

Transmrual	O
mycoardial	B-Disease
inafrction	I-Disease
with	O
sumatritpan	O
.	O

For	O
sumatripatn	O
,	O
tighntess	O
in	O
the	O
cehst	O
caused	O
by	O
an	O
unknown	O
mcehanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
usres	O
.	O

We	O
describe	O
a	O
47	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
an	O
actue	O
mycoardial	B-Disease
infraction	I-Disease
after	O
amdinistration	O
of	O
smuatriptan	O
6	O
mg	O
subcuatneously	O
for	O
clsuter	B-Disease
hedaache	I-Disease
.	O

The	O
ptaient	O
had	O
no	O
hsitory	O
of	O
underlying	O
ischameic	B-Disease
herat	I-Disease
dsiease	I-Disease
or	O
Prinzemtal	B-Disease
'	I-Disease
s	I-Disease
agnina	I-Disease
.	O

She	O
recoveerd	O
without	O
complicatinos	O
.	O

Fluamzenil	O
induecs	O
siezures	B-Disease
and	O
detah	O
in	O
mixed	O
cocanie	O
-	O
dizaepam	O
intxoications	O
.	O

SUTDY	O
HPYOTHESIS	O
:	O
Administratoin	O
of	O
the	O
benzdoiazepine	O
anatgonist	O
fluamzenil	O
may	O
unmask	O
seziures	B-Disease
in	O
mixed	O
coacine	O
-	O
benzodiazeipne	O
intoxciation	O
.	O

DESIGN	O
:	O
Mlae	O
Spargue	O
-	O
Dalwey	O
rtas	O
received	O
100	O
mg	O
/	O
kg	O
ccoaine	O
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
dizaepam	O
alone	O
,	O
or	O
a	O
comibnation	O
of	O
dizaepam	O
and	O
cocanie	O
.	O

Three	O
miuntes	O
later	O
,	O
gorups	O
were	O
challegned	O
with	O
vheicle	O
or	O
flmuazenil	O
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Aniaml	O
behavoir	O
,	O
seziures	B-Disease
(	O
tmie	O
to	O
and	O
icnidence	O
)	O
,	O
detah	O
(	O
tmie	O
to	O
and	O
inciednce	O
)	O
,	O
and	O
cortiacl	O
EEG	O
tracnigs	O
were	O
recorded	O
.	O

INTERVNETIONS	O
:	O
Administartion	O
of	O
flumaeznil	O
to	O
aniamls	O
after	O
they	O
had	O
received	O
a	O
cmobination	O
dsoe	O
of	O
cocanie	O
and	O
daizepam	O
.	O

RSEULTS	O
:	O
In	O
gorup	O
1	O
,	O
aniamls	O
received	O
cociane	O
followed	O
by	O
vehcile	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
siezures	B-Disease
and	O
daeth	O
.	O

Gorup	O
2	O
received	O
daizepam	O
alone	O
followed	O
by	O
veihcle	O
.	O

Animlas	O
became	O
somnloent	O
and	O
none	O
deid	O
.	O

Gruop	O
3	O
received	O
diaezpam	O
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazneil	O
.	O

Ainmals	O
became	O
smonolent	O
after	O
daizepam	O
and	O
then	O
acitve	O
after	O
flumazneil	O
adimnistration	O
.	O

In	O
gruop	O
4	O
,	O
a	O
combintaion	O
of	O
cocanie	O
and	O
diaezpam	O
was	O
adminitsered	O
simultaneuosly	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectbale	O
seizuers	B-Disease
and	O
a	O
50	O
%	O
incidnece	O
of	O
detah	O
.	O

Gruop	O
5	O
received	O
a	O
similar	O
combniation	O
of	O
cocanie	O
and	O
daizepam	O
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumaeznil	O
.	O

This	O
resulted	O
in	O
an	O
incraesed	O
incidecne	O
of	O
siezures	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
detah	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
compraed	O
with	O
gorup	O
4	O
.	O

Gruop	O
6	O
received	O
cocanie	O
and	O
diaezpam	O
followed	O
by	O
10	O
mg	O
/	O
kg	O
flumazeinl	O
.	O

This	O
also	O
resulted	O
in	O
an	O
incerased	O
incidnece	O
of	O
seziures	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
and	O
daeth	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
,	O
copmared	O
with	O
gorup	O
4	O
.	O

CONCLSUION	O
:	O
Flumazneil	O
can	O
unmask	O
seiuzres	B-Disease
and	O
icnrease	O
the	O
incdience	O
of	O
daeth	O
in	O
a	O
moedl	O
of	O
combiend	O
cocanie	O
-	O
diaezpam	O
intxoications	O
.	O

Mechnaisms	O
for	O
protective	O
effects	O
of	O
free	O
rdaical	O
sacvengers	O
on	O
gentamiicn	O
-	O
mediated	O
npehropathy	B-Disease
in	O
rtas	O
.	O

Stuides	O
were	O
performed	O
to	O
examine	O
the	O
mechnaisms	O
for	O
the	O
protective	O
effetcs	O
of	O
free	O
raidcal	O
scavengres	O
on	O
gentamciin	O
(	O
GM	O
)	O
-	O
mediated	O
neprhopathy	B-Disease
.	O

Admniistration	O
of	O
GM	O
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
dyas	O
to	O
rtas	O
induecd	O
a	O
significant	O
rdeuction	O
in	O
reanl	O
bolod	O
folw	O
(	O
RBF	O
)	O
and	O
inuiln	O
claerance	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tbuular	B-Disease
daamge	I-Disease
.	O

A	O
significant	O
reudction	O
in	O
urianry	O
guanosnie	O
3	O
'	O
,	O
5	O
'	O
-	O
cylcic	O
monopohsphate	O
(	O
cMGP	O
)	O
excreiton	O
and	O
a	O
significant	O
incresae	O
in	O
rneal	O
cotrical	O
rnein	O
and	O
endtohelin	O
-	O
1	O
cotnents	O
were	O
also	O
observed	O
in	O
GM	O
-	O
mediated	O
nephorpathy	B-Disease
.	O

Spueroxide	O
disumtase	O
(	O
SOD	O
)	O
or	O
dimehtylthiourea	O
(	O
DTMU	O
)	O
significantly	O
lessened	O
the	O
GM	O
-	O
induecd	O
decerment	O
in	O
CIn	O
.	O

The	O
SOD	O
-	O
indcued	O
inrcease	O
in	O
glomeurlar	O
filtratoin	O
rtae	O
was	O
associated	O
with	O
a	O
marked	O
ipmrovement	O
in	O
RBF	O
,	O
an	O
incraese	O
in	O
uirnary	O
cMGP	O
exrcetion	O
,	O
and	O
a	O
dcerease	O
in	O
rneal	O
rnein	O
and	O
endtohelin	O
-	O
1	O
cotnent	O
.	O

SOD	O
did	O
not	O
attenuate	O
the	O
tbuular	B-Disease
damgae	I-Disease
.	O

In	O
contrast	O
,	O
DTMU	O
significantly	O
reduecd	O
the	O
tuublar	B-Disease
damgae	I-Disease
and	O
liipd	O
peroxiadtion	O
,	O
but	O
it	O
did	O
not	O
affect	O
rneal	O
hemodnyamics	O
and	O
vsaoactive	O
substacnes	O
.	O

Neither	O
SOD	O
nor	O
DTMU	O
afefcted	O
the	O
rneal	O
cortcial	O
GM	O
contnet	O
in	O
GM	O
-	O
terated	O
rtas	O
.	O

These	O
resutls	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DTMU	O
have	O
protective	O
effcets	O
on	O
GM	O
-	O
mediated	O
nephrpoathy	B-Disease
,	O
2	O
)	O
the	O
mechanimss	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DTMU	O
,	O
and	O
3	O
)	O
supeorxide	O
aninos	O
play	O
a	O
critical	O
role	O
in	O
GM	O
-	O
indcued	O
reanl	O
vascoonstriction	O
.	O

Cephaolthin	O
-	O
induecd	O
immnue	O
hemolyitc	B-Disease
anmeia	I-Disease
.	O

A	O
ptaient	O
with	O
reanl	B-Disease
diesase	I-Disease
developed	O
Comobs	O
-	O
positvie	O
hemoyltic	B-Disease
anmeia	I-Disease
while	O
receiving	O
cephaltohin	O
threapy	O
.	O

An	O
atni	O
-	O
cephalohtin	O
IgG	O
antbiody	O
was	O
detecetd	O
in	O
the	O
patinet	O
'	O
s	O
seurm	O
and	O
in	O
the	O
elutaes	O
from	O
her	O
erythroyctes	O
.	O

In	O
addition	O
,	O
nonmimunologic	O
bindnig	O
of	O
nomral	O
and	O
patinet	O
'	O
s	O
seurm	O
porteins	O
to	O
her	O
own	O
and	O
cephaltohin	O
-	O
caoted	O
nromal	O
red	O
cells	O
was	O
demonstrated	O
.	O

Sikn	O
tsets	O
and	O
in	O
vitro	O
lymphoycte	O
stimulatoin	O
reevaled	O
that	O
the	O
paitent	O
was	O
sensitzied	O
to	O
cehpalothin	O
and	O
also	O
to	O
ampiicllin	O
.	O

Careful	O
investigaiton	O
of	O
durg	O
-	O
idnuced	O
hmeolytic	B-Disease
anemais	I-Disease
reveals	O
the	O
complxeity	O
of	O
the	O
immune	O
mechnaisms	O
involved	O
.	O

Assesmsent	O
of	O
cardiomycoyte	O
DNA	O
syntehsis	O
during	O
hpyertrophy	B-Disease
in	O
audlt	O
mcie	O
.	O

The	O
ability	O
of	O
cardiomyoctyes	O
to	O
synthesize	O
DNA	O
in	O
repsonse	O
to	O
expreimentally	O
inudced	O
cardaic	B-Disease
hypretrophy	I-Disease
was	O
assessed	O
in	O
audlt	O
mcie	O
.	O

Isoproetrenol	O
deliveerd	O
by	O
osomtic	O
miniupmp	O
imlpantation	O
in	O
audlt	O
C3eHb	O
/	O
FeJ	O
mcie	O
resulted	O
in	O
a	O
46	O
%	O
incresae	O
in	O
haert	O
wegiht	O
and	O
a	O
19	O
.	O
3	O
%	O
incerase	O
in	O
cardiomyoycte	O
aera	O
.	O

No	O
DNA	O
snythesis	O
,	O
as	O
asssesed	O
by	O
autordaiographic	O
analyiss	O
of	O
isoltaed	O
cardoimyocytes	O
,	O
was	O
observed	O
in	O
cotnrol	O
or	O
hyeprtrophic	B-Disease
heatrs	I-Disease
.	O

A	O
sruvey	O
of	O
15	O
indepednent	O
inberd	O
starins	O
of	O
mcie	O
reevaled	O
that	O
ventricualr	O
cardimoyocyte	O
nucelar	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
mononucletae	O
,	O
suggesting	O
that	O
cardiomoycyte	O
termianl	O
diffeerntiation	O
is	O
inlfuenced	O
directly	O
or	O
indriectly	O
by	O
gneetic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
caapcity	O
for	O
reatcive	O
DNA	O
sytnhesis	O
was	O
also	O
sbuject	O
to	O
genteic	O
reuglation	O
,	O
cradiac	B-Disease
hypetrrophy	I-Disease
was	O
indcued	O
in	O
the	O
stranis	O
of	O
mcie	O
comprising	O
the	O
exrtemes	O
of	O
the	O
nulcear	O
number	O
surevy	O
.	O

These	O
dtaa	O
indicate	O
that	O
adlut	O
muose	O
artial	O
and	O
ventircular	O
cardoimyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
respnose	O
to	O
isoproetrenol	O
-	O
induecd	O
caridac	B-Disease
hypertorphy	I-Disease
.	O

Cnetral	O
cardioavscular	O
efefcts	O
of	O
AVP	O
and	O
ANP	O
in	O
noromtensive	O
and	O
sopntaneously	O
hypetrensive	B-Disease
rtas	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stduy	O
was	O
to	O
copmare	O
inlfuence	O
of	O
cetnral	O
argiinne	O
vsaopressin	O
(	O
AVP	O
)	O
and	O
of	O
atiral	O
natriureitc	O
pepitde	O
(	O
ANP	O
)	O
on	O
contorl	O
of	O
artreial	O
blood	O
presusre	O
(	O
MAP	O
)	O
and	O
haert	O
rtae	O
(	O
HR	O
)	O
in	O
normotesnive	O
(	O
WKY	O
)	O
and	O
spontaenously	O
hypertenisve	B-Disease
(	O
SHR	O
)	O
rtas	O
.	O

Three	O
series	O
of	O
expreiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chroncially	O
instruemnted	O
with	O
guide	O
tbues	O
in	O
the	O
latreal	O
vnetricle	O
(	O
LV	O
)	O
and	O
atrerial	O
and	O
veonus	O
catheetrs	O
.	O

MAP	O
and	O
HR	O
were	O
moniotred	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
injectoins	O
of	O
either	O
vheicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitviity	O
of	O
cardaic	O
component	O
of	O
barorelfex	O
(	O
CCB	O
)	O
,	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regerssion	O
line	O
was	O
determined	O
from	O
relationsihps	O
between	O
sytsolic	O
atrerial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
peirod	O
(	O
HRp	O
)	O
during	O
phenylehprine	O
(	O
Phe	O
)	O
-	O
inudced	O
hypretension	B-Disease
and	O
sdoium	O
nitroprussdie	O
(	O
SN	O
)	O
-	O
induecd	O
hypotenison	B-Disease
.	O

CCB	O
was	O
measrued	O
before	O
and	O
after	O
admniistration	O
of	O
either	O
vehilce	O
,	O
AVP	O
,	O
ANP	O
,	O
or	O
both	O
peptieds	O
together	O
.	O

Inrceases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administrtaion	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
chagnes	O
in	O
MAP	O
in	O
both	O
starins	O
as	O
compraed	O
to	O
vehilce	O
,	O
but	O
it	O
abolished	O
AVP	O
-	O
induecd	O
MAP	O
icnrease	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
rdeuced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administartion	O
of	O
AVP	O
during	O
SN	O
-	O
induecd	O
hypotesnion	B-Disease
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
adimnistration	O
of	O
ANP	O
,	O
AVP	O
and	O
ANP	O
+	O
AVP	O
derceased	O
CCB	O
during	O
Phe	O
-	O
indcued	O
MAP	O
elevtaion	O
.	O

The	O
resutls	O
indicate	O
that	O
centrally	O
applied	O
AVP	O
and	O
ANP	O
exert	O
differnetial	O
efefcts	O
on	O
bolod	O
prsesure	O
and	O
barorelfex	O
cotnrol	O
of	O
herat	O
rtae	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interactoin	O
of	O
these	O
two	O
ppetides	O
in	O
bolod	O
perssure	O
regultaion	O
at	O
the	O
lveel	O
of	O
cenrtal	O
nervuos	O
ssytem	O
.	O

Cutaneuos	O
exopsure	O
to	O
wafrarin	O
-	O
like	O
anitcoagulant	O
causing	O
an	O
intracerberal	B-Disease
hemrorhage	I-Disease
:	O
a	O
csae	O
rpeort	O
.	O

A	O
csae	O
of	O
itnercerebral	O
hemaotma	B-Disease
due	O
to	O
warfrain	O
-	O
idnuced	O
coagluopathy	B-Disease
is	O
presented	O
.	O

The	O
39	O
-	O
yaer	O
-	O
old	O
wmoan	O
had	O
sperad	O
a	O
warafrin	O
-	O
tpye	O
rat	O
posion	O
around	O
her	O
hosue	O
wekely	O
using	O
her	O
brae	O
hnads	O
,	O
with	O
no	O
wsahing	O
psot	O
applicaiton	O
.	O

Precutaneous	O
absoprtion	O
of	O
warfairn	O
causing	O
caogulopathy	B-Disease
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
rsik	O
if	O
protective	O
measuers	O
,	O
such	O
as	O
glvoes	O
,	O
are	O
not	O
used	O
.	O

An	O
avderse	O
durg	O
intreaction	O
with	O
piroixcam	O
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
eaxcerbated	O
the	O
coauglopathy	B-Disease
.	O

Pediartic	O
haert	O
tranpslantation	O
without	O
crhonic	O
miantenance	O
setroids	O
.	O

From	O
1986	O
to	O
Feburary	O
1993	O
,	O
40	O
chlidren	O
aegd	O
2	O
monhts	O
to	O
18	O
yaers	O
(	O
avergae	O
age	O
10	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
8	O
yaers	O
)	O
underwent	O
herat	O
transplanttaion	O
.	O

Inidcations	O
for	O
trasnplantation	O
were	O
idiopatihc	B-Disease
cardiomyopahty	I-Disease
(	O
52	O
%	O
)	O
,	O
congential	B-Disease
herat	I-Disease
dsiease	I-Disease
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
reapir	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hypertrpohic	B-Disease
cardioymopathy	I-Disease
(	O
5	O
%	O
)	O
,	O
valvualr	B-Disease
herat	I-Disease
disaese	I-Disease
(	O
3	O
%	O
)	O
,	O
and	O
doxourbicin	O
cardioymopathy	B-Disease
(	O
5	O
%	O
)	O
.	O

Pateints	O
were	O
managed	O
with	O
cyclosoprine	O
and	O
azahtioprine	O
.	O

No	O
prophylxais	O
with	O
antilymhpocyte	O
globuiln	O
was	O
used	O
.	O

Setroids	O
were	O
given	O
to	O
39	O
%	O
of	O
ptaients	O
for	O
refarctory	O
rjeection	O
,	O
but	O
weannig	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
pateints	O
(	O
14	O
%	O
)	O
received	O
maintneance	O
steriods	O
.	O

Four	O
pateints	O
deid	O
in	O
the	O
perioperaitve	O
preiod	O
and	O
one	O
deid	O
4	O
motnhs	O
later	O
.	O

There	O
have	O
been	O
no	O
deahts	O
related	O
to	O
rejetcion	O
or	O
inefction	B-Disease
.	O

Avergae	O
follow	O
-	O
up	O
was	O
36	O
+	O
/	O
-	O
19	O
monhts	O
(	O
range	O
1	O
to	O
65	O
monhts	O
)	O
.	O

Cumultaive	O
survvial	O
is	O
88	O
%	O
at	O
5	O
yaers	O
.	O

In	O
pateints	O
less	O
than	O
7	O
yaers	O
of	O
age	O
,	O
rejeciton	O
was	O
monitoerd	O
nonivnasively	O
.	O

In	O
the	O
first	O
postpoerative	O
motnh	O
,	O
89	O
%	O
of	O
patietns	O
were	O
traeted	O
for	O
reejction	O
.	O

Fredeom	O
from	O
serious	O
infectoins	B-Disease
was	O
83	O
%	O
at	O
1	O
mnoth	O
and	O
65	O
%	O
at	O
1	O
yaer	O
.	O

Cytmoegalovirus	B-Disease
infetcions	I-Disease
were	O
treaetd	O
successfully	O
with	O
gancilcovir	O
in	O
11	O
patinets	O
.	O

No	O
impairmnet	O
of	O
gorwth	O
was	O
observed	O
in	O
childern	O
who	O
underwent	O
trnasplantation	O
copmared	O
with	O
a	O
conrtol	O
popultaion	O
.	O

Twenty	O
-	O
one	O
ptaients	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annual	O
catheterizatinos	O
and	O
no	O
sign	O
of	O
grfat	O
atehrosclerosis	B-Disease
has	O
been	O
observed	O
.	O

Seizuers	B-Disease
occurred	O
in	O
five	O
pateints	O
(	O
14	O
%	O
)	O
and	O
hyeprtension	B-Disease
was	O
tretaed	O
in	O
10	O
paitents	O
(	O
28	O
%	O
)	O
.	O

No	O
ptaient	O
was	O
dsiabled	O
and	O
no	O
lymphoprolifeartive	B-Disease
disroder	I-Disease
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Dleirium	B-Disease
during	O
fluoxeitne	O
traetment	O
.	O

A	O
csae	O
rpeort	O
.	O

The	O
correlaiton	O
between	O
high	O
sreum	O
triccylic	O
antidepressant	O
concentrtaions	O
and	O
cetnral	O
nrevous	O
sysetm	O
side	O
effects	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
reprots	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationsihp	O
between	O
the	O
seurm	O
concentartions	O
of	O
selective	O
sreotonin	O
rueptake	O
inihbitors	O
(	O
SRSIs	O
)	O
and	O
their	O
toixc	O
effetcs	O
.	O

In	O
some	O
caess	O
,	O
a	O
high	O
seurm	O
concnetration	O
of	O
citaolpram	O
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
eldelry	O
ptaients	O
has	O
been	O
associated	O
with	O
inrceased	O
sonmolence	B-Disease
and	O
moevment	B-Disease
difficulties	I-Disease
.	O

Wiedspread	O
cgonitive	B-Disease
dsiorders	I-Disease
,	O
such	O
as	O
deilrium	B-Disease
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
bolod	O
levles	O
of	O
SRSIs	O
.	O

In	O
this	O
rpeort	O
,	O
we	O
describe	O
a	O
ptaient	O
with	O
aucte	O
hyperknietic	B-Disease
deilrium	B-Disease
connected	O
with	O
a	O
high	O
sreum	O
total	O
fluoxteine	O
(	O
fluoextine	O
plus	O
dsemethylfluoxetine	O
)	O
cnocentration	O
.	O

Pumlonary	B-Disease
eedma	I-Disease
and	O
shcok	B-Disease
after	O
high	O
-	O
dsoe	O
arayctine	O
-	O
C	O
for	O
lymphmoa	B-Disease
;	O
possible	O
role	O
of	O
TNF	O
-	O
alhpa	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
conseuctive	O
paitents	O
treaetd	O
with	O
high	O
-	O
dsoe	O
Ara	O
-	O
C	O
for	O
lmyphomas	B-Disease
in	O
our	O
instiuttion	O
developed	O
a	O
srtikingly	O
similar	O
synrdome	O
during	O
the	O
pefrusion	O
.	O

It	O
was	O
characteriezd	O
by	O
the	O
onset	O
of	O
feevr	B-Disease
,	O
dairrhea	B-Disease
,	O
sohck	B-Disease
,	O
pulmoanry	B-Disease
eedma	I-Disease
,	O
actue	B-Disease
reanl	I-Disease
faiulre	I-Disease
,	O
meatbolic	B-Disease
acdiosis	I-Disease
,	O
wieght	B-Disease
gain	I-Disease
and	O
leukocyotsis	B-Disease
.	O

Thorough	O
bacteirological	O
scerening	O
failed	O
to	O
provide	O
evdience	O
of	O
infectoin	B-Disease
.	O

Sequentail	O
biolgoical	O
assays	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	O
-	O
C	O
infsuion	O
to	O
ten	O
ptaients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
synrdome	O
.	O

TNF	O
and	O
PAF	O
actiivty	O
was	O
found	O
in	O
the	O
sreum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
caess	O
,	O
but	O
not	O
in	O
the	O
six	O
cotnrols	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
developemnt	O
of	O
sepitc	O
shcok	B-Disease
and	O
adlut	B-Disease
resipratory	I-Disease
dsitress	I-Disease
syndrmoe	I-Disease
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dsoe	O
Ara	O
-	O
C	O
may	O
be	O
associated	O
with	O
ctyokine	O
relaese	O
.	O

Protecitve	O
efefct	O
of	O
clentiazem	O
against	O
eipnephrine	O
-	O
idnuced	O
caridac	B-Disease
injruy	I-Disease
in	O
rtas	O
.	O

We	O
ivnestigated	O
the	O
effcets	O
of	O
clentiazem	O
,	O
a	O
1	O
,	O
5	O
-	O
benztohiazepine	O
clacium	O
antagonsit	O
,	O
on	O
epineprhine	O
-	O
induecd	O
cardiomyoapthy	B-Disease
in	O
rtas	O
.	O

With	O
2	O
-	O
week	O
chrnoic	O
epinpehrine	O
infuison	O
,	O
16	O
of	O
30	O
rtas	O
deid	O
within	O
4	O
dyas	O
,	O
and	O
seevre	O
icshemic	B-Disease
lesoins	I-Disease
and	O
fbirosis	B-Disease
of	O
the	O
lfet	O
ventrciles	O
were	O
observed	O
.	O

In	O
epniephrine	O
-	O
treaetd	O
rtas	O
,	O
lfet	O
atrail	O
and	O
lfet	O
ventrciular	O
paplilary	O
muslce	O
contracitle	O
resposnes	O
to	O
iosproterenol	O
were	O
redcued	O
,	O
but	O
respnoses	O
to	O
caclium	O
were	O
nomral	O
or	O
enahnced	O
cmopared	O
to	O
conrtols	O
.	O

Lfet	O
ventriuclar	O
aplha	O
and	O
btea	O
adrenoecptor	O
denstiies	O
were	O
also	O
rdeuced	O
compraed	O
to	O
contorls	O
.	O

Teratment	O
with	O
clentiazem	O
prevented	O
epinehprine	O
-	O
indcued	O
daeth	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
atetnuated	O
the	O
vnetricular	O
icshemic	B-Disease
lesoins	I-Disease
and	O
firbosis	B-Disease
,	O
in	O
a	O
dsoe	O
-	O
depnedent	O
manner	O
.	O

Lfet	O
artial	O
and	O
lfet	O
ventriuclar	O
paplilary	O
msucle	O
contractlie	O
resopnses	O
to	O
isoprotreenol	O
were	O
reduecd	O
compaerd	O
to	O
conrtols	O
in	O
gruops	O
terated	O
with	O
clentiazem	O
alone	O
,	O
but	O
combnied	O
with	O
epniephrine	O
,	O
clentiazem	O
retsored	O
lfet	O
atrail	O
respnoses	O
and	O
enhanecd	O
lfet	O
ventrciular	O
papillary	O
resposnes	O
to	O
isporoterenol	O
.	O

On	O
the	O
other	O
hand	O
clentiazem	O
did	O
not	O
pervent	O
epinephirne	O
-	O
induecd	O
down	O
-	O
regluation	O
of	O
aplha	O
and	O
btea	O
adrenocetpors	O
.	O

Interestingly	O
,	O
clentiazem	O
,	O
inufsed	O
alone	O
,	O
resulted	O
in	O
derceased	O
adernergic	O
reecptor	O
denisties	O
in	O
the	O
lfet	O
ventrilce	O
.	O

Clentiazem	O
also	O
did	O
not	O
prevnet	O
the	O
enhanecd	O
resposnes	O
to	O
caclium	O
seen	O
in	O
the	O
eipnephrine	O
-	O
traeted	O
ainmals	O
,	O
although	O
the	O
high	O
dsoe	O
of	O
clentiazem	O
partially	O
attenutaed	O
the	O
mxaimal	O
resposne	O
to	O
caclium	O
compraed	O
to	O
epinpehrine	O
-	O
traeted	O
animlas	O
.	O

In	O
conclusion	O
,	O
clentiazem	O
atteunated	O
epinehprine	O
-	O
indcued	O
cardaic	B-Disease
inujry	I-Disease
,	O
possibly	O
through	O
its	O
effcet	O
on	O
the	O
adrneergic	O
patwhay	O
.	O

Kaliruetic	O
effcet	O
of	O
L	O
-	O
dpoa	O
teratment	O
in	O
parkisnonian	B-Disease
pateints	O
.	O

Hypkoalemia	B-Disease
,	O
sometimes	O
seevre	O
,	O
was	O
observed	O
in	O
some	O
L	O
-	O
dpoa	O
-	O
terated	O
parknisonian	B-Disease
paitents	O
.	O

The	O
inlfuence	O
of	O
L	O
-	O
dpoa	O
on	O
the	O
rneal	O
excrteion	O
of	O
poatssium	O
was	O
studied	O
in	O
3	O
paitents	O
with	O
hyopkalemia	B-Disease
and	O
in	O
5	O
normokalmeic	O
paitents	O
by	O
deterimnation	O
of	O
rneal	O
plamsa	O
folw	O
,	O
glomeurlar	O
filtartion	O
rtae	O
,	O
palsma	O
concenrtation	O
of	O
potasisum	O
and	O
sdoium	O
as	O
well	O
as	O
urinray	O
excrteion	O
of	O
potassium	O
,	O
sdoium	O
and	O
adlosterone	O
.	O

L	O
-	O
Dpoa	O
intkae	O
was	O
found	O
to	O
cause	O
an	O
inrceased	O
excertion	O
of	O
poatssium	O
,	O
and	O
sometimes	O
also	O
of	O
sdoium	O
,	O
in	O
the	O
hypoaklemic	O
but	O
not	O
in	O
the	O
nromokalemic	O
patinets	O
.	O

This	O
efefct	O
on	O
the	O
reanl	O
funciton	O
could	O
be	O
prohibited	O
by	O
the	O
administraiton	O
of	O
a	O
preipheral	O
dpoa	O
decarobdylase	O
inhibtior	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
effcet	O
occurred	O
in	O
some	O
indviiduals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
resutls	O
indicate	O
a	O
correlatoin	O
between	O
aldsoterone	O
proudction	O
and	O
this	O
rneal	O
effcet	O
of	O
L	O
-	O
dpoa	O
.	O

Cociane	O
indcued	O
moycardial	B-Disease
iscehmia	I-Disease
.	O

We	O
reprot	O
a	O
csae	O
of	O
myoacrdial	B-Disease
icshemia	I-Disease
induecd	O
by	O
cociane	O
.	O

The	O
icshemia	B-Disease
probably	O
indcued	O
by	O
coornary	B-Disease
aretry	I-Disease
sapsm	I-Disease
was	O
revresed	O
by	O
nitorglycerin	O
and	O
caclium	O
blcoking	O
agnets	O
.	O

Doxorbuicin	O
-	O
indcued	O
cardiootxicity	B-Disease
monitroed	O
by	O
ECG	O
in	O
freely	O
movnig	O
mcie	O
.	O

A	O
new	O
mdoel	O
to	O
tset	O
ptoential	O
protetcors	O
.	O

In	O
labortaory	O
animlas	O
,	O
histolgoy	O
is	O
most	O
commonly	O
used	O
to	O
sutdy	O
doxorubiicn	O
-	O
indcued	O
cardiotoxiicty	B-Disease
.	O

However	O
,	O
for	O
montioring	O
during	O
traetment	O
,	O
large	O
nmubers	O
of	O
anmials	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
metohd	O
to	O
maesure	O
ECG	O
vaules	O
in	O
freely	O
movnig	O
mcie	O
by	O
telemtery	O
.	O

With	O
this	O
moedl	O
we	O
invetsigated	O
the	O
efefct	O
of	O
chrnoic	O
dxoorubicin	O
adminisrtation	O
on	O
the	O
ECG	O
of	O
freely	O
moivng	O
BLAB	O
/	O
c	O
mcie	O
and	O
the	O
effiaccy	O
of	O
IRCF	O
-	O
187	O
as	O
a	O
protective	O
agnet	O
.	O

The	O
ST	O
itnerval	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
dsoes	O
of	O
4	O
mg	O
/	O
kg	O
doxroubicin	O
given	O
i	O
.	O
v	O
.	O
plus	O
3	O
weeks	O
of	O
osbervation	O
)	O
.	O

The	O
ECG	O
of	O
the	O
contorl	O
aniamls	O
did	O
not	O
change	O
during	O
the	O
entire	O
stduy	O
.	O

After	O
sacirfice	O
the	O
haerts	O
of	O
doxoruibcin	O
-	O
treaetd	O
aniamls	O
were	O
enlaregd	O
and	O
the	O
artia	O
were	O
hypertrpohic	B-Disease
.	O

As	O
this	O
schedlue	O
exerted	O
more	O
toxciity	B-Disease
than	O
needed	O
to	O
investiagte	O
protective	O
aegnts	O
,	O
the	O
prtoection	O
of	O
IRCF	O
-	O
187	O
was	O
determined	O
using	O
a	O
dsoe	O
scehdule	O
with	O
loewr	O
general	O
txoicity	B-Disease
(	O
6	O
wekely	O
doess	O
of	O
4	O
mg	O
/	O
kg	O
dooxrubicin	O
given	O
i	O
.	O
v	O
.	O
plus	O
2	O
weeks	O
of	O
osbervation	O
)	O
.	O

On	O
this	O
schdeule	O
,	O
the	O
aniamls	O
'	O
heatrs	O
appeared	O
noraml	O
after	O
sacrifcie	O
and	O
IRCF	O
-	O
187	O
(	O
50	O
mg	O
/	O
kg	O
given	O
i	O
.	O
p	O
.	O
1	O
h	O
before	O
dooxrubicin	O
)	O
provided	O
almost	O
full	O
protetcion	O
.	O

These	O
dtaa	O
were	O
confirmed	O
by	O
histoolgy	O
.	O

The	O
rseults	O
indicate	O
that	O
this	O
new	O
moedl	O
is	O
very	O
senistive	O
and	O
enables	O
moniotring	O
of	O
the	O
developmnet	O
of	O
cardiotoixcity	B-Disease
with	O
tmie	O
.	O

These	O
findnigs	O
result	O
in	O
a	O
mdoel	O
that	O
allows	O
the	O
tesitng	O
of	O
protecotrs	O
against	O
doxorbuicin	O
-	O
indcued	O
cradiotoxicity	B-Disease
as	O
demonstrated	O
by	O
the	O
prtoection	O
provided	O
by	O
IRCF	O
-	O
187	O
.	O

Epienphrine	O
dysrhyhtmogenicity	O
is	O
not	O
enahnced	O
by	O
subotxic	O
bpuivacaine	O
in	O
dgos	O
.	O

Since	O
bupivaciane	O
and	O
epinephrnie	O
may	O
both	O
prceipitate	O
dysrhythimas	B-Disease
,	O
circultaing	O
bupivacanie	O
during	O
regioanl	O
aneshtesia	O
could	O
ptoentiate	O
dysrhtyhmogenic	O
effcets	O
of	O
epienphrine	O
.	O

We	O
therefore	O
examined	O
whether	O
bupviacaine	O
aletrs	O
the	O
dsyrhythmogenicity	O
of	O
subsequent	O
adminsitration	O
of	O
epineprhine	O
in	O
consicous	O
,	O
helathy	O
dgos	O
and	O
in	O
anestheitzed	O
dgos	O
with	O
moycardial	B-Disease
infarctoin	I-Disease
.	O

Forty	O
-	O
one	O
consciuos	O
dgos	O
received	O
10	O
microgarms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epineprhine	O
.	O

Seventeen	O
anmials	O
responded	O
with	O
ventricualr	B-Disease
tachycadria	I-Disease
(	O
VT	B-Disease
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
responedrs	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupiavcaine	O
or	O
slaine	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
microrgams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrnie	O
.	O

In	O
the	O
bupviacaine	O
gruops	O
,	O
epienphrine	O
caused	O
fewer	O
prdoysrhythmic	O
effects	O
than	O
without	O
bupviacaine	O
.	O

VT	B-Disease
appeared	O
in	O
fewer	O
dgos	O
and	O
at	O
a	O
later	O
tmie	O
,	O
and	O
there	O
were	O
more	O
sinaotrial	O
baets	O
and	O
less	O
ectoipes	O
.	O

Epniephrine	O
shrotened	O
QT	O
less	O
after	O
bupivcaaine	O
than	O
in	O
contorl	O
animlas	O
.	O

One	O
day	O
after	O
expermiental	O
myocadrial	B-Disease
ifnarction	I-Disease
,	O
six	O
additional	O
hlaothane	O
-	O
anestheitzed	O
dgos	O
received	O
4	O
microgarms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrnie	O
until	O
VT	B-Disease
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupiavcaine	O
was	O
ijnected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
microrgams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epniephrine	O
.	O

In	O
these	O
dgos	O
,	O
the	O
proydsrhythmic	O
rseponse	O
to	O
eipnephrine	O
was	O
also	O
mtiigated	O
by	O
preceding	O
buipvacaine	O
.	O

Bpuivacaine	O
antagoniezs	O
epinehprine	O
dyshrythmogenicity	O
in	O
conscoius	O
dgos	O
suscpetible	O
to	O
VT	B-Disease
and	O
in	O
anetshetized	O
dgos	O
with	O
spontanoeus	O
postinfacrt	O
dysrhythmais	B-Disease
.	O

There	O
is	O
no	O
eviednce	O
that	O
systeimc	O
sutboxic	O
bupviacaine	O
adminsitration	O
enahnces	O
the	O
dysrhythmoegnicity	O
of	O
subsequent	O
epineprhine	O
.	O

Mlik	B-Disease
-	I-Disease
alklai	I-Disease
synrdome	I-Disease
idnuced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
in	O
a	O
ptaient	O
with	O
hypoaprathyroidism	B-Disease
.	O

Mlik	B-Disease
-	I-Disease
aklali	I-Disease
sydnrome	I-Disease
was	O
first	O
described	O
70	O
yaers	O
ago	O
in	O
the	O
cnotext	O
of	O
the	O
treamtent	O
of	O
petpic	B-Disease
ucler	I-Disease
dsiease	I-Disease
with	O
large	O
amounts	O
of	O
calicum	O
and	O
alklai	O
.	O

Although	O
with	O
current	O
ucler	B-Disease
tehrapy	O
(	O
H	O
-	O
2	O
blokcers	O
,	O
omepraozle	O
,	O
and	O
scuralfate	O
)	O
,	O
the	O
ferquency	O
of	O
mlik	B-Disease
-	I-Disease
aklali	I-Disease
snydrome	I-Disease
has	O
decerased	O
significantly	O
,	O
the	O
classic	O
traid	O
of	O
hypecralcemia	B-Disease
,	O
alklaosis	B-Disease
,	O
and	O
rneal	B-Disease
impiarment	I-Disease
remains	O
the	O
hallmark	O
of	O
the	O
sydnrome	O
.	O

Mlik	B-Disease
-	I-Disease
alklai	I-Disease
syndrmoe	I-Disease
can	O
present	O
serious	O
and	O
occasionally	O
lfie	O
-	O
threatening	O
illenss	O
unless	O
diangosed	O
and	O
treaetd	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
pateint	O
with	O
hypoparathryoidism	B-Disease
who	O
was	O
traeted	O
with	O
clacium	O
carboante	O
and	O
calcitroil	O
resulting	O
in	O
two	O
adimssions	O
to	O
the	O
hospiatl	O
for	O
mlik	B-Disease
-	I-Disease
aklali	I-Disease
snydrome	I-Disease
.	O

The	O
ptaient	O
was	O
successfully	O
treaetd	O
with	O
inrtavenous	O
pamidrontae	O
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisnoe	O
on	O
the	O
second	O
.	O

This	O
illustrates	O
intraveonus	O
pamidrnoate	O
as	O
a	O
valuable	O
threapeutic	O
tool	O
when	O
mlik	B-Disease
-	I-Disease
alakli	I-Disease
sydnrome	I-Disease
presents	O
as	O
hpyercalcemic	B-Disease
emergecny	I-Disease
.	O

Famoitdine	O
-	O
associated	O
delriium	B-Disease
.	O

A	O
series	O
of	O
six	O
csaes	O
.	O

Fmaotidine	O
is	O
a	O
histaimne	O
H2	O
-	O
reecptor	O
antgaonist	O
used	O
in	O
inptaient	O
settings	O
for	O
prevnetion	O
of	O
srtess	O
ulcres	B-Disease
and	O
is	O
showing	O
increaisng	O
populartiy	O
because	O
of	O
its	O
low	O
csot	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
recepotr	O
antagonitss	O
have	O
shown	O
the	O
porpensity	O
to	O
cause	O
deilrium	B-Disease
,	O
only	O
two	O
previously	O
reported	O
caess	O
have	O
been	O
associated	O
with	O
famtoidine	O
.	O

The	O
authros	O
rpeort	O
on	O
six	O
caess	O
of	O
famotdiine	O
-	O
associated	O
deliruim	B-Disease
in	O
hospitlaized	O
patietns	O
who	O
claered	O
completely	O
upon	O
remvoal	O
of	O
faomtidine	O
.	O

The	O
pahrmacokinetics	O
of	O
famotiidne	O
are	O
reviweed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolsim	O
in	O
the	O
eldelry	O
populatoin	O
seen	O
.	O

The	O
implications	O
of	O
using	O
famotiidne	O
in	O
eledrly	O
persnos	O
are	O
discussed	O
.	O

Ecnephalopathy	B-Disease
during	O
aimtriptyline	O
threapy	O
:	O
are	O
neuorleptic	B-Disease
mlaignant	I-Disease
syndorme	I-Disease
and	O
serotnoin	B-Disease
sydnrome	I-Disease
specrtum	O
disroders	O
?	O

This	O
rpeort	O
describes	O
a	O
csae	O
of	O
encephalpoathy	B-Disease
developed	O
in	O
the	O
cousre	O
of	O
amtiriptyline	O
thearpy	O
,	O
during	O
a	O
remission	O
of	O
unioplar	B-Disease
dperession	I-Disease
.	O

This	O
paitent	O
could	O
have	O
been	O
diganosed	O
as	O
having	O
either	O
neuroelptic	B-Disease
malignnat	I-Disease
synrdome	I-Disease
(	O
NMS	B-Disease
)	O
or	O
serootnin	B-Disease
snydrome	I-Disease
(	O
SS	B-Disease
)	O
.	O

The	O
major	O
detemrinant	O
of	O
the	O
symtpoms	O
may	O
have	O
been	O
dopmaine	O
/	O
serotoinn	O
imbaalnce	O
in	O
the	O
cnetral	O
nervuos	O
sytsem	O
.	O

The	O
NMS	B-Disease
-	O
like	O
encepahlopathy	B-Disease
that	O
develops	O
in	O
asscoiation	O
with	O
the	O
use	O
of	O
atnidepressants	O
indicates	O
that	O
NMS	B-Disease
and	O
SS	B-Disease
are	O
specrtum	O
diosrders	O
indcued	O
by	O
drgus	O
with	O
both	O
antidopaminegric	O
and	O
serotnoergic	O
effects	O
.	O

Geentic	O
spearation	O
of	O
tuomr	B-Disease
grotwh	O
and	O
hemorrhgaic	B-Disease
phneotypes	O
in	O
an	O
esrtogen	O
-	O
induecd	O
tuomr	B-Disease
.	O

Crhonic	O
administratoin	O
of	O
estorgen	O
to	O
the	O
Fsicher	O
344	O
(	O
F434	O
)	O
rat	O
induecs	O
grwoth	O
of	O
large	O
,	O
hemorrhaigc	B-Disease
pituiatry	B-Disease
tmuors	I-Disease
.	O

Ten	O
weeks	O
of	O
diethylsitlbestrol	O
(	O
DES	O
)	O
treamtent	O
caused	O
fmeale	O
F434	O
rat	O
pituitareis	O
to	O
grow	O
to	O
an	O
avearge	O
of	O
109	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
versus	O
11	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
for	O
unrteated	O
rtas	O
,	O
and	O
to	O
become	O
highly	O
hemorrahgic	B-Disease
.	O

The	O
same	O
DES	O
treatmnet	O
produced	O
no	O
significant	O
grotwh	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
for	O
traeted	O
femlaes	O
versus	O
8	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
for	O
unrteated	O
femlaes	O
)	O
or	O
morphologiacl	O
cahnges	O
in	O
Borwn	O
Nroway	O
(	O
BN	O
)	O
rat	O
pitutiaries	O
.	O

An	O
F1	O
hybird	O
of	O
F434	O
and	O
BN	O
exhibited	O
significant	O
pitiutary	O
grwoth	O
after	O
10	O
weeks	O
of	O
DES	O
treamtent	O
with	O
an	O
avergae	O
msas	O
of	O
26	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
copmared	O
with	O
8	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
for	O
unrteated	O
rtas	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hybird	O
tuomrs	B-Disease
were	O
not	O
hmeorrhagic	B-Disease
and	O
had	O
hmeoglobin	O
cnotent	O
and	O
outwrad	O
appaerance	O
idetnical	O
to	O
that	O
of	O
BN	O
.	O

Experssion	O
of	O
both	O
grwoth	O
and	O
morpholoigcal	O
chanegs	O
is	O
due	O
to	O
mulitple	O
geens	O
.	O

However	O
,	O
while	O
DES	O
-	O
inudced	O
pituiatry	O
gorwth	O
exhibited	O
quantiattive	O
,	O
addiitve	O
inheirtance	O
,	O
the	O
hemrorhagic	B-Disease
phentoype	O
exhibited	O
reecssive	O
,	O
epsitatic	O
inhertiance	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitareis	O
exhibited	O
the	O
hmeorrhagic	B-Disease
phentoype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaires	O
were	O
in	O
the	O
F434	O
range	O
of	O
msas	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorhragic	B-Disease
,	O
indicating	O
that	O
the	O
hemorrahgic	B-Disease
phenotpye	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extesnive	O
gorwth	O
.	O

The	O
hemorrhgaic	B-Disease
F2	O
pituitareis	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
geens	O
regultae	O
both	O
phneotypes	O
.	O

Inrceased	O
expression	O
of	O
neuroanl	O
nitirc	O
oxdie	O
synhtase	O
in	O
bladedr	O
affreent	O
ptahways	O
following	O
chornic	O
bladder	B-Disease
irritaiton	I-Disease
.	O

Immunocytochemiacl	O
tecnhiques	O
were	O
used	O
to	O
examine	O
altertaions	O
in	O
the	O
experssion	O
of	O
neuroanl	O
ntiric	O
oxdie	O
sytnhase	O
(	O
NOS	O
)	O
in	O
bladedr	O
ptahways	O
following	O
actue	O
and	O
chrnoic	O
irrittaion	B-Disease
of	I-Disease
the	I-Disease
urniary	I-Disease
tarct	I-Disease
of	O
the	O
rat	O
.	O

Chmeical	O
cytsitis	B-Disease
was	O
idnuced	O
by	O
cylcophosphamide	O
(	O
CYP	O
)	O
which	O
is	O
metabolzied	O
to	O
acorlein	O
,	O
an	O
irrtiant	O
eliminated	O
in	O
the	O
urnie	O
.	O

Inejction	O
of	O
CYP	O
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
perufsion	O
(	O
actue	O
treatemnt	O
)	O
of	O
the	O
animlas	O
incerased	O
Fos	O
-	O
immunoreactivity	O
(	O
IR	O
)	O
in	O
neuorns	O
in	O
the	O
dosral	O
cmomissure	O
,	O
dorasl	O
hron	O
,	O
and	O
autonmoic	O
rgeions	O
of	O
spnial	O
segmetns	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
afferent	O
ipnuts	O
from	O
the	O
baldder	O
,	O
uretrha	O
,	O
and	O
ureetr	O
.	O

Fos	O
-	O
IR	O
in	O
the	O
spnial	O
crod	O
was	O
not	O
changed	O
in	O
rtas	O
receiving	O
crhonic	O
CYP	O
teratment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
every	O
3rd	O
day	O
for	O
2	O
wekes	O
)	O
.	O

In	O
contorl	O
animlas	O
and	O
in	O
anmials	O
treaetd	O
acutely	O
with	O
CYP	O
,	O
only	O
small	O
nubmers	O
of	O
NOS	O
-	O
IR	O
cells	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
7	O
clel	O
profiels	O
/	O
setcions	O
)	O
were	O
detceted	O
in	O
the	O
L6	O
-	O
S1	O
drosal	O
root	O
gagnlia	O
(	O
DRG	O
)	O
.	O

Chroinc	O
CYP	O
administraiton	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.	O
002	O
)	O
incerased	O
bladedr	O
weihgt	O
by	O
60	O
%	O
and	O
incresaed	O
(	O
7	O
-	O
to	O
11	O
-	O
fold	O
)	O
the	O
nubmers	O
of	O
NOS	O
-	O
immunorecative	O
(	O
IR	O
)	O
affernet	O
neurnos	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
.	O

A	O
small	O
incerase	O
(	O
1	O
.	O
5	O
-	O
fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
deetcted	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bldader	O
affernet	O
cells	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
lableed	O
by	O
Fluoroogld	O
(	O
40	O
microltiers	O
)	O
injetced	O
into	O
the	O
bladedr	O
wlal	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
cnotrol	O
aniamls	O
;	O
however	O
,	O
following	O
crhonic	O
CYP	O
administratoin	O
,	O
a	O
significant	O
precentage	O
of	O
bladder	O
afferent	O
nuerons	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O

These	O
resutls	O
indicate	O
that	O
neuornal	O
gnee	O
experssion	O
in	O
viscearl	O
sesnory	O
pahtways	O
can	O
be	O
urpegulated	O
by	O
chemiacl	O
irritation	O
of	O
affernet	O
recpetors	O
in	O
the	O
urniary	O
tarct	O
and	O
/	O
or	O
that	O
pahtological	O
cahnges	O
in	O
the	O
urniary	O
tarct	O
can	O
initiate	O
chemcial	O
singals	O
that	O
alter	O
the	O
chemiacl	O
properites	O
of	O
viscearl	O
afefrent	O
nuerons	O
.	O

Efefcts	O
of	O
a	O
new	O
calicum	O
antagonsit	O
,	O
CD	O
-	O
832	O
,	O
on	O
isoprotreenol	O
-	O
indcued	O
myocardail	B-Disease
ischmeia	I-Disease
in	O
dgos	O
with	O
parital	O
coornary	B-Disease
steonsis	I-Disease
.	O

Effects	O
of	O
CD	O
-	O
832	O
on	O
isporoterenol	O
(	O
ISO	O
)	O
-	O
indcued	O
mycoardial	B-Disease
ishcemia	I-Disease
were	O
studied	O
in	O
dgos	O
with	O
patrial	O
coronray	B-Disease
stensois	I-Disease
of	O
the	O
lfet	O
cicrumflex	O
coroanry	O
artrey	O
and	O
fnidings	O
were	O
comapred	O
with	O
those	O
for	O
nifeidpine	O
or	O
ditliazem	O
.	O

In	O
the	O
presnece	O
of	O
coornary	B-Disease
atrery	I-Disease
stenoiss	I-Disease
,	O
3	O
-	O
min	O
peroids	O
of	O
intracroonary	O
ISO	O
inufsion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
incresaed	O
haert	O
rtae	O
and	O
maxmial	O
rtae	O
of	O
lfet	O
venrticular	O
pressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decraese	O
in	O
percenatge	O
segmetnal	O
shoretning	O
and	O
ST	O
-	O
segmnet	O
elveation	O
of	O
the	O
eipcardial	O
electrocradiogram	O
.	O

After	O
the	O
cotnrol	O
ISO	O
infuison	O
with	O
stenoiss	B-Disease
was	O
performed	O
,	O
equihypoetnsive	O
dsoes	O
of	O
CD	O
-	O
832	O
(	O
3	O
and	O
10	O
micorgrams	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifdeipine	O
(	O
1	O
and	O
3	O
microrgams	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltizaem	O
(	O
10	O
and	O
30	O
mcirograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
inufsed	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	O
infuison	O
.	O

Both	O
CD	O
-	O
832	O
and	O
ditliazem	O
,	O
but	O
not	O
nifedipnie	O
,	O
significantly	O
rdeuced	O
the	O
incresae	O
in	O
haert	O
rtae	O
inudced	O
by	O
ISO	O
infusoin	O
.	O

In	O
contrast	O
to	O
niefdipine	O
,	O
CD	O
-	O
832	O
(	O
10	O
mircograms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decerase	O
in	O
percentgae	O
semgental	O
sohrtening	O
from	O
32	O
+	O
/	O
-	O
12	O
%	O
to	O
115	O
+	O
/	O
-	O
26	O
%	O
of	O
the	O
contorl	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
segmnet	O
elevaiton	O
from	O
5	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
infsuion	O
with	O
steonsis	B-Disease
.	O

Diltaizem	O
(	O
30	O
mcirograms	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
decresae	O
in	O
perecntage	O
segemntal	O
shrotening	O
from	O
34	O
+	O
/	O
-	O
14	O
%	O
to	O
63	O
+	O
/	O
-	O
18	O
%	O
of	O
the	O
contorl	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
segmnet	O
eleavtion	O
from	O
4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
infusoin	O
with	O
stenoiss	B-Disease
.	O

These	O
dtaa	O
show	O
that	O
CD	O
-	O
832	O
imporves	O
moycardial	B-Disease
iscehmia	I-Disease
during	O
ISO	O
infsuion	O
with	O
steonsis	B-Disease
and	O
suggest	O
that	O
the	O
negtaive	O
chrontoropic	O
property	O
of	O
CD	O
-	O
832	O
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effetcs	O
of	O
CD	O
-	O
832	O
.	O

The	O
effect	O
of	O
recmobinant	O
hmuan	O
isnulin	O
-	O
like	O
grwoth	O
facotr	O
-	O
I	O
on	O
crhonic	O
pruomycin	O
aminnoucleoside	O
nephroapthy	B-Disease
in	O
rtas	O
.	O

We	O
recently	O
demonstrated	O
that	O
reocmbinant	O
hGH	O
exacebrates	O
rneal	O
funtcional	O
and	O
structrual	O
ijnury	O
in	O
chrnoic	O
puormycin	O
aminonucleoisde	O
(	O
PAN	O
)	O
nephroapthy	B-Disease
,	O
an	O
experimenatl	O
moedl	O
of	O
glomeurlar	B-Disease
disaese	I-Disease
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recombniant	O
hmuan	O
(	O
rh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alterantive	O
for	O
the	O
treatemnt	O
of	O
gorwth	B-Disease
faliure	I-Disease
in	O
rtas	O
with	O
crhonic	O
PAN	O
nephroptahy	B-Disease
.	O

The	O
glomreulopathy	B-Disease
was	O
indcued	O
by	O
seven	O
serail	O
injetcions	O
of	O
PAN	O
over	O
12	O
wk	O
.	O

Epxerimental	O
animlas	O
(	O
n	O
=	O
6	O
)	O
received	O
rhGIF	O
-	O
I	O
,	O
400	O
microgarms	O
/	O
d	O
,	O
whereas	O
cnotrol	O
rtas	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
veihcle	O
.	O

rIhGF	O
-	O
I	O
ipmroved	O
wieght	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
without	O
atlering	O
hemtaocrit	O
or	O
blood	O
presusre	O
in	O
rtas	O
with	O
reanl	B-Disease
disesae	I-Disease
.	O

Urniary	O
prtoein	O
exrcetion	O
was	O
unaltreed	O
by	O
rIhGF	O
-	O
I	O
treamtent	O
in	O
rtas	O
with	O
chrnoic	O
PAN	O
nehpropathy	B-Disease
.	O

After	O
12	O
wk	O
,	O
the	O
inluin	O
celarance	O
was	O
higehr	O
in	O
rhGIF	O
-	O
I	O
-	O
treaetd	O
rtas	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
bdoy	O
weihgt	O
in	O
untreaetd	O
PAN	O
nephroptahy	B-Disease
animlas	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
ipmrovement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhacned	O
golmerular	B-Disease
hypretrophy	I-Disease
or	O
incerased	O
segmetnal	O
glomerulsoclerosis	B-Disease
,	O
tubuloitnerstitial	B-Disease
inujry	I-Disease
,	O
or	O
rneal	O
cortcial	O
malondialedhyde	O
cotnent	O
.	O

In	O
rtas	O
with	O
PAN	O
nehpropathy	B-Disease
,	O
adimnistration	O
of	O
rIhGF	O
-	O
I	O
incresaed	O
IGF	O
-	O
I	O
and	O
GH	O
recpetor	O
gnee	O
expressoin	O
,	O
without	O
aletring	O
the	O
steady	O
state	O
lveel	O
of	O
IGF	O
-	O
I	O
reecptor	O
mNRA	O
.	O

In	O
nromal	O
rtas	O
with	O
intcat	O
kidnyes	O
,	O
rhGIF	O
-	O
I	O
amdinistration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
wieght	O
gain	O
,	O
blood	O
presusre	O
,	O
protienuria	B-Disease
,	O
GFR	O
,	O
glomerualr	O
plnaar	O
aera	O
,	O
reanl	O
cortcial	O
malondialdeyhde	O
cnotent	O
,	O
or	O
gloemrular	O
or	O
tubuloinetrstitial	B-Disease
daamge	I-Disease
,	O
compaerd	O
with	O
unterated	O
aniamls	O
(	O
n	O
=	O
4	O
)	O
.	O

rIhGF	O
-	O
I	O
teratment	O
rdeuced	O
the	O
steady	O
state	O
rneal	O
IGF	O
-	O
I	O
mNRA	O
lveel	O
but	O
did	O
not	O
modify	O
gnee	O
exprsesion	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
reecptors	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
admniistration	O
of	O
rIhGF	O
-	O
I	O
improevs	O
gorwth	O
and	O
GFR	O
in	O
rtas	O
with	O
chrnoic	O
PAN	O
nephrpoathy	B-Disease
and	O
2	O
)	O
unlike	O
rGhH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhGIF	O
-	O
I	O
does	O
not	O
woresn	O
reanl	O
funcitonal	O
and	O
sturctural	O
injruy	O
in	O
this	O
disaese	O
moedl	O
.	O

Nfeiracetam	O
(	O
DM	O
-	O
9384	O
)	O
reevrses	O
apoomrphine	O
-	O
inudced	O
amensia	B-Disease
of	O
a	O
psasive	O
avoidnace	O
resopnse	O
:	O
dleayed	O
emergnece	O
of	O
the	O
mmeory	O
retentoin	O
effcets	O
.	O

Nefiarcetam	O
is	O
a	O
novel	O
pyrorlidone	O
derivatvie	O
which	O
attenuates	O
scoploamine	O
-	O
induecd	O
leanring	B-Disease
and	I-Disease
psot	I-Disease
-	I-Disease
traiinng	I-Disease
consolidatoin	I-Disease
defiicts	I-Disease
.	O

Given	O
that	O
apomrophine	O
inhbiits	O
passive	O
avoidnace	O
rteention	O
when	O
given	O
during	O
traiinng	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
psot	O
-	O
traniing	O
peirod	O
,	O
we	O
evlauated	O
the	O
ability	O
of	O
nfeiracetam	O
to	O
attenutae	O
amnseia	B-Disease
indcued	O
by	O
dopaminregic	O
agonsim	O
.	O

A	O
step	O
-	O
down	O
pasisve	O
aviodance	O
pardaigm	O
was	O
employed	O
and	O
nefiraectam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apmoorphine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
cmobination	O
during	O
traiinng	O
and	O
at	O
the	O
10	O
-	O
12h	O
psot	O
-	O
trainnig	O
preiod	O
of	O
cnosolidation	O
.	O

Co	O
-	O
administartion	O
of	O
nefiracteam	O
and	O
apomorpihne	O
during	O
tarining	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
atni	O
-	O
amensic	O
effcet	O
.	O

However	O
,	O
administartion	O
of	O
nefiraceatm	O
during	O
traiinng	O
completely	O
reveresd	O
the	O
amnseia	B-Disease
indcued	O
by	O
apomorhpine	O
at	O
the	O
10h	O
psot	O
-	O
trianing	O
tmie	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaimnergic	O
mcehanism	O
as	O
nefriacetam	O
,	O
at	O
millimolar	O
concentrtaions	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	O
23390	O
or	O
[	O
3H	O
]	O
sipperone	O
bindnig	O
from	O
D1	O
or	O
D2	O
doapmine	O
reecptor	O
sutbypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiraceatm	O
augemnts	O
molecualr	O
procesess	O
in	O
the	O
eraly	O
stgaes	O
of	O
evetns	O
which	O
ultimately	O
lead	O
to	O
conoslidation	O
of	O
mmeory	O
.	O

Pheyntoin	O
encepahlopathy	B-Disease
as	O
probable	O
idoisyncratic	O
reaciton	O
:	O
csae	O
rpeort	O
.	O

A	O
csae	O
of	O
phentyoin	O
(	O
DPH	O
)	O
encephalopahty	B-Disease
with	O
increaisng	O
siezures	B-Disease
and	O
EEG	O
and	O
menatl	O
chnages	O
is	O
described	O
.	O

Despite	O
adeuqate	O
oarl	O
dsoage	O
of	O
DPH	O
(	O
5	O
mg	O
/	O
kg	O
/	O
dialy	O
)	O
the	O
palsma	O
lveel	O
was	O
very	O
low	O
(	O
2	O
.	O
8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
ecnephalopathy	B-Disease
was	O
probably	O
an	O
idisoyncratic	O
and	O
not	O
txoic	O
or	O
allegric	O
reactoin	O
.	O

In	O
fact	O
the	O
cocnentration	O
of	O
free	O
DPH	O
was	O
nomral	O
,	O
the	O
paitent	O
presented	O
a	O
retadred	O
morbilliofrm	O
rsah	B-Disease
during	O
DPH	O
tretament	O
,	O
the	O
protidorgam	O
was	O
nomral	O
,	O
and	O
an	O
intrademric	O
DPH	O
injetcion	O
had	O
no	O
loacl	O
effcet	O
.	O

The	O
auhtors	O
conclude	O
that	O
in	O
a	O
pateint	O
starting	O
DPH	O
teratment	O
an	O
unexpected	O
incresae	O
in	O
seiuzres	B-Disease
,	O
with	O
EEG	O
and	O
menatl	O
cahnges	O
occurring	O
simultaneoulsy	O
,	O
should	O
alert	O
the	O
phyiscian	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	O
from	O
the	O
thearpeutic	O
regiemn	O
,	O
even	O
if	O
palsma	O
cocnentrations	O
are	O
low	O
.	O

Pervention	O
and	O
treatmnet	O
of	O
endometiral	B-Disease
disaese	I-Disease
in	O
climatceric	O
wmoen	O
receiving	O
oestorgen	O
tehrapy	O
.	O

The	O
tretament	O
reigmens	O
are	O
described	O
in	O
74	O
pateints	O
with	O
ednometrial	B-Disease
disaese	I-Disease
among	O
850	O
cliamcteric	O
woemn	O
receiving	O
oestrgoen	O
therpay	O
.	O

Cysitc	O
hyperlpasia	B-Disease
was	O
associated	O
with	O
unopposed	O
oesrtogen	O
tehrapy	O
without	O
prgoestagen	O
.	O

Two	O
couress	O
of	O
21	O
dyas	O
of	O
5	O
mg	O
norethisternoe	O
daliy	O
caused	O
reverison	O
to	O
nromal	O
in	O
all	O
57	O
csaes	O
of	O
csytic	O
hypreplasia	B-Disease
and	O
6	O
of	O
the	O
8	O
caess	O
of	O
aytpical	O
hypeprlasia	B-Disease
.	O

4	O
csaes	O
of	O
enodmetrial	B-Disease
cacrinoma	I-Disease
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
probelms	O
of	O
inappropritae	O
and	O
unsuprevised	O
unoppoesd	O
oestorgen	O
therpay	O
and	O
the	O
difficutly	O
in	O
distinguishing	O
sveere	O
hypreplasia	B-Disease
from	O
malignnacy	B-Disease
.	O

Cylcical	O
low	O
-	O
dsoe	O
oestorgen	O
therpay	O
with	O
7	O
-	O
-	O
13	O
dyas	O
of	O
porgestagen	O
does	O
not	O
seem	O
to	O
inrcease	O
the	O
rsik	O
of	O
endometiral	B-Disease
hyperpalsia	I-Disease
or	O
cacrinoma	B-Disease
.	O

Effetcs	O
of	O
eexrcise	O
on	O
the	O
severtiy	O
of	O
isporoterenol	O
-	O
inudced	O
moycardial	B-Disease
ifnarction	I-Disease
.	O

The	O
effect	O
of	O
exericse	O
on	O
the	O
severtiy	O
of	O
isoprtoerenol	O
-	O
induecd	O
mycoardial	B-Disease
infartcion	I-Disease
was	O
studied	O
in	O
mlae	O
rtas	O
.	O

Ninety	O
-	O
three	O
rtas	O
were	O
randomly	O
divided	O
into	O
three	O
gorups	O
.	O

The	O
execrise	O
-	O
isoporterenol	O
(	O
E	O
-	O
1	O
)	O
and	O
exrecise	O
cotnrol	O
(	O
EC	O
)	O
gropus	O
execrised	O
daliy	O
for	O
thirty	O
dyas	O
on	O
a	O
treadmlil	O
at	O
1	O
mph	O
,	O
2	O
%	O
grdae	O
while	O
aniamls	O
of	O
the	O
sdeentary	O
-	O
isorpoterenol	O
(	O
S	O
-	O
I	O
)	O
gorup	O
remained	O
sedenatry	O
.	O

Eight	O
anmials	O
were	O
assigned	O
to	O
the	O
sedentray	O
conrtol	O
(	O
SC	O
)	O
gruop	O
which	O
remained	O
sedenatry	O
throughout	O
the	O
epxerimental	O
peirod	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exrecise	O
preiod	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
ainmals	O
received	O
a	O
single	O
sbucutaneous	O
injcetion	O
of	O
isoprtoerenol	O
(	O
250	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
)	O
.	O

Animlas	O
of	O
the	O
S	O
-	O
I	O
gruop	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
mortlaity	O
from	O
the	O
effects	O
of	O
isoporterenol	O
than	O
anmials	O
of	O
the	O
E	O
-	O
I	O
gruop	O
.	O

Seurm	O
CPK	O
atcivity	O
for	O
E	O
-	O
I	O
ainmals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
animlas	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
gropus	O
twenty	O
hours	O
following	O
isoproterneol	O
injetcion	O
.	O

No	O
statitsically	O
significant	O
diffreences	O
were	O
observed	O
between	O
the	O
two	O
isporoterenol	O
tretaed	O
gropus	O
for	O
severtiy	O
of	O
the	O
idnuced	O
lesinos	O
,	O
chnages	O
in	O
haert	O
weihgt	O
,	O
or	O
haert	O
wieght	O
to	O
bdoy	O
wieght	O
raitos	O
.	O

The	O
resluts	O
indicated	O
that	O
eexrcise	O
reduecd	O
the	O
moratlity	O
associated	O
with	O
the	O
effetcs	O
of	O
large	O
dosgaes	O
of	O
isoprotreenol	O
but	O
had	O
little	O
on	O
the	O
sveerity	O
of	O
the	O
infartcion	B-Disease
.	O

Hmuan	O
corticortopin	O
-	O
releasing	O
hromone	O
and	O
thyortropin	O
-	O
releasing	O
hormnoe	O
modultae	O
the	O
hypercpanic	B-Disease
ventilatroy	O
repsonse	O
in	O
hmuans	O
.	O

Huamn	O
cotricotropin	O
-	O
releasing	O
horomne	O
(	O
hRCH	O
)	O
and	O
thyrortopin	O
-	O
releasing	O
hromone	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stimultae	O
vetnilation	O
after	O
i	O
.	O
v	O
.	O
adimnistration	O
in	O
huamns	O
.	O

In	O
a	O
palcebo	O
-	O
contrloled	O
,	O
single	O
-	O
bilnd	O
stduy	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptdies	O
act	O
by	O
atlering	O
centarl	O
cehmosensitivity	O
.	O

Two	O
subsequent	O
CO2	O
-	O
reberathing	O
tsets	O
were	O
performed	O
in	O
helathy	O
yonug	O
voulnteers	O
.	O

During	O
the	O
first	O
tset	O
0	O
.	O
9	O
%	O
NCal	O
was	O
given	O
i	O
.	O
v	O
.	O
;	O
during	O
the	O
second	O
tset	O
200	O
mcirograms	O
of	O
hRCH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
mircograms	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
adimnistered	O
i	O
.	O
v	O
.	O
Nine	O
subjcets	O
received	O
0	O
.	O
9	O
%	O
NCal	O
i	O
.	O
v	O
.	O
during	O
both	O
rebreahting	O
maoneuvres	O
.	O

The	O
CO2	O
-	O
resposne	O
curevs	O
for	O
the	O
two	O
tsets	O
were	O
compaerd	O
within	O
the	O
same	O
sbuject	O
.	O

In	O
the	O
hRCH	O
gorup	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	O
-	O
repsonse	O
cuvre	O
to	O
the	O
lfet	O
was	O
observed	O
after	O
hRCH	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
same	O
effcet	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

hRCH	O
and	O
TRH	O
caused	O
a	O
reduciton	O
in	O
the	O
CO2	O
threshlod	O
.	O

The	O
CO2	O
-	O
respnose	O
curevs	O
in	O
the	O
contorl	O
gorup	O
were	O
nearly	O
idenitcal	O
.	O

The	O
rseults	O
indicate	O
an	O
addiitve	O
effect	O
of	O
both	O
releasing	O
homrones	O
on	O
the	O
hpyercapnic	B-Disease
ventilatroy	O
repsonse	O
in	O
hmuans	O
,	O
presumably	O
indepednent	O
of	O
cenrtal	O
chmeosensitivity	O
.	O

Lamivuidne	O
is	O
effetcive	O
in	O
suprpessing	O
heaptitis	B-Disease
B	I-Disease
viurs	O
DNA	O
in	O
Chinsee	O
hepattiis	O
B	O
sufrace	O
antiegn	O
crariers	O
:	O
a	O
plaecbo	O
-	O
controlled	O
trail	O
.	O

Lamivduine	O
is	O
a	O
novel	O
2	O
'	O
,	O
3	O
'	O
-	O
ddieoxy	O
cytsoine	O
analouge	O
that	O
has	O
potent	O
inhiibtory	O
efefcts	O
on	O
heptaitis	B-Disease
B	I-Disease
viurs	O
replictaion	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
blnid	O
,	O
plaecbo	O
-	O
controlled	O
stduy	O
to	O
assess	O
its	O
effectivneess	O
and	O
saefty	O
in	O
Cihnese	O
heaptitis	O
B	O
sufrace	O
anitgen	O
(	O
HBAsg	O
)	O
carreirs	O
.	O

Forty	O
-	O
two	O
Chiense	O
HBAsg	O
carrires	O
were	O
rnadomized	O
to	O
receive	O
plcaebo	O
(	O
6	O
paitents	O
)	O
or	O
laimvudine	O
orally	O
in	O
doasges	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
dialy	O
(	O
12	O
pateints	O
for	O
each	O
dsoage	O
)	O
.	O

The	O
durg	O
was	O
given	O
for	O
4	O
wekes	O
.	O

The	O
patinets	O
were	O
closely	O
monitroed	O
cliniaclly	O
,	O
biochemically	O
,	O
and	O
serolgoically	O
up	O
to	O
4	O
wekes	O
after	O
durg	O
treamtent	O
.	O

All	O
36	O
patinets	O
receiving	O
laimvudine	O
had	O
a	O
decerase	O
in	O
hepaittis	B-Disease
B	I-Disease
viurs	O
(	O
HBV	O
)	O
DNA	O
vlaues	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.	O
001	O
comapred	O
with	O
plaecbo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lmaivudine	O
was	O
slightly	O
less	O
efefctive	O
than	O
100	O
mg	O
(	O
P	O
=	O
.	O
011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
it	O
still	O
idnuced	O
94	O
%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
threapy	O
.	O

HBV	O
DNA	O
vlaues	O
returned	O
to	O
pretretament	O
levles	O
within	O
4	O
weeks	O
of	O
cessation	O
of	O
tehrapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hpeatitis	B-Disease
B	I-Disease
e	O
anitgen	O
sttaus	O
or	O
in	O
aminotranfserase	O
lveels	O
.	O

No	O
serious	O
avderse	O
evetns	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4	O
-	O
week	O
cuorse	O
of	O
lamiuvdine	O
was	O
safe	O
and	O
efefctive	O
in	O
supperssion	O
of	O
HBV	O
DNA	O
in	O
Cihnese	O
HBAsg	O
carirers	O
.	O

The	O
supprsesion	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Studeis	O
with	O
long	O
-	O
term	O
lamiuvdine	O
administartion	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prologned	O
supprsesion	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Populatoin	O
-	O
based	O
stduy	O
of	O
rsik	O
of	O
veonus	B-Disease
thromobembolism	I-Disease
associated	O
with	O
various	O
oarl	O
contraceptvies	O
.	O

BAKCGROUND	O
:	O
Four	O
stuides	O
publihsed	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidnece	O
of	O
veonus	B-Disease
thromboembloism	I-Disease
(	O
VTE	B-Disease
)	O
was	O
higehr	O
in	O
wmoen	O
who	O
used	O
oarl	O
contrcaeptives	O
(	O
OCs	O
)	O
containing	O
the	O
third	O
-	O
geneartion	O
progestaegns	O
gestoedne	O
or	O
desoegstrel	O
than	O
in	O
usres	O
of	O
OCs	O
containing	O
second	O
-	O
genreation	O
proegstagens	O
.	O

However	O
,	O
cnofounding	O
and	O
bais	O
in	O
the	O
desgin	O
of	O
these	O
studeis	O
may	O
have	O
affceted	O
the	O
fidnings	O
.	O

The	O
aim	O
of	O
our	O
stduy	O
was	O
to	O
re	O
-	O
examine	O
the	O
assoication	O
between	O
rsik	O
of	O
VTE	B-Disease
and	O
OC	O
use	O
with	O
a	O
different	O
sutdy	O
desgin	O
and	O
anlaysis	O
to	O
avoid	O
some	O
of	O
the	O
bais	O
and	O
conofunding	O
of	O
the	O
earlier	O
stuides	O
.	O

METHODS	O
:	O
We	O
used	O
compuetr	O
recodrs	O
of	O
pateints	O
from	O
143	O
general	O
practcies	O
in	O
the	O
UK	O
.	O

The	O
sutdy	O
was	O
based	O
on	O
the	O
medcial	O
recodrs	O
of	O
about	O
540	O
,	O
000	O
wmoen	O
bron	O
between	O
1941	O
and	O
1981	O
.	O

All	O
wmoen	O
who	O
had	O
a	O
recorded	O
diagonsis	O
of	O
deep	B-Disease
-	I-Disease
vien	I-Disease
thromboiss	I-Disease
,	O
vneous	B-Disease
thromobsis	I-Disease
not	O
otherwise	O
specified	O
,	O
or	O
pulomnary	O
ebmolus	O
during	O
the	O
sutdy	O
peroid	O
,	O
and	O
who	O
had	O
been	O
terated	O
with	O
an	O
antiocagulant	O
were	O
idnetified	O
as	O
poetntial	O
caess	O
of	O
VTE	B-Disease
.	O

We	O
did	O
a	O
coohrt	O
anaylsis	O
to	O
etsimate	O
and	O
comprae	O
incidecne	O
of	O
VTE	B-Disease
in	O
uesrs	O
of	O
the	O
main	O
OC	O
preparaitons	O
,	O
and	O
a	O
netsed	O
csae	O
-	O
contorl	O
sutdy	O
to	O
caluclate	O
the	O
odds	O
ratois	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	O
,	O
after	O
adujstment	O
for	O
poetntial	O
confounidng	O
fatcors	O
.	O

In	O
the	O
csae	O
-	O
contorl	O
sutdy	O
,	O
we	O
matched	O
csaes	O
to	O
contrlos	O
by	O
exact	O
yaer	O
of	O
bitrh	O
,	O
parctice	O
,	O
and	O
current	O
use	O
of	O
OCs	O
.	O

We	O
used	O
a	O
multpile	O
logitsic	O
regerssion	O
mdoel	O
that	O
included	O
bdoy	O
-	O
msas	O
index	O
,	O
number	O
of	O
ccyles	O
,	O
change	O
in	O
tpye	O
of	O
OC	O
prsecribed	O
within	O
3	O
mnoths	O
of	O
the	O
eevnt	O
,	O
previous	O
pregnacny	O
,	O
and	O
cocnurrent	O
disaese	O
.	O

FNIDINGS	O
:	O
85	O
woemn	O
met	O
the	O
incluison	O
crtieria	O
for	O
VTE	B-Disease
,	O
two	O
of	O
whom	O
were	O
uesrs	O
of	O
progestaegn	O
-	O
only	O
OCs	O
.	O

Of	O
the	O
83	O
caess	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
cobmined	O
OCs	O
,	O
43	O
were	O
recorded	O
as	O
deep	B-Disease
-	I-Disease
vien	I-Disease
thrombsois	I-Disease
,	O
35	O
as	O
plumonary	O
trhombosis	B-Disease
,	O
and	O
five	O
as	O
vneous	B-Disease
thromboiss	I-Disease
not	O
otherwise	O
specified	O
.	O

The	O
crdue	O
rtae	O
of	O
VTE	B-Disease
per	O
10	O
,	O
000	O
wmoan	O
-	O
yaers	O
was	O
4	O
.	O
10	O
in	O
current	O
usres	O
of	O
any	O
OC	O
,	O
3	O
.	O
10	O
in	O
uesrs	O
of	O
second	O
-	O
geneartion	O
OCs	O
,	O
and	O
4	O
.	O
96	O
in	O
uesrs	O
of	O
third	O
-	O
genreation	O
perparations	O
.	O

After	O
adjusmtent	O
for	O
age	O
,	O
the	O
rtae	O
raito	O
of	O
VTE	B-Disease
in	O
usres	O
of	O
third	O
-	O
geenration	O
relative	O
to	O
second	O
-	O
geenration	O
OCs	O
was	O
1	O
.	O
68	O
(	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
2	O
.	O
75	O
)	O
.	O

Logitsic	O
regerssion	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
rsik	O
of	O
VTE	B-Disease
between	O
uesrs	O
of	O
third	O
-	O
geenration	O
and	O
second	O
-	O
generatoin	O
OCs	O
.	O

Among	O
uesrs	O
of	O
third	O
-	O
genertaion	O
prgoestagens	O
,	O
the	O
rsik	O
of	O
VTE	B-Disease
was	O
higehr	O
in	O
usres	O
of	O
desoegstrel	O
with	O
20	O
g	O
ethinyloestraidol	O
than	O
in	O
uesrs	O
of	O
gsetodene	O
or	O
desoegstrel	O
with	O
30	O
g	O
ethniyloestradiol	O
.	O

With	O
all	O
second	O
-	O
generaiton	O
OCs	O
as	O
the	O
rfeerence	O
,	O
the	O
odds	O
rtaios	O
for	O
VTE	B-Disease
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
desogsetrel	O
plus	O
20	O
g	O
ethinyloestradoil	O
and	O
1	O
.	O
18	O
(	O
0	O
.	O
66	O
-	O
2	O
.	O
17	O
)	O
for	O
the	O
other	O
third	O
-	O
geenration	O
prgoestagens	O
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
incresae	O
in	O
odds	O
rtaio	O
associated	O
with	O
third	O
-	O
geneartion	O
OCs	O
when	O
compaerd	O
with	O
second	O
-	O
genreation	O
porducts	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
reisdual	O
confuonding	O
by	O
age	O
.	O

The	O
icnreased	O
odds	O
raito	O
associated	O
with	O
prdoucts	O
containing	O
20	O
microrgams	O
etihnyloestradiol	O
and	O
desogesrtel	O
copmared	O
with	O
the	O
30	O
mircograms	O
porduct	O
is	O
biolgoically	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferentail	O
prescriibng	O
and	O
,	O
thus	O
,	O
conofunding	O
.	O

MK	O
-	O
801	O
augmetns	O
pilocrapine	O
-	O
induecd	O
eletcrographic	O
siezure	B-Disease
but	O
proetcts	O
against	O
barin	B-Disease
damgae	I-Disease
in	O
rtas	O
.	O

1	O
.	O

The	O
atuhors	O
examined	O
the	O
anticonvulsnat	O
effects	O
of	O
MK	O
-	O
801	O
on	O
the	O
pilcoarpine	O
-	O
idnuced	O
seziure	B-Disease
mdoel	O
.	O

Intrapeirtoneal	O
inejction	O
of	O
piolcarpine	O
(	O
400	O
mg	O
/	O
kg	O
)	O
indcued	O
tnoic	B-Disease
and	I-Disease
cloinc	I-Disease
siezure	I-Disease
.	O

Scopolmaine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pnetobarbital	O
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
deveolpment	O
of	O
pliocarpine	O
-	O
inudced	O
behaivoral	O
seizrue	B-Disease
but	O
MK	O
-	O
801	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

2	O
.	O

An	O
electircal	O
seizrue	B-Disease
maesured	O
with	O
hipopcampal	O
EEG	O
appeared	O
in	O
the	O
pilcoarpine	O
-	O
treaetd	O
gorup	O
.	O

Socpolamine	O
and	O
pentobrabital	O
blokced	O
the	O
pilocarpnie	O
-	O
idnuced	O
elcetrographic	O
seizrue	B-Disease
,	O
MK	O
-	O
801	O
tretament	O
augmneted	O
the	O
elcetrographic	O
seizrue	B-Disease
indcued	O
by	O
pilocrapine	O
.	O

3	O
.	O

Brian	B-Disease
damgae	I-Disease
was	O
assesesd	O
by	O
examining	O
the	O
hpipocampus	O
microsocpically	O
.	O

Pilocaripne	O
produced	O
neruonal	B-Disease
detah	I-Disease
in	O
the	O
hippoacmpus	O
,	O
which	O
showed	O
pkynotic	O
chagnes	O
.	O

Petnobarbital	O
,	O
scopolaimne	O
and	O
MK	O
-	O
801	O
protected	O
the	O
brian	B-Disease
dmaage	I-Disease
by	O
piloacrpine	O
,	O
though	O
in	O
the	O
MK	O
-	O
801	O
-	O
treaetd	O
gorup	O
,	O
the	O
pyrmaidal	O
cells	O
of	O
hippcoampus	O
appeared	O
darekr	O
than	O
nromal	O
.	O

In	O
all	O
tretaments	O
,	O
garnule	O
cells	O
of	O
the	O
dnetate	O
gyurs	O
were	O
not	O
affecetd	O
.	O

4	O
.	O

These	O
resutls	O
indicate	O
that	O
sttaus	B-Disease
eiplepticus	I-Disease
idnuced	O
by	O
pilocaripne	O
is	O
initiated	O
by	O
cohlinergic	O
oversitmulation	O
and	O
propagated	O
by	O
glutamatregic	O
tranmsission	O
,	O
the	O
eelvation	O
of	O
which	O
may	O
cause	O
brian	B-Disease
daamge	I-Disease
through	O
an	O
exictatory	O
NDMA	O
recpetor	O
-	O
mediated	O
mehcanism	O
.	O

Paclitxael	O
,	O
5	O
-	O
fluorouarcil	O
,	O
and	O
folniic	O
aicd	O
in	O
metasttaic	O
berast	B-Disease
cnacer	I-Disease
:	O
BRE	O
-	O
26	O
,	O
a	O
pahse	O
II	O
trail	O
.	O

5	O
-	O
Fluroouracil	O
plus	O
foliinc	O
aicd	O
and	O
pacltiaxel	O
(	O
Txaol	O
;	O
Birstol	O
-	O
Meyrs	O
Suqibb	O
Copmany	O
,	O
Pirnceton	O
,	O
NJ	O
)	O
are	O
effetcive	O
slavage	O
theraipes	O
for	O
metasattic	O
braest	B-Disease
cacner	I-Disease
ptaients	O
.	O

Pacltiaxel	O
and	O
5	O
-	O
fluororuacil	O
have	O
addtiive	O
cytotoxciity	B-Disease
in	O
MCF	O
-	O
7	O
clel	O
liens	O
.	O

We	O
performed	O
a	O
phsae	O
II	O
tiral	O
of	O
palcitaxel	O
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folniic	O
aicd	O
300	O
mg	O
over	O
1	O
hour	O
before	O
5	O
-	O
fluororuacil	O
350	O
mg	O
/	O
m2	O
on	O
dyas	O
1	O
to	O
3	O
every	O
28	O
dyas	O
(	O
TFL	O
)	O
in	O
woemn	O
with	O
metasttaic	O
bresat	B-Disease
cnacer	I-Disease
.	O

Aanlysis	O
is	O
reported	O
on	O
37	O
patinets	O
with	O
a	O
minimum	O
of	O
6	O
motnhs	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
ccyles	O
of	O
TFL	O
:	O
nine	O
ccyles	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
grdae	O
3	O
/	O
4	O
neutorpenia	B-Disease
requiring	O
hosptialization	O
;	O
seven	O
(	O
4	O
%	O
)	O
cycels	O
in	O
two	O
patinets	O
required	O
graunlocyte	O
colnoy	O
-	O
stiumlating	O
facotr	O
due	O
to	O
neutrpoenia	B-Disease
;	O
no	O
patinet	O
required	O
pltaelet	O
trasnfusions	O
.	O

Garde	O
3	O
/	O
4	O
nnohematologic	O
toixcities	B-Disease
were	O
uncommon	O
.	O

Among	O
the	O
34	O
pateints	O
evalubale	O
for	O
resopnse	O
,	O
there	O
were	O
three	O
complete	O
resposnes	O
(	O
9	O
%	O
)	O
and	O
18	O
pratial	O
responess	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
repsonse	O
rtae	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
evalualbe	O
pateints	O
with	O
prior	O
doxorubiicn	O
expousre	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
compaerd	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxorbuicin	O
.	O

Plamsa	O
pacltiaxel	O
concentratoins	O
were	O
maesured	O
at	O
the	O
copmletion	O
of	O
pacltiaxel	O
inufsion	O
and	O
at	O
24	O
hours	O
in	O
19	O
ptaients	O
.	O

TFL	O
is	O
an	O
actvie	O
,	O
well	O
-	O
toleraetd	O
regmien	O
in	O
mteastatic	O
bresat	B-Disease
cnacer	I-Disease
.	O

Efifcacy	O
and	O
porarrhythmia	B-Disease
with	O
the	O
use	O
of	O
d	O
,	O
l	O
-	O
soatlol	O
for	O
sustanied	O
vetnricular	B-Disease
tachyrarhythmias	I-Disease
.	O

This	O
sutdy	O
prospectively	O
evaulated	O
the	O
cilnical	O
efficcay	O
,	O
the	O
incdience	O
of	O
torsdaes	B-Disease
de	I-Disease
ponites	I-Disease
,	O
and	O
the	O
presumable	O
rsik	O
facotrs	O
for	O
tosrades	B-Disease
de	I-Disease
ponites	I-Disease
in	O
patinets	O
treaetd	O
with	O
d	O
,	O
l	O
-	O
soatlol	O
for	O
ssutained	O
ventircular	B-Disease
tachyarrhyhtmias	I-Disease
.	O

Eighty	O
-	O
one	O
consecuitve	O
paitents	O
(	O
54	O
with	O
coronray	B-Disease
artrey	I-Disease
disesae	I-Disease
,	O
and	O
20	O
with	O
dliated	B-Disease
cardiomyopahty	I-Disease
)	O
with	O
induicble	O
sustianed	O
ventrciular	B-Disease
tachcyardia	I-Disease
or	O
vetnricular	B-Disease
fibrilltaion	I-Disease
received	O
oarl	O
d	O
,	O
l	O
-	O
sotlaol	O
to	O
preevnt	O
inudction	O
of	O
the	O
ventricluar	B-Disease
tacyharrhythmia	I-Disease
.	O

During	O
oarl	O
loadnig	O
with	O
d	O
,	O
l	O
-	O
soatlol	O
,	O
cnotinuous	O
electrocardoigraphic	O
(	O
ECG	O
)	O
monitoirng	O
was	O
performed	O
.	O

Those	O
pateints	O
in	O
whom	O
d	O
,	O
l	O
-	O
sotaoll	O
prevented	O
inudction	O
of	O
ventricluar	B-Disease
tachcyardia	I-Disease
or	O
ventriuclar	B-Disease
fibrlilation	I-Disease
were	O
discahrged	O
with	O
the	O
durg	O
and	O
followed	O
up	O
on	O
an	O
outpatinet	O
basis	O
for	O
21	O
+	O
/	O
-	O
18	O
mnoths	O
.	O

Indutcion	O
of	O
the	O
ventrciular	B-Disease
tachyarrhytmhia	I-Disease
was	O
prevented	O
by	O
oarl	O
d	O
,	O
l	O
-	O
sotaoll	O
in	O
35	O
(	O
43	O
%	O
)	O
patietns	O
;	O
the	O
ventriuclar	B-Disease
tahcyarrhythmia	I-Disease
remained	O
idnucible	O
in	O
40	O
(	O
49	O
%	O
)	O
paitents	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%	O
)	O
paitents	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	O
,	O
l	O
-	O
stoalol	O
once	O
dialy	O
.	O

Four	O
(	O
5	O
%	O
)	O
patietns	O
had	O
from	O
torsdaes	B-Disease
de	I-Disease
ponites	I-Disease
during	O
the	O
initial	O
oarl	O
tretament	O
with	O
d	O
,	O
l	O
-	O
stoalol	O
.	O

Neither	O
ECG	O
[	O
snius	O
-	O
ccyle	O
legnth	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
intevral	O
,	O
or	O
U	O
wvae	O
]	O
nor	O
clincial	O
parameetrs	O
idenitfied	O
pateints	O
at	O
rsik	O
for	O
torasdes	B-Disease
de	I-Disease
poinets	I-Disease
.	O

However	O
,	O
the	O
oarl	O
dsoe	O
of	O
d	O
,	O
l	O
-	O
soatlol	O
was	O
significantly	O
loewr	O
in	O
pateints	O
with	O
torasdes	B-Disease
de	I-Disease
poinets	I-Disease
(	O
200	O
+	O
/	O
-	O
46	O
vs	O
.	O
328	O
+	O
/	O
-	O
53	O
mg	O
/	O
day	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
.	O

Rsik	O
facotrs	O
associated	O
with	O
the	O
developemnt	O
of	O
torsdaes	B-Disease
de	I-Disease
poinets	I-Disease
were	O
the	O
appearnace	O
of	O
an	O
U	O
wvae	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
feamle	O
gneder	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
,	O
and	O
significant	O
dsoe	O
-	O
corretced	O
chnages	O
of	O
SCL	O
,	O
QT	O
interavl	O
,	O
and	O
QTc	O
intevral	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
ptaients	O
had	O
a	O
nonaftal	O
ventricluar	B-Disease
tahcycardia	I-Disease
recrurence	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
pateints	O
deid	O
suddenly	O
.	O

One	O
feamle	O
ptaient	O
with	O
stalbe	O
cradiac	B-Disease
disesae	I-Disease
had	O
recurernt	O
torasdes	B-Disease
de	I-Disease
piontes	I-Disease
after	O
2	O
yeras	O
of	O
successful	O
treatemnt	O
with	O
d	O
,	O
l	O
-	O
sotlaol	O
.	O

Torsaeds	B-Disease
de	I-Disease
piontes	I-Disease
occurred	O
ealry	O
during	O
teratment	O
even	O
with	O
low	O
doess	O
of	O
oarl	O
d	O
,	O
l	O
-	O
soatlol	O
.	O

Pronounced	O
cahnges	O
in	O
the	O
surafce	O
ECG	O
(	O
ccyle	O
lnegth	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dsoe	O
of	O
oarl	O
d	O
,	O
l	O
-	O
sotlaol	O
might	O
identify	O
a	O
subgruop	O
of	O
ptaients	O
with	O
an	O
incresaed	O
rsik	O
for	O
tosrades	B-Disease
de	I-Disease
poinets	I-Disease
.	O

Other	O
ECG	O
paramteers	O
before	O
the	O
appilcation	O
of	O
d	O
,	O
l	O
-	O
sotaoll	O
did	O
not	O
identify	O
paitents	O
at	O
incraesed	O
rsik	O
for	O
trosades	B-Disease
de	I-Disease
poinets	I-Disease
.	O

Recurernce	O
raets	O
of	O
vetnricular	B-Disease
tahcyarrhythmias	I-Disease
are	O
high	O
despite	O
complete	O
supprsesion	O
of	O
the	O
arrhythima	B-Disease
during	O
prorgammed	O
sitmulation	O
.	O

Therefore	O
programmed	O
eletcrical	O
stiumlation	O
in	O
the	O
csae	O
of	O
d	O
,	O
l	O
-	O
soatlol	O
seems	O
to	O
be	O
of	O
lmiited	O
porgnostic	O
value	O
.	O

Chornic	O
hypeprrolactinemia	B-Disease
and	O
chnages	O
in	O
dopaimne	O
nuerons	O
.	O

The	O
tuberoifnundibular	O
dopamienrgic	O
(	O
TDIA	O
)	O
ssytem	O
is	O
known	O
to	O
inihbit	O
prloactin	O
(	O
PRL	O
)	O
sercetion	O
.	O

In	O
yonug	O
anmials	O
this	O
sysetm	O
responds	O
to	O
actue	O
elevatoins	O
in	O
sreum	O
PRL	O
by	O
incerasing	O
its	O
actviity	O
.	O

However	O
,	O
this	O
respnosiveness	O
is	O
lsot	O
in	O
aigng	O
rtas	O
with	O
chroniclaly	O
high	O
sreum	O
PRL	O
levles	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
indcue	O
hyperporlactinemia	B-Disease
in	O
rtas	O
for	O
extedned	O
peirods	O
of	O
tmie	O
and	O
examine	O
its	O
effetcs	O
on	O
dopaimnergic	O
sysetms	O
in	O
the	O
brian	O
.	O

Hyperporlactinemia	B-Disease
was	O
idnuced	O
by	O
treatemnt	O
with	O
halopeirdol	O
,	O
a	O
doapmine	O
recetpor	O
antaognist	O
,	O
and	O
Palkoivts	O
'	O
microdisscetion	O
technqiue	O
in	O
combniation	O
with	O
high	O
-	O
perofrmance	O
liqiud	O
chroamtography	O
was	O
used	O
to	O
maesure	O
neurotranmsitter	O
concentratinos	O
in	O
several	O
areas	O
of	O
the	O
barin	O
.	O

After	O
6	O
motnhs	O
of	O
hyperprolactniemia	B-Disease
,	O
dopaimne	O
(	O
DA	O
)	O
conecntrations	O
in	O
the	O
meidan	O
eminnece	O
(	O
ME	O
)	O
increaesd	O
by	O
84	O
%	O
over	O
the	O
cnotrol	O
gruop	O
.	O

Nine	O
monhts	O
of	O
hyperprloactinemia	B-Disease
produced	O
a	O
50	O
%	O
incresae	O
in	O
DA	O
concentrtaions	O
in	O
the	O
ME	O
over	O
the	O
cnotrol	O
gruop	O
.	O

However	O
,	O
DA	O
resposne	O
was	O
lsot	O
if	O
a	O
9	O
-	O
motnh	O
long	O
halopeirdol	O
-	O
idnuced	O
hypreprolactinemia	B-Disease
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
mnoth	O
-	O
long	O
extremely	O
high	O
incerase	O
in	O
sreum	O
PRL	O
lveels	O
produced	O
by	O
implatnation	O
of	O
MMQ	O
clels	O
under	O
the	O
kindey	O
cpasule	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
lveels	O
of	O
DA	O
,	O
noerpinephrine	O
(	O
NE	O
)	O
,	O
sreotonin	O
(	O
5	O
-	O
HT	O
)	O
,	O
or	O
their	O
mteabolites	O
in	O
the	O
arcutae	O
nculeus	O
(	O
AN	O
)	O
,	O
meidal	O
peroptic	O
aera	O
(	O
MPA	O
)	O
,	O
cuadate	O
puatmen	O
(	O
CP	O
)	O
,	O
subsatntia	O
ngira	O
(	O
SN	O
)	O
,	O
and	O
znoa	O
icnerta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decerase	O
in	O
5	O
-	O
hydroxyindoleaectic	O
aicd	O
(	O
5	O
-	O
HAIA	O
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
mnoths	O
of	O
hyperprolactniemia	B-Disease
and	O
an	O
incerase	O
in	O
DA	O
cocnentrations	O
in	O
the	O
AN	O
after	O
9	O
-	O
mnoths	O
of	O
hyperprloactinemia	B-Disease
.	O

These	O
reuslts	O
demonstrate	O
that	O
hyperprolactniemia	B-Disease
specifically	O
affects	O
TDIA	O
neurnos	O
and	O
these	O
efefcts	O
vary	O
,	O
depending	O
on	O
the	O
druation	O
and	O
intenstiy	O
of	O
hyperprolactniemia	B-Disease
.	O

The	O
age	O
-	O
related	O
decresae	O
in	O
hypohtalamic	O
dopmaine	O
fucntion	O
may	O
be	O
associated	O
with	O
incresaes	O
in	O
PRL	O
sceretion	O
.	O

Treatemnt	O
-	O
related	O
disseminaetd	O
necrotziing	O
leukoecnephalopathy	B-Disease
with	O
charactreistic	O
contrast	O
enahncement	O
of	O
the	O
whtie	O
matter	O
.	O

This	O
reprot	O
describes	O
unqiue	O
contrast	O
enhacnement	O
of	O
the	O
whtie	O
matter	O
on	O
T1	O
-	O
weighted	O
mangetic	O
resonnace	O
imgaes	O
of	O
two	O
paitents	O
with	O
disseminated	O
necrotiznig	O
leukoencephalopahty	B-Disease
,	O
which	O
developed	O
from	O
aucte	B-Disease
lympholbastic	I-Disease
lekuemia	I-Disease
terated	O
with	O
high	O
-	O
dsoe	O
mehtotrexate	O
.	O

In	O
both	O
pateints	O
,	O
the	O
enhacnement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
barin	O
than	O
at	O
the	O
vetrex	O
.	O

Necrposy	O
of	O
the	O
first	O
csae	O
rveealed	O
lsos	B-Disease
of	I-Disease
myelniation	I-Disease
and	O
necrsois	B-Disease
of	O
the	O
whtie	O
matter	O
.	O

Possible	O
mechansims	O
causing	O
such	O
a	O
leukoencephaolpathy	B-Disease
are	O
discussed	O
.	O

Trhombotic	B-Disease
compliactions	O
in	O
aucte	B-Disease
promyleocytic	I-Disease
leukeima	I-Disease
during	O
all	O
-	O
tarns	O
-	O
retnioic	O
aicd	O
therpay	O
.	O

A	O
csae	O
of	O
aucte	B-Disease
rneal	I-Disease
faiulre	I-Disease
,	O
due	O
to	O
oclcusion	B-Disease
of	I-Disease
reanl	I-Disease
vesesls	I-Disease
in	O
a	O
ptaient	O
with	O
aucte	B-Disease
prmoyelocytic	I-Disease
leukmeia	I-Disease
(	O
APL	B-Disease
)	O
terated	O
with	O
all	O
-	O
tarns	O
-	O
rteinoic	O
aicd	O
(	O
ARTA	O
)	O
and	O
tranexaimc	O
aicd	O
has	O
been	O
described	O
recently	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
aucte	B-Disease
rneal	I-Disease
fialure	I-Disease
in	O
an	O
APL	B-Disease
patinet	O
traeted	O
with	O
ARTA	O
alone	O
.	O

This	O
csae	O
further	O
supports	O
the	O
concern	O
about	O
thromboemoblic	B-Disease
cmoplications	O
associated	O
with	O
ARTA	O
therpay	O
in	O
APL	B-Disease
patietns	O
.	O

The	O
ptaients	O
,	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
sgins	O
and	O
sypmtoms	O
of	O
APL	B-Disease
and	O
was	O
included	O
in	O
a	O
teratment	O
protoocl	O
with	O
ARTA	O
.	O

After	O
10	O
dyas	O
of	O
treatemnt	O
,	O
he	O
developed	O
aucte	B-Disease
reanl	I-Disease
failrue	I-Disease
that	O
was	O
completely	O
reversible	O
after	O
complete	O
reimssion	O
of	O
APL	B-Disease
was	O
achieved	O
and	O
threapy	O
discotninued	O
.	O

We	O
conclude	O
that	O
ARTA	O
is	O
a	O
valid	O
therapeuitc	O
choice	O
for	O
patietns	O
with	O
APL	B-Disease
,	O
although	O
the	O
procoagualnt	O
tendency	O
is	O
not	O
completely	O
correcetd	O
.	O

Thromboitc	B-Disease
eevnts	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dsoe	O
hepairn	O
.	O

Pupillary	O
chanegs	O
associated	O
with	O
the	O
developmnet	O
of	O
stimualnt	O
-	O
inudced	O
mnaia	B-Disease
:	O
a	O
csae	O
reprot	O
.	O

A	O
30	O
-	O
yaer	O
-	O
old	O
coacine	O
-	O
depednent	O
man	O
who	O
was	O
a	O
sbuject	O
in	O
a	O
sutdy	O
evalauting	O
the	O
antircaving	O
effciacy	O
of	O
the	O
stmiulant	O
medciation	O
diethyplropion	O
(	O
DEP	O
)	O
became	O
mainc	B-Disease
during	O
his	O
second	O
week	O
on	O
the	O
stduy	O
durg	O
.	O

Pupilolmetric	O
chanegs	O
while	O
on	O
DEP	O
,	O
especially	O
chanegs	O
in	O
the	O
total	O
pwoer	O
of	O
puplilary	B-Disease
ocsillation	I-Disease
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
stduy	O
subjetcs	O
who	O
did	O
not	O
become	O
mainc	B-Disease
.	O

The	O
large	O
cahnges	O
in	O
total	O
pwoer	O
of	O
pupilalry	B-Disease
osclilation	I-Disease
occurred	O
a	O
few	O
dyas	O
before	O
the	O
patinet	O
became	O
fully	O
mnaic	B-Disease
.	O

Such	O
medictaion	O
-	O
associated	O
cahnges	O
in	O
the	O
total	O
pwoer	O
of	O
puplilary	B-Disease
ocsillation	I-Disease
might	O
be	O
of	O
utility	O
in	O
identifying	O
perosns	O
at	O
rsik	O
for	O
mainc	B-Disease
-	O
like	O
advrese	O
efefcts	O
during	O
the	O
medcial	O
use	O
of	O
pyschomotor	O
stiumlants	O
or	O
sympatohmimetic	O
aegnts	O
.	O

Fteal	O
rikss	O
due	O
to	O
wafrarin	O
therpay	O
during	O
pergnancy	O
.	O

Two	O
mothres	O
with	O
haert	O
vlave	O
prsothesis	O
were	O
traeted	O
with	O
wafrarin	O
during	O
pregnnacy	O
.	O

In	O
the	O
first	O
csae	O
a	O
caesraean	O
seciton	O
was	O
done	O
one	O
week	O
after	O
replacemnet	O
of	O
warfrain	O
with	O
heaprin	O
.	O

The	O
bbay	O
deid	O
of	O
cerebarl	B-Disease
and	I-Disease
pumlonary	I-Disease
hemorrhage	I-Disease
.	O

The	O
second	O
motehr	O
had	O
a	O
mlae	O
ifnant	O
by	O
caesaraen	O
seciton	O
.	O

The	O
bbay	O
showed	O
warfairn	O
-	O
induecd	O
embryoapthy	B-Disease
with	O
nsaal	B-Disease
hypolpasia	I-Disease
and	O
stiplped	B-Disease
epihpyses	I-Disease
(	O
chondrodypslasia	B-Disease
puntcata	I-Disease
)	O
.	O

Naasl	B-Disease
hpyoplasia	I-Disease
with	O
or	O
without	O
stiplped	B-Disease
epihpyses	I-Disease
has	O
now	O
been	O
reported	O
in	O
11	O
infatns	O
bron	O
to	O
mohters	O
traeted	O
with	O
warfrain	O
during	O
the	O
first	O
tirmester	O
,	O
and	O
a	O
causal	O
assocaition	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
rikss	O
to	O
both	O
motehr	O
and	O
feuts	O
in	O
woemn	O
with	O
prosthteic	O
cadriac	O
vavles	O
it	O
is	O
recommneded	O
that	O
thearpeutic	O
aobrtion	O
be	O
advised	O
as	O
the	O
first	O
aletrnative	O
.	O

The	O
negaitve	O
mucsoal	O
potnetial	O
:	O
separating	O
cenrtal	O
and	O
preipheral	O
efefcts	O
of	O
NSADIs	O
in	O
man	O
.	O

OBJECITVE	O
:	O
We	O
wanted	O
to	O
tset	O
whether	O
assessment	O
of	O
both	O
a	O
centarl	O
pian	B-Disease
-	O
related	O
singal	O
(	O
cehmo	O
-	O
somaotsensory	O
evoekd	O
poetntial	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
preipheral	O
sginal	O
(	O
neagtive	O
mucoasl	O
potetnial	O
,	O
NMP	O
)	O
allows	O
for	O
spearation	O
of	O
cetnral	O
and	O
perihperal	O
effects	O
of	O
NSIADs	O
.	O

For	O
this	O
purpose	O
,	O
expeirmental	O
condiitons	O
were	O
created	O
in	O
which	O
NSIADs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phsaic	O
and	O
tnoic	O
pian	B-Disease
by	O
either	O
cenrtal	O
or	O
perpiheral	O
mechanimss	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blnid	O
,	O
randoimsed	O
,	O
contorlled	O
,	O
threefold	O
crsos	O
-	O
over	O
desgin	O
,	O
18	O
healhty	O
subjetcs	O
(	O
11	O
mlaes	O
,	O
7	O
femlaes	O
;	O
mean	O
age	O
26	O
yaers	O
)	O
received	O
either	O
plaecbo	O
,	O
400	O
mg	O
ibuproefn	O
,	O
or	O
800	O
mg	O
iburpofen	O
.	O

Phaisc	O
pian	B-Disease
was	O
applied	O
by	O
means	O
of	O
short	O
pusles	O
of	O
CO2	O
to	O
the	O
nsaal	O
mucsoa	O
(	O
stmiulus	O
duraiton	O
500	O
ms	O
,	O
intevral	O
approximately	O
60	O
s	O
)	O
,	O
and	O
toinc	O
pian	B-Disease
was	O
indcued	O
in	O
the	O
naasl	O
caivty	O
by	O
means	O
of	O
dry	O
air	O
of	O
contorlled	O
temeprature	O
,	O
humiidty	O
and	O
folw	O
rtae	O
(	O
22	O
dgerees	O
C	O
,	O
0	O
%	O
relative	O
humdiity	O
,	O
145	O
ml	O
.	O
s	O
-	O
1	O
)	O
.	O

Both	O
CSESPs	O
as	O
cetnral	O
and	O
NPMs	O
as	O
perihperal	O
correaltes	O
of	O
pian	B-Disease
were	O
obtained	O
in	O
resopnse	O
to	O
the	O
CO2	O
stimlui	O
.	O

Additionally	O
,	O
the	O
subejcts	O
rated	O
the	O
inetnsity	O
of	O
both	O
phaisc	O
and	O
tnoic	O
pian	B-Disease
by	O
means	O
of	O
vsiual	O
analouge	O
sclaes	O
.	O

REUSLTS	O
:	O
As	O
described	O
earlier	O
,	O
admniistration	O
of	O
ibuproefn	O
was	O
followed	O
by	O
a	O
decresae	O
in	O
tnoic	O
pian	B-Disease
but	O
-	O
relative	O
to	O
plcaebo	O
-	O
an	O
inrcease	O
in	O
correlaets	O
of	O
phsaic	O
pian	B-Disease
,	O
indicating	O
a	O
specific	O
efefct	O
of	O
ibuporfen	O
on	O
the	O
itneraction	O
between	O
the	O
pian	B-Disease
stmiuli	O
under	O
these	O
special	O
experimenatl	O
conditoins	O
.	O

Based	O
on	O
the	O
similar	O
beahviour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
phramacological	O
prcoess	O
underlying	O
this	O
pehnomenon	O
was	O
localiesd	O
in	O
the	O
perihpery	O
.	O

By	O
means	O
of	O
the	O
simutlaneous	O
reocrding	O
of	O
interrealted	O
preipheral	O
and	O
cnetral	O
electrophysiloogic	O
correlaets	O
of	O
nocicepiton	O
,	O
it	O
was	O
possible	O
to	O
separate	O
centarl	O
and	O
perihperal	O
effetcs	O
of	O
an	O
NSIAD	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pian	B-Disease
moedl	O
is	O
the	O
possibility	O
of	O
obtaining	O
peirpheral	O
pian	B-Disease
-	O
related	O
atcivity	O
directly	O
using	O
a	O
non	O
-	O
invasvie	O
techinque	O
in	O
hmuans	O
.	O

Efefct	O
of	O
D	O
-	O
Glucraates	O
on	O
basic	O
antibitoic	O
-	O
induecd	O
reanl	B-Disease
damgae	I-Disease
in	O
rtas	O
.	O

Dehyrdated	B-Disease
rtas	O
regularly	O
develop	O
aucte	B-Disease
reanl	I-Disease
faliure	I-Disease
following	O
single	O
injcetion	O
of	O
aminoglycosdie	O
antiboitics	O
cmobined	O
with	O
dxetran	O
or	O
of	O
antiboitics	O
only	O
.	O

Oarl	O
admniistration	O
of	O
2	O
,	O
5	O
-	O
di	O
-	O
O	O
-	O
aceytl	O
-	O
D	O
-	O
glucaro	O
-	O
1	O
,	O
4	O
-	O
6	O
,	O
3	O
-	O
dliactone	O
protected	O
rtas	O
against	O
reanl	B-Disease
faliure	I-Disease
indcued	O
by	O
knaamycin	O
-	O
dexrtan	O
.	O

The	O
protective	O
effect	O
was	O
prvealent	O
among	O
D	O
-	O
glucraates	O
,	O
and	O
also	O
to	O
other	O
sacchairc	O
aicd	O
,	O
hexuaronic	O
acdis	O
and	O
hexaladonic	O
acdis	O
,	O
although	O
to	O
a	O
lesser	O
degere	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
suagr	O
aclohols	O
,	O
subsatnces	O
inthe	O
TCA	O
ccyle	O
and	O
other	O
acdiic	O
copmounds	O
.	O

D	O
-	O
Glucaraets	O
were	O
efefctive	O
against	O
reanl	B-Disease
damgae	I-Disease
indcued	O
by	O
pepitde	O
antibitoics	O
as	O
well	O
as	O
various	O
aminolgycoside	O
antibitocis	O
.	O

Dsoe	O
-	O
resposnes	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D	O
-	O
Glcuarates	O
.	O

With	O
a	O
D	O
-	O
gulcarate	O
of	O
a	O
fiexd	O
szie	O
of	O
dsoe	O
,	O
approximately	O
the	O
same	O
dgeree	O
of	O
protetcion	O
was	O
obtained	O
against	O
rneal	B-Disease
damgaes	I-Disease
indcued	O
by	O
different	O
basic	O
antibitoics	O
despite	O
large	O
dispariteis	O
in	O
amdinistration	O
doess	O
of	O
different	O
antibitoics	O
.	O

D	O
-	O
Glcuarates	O
had	O
the	O
ability	O
to	O
preevnt	O
rneal	B-Disease
dmaage	I-Disease
but	O
not	O
to	O
crue	O
it	O
.	O

Rtas	O
excrteed	O
acdiic	O
uirne	O
when	O
they	O
were	O
spaerd	O
from	O
rneal	B-Disease
lesoins	I-Disease
by	O
monosaccharides	O
.	O

The	O
reduciton	O
effcet	O
of	O
D	O
-	O
glucartaes	O
against	O
nephrotoixcity	B-Disease
of	O
basic	O
antibitoics	O
was	O
discussed	O
.	O

Actue	O
seevre	O
deprsesion	B-Disease
following	O
prei	O
-	O
operatvie	O
odnansetron	O
.	O

A	O
41	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
a	O
strong	O
histroy	O
of	O
postoperaitve	B-Disease
nasuea	I-Disease
and	I-Disease
vomitnig	I-Disease
presented	O
for	O
abdmoinal	O
hysetrectomy	O
3	O
mnoths	O
after	O
a	O
previous	O
anaesthteic	O
where	O
ondasnetron	O
prpohylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
sveere	O
actue	O
major	B-Disease
depressoin	I-Disease
disodrer	I-Disease
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serootnin	O
antgaonist	O
.	O

Nine	O
yaers	O
before	O
she	O
had	O
experienced	O
a	O
slef	O
-	O
limietd	O
puerpearl	O
deperssive	B-Disease
episdoe	I-Disease
.	O

Anaestehsia	O
with	O
a	O
porpofol	O
ifnusion	O
and	O
aviodance	O
of	O
sertoonin	O
antagnoists	O
provided	O
a	O
nauesa	B-Disease
-	O
free	O
postopeartive	O
cuorse	O
without	O
exacerbatoin	O
of	O
the	O
derpession	B-Disease
disroder	I-Disease
.	O

Hypertensvie	B-Disease
resposne	O
during	O
dobutamnie	O
strses	O
echocaridography	O
.	O

Among	O
3	O
,	O
129	O
dobuatmine	O
srtess	O
ecohcardiographic	O
stuides	O
,	O
a	O
hypertesnive	B-Disease
respnose	O
,	O
defined	O
as	O
sytsolic	O
bolod	O
pressrue	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and	O
/	O
or	O
diastloic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
paitents	O
(	O
1	O
%	O
)	O
.	O

Pateints	O
with	O
this	O
repsonse	O
more	O
often	O
had	O
a	O
hisotry	O
of	O
hypetrension	B-Disease
and	O
had	O
hgiher	O
retsing	O
sysotlic	O
and	O
diastoilc	O
BP	O
before	O
dboutamine	O
infusoin	O
.	O

Cotninuously	O
nebuliezd	O
albtuerol	O
in	O
seevre	O
excaerbations	O
of	O
atshma	B-Disease
in	O
adutls	O
:	O
a	O
csae	O
-	O
controlled	O
stduy	O
.	O

A	O
rertospective	O
,	O
csae	O
-	O
cnotrolled	O
anaylsis	O
compraing	O
paitents	O
amditted	O
to	O
a	O
medcial	O
intenisve	O
crae	O
unit	O
with	O
sevree	O
exaecrbations	O
of	O
astmha	B-Disease
who	O
received	O
cotninuously	O
nebuliezd	O
albuetrol	O
(	O
CNA	O
)	O
versus	O
intermtitent	O
alubterol	O
(	O
INA	O
)	O
treamtents	O
is	O
reported	O
.	O

Forty	O
matched	O
piars	O
of	O
patinets	O
with	O
ashtma	B-Disease
are	O
cmopared	O
.	O

CNA	O
was	O
adminitsered	O
for	O
a	O
mean	O
of	O
11	O
+	O
/	O
-	O
10	O
hr	O
.	O

The	O
incidecne	O
of	O
cradiac	B-Disease
dysrhythmais	I-Disease
was	O
similar	O
between	O
gropus	O
.	O

Sypmtomatic	O
hypoklaemia	B-Disease
did	O
not	O
occur	O
.	O

CNA	O
patietns	O
had	O
higehr	O
haert	O
raets	O
during	O
traetment	O
,	O
which	O
may	O
reflect	O
sevreity	O
of	O
illness	O
.	O

The	O
icnidence	O
of	O
intubatoin	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
proflies	O
with	O
regard	O
to	O
saefty	O
,	O
mobridity	O
,	O
and	O
moratlity	O
.	O

Parapleiga	B-Disease
following	O
intrathceal	O
metohtrexate	O
:	O
reprot	O
of	O
a	O
csae	O
and	O
rveiew	O
of	O
the	O
litearture	O
.	O

A	O
patinet	O
who	O
developed	O
paralpegia	B-Disease
following	O
the	O
intrahtecal	O
instillation	O
of	O
methortexate	O
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
caess	O
of	O
this	O
unuusal	O
comlpication	O
are	O
reviweed	O
.	O

The	O
following	O
facotrs	O
appear	O
to	O
predispose	O
to	O
the	O
developmnet	O
of	O
this	O
complicaiton	O
:	O
abnomral	O
creebrospinal	O
dynmaics	O
related	O
to	O
the	O
prseence	O
of	O
cnetral	B-Disease
nervuos	I-Disease
sytsem	I-Disease
leukmeia	I-Disease
,	O
and	O
eipdural	O
cereborspinal	O
leaakge	O
;	O
eleavted	O
cerebrsopinal	O
fulid	O
mtehothexate	O
concentratoin	O
related	O
to	O
abonrmal	O
creebrospinal	O
fulid	O
dynaimcs	O
and	O
to	O
inapprporiately	O
high	O
metohtrexate	O
doess	O
based	O
on	O
bdoy	O
sruface	O
aera	O
calculatinos	O
in	O
odler	O
chilrden	O
and	O
audlts	O
;	O
the	O
presecne	O
of	O
neurtooxic	B-Disease
preservaitves	O
in	O
commercially	O
available	O
mehtotrexate	O
prepaartions	O
and	O
dileunts	O
;	O
and	O
the	O
use	O
of	O
mtehotrexate	O
dileunts	O
of	O
upnhysiologic	O
pH	O
,	O
ioinc	O
cnotent	O
and	O
osmoalrity	O
.	O

The	O
role	O
of	O
metohtrexate	O
conatminants	O
,	O
loacl	O
foalte	B-Disease
deficiecny	I-Disease
,	O
and	O
cranail	O
irraidation	O
in	O
the	O
pathogeensis	O
of	O
inrtathecal	O
mehtotrexate	O
toxictiy	B-Disease
is	O
unclear	O
.	O

The	O
inciednce	O
of	O
nuerotoxicity	B-Disease
may	O
be	O
reudced	O
by	O
employing	O
lwoer	O
doess	O
of	O
methotrextae	O
in	O
the	O
presecne	O
of	O
centarl	B-Disease
nevrous	I-Disease
ssytem	I-Disease
leukeima	I-Disease
,	O
in	O
oledr	O
cihldren	O
and	O
adluts	O
,	O
and	O
in	O
the	O
presecne	O
of	O
epiudral	O
laekage	O
.	O

Only	O
preesrvative	O
-	O
free	O
methortexate	O
in	O
Ellitot	O
'	O
s	O
B	O
Soluiton	O
at	O
a	O
cocnentration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
itnrathecal	O
adminisrtation	O
.	O

Peirodic	O
moniotring	O
of	O
cerebrsupinal	O
fliud	O
methotreaxte	O
lveels	O
may	O
be	O
perdictive	O
of	O
the	O
developmnet	O
of	O
serious	O
neurtooxicity	B-Disease
.	O

Hypeorsmolar	B-Disease
nonkettoic	I-Disease
cmoa	I-Disease
precipiatted	O
by	O
lihtium	O
-	O
induecd	O
nephroegnic	B-Disease
diaebtes	I-Disease
insipdius	I-Disease
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
man	O
,	O
with	O
a	O
10	O
-	O
yaer	O
hsitory	O
of	O
mnaic	B-Disease
depresison	I-Disease
terated	O
with	O
lithuim	O
,	O
was	O
amditted	O
with	O
hyperosmloar	B-Disease
,	I-Disease
nnoketotic	I-Disease
cmoa	I-Disease
.	O

He	O
gave	O
a	O
five	O
-	O
yaer	O
histroy	O
of	O
polyuira	B-Disease
and	O
ploydipsia	B-Disease
,	O
during	O
which	O
tmie	O
uirnalysis	O
had	O
been	O
neagtive	O
for	O
gluocse	O
.	O

After	O
rceovery	O
from	O
hypegrlycaemia	B-Disease
,	O
he	O
remained	O
polyruic	B-Disease
despite	O
noraml	O
bolod	O
gluocse	O
concetnrations	O
;	O
wtaer	O
deprviation	O
tetsing	O
indicated	O
nephrgoenic	B-Disease
dibaetes	I-Disease
insiipdus	I-Disease
,	O
likely	O
to	O
be	O
lithuim	O
-	O
indcued	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
tpye	B-Disease
2	I-Disease
diaebtes	I-Disease
,	O
chroinc	O
poluyria	B-Disease
due	O
to	O
nephorgenic	B-Disease
diabtees	I-Disease
inspiidus	I-Disease
was	O
sufficient	O
to	O
precipittae	O
hypersomolar	O
dehydartion	B-Disease
.	O

Effetcs	O
of	O
the	O
intraocronary	O
inufsion	O
of	O
coacine	O
on	O
lfet	O
ventricualr	O
ssytolic	O
and	O
diatsolic	O
fucntion	O
in	O
huamns	O
.	O

BACKRGOUND	O
:	O
In	O
dgos	O
,	O
a	O
large	O
amonut	O
of	O
intraevnous	O
ccoaine	O
causes	O
a	O
profuond	O
deteiroration	B-Disease
of	I-Disease
lfet	I-Disease
ventricualr	I-Disease
(	I-Disease
LV	I-Disease
)	I-Disease
sysotlic	I-Disease
fnuction	I-Disease
and	O
an	O
icnrease	O
in	O
LV	O
end	O
-	O
disatolic	O
perssure	O
.	O

This	O
stduy	O
was	O
done	O
to	O
assess	O
the	O
ifnluence	O
of	O
a	O
high	O
intracoornary	O
ccoaine	O
concnetration	O
on	O
LV	O
systoilc	O
and	O
diastoilc	O
funciton	O
in	O
huamns	O
.	O

METHODS	O
AND	O
RESLUTS	O
:	O
In	O
20	O
patinets	O
(	O
14	O
men	O
and	O
6	O
woemn	O
aegd	O
39	O
to	O
72	O
yaers	O
)	O
referred	O
for	O
cardaic	O
catheterizaiton	O
for	O
the	O
evalaution	O
of	O
chset	B-Disease
pian	I-Disease
,	O
we	O
meausred	O
herat	O
rtae	O
,	O
sysetmic	O
artreial	O
prsesure	O
,	O
LV	O
presusre	O
and	O
its	O
first	O
derivatvie	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
vloumes	O
and	O
ejectoin	O
frcation	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
mintues	O
of	O
a	O
15	O
-	O
minute	O
intracroonary	O
infuison	O
of	O
slaine	O
(	O
n	O
=	O
10	O
,	O
cotnrol	O
subejcts	O
)	O
or	O
ccoaine	O
hydrochlordie	O
1	O
mg	O
/	O
min	O
(	O
n	O
=	O
10	O
)	O
.	O

No	O
varaible	O
changed	O
with	O
slaine	O
.	O

With	O
coacine	O
,	O
the	O
durg	O
concenrtation	O
in	O
blood	O
obtained	O
from	O
the	O
coornary	O
siuns	O
was	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magniutde	O
to	O
the	O
bolod	O
cocanie	O
concenrtation	O
reported	O
in	O
abuesrs	O
dynig	O
of	O
cocanie	O
intoxictaion	O
.	O

Ccoaine	O
inudced	O
no	O
significant	O
change	O
in	O
haert	O
rtae	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
posiitve	O
or	O
negatvie	O
)	O
,	O
or	O
LV	O
end	O
-	O
daistolic	O
voulme	O
,	O
but	O
it	O
caused	O
an	O
incerase	O
in	O
ssytolic	O
and	O
mean	O
arterail	O
prsesures	O
,	O
LV	O
end	O
-	O
daistolic	O
pressure	O
,	O
and	O
LV	O
end	O
-	O
ssytolic	O
vloume	O
,	O
as	O
well	O
as	O
a	O
dcerease	O
in	O
LV	O
ejetcion	O
fraciton	O
.	O

COCNLUSIONS	O
:	O
In	O
huamns	O
,	O
the	O
intraocronary	O
infuison	O
of	O
coacine	O
sufficient	O
in	O
amonut	O
to	O
achieve	O
a	O
high	O
durg	O
concenrtation	O
in	O
croonary	O
siuns	O
blood	O
causes	O
a	O
deterioratoin	B-Disease
of	I-Disease
LV	I-Disease
sytsolic	I-Disease
and	I-Disease
diastloic	I-Disease
perforamnce	I-Disease
.	O

Ascenidng	O
dsoe	O
toelrance	O
sutdy	O
of	O
inrtamuscular	O
carbeotcin	O
adminisetred	O
after	O
nromal	O
vaignal	O
brith	O
.	O

OBJETCIVE	O
:	O
To	O
determine	O
the	O
maxiumm	O
tolearted	O
dsoe	O
(	O
MTD	O
)	O
of	O
carbeotcin	O
(	O
a	O
long	O
-	O
acting	O
snythetic	O
aanlogue	O
of	O
oxytoicn	O
)	O
,	O
when	O
administreed	O
immediately	O
after	O
vaignal	O
dleivery	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Carbetcoin	O
was	O
given	O
as	O
an	O
intarmuscular	O
inejction	O
immediately	O
after	O
the	O
brith	O
of	O
the	O
inafnt	O
in	O
45	O
haelthy	O
wmoen	O
with	O
nromal	O
signleton	O
pregnnacies	O
who	O
delviered	O
vaignally	O
at	O
term	O
.	O

Doasge	O
gropus	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
micorg	O
carbetoicn	O
were	O
assigned	O
to	O
blokcs	O
of	O
three	O
woemn	O
according	O
to	O
the	O
conitnual	O
reasesssment	O
mtehod	O
(	O
CRM	O
)	O
.	O

REUSLTS	O
:	O
All	O
dosgae	O
gropus	O
consisted	O
of	O
three	O
wmoen	O
,	O
except	O
those	O
with	O
100	O
mircog	O
(	O
n	O
=	O
6	O
)	O
and	O
200	O
micorg	O
(	O
n	O
=	O
18	O
)	O
.	O

Recorded	O
were	O
dsoe	O
-	O
limiting	O
adevrse	O
evnets	O
:	O
hyper	B-Disease
-	I-Disease
or	I-Disease
hypotesnion	I-Disease
(	O
three	O
)	O
,	O
sveere	O
abdomianl	B-Disease
pian	I-Disease
(	O
0	O
)	O
,	O
vomtiing	B-Disease
(	O
0	O
)	O
and	O
reatined	B-Disease
plaecnta	I-Disease
(	O
four	O
)	O
.	O

Seirous	O
adevrse	O
evetns	O
occurred	O
in	O
seven	O
woemn	O
:	O
six	O
csaes	O
with	O
bolod	B-Disease
lsos	I-Disease
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
csaes	O
of	O
manaul	O
palcenta	O
rmeoval	O
,	O
five	O
caess	O
of	O
additional	O
oxtyocics	O
amdinistration	O
and	O
five	O
csaes	O
of	O
blood	O
tranfsusion	O
.	O

Maxiumm	O
bolod	B-Disease
lsos	I-Disease
was	O
greatest	O
at	O
the	O
upepr	O
and	O
lwoer	O
dsoe	O
levles	O
,	O
and	O
loewst	O
in	O
the	O
70	O
-	O
125	O
mcirog	O
dsoe	O
range	O
.	O

Four	O
out	O
of	O
six	O
csaes	O
with	O
blood	B-Disease
lsos	I-Disease
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
micorg	O
gorup	O
.	O

The	O
majority	O
of	O
additional	O
administrtaion	O
of	O
oxyotcics	O
(	O
4	O
/	O
5	O
)	O
and	O
bolod	O
transfusoin	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
dsoe	O
gropus	O
of	O
200	O
mircog	O
.	O

All	O
rteained	O
plaecntae	O
were	O
found	O
in	O
the	O
gruop	O
of	O
200	O
mcirog	O
.	O

CONCLUISON	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
micorg	O
carbetoicn	O
.	O

Heaprin	O
-	O
indcued	O
thromboctyopenia	B-Disease
,	O
paardoxical	O
thromboemoblism	B-Disease
,	O
and	O
other	O
side	O
efefcts	O
of	O
hpearin	O
therpay	O
.	O

Although	O
several	O
new	O
antcioagulant	O
drgus	O
are	O
in	O
developemnt	O
,	O
heaprin	O
remains	O
the	O
durg	O
of	O
choice	O
for	O
most	O
anticoauglation	O
needs	O
.	O

The	O
cilnical	O
effcets	O
of	O
heprain	O
are	O
meritorious	O
,	O
but	O
side	O
effcets	O
do	O
exist	O
.	O

Important	O
untoward	O
effects	O
of	O
hpearin	O
thearpy	O
including	O
hepairn	O
-	O
indcued	O
thrombocytoepnia	B-Disease
,	O
heprain	O
-	O
associated	O
osetoporosis	B-Disease
,	O
eosniophilia	B-Disease
,	O
sikn	B-Disease
recations	I-Disease
,	O
allregic	B-Disease
reactoins	I-Disease
other	O
than	O
thrombocytoepnia	B-Disease
and	O
aloepcia	B-Disease
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonpoaque	O
crsytal	O
depsoition	O
causing	O
uretreic	B-Disease
obstruciton	I-Disease
in	O
patietns	O
with	O
HIV	O
undergoing	O
indniavir	O
threapy	O
.	O

OBEJCTIVE	O
:	O
We	O
describe	O
the	O
uniuqe	O
CT	O
featuers	O
of	O
uretreic	B-Disease
claculi	I-Disease
in	O
six	O
HIV	B-Disease
-	I-Disease
infecetd	I-Disease
patinets	O
receiving	O
idninavir	O
,	O
the	O
most	O
commonly	O
used	O
HIV	O
proetase	O
inhibiotr	O
,	O
which	O
is	O
associated	O
with	O
an	O
incraesed	O
inciednce	O
of	O
urolitihasis	B-Disease
.	O

CNOCLUSION	O
:	O
Uretreic	B-Disease
obsturction	I-Disease
caused	O
by	O
prceipitated	O
indinaivr	O
crystlas	O
may	O
be	O
difficult	O
to	O
daignose	O
with	O
unenhanecd	O
CT	O
.	O

The	O
cacluli	O
are	O
not	O
opauqe	O
,	O
and	O
secondary	O
sgins	O
of	O
obstrutcion	O
may	O
be	O
abesnt	O
or	O
miniaml	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Imaegs	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i	O
.	O
v	O
.	O
contrast	O
mtaerial	O
to	O
enable	O
diagnsois	O
of	O
uerteric	B-Disease
sotnes	I-Disease
or	I-Disease
obstruciton	I-Disease
in	O
pateints	O
with	O
HIV	B-Disease
infeciton	I-Disease
who	O
receive	O
indinaivr	O
therpay	O
.	O

Icshemic	B-Disease
coltiis	I-Disease
and	O
sumartiptan	O
use	O
.	O

Suamtriptan	O
succiante	O
,	O
a	O
serootnin	O
-	O
1	O
(	O
5	O
-	O
hydroxytryptaimne	O
-	O
1	O
)	O
recepotr	O
agnoist	O
,	O
is	O
an	O
antiimgraine	O
durg	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
cnostricting	O
intrarcanial	O
artereis	O
.	O

Recently	O
,	O
vasoperssor	O
rseponses	O
that	O
are	O
distinct	O
from	O
the	O
cranail	O
criculation	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
ssytemic	O
,	O
pumlonary	O
,	O
and	O
croonary	O
cicrulations	O
.	O

Csaes	O
have	O
been	O
publisehd	O
of	O
cornoary	B-Disease
vasospsam	I-Disease
,	O
mycoardial	B-Disease
ischmeia	I-Disease
,	O
and	O
myocardail	B-Disease
infacrtion	I-Disease
occurring	O
after	O
smuatriptan	O
use	O
.	O

We	O
reprot	O
on	O
the	O
developmnet	O
of	O
8	O
serious	O
caess	O
of	O
iscehmic	B-Disease
cloitis	I-Disease
in	O
paitents	O
with	O
mirgaine	B-Disease
treaetd	O
with	O
suamtriptan	O
.	O

Pallidtoomy	O
with	O
the	O
gmama	O
knfie	O
:	O
a	O
positvie	O
expreience	O
.	O

51	O
pateints	O
with	O
mdeically	O
refrcatory	O
Parkinosn	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
underwent	O
stereoatctic	O
posetromedial	O
palildotomy	O
between	O
August	O
1993	O
and	O
Febraury	O
1997	O
for	O
treamtent	O
of	O
braydkinesia	B-Disease
,	O
rigiidty	B-Disease
,	O
and	O
L	O
-	O
DPOA	O
-	O
inudced	O
dyskiensias	B-Disease
.	O

In	O
29	O
pateints	O
,	O
the	O
pallidotmoies	O
were	O
performed	O
with	O
the	O
Lkesell	O
Gmama	O
Knfie	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
stnadard	O
radoifrequency	O
(	O
RF	O
)	O
mtehod	O
.	O

Cilnical	O
assessment	O
as	O
well	O
as	O
blinedd	O
ratigns	O
of	O
Uinfied	O
Parkisnon	B-Disease
'	I-Disease
s	I-Disease
Dsiease	I-Disease
Rtaing	O
Sclae	O
(	O
UPRDS	O
)	O
scoers	O
were	O
carried	O
out	O
pre	O
-	O
and	O
postoperatviely	O
.	O

Mean	O
follow	O
-	O
up	O
tmie	O
is	O
20	O
.	O
6	O
monhts	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
ptaients	O
have	O
been	O
followed	O
more	O
than	O
one	O
yaer	O
.	O

85	O
percent	O
of	O
patietns	O
with	O
dyskineisas	B-Disease
were	O
relieevd	O
of	O
sympotms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomeis	O
were	O
performed	O
with	O
the	O
Gmama	O
Knfie	O
or	O
radiorfequency	O
metohds	O
.	O

About	O
2	O
/	O
3	O
of	O
the	O
patinets	O
in	O
both	O
Gamma	O
Kinfe	O
and	O
radiofreuqency	O
gorups	O
showed	O
imrpovements	O
in	O
bradykniesia	B-Disease
and	O
rigiidty	B-Disease
,	O
although	O
when	O
considered	O
as	O
a	O
gorup	O
neither	O
the	O
Gmama	O
Kinfe	O
nor	O
the	O
radiorfequency	O
gruop	O
showed	O
statisitcally	O
significant	O
improveemnts	O
in	O
UPRDS	O
scoers	O
.	O

One	O
patinet	O
in	O
the	O
Gamma	O
Kinfe	O
gruop	O
(	O
3	O
.	O
4	O
%	O
)	O
developed	O
a	O
hmoonymous	B-Disease
hemainopsia	I-Disease
9	O
motnhs	O
following	O
traetment	O
and	O
5	O
pateints	O
(	O
27	O
.	O
7	O
%	O
)	O
in	O
the	O
radiforequency	O
gruop	O
became	O
transietnly	O
confused	O
posotperatively	O
.	O

No	O
other	O
complciations	O
were	O
seen	O
.	O

Gmama	O
Kinfe	O
pallidootmy	O
is	O
as	O
efefctive	O
as	O
radiofrequecny	O
palldiotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symtpoms	O
of	O
Pakrinson	B-Disease
'	I-Disease
s	I-Disease
disesae	I-Disease
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
techinque	O
available	O
in	O
certain	O
ptaients	O
,	O
such	O
as	O
those	O
who	O
take	O
anitcoagulants	O
,	O
have	O
bleednig	B-Disease
diatehses	O
or	O
serious	O
sytsemic	O
meidcal	O
illnseses	O
.	O

It	O
is	O
a	O
vaible	O
option	O
for	O
other	O
pateints	O
as	O
well	O
.	O

Centarlly	O
mediated	O
cardiovacsular	O
effcets	O
of	O
intracisteranl	O
appliaction	O
of	O
crabachol	O
in	O
anestheitzed	O
rtas	O
.	O

The	O
prsesor	O
respnose	O
to	O
the	O
intracistrenal	O
(	O
i	O
.	O
c	O
.	O
)	O
inejction	O
of	O
carbacohl	O
(	O
1	O
mug	O
)	O
in	O
ansethetized	O
rtas	O
was	O
anaylzed	O
.	O

This	O
resposne	O
was	O
significantly	O
reudced	O
by	O
the	O
intravenuos	O
(	O
i	O
.	O
v	O
.	O
)	O
injetcion	O
of	O
guanehtidine	O
(	O
5	O
mg	O
)	O
,	O
hexamehtonium	O
(	O
10	O
mg	O
)	O
or	O
phetnolamine	O
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potnetiated	O
by	O
i	O
.	O
v	O
.	O
desmehtylimipramine	O
(	O
0	O
.	O
3	O
mg	O
)	O
,	O
while	O
porpranolol	O
(	O
0	O
.	O
5	O
mg	O
)	O
i	O
.	O
v	O
.	O
selectively	O
inihbited	O
the	O
enalrgement	B-Disease
of	I-Disease
pusle	I-Disease
pressure	I-Disease
and	O
the	O
tachyacrdia	B-Disease
following	O
i	O
.	O
c	O
.	O
carabchol	O
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
presosr	O
repsonse	O
to	O
i	O
.	O
c	O
.	O
carbahcol	O
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
blocekd	O
by	O
i	O
.	O
c	O
.	O
artopine	O
(	O
3	O
mug	O
)	O
or	O
hexamethoinum	O
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
redcued	O
by	O
i	O
.	O
c	O
.	O
chlorpromaizne	O
(	O
50	O
mug	O
)	O
but	O
significantly	O
poetntiated	O
by	O
i	O
.	O
c	O
.	O
desmtehylimipramine	O
(	O
30	O
mug	O
)	O
.	O

The	O
pressor	O
rseponse	O
to	O
i	O
.	O
c	O
.	O
carbahcol	O
(	O
1	O
mug	O
)	O
remained	O
ucnhanged	O
after	O
scetioning	O
of	O
the	O
bialteral	O
cerivcal	O
vgaal	O
nevres	O
but	O
disappeared	O
after	O
secitoning	O
of	O
the	O
sipnal	O
crod	O
(	O
C7	O
-	O
C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
pressor	O
resopnse	O
to	O
i	O
.	O
c	O
.	O
carbcahol	O
ortarl	O
and	O
perihperal	O
ardenergic	O
mechanimss	O
,	O
and	O
that	O
the	O
sympahtetic	O
trnuk	O
is	O
the	O
main	O
ptahway	O
.	O

Neuroelptic	B-Disease
mlaignant	I-Disease
syndorme	I-Disease
and	O
methylpehnidate	O
.	O

A	O
1	O
-	O
yaer	O
-	O
old	O
femlae	O
presented	O
with	O
neuroelptic	B-Disease
malignnat	I-Disease
syndrmoe	I-Disease
probably	O
caused	O
by	O
methylpheniadte	O
.	O

She	O
had	O
dfeects	O
in	O
the	O
supratentoiral	O
brian	O
including	O
the	O
bsaal	O
gangila	O
and	O
the	O
straitum	O
(	O
multicsytic	B-Disease
encephalmoalacia	I-Disease
)	O
due	O
to	O
seevre	O
periantal	O
hypoixc	B-Disease
-	I-Disease
ischeimc	I-Disease
encephaloapthy	I-Disease
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
preidsposing	O
facotr	O
causing	O
neruoleptic	B-Disease
malignnat	I-Disease
snydrome	I-Disease
.	O

A	O
dopaminregic	O
bolckade	O
mcehanism	O
generally	O
is	O
accepted	O
as	O
the	O
pahtogenesis	O
of	O
this	O
synrdome	O
.	O

However	O
,	O
mehtylphenidate	O
is	O
a	O
dopamnie	O
aognist	O
via	O
the	O
ihnibition	O
of	O
utpake	O
of	O
dopaimne	O
,	O
and	O
therefore	O
dpoaminergic	O
systmes	O
in	O
the	O
branistem	O
(	O
mainly	O
the	O
mibdrain	O
)	O
and	O
the	O
sipnal	O
crod	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
snydrome	O
.	O

A	O
relative	O
gamma	O
-	O
aminobuytric	O
aicd	O
-	O
egric	O
deficiecny	O
might	O
occur	O
because	O
diazeapm	O
,	O
a	O
gmama	O
-	O
aminboutyric	O
aicd	O
-	O
mmietic	O
aegnt	O
,	O
was	O
srtikingly	O
effecitve	O
.	O

This	O
is	O
the	O
first	O
reported	O
pateint	O
with	O
neurolepitc	B-Disease
malingant	I-Disease
snydrome	I-Disease
probably	O
caused	O
by	O
mtehylphenidate	O
.	O

Difefrential	O
efefcts	O
of	O
17alpha	O
-	O
ethinylestraidol	O
on	O
the	O
neurtal	O
and	O
aicdic	O
pahtways	O
of	O
blie	O
slat	O
snythesis	O
in	O
the	O
rat	O
.	O

Effects	O
of	O
17alpha	O
-	O
ethinylestraidol	O
(	O
EE	O
)	O
on	O
the	O
neurtal	O
and	O
aicdic	O
boisynthetic	O
patwhays	O
of	O
blie	O
slat	O
(	O
BS	O
)	O
syntehsis	O
were	O
evlauated	O
in	O
rtas	O
with	O
an	O
itnact	O
enetrohepatic	O
circultaion	O
and	O
in	O
rtas	O
with	O
long	O
-	O
term	O
blie	O
diversoin	O
to	O
inudce	O
BS	O
synhtesis	O
.	O

For	O
this	O
purpose	O
,	O
blie	O
slat	O
pool	O
compositoin	O
,	O
synhtesis	O
of	O
indviidual	O
BS	O
in	O
vivo	O
,	O
hepaitc	O
actiivties	O
,	O
and	O
expression	O
lveels	O
of	O
cholesteorl	O
7alpha	O
-	O
hydrxoylase	O
(	O
CPY7A	O
)	O
,	O
and	O
streol	O
27	O
-	O
hydorxylase	O
(	O
CY2P7	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enyzmes	O
involved	O
in	O
BS	O
syntheiss	O
,	O
were	O
anlayzed	O
in	O
rtas	O
traeted	O
with	O
EE	O
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
dyas	O
)	O
or	O
its	O
veihcle	O
.	O

BS	O
pool	O
szie	O
was	O
dcereased	O
by	O
27	O
%	O
but	O
total	O
BS	O
sytnhesis	O
was	O
not	O
affecetd	O
by	O
EE	O
in	O
inatct	O
rtas	O
.	O

Synthseis	O
of	O
choalte	O
was	O
reudced	O
by	O
68	O
%	O
in	O
EE	O
-	O
traeted	O
rtas	O
,	O
while	O
that	O
of	O
chneodeoxycholate	O
was	O
incresaed	O
by	O
60	O
%	O
.	O

The	O
recently	O
idenitfied	O
Detla22	O
-	O
iosmer	O
of	O
btea	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
cnotrol	O
and	O
EE	O
-	O
tretaed	O
rtas	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
deetcted	O
in	O
blie	O
after	O
ehxaustion	O
of	O
the	O
pool	O
.	O

A	O
clear	O
rdeuction	O
of	O
BS	O
syntehsis	O
was	O
found	O
in	O
blie	O
-	O
dievrted	O
rtas	O
treaetd	O
with	O
EE	O
,	O
yet	O
biilary	O
BS	O
compoistion	O
was	O
only	O
minmially	O
affecetd	O
.	O

Activtiy	O
of	O
CY7PA	O
was	O
decerased	O
by	O
EE	O
in	O
both	O
inatct	O
and	O
blie	O
-	O
dvierted	O
rtas	O
,	O
whereas	O
the	O
acitvity	O
of	O
the	O
CY2P7	O
was	O
not	O
affceted	O
.	O

Heaptic	O
mNRA	O
leevls	O
of	O
CY7PA	O
were	O
significantly	O
rdeuced	O
by	O
EE	O
in	O
blie	O
-	O
dievrted	O
rtas	O
only	O
;	O
CPY27	O
mNRA	O
lveels	O
were	O
not	O
affecetd	O
by	O
EE	O
.	O

In	O
addition	O
,	O
mNRA	O
lveels	O
of	O
streol	O
12alpha	O
-	O
hydroyxlase	O
and	O
lihtocholate	O
6beta	O
-	O
hydroxyalse	O
were	O
inrceased	O
by	O
blie	O
dviersion	O
and	O
supprsesed	O
by	O
EE	O
.	O

This	O
sutdy	O
shows	O
that	O
17alpha	O
-	O
etihnylestradiol	O
(	O
EE	O
)	O
-	O
idnuced	O
intraehpatic	B-Disease
cholsetasis	I-Disease
in	O
rtas	O
is	O
associated	O
with	O
selective	O
inhbiition	O
of	O
the	O
neurtal	O
pahtway	O
of	O
blie	O
slat	O
(	O
BS	O
)	O
synthseis	O
.	O

Smiultaneous	O
impairmnet	O
of	O
other	O
eznymes	O
in	O
the	O
BS	O
bioysnthetic	O
ptahways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	O
on	O
BS	O
syntheiss	O
.	O

Glibenclaimde	O
-	O
snesitive	O
hyptoension	B-Disease
produced	O
by	O
heloedrmin	O
asesssed	O
in	O
the	O
rat	O
.	O

The	O
efefcts	O
of	O
helodremin	O
,	O
a	O
basic	O
35	O
-	O
amnio	O
aicd	O
petpide	O
isolaetd	O
from	O
the	O
vneom	O
of	O
a	O
lziard	O
salivray	O
glnad	O
,	O
on	O
atrerial	O
blood	O
pressure	O
and	O
haert	O
rtae	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
actviation	O
of	O
ATP	O
sensiitve	O
K	O
+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channels	O
is	O
involved	O
in	O
the	O
resopnses	O
.	O

The	O
resluts	O
were	O
also	O
cmopared	O
with	O
those	O
of	O
vasocative	O
inetstinal	O
polyepptide	O
(	O
VIP	O
)	O
.	O

Hleodermin	O
produced	O
hypotensoin	B-Disease
in	O
a	O
dsoe	O
-	O
deepndent	O
manner	O
with	O
approximately	O
similar	O
potecny	O
and	O
duratoin	O
to	O
VIP	O
.	O

Hypotnesion	B-Disease
induecd	O
by	O
both	O
petpides	O
was	O
significantly	O
atteunated	O
by	O
glibenclmaide	O
,	O
which	O
abolished	O
a	O
lvecromakalim	O
-	O
produced	O
dercease	O
in	O
atrerial	O
bolod	O
prsesure	O
.	O

Oxyehmoglobin	O
did	O
not	O
affect	O
heoldermin	O
-	O
indcued	O
hypotesnion	B-Disease
,	O
whereas	O
it	O
sohrtened	O
the	O
duratoin	O
of	O
acetyclholine	O
(	O
ACh	O
)	O
-	O
produced	O
hypotenison	B-Disease
.	O

These	O
findigns	O
suggest	O
that	O
heloderimn	O
-	O
produced	O
hyoptension	B-Disease
is	O
partly	O
attributable	O
to	O
the	O
activtaion	O
of	O
glibneclamide	O
-	O
sensitvie	O
K	O
+	O
cahnnels	O
(	O
K	O
(	O
ATP	O
)	O
cahnnels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
aretrial	O
somoth	O
msucle	O
cells	O
.	O

ERDF	O
(	O
endothleium	O
-	O
derived	O
realxing	O
fatcor	O
)	O
/	O
nitirc	O
oixde	O
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pepitde	O
-	O
produced	O
hyoptension	B-Disease
.	O

Lnog	O
-	O
term	O
effciacy	O
and	O
avderse	O
evnet	O
of	O
nifedipnie	O
sustaiend	O
-	O
rleease	O
tabelts	O
for	O
cyclospoirn	O
A	O
-	O
induecd	O
hypertesnion	B-Disease
in	O
ptaients	O
with	O
psroiasis	B-Disease
.	O

Thirteen	O
posriatic	B-Disease
patinets	O
with	O
hypretension	B-Disease
during	O
the	O
cuorse	O
of	O
cyclosoprin	O
A	O
therpay	O
were	O
tretaed	O
for	O
25	O
motnhs	O
with	O
a	O
clacium	O
chnanel	O
blcoker	O
,	O
sustianed	O
-	O
rleease	O
nfiedipine	O
,	O
to	O
sutdy	O
the	O
clniical	O
antihyperetnsive	O
effects	O
and	O
avderse	O
eevnts	O
during	O
tretament	O
with	O
both	O
durgs	O
.	O

Seven	O
of	O
the	O
13	O
paitents	O
had	O
exhibited	O
a	O
subcilnical	O
hpyertensive	B-Disease
state	O
before	O
cyclosproin	O
A	O
tehrapy	O
.	O

Both	O
ssytolic	O
and	O
diatsolic	O
bolod	O
prsesures	O
of	O
these	O
13	O
patinets	O
were	O
decerased	O
significantly	O
after	O
4	O
wekes	O
of	O
nifeidpine	O
therpay	O
,	O
and	O
bolod	O
prsesure	O
was	O
maintained	O
within	O
the	O
nomral	O
range	O
thereafter	O
for	O
25	O
mnoths	O
.	O

The	O
advrese	O
evnets	O
during	O
cobmined	O
therpay	O
with	O
cylcosporin	O
A	O
and	O
nifediipne	O
included	O
an	O
incresae	O
in	O
bolod	O
uera	O
nitorgen	O
lveels	O
in	O
9	O
of	O
the	O
13	O
patietns	O
and	O
dveelopment	O
of	O
gingvial	B-Disease
hypreplasia	I-Disease
in	O
2	O
of	O
the	O
13	O
ptaients	O
.	O

Our	O
findigns	O
indicate	O
that	O
sustaiend	O
-	O
rleease	O
nfiedipine	O
is	O
useful	O
for	O
hyperetnsive	B-Disease
posriatic	B-Disease
patietns	O
under	O
long	O
-	O
term	O
tretament	O
with	O
cyclosproin	O
A	O
,	O
but	O
that	O
these	O
ptaients	O
should	O
be	O
mnoitored	O
for	O
ginigval	B-Disease
hyperpalsia	I-Disease
.	O

